PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BARACCA, A; GABELLIERI, E; BAROGI, S; SOLAINI, G				BARACCA, A; GABELLIERI, E; BAROGI, S; SOLAINI, G			CONFORMATIONAL-CHANGES OF THE MITOCHONDRIAL F-1-ATPASE EPSILON-SUBUNIT INDUCED BY NUCLEOTIDE-BINDING AS OBSERVED BY PHOSPHORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; LIVER ALCOHOL-DEHYDROGENASE; CHLOROPLAST COUPLING FACTOR; COLI F1 ATPASE; ESCHERICHIA-COLI; CATALYTIC SITES; ADENOSINE-TRIPHOSPHATASE; NONCATALYTIC SITES; TRYPTOPHAN PHOSPHORESCENCE; COOPERATIVE INTERACTIONS	Changes in conformation of the E-subunit of the bovine heart mitochondrial F-1-ATPase complex as a result of nucleotide binding have been demonstrated from the phosphorescence emission of tryptophan. The triplet state lifetime shows that whereas nucleoside triphosphate binding to the enzyme in the presence of Mg2+ increases the flexibility of the protein structure surrounding the chromophore, nucleoside diphosphate acts in an opposite manner, enhancing the rigidity of this region of the macromolecule. Such changes in dynamic structure of the epsilon-subunit are evident at high ligand concentration added to both the nucleotide depleted F-1 (Nd-F-1) and the F-1 preparation containing the three tightly bound nucleotides (F-1(2,1)). Since the effects observed are similar in both the F-1 forms, the binding to the low affinity sites must be responsible for the conformational changes induced in the epsilon-subunit. This is partially supported by the observation that the Trp lifetime is not significantly affected by adding an equimolar concentration of adenine nucleotide to Nd-F-1. The effects on protein structure of nucleotide binding to either catalytic or noncatalytic sites have been distinguished by studying the phosphorescence emission of the F-1 complex prepared with the three noncatalytic sites filled and the three catalytic sites vacant (F-1(3,0)). Phosphorescence lifetime measurements on this F-1 form demonstrate that the binding of Mg-NTP to catalytic sites induces a slight enhancement of the rigidity of the epsilon-subunit. This implies that the binding to the vacant noncatalytic site of F-1(2,1) must exert the opposite and larger effect of enhancing the flexibility of the protein structure observed in both Nd-F-1 and F-1(2,1). The observation that enhanced flexibility of the protein occurs upon addition of adenine nucleotides to F-1(2,1) in the absence of Mg2+ provides direct support for this suggestion. The connection between changes in structure and the possible functional role of the epsilon-subunit is discussed.	SCUOLA SUPER SANT ANNA, DIPARTIMENTO BIOCHIM G MORUZZI, I-56100 PISA, ITALY; UNIV BOLOGNA, IST BIOFIS, BOLOGNA, ITALY; CNR, I-56100 PISA, ITALY	Scuola Superiore Sant'Anna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Bologna; Consiglio Nazionale delle Ricerche (CNR)				SOLAINI, GIANCARLO/0000-0001-7825-0446; Gabellieri, Edi/0000-0003-0750-4095				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALOISE P, 1991, J BIOL CHEM, V266, P10368; BARACCA A, 1992, COMP BIOCHEM PHYS B, V101, P421, DOI 10.1016/0305-0491(92)90022-J; BARACCA A, 1989, BIOCHIM BIOPHYS ACTA, V976, P77, DOI 10.1016/S0005-2728(89)80191-4; BARACCA A, 1995, BIOCHEM BIOPH RES CO, V207, P369, DOI 10.1006/bbrc.1995.1197; BARACCA A, 1993, INT J BIOCHEM, V25, P701, DOI 10.1016/0020-711X(93)90356-J; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1987, BIOCHIM BIOPHYS ACTA, V894, P127, DOI 10.1016/0005-2728(87)90182-4; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BURGARD S, 1994, J BIOL CHEM, V269, P17815; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CIONI P, 1989, EUR J BIOCHEM, V185, P573, DOI 10.1111/j.1432-1033.1989.tb15152.x; CIONI P, 1989, J MOL BIOL, V207, P237, DOI 10.1016/0022-2836(89)90453-1; CLELAND WW, 1979, ADV INORG BIOCHEM, V1, P163; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1988, BIOCHEM BIOPH RES CO, V152, P1319, DOI 10.1016/S0006-291X(88)80429-7; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; GABELLIERI E, 1994, EUR J BIOCHEM, V221, P77, DOI 10.1111/j.1432-1033.1994.tb18716.x; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; GUELIN E, 1993, J BIOL CHEM, V268, P161; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; ISSARTEL JP, 1983, BIOCHEMISTRY-US, V22, P3485, DOI 10.1021/bi00283a027; ISSARTEL JP, 1986, J BIOL CHEM, V261, P895; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JAULT JM, 1994, J BIOL CHEM, V269, P319; JOSHI S, 1990, J BIOL CHEM, V265, P14518; KAMP G, 1987, BIOCHIM BIOPHYS ACTA, V929, P121, DOI 10.1016/0167-4889(87)90166-2; KAWANO Y, 1988, J PHYSIOL-LONDON, V407, P243, DOI 10.1113/jphysiol.1988.sp017413; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; NALIN CM, 1982, J BIOL CHEM, V257, P8055; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1975, METHOD ENZYMOL, V55, P304; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; ROSEN G, 1979, J BIOL CHEM, V254, P654; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; RYRIE IJ, 1972, J BIOL CHEM, V247, P4553; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SENIOR AE, 1979, J BIOL CHEM, V254, P1319; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SOLAINI G, 1993, EUR J BIOCHEM, V214, P729, DOI 10.1111/j.1432-1033.1993.tb17974.x; STANLOTTER H, 1986, EUR J BIOCHEM, V154, P321, DOI 10.1111/j.1432-1033.1986.tb09400.x; STRAMBINI GB, 1983, BIOPHYS J, V43, P127, DOI 10.1016/S0006-3495(83)84331-8; STRAMBINI GB, 1987, BIOCHEMISTRY-US, V26, P6527, DOI 10.1021/bi00394a036; STRAMBINI GB, 1989, J MOL LIQ, V42, P155, DOI 10.1016/0167-7322(89)80031-5; STRAMBINI GB, 1986, BIOCHEMISTRY-US, V25, P2471, DOI 10.1021/bi00357a027; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; STRAMBINI GB, 1995, IN PRESS J AM CHEM S; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; [No title captured]	74	8	8	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21845	21851		10.1074/jbc.270.37.21845	http://dx.doi.org/10.1074/jbc.270.37.21845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665607	hybrid			2022-12-27	WOS:A1995RU75700067
J	FENNEWALD, SM; RANDO, RF				FENNEWALD, SM; RANDO, RF			INHIBITION OF HIGH-AFFINITY BASIC FIBROBLAST GROWTH-FACTOR BINDING BY OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ANTISENSE OLIGODEOXYNUCLEOTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; CELL-PROLIFERATION; HEPARAN-SULFATE; TYPE-2 GROWTH; RNASE H; RECEPTOR; ANGIOPLASTY; PROTEINS	Oligonucleotides can be used to inhibit the binding of basic fibroblast growth factor to cells. Though standard phosphodiester oligonucleotides show a slight inhibition of binding, the oligonucleotides with phosphorothioate internucleoside linkages have inhibition levels equivalent to that of the polyanion heparin. Variations in sequence of the oligonucleotides does lead to differences in the inhibitory action of the oligonucleotides, This inhibition of basic fibroblast growth factor by phosphorothioate oligonucleotides may account for much of the published data on inhibition of various genes by proposed antisense oligonucleotides and needs to be taken into account when considering the mechanism of action of oligonucleotides in biological systems.			FENNEWALD, SM (corresponding author), TRIPLEX PHARMACEUT CORP,9391 GROGANS MILL RD,SUITE A1,THE WOODLANDS,TX 77380, USA.							AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COWSERT LM, 1993, ANTIMICROB AGENTS CH, V37, P171, DOI 10.1128/AAC.37.2.171; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; EDELMAN ER, 1994, CIRCULATION, V89, P770, DOI 10.1161/01.CIR.89.2.770; FENNEWALD SM, 1995, ANTIVIR RES, V26, P37, DOI 10.1016/0166-3542(94)00064-F; GAO WY, 1990, J BIOL CHEM, V265, P20172; GAO WY, 1992, MOL PHARMACOL, V41, P223; GAO WY, 1990, ANTIMICROB AGENTS CH, V34, P808, DOI 10.1128/AAC.34.5.808; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MORE RS, 1993, EUR HEART J, V14, P1543, DOI 10.1093/eurheartj/14.11.1543; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7187, DOI 10.1093/nar/17.18.7187; OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; Praseuth D, 1993, Antisense Res Dev, V3, P33; RAMANATHAN M, 1994, J BIOL CHEM, V269, P24564; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHMID KM, 1993, SEMIN THROMB HEMOST, V19, P155; SETH R, 1993, DEV BIOL, V158, P555, DOI 10.1006/dbio.1993.1213; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yaswen P, 1993, Antisense Res Dev, V3, P67	45	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21718	21721		10.1074/jbc.270.37.21718	http://dx.doi.org/10.1074/jbc.270.37.21718			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665590	hybrid			2022-12-27	WOS:A1995RU75700048
J	GHISLAIN, J; SUSSMAN, G; GOELZ, S; LING, LE; FISH, EN				GHISLAIN, J; SUSSMAN, G; GOELZ, S; LING, LE; FISH, EN			CONFIGURATION OF THE INTERFERON-ALPHA/BETA RECEPTOR COMPLEX DETERMINES THE CONTEXT OF THE BIOLOGICAL RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERLEUKIN-2 RECEPTOR; EXTRACELLULAR DOMAIN; GAMMA RECEPTOR; HUMAN-CELLS; IFN-ALPHA; GENE; BINDING	Constituents of the Type 1 interferon (IFN) receptor (IFNABR) identified to date include the alpha and beta transmembrane subunits and the associated intracellular kinases, Jak 1 and Tyk 2, In this report, we demonstrate that a human cell type that expresses both subunits of IFNABR, together with Jak 1 and Tyk 2, exhibits a limited binding capacity for and is only partially sensitive to the effects of IFN-alpha/beta, despite adequate levels of the cytoplasmic transcription factors Stat1, Stat2, and Stat3. Specifically, a low affinity interaction between IFN-alpha/beta and cell surface receptors results in ISGF3 (Stat1:2) activation and an antiviral response, yet no IFN-inducible growth inhibition, Using a panel of murine cells that are variably configured with respect to the human IFNABR-alpha/beta subunits, we provide evidence that an additional component(s) encoded on human chromosome 21 is required to confer high affinity binding and IFN-inducible growth inhibition to cells that express the alpha and beta subunits of the IFNABR, The data indicate that transcriptional activation that leads to an antiviral response is mediated by IFN-alpha/beta activation of IFNABR-alpha and IFNABR-beta in the context of a low affinity interaction, yet a high affinity interaction is necessary for signal transducing events that mediate growth inhibition. We provide evidence that the extent of ISGF3 activation correlates directly with the magnitude of an antiviral but not a growth inhibitory response.	UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5S 1A8,CANADA; BIOGEN INC,CAMBRIDGE,MA 02142	University of Toronto; Biogen								Aguet M, 1983, Interferon, V5, P1; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V18, P6934; BENOIT P, 1993, J IMMUNOL, V150, P707; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EID P, 1983, FEBS LETT, V156, P157, DOI 10.1016/0014-5793(83)80268-3; FALTYNEK CR, 1983, P NATL ACAD SCI-BIOL, V80, P3269, DOI 10.1073/pnas.80.11.3269; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1988, VIROLOGY, V165, P87, DOI 10.1016/0042-6822(88)90661-7; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FISH EN, 1989, J INTERFERON RES, V9, P97, DOI 10.1089/jir.1989.9.97; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAHAM FI, 1979, VIROLOGY, V62, P456; HANNIGAN GE, 1986, EUR J BIOCHEM, V15, P187; HANNIGAN GE, 1984, BIOCHEM BIOPH RES CO, V110, P537; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOSHI AR, 1982, J BIOL CHEM, V257, P3884; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KORN AP, 1994, J INTERFERON RES, V14, P1, DOI 10.1089/jir.1994.14.1; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LING L, 1994, J INTERFERON RES, V15, P55; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MOGENSEN KE, 1989, EXPERIENTIA, V45, P500, DOI 10.1007/BF01990498; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAZ R, 1994, J BIOL CHEM, V269, P24391; Raziuddin A, 1985, Prog Clin Biol Res, V202, P219; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; Stewart W E, 1981, INTERFERON SYSTEM; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21785	21792		10.1074/jbc.270.37.21785	http://dx.doi.org/10.1074/jbc.270.37.21785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665599	hybrid			2022-12-27	WOS:A1995RU75700058
J	LEE, SH; KIM, JC; LEE, MS; HEO, WD; SEO, HY; YOON, HW; HONG, JC; LEE, SY; BAHK, JD; HWANG, I; CHO, MJ				LEE, SH; KIM, JC; LEE, MS; HEO, WD; SEO, HY; YOON, HW; HONG, JC; LEE, SY; BAHK, JD; HWANG, I; CHO, MJ			IDENTIFICATION OF A NOVEL DIVERGENT CALMODULIN ISOFORM FROM SOYBEAN WHICH HAS DIFFERENTIAL ABILITY TO ACTIVATE CALMODULIN-DEPENDENT ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; NAD KINASE; MONOCLONAL-ANTIBODIES; PLANT CALMODULIN; MESSENGER-RNAS; PROTEIN; EXPRESSION; SEQUENCE; CDNA; GENES	Calmodulin plays pivotal roles in the transduction of various Ca2+-mediated signals and is one of the most highly conserved proteins in eukaryotic cells. In plants, multiple calmodulin isoforms with minor amino acid sequence differences were identified but their functional significances are unknown. To investigate the biological function of calmodulins in the regulation of calmodulin-dependent enzymes, we cloned cDNAs encoding calmodulins in soybean. Among the five cDNAs isolated from soybean, designated as SCam-1 to -5, SCaM-4 and -5 encoded very divergent calmodulin iso forms which have 32 amino acid substitutions from the highly conserved calmodulin, SCaM-1 encoded by SCaM-1 and SCaM-3. SCaM-4 protein produced in Escherichia coli showed typical characteristics of calmodulin such as Ca2+-dependent electrophoretic mobility shift and the ability to activate phosphodiesterase. However, the extent of mobility shift and antigenicity of SCaM-4 were different from those of SCaM-1. Moreover, SCaM-4 did not activate NAD kinase at all in contrast to SCaM-1. Also there were differences in the expression pattern of SCaM-1 and SCaM-4. Expression levels of SCaM-4 were approximately 5-fold lower than those of SCaM-1 in apical and elongating regions of hypocotyls. In addition, SCaM-4 transcripts were barely detectable in root whereas SCaM-1 transcripts were as abundant as in apical and elongating regions of hypocotyls. In conclusion, the different biochemical properties together with differential expression of SCaM-4 suggest that this novel calmodulin may have different functions in plant cells.	GYEONGSANG NATL UNIV,PLANT MOLEC BIOL & BIOTECHNOL RES CTR,CHINJU 660701,SOUTH KOREA; GYEONGSANG NATL UNIV,DEPT BIOCHEM,CHINJU 660701,SOUTH KOREA	Gyeongsang National University; Gyeongsang National University			Cho, Moo Je/F-1649-2010					BARNETT MJ, 1990, NUCLEIC ACIDS RES, V18, P3395, DOI 10.1093/nar/18.11.3395; BOTELLA JR, 1994, PLANT MOL BIOL, V24, P757, DOI 10.1007/BF00029857; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHAFOULEAS JG, 1983, METHOD ENZYMOL, V102, P104; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHOI YJ, 1993, MOL CELLS, V3, P255; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER R, 1988, J BIOL CHEM, V263, P17055; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Galea E, 1992, PCR Methods Appl, V2, P66; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GAWIENOWSKI MC, 1993, PLANT MOL BIOL, V22, P215, DOI 10.1007/BF00014930; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HARMON AC, 1984, ANAL BIOCHEM, V141, P168, DOI 10.1016/0003-2697(84)90441-X; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HONG JC, 1989, PLANT CELL, V1, P937, DOI 10.1105/tpc.1.9.937; JABLONSKY PP, 1991, PLANT SCI, V76, P175, DOI 10.1016/0168-9452(91)90139-Y; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1982, GRAFIT VERSION 3 0; LING V, 1992, PLANT PHYSIOL, V100, P970, DOI 10.1104/pp.100.2.970; LING V, 1989, PLANT PHYSIOL, V90, P714, DOI 10.1104/pp.90.2.714; LING V, 1991, PLANT PHYSIOL, V96, P1196, DOI 10.1104/pp.96.4.1196; MEANS AR, 1985, CALCIUM CELL PHYSL, P127; MUTO S, 1977, PLANT PHYSIOL, V59, P55, DOI 10.1104/pp.59.1.55; NOJIMA H, 1989, J MOL BIOL, V208, P269, DOI 10.1016/0022-2836(89)90388-4; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; OTA T, 1994, J MOL EVOL, V38, P642; PERERA IY, 1992, PLANT MOL BIOL, V19, P649, DOI 10.1007/BF00026791; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTELE C, 1988, CALCIUM BINDING PROT, V1, P83; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	44	119	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21806	21812		10.1074/jbc.270.37.21806	http://dx.doi.org/10.1074/jbc.270.37.21806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665602	hybrid			2022-12-27	WOS:A1995RU75700061
J	MARKSITZER, R; STIEF, A; MENOUD, PA; NAGAMINE, Y				MARKSITZER, R; STIEF, A; MENOUD, PA; NAGAMINE, Y			ROLE OF LFB3 IN CELL-SPECIFIC CAMP INDUCTION OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MESSENGER-RNA DEGRADATION; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; DOWN-REGULATION; LLC-PK1 CELLS; EXPRESSION; REGION; FOS	In previous work we suggested that a kidney specific transcription factor LFB3 cooperates with cAMP-response element (CRE)-binding proteins within a cAMP regulatory unit comprised of three protein-binding domains and located 3.4 kilobase pairs upstream of the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells (Menoud, P.-A., Matthies, R., Hofsteenge, J., and Nagamine, Y. (1993) Nucleic Acids Res, 21, 1845-1852). The two domains contain a CRE-like sequence, and the third domain is recognized by LFB3. The absolute requirement of LFB3 as well as the cooperation among the three domains for cAMP regulation were confirmed by transient transfection assays in F9 teratocarcinoma cells, in which the level of LFB3 was negligible. Suspecting a possible feedback regulation of LFB3 mRNA expression during cAMP-dependent uPA gene induction in LLC-PK1 cells, we measured LFB3 mRNA levels after cAMP treatment and found a strong reduction. This reduction was not due to a change in template activity of the LFB3 gene because run-on transcription showed no significant change in LFB3 gene transcription. RNA synthesis inhibitor-chase experiments indicated that the down-regulation was post-transcriptional. Interestingly, when the inhibitor was added at the same time as cAMP, the cAMP-induced decrease in LFB3 mRNA levels was abrogated, suggesting that ongoing RNA synthesis is required for the decrease. Similar effects on LFB3 mRNA metabolism were observed with all agents that induce uPA mRNA in LLC-PK1 cells, including 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, colchicine, and cytochalasin. We discuss the significance of this regulation in uPA gene expression.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								AKASHI M, 1991, BLOOD, V78, P2005; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BESSER D, 1995, IN PRESS CELL GROWTH; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROACH AAD, 1994, ADV ENZYME REGUL, V34, P199; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SODERQUIST AM, 1986, J MEMBRANE BIOL, V90, P97, DOI 10.1007/BF01869927; STACEY KJ, 1994, FEBS LETT, V356, P311, DOI 10.1016/0014-5793(94)01294-6; TAMM I, 1978, ADV VIRUS RES, V22, P188; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21833	21838		10.1074/jbc.270.37.21833	http://dx.doi.org/10.1074/jbc.270.37.21833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665606	hybrid			2022-12-27	WOS:A1995RU75700065
J	SEKLER, I; KOPITO, R; CASEY, JR				SEKLER, I; KOPITO, R; CASEY, JR			HIGH-LEVEL EXPRESSION, PARTIAL-PURIFICATION, AND FUNCTIONAL RECONSTITUTION OF THE HUMAN AE1 ANION-EXCHANGER IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HIGH-EFFICIENCY TRANSFORMATION; HUMAN ERYTHROCYTE-MEMBRANE; INTACT YEAST-CELLS; PLASMA-MEMBRANE; TRANSPORT PROTEIN; DIRECTED MUTAGENESIS; BAND-3 PROTEIN; CLONING; DEGLYCOSYLATION	Human erythroid anion exchanger AE1 (Band 3) was expressed in the yeast Saccharomyces cerevisiae under the control of the constitutive promoter and transcriptional terminator of the yeast phosphoglycerate kinase gene, AE1 expression in stable yeast transformants was estimated to be approximately 0.7 mg AE1 per liter, Density gradient sedimentation analysis indicated that the AE1 protein was associated with a membrane fraction distinct from plasma membrane, most likely the endoplasmic reticulum. AE1 protein was solubilized from yeast membranes with lysophosphatidyl choline, and the protein, tagged with six histidines at its amino terminus, was purified to 35% homogeneity by metal chelation affinity chromatography, Size-exclusion chromatography in the presence of octaethylene glycol monododecyl ether indicated that the solubilized yeast-expressed AE1, like endogenous erythroid AE1, eluted at a stokes radius of 77 Angstrom, consistent with a dimeric oligomeric state, Binding of partially purified yeast expressed AE1 to 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonate resin was competitive with the transportable substrate chloride but not the nontransported anion citrate, suggesting that the structure of the anion binding site is preserved, The specific activity of sulfate transport by partially purified yeast AE1 was determined in proteoliposomes to be similar to that of authentic AE1 purified from erythrocyte membranes, These data show that this expression system has the capacity to produce functional mammalian plasma membrane anion exchangers at levels sufficient for biochemical and biophysical analysis.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CASEY JR, 1994, BIOCH CELL BIOL, V71; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; EALKE KA, 1992, J BIOL CHEM, V89, P2834; EBLE R, 1992, BIOTECHNIQUES, V13, P18; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FALKE JJ, 1986, BIOCHEMISTRY-US, V25, P7888, DOI 10.1021/bi00372a015; FERREIRA GC, 1992, J BIOL CHEM, V267, P5460; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HE XJ, 1993, AM J PHYSIOL, V264, pC1075, DOI 10.1152/ajpcell.1993.264.4.C1075; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOLZER KP, 1989, J BIOL CHEM, V264, P14389; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MELLOR J, 1983, GENE, V24, P1, DOI 10.1016/0378-1119(83)90126-9; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; OKUBO K, 1994, J BIOL CHEM, V269, P1918; PIMPLIKAR SW, 1988, BIOCHIM BIOPHYS ACTA, V942, P253, DOI 10.1016/0005-2736(88)90027-2; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUETZ S, 1994, J BIOL CHEM, V269, P12277; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SEKLER I, 1995, J BIOL CHEM, V270, P11251, DOI 10.1074/jbc.270.19.11251; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THOMAS HA, 1989, AM J PHYSIOL, V26, pC537; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUITE MF, 1982, EMBO J, V1, P603, DOI 10.1002/j.1460-2075.1982.tb01215.x; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	54	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21028	21034		10.1074/jbc.270.36.21028	http://dx.doi.org/10.1074/jbc.270.36.21028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673129	hybrid			2022-12-27	WOS:A1995RU05400026
J	THOMAS, JL; FRIEDEN, C; NASH, WE; STRICKLER, RC				THOMAS, JL; FRIEDEN, C; NASH, WE; STRICKLER, RC			AN NADH-INDUCED CONFORMATIONAL CHANGE THAT MEDIATES THE SEQUENTIAL 3-BETA-HYDROXYSTEROID DEHYDROGENASE/ISOMERASE ACTIVITIES IS SUPPORTED BY AFFINITY LABELING AND THE TIME-DEPENDENT ACTIVATION OF ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; COLI DIHYDROFOLATE-REDUCTASE; STEROID 5->4-ENE-ISOMERASE; 3-BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE; 5-ENE-4-ENE ISOMERASE; SUBSTRATE-BINDING; ACTIVE-SITE; PURIFICATION; PROTEIN; 5'-DIPHOSPHATE	3 beta-Hydroxysteroid dehydrogenase (3 beta-HSD) and steroid Delta-isomerase were copurified as a single protein from human placental microsomes, Because NADH is an essential activator of isomerase (K-act = 2.4 mu M, V-max = 0.6 mu mol/min/mg), the affinity alkylating nucleotide, 8-[(4-bromo-2,3- dioxobutyl)thio]adenosine 5'-diphosphate (8-BDB-TADP), was synthesized. 8-BDB-TADP activates isomerase (K-act = 338 mu M, V-max = 2.1 mu mol/min/mg) prior to inactivating the enzyme, The inactivation kinetics for isomerase fit the Kitz and Wilson model for time-dependent, irreversible inhibition by 8-BDB-TADP (K-I = 314 mu M, first order maximal rate constant k(obs) = 7.8 x 10(-3) s(-1)). NADH (50 mu M) significantly protects isomerase from inactivation by 8-BDB-TADP (100 mu M) The isomerase activity is inactivated more rapidly by 8-BDB-TADP as the concentration of the affinity alkylator increases from 67 mu M (t(1/2) = 8.4 min) to 500 mu M (t(1/2) = 2.4 min), In sharp contrast, the 3 beta-HSD activity is inactivated more slowly as the concentration of 8-BDB-TADP increases from 67 mu M (t(1/2) = 4.8 min) to 500 mu M (t(1/2) = 60.0 min), We hypothesized that the paradoxical kinetics of 3 beta-HSD inactivation is a consequence of the activation of isomerase by 8-BDB-TADP via a nucleotide induced shift in enzyme conformation, Biophysical support for an NADH-induced conformational change was obtained using stopped-flow fluorescence spectroscopy. The binding of NADH (10 mu M) quenches the intrinsic fluorescence of the enzyme protein in a time-dependent manner (rate constant k(app) = 8.1 X 10(-3) s(-1), t(1/2) = 85 s), A time lag is also observed for the activation of isomerase by NADH, This combination of affinity labeling and biophysical data using nucleotide derivatives supports our model for the sequential reaction mechanism; the cofactor product of the 3 beta-HSD reaction, NADH, activates isomerase by inducing a conformational change in the single, bifunctional enzyme protein,	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	THOMAS, JL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,4911 BARNES HOSP PL,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [HD-20055, R01 HD020055] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILEY JM, 1987, J BIOL CHEM, V262, P12620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1984, BIOCHEMISTRY-US, V23, P3281, DOI 10.1021/bi00309a025; DECAMP DL, 1988, BIOCHEMISTRY-US, V27, P7651, DOI 10.1021/bi00420a012; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V25, P555; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V24, P753; KITZ R, 1962, J BIOL CHEM, V237, P3245; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; PENNER MH, 1985, J BIOL CHEM, V260, P5366; RUTHERFURD KJ, 1991, BIOCHEMISTRY-US, V30, P8108, DOI 10.1021/bi00247a003; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; STRICKLER RC, 1993, AM J OBSTET GYNECOL, V168, P1216, DOI 10.1016/0002-9378(93)90372-P; THOMAS JL, 1991, J STEROID BIOCHEM, V39, P471, DOI 10.1016/0960-0760(91)90240-6; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; THOMAS JL, 1993, J BIOL CHEM, V268, P18507; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; THOMAS JL, 1994, J SOC GYNECOL INVEST, V1, P155, DOI 10.1177/107155769400100211; THOMAS JL, 1990, J STEROID BIOCHEM, V36, P117, DOI 10.1016/0022-4731(90)90121-8; THOMAS JL, 1992, BIOCHEMISTRY-US, V31, P5522, DOI 10.1021/bi00139a014	20	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21003	21008		10.1074/jbc.270.36.21003	http://dx.doi.org/10.1074/jbc.270.36.21003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673125	hybrid			2022-12-27	WOS:A1995RU05400022
J	HACKETT, M; WALKER, CB; GUO, L; GRAY, MC; VANCUYK, S; ULLMANN, A; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL; SEBO, P				HACKETT, M; WALKER, CB; GUO, L; GRAY, MC; VANCUYK, S; ULLMANN, A; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL; SEBO, P			HEMOLYTIC, BUT NOT CELL-INVASIVE ACTIVITY, OF ADENYLATE-CYCLASE TOXIN IS SELECTIVELY AFFECTED BY DIFFERENTIAL FATTY-ACYLATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRAM-NEGATIVE BACTERIA; BORDETELLA-PERTUSSIS; ACTIVATION; PROTEIN; PROHAEMOLYSIN; MEMBRANE; CYAC	Adenylate cyclase toxin from Bordetella pertussis requires posttranslational acylation of lysine 983 for the ability to deliver its catalytic domain to the target cell interior and produce cyclic adenosine monophosphate (cell-invasive activity) and to form transmembrane channels (hemolytic activity). When the toxin is expressed in Escherichia coli, it has reduced hemolytic activity, but comparable cell-invasive activity to that of adenylate cyclase toxin from B. pertussis. In contrast to the native protein from B. pertussis, which is exclusively palmitoylated, recombinant toxin from E. coli is acylated at lysine 983 with about 87% palmitoylated and the remainder myristoylated. Furthermore, the recombinant toxin contains an additional palmitoylation on approximately two-thirds of the lysines at position 860. These observations suggest that the site and nature of posttranslational fatty-acylation can be dictated by the bacterial host used for expression and can have a significant, but selective, effect on protein function.	UNIV VIRGINIA,SCH MED,DEPT MED & PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE	University of Virginia; University of Virginia; University of Virginia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Hunt, Donald F/I-6936-2012; SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011; Bazemore-Walker, Carthene/I-1879-2013	Hunt, Donald F/0000-0003-2815-6368; SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; gray, mary/0000-0003-4441-5905	NIAID NIH HHS [AI18000] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT D, 1992, 40TH P AM SOC MASS S, P328; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; Gulden Pamela H., 1995, P281; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; Hanski E, 1991, SOURCEBOOK BACTERIAL, P349; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEVEKER N, 1994, J BIOL CHEM, V269, P32844; HEWLETT EL, 1994, HDB NATURAL TOXINS, V8, P425; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LADANT D, 1989, J BIOL CHEM, V264, P4015; MILLER JC, 1984, STAT ANAL CHEM, P33; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; SZABO G, 1994, J BIOL CHEM, V269, P22496; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; 1993, 393 NOV TECHN NOT	32	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20250	20253		10.1074/jbc.270.35.20250	http://dx.doi.org/10.1074/jbc.270.35.20250			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657593	hybrid			2022-12-27	WOS:A1995RR58400005
J	STRANICK, KS; PAYVANDI, F; ZAMBAS, DN; UMLAND, SP; EGAN, RW; BILLAH, MM				STRANICK, KS; PAYVANDI, F; ZAMBAS, DN; UMLAND, SP; EGAN, RW; BILLAH, MM			TRANSCRIPTION OF THE MURINE INTERLEUKIN-5 GENE IS REGULATED BY MULTIPLE PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CIS-ACTING ELEMENT; T-CELLS; DIFFERENTIAL REGULATION; BINDING-PROTEINS; CDNA CLONE; GM-CSF; EXPRESSION; MOUSE; IL-4	Cis-acting regions in the 5'-flank of the mouse interleukin 5 (IL-5) gene involved in the specific and inducible regulation of IL-5 transcription in an untransformed mouse T cell clone, D10.G4.1, have been identified. Transient transfection assays with a series of deletion IL-5 promoter reporter constructs indicate that multiple regulatory elements in the 5'-flanking region of the IL-5 promoter play a role in regulating IL-5 transcription in Th2 cells. Negatively acting elements, NRE I and NRE II, map to the regions between positions -431 and -392 and positions -300 and -261. A positive regulatory element has been mapped to the region between positions -224 and -81. The activity of these elements is dependent on activation of the cells. A 40-bp sequence within this region, termed the IL-5 PRE, has been shown to bind at least two specific nuclear protein complexes from unstimulated and stimulated D10.G4.1 cells. An additional protein complex specific for this site has been identified in nuclear fractions from cells stimulated in the presence of the protein synthesis inhibitor, cycloheximide. Proteins that bind to these elements are likely to be important inducible and specific factors essential for control of IL-5 transcription in response to T cell receptor-mediated signaling events.			STRANICK, KS (corresponding author), SCHERING PLOUGH CORP, RES INST, DEPT ALLERGY, KENILWORTH, NJ 07033 USA.							ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LEDERER JA, 1994, J IMMUNOL, V152, P77; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEE HJ, 1993, J IMMUNOL, V151, P6135; LIWEBER M, 1993, J IMMUNOL, V151, P1371; Lund P K, 1994, Growth Regul, V4 Suppl 1, P1; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; MIN LW, 1992, J IMMUNOL, V148, P1913; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ E, 1989, P NATL ACAD SCI USA, V86, P9461, DOI 10.1073/pnas.86.23.9461; NAORA H, 1994, J IMMUNOL, V153, P3466; NAORA H, 1994, BLOOD, V83, P3620; NAORA H, 1994, J IMMUNOL, V152, P5691; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARK JH, 1993, J BIOL CHEM, V268, P6299; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; STAYNOV DZ, 1992, IMMUNOLOGY, V75, P196; SZABO SJ, 1993, MOL CELL BIOL, V13, P4973; TAMURA T, 1993, J IMMUNOL, V151, P6051; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TOKUMITSU H, 1993, BIOCHEM BIOPH RES CO, V196, P737, DOI 10.1006/bbrc.1993.2311; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; VANSTRAATEN JFM, 1994, CYTOKINE, V6, P229, DOI 10.1016/1043-4666(94)90017-5; WOLFF CHJ, 1993, J IMMUNOL, V151, P1337; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070	51	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20575	20582		10.1074/jbc.270.35.20575	http://dx.doi.org/10.1074/jbc.270.35.20575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657635	hybrid			2022-12-27	WOS:A1995RR58400054
J	VEKSLER, VI; KUZNETSOV, AV; ANFLOUS, K; MATEO, P; VANDEURSEN, J; WIERINGA, B; VENTURACLAPIER, R				VEKSLER, VI; KUZNETSOV, AV; ANFLOUS, K; MATEO, P; VANDEURSEN, J; WIERINGA, B; VENTURACLAPIER, R			MUSCLE CREATINE KINASE-DEFICIENT MICE .2. CARDIAC AND SKELETAL-MUSCLES EXHIBIT TISSUE-SPECIFIC ADAPTATION OF THE MITOCHONDRIAL-FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DIFFUSION; SARCOPLASMIC-RETICULUM; ENERGY-METABOLISM; OUTER-MEMBRANE; RAT-HEART; PHOSPHOCREATINE; PHOSPHOKINASE; ADP; CARDIOMYOCYTES; RESPIRATION	Functional properties of in situ mitochondria and of mitochondrial creatine kinase were studied in saponin-skinned fibers taken from normal and M-creatine kinase-deficient mice. In control animals, apparent K-m values of mitochondrial respiration for ADP in cardiac (ventricular) and slow-twitch (soleus) muscles (137 +/- 16 mu M and 209 +/- 10 mu M, respectively) were manyfold higher than that in fast-twitch (gastrocnemius) muscle (7.5 +/- 0.5 mu M). Creatine substantially decreased the K-m values only in cardiac and slow-twitch muscles (73 +/- 11 mu M and 131 +/- 21 mu M, respectively), As compared to control, in situ mitochondria in transgenic ventricular and slow-twitch muscles showed two times lower K-m values for ADP, and the presence of creatine only slightly decreased the K-m values, In mutant fast-twitch muscle, a decrease rather than increase in mitochondrial sensitivity to ADP occurred, but creatine still had no effect. Furthermore, in these muscles, relatively low oxidative capacity was considerably elevated, It is suggested that in the mutant mice, impairment of energy transport function in ventricular and slow-twitch muscles is compensated by a facilitation of adenine nucleotide transportation between mitochondria and cellular ATPases; in fast-twitch muscle, mainly energy buffering function is depressed, and that is overcome by an increase in energy-producing potential.	UNIV NIJMEGEN,FAC MED SCI,DEPT HISTOL & CELL BIOL,6500 HB NIJMEGEN,NETHERLANDS; CARDIOL RES CTR,MOSCOW 121552,RUSSIA	Radboud University Nijmegen; National Medical Research Center of Cardiology	VEKSLER, VI (corresponding author), UNIV PARIS SUD,FAC PHARM,INSERM,CJF9211,CARDIOL CELLULAIRE & MOLEC LAB,F-92296 CHATENAY MALABRY,FRANCE.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				AWAJI Y, 1990, CARDIOVASC RES, V24, P547, DOI 10.1093/cvr/24.7.547; BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BYGRAVE FL, 1967, P NATL ACAD SCI USA, V57, P1409, DOI 10.1073/pnas.57.5.1409; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHEVLI R, 1979, BIOCHEM MED METAB B, V21, P162, DOI 10.1016/0006-2944(79)90068-1; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; FIELD ML, 1994, CARDIOVASC RES, V28, P86, DOI 10.1093/cvr/28.1.86; FITCH CD, 1974, J BIOL CHEM, V249, P1060; FREYSSENET D, 1994, BBA-BIOENERGETICS, V1186, P232, DOI 10.1016/0005-2728(94)90182-1; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; JOCKERSWRETOU E, 1977, HISTOCHEMISTRY, V54, P83, DOI 10.1007/BF00493332; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; PHILIPPI M, 1994, J EXP BIOL, V189, P1; POPOVICH BK, 1989, AM J PHYSIOL, V257, pE573, DOI 10.1152/ajpendo.1989.257.4.E573; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; SAVABI F, 1991, J MOL CELL CARDIOL, V23, P1323, DOI 10.1016/0022-2828(91)90089-5; SEPPET EK, 1991, J APPL CARDIOL, V6, P301; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER V, 1994, J MOL CELL CARDIOL, V26, P335, DOI 10.1006/jmcc.1994.1042; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WILLIMANN T, 1977, J CELL BIOL, V75, P297; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172	36	158	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19921	19929		10.1074/jbc.270.34.19921	http://dx.doi.org/10.1074/jbc.270.34.19921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650007	Green Published, hybrid			2022-12-27	WOS:A1995RQ99100039
J	KAMIYA, H; KASAI, H				KAMIYA, H; KASAI, H			FORMATION OF 2-HYDROXYDEOXYADENOSINE TRIPHOSPHATE, AN OXIDATIVELY DAMAGED NUCLEOTIDE, AND ITS INCORPORATION BY DNA-POLYMERASES - STEADY-STATE KINETICS OF THE INCORPORATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR; 8-HYDROXYGUANINE; SEQUENCES; INSERTION; PROTEIN; RAS	We found that hydroxylation occurs at the C-2 position of adenine by oxygen radical treatment (Fe2+-EDTA) of dA, dATP, and single- and double-stranded DNA. This oxidatively damaged base, 2-hydroxyadenine, was produced 3-6-fold and 40-fold less than 8-hydroxyguanine when monomers and polynucleotides, respectively, were treated. To determine whether the damaged nucleotide, 2-hydroxydeoxyadenosine triphosphate (2-OH-dATP), is incorporated into a growing DNA, and to reveal the kinds of nucleotides opposite which 2-OH-dATP is incorporated, calf thymus DNA polymerase alpha and the Klenow fragment of Escherichia coli DNA polymerase I were used in in vitro DNA synthesis in the presence of 2-OH-dATP. DNA polymerase alpha incorporated the nucleotide opposite T and C in the DNA template. On the other hand, in an experiment using the Klenow fragment, incorporation of 2-OH-dATP was observed only opposite T. Steady-state kinetic studies indicated that incorporation of 2-OH-dATP by DNA polymerase alpha opposite T was favored over that opposite C by a factor of only 4.5, These results indicate that 2-OH-dATP, an oxidatively damaged nucleotide, is a substrate for DNA polymerases and is incorporated incorrectly by the replicative DNA polymerase.	UNIV OCCUPAT & ENVIRONM HLTH,INST IND ECOL SCI,DEPT ENVIRONM ONCOL,YAKAHTANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Occupational & Environmental Health - Japan			Kamiya, Hiroyuki/G-2383-2019	Kamiya, Hiroyuki/0000-0001-6866-5322				CHENG KC, 1992, J BIOL CHEM, V267, P166; DAVOLL J, 1951, J AM CHEM SOC, V73, P3174, DOI 10.1021/ja01151a052; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; FERSHT A, 1977, ENZYME STRUCTURE MEC, P91; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KAMIYA H, 1992, CANCER RES, V52, P3483; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P761, DOI 10.1093/nar/23.5.761; KAMIYA H, 1992, CHEM PHARM BULL, V40, P2792, DOI 10.1248/cpb.40.2792; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NOFRE C, 1961, B SOC CHIM FR, V5, P530; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P3930, DOI 10.1093/nar/22.19.3930; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; SWITZER CY, 1993, BIOCHEMISTRY-US, V32, P10489, DOI 10.1021/bi00090a027; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	20	146	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19446	19450		10.1074/jbc.270.33.19446	http://dx.doi.org/10.1074/jbc.270.33.19446			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642627				2022-12-27	WOS:A1995RP70300041
J	PAYNE, DW; SHACKLETON, C; TOMS, H; BENSHLOMO, I; KOL, S; DEMOURA, M; STRAUSS, JF; ADASHI, EY				PAYNE, DW; SHACKLETON, C; TOMS, H; BENSHLOMO, I; KOL, S; DEMOURA, M; STRAUSS, JF; ADASHI, EY			A NOVEL NONHEPATIC HYDROXYCHOLESTEROL 7-ALPHA-HYDROXYLASE THAT IS MARKEDLY STIMULATED BY INTERLEUKIN-1-BETA - CHARACTERIZATION IN THE IMMATURE RAT OVARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-MEDIATED REGULATION; BILE-ACID SYNTHESIS; DENSITY-LIPOPROTEIN RECEPTOR; CELL-CELL INTERACTION; CHOLESTEROL 7-ALPHA-HYDROXYLASE; ANDROGEN BIOSYNTHESIS; MESSENGER-RNA; MITOCHONDRIAL CYTOCHROME-P-450; STEROID-HORMONES; GRANULOSA-CELLS	During studies on the regulation of rat ovarian steroidogenic enzymes by interleukin-1 beta (IL-1 beta), we observed substantial metabolism of 25-hydroxycholesterol to two unusual polar products. This unexpected effect was observed both in isolated granulosa cells and in whole ovarian dispersates and was also induced by tumor necrosis factor alpha but not by insulin-like growth factor I or follicle-stimulating hormone. The effect was dependent on time and the dose of IL-1 beta and was blocked by an IL-1 receptor antagonist, The formation of the polar metabolites was inhibited by ketoconazole and trilostane, but not by aminoglutethimide. Subsequent purification of these novel metabolites and analysis by gas chromatography/mass spectrometry, NMR, and high performance liquid chromatography revealed them to be related 7 alpha-hydroxylated hydroxycholesterols (cholest-4-ene-7 alpha,25-diol-3-one and cholest-5-ene-3 beta,7 alpha 25-triol). IL-1 beta-stimulated ovarian 7 alpha-hydroxylase activity (3-10 pmol/min/mg of cellular protein) was nearly 4-fold that of control levels using 25-hydroxycholesterol as substrate, Activities at or below control levels were observed when IL-1 beta-treated cell sonicates were boiled or assayed in the presence of NADH (rather than NADPH), indicating that involvement of a nonenzymatic process was unlikely, IL-1 beta-stimulated 7 alpha-hydroxylase activity was inhibited to basal levels by a 10-fold excess of unlabeled 25- or 27-hydroxycholesterol, but not by cholesterol, pregnenolone, progesterone, testosterone, or dehydroepiandrosterone, suggesting that ovarian 7 alpha-hydroxylase is specific for hydroxycholesterols, Furthermore, when IL-1 beta-treated ovarian cultures were incubated with radiolabeled cholesterol or testosterone, no 7 alpha-hydroxylated products were observed, We were also unable to detect any mRNA transcripts for liver cholesterol 7 alpha-hydroxylase in IL-1 beta-stimulated ovarian cultures, This study describes an ovarian hydroxycholesterol 7 alpha-hydroxylase that differs from liver cholesterol 7 alpha-hydroxylase and from other nonhepatic progestin/androgen 7 alpha-hydroxylases, The novel finding of the regulation of a 7 alpha-hydroxylase by IL-1 beta (and tumor necrosis factor alpha) suggests a unique role for cytokines in the regulation of cholesterol metabolism in the ovary and possibly other tissues.	CHILDRENS HOSP OAKLAND, RES INST, OAKLAND, CA 94609 USA; UNIV LONDON, UNIV LONDON QUEEN MARY & WESTFIELD COLL, LONDON E1 4NS, ENGLAND; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of London; Queen Mary University London; University of Pennsylvania	PAYNE, DW (corresponding author), UNIV MARYLAND, SCH MED,DEPT OBSTET GYNECOL,DIV REPROD ENDOCRINOL, 655 W BALTIMORE ST, RM 11-010, BALTIMORE, MD 21201 USA.		Kol, Shahar/R-7180-2019	Kol, Shahar/0000-0002-2899-5295	NICHD NIH HHS [HD-O6274, HD-19998, HD-30288] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030288, R01HD019998] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADASHI EY, 1990, AM J OBSTET GYNECOL, V162, P889, DOI 10.1016/0002-9378(90)91289-O; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; AKWA Y, 1992, BIOCHEM J, V288, P959, DOI 10.1042/bj2880959; ALSEMA GJ, 1982, J STEROID BIOCHEM, V17, P31, DOI 10.1016/0022-4731(82)90588-X; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; ARINGER L, 1981, BIOMED MASS SPECTROM, V8, P183, DOI 10.1002/bms.1200080502; AXELSON M, 1992, J BIOL CHEM, V267, P1701; AYAKI Y, 1989, J BIOL CHEM, V264, P3818; BAKOS JT, 1993, J STEROID BIOCHEM, V46, P415, DOI 10.1016/0960-0760(93)90096-F; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BENSHLOMO I, 1994, BIOL REPROD, V94, P1463; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAN YL, 1987, J BIOL CHEM, V262, P1111; DECAPRIO J, 1992, J LIPID RES, V33, P441; DEXTER RN, 1967, J CLIN ENDOCR METAB, V27, P473, DOI 10.1210/jcem-27-4-473; DUELAND S, 1992, J BIOL CHEM, V267, P22695; EINARSSON K, 1992, J LIPID RES, V33, P1591; FALKE HE, 1975, MOL CELL ENDOCRINOL, V3, P375, DOI 10.1016/0303-7207(75)90037-4; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; GUPTA A, 1986, J BIOL CHEM, V261, P8348; HARDARDOTTIR I, 1994, LYMPHOKINE CYTOK RES, V13, P161; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1603, DOI 10.1210/endo-122-4-1603; HURWITZ A, 1991, ENDOCRINOLOGY, V129, P1250, DOI 10.1210/endo-129-3-1250; HURWITZ A, 1992, J CLIN INVEST, V89, P1746, DOI 10.1172/JCI115777; HURWITZ A, 1991, ENDOCRINOLOGY, V129, P3427, DOI 10.1210/endo-129-6-3427; HURWITZ A, 1992, ENDOCRINOLOGY, V131, P1643, DOI 10.1210/en.131.4.1643; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; INANO H, 1971, BIOCHEMISTRY-US, V10, P1503; JAVITT NB, 1990, J LIPID RES, V31, P1527; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KHALIL MW, 1994, J STEROID BIOCHEM, V48, P545, DOI 10.1016/0960-0760(94)90206-2; KHALIL MW, 1993, J STEROID BIOCHEM, V46, P585, DOI 10.1016/0960-0760(93)90186-Z; KIRK DN, 1990, J CHEM SOC PERK T 2, P1567, DOI 10.1039/p29900001567; KLEBE RJ, 1984, IN VITRO CELL DEV B, V20, P127; KOKIA E, 1992, ENDOCRINOLOGY, V130, P3095, DOI 10.1210/en.130.5.3095; KOKIA E, 1995, FERTIL STERIL, V63, P176, DOI 10.1016/S0015-0282(16)57314-2; KOKIA E, 1993, ENDOCRINOLOGY, V133, P2391, DOI 10.1210/en.133.5.2391; KUIPERS F, 1989, LIPIDS, V24, P759, DOI 10.1007/BF02544580; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; MARTIN KO, 1993, J LIPID RES, V34, P581; MITTON JR, 1971, EUR J BIOCHEM, V20, P569, DOI 10.1111/j.1432-1033.1971.tb01429.x; MORFIN R, 1994, J STEROID BIOCHEM, V50, P91, DOI 10.1016/0960-0760(94)90176-7; PAYNE DW, 1991, SERONO SYMP, P190; PAYNE DW, 1988, BIOL REPROD, V39, P581, DOI 10.1095/biolreprod39.3.581; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PINKERTON FD, 1993, BIOCHEM BIOPH RES CO, V193, P1091, DOI 10.1006/bbrc.1993.1737; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; PRINCEN HMG, 1986, J CLIN INVEST, V78, P1064, DOI 10.1172/JCI112662; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; SHACKLETON CHL, 1986, J CHROMATOGR, V379, P91, DOI 10.1016/S0378-4347(00)80683-0; SONDERFAN AJ, 1989, ENDOCRINOLOGY, V125, P857, DOI 10.1210/endo-125-2-857; SRINIVASAN G, 1993, RECEPTOR, V3, P99; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; STRAUSS JF, 1981, ADV LIPID RES, V18, P99; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SUDJANASUGIAMAN E, 1994, BIOCHEM BIOPH RES CO, V202, P896, DOI 10.1006/bbrc.1994.2014; SWELL L, 1981, BIOCHIM BIOPHYS ACTA, V663, P163, DOI 10.1016/0005-2760(81)90202-2; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TINT GS, 1978, J LIPID RES, V19, P956; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331	66	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18888	18896		10.1074/jbc.270.32.18888	http://dx.doi.org/10.1074/jbc.270.32.18888			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642545	hybrid			2022-12-27	WOS:A1995RN95400032
J	DOLENC, I; TURK, B; PUNGERCIC, G; RITONJA, A; TURK, V				DOLENC, I; TURK, B; PUNGERCIC, G; RITONJA, A; TURK, V			OLIGOMERIC STRUCTURE AND SUBSTRATE-INDUCED INHIBITION OF HUMAN CATHEPSIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; AMINO-ACID SEQUENCES; CYSTEINE PROTEINASES; MOLECULAR-CLONING; BOVINE SPLEEN; PAPAIN; CDNA; PURIFICATION; DEPENDENCE; EXPRESSION	Cathepsin C has been purified from human kidney by a modified procedure. Human cathepsin C was isolated as pure protein with a pI close to 6.0. The enzyme was shown to have a molecular mass of 200 kDa and to consist of four identical subunits, each composed of three different polypeptide chains, two of them disulfide-bound. Their NH2-terminal amino acid sequences were determined. Two chains showed pronounced similarity with the heavy and light chains of other papain-like cysteine proteinases, whereas the third one corresponded to the prosequence of the enzyme, thus showing that a substantial part of the proregion remains bound in the mature enzyme. The kinetics of substrate hydrolysis deviated substantially from standard Michaelis-Menten kinetics, demonstrating substrate inhibition at higher substrate concentrations. These data are explained by a sequential cooperative interaction model, where an enzyme molecule can bind up to four substrate molecules but where only the binary enzyme-substrate complex is catalytically active. Substrate inhibition was observed over the whole range of pH activity. From the pH activity profile it can be concluded that at least three ionizable groups with pK(a) values 4.2, 6.8, and 7.7 are involved in substrate hydrolysis. Human cathepsin C thus appears to differ qualitatively from other cysteine proteinases of different origin.	SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN	Swedish University of Agricultural Sciences	DOLENC, I (corresponding author), JOZEF STEFAN INST, DEPT BIOCHEM & MOLEC BIOL, LJUBLJANA 61111, SLOVENIA.			Turk, Boris/0000-0002-9007-5764				Barrett A. J., 1977, PROTEINASES MAMMALIA, P181; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAUDYS M, 1991, BIOMED BIOCHIM ACTA, V50, P569; BOUMA JMW, 1964, BIOCHIM BIOPHYS ACTA, V89, P545, DOI 10.1016/0926-6569(64)90082-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKLEHURST K, 1973, BIOCHEM J, V133, P573, DOI 10.1042/bj1330573; BROCKLEHURST K, 1994, PROTEIN ENG, V7, P291, DOI 10.1093/protein/7.3.291; BROMME D, 1993, J BIOL CHEM, V268, P4832; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; DAVIE EW, 1975, ANNU REV BIOCHEM, V44, P729, DOI 10.1146/annurev.bi.44.070175.004055; Dixon M., 1979, ENZYMES, Vthird; FRUTON JS, 1956, ARCH BIOCHEM BIOPHYS, V65, P11, DOI 10.1016/0003-9861(56)90172-2; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HEINRICH CP, 1968, BIOCHEMISTRY-US, V7, P3556, DOI 10.1021/bi00850a033; HUSAIN SS, 1969, BIOCHEM J, V114, P279, DOI 10.1042/bj1140279; ISHIDOH K, 1987, FEBS LETT, V226, P33, DOI 10.1016/0014-5793(87)80545-8; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; IZUMIYA N, 1956, J BIOL CHEM, V218, P59; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; LIAO JCR, 1984, BIOCHEM BIOPH RES CO, V124, P909, DOI 10.1016/0006-291X(84)91044-1; LYNN KR, 1984, CAN J BIOCHEM CELL B, V62, P1301, DOI 10.1139/o84-166; MCDONALD JK, 1969, J BIOL CHEM, V244, P6199; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCDONALD JK, 1966, J BIOL CHEM, V241, P1494; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MELLOR GW, 1993, BIOCHEM J, V294, P201, DOI 10.1042/bj2940201; METRIONE RM, 1975, BIOCHEMISTRY-US, V14, P5249, DOI 10.1021/bi00695a002; METRIONE RM, 1970, BIOCHEMISTRY-US, V9, P2427, DOI 10.1021/bi00814a006; METRIONE RM, 1966, BIOCHEMISTRY-US, V5, P1597, DOI 10.1021/bi00869a021; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; NIKAWA T, 1992, EUR J BIOCHEM, V204, P381, DOI 10.1111/j.1432-1033.1992.tb16647.x; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PLANTA RJ, 1964, BIOCHIM BIOPHYS ACTA, V89, P511, DOI 10.1016/0926-6569(64)90077-X; PLANTA RJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P443, DOI 10.1016/0006-3002(61)90469-3; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; Rosengren A, 1977, ELECTROFOCUSING ISOT, P165; Segel I. H., 1975, ENZYME KINETICS, P355; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; VANKAPERTTULA T, 1973, CLIN CHIM ACTA, V44, P249; WONG JTF, 1971, CAN J BIOCHEM CELL B, V49, P568, DOI 10.1139/o71-084	52	102	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21626	21631		10.1074/jbc.270.37.21626	http://dx.doi.org/10.1074/jbc.270.37.21626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665576	hybrid			2022-12-27	WOS:A1995RU75700033
J	HU, LQ; COLMAN, RF				HU, LQ; COLMAN, RF			MONOBROMOBIMANE AS AN AFFINITY LABEL OF THE XENOBIOTIC BINDING-SITE OF RAT GLUTATHIONE-S-TRANSFERASE-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SEQUENCE ANALYSIS; ISOENZYME 3-3; CDNA CLONE; RESOLUTION; SUBSTRATE; COMPLEX; LIVER; TYR(115)	Monobromobimane (mBBr), besides being a substrate in the presence of glutathione, inactivates rat liver glutathione S-transferase 3-3 at pH 7.5 and 25 degrees C as assayed using 1-chloro-2,4-dinitrobenzene (CDNB). The rate of inactivation is enhanced about 5-fold by S-methylglutathione. Substrate analogs bromosulfophthalein and 2,4-dinitrophenol decrease the rate of inactivation at least 20-fold. Upon incubation for 60 min with 0.25 mM mBBr and S-methylglutathione, the enzyme loses 91% of its activity toward CDNB and incorporates 2.14 mol of reagent/mol of subunit, whereas incubation under the same conditions but with added protectant 2,4-dinitrophenol yields an enzyme that is catalytically active and contains only 0.89 mol of reagent/mol of subunit. mBBr-modified enzyme is fluorescent, and fluorescence energy transfer occurs between intrinsic tryptophan and covalently bound bimane in modified enzyme. Both Tyr(115) and Cys(114) are modified, but Tyr(115) is the initial reaction target and its modification correlates with loss of activity toward CDNB. The fact that the activity toward mBBr is retained by the enzyme after modification suggests that rat isozyme 3-3 has two binding sites for mBBr.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware			Hu, Longqin/AAR-7076-2021	Hu, Longqin/0000-0002-1799-5652	NCI NIH HHS [F32 CA66276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA066276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BHARGAVA MM, 1978, J BIOL CHEM, V253, P4112; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, P62; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLMAN RF, 1984, BIOCHEMISTRY-US, V23, P3281, DOI 10.1021/bi00309a025; COOKE RJ, 1994, BIOCHEM J, V302, P383, DOI 10.1042/bj3020383; COWAN SW, 1989, J MOL BIOL, V208, P369, DOI 10.1016/0022-2836(89)90398-7; DING GJF, 1986, J BIOL CHEM, V261, P7952; DING GJF, 1985, J BIOL CHEM, V260, P3268; FAIRCLOUGH RH, 1979, METHOD ENZYMOL, V48, P347; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HU L, 1994, PROTEIN SCI, V3, P127; HUANG YC, 1984, J BIOL CHEM, V259, P2481; HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PLOEMEN JHT, 1994, J BIOL CHEM, V269, P26980; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROWE J, 1994, FASEB J, V8, pA1467; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VANDERJAGT DL, 1985, J BIOL CHEM, V260, P1603; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; WUNSCH E, 1958, CHEM BER-RECL, V91, P542, DOI 10.1002/cber.19580910312; ZALL DM, 1956, ANAL CHEM, V28, P1665, DOI 10.1021/ac60119a009	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21875	21883		10.1074/jbc.270.37.21875	http://dx.doi.org/10.1074/jbc.270.37.21875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665611	hybrid			2022-12-27	WOS:A1995RU75700071
J	LOBIE, PE; ALLEVATO, G; NIELSEN, JH; NORSTEDT, G; BILLESTRUP, N				LOBIE, PE; ALLEVATO, G; NIELSEN, JH; NORSTEDT, G; BILLESTRUP, N			REQUIREMENT OF TYROSINE-RESIDUE-333 AND TYROSINE-RESIDUE-338 OF THE GROWTH-HORMONE (GH) RECEPTOR FOR SELECTED GH-STIMULATED FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-F442A FIBROBLASTS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; KINASE; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; ADIPOCYTES; EXPRESSION	We have examined the involvement of tyrosine residues 333 and 338 of the growth hormone (GH) receptor in the cellular response to GH. Stable Chinese hamster ovary (CHO) cell clones expressing a receptor with tyrosine residues at position 333 and 338 of the receptor substituted for phenylalanine (CHO-GHR(1-638)Y333F, Y338F) were generated by cDNA transfection. Compared with the wild type receptor the Y333F,Y338F mutant possessed normal high affinity ligand binding, hormone internalization, and ligand-induced receptor down-regulation. GH activation of mitogen associated protein kinase was also similar in CHO clones expressing similar wild type and Y333F,Y338F receptor number. However, two GH-regulated cellular events (lipogenesis, and protein synthesis) were deficient in the tyrosine substituted receptor. In contrast, transcriptional regulation by GH (as evidenced by chloramphenicol acetyltransferase cDNA expression driven by the GH-responsive region of the SPI 2.1 gene) was not affected by Y333F,Y338F substitution. Thus we provide the first experimental evidence that specific tyrosine residues of the GH receptor are required for selected cellular responses to GH.	HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	Novo Nordisk; Hagedorn Research Institute	LOBIE, PE (corresponding author), KAROLINSKA INST, NOVUM, INST MED NARINGSLARA, S-14186 HUDDINGE, SWEDEN.			Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067				AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BILLESTRUP N, 1994, P SOC EXP BIOL MED, V206, P205; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Catalioto RM, 1992, GROWTH FACTORS, V6, P255, DOI 10.3109/08977199209021538; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; ENBERG B, 1994, J MOL ENDOCRINOL, V12, P39, DOI 10.1677/jme.0.0120039; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOSTYO JL, 1971, ENDOCRINOLOGY, V88, P1054, DOI 10.1210/endo-88-4-1054; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; LOBIE PE, 1994, ACTA PAEDIATR, V83, P39, DOI 10.1111/j.1651-2227.1994.tb13420.x; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MARTIN TE, 1965, NATURE, V208, P684, DOI 10.1038/208684a0; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1994, MOL CELL ENDOCRINOL, V99, P111, DOI 10.1016/0303-7207(94)90153-8; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PALEN E, 1987, J BIOL CHEM, V262, P3518; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SINGH H, 1993, GEN COMP ENDOCR, V89, P341, DOI 10.1006/gcen.1993.1042; SLIVA D, 1994, J BIOL CHEM, V269, P26208; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YOON JB, 1990, J BIOL CHEM, V265, P19947	62	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21745	21750		10.1074/jbc.270.37.21745	http://dx.doi.org/10.1074/jbc.270.37.21745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665593	hybrid			2022-12-27	WOS:A1995RU75700052
J	PAN, ZQ; REARDON, JT; LI, L; FLORESROZAS, H; LEGERSKI, R; SANCAR, A; HURWITZ, J				PAN, ZQ; REARDON, JT; LI, L; FLORESROZAS, H; LEGERSKI, R; SANCAR, A; HURWITZ, J			INHIBITION OF NUCLEOTIDE EXCISION-REPAIR BY THE CYCLIN-DEPENDENT KINASE INHIBITOR P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; P53 PROTEIN; EPSILON; ORIGIN; COMPLEMENTATION; ACTIVATOR-1; INITIATION	p21, a p53-induced gene product that blocks cell cycle progression at the G(1) phase, interacts with both cyclin-dependent kinases and proliferating cell nuclear antigen (PCNA). PCNA functions as a processivity factor for DNA polymerases delta and epsilon and is required for both DNA replication and nucleotide excision repair. Previous studies have shown that p21 inhibits simian virus 40 (SV40) DNA replication in HeLa cell extracts by interacting with PCNA. In this report we show that p21 blocks nucleotide excision repair of DNA that has been damaged by either ultraviolet radiation or alkylating agents, and that this inhibition can be reversed following addition of PCNA. We have determined that p21 is more effective in blocking DNA resynthesis than in inhibiting the excision step. We further show that a peptide derived from the carboxyl terminus of p21, which specifically interacts with PCNA, inhibits polymerase delta-catalyzed elongation of DNA chains almost stoichiometrically relative to the concentration of PCNA. When added at higher levels, this peptide also blocks both SV40 DNA replication and nucleotide excision repair in HeLa cell extracts. These results indicate that p21 interferes with the function of PCNA in both in vitro DNA replication and nucleotide excision repair.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; UTMD Anderson Cancer Center	PAN, ZQ (corresponding author), MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, 1275 YORK AVE, BOX 97, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA52461] Funding Source: Medline; NIGMS NIH HHS [GM38559, GM32833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN J, 1995, NATURE, V374, P336; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRIEDBERG EC, 1995, DNA REPAIR; FRITSCHE M, 1993, ONCOGENE, V8, P307; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LANDEGENT JE, 1984, EXP CELL RES, V153, P61, DOI 10.1016/0014-4827(84)90448-8; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LEE SH, 1989, P NATL ACAD SCI USA, V85, P9469; LEGERSKI RJ, 1977, J BIOL CHEM, V252, P8740; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, IN PRESS J BIOL CHEM; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1994, CURR BIOL, V12, P1062; SIBGHATULLAH, 1990, BIOCHEMISTRY-US, V29, P5711, DOI 10.1021/bi00476a011; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	57	162	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22008	22016		10.1074/jbc.270.37.22008	http://dx.doi.org/10.1074/jbc.270.37.22008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665622	Green Published, hybrid			2022-12-27	WOS:A1995RU75700087
J	FOHR, UG; HEIZMANN, CW; ENGELKAMP, D; SCHAFER, BW; COX, JS				FOHR, UG; HEIZMANN, CW; ENGELKAMP, D; SCHAFER, BW; COX, JS			PURIFICATION AND CATION-BINDING PROPERTIES OF THE RECOMBINANT HUMAN S100 CALCIUM-BINDING PROTEIN A3, AN EF-HAND MOTIF PROTEIN WITH HIGH-AFFINITY FOR ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-100 PROTEIN; IDENTIFICATION; CALMODULIN; CALCYCLIN; CA-2+; GENE	The calcium-binding protein S100A3 is an unusual member of the S100 family, characterized by its very high content of Cys. In order to study the biochemical, cation-binding, and conformational properties, we produced and purified the recombinant human protein in Escherichia coli. The recombinant protein forms noncovalent homodimers, tetramers, and polymers in vitro with a subunit molecular weight of 11,712. The Zn2+- binding parameters of S100A3 were studied by equilibrium gel filtration and yielded a stoichiometry of four Zn2+ per monomer with a [Zn2+](0.5) of 11 mu M and a Hill coefficient of 1.4 at physiological ionic strength. The affinity for Ca2+ is too low to be determined by direct methods (K-Ca > 10 mM). Ca2+- and Zn2+-binding can be followed by optical methods: the Trp-45 fluorescence is high in the metal-free form and addition of Zn2+ and Ca2+, but not of Mg2+, leads to a 4-fold quenching. Ca2+ and Zn2+ promote also quite similar conformational changes in the Tyr and Trp environment as monitored by difference spectrophotometry. Fluorescence titrations with Zn2+ confirmed that there is one set of high affinity binding sites with a [Zn2+](0.5) of 8 mu M and a Hill coefficient of 1.3. Binding of Zn2+ to a second set of low affinity sites induces protein precipitation. Fluorescence titrations with Ca2+ confirmed the very low affinity of S100A3 for this ion with a [Ca2+](0.5) of 30 mM and slight negative cooperativity. Mg2+ has no effect on this binding curve. Of the 10 Cys residues in S100A3, 5 only are free thiols, and accessible to 5,5'-dithiobis(2-nitrobenzoic acid); they display a high reactivity in the metal-free and Ca2+ form, but a 20-fold lowered reactivity in the Zn2+ form of S100A3. Ca2+-binding promotes the formation of a solvent-accessible hydrophobic surface as monitored by the 60-fold fluorescence increase of 2-p- toluidinylnaphthalene-6-sulfonate, whereas Zn2+ has no noticeable influence. Our data indicate that Ca2+ and Zn2+ do not bind to the same sites and that under physiological conditions S100A3 is a Zn2+-binding rather than a Ca2+-binding protein; nevertheless, very specific conformational changes are introduced by either Ca2+ or Zn2+. Since no Zn2+ binding motif of known structure was identified in the primary sequence of S100A3, the results are suggestive for a novel Zn2+-binding motif.	UNIV ZURICH, DEPT PEDIAT, DIV CLIN CHEM, CH-8032 ZURICH, SWITZERLAND; UNIV GENEVA, DEPT BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND	University of Zurich; University of Geneva				Schafer, Beat/0000-0001-5988-2915				BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; COX JA, 1994, J BIOL CHEM, V269, P32807; DAVIES BR, 1993, ONCOGENE, V8, P999; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P6089, DOI 10.1021/bi00074a021; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Heizmann C. W., 1995, CALCIUM REGULATION C; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HOMMEL U, 1944, NAT STRUCT BIOL, V1, P384; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ILICH P, 1988, BIOPHYS CHEM, V29, P341, DOI 10.1016/0301-4622(88)85056-7; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LEUNG IKM, 1987, FEBS LETT, V214, P35, DOI 10.1016/0014-5793(87)80008-X; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PEREZALVARADO G, 1944, NAT STRUCT BIOL, V1, P389; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwabe JWR, 1994, STRUCT BIOL, V1, P345; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9	37	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21056	21061		10.1074/jbc.270.36.21056	http://dx.doi.org/10.1074/jbc.270.36.21056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673133	hybrid			2022-12-27	WOS:A1995RU05400031
J	TAWFIC, S; OLSON, MOJ; AHMED, K				TAWFIC, S; OLSON, MOJ; AHMED, K			ROLE OF PROTEIN-PHOSPHORYLATION IN POSTTRANSLATIONAL REGULATION OF PROTEIN B23 DURING PROGRAMMED CELL-DEATH IN THE PROSTATE-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX PROTEIN; RAT VENTRAL PROSTATE; NUMATRIN B23; PROLIFERATION; INDUCTION; APOPTOSIS; GENE; IDENTIFICATION; KINASE; PHOSPHOPROTEIN-B23	Protein B23 is a nucleolar and nuclear matrix-associated phosphoprotein that is involved in ribosome synthesis, Its expression and phosphorylation in rat ventral prostate, an androgen target organ, are profoundly influenced by androgens, Induction of programmed cell death (apoptosis) in the prostatic epithelium by androgen deprivation in the animal induces an early decline in protein B23 in the absence of a corresponding loss of protein B23 mRNA. We have now demonstrated that prostatic nuclei retain the ability to transcribe the B23 mRNA and that a significant amount of this mRNA persists even after 7 days of androgen deprivation when >80% of the prostatic epithelial cells have undergone apoptosis. The B23 mRNA from these nuclei is also translatable in vitro. However, the majority of the B23 mRNA is associated with free and short stretch polysomes, which may account for the castration-induced decline in synthesis of protein B23 in vivo. In addition, the mechanism of down-regulation of protein B23 in apoptotic prostatic cells appears to relate to two coordinate signals, which include loss of phosphorylation of the protein as well as the expression of a protease active toward dephosphorylated protein B23, under these conditions.	UNIV MINNESOTA, DEPT VET AFFAIRS MED CTR, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT VET AFFAIRS MED CTR, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55417 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center					NATIONAL CANCER INSTITUTE [R01CA015062, R37CA015062, U01CA015062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028349] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15062] Funding Source: Medline; NIGMS NIH HHS [GM-28349] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED K, 1993, CELL MOL BIOL RES, V39, P451; BERGES R, 1993, CLIN CHEM, V39, P356; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; INGBER DE, 1993, J CELL SCI, V104, P613; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; MAINWARING WI, 1973, BIOCHEM J, V134, P795, DOI 10.1042/bj1340795; MAINWARING WIP, 1983, J STEROID BIOCHEM, V19, P101, DOI 10.1016/S0022-4731(83)80012-0; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OLSON MOJ, 1975, J MOL BIOL, V97, P611, DOI 10.1016/S0022-2836(75)80062-3; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; SMYTH MJ, 1994, CLIN EXP PHARMACOL P, V21, P67, DOI 10.1111/j.1440-1681.1994.tb02438.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1994, J BIOL CHEM, V269, P24615; TAWFIC S, 1993, CELL MOL BIOL RES, V39, P43; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; WANG DR, 1994, J BIOL CHEM, V269, P30994; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1992, LIFE SCI, V51, P915, DOI 10.1016/0024-3205(92)90399-A	50	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21009	21015		10.1074/jbc.270.36.21009	http://dx.doi.org/10.1074/jbc.270.36.21009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673126	hybrid			2022-12-27	WOS:A1995RU05400023
J	BARWELL, JA; BOCHKAREV, A; PFUETZNER, RA; TONG, H; YANG, DSC; FRAPPIER, L; EDWARDS, AM				BARWELL, JA; BOCHKAREV, A; PFUETZNER, RA; TONG, H; YANG, DSC; FRAPPIER, L; EDWARDS, AM			OVEREXPRESSION, PURIFICATION, AND CRYSTALLIZATION OF THE DNA-BINDING AND DIMERIZATION DOMAINS OF THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; EBNA-1; CELLS; ENHANCER; PROMOTER; PROTEIN; ORIGIN	The Epstein-Barr virus nuclear antigen (EBNA) 1 binds to and activates DNA replication from the latent origin of Epstein-Barr virus. Six different fragments of EBNA1 that retain DNA binding activity were expressed in bacteria, purified, and crystallized. Two fragments, EBNA(470-619) and EBNA(470-607), formed well ordered crystals that diffracted beyond 2.5-Angstrom resolution. Two different EBNA(470-619) crystals were grown from sodium formate, pH 6-6.5. One crystal belonged to the trigonal space group 3 with unit cell dimensions a = b = 86.5 Angstrom and c = 31.8 Angstrom and with two molecules in the asymmetric unit. The other crystal, which appeared only twice and was likely related to the P3 crystal form, belonged to the trigonal space group P312 with cell dimensions a = b = 86.7 Angstrom and c = 31.8 Angstrom. Crystals of EBNA(470-607) were grown by lowering the salt concentration to 0-100 mM NaCl at pH 6.0. These crystals belonged to the orthorhombic space group P2(1)2(1)2(1) and had cell dimensions a = 59 Angstrom, b = 66.9 Angstrom, and c = 69.8 Angstrom with two molecules in the asymmetric unit.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8S 4B2,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; HEMMING SA, 1995, J MOL BIOL, V246, P308, DOI 10.1006/jmbi.1994.0086; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	18	29	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20556	20559		10.1074/jbc.270.35.20556	http://dx.doi.org/10.1074/jbc.270.35.20556			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657632	hybrid			2022-12-27	WOS:A1995RR58400051
J	HUANG, XF; ARVAN, P				HUANG, XF; ARVAN, P			INTRACELLULAR-TRANSPORT OF PROINSULIN IN PANCREATIC BETA-CELLS - STRUCTURAL MATURATION PROBED BY DISULFIDE ACCESSIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; BREFELDIN-A; SECRETORY PATHWAY; PROTEIN-TRANSPORT; TREATED CELLS; INSULIN; OCCURS; GOLGI; ZINC	In pancreatic islets, formation of beta-secretory granule cores involves early proinsulin homohexamerization and subsequent insulin condensation. We examined proinsulin conformational maturation by monitoring accessibility of protein disulfide bonds. Proinsulin disulfides are intact immediately upon synthesis, but are greater than or equal to 90% sensitive to in vivo reduction with 2 mM dithiothreitol; wash out of dithiothreitol leads to reoxidation, proinsulin transport, and conversion to insulin. With t(1/2) similar to 10 min, newly synthesized proinsulin becomes resistant to disulfide reduction, correlating with endoplasmic reticulum (ER) export. However, inhibition of ER export with brefeldin A blocks acquisition of resistance to reduction, and once proinsulin arrives in the Golgi, it resists reduction despite brefeldin treatment, Moreover, in vivo, resistance of proinsulin disulfides is overcome after increasing [dithiothreitol] > 10-fold, or in vitro, in islets lysed in a zinc-free, but not a zinc-containing, medium. Employing 30 mM dithiothreitol in vivo, a further decrease in disulfide accessibility is observed following proinsulin conversion to insulin. Incubation of islets with chloroquine or zinc enhances and diminishes accessibility of insulin disulfides, respectively. We hypothesize that two major conformational changes culminating in granule core formation, proinsulin hexamerization and insulin condensation, are sensitive to zinc and occur upon ER exit and arrival in immature secre tory granules, respectively.	BETH ISRAEL HOSP,DIV ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35209	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BENTLEY GA, 1992, J MOL BIOL, V228, P1163, DOI 10.1016/0022-2836(92)90323-C; BEWLEY TA, 1969, INT J PROT RES, V1, P117; Blundell T L, 1971, Recent Prog Horm Res, V27, P1; BLUNDELL TL, 1972, DIABETES, V21, P492, DOI 10.2337/diab.21.2.S492; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHEN SY, 1991, J VIROL, V65, P1427, DOI 10.1128/JVI.65.3.1427-1439.1991; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; COLLINS PL, 1992, J GEN VIROL, V73, P849, DOI 10.1099/0022-1317-73-4-849; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FARQUHAR MG, 1978, ENDOCRINOLOGY, V102, P296, DOI 10.1210/endo-102-1-296; FRANK BH, 1968, BIOCHEM BIOPH RES CO, V32, P155, DOI 10.1016/0006-291X(68)90362-8; FRANK BH, 1970, BIOCHEM BIOPH RES CO, V38, P284, DOI 10.1016/0006-291X(70)90710-2; FREEDMAN SD, 1993, EUR J CELL BIOL, V61, P229; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; GRANT PT, 1972, BIOCHEM J, V126, P433, DOI 10.1042/bj1260433; GRUPPUSO PA, 1984, NEW ENGL J MED, V311, P629, DOI 10.1056/NEJM198409063111003; HOSHINA H, 1982, P NATL ACAD SCI-BIOL, V79, P7649, DOI 10.1073/pnas.79.24.7649; HOWELL SL, 1969, J CELL BIOL, V42, P695, DOI 10.1083/jcb.42.3.695; HUANG XF, 1994, J BIOL CHEM, V269, P20838; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JEFFREY PD, 1966, BIOCHEMISTRY-US, V5, P489, DOI 10.1021/bi00866a014; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MEANS GE, 1971, CHEM MODIFICATION PR, P37; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PALADE GE, 1975, SCIENCE, V230, P25; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; RUSS G, 1991, CELL REGUL, V2, P549, DOI 10.1091/mbc.2.7.549; SALPETER MM, 1981, J CELL BIOL, V91, P240, DOI 10.1083/jcb.91.1.240; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STEINER DF, 1986, CLIN INVEST MED, V9, P328; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028	58	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20417	20423		10.1074/jbc.270.35.20417	http://dx.doi.org/10.1074/jbc.270.35.20417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657617	hybrid			2022-12-27	WOS:A1995RR58400030
J	MASSON, L; LUN, YJ; MAZZA, A; BROUSSEAU, R; ADANG, MJ				MASSON, L; LUN, YJ; MAZZA, A; BROUSSEAU, R; ADANG, MJ			THE CRYIA(C) RECEPTOR PURIFIED FROM MANDUCA-SEXTA DISPLAYS MULTIPLE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; THURINGIENSIS DELTA-ENDOTOXINS; SURFACE-PLASMON RESONANCE; BUTTERFLY PIERIS-BRASSICAE; PLANAR LIPID BILAYERS; BACILLUS-THURINGIENSIS; SELECTIVE CHANNELS; BINDING-SITES; BOMBYX-MORI; PROTEINS	The kinetic binding characteristics of four Bacillus thuringiensis CryI insecticidal crystal proteins to a Cry-binding protein, purified from Manduca sexta brush-border vesicles, were analyzed by an optical biosensor. This 120-kilodalton binding protein, previously determined to be aminopeptidase N, was converted to a 115-kilodalton water-soluble form by removing the attached glycosylphosphatidylinositol anchor with phospholipase C. The solubilized form recognized the three major subclasses of CryIA toxins but not CryIC even though all four CryI proteins are toxic to larvae of M. sexta. CryIA(a) and CryIA(b) toxins bound to a single site on the solubilized aminopeptidase N molecule whereas CryIA(c) bound to two distinct sites. Apparent kinetic rate constants were determined for each binding reaction. All three CryIA toxins exhibited moderately fast on rates (similar to 10(-5) M(-1) s(-1)) and a slow reversible off rate (similar to 10(-3) s(-1)). Although the second CryIA(c)-binding site retained a moderately fast association rate, it was characterized by a rate of dissociation from the aminopeptidase an order of magnitude faster than observed for the other CryIA-binding sites. CryIA(c) binding to both sites was strongly inhibited in the presence of N-acetylgalactosamine (IC50 = 5 mM) but not N-acetylglucosamine, mannose, or glucose. CryIA(a) and CryIA(b) binding were unaffected in the presence of the same sugars. Our results serve to illustrate both the complexity and the diverse nature of toxin interactions with Cry-binding proteins.	UNIV GEORGIA, DEPT ENTOMOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia	MASSON, L (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 ROYALMOUNT AVE, MONTREAL, PQ H4P 2R2, CANADA.							ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; BORISOVA S, 1994, J MOL BIOL, V243, P530, DOI 10.1006/jmbi.1994.1678; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; ESTADA U, 1994, APPL ENVIRON MICROB, V60, P3840, DOI 10.1128/AEM.60.10.3840-3846.1994; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FENG Q, 1994, BIOCHEMISTRY-US, V33, P8521, DOI 10.1021/bi00194a017; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; GROCHULSKI P, 1994, 6TH INT C INV PATH M; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INDRASITH LS, 1992, COMP BIOCHEM PHYS B, V102, P605, DOI 10.1016/0305-0491(92)90054-U; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KNOWLES BH, 1986, J CELL SCI, V83, P89; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MARTINEZRAMIREZ AC, 1994, BIOCHEM BIOPH RES CO, V201, P782, DOI 10.1006/bbrc.1994.1769; MASSON L, 1990, BIOCHEM J, V269, P507, DOI 10.1042/bj2690507; MASSON L, 1995, J BIOL CHEM, V270, P11887, DOI 10.1074/jbc.270.20.11887; MASSON L, 1994, MOL MICROBIOL, V14, P851, DOI 10.1111/j.1365-2958.1994.tb01321.x; MASSON L, 1994, ANAL BIOCHEM, V218, P405, DOI 10.1006/abio.1994.1199; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; ODDOU P, 1993, EUR J BIOCHEM, V212, P145, DOI 10.1111/j.1432-1033.1993.tb17644.x; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PFANNENSTIEL MA, 1987, J BACTERIOL, V169, P796, DOI 10.1128/jb.169.2.796-801.1987; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TABASHNIK BE, 1994, P NATL ACAD SCI USA, V91, P4120, DOI 10.1073/pnas.91.10.4120; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; VANFRANKENHUYZEN K, 1993, J INVERTEBR PATHOL, V62, P295, DOI 10.1006/jipa.1993.1116; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475, DOI 10.1007/BF01954236	48	135	152	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20309	20315		10.1074/jbc.270.35.20309	http://dx.doi.org/10.1074/jbc.270.35.20309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657602	hybrid			2022-12-27	WOS:A1995RR58400015
J	BISAHA, JG; SIMON, TC; GORDON, JI; BRESLOW, JL				BISAHA, JG; SIMON, TC; GORDON, JI; BRESLOW, JL			CHARACTERIZATION OF AN ENHANCER ELEMENT IN THE HUMAN APOLIPOPROTEIN C-III GENE THAT REGULATES HUMAN APOLIPOPROTEIN-A-I GENE-EXPRESSION IN THE INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL INTESTINE; HORMONE RECEPTOR SUPERFAMILY; CIS-ACTING ELEMENTS; E MESSENGER-RNA; STEM-CELL ZONE; TRANSGENIC MICE; GUT EPITHELIUM; PLASMA-LEVELS; MUCOUS CELLS; PANETH CELLS	Studies using transgenic mice indicate that expression of the human apolipoprotein (ape) A-I gene in the liver and small intestine is controlled by spatially distinct cis-acting DNA elements; hepatic expression is controlled by a domain defined by nucleotides -256 to -1, while small intestinal expression requires elements positioned 9 kilobases 3' to the gene, between nucleotides -1300 and -200 of the convergently transcribed apoC-III gene, In this report we have mapped this enhancer to a 260-base pair (bp) region of the apoC-III promoter spanning nucleotides -780 to -520, The elements contained within this 260-bp apoC-III domain are sufficient to direct a pattern of expression in villus-associated enterocytes distributed along the duodenal-to-ileal axis that resembles that of mouse and human apoA-I. However, the elements produce inappropriate activation of apoA-I expression in proliferating and nonproliferating crypt epithelial cells, and in subpopulations of cholecystokinin- and serotonin-producing enteroendocrine cells, Cis-acting suppressors of these inappropriate patterns of expression are located outside of nucleotides -1300 to -200 of the human apoC-III gene, DNase I protection and gel mobility gel shift assays identified two 21-bp sequences, nucleotides -745 to -725 and -700 to -680 of human apoC-III, which bind nuclear proteins present in a human enterocyte-like cell line (Caco-2), These sequences are conserved in the orthologous mouse apoC-III gene, The 260-bp apoC-III element is the first intestinal enhancer that has been identified in an in vivo system and should provide insights about how cell lineage-specific, differentiation-dependent, and cephalocaudal patterns of gene expression are established and maintained in the perpetually renewing gut epithelium, In addition, novel intestinal transcription factors may bind to the enhancer and regulate its activity.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Rockefeller University; Washington University (WUSTL)			Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008695, R01HL033714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08695, HL33714] Funding Source: Medline; NIDDK NIH HHS [DK30292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; AZROLAN N, 1990, J LIPID RES, V31, P1141; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; GE RW, 1994, J BIOL CHEM, V269, P13185; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREEN PHR, 1982, GASTROENTEROLOGY, V83, P1223; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAUER SJ, 1991, CIRCULATION S2, V84, P17; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OPRINS A, 1994, J HISTOCHEM CYTOCHEM, V42, P497, DOI 10.1177/42.4.8126376; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	51	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19979	19988		10.1074/jbc.270.34.19979	http://dx.doi.org/10.1074/jbc.270.34.19979			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650015	hybrid			2022-12-27	WOS:A1995RQ99100048
J	NATHAN, BP; CHANG, KC; BELLOSTA, S; BRISCH, E; GE, NF; MAHLEY, RW; PITAS, RE				NATHAN, BP; CHANG, KC; BELLOSTA, S; BRISCH, E; GE, NF; MAHLEY, RW; PITAS, RE			THE INHIBITORY EFFECT OF APOLIPOPROTEIN E4 ON NEURITE OUTGROWTH IS ASSOCIATED WITH MICROTUBULE DEPOLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC ALZHEIMERS-DISEASE; RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; CHOLESTEROL TRANSPORT; E APOPROTEIN; CELLS; LIPOPROTEINS; BINDING; ALLELE; BRAIN	Evidence is presented for the differential effects of two isoforms of apolipoprotein (ape) E, apoE3 and apoE4, on neurite outgrowth and on the cytoskeleton of neuronal cells (Neuro aa) in culture. in the presence of a lipid source, apoE3 enhances and apoE4 inhibits neurite outgrowth. Immunocytochemical studies demonstrate that there is a higher concentration of apoE3 than apoE4 in both the cell bodies and neurites. Cells treated with apoE4 showed fewer microtubules and a greatly reduced ratio of polymerized to monomeric tubulin than did cells treated with apoE3. The effect of apoE4 on depolymerization of microtubules was shown by biochemical, immunocytochemical, and ultrastructural studies. The depolymerization of microtubules and the inhibition of neurite outgrowth associated with apoE4 suggest a mechanism whereby apoE4, which has been linked to the pathogenesis of Alzheimer's disease, may prevent normal neuronal remodeling from occurring later in life, when this neurodegenerative disorder develops.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV KANSAS,DEPT PHYSIOL & CELL BIOL,DIV BIOL SCI,LAWRENCE,KS 66045	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Kansas			Bellosta, Stefano/B-4473-2010	Bellosta, Stefano/0000-0001-5344-7824	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVILA J, 1994, CELL BIOL INT, V18, P309, DOI 10.1006/cbir.1994.1079; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BROWNING PJ, 1994, J EXP MED, V180, P1949, DOI 10.1084/jem.180.5.1949; BU GJ, 1994, J BIOL CHEM, V269, P18521; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS HK, 1985, J BIOL CHEM, V260, P6240; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUANG DY, 1994, NEUROSCI LETT, V182, P55, DOI 10.1016/0304-3940(94)90204-6; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IQBAL K, 1986, LANCET, V2, P421; KEITH CH, 1990, CELL MOTIL CYTOSKEL, V17, P95, DOI 10.1002/cm.970170205; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MANDELKOW EM, 1983, TRENDS BIOCHEM SCI, V18, P480; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PERRY G, 1987, ALTERATIONS NEURONAL; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REBECK GW, 1993, NEURON, V11, P575; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHEA TB, 1992, J NEUROSCI RES, V32, P363, DOI 10.1002/jnr.490320308; SHEA TB, 1990, CELL BIOL INT REP, V14, P1093, DOI 10.1016/0309-1651(90)90017-S; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; TIWARI SC, 1993, ANAL BIOCHEM, V215, P96, DOI 10.1006/abio.1993.1560; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; YAN SCB, 1985, NEUROCHEM RES, V10, P1, DOI 10.1007/BF00964768; YU WQ, 1994, J NEUROSCI, V14, P5872	48	243	252	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19791	19799		10.1074/jbc.270.34.19791	http://dx.doi.org/10.1074/jbc.270.34.19791			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649988	Green Submitted, hybrid			2022-12-27	WOS:A1995RQ99100020
J	TINI, M; FRASER, RA; GIGUERE, V				TINI, M; FRASER, RA; GIGUERE, V			FUNCTIONAL INTERACTIONS BETWEEN RETINOIC ACID RECEPTOR-RELATED ORPHAN NUCLEAR RECEPTOR (ROR-ALPHA) AND THE RETINOIC ACID RECEPTORS IN THE REGULATION OF THE GAMMA-F-CRYSTALLIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LENS DEVELOPMENT; THYROID-HORMONE; RESPONSIVE ELEMENT; BINDING-SITE; NGFI-B; IDENTIFICATION; GENE; TRANSCRIPTION; EXPRESSION; INDUCTION	We have previously demonstrated that an everted repeat of the hexamer PuGGTCA located within the gamma F-crystallin promoter mediates activation of the murine gamma F-crystallin gene by retinoic acid and thyroid hormone receptors. Here, we show that the recently identified retinoic acid receptor-related orphan nuclear receptor (ROR alpha) is expressed in the murine lens and activates the gamma F-crystallin promoter. In contrast 60 the retinoic acid and thyroid hormone receptors, activation of the gamma F-crystallin promoter by ROR alpha requires binding to the single 3' half-site and spacer sequences of gamma F-crystallin hormone response element (gamma F-HRE). We further demonstrate that ROR alpha-dependent activation is repressed by the competitive binding of retinoic acid receptor/retinoid X receptor heterodimers to the gamma F-HRE in the absence of all-trans-retinoic acid. These studies suggest that the interplay of retinoid receptors and ROR alpha on the gamma F-HRE may constitute an important mechanism regulating gamma F-crystallin gene expression in the murine lens.	ROYAL VICTORIA HOSP,MOLEC ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University			, MT/AAU-2370-2020	Giguere, Vincent/0000-0001-9567-3694				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARTER ME, 1993, J BIOL CHEM, V268, P13805; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COULOMBRE JL, 1963, SCIENCE, V142, P1489, DOI 10.1126/science.142.3598.1489; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; REYER RW, 1977, EXP EYE RES, V24, P501, DOI 10.1016/0014-4835(77)90271-8; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YAMAMOTO Y, 1976, DEV GROWTH DIFFER, V18, P273	40	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20156	20161		10.1074/jbc.270.34.20156	http://dx.doi.org/10.1074/jbc.270.34.20156			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650034	hybrid			2022-12-27	WOS:A1995RQ99100071
J	VERGERES, G; MANENTI, S; WEBER, T; STURZINGER, C				VERGERES, G; MANENTI, S; WEBER, T; STURZINGER, C			THE MYRISTOYL MOIETY OF MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) AND MARCKS-RELATED PROTEIN IS EMBEDDED IN THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; DEPENDENT BINDING; BOVINE BRAIN; PHOSPHORYLATION; RECEPTOR; AFFINITY; FAMILY; CELLS; TRANSFORMATION; MYRISTYLATION	Members of the myristoylated alanine-rich protein kinase C substrate (MARCKS) family are involved in several cellular processes such as secretion, motility, mitosis, and transformation, In addition to their ability to bind calmodulin and to cross-link actin filaments, reversible binding to the plasma membrane is most certainly an important component of the so far unknown functions of these proteins, We have therefore investigated the binding of murine MARCKS-related protein (MRP) to lipid vesicles, The partition coefficient, K-p, describing the affinity of myristoylated MRP for acidic lipid vesicles (20% phosphatidylserine, 80% phosphatidylcholine) is 5-8 x 10(3) M(-1), which is only 2-4 times larger than the partition coefficient for the unmyristoylated protein, Interestingly, the affinity of MRP for acidic lipid membranes is 20-30-fold smaller than reported for murine MARCKS (Rim, J., Shishido, T,, Jiang, X, Aderem, A, A, and McLaughlin, S, (1994) J. Biol, Chem. 269, 28214-28219), Since only a marginal binding could be observed with neutral phosphatidylcholine vesicles, we propose that electrostatic interactions are the major determinant of the binding of MRP to pure lipid membranes. Although the myristoyl moiety does not contribute drastically to the binding of MRP to vesicles, photolabeling experiments with a photoreactive phospholipid probe show that the fatty acid is embedded in the bilayer, The same membrane topology was found for bovine brain MARCKS, Since the relatively low affinity of MRP for vesicles is insufficient to account for a stable anchoring of the protein to cellular membranes, insertion of the myristoyl moiety into the bilayer might favor the interaction of MRP with additional factors required for the binding of the protein to intracellular membranes.	ETH ZURICH,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	VERGERES, G (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014; Weber, Thomas/A-2363-2008; Weber, Thomas/GLS-9125-2022	manenti, stephane/0000-0002-4793-3196; Weber, Thomas/0000-0002-0494-0484; Weber, Thomas/0000-0002-0494-0484				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLENIS J, 1992, CUR OPIN CELL BIOL, V119, P984; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DENKAMP JAF, 1981, MEMBRANE STRUCTURE, P83; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HARRIS MPG, 1994, J MOL BIOL, V241, P136; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG M, 1994, J VIROL, V68, P5648, DOI 10.1128/JVI.68.9.5648-5655.1994; JAMES G, 1989, J BIOL CHEM, V264, P20928; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MOENCH SJ, 1994, BIOCHEMISTRY-US, V17, P5791; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSE SD, 1994, J NEUROCHEM, V63, P2314; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VERGERES G, 1995, SIGNAL MECHANISMS H, V92, P125; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X	55	75	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19879	19887		10.1074/jbc.270.34.19879	http://dx.doi.org/10.1074/jbc.270.34.19879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650001	hybrid			2022-12-27	WOS:A1995RQ99100033
J	BACHURSKI, CJ; PRYHUBER, GS; GLASSER, SW; KELLY, SE; WHITSETT, JA				BACHURSKI, CJ; PRYHUBER, GS; GLASSER, SW; KELLY, SE; WHITSETT, JA			TUMOR-NECROSIS-FACTOR-ALPHA INHIBITS SURFACTANT PROTEIN-C GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; TRANSGENIC MICE; PHORBOL ESTER; MOLECULAR-CLONING; FACTOR RECEPTORS; EXPRESSION; ADHESION; ELEMENTS; MOUSE; CYTOKINES	Pulmonary surfactant protein C (SP-C) is a 3.7-kDa, hydrophobic peptide secreted by alveolar type II epithelial cells. SP-C enhances surface tension lowering activity of surfactant phospholipids that is critical to the maintenance of alveolar volume at end expiration. The proinflammatory cytokine, tumor necrosis factor alpha (TNF-alpha), decreased SP-C mRNA within 24 h of intratracheal administration to mice. In vitro, TNF-alpha decreased SP-C mRNA in a time- and dose-dependent manner, reducing the steady state levels of SP-C mRNA by 3-5-fold. In contrast, TNF-alpha induced intercellular adhesion molecule-1 expression in both mouse lung and murine lung epithelial cell lines. Nuclear run-on analysis demonstrated that transcription of both the endogenous SP-C gene and a human SP-C promoter-driven transgene was inhibited by TNF-alpha. TNF-alpha decreased mouse SP-C chloramphenicol acetyltransferase mRNA in stably transfected murine lung epithelial cells, Deletion analysis of the SP-C promoter region demonstrated that TNF-alpha inhibited gene expression in constructs containing 320 base pairs 5' from the start of transcription of the mouse SP-C gene. Inhibition of surfactant protein C gene transcription by TNF-alpha may contribute to the abnormalities of surfactant homeostasis associated with pulmonary injury and infection.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center				Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07752, HL40043] Funding Source: Medline; NICHD NIH HHS [HD07200] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGITZ K, 1991, J BIOL CHEM, V206, P14024; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MULLIGAN MS, 1993, AM J PATHOL, V142, P1739; PRYHUBER GS, 1994, AM J PHYSIOL, V267, pL16, DOI 10.1152/ajplung.1994.267.1.L16; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; ULICH TR, 1991, AM J PATHOL, V138, P1485; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929	39	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19402	19407		10.1074/jbc.270.33.19402	http://dx.doi.org/10.1074/jbc.270.33.19402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642621	hybrid			2022-12-27	WOS:A1995RP70300035
J	LOPEZ, I; BURNS, DJ; LAMBETH, JD				LOPEZ, I; BURNS, DJ; LAMBETH, JD			REGULATION OF PHOSPHOLIPASE-D BY PROTEIN-KINASE-C IN HUMAN NEUTROPHILS - CONVENTIONAL ISOFORMS OF PROTEIN-KINASE-C PHOSPHORYLATE A PHOSPHOLIPASE D-RELATED COMPONENT IN THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PHOSPHATIDYLCHOLINE HYDROLYSIS; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHORBOL ESTERS; D ACTIVATION; HL-60 CELLS; CALCIUM; OVEREXPRESSION; MECHANISM	In a variety of intact cells, phorbol esters are known to activate phospholipase D. In a cell-free system consisting of plasma membrane and cytosol from human neutrophils, phorbol esters activated phospholipase D in an adenosine nucleotide triphosphate-dependent manner. ATP gamma S (adenosine 5'-O-(thiotriphosphate)) was 2-3-fold more effective than ATP, while ADP and AppNHp (adenyl-5'-yl imidodiphosphate) were ineffective, and activation was blocked by the kinase inhibitor staurosporine, In cytosol depleted of protein kinase C by chromatography on threonine Sepharose, phorbol ester-dependent activation was lost, but was restored upon addition of purified rat brain protein kinase C, The target for phosphorylation was shown to be the plasma membrane: plasma membrane was phosphorylated using ATP gamma S/phorbol 12,13-dibutyrate and protein kinase C and was reisolated to remove activators, Upon adding nucleotide depleted cytosol, activator-independent phospho lipase D activity was seen, Using this prephosphorylation protocol, PKC-dependent activation of plasma membranes was found to require micromolar calcium, implicating a conventional protein kinase C, Using recombinant isoforms of protein kinase C, only the conventional isoforms showed significant activation, with the following rank order of potency: beta(1) > alpha > gamma; the beta(2), delta, epsilon, eta, and zeta isoforms showed little or no activity. Thus, conventional isoform(s) of protein kinase C activate neutrophil phospholipase D by phosphorylating a target protein located in the plasma membrane.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; SPHINX PHARMACEUT,DURHAM,NC 27707	Emory University					NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BELL RM, 1991, J BIOL CHEM, V266, P4661; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; ELDAR H, 1993, J BIOL CHEM, V268, P12560; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GO M, 1987, METHOD ENZYMOL, V141, P424; HARLOW E, 1988, ANTIBODIES LAB MANUA, P493; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LAMBETH D, 1995, J BIOL CHEM, V270, P2431; LAMBETH JD, 1994, PROTEIN KINASE C, P121; LIN PY, 1992, EUR J BIOCHEM, V207, P163, DOI 10.1111/j.1432-1033.1992.tb17033.x; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MCKINNON M, 1994, BBA-MOL CELL RES, V1222, P109, DOI 10.1016/0167-4889(94)90031-0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEL D, 1991, SCAND J CLIN LAB INV, V51, P299, DOI 10.3109/00365519109091618; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PFEILSCHIFTER J, 1993, FEBS LETT, V331, P267, DOI 10.1016/0014-5793(93)80350-4; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YAMADA K, 1991, BIOCHEM BIOPH RES CO, V175, P159, DOI 10.1016/S0006-291X(05)81214-8; YANG SF, 1967, J BIOL CHEM, V242, P477	55	123	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19465	19472		10.1074/jbc.270.33.19465	http://dx.doi.org/10.1074/jbc.270.33.19465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642630	hybrid			2022-12-27	WOS:A1995RP70300044
J	ZABNER, J; FASBENDER, AJ; MONINGER, T; POELLINGER, KA; WELSH, MJ				ZABNER, J; FASBENDER, AJ; MONINGER, T; POELLINGER, KA; WELSH, MJ			CELLULAR AND MOLECULAR BARRIERS TO GENE-TRANSFER BY A CATIONIC LIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-TRANSPORT DEFECT; ALKALINE-PHOSPHATASE; LIPOSOME COMPLEXES; MAMMALIAN-CELLS; EXPRESSION; DNA; DELIVERY; ADENOVIRUS; EFFICIENT; VESICLES	Cationic lipids are widely used for gene transfer in vitro and show promise as a vector for in vivo gene therapy applications. However, there is limited understanding of the cellular and molecular mechanisms involved, We investigated the individual steps in cationic lipid-mediated gene transfer to cultured cell lines, We used DMRIE/DOPE (a 1:1 mixture of N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl)ammonium bromide (DMRIE) and dioleoyl phosphatidylethanolamine (DOPE)) as a model lipid because of its efficacy and because it is being used for clinical trials in humans, The data show that cationic lipid mediated gene transfer is an inefficient process, Part of the inefficiency may result from the fact that the population of lipid-DNA complexes was very heterogeneous, even under conditions that have been optimized to produce the best transfection, Inefficiency was not due to inability of the complex to enter the cells because most cells took up the DNA, However, in contrast to previous speculation, the results indicate that endocytosis was the major mechanism of entry, After endocytosis, the lipid-DNA aggregated into large perinuclear complexes, which often showed a highly ordered tubular structure, Although much of the DNA remained aggregated in a vesicular compartment, there was at least a small amount of DNA in the cytoplasm of most cells, That observation plus results from direct injection of DNA and lipid-DNA into the nucleus and cytoplasm indicate that movement of DNA from the cytoplasm to the nucleus may be one of the most important limitations to successful gene transfer, Finally, before transcription can occur, the data show that lipid and DNA must dissociate, These results provide new insights into the physical limitations to cationic lipid-mediated gene transfer and suggest that attention to specific steps in the cellular process may further improve the efficiency of transfection and increase its use in a number of applications.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYS & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206; Zabner, Joseph/0000-0002-9606-1339	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BOLTON PH, 1978, NUCLEIC ACIDS RES, V5, P4891; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CANTRELL CE, 1979, MOL PHARMACOL, V15, P322; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CHIN D J, 1990, New Biologist, V2, P1091; COGGINS LW, 1995, ELECTRON MICROS, P1; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FASBENDER AJ, 1995, IN PRESS AM J PHYSL; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HAZINSKI TA, 1991, AM J RESP CELL MOL, V4, P206, DOI 10.1165/ajrcmb/4.3.206; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORWITZ MS, 1990, VIROLOGY, P01679; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LOGAN J, 1993, PEDIATR PULM, V9, P245; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MOSS B, 1991, J BIOL CHEM, V266, P1355; MURPHY RF, 1985, P NATL ACAD SCI USA, V82, P8523, DOI 10.1073/pnas.82.24.8523; NABEL GJ, 1994, HUM GENE THER, V5, P57, DOI 10.1089/hum.1994.5.1-57; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; RUBIN J, 1994, HUM GENE THER, V5, P1385, DOI 10.1089/hum.1994.5.11-1385; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; VOGELZANG NJ, 1994, HUM GENE THER, V5, P1357, DOI 10.1089/hum.1994.5.11-1357; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	47	1226	1302	0	108	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18997	19007		10.1074/jbc.270.32.18997	http://dx.doi.org/10.1074/jbc.270.32.18997			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642560	hybrid			2022-12-27	WOS:A1995RN95400048
J	LIANG, QW; FULCO, AJ				LIANG, QW; FULCO, AJ			TRANSCRIPTIONAL REGULATION OF THE GENES ENCODING CYTOCHROMES P450(BM-1) AND P450(BM-3) IN BACILLUS-MEGATERIUM BY THE BINDING OF BM3R1 REPRESSOR TO BARBIE BOX ELEMENTS AND OPERATOR SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SEQUENCE; P-450BM-3; PROTEIN; DNA	We previously reported (Liang, and., He, J.-S., and Fulco, A. J. (1995) J. Biol. Chem. 270, 4438-4450) that Bm3R1, a repressor regulating the expression of P450(BM-3) in Bacillus megaterium, could bind to Barbie box sequences in the 5'-flanking regions of barbiturate inducible genes. We've now shown that pentobarbital does not inhibit in vitro binding of Bm3R1 to the P450(BM-3) and P450(BM-3) Barbie boxes (BB3 and BB1), although the palindromic operator sequence (O-III) of P450(BM-3) did have a strong competitive effect on such binding. G39E-Bm3R1, a mutant of Bm3R1, did not bind to either Barbie box. In the presence of Bm3R1, portions of the regulatory regions of P450(BM-3) and P450(BM-1) were protected from DNase I digestion. These included 11 of the 15 base pairs of BB3 plus 7 base pairs 3' to BB3, BB1 plus 16 base pairs 3' to BB1, and, in the 5'-flanking region of P450(BM-1), segments covering most of two palindromic sequences (O-II and O-III) of 24 and 52 base pairs. These DNase I-protected regions (including O-III) showed considerable sequence identity, especially in a conserved poly(A) motif. Barbiturates did not inhibit binding of Bm3R1 to O-I . O-II in vitro while G39E-Bm3R1 did not bind. The regulatory effects of Bm3R1 on P450(BM-1) and P450(BM-3) were also evaluated in vivo using heterologous chloramphenicol acetyltransferase constructs and Western blotting. In the G39E mutant strain, both P450(BM-1) and P450(BM-3) were constitutively expressed, and the regulatory proteins Bm1P1 and Bm3P1, although still pentobarbital-inducible, had significantly higher basal levels of synthesis, In toto, our results show that Bm3R1 represses both P450(BM-1) and P450(BM-3) expression and that it may effect this by coordinate binding to operator and Barbie box sequences to produce looping of the P450(BM-1) and P450(BM-3) regulatory regions through protein-protein interaction.	UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM23913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; FERNANDEZ LM, 1994, CYTOCHROME P450, P663; FOURNIER T, 1994, J BIOL CHEM, V44, P27175; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HAHN CN, 1991, J BIOL CHEM, V266, P17031; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HE JS, 1991, J BIOL CHEM, V266, P7864; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HE JS, 1995, IN PRESS J BIOL CHEM; IMANAKA T, 1982, J BACTERIOL, V149, P824, DOI 10.1128/JB.149.3.824-830.1982; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; NARHI LO, 1986, J BIOL CHEM, V261, P7160; PADMANABAN G, 1994, CYTOCHROME P450, P133; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SHERVINGTON A, 1994, CYTOCHROME P450, P137; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEN LP, 1989, J BIOL CHEM, V264, P10996	24	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18606	18614		10.1074/jbc.270.31.18606	http://dx.doi.org/10.1074/jbc.270.31.18606			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629191	hybrid			2022-12-27	WOS:A1995RM64200071
J	TSUMOTO, K; OGASAHARA, K; UEDA, Y; WATANABE, K; YUTANI, K; KUMAGAI, I				TSUMOTO, K; OGASAHARA, K; UEDA, Y; WATANABE, K; YUTANI, K; KUMAGAI, I			ROLE OF TYR RESIDUES IN THE CONTACT REGION OF ANTILYSOZYME MONOCLONAL-ANTIBODY HYHEL10 FOR ANTIGEN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; FAB FRAGMENT; AMINO-ACIDS; COMPLEX; RECOGNITION; PROTEINS; SITES; SUBSTITUTIONS; MUTAGENESIS; RESOLUTION	It has been shown that Tyr residues are unusually localized in the regions of antibodies responsible for contact with antigens (Padlan, E. A. (1990) Proteins Struct. Funct. Genet. 7, 112-124). In order to clarify the role of these Tyr residues in antigen binding, the interaction between hen egg white lysozyme (HEL) and its monoclonal antibody HyHEL10, whose structure has been well studied in complex with its antigen, was investigated. Four Tyr residues in the VH chain (HTyr-33, HTyr-50, HTyr-53, and HTyr-58) were replaced with Ala, Leu, Phe, or Trp, and the interactions between these mutant Fv fragments and HEL were studied by inhibition assay of the enzymatic activity of HEL and isothermal titration calorimetry. Twelve mutant Fv fragments could be expressed, but two mutants (HY50W and HY58W) could not be obtained in the Escherichia coli expression system, and a further two mutants (HY33A and HY50A) could not be purified by affinity chromatography. It was shown by inhibition assay that Tyr residues at each mutated site made positive contributions to the interaction to different degrees. Thermodynamic studies showed that the role of Tyr residues in antigen binding was to obtain enthalpic energy. The roles of Tyr residues in antibody HyHEL10 for the association with antigen, HEL, can be summarized as follows: 1) formation of hydrogen bonds by the hydroxyl group, 2), creating more favorable interactions through the aromatic ring and decreasing the entropic loss upon binding, and 3) allowing hydrophobic interaction through the side chain. The four Tyr residues studied here were found to play significant roles in the association in various ways.	UNIV TOKYO, FAC ENGN, DEPT CHEM & BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Imoto T., 1972, ENZYMES, V7, P665; ITO W, 1993, J BIOL CHEM, V268, P16639; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kabat EA, 1991, SEQUENCES PROTEINS I; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROKI R, 1992, J BIOL CHEM, V267, P24297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Sambrook J, 1989, MOL CLONING LABORATO; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; UEDA Y, 1993, GENE, V129, P129; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	39	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18551	18557		10.1074/jbc.270.31.18551	http://dx.doi.org/10.1074/jbc.270.31.18551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629185	hybrid			2022-12-27	WOS:A1995RM64200063
J	JIANG, Y; PROTEAU, P; POULTER, D; FERRONOVICK, S				JIANG, Y; PROTEAU, P; POULTER, D; FERRONOVICK, S			BTS1 ENCODES A GERANYLGERANYL DIPHOSPHATE SYNTHASE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; FARNESYL DIPHOSPHATE; PYROPHOSPHATE SYNTHETASE; MOLECULAR-CLONING; ALPHA-SUBUNIT; GENE; PRENYLATION; PATHWAY; FARNESYLTRANSFERASE; PRENYLTRANSFERASE	Protein prenylation utilizes different types of isoprenoids groups, namely farnesyl and geranylgeranyl, to modify proteins. These lipophilic moieties attach to carboxyl-terminal cysteine residues to promote the association of soluble proteins to membranes. Most prenylated proteins are geranylgeranylated. Geranylgeranylation is catalyzed by two different prenyltransferases, the type I and type II geranylgeranyl transferases, both of which utilize geranylgeranyl diphosphate as a lipid donor. In the yeast Saccharomyces cerevisiae, the BET2 gene encodes the beta-subunit of the type II geranylgeranyl transferase. Mutations in this gene cause a defect in the geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic. In an attempt to analyze those genes whose products may interact with Bet2, we isolated a suppressor of the bet2-1 mutant. This suppressor gene, called BTS1, encodes the yeast geranylgeranyl diphosphate synthase. BTS1 is not essential for the vegetative growth of cells; however, disrupting it impedes the geranylgeranylation of many cellular proteins and renders cells cold sensitive for growth. Our findings imply that BTS1 suppresses the bet2-1 mutant by increasing the intracellular pool of geranylgeranyl diphosphate.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06536; UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	Howard Hughes Medical Institute; Yale University; Yale University; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM021328, R37GM021328, F32GM016732, R01GM021328] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM21328, GM16732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTLETT DL, 1985, METHOD ENZYMOL, V110, P171; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHEN AJ, 1993, J BIOL CHEM, V268, P11002; CHEN AJ, 1994, PROTEIN SCI, V3, P600; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; JOLY A, 1993, J BIOL CHEM, V268, P26983; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; MCCASKILL D, 1993, MOL CELL BIOL, V8, P1309; NAUMOVSKI L, 1984, MOL CELL BIOL, V4, P290, DOI 10.1128/MCB.4.2.290; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; RUNQUIST M, 1992, BIOCHEM BIOPH RES CO, V186, P157, DOI 10.1016/S0006-291X(05)80788-0; SAGAMI H, 1993, J BIOCHEM-TOKYO, V114, P118, DOI 10.1093/oxfordjournals.jbchem.a124125; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SAGAMI H, 1985, METHOD ENZYMOL, V110, P184; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044	36	84	96	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21793	21799		10.1074/jbc.270.37.21793	http://dx.doi.org/10.1074/jbc.270.37.21793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665600	hybrid			2022-12-27	WOS:A1995RU75700059
J	STDENIS, JF; BERTELOOT, A; VIDAL, H; ANNABI, B; VANDEWERVE, G				STDENIS, JF; BERTELOOT, A; VIDAL, H; ANNABI, B; VANDEWERVE, G			GLUCOSE-TRANSPORT AND GLUCOSE-6-PHOSPHATE HYDROLYSIS IN INTACT RAT-LIVER MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; GLUCOSE-6-PHOSPHATE TRANSPORT; MULTIFUNCTIONAL GLUCOSE-6-PHOSPHATASE; PROTEIN; SYSTEM; IDENTIFICATION; PYROPHOSPHATE; PHOSPHATE; KINETICS; VESICLES	Glucose transport was investigated in rat liver microsomes in relation to glucose 6-phosphatase (Glu-6-Pase) activity using a fast sampling, rapid filtration apparatus. 1) The rapid phase in tracer uptake and the burst phase in glucose 6-phosphate (Glu-6-P) hydrolysis appear synchronous, while the slow phase of glucose accumulation occurs during the steady-state phase of glucose production. 2) [C-14]Glucose efflux from preloaded microsomes can be observed upon addition of either cold Glu-6-P or Glu-6-Pase inhibitors, but not cold glucose. 3) Similar steady-state levels of intramicrosomal glucose are observed under symmetrical conditions of Glu-6-P or vanadate concentrations during influx and efflux experiments, and those levels are directly proportional to Glu-6-Pase activity. 4) The rates of both glucose influx and efflux are characterized by t(1/2) values that are independent of Glu-6-P concentrations. 5) Glucose efflux in the presence of saturating concentrations of vanadate was not blocked by 1 mM phloretin, and the initial rates of efflux appear directly proportional to intravesicular glucose concentrations. 6) It is concluded that glucose influx into microsomes is tightly linked to Glu-6-Pase activity, while glucose efflux may occur independent of hydrolysis, so that microsomal glucose transport appears unidirectional even though it can be accounted for by diffusion only over the accessible range of sugar concentrations.	UNIV MONTREAL,DEPT NUTR,ENDOCRINOL METAB LAB,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH TRANSPORT MEMBRANAIRE,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal			Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317				ARION WJ, 1980, J BIOL CHEM, V255, P396; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1995, J BIOL CHEM, V270, P21098, DOI 10.1074/jbc.270.36.21098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1994, BIOCHEM SOC T, V22, P658, DOI 10.1042/bst0220658; CHENU C, 1993, J MEMBRANE BIOL, V132, P95; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; NORDLIE RC, 1982, METHOD ENZYMOL, V87, P319; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SCHULZE HU, 1980, EUR J BIOCHEM, V106, P505, DOI 10.1111/j.1432-1033.1980.tb04597.x; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STEIN WD, 1981, MEMBRANE TRANSPORT, P123; VIDAL H, 1992, FEBS LETT, V302, P197, DOI 10.1016/0014-5793(92)80439-N; WADDELL ID, 1988, FEBS LETT, V229, P179, DOI 10.1016/0014-5793(88)80822-6; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; ZERR C, 1968, BIOCHEM BIOPH RES CO, V32, P129, DOI 10.1016/0006-291X(68)90357-4	25	32	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21092	21097		10.1074/jbc.270.36.21092	http://dx.doi.org/10.1074/jbc.270.36.21092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673139	hybrid			2022-12-27	WOS:A1995RU05400037
J	CASEY, EB; ZHAO, HR; ABRAHAM, EC				CASEY, EB; ZHAO, HR; ABRAHAM, EC			ROLE OF GLYCINE-1 AND LYSINE-2 IN THE GLYCATION OF BOVINE GAMMA-B-CRYSTALLIN - SITE-DIRECTED MUTAGENESIS OF LYSINE TO THREONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; LENS CRYSTALLINS; EYE LENS; DIABETIC CATARACT; ALPHA-CRYSTALLINS; CROSS-LINKING; END-PRODUCTS; PROTEINS; GLYCOSYLATION; AGGREGATION	To determine the role of Gly-1 and Lys-8 of bovine gamma B crystallin in glycation and cross-linking, Lys-2 was changed to Thr by site-directed mutagenesis. A polymerase chain reaction was used to perform site directed mutagenesis on the third codon (AAG --> ACG) of bovine gamma B-crystallin cDNA. The wild type and mutant cDNAs were cloned into pMON5743 and expressed in JM101 Escherichia coli cells, and the identity of gamma B-crystallin was confirmed by Western blotting after purification by cation exchange high performance liquid chromatography. Glycation of gamma B-crystallin by [C-14]glucose was reduced significantly due to the mutation of Lys-2, supporting the view that Lys-2 is a major glycation site. Peptide mapping showed the presence of two major labeled peptides containing N-terminal sequences, and in the mutant these peptides had longer retention times and reduced radioactivity. Amino acid analysis, after glycation with [C-14]glucose, revealed N-terminal glycine as the most predominant glycation site. Lys-8 was glycated slower than Gly-1 but faster than Lys-163. Glycation with DL-glyceraldehyde showed an important role for both Gly-1 and Lys-2 in the glycation-mediated gamma B-crystallin cross-linking.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					NATIONAL EYE INSTITUTE [R01EY007394] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07394] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAHAM EC, 1991, EXP EYE RES, V52, P107, DOI 10.1016/0014-4835(91)90135-2; ABRAHAM EC, 1994, BIOCHEM BIOPH RES CO, V201, P1451, DOI 10.1006/bbrc.1994.1866; ABRAHAM EC, 1985, GLYCOSYLATED HEMOGLO, P33; ABRAHAM EC, 1989, MAILLARD REACTION AG, P123; ACHARYA AS, 1988, BIOCHEMISTRY-US, V27, P4522, DOI 10.1021/bi00412a045; ARAKI N, 1992, J BIOL CHEM, V267, P10211; BESWICK HT, 1987, BIOCHEM J, V246, P761, DOI 10.1042/bj2460761; BLOEMENDAL H, 1989, EXP EYE RES, V48, P465, DOI 10.1016/0014-4835(89)90029-8; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; HARDING JJ, 1987, P INT SOC EYE RES, V5, P95; Harding JJ, 1984, EYE B, V1b, P207; HAY RE, 1994, EXP EYE RES, V58, P573, DOI 10.1006/exer.1994.1052; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; KODAMA T, 1988, INVEST OPHTH VIS SCI, V29, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTHRA M, 1993, J BIOL CHEM, V268, P18119; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1989, MAILLARD REACTION AG, P1; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; ORTWERTH BJ, 1992, BIOCHIM BIOPHYS ACTA, V1117, P207, DOI 10.1016/0304-4165(92)90081-5; PENNINGTON J, 1994, BBA-MOL BASIS DIS, V1226, P163, DOI 10.1016/0925-4439(94)90024-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SIEZEN RJ, 1985, BIOCHEM BIOPH RES CO, V127, P153, DOI 10.1016/S0006-291X(85)80138-8; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; SUMMERS L, 1984, PEPTIDE PROTEIN REV, V3, P147; SWAMY MS, 1991, EXP EYE RES, V52, P439, DOI 10.1016/0014-4835(91)90040-L; SWAMY MS, 1987, INVEST OPHTH VIS SCI, V28, P1693; SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025; SWAMY MS, 1989, CURR EYE RES, V8, P989, DOI 10.3109/02713688908997391; SWAMY MS, 1992, CURR EYE RES, V9, P833; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20781	20786		10.1074/jbc.270.35.20781	http://dx.doi.org/10.1074/jbc.270.35.20781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657661	hybrid			2022-12-27	WOS:A1995RR58400082
J	JOHANSSON, E; LONNROTH, I; LANGE, S; JONSON, I; JENNISCHE, E; LONNROTH, C				JOHANSSON, E; LONNROTH, I; LANGE, S; JONSON, I; JENNISCHE, E; LONNROTH, C			MOLECULAR-CLONING AND EXPRESSION OF A PITUITARY-GLAND PROTEIN MODULATING INTESTINAL FLUID SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROLYTE TRANSPORT; DIARRHEAL DISEASE; CHOLERA-TOXIN; PURIFICATION; KINASE; MODEL	Antisecretory factor (AF) is a protein known to inhibit intestinal fluid secretion induced by cholera toxin. cDNA clones, expressing immunoreactivity to AF were isolated from a human pituitary gland library and sequenced. The sequence contained 1309 base pairs plus a poly(A) tail; Northern blot analysis of pituitary RNA confirmed this size. One large open reading frame was found to code for 382 amino acids. The protein was expressed in pGEX-lambda 1T/Escherichia coli and purified. The recombinant AF was extremely potent, 9 ng (2.10(-13) mel), giving a significant antisecretory activity against cholera toxin-induced fluid secretion in rat. Antiserum against recombinant AF was used in immunohistochemical and Western blot analysis. Sections from human pituitary glands manifested specific intracellular staining in cells exclusively located in the anterior part. Both recombinant AF and AF extracted from pituitary gland appeared in SDS-polyacrylamide to have a molecular mass of 60 kDa, although the real value was 41 kDa. The protein sequence manifested homology (29% identity) with one protein, a putative Saccharomyces cerevisiae 30-kDa protein of unknown function.	GOTHENBURG UNIV, DEPT MED MICROBIOL & IMMUNOL, S-41346 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT CLIN BACTERIOL, S-41346 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT ANAT & CELL BIOL, S-41346 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT SURG, S-41346 GOTHENBURG, SWEDEN	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg								APTE AN, 1993, BIOTECHNIQUES, V15, P890; BROWN MR, 1990, ANN NY ACAD SCI, V579, P8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOUSE C, 1984, EUR J BIOCHEM, V140, P363, DOI 10.1111/j.1432-1033.1984.tb08109.x; JENNISCHE E, 1992, ACTA PHYSIOL SCAND, V146, P79, DOI 10.1111/j.1748-1716.1992.tb09395.x; JODAL M, 1993, GASTROENTEROLOGY, V105, P1286, DOI 10.1016/0016-5085(93)90130-5; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KREJS GJ, 1987, AM J MED, V82, P37, DOI 10.1016/0002-9343(87)90425-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE S, 1982, FEMS MICROBIOL LETT, V15, P239, DOI 10.1111/j.1574-6968.1982.tb00075.x; LANGE S, 1987, PFLUG ARCH EUR J PHY, V410, P648, DOI 10.1007/BF00581326; LONNROTH I, 1988, COMP BIOCHEM PHYS A, V90, P611, DOI 10.1016/0300-9629(88)90675-5; LONNROTH I, 1986, BIOCHIM BIOPHYS ACTA, V883, P138, DOI 10.1016/0304-4165(86)90144-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tache Y, 1991, BRAIN GUT INTERACTIO; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	25	71	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20615	20620		10.1074/jbc.270.35.20615	http://dx.doi.org/10.1074/jbc.270.35.20615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657640	hybrid			2022-12-27	WOS:A1995RR58400059
J	WADA, I; IMAI, S; KAI, M; SAKANE, F; KANOH, H				WADA, I; IMAI, S; KAI, M; SAKANE, F; KANOH, H			CHAPERONE FUNCTION OF CALRETICULIN WHEN EXPRESSED IN THE ENDOPLASMIC-RETICULUM AS THE MEMBRANE-ANCHORED AND SOLUBLE FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN CALRETICULIN; GLYCOPROTEIN GLUCOSYLTRANSFERASE; SECRETORY GLYCOPROTEINS; MOLECULAR CHAPERONE; CELL-SURFACE; RAT-LIVER; CALNEXIN; IDENTIFICATION; OLIGOSACCHARIDES; GLUCOSYLATION	A unique type of chaperone that requires glucose trimming of the target proteins has been shown to be important for their maturation in the endoplasmic reticulum (ER). Calnexin, an ER membrane chaperone, is the first example of such a class. Here, we focus on calreticulin, a major ER luminal protein, which shares with calnexin two sets of characteristic sequence repeat. We evaluated the chaperone function of calreticulin by expressing it on the ER luminal membrane surface. We constructed a membrane-anchored calreticulin chimera by fusing truncated calreticulin to the membrane-anchoring tagged segment of calnexin. When expressed in HepG2 cells, the calreticulin chimera transiently interacted with a set of nascent secretory proteins in a castanospermine-sensitive manner. The spectrum of proteins recognized by the membrane-anchored calreticulin was remarkably similar to that observed with calnexin. Next, we tested if such a chaperone function of calreticulin is expressed at its physiological location. Luminally expressed calreticulin preferentially bound to nascent transferrin and released it upon chase. Association with other calnexin ligands was observed, however, at low efficiencies. Interactions were abrogated by castanospermine treatment. We conclude that calreticulin per se is another chaperone with apparently the same characteristics as calnexin and selectively interacts with nascent transferrin in the lumen, suggesting that calreticulin may cover the diversity of maturations.			WADA, I (corresponding author), SAPPORO MED UNIV, SCH MED, DEPT BIOCHEM, SOUTH 1, WEST 17, SAPPORO, HOKKAIDO 060, JAPAN.		Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOUMA ME, 1989, IN VITRO CELL DEV B, V25, P267; BURNS K, 1992, J BIOL CHEM, V267, P19039; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; FITTING T, 1982, J BIOL CHEM, V257, P4011; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GROSS V, 1983, J BIOL CHEM, V258, P2203; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KOCH GLE, 1987, J CELL SCI, V87, P491; LE AQ, 1994, J BIOL CHEM, V269, P7514; LENTER M, 1994, J BIOL CHEM, V269, P12263; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MICHALAK M, 1991, EXP CELL RES, V197, P91, DOI 10.1016/0014-4827(91)90484-C; MORIMOTO T, 1983, METHOD ENZYMOL, V96, P121; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1984, J BIOL CHEM, V259, P6351; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PIND S, 1994, J BIOL CHEM, V269, P12784; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; TREVES S, 1992, BIOCHEM J, V287, P579, DOI 10.1042/bj2870579; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	58	131	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20298	20304		10.1074/jbc.270.35.20298	http://dx.doi.org/10.1074/jbc.270.35.20298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657600	hybrid			2022-12-27	WOS:A1995RR58400013
J	POND, L; KUHN, LA; TEYTON, L; SCHUTZE, MP; TAINER, JA; JACKSON, MR; PETERSON, PA				POND, L; KUHN, LA; TEYTON, L; SCHUTZE, MP; TAINER, JA; JACKSON, MR; PETERSON, PA			A ROLE FOR ACIDIC RESIDUES IN DI-LEUCINE MOTIF-BASED TARGETING TO THE ENDOCYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; INVARIANT CHAIN CONTAINS; CYTOPLASMIC DOMAIN; INTRACELLULAR-TRANSPORT; CARBOXYL-TERMINUS; CELL BIOLOGY; MOLECULES; INTERNALIZATION; COMPARTMENTS	Recent reports have suggested that major histocompatibility complex class II molecules load peptide through a specialized compartment of the endocytic pathway and are targeted to this pathway by association with invariant chain (Iip31). Therefore we used a site-directed mutagenesis approach to determine whether Iip31 possesses novel protein targeting signals. Our results indicate that two di-leucine-like pairs mediate Iip31 targeting and that an acidic amino acid residue four or five residues N-terminal to each Iip31 di-leucine-like pair is required for endocytic targeting. Results from additional testing with hybrid Iip31 molecules indicate that the acidic residues N-terminal to di-leucine pairs are critical for accumulation of these molecules in large endocytic vesicles and in some cases provide a structure favorable for internalization. The acidic residues N-terminal to di-leucine pairs are important in some sequence contexts in providing a structure favorable for internalization, whereas in other contexts an acidic residue is critical for targeting to, and formation of, large endocytic vesicles. Although our results do not support the idea that Iip31 possesses unique protein targeting motifs, they do suggest that di-leucine motifs may be recognized as part of a larger secondary structure. In addition, our data imply that the targeting motif requirements for internalization may differ from the requirements for further transport in the endocytic pathway.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Michigan State University; Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BAKKE O, 1993, J CELL BIOCHEM, V17, P25; BREMNES B, 1994, J CELL SCI, V107, P2021; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OGATA S, 1994, J BIOL CHEM, V269, P5210; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1993, J CELL SCI, V106, P831; QUI Y, 1994, J CELL BIOL, V125, P595, DOI DOI 10.1083/JCB.125.3.595; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	43	195	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19989	19997		10.1074/jbc.270.34.19989	http://dx.doi.org/10.1074/jbc.270.34.19989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650016	hybrid			2022-12-27	WOS:A1995RQ99100049
J	WHEELAN, P; MURPHY, RC				WHEELAN, P; MURPHY, RC			METABOLISM OF 6-TRANS-ISOMERS OF LEUKOTRIENE B-4 IN CULTURED HEPATOMA-CELLS AND IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES - IDENTIFICATION OF A DELTA(6)-REDUCTASE METABOLIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; PORCINE LEUKOCYTES; OMEGA-OXIDATION; RAT HEPATOCYTES; DIHYDRO; PRODUCTS; DEHYDROGENASE; MACROPHAGES; ETHANOL; POTENT	The intermediate metabolic events which degrade hydroxy polyunsaturated fatty acids is largely unknown. Such molecules are common products of lipid peroxidation and lipoxygenase catalyzed oxidation of arachidonic acid, Metabolism of two 5,12-dihydroxyeicosatetraenoic acids, 6-trans-LTB(4) (leukotriene B-4), and 6-trans-12-epi-LTB(4) was studied in HepG2 cells (a human-derived hepatoma cell line). Extensive metabolism was observed with a major metabolite identified as 4-hydroxy-6-dodecenoic acid for both epimers. Incubation of 6-trans-LTB(4) epimers at shorter times revealed the formation of intermediate metabolites, including 6-hydroxy-4,8-tetradecadienoic acid and 8-hydroxy-4,6,10-hexadecatrienoic acid suggesting beta-oxidation as the major pathway leading to the formation of the common terminal metabolite. Two additional metabolites were structurally elucidated as 5-oxo-6,7-dihydro-LTB(4) and 6,7-dihydro-LTB(4) which have not been previously described. Formation of 5-oxo-6,7-dihydro-LTB(4) and 6,7-dihydro-LTB(4) were also observed during metabolism of 6-trans-12-epi-LTB(4) in human polymorphonuclear leukocytes. Of particular interest is the metabolism of these compounds by beta-oxidation from the carboxyl terminus, a process which is not observed with leukotriene B-4 or leukotriene C-4. Identification of these metabolites suggested the operation of the 5-hydroxyeicosanoid dehydrogenase pathway followed by a Delta(6)-reductase metabolic pathway which has not been previously described, This pathway of beta-oxidation may limit the activity of various 5,12-diHETEs including nonenzymatic hydrolysis products of LTA(4) and also the recently described B-4-isoleukotrienes.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT K929,DENVER,CO 80206	National Jewish Health					NHLBI NIH HHS [HL25785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025785, R37HL025785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; DICZFALUSY U, 1994, PROG LIPID RES, V33, P403, DOI 10.1016/0163-7827(94)90025-6; ELLIS CK, 1979, J BIOL CHEM, V254, P4152; FAULER J, 1989, PROSTAG LEUKOTR ESS, V37, P193, DOI 10.1016/0952-3278(89)90085-9; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; KAEVER V, 1990, LIFE SCI, V46, P1495; LUO MJ, 1994, J BIOL CHEM, V269, P2384; LYNCH JM, 1986, J IMMUNOL, V137, P2653; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; PALMBLAD J, 1981, BLOOD, V58, P658; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1989, J BIOL CHEM, V264, P5364; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCHONFELD W, 1988, IMMUNOLOGY, V65, P529; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIRLEY MA, 1990, J BIOL CHEM, V265, P16288; SHIRLEY MA, 1992, J AM SOC MASS SPECTR, V3, P762, DOI 10.1016/1044-0305(92)87090-L; SHIRLEY MA, 1992, BIOCHEM BIOPH RES CO, V185, P604, DOI 10.1016/0006-291X(92)91667-F; SILVERSTEIN RM, 1981, SPECTROMETRIC IDENTI, P320; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SUMIMOTO H, 1990, J BIOL CHEM, V265, P4348; WHEELAN P, 1993, J BIOL CHEM, V268, P25439; WHEELAN P, 1995, J AM SOC MASS SPECTR, V6, P40, DOI 10.1016/1044-0305(94)00090-M; WHEELAN P, 1995, IN PRESS ARCH BIOCH; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; YOKUMOTO H, 1982, J BIOL CHEM, V257, P13576	35	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19845	19852		10.1074/jbc.270.34.19845	http://dx.doi.org/10.1074/jbc.270.34.19845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649996	hybrid			2022-12-27	WOS:A1995RQ99100028
J	WOLUCKA, BA; DEHOFFMANN, E				WOLUCKA, BA; DEHOFFMANN, E			THE PRESENCE OF BETA-D-RIBOSYL-1-MONOPHOSPHODECAPRENOL IN MYCOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS; STRUCTURAL FEATURES; ESCHERICHIA-COLI; POLYSACCHARIDE; BIOSYNTHESIS; LIPOPOLYSACCHARIDES; TUBERCULOSIS; ARABINOGALACTAN; CONFIGURATION; COMPLEX	Biosynthesis of the cell envelope in mycobacteria is largely unknown; however, several antituberculosis drugs apparently interfere with this process, Recently, we described a lipid intermediate for the biosynthesis of the cell wall arabinogalactan/arabinomannan of Mycobacterium smegmatis: beta-D-arabinofuranosyl-1-monophosphodecaprenol (Wolucka, B. A., McNeil, M. R., de Hoffmann, E., Chojnacki, T., and Brennan, P. J. (1994) J. Biol. Chem. 269, 23328-23335). In the present work, by means of gas chromatography-mass spectrometry, fast atom bombardment tandem mass spectrometry, and proton NMR, the major pentose-containing component of the polyprenyl-P-sugar family from M. smegmatis was characterized as beta-D-ribosyl-1-monophosphodecaprenol (decaprenyl-P-ribose). Additionally, the structure of a minor arabinose-containing compound, beta-D-arabinosyl-1-monophosphooctahydroheptaprenol, could be deduced. In vivo labeling experiments with [C-14]glucose demonstrated unequivocally that decaprenyl-P-ribose is actively synthesized in Mycobacterium tuberculosis H37Ra and Mycobacterium avium serovar 4. It is proposed that decaprenyl-P-ribose could be a precursor for the biosynthesis of either some unknown ribose-containing cell envelope polymers of mycobacteria or the arabinan part of the cell wall arabinogalactan/arabinomannan due to the presence of a 2'-epimerase activity at some late stages of the arabinogalactan/arabinomannan biosynthesis.			WOLUCKA, BA (corresponding author), UNIV CATHOLIQUE LOUVAIN, DEPT CHEM, 1 PL LOUIS PASTEUR, B-1348 LOUVAIN, BELGIUM.							AMANO KI, 1993, INFECT IMMUN, V61, P4350, DOI 10.1128/IAI.61.10.4350-4355.1993; BERST M, 1969, EUR J BIOCHEM, V11, P353, DOI 10.1111/j.1432-1033.1969.tb00779.x; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHU CK, 1984, NUCLEOS NUCLEOT, V3, P1, DOI 10.1080/07328318408079416; CRISEL RM, 1975, J BIOL CHEM, V250, P4926; DABBS ER, 1995, ANTIMICROB AGENTS CH, V39, P1007, DOI 10.1128/AAC.39.4.1007; DAFFE M, 1990, J BIOL CHEM, V265, P6734; FARMER PB, 1973, J BIOL CHEM, V248, P1844; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GOETHALS K, 1992, MOL PLANT MICROBE IN, V5, P405, DOI 10.1094/MPMI-5-405; HACKLAND PL, 1991, CARBOHYD RES, V219, P193; HOOK M, 1974, J BIOL CHEM, V249, P3908; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; KOCHAROVA NA, 1989, J BIOL CHEM, V264, P15569; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; LVOV VL, 1991, BIOORG KHIM+, V17, P111; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MERELLO S, 1994, J BIOL CHEM, V269, P20294; MERELLO S, 1995, MOL BIOCHEM PARASIT, V69, P73, DOI 10.1016/0166-6851(94)00195-S; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PINDAR DF, 1975, BIOCHEM J, V152, P617, DOI 10.1042/bj1520617; SAWADA S, 1985, J INFECT DIS, V152, P1290, DOI 10.1093/infdis/152.6.1290; SHASHKOV AS, 1993, CARBOHYD RES, V241, P177, DOI 10.1016/0008-6215(93)80104-M; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SUTHERLAND IW, 1973, J GEN MICROBIOL, V74, P259, DOI 10.1099/00221287-74-2-259; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WATANABE M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P53, DOI 10.1016/0005-2760(92)90075-7; WIELAND F, 1988, BIOCHIMIE, V70, P1493, DOI 10.1016/0300-9084(88)90286-6; WILKINSON SG, 1983, CARBOHYD RES, V112, P241, DOI 10.1016/0008-6215(83)88289-5; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J AM SOC MASS SPECTR, V6, P516, DOI 10.1016/1044-0305(95)00030-H; Wolucka Beata A., 1994, Acta Biochimica Polonica, V41, P345; YORK WS, 1986, METHOD ENZYMOL, V118, P3	41	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20151	20155		10.1074/jbc.270.34.20151	http://dx.doi.org/10.1074/jbc.270.34.20151			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650033	hybrid			2022-12-27	WOS:A1995RQ99100070
J	NAVARATNAM, DS; ESCOBAR, L; COVARRUBIAS, M; OBERHOLTZER, JC				NAVARATNAM, DS; ESCOBAR, L; COVARRUBIAS, M; OBERHOLTZER, JC			PERMEATION PROPERTIES AND DIFFERENTIAL EXPRESSION ACROSS THE AUDITORY RECEPTOR EPITHELIUM OF AN INWARD RECTIFIER K+ CHANNEL CLONED FROM THE CHICK INNER-EAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CALCIUM-BINDING PROTEIN; SACCULAR HAIR-CELLS; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; SUBUNIT STOICHIOMETRY; ELECTRICAL RESONANCE; BASILAR PAPILLA; COCHLEA; CURRENTS	The auditory receptor epithelium is an excellent model system for studying the differential expression of ion channel genes, An inward rectifier potassium cur rent is among those which have been measured in only subsets of chick cochlear hair cells. We have cloned and characterized an inward rectifier potassium channel (cIRK1) from the chick cochlear sensory epithelium, cIRK1 functional properties are similar to those of the native channel, and the transcript encoding cIRK1 is limited to the low frequency half of the epithelium. This localization is in agreement with the distribution of the native hair cell current, suggesting that the differential current expression is transcriptionally regulated. The primary structure of cIRK1 is highly homologous to the mouse inward rectifier IRK1. However, we found that cIRK1 exhibited reduced single-channel conductance (17 picosiemens) and lower sensitivity to Ba2+ block (K-1/2 = 12 mu M). We identified Gln-125 near the putative pore region as being responsible for these differences. Site-directed mutagenesis was used to change Gln-125 to Glu (the residue in IRK1), resulting in a channel with a single channel conductance of 28 picosiemens and a Ba2+ block of K-1/2 = 2 mu M. We propose that Gln-125 may form part of the external vestibule of the pore.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	University of Pennsylvania; Jefferson University				Covarrubias, Manuel/0000-0002-0881-4143	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032337, R01NS032337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069] Funding Source: NIH RePORTER; NIDCD NIH HHS [K08-DC-00069] Funding Source: Medline; NINDS NIH HHS [NS32337-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN WJ, 1978, J PHYSIOL-LONDON, V276, P13, DOI 10.1113/jphysiol.1978.sp012217; ARMSTRONG CM, 1988, BIOPHYS J, V30, P473; ART JJ, 1993, J PHYSIOL-LONDON, V470, P109, DOI 10.1113/jphysiol.1993.sp019850; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; EATOCK RA, 1993, J NEUROSCI, V13, P1767; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER FP, 1992, HEARING RES, V61, P167, DOI 10.1016/0378-5955(92)90048-R; FUCHS PA, 1990, J PHYSIOL-LONDON, V429, P529, DOI 10.1113/jphysiol.1990.sp018271; FUCHS PA, 1988, J NEUROSCI, V8, P2460; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P275, DOI 10.1113/jphysiol.1988.sp017120; HUNZIKER W, 1986, P NATL ACAD SCI USA, V83, P7578, DOI 10.1073/pnas.83.20.7578; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; ISHII K, 1994, FEBS LETT, V338, P107, DOI 10.1016/0014-5793(94)80126-6; JOSOPHSON IR, 1988, MOL CELL BIOCHEM, V80, P21; KOROTZER AR, 1992, GLIA, V6, P81, DOI 10.1002/glia.440060202; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MINGHETTI PP, 1988, MOL ENDOCRINOL, V2, P355, DOI 10.1210/mend-2-4-355; MURROW BW, 1994, J PHYSIOL-LONDON, V480, P247, DOI 10.1113/jphysiol.1994.sp020357; OBERHOLTZER JC, 1994, DNA CELL BIOL, V13, P857, DOI 10.1089/dna.1994.13.857; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; OBERHOLTZER JC, 1992, HEARING RES, V60, P103, DOI 10.1016/0378-5955(92)90063-S; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; ROBERTS WM, 1993, NATURE, V363, P74, DOI 10.1038/363074a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINGAI R, 1986, BRAIN RES, V369, P65, DOI 10.1016/0006-8993(86)90513-5; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, J BIOL CHEM, V269, P13867; TANAKA K, 1978, AM J ANAT, V153, P251, DOI 10.1002/aja.1001530206; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; vonBekesy G., 1960, EXPT HEARING; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	55	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19238	19245		10.1074/jbc.270.33.19238	http://dx.doi.org/10.1074/jbc.270.33.19238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642595	hybrid			2022-12-27	WOS:A1995RP70300009
J	SARGE, KD				SARGE, KD			MALE GERM CELL-SPECIFIC ALTERATION IN TEMPERATURE SET-POINT OF THE CELLULAR STRESS-RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK FACTOR; MOUSE SPERMATOGENIC CELLS; AMINO-ACID-ANALOGS; DNA-BINDING; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; PROTEINS; ACTIVATION; EXPRESSION; OLIGOMERIZATION	Heat shock factor (HSF), a transcriptional regulator with heat-activatable DNA binding ability, mediates the stress-induced expression of eukaryotic heat shock protein genes, Previous results from this laboratory demonstrated that a preparation of mixed male germ cell types from mouse testis exhibited a lower temperature threshold for activation of HSF1 DNA binding relative to other mouse cell types (Sarge, K. D., Pray, A. E., and Goodson, M. L. (1995) Nature 374, 126), The purpose of the present study was to determine whether the phenomenon of reduced HSF1 activation temperature is common to all testis cell types, both somatic and germ cell types, or whether it is a special property of male germ cells, The results show that a purified population of pachytene spermatocytes, one of the male germ cell types, exhibits a profile of reduced HSF1 activation temperature identical to that observed for the mixed germ cell preparation, with a threshold HSF1 activation temperature of 35 degrees C, Activation of HSF1 DNA binding in male germ cells by incubation at 38 degrees C is accompanied by the classic cellular stress response parameters of heat-induced HSF1 phosphorylation and increased expression of the hsp72 stress protein, In contrast, a preparation of somatic testis cell types exhibits HSF1 activation only at temperatures of 42 degrees C and above, a profile identical to that observed for mouse liver cells and mammalian cell lines, These results demonstrate that the phenomenon of reduced HSF1 activation temperature is a unique property of male germ cell types within the mammalian testis and demonstrate that HSF1 activated at this lower temperature threshold is fully capable of mediating a productive cellular stress response in these cell types.			SARGE, KD (corresponding author), UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,800 ROSE ST,LEXINGTON,KY 40536, USA.							ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ALLEN RL, 1988, MOL CELL BIOL, V8, P828, DOI 10.1128/MCB.8.2.828; ALLEN RL, 1988, MOL CELL BIOL, V8, P3260, DOI 10.1128/MCB.8.8.3260; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1993, NATURE, V364, P252, DOI 10.1038/364252a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; Eddy EM, 1993, MOL BIOL MALE REPROD, P181; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; HARRISON RG, 1948, J PHYSIOL-LONDON, V107, pP48; HECHT NB, 1992, CELL MOL BIOL TESTIS, P464; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1991, HORMONAL CONTROL GEN, P377; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEMAIRE L, 1991, LIFE SCI, V48, P365, DOI 10.1016/0024-3205(91)90557-R; LIS J, 1992, TRANSCRIPTIONAL REGU, P907; LIU AYC, 1994, J BIOL CHEM, V269, P14768; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1995, NATURE, V374, P126, DOI 10.1038/374126a0; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAKERI ZF, 1990, J CELL BIOL, V111, P1785, DOI 10.1083/jcb.111.5.1785; ZORGNIOTTI AW, 1989, TEMPERATURE ENV EFFE	37	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18745	18748		10.1074/jbc.270.32.18745	http://dx.doi.org/10.1074/jbc.270.32.18745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642523	hybrid			2022-12-27	WOS:A1995RN95400010
J	SEEDORF, K; SHEARMAN, M; ULLRICH, A				SEEDORF, K; SHEARMAN, M; ULLRICH, A			RAPID AND LONG-TERM EFFECTS OF PROTEIN-KINASE-C ON RECEPTOR TYROSINE KINASE PHOSPHORYLATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SWISS 3T3 CELLS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PHORBOL ESTERS; EGF RECEPTOR; S6 KINASE; SERINE PHOSPHORYLATION; CHIMERIC RECEPTOR	Rapid and long term effects of protein kinase C alpha activation on receptor tyrosine kinase signaling parameters were investigated in human 293 embryonic fibroblasts and mouse NIH 3T3 cells, Within minutes of phorbol 12-myristate 13-acetate treatment, epidermal growth factor receptor and HER2 tyrosine phosphorylation was decreased, while platelet derived growth factor receptor and insulin receptor autophosphorylation was upregulated, These effects are not mediated by protein kinase C-dependent receptor tyrosine kinase phosphorylation but apparently by activation or inactivation of receptor tyrosine kinase specific phosphatases, as indicated by neutralization of these phenomena upon treatment of cells with sodium orthovanadate. In contrast to these short term effects, sustained activation of protein kinase C alpha by phorbol 12-myristate 13-acetate results in translocation of protein kinase C from the cytosol to the membrane fraction where it forms stable complexes with all receptor tyrosine kinases investigated, Ligand-induced receptor tyrosine kinase/protein kinase C association in NIH 3T3 fibroblasts is accompanied by a mobility shift of the receptor, indicating phosphorylation by activated protein kinase C. This phenomenon correlates with the disappearance of receptor tyrosine kinases from the cell surface, implying that this interaction plays a role in the process of receptor internalization and degradation, Interestingly, ligand-stimulated receptor down-regulation is also enhanced by overexpression of phospholipase C gamma, which strongly indicates a role for this common receptor tyrosine kinase substrate in negative regulation of growth factor signals.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								AHN NG, 1991, J BIOL CHEM, V266, P4220; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOWEN S, 1991, J BIOL CHEM, V266, P1162; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1985, J BIOL CHEM, V260, P2003; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HARING H, 1986, BIOCHEM J, V234, P59; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOUSLAY MD, 1989, BRIT MED BULL, V45, P264, DOI 10.1093/oxfordjournals.bmb.a072316; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HUCKLE WR, 1990, ENDOCRINOLOGY, V127, P1697, DOI 10.1210/endo-127-4-1697; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KASUGA K, 1989, FEBS LETT, V254, P22; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS JDH, 1988, ONCOGENE, V4, P27; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1992, SCIENCE, V233, P305; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOZERI O, 1992, ONCOGENE, V7, P2259; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	79	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18953	18960		10.1074/jbc.270.32.18953	http://dx.doi.org/10.1074/jbc.270.32.18953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642554	hybrid			2022-12-27	WOS:A1995RN95400042
J	SUGAYA, T; NISHIMATSU, SI; TANIMOTO, K; TAKIMOTO, E; YAMAGISHI, T; IMAMURA, K; GOTO, S; IMAIZUMI, K; HISADA, Y; OTSUKA, A; UCHIDA, H; SUGIURA, M; FUKUTA, K; FUKAMIZU, A; MURAKAMI, K				SUGAYA, T; NISHIMATSU, SI; TANIMOTO, K; TAKIMOTO, E; YAMAGISHI, T; IMAMURA, K; GOTO, S; IMAIZUMI, K; HISADA, Y; OTSUKA, A; UCHIDA, H; SUGIURA, M; FUKUTA, K; FUKAMIZU, A; MURAKAMI, K			ANGIOTENSIN-II TYPE 1A RECEPTOR-DEFICIENT MICE WITH HYPOTENSION AND HYPERRENINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECRETION; RENIN	Angiotensin (AT) II, the bioactive octapeptide in the renin-angiotensin system that plays a key role in cardiovascular homeostasis, exerts its multiple effects through the different types of AT receptors, AT1a, AT1b, and AT2. Previously, we showed chronic hypotension in angiotensinogen (the precursor of AT)-deficient mice and a dramatic increase in renin mRNA levels in its kidney, but it remains unclear which types of AT receptors regulate the blood pressure and renin gene expression, In order to elucidate the physiological roles of AT1a receptor, we generated mutant mice with a targeted replace ment of the AT1a receptor loci by the lacZ gene, In the heterozygous mutant mice, the strong lacZ staining was found in the glomerulus and juxtaglomerular apparatus of the renal cortex, which coincided with that of the signals detected by in situ hybridization, Chronic hypotension was observed in the heterozygous and homozygous mutant mice, with 10 and 22 mm Mg lower systolic blood pressure, respectively, than that of wild-type littermates. Both the levels of renin mRNA in the kidney and plasma renin activity were markedly increased only in the homozygous mutant mice, These results demonstrated that an AT1a-mediated signal transduction pathway is, at least in part, involved in the regulation of blood pressure and renin gene expression.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; NATL INST ANIM HLTH,TSUKUBA,IBARAKI 305,JAPAN; TANABE SEIYAKU CO LTD,LEAD GENERAT RES LABS,KASHIMA,OSAKA 532,JAPAN	University of Tsukuba; University of Tsukuba; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; Mitsubishi Tanabe Pharma Corporation			Nishimatsu, Shin-ichiro/C-4188-2012; fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546				BLAIRWEST JR, 1971, AM J PHYSIOL, V220, P1309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HEALY DP, 1995, AM J PHYSIOL-RENAL, V268, pF220, DOI 10.1152/ajprenal.1995.268.2.F220; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; PINET F, 1987, J CLIN INVEST, V80, P724, DOI 10.1172/JCI113127; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Tanimoto Keiji, 1993, Journal of Reproduction and Development, V39, P19; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VANDONGEN R, 1974, AM J PHYSIOL, V226, P277, DOI 10.1152/ajplegacy.1974.226.2.277; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	18	337	341	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18719	18722		10.1074/jbc.270.32.18719	http://dx.doi.org/10.1074/jbc.270.32.18719			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642517	hybrid			2022-12-27	WOS:A1995RN95400003
J	BALI, D; SVETLANOV, A; LEE, HW; FUSCODEMANE, D; LEISER, M; LI, BJ; BARZILAI, N; SURANA, M; HOU, H; FLEISCHER, N; DEPINHO, R; ROSSETTI, L; EFRAT, S				BALI, D; SVETLANOV, A; LEE, HW; FUSCODEMANE, D; LEISER, M; LI, BJ; BARZILAI, N; SURANA, M; HOU, H; FLEISCHER, N; DEPINHO, R; ROSSETTI, L; EFRAT, S			ANIMAL-MODEL FOR MATURITY-ONSET DIABETES OF THE YOUNG GENERATED BY DISRUPTION OF THE MOUSE GLUCOKINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC BETA-CELL; MUTATIONS; ISLETS; RATS; HYPERGLYCEMIA; MELLITUS	Glucokinase catalyzes a rate-limiting step in glucose metabolism in hepatocytes and pancreatic beta cells and is considered the ''glucose sensor'' for regulation of insulin secretion, Patients with maturity-onset diabetes of the young (MODY) have heterozygous point mutations in the glucokinase gene that result in reduced enzymatic activity and decreased insulin secretion, However, it remains unclear whether abnormal liver glucose metabolism contributes to the MODY disease, Here we show that disruption of the glucokinase gene results in a phenotype similar to MODY in heterozygous mice, Reduced islet glucokinase activity causes mildly elevated fasting blood glucose levels. Hyperglycemic clamp studies reveal decreased glucose tolerance and abnormal liver glucose metabolism, These findings demonstrate a key role for glucokinase in glucose homeostasis and implicate both islets and liver in the MODY disease.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine								BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FROUGEL P, 1992, NATURE, V356, P162; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0	17	122	125	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21464	21467		10.1074/jbc.270.37.21464	http://dx.doi.org/10.1074/jbc.270.37.21464			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665557	hybrid			2022-12-27	WOS:A1995RU75700010
J	FLYNN, A; PROUD, CG				FLYNN, A; PROUD, CG			SERINE-209, NOT SERINE-53, IS THE MAJOR SITE OF PHOSPHORYLATION IN INITIATION-FACTOR EIF-4E IN SERUM-TREATED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; CAP-BINDING-PROTEIN; TRANSLATIONAL CONTROL; MESSENGER-RNAS; FACTOR-II; OVEREXPRESSION; SEQUENCE; COMPLEX; SUBUNIT; GROWTH	Ser-53 has previously been considered the major phosphorylation site in eukaryotic initiation factor (eIF)-4E, and this appeared to be supported by studies using a S53A mutant. Recently, however, several lines of evidence have indicated that Ser-53 might not be the true phosphorylation site. This prompted us to re-examine the phosphorylation site in eIF-4E using factor purified from P-32-labeled, serum-treated Chinese hamster ovary cells. Isoelectric focusing and phosphoamino acid analysis indicated the existence of a single phosphorylated serine. Edman degradation of the major radiolabeled tryptic product from P-32-labeled eIF-4E showed that the phosphorylated site was positioned three residues from the N terminus of this peptide. There are three serines in the sequence of eIF-4E that are three residues away from a tryptic cleavage site (i.e. lysine or arginine). P-32-Labeled eIF-4E was digested with trypsin, Lys-C, or trypsin followed by Glu-C and subjected to two-dimensional mapping; the data obtained eliminated two of these potential sites, leaving Ser-209. Comigration of the synthetic peptide SGS(P)(TTK)-T-209 with the radiolabeled tryptic product on (i) reverse-phase chromatography and (ii) two-dimensional mapping at different pH values confirmed that Ser-209 is the major phosphorylation site in eIF-4E in serum-stimulated Chinese hamster ovary cells.			FLYNN, A (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BU X, 1993, J BIOL CHEM, V268, P4975; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CHOI SY, 1992, J BIOL CHEM, V267, P286; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; DUNCAN R, 1987, J BIOL CHEM, V262, P380; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MCCUBBIN WD, 1988, J BIOL CHEM, V263, P17663; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6	27	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21684	21688		10.1074/jbc.270.37.21684	http://dx.doi.org/10.1074/jbc.270.37.21684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665584	hybrid			2022-12-27	WOS:A1995RU75700042
J	NANEVICZ, T; ISHII, M; WANG, L; CHEN, M; CHEN, J; TURCK, CW; COHEN, FE; COUGHLIN, SR				NANEVICZ, T; ISHII, M; WANG, L; CHEN, M; CHEN, J; TURCK, CW; COHEN, FE; COUGHLIN, SR			MECHANISMS OF THROMBIN RECEPTOR AGONIST SPECIFICITY - CHIMERIC RECEPTORS AND COMPLEMENTARY MUTATIONS IDENTIFY AN AGONIST RECOGNITION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; EXTRACELLULAR DOMAIN; BINDING; ACTIVATION; PEPTIDES; ANTAGONIST	Identification of the docking interactions by which peptide agonists activate their receptors is critical for understanding signal transduction at the molecular level. The human and Xenopus thrombin receptors respond selectively to their respective hexapeptide agonists, SFLLRN and TFRIFD. A systematic analysis of human/Xenopus thrombin receptor chimeras revealed that just two human-for-Xenopus amino acid substitutions, Phe for Asn(87) in the Xenopus receptor's amino terminal exodomain and Glu for Leu(260) in the second extracellular loop, conferred human receptor-like specificity to the Xenopus receptor. This observation prompted complementation studies to test the possibility that Arg(5a) in the human agonist peptide might normally interact with Glu(260) in, the human receptor. The mutant agonist peptide SFLLEN was a poor agonist at the wild type human receptor but an effective agonist at a mutant human receptor in which Glu(260) was converted to Arg. An ''arginine scan'' of the receptor's extracellular surface revealed additional complementary mutations in the vicinity of position 260 and weak complementation at position 87 but not elsewhere in the receptor. Strikingly, a double alanine substitution that removed negative charge from the Glu(260) region of the human receptor also effectively complemented the SFLLEN agonist. The functional complementation achieved with single Arg substitutions was thus due at least in part to neutralization of a negatively charged surface on the receptor and not necessarily to introduction of a new salt bridge. By contrast, charge neutralization did not account for the gain of responsiveness to SFLLRN seen in the human/Xenopus receptor chimeras. Thus two independent approaches, chimeric receptors and arginine scanning for complementary mutations, identified the Glu(260) region and to a lesser degree Phe(87) as important determinants of agonist specificity. These extracellular sites promote receptor responsiveness to the ''correct'' agonist and inhibit responsiveness to an ''incorrect'' agonist. They may participate directly in agonist binding or regulate agonist access to a nearby docking site.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline; NIGMS NIH HHS [GM39900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; CHEN J, 1994, J BIOL CHEM, V269, P16041; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	24	105	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21619	21625		10.1074/jbc.270.37.21619	http://dx.doi.org/10.1074/jbc.270.37.21619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665575	hybrid			2022-12-27	WOS:A1995RU75700032
J	DAVISSALINAS, J; VANNOSTRAND, WE				DAVISSALINAS, J; VANNOSTRAND, WE			AMYLOID BETA-PROTEIN AGGREGATION NULLIFIES ITS PATHOLOGICAL PROPERTIES IN CULTURED CEREBROVASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEXIN-II; PEPTIDE; DOMAIN; CDNA; DEGENERATION; DERIVATIVES; CLEAVAGE	Alzheimer's disease and related disorders are characterized by deposition of aggregated amyloid beta-protein (A beta) and accompanying pathologic changes in the neuropil and in the walls of cerebral blood vessels. A beta induces neurotoxicity in vitro, and this effect is markedly enhanced when the peptide is preaggregated. Recently, we reported that freshly solubilized A beta(1-42) can induce cellular degeneration and a striking increase in the levels of cellular amyloid beta-protein precursor and soluble A beta peptide in cultured cerebrovascular smooth muscle cells (Davis-Salinas, J., Saporito-Irwin, S. M., Cotman, C. W., and Van Nostrand, W. E, (1995) J, Neurochem. 65, 931-934). In the present study, we show that preaggregation of A beta(1-42) abolishes the ability of the peptide to induce these cellular pathologic responses in these cells in vitro. These findings suggest that distinct mechanisms for A beta-induced cytotoxicity exist for cultured neurons and cerebrovascular smooth muscle cells, supporting that different processes may be involved in the parenchymal and cerebrovascular pathology of Alzheimer's disease and related disorders.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003229, R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03229, HL49566] Funding Source: Medline; NIA NIH HHS [AG00538] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDICK D, 1992, J BIOL CHEM, V267, P546; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V54, P648; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANNOSTRAND WE, 1994, AMYLOID, V1, P1, DOI 10.3109/13506129409148618; VANNOSTRAND WE, 1989, NATURE, V341, P546; WANG R, 1991, J BIOL CHEM, V266, P16960; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; WISNIEWSKI HM, 1994, ACTA NEUROPATHOL, V87, P233; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	39	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20887	20890		10.1074/jbc.270.36.20887	http://dx.doi.org/10.1074/jbc.270.36.20887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673109	hybrid			2022-12-27	WOS:A1995RU05400005
J	LEGAULT, DJ; KELLY, RJ; NATSUKA, Y; LOWE, JB				LEGAULT, DJ; KELLY, RJ; NATSUKA, Y; LOWE, JB			HUMAN ALPHA(1,3/1,4)-FUCOSYL-TRANSFERASES DISCRIMINATE BETWEEN DIFFERENT OLIGOSACCHARIDE ACCEPTOR SUBSTRATES THROUGH A DISCRETE PEPTIDE FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; SIALYL-LEWIS-X; DETERMINES EXPRESSION; CARBOHYDRATE LIGANDS; EMBRYONIC ANTIGEN; MOLECULAR-CLONING; LUNG INJURY; ELAM-1; RECOGNITION	Five different human alpha(1,3)-fucosyltransferase (alpha(1,3)-Fuc-T) genes have been cloned, Their corresponding enzymes catalyze the formation of various alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides, including several that mediate leukocyte-endothelial cell adhesion during inflammation, Inhibitors of such enzymes are predicted to operate as anti-inflammatory agents; in principle, the isolation or design of such agents may be facilitated by identifying peptide segment(s) within these enzymes that interact with their oligosaccharide acceptor substrates, Little is known, however, about the structural features of alpha(1,3)-Fuc-Ts that dictate acceptor substrate specificity. To begin to address this problem, we have created and functionally characterized a series of 21 recombinant alpha(1,3)-Fuc-T chimeras derived from three human alpha(1,3)-Fuc-Ts (Fuc-TIII, Fuc-TV, and Fuc-TVI) that maintain shared and distinct polypeptide domains and that exhibit common as well as idiosyncratic acceptor substrate specificities, The in vivo acceptor substrate specificities of these alpha(1,3)-Fuc-T chimeras, and of their wild type progenitors, were determined by characterizing the cell surface glycosylation phenotype determined by these enzymes, after expressing them in a mammalian cell line informative for the synthesis of four distinct alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides (Lewis x, sialyl Lewis x, Lewis a, and sialyl Lewis a), Our results indicate that as few as 11 nonidentical amino acids, found within a ''hypervariable'' peptide segment positioned at the NH2 terminus of the enzymes' sequence-constant COOH-terminal domains, determines whether or not these alpha(1,3)-Fuc-T can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIDDK NIH HHS [K11 DK02189] Funding Source: Medline; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; AUSUBEL J, 1987, MOL BIOL LABORATORY, V2; AUSUBEL J, 1987, MOL BIOL LABORATORY, V1; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BERG EL, 1991, J BIOL CHEM, V266, P14869; BLASZCZYK M, 1984, ARCH BIOCHEM BIOPHYS, V233, P161, DOI 10.1016/0003-9861(84)90612-X; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BUERKE M, 1994, J CLIN INVEST, V93, P1140, DOI 10.1172/JCI117066; CHIA D, 1985, CANCER RES, V45, P435; ERNST LK, 1989, J BIOL CHEM, V265, P3436; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWER JB, 1994, FRONTIERS MOL BIOL; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maniatis T, 1989, DECONTAMINATION DILU; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAIKI RK, 1985, SCIENCE, V230, P1370; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SMITH PL, 1994, J BIOL CHEM, V269, P15162; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YOUNG WW, 1981, J BIOL CHEM, V256, P967; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	47	78	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20987	20996		10.1074/jbc.270.36.20987	http://dx.doi.org/10.1074/jbc.270.36.20987			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673123	hybrid			2022-12-27	WOS:A1995RU05400020
J	ABRAMOCHKIN, G; SHRADER, TE				ABRAMOCHKIN, G; SHRADER, TE			THE LEUCY/PHENYLALANYL-TRANSFER-RNA-PROTEIN TRANSFERASE - OVEREXPRESSION AND CHARACTERIZATION OF SUBSTRATE RECOGNITION, DOMAIN-STRUCTURE, AND SECONDARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ESCHERICHIA-COLI; ENZYMATIC MODIFICATION; PEPTIDYL TRANSFERASE; CLONING; GENE; RNA; PURIFICATION; LEUCYL; BIOSYNTHESIS	Previous work has shown that, in the bacterium Escherichia coli, the aat gene is essential for the degradation of proteins bearing amino-terminal Arg and Lys residues via the N-end rule pathway of protein degradation. We now show that the aat gene encodes directly the leucy/phenylalanyl-tRNA-protein transferase (L/F-transferase). This enzyme catalyzes the transfer of Leu, Phe, and, less efficiently, Met and Trp, from aminoacyl-tRNAs, to the amino terminus of acceptor proteins. We have used the cloned oat gene to overexpress and purify an affinity tagged L/F-transferase. The recombinant L/F-transferase is as active as the previously purified wild type enzyme and contains no detectable RNA component. We have used the recombinant enzyme to demonstrate that both the solubility and substrate specificity, for aminoacyl-tRNA substrates, of the L/F transferase are dependent on ionic strength conditions and that the modified nucleotides found in natural tRNAs are not essential for recognition by the enzyme. Limited digestion of the L/F-transferase with trypsin removes the proline rich NH2 terminus of the enzyme identifying a globular core, and circular dichroism demonstrates that the L/F-transferase is predominantly alpha-helical. Finally, a region of sequence conservation between the LIF-transferase and the NH2-terminal protein acetylases has been identified.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT ANAT,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT BIOL STRUCT,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine								BALZI E, 1990, J BIOL CHEM, V265, P7464; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; Clark Brian F. C., 1995, P423; CONGDON RW, 1993, ANAL BIOCHEM, V213, P417; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P10199, DOI 10.1093/nar/15.24.10199; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAJI A, 1965, J BIOL CHEM, V240, P1185; LEIBOWITZ MJ, 1971, J BIOL CHEM, V246, P5207; LEIBOWITZ MJ, 1971, J BIOL CHEM, V246, P4431; LEIBOWITZ MJ, 1970, J BIOL CHEM, V245, P2066; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; Miller J. H, 1972, EXPT MOL GENETICS; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PETERSON ET, 1993, EMBO J, V12, P2959, DOI 10.1002/j.1460-2075.1993.tb05958.x; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCARPULLA RC, 1976, BIOCHEM BIOPH RES CO, V71, P584, DOI 10.1016/0006-291X(76)90827-5; SHERMAN MY, 1992, EMBO J, V11, P71; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIEGELE DA, 1993, GENE DEV, V7, P2629, DOI 10.1101/gad.7.12b.2629; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SOFFER RL, 1973, J BIOL CHEM, V248, P8424; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; YANG JT, 1986, METHOD ENZYMOL, V130, P208; [No title captured]	35	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20621	20628		10.1074/jbc.270.35.20621	http://dx.doi.org/10.1074/jbc.270.35.20621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657641	hybrid			2022-12-27	WOS:A1995RR58400060
J	BOOR, KJ; DUNCAN, ML; PRICE, CW				BOOR, KJ; DUNCAN, ML; PRICE, CW			GENETIC AND TRANSCRIPTIONAL ORGANIZATION OF THE REGION ENCODING THE BETA-SUBUNIT OF BACILLUS-SUBTILIS RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIFAMPICIN-RESISTANT; NUCLEOTIDE-SEQUENCE; AUTOGENOUS REGULATION; RPOB GENE; TERMINATION; MUTATIONS; PROTEIN; DNA; CLUSTER	The gene encoding the beta subunit of Bacillus subtilis RNA polymerase was isolated from a lambda gt11 expression library using an antibody probe. Gene identity was confirmed by the similarity of its predicted product to the Escherichia coli beta subunit and by mapping an alteration conferring rifampicin resistance within the conserved rif coding region. Including the rif region, four colinear blocks of sequence similarity were shared between the B. subtilis and E. coli beta subunits. In E. coli, these conserved blocks are separated by three regions that either were not conserved or were entirely absent from the B. subtilis protein. The B. subtilis beta gene was part of a cluster with the order rplL (encoding ribosomal protein L7/L12), orf23 (encoding a 22,513-dalton protein that is apparently essential for growth), rpoB (beta), and rpoC (beta'). This organization differs from the corresponding region in E. coli by the inclusion of orf23. Experiments using promoter probe vectors and site directed mutagenesis located a major rpoB promoter overlapping the 3'-coding region of orf23, 250 nucleotides upstream from the beta initiation codon. Thus, the B. subtilis rpoB region differs from its E. coli counterpart in both genetic and transcriptional organization.	UNIV CALIF DAVIS,DEPT FOOD SCI & TECHNOL,DAVIS,CA 95616	University of California System; University of California Davis			Price, Chester/M-6900-2019; Boor, Kathryn/B-3545-2009	Boor, Kathryn/0000-0001-6810-3434	NIGMS NIH HHS [GM08343, GM42077] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008343, R01GM042077] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BARRY G, 1979, P NATL ACAD SCI USA, V76, P4922, DOI 10.1073/pnas.76.10.4922; BEDWELL DM, 1986, MOL GEN GENET, V204, P17, DOI 10.1007/BF00330181; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BOYLAN SA, 1989, J BACTERIOL, V171, P2553, DOI 10.1128/jb.171.5.2553-2562.1989; CLARK MA, 1992, CURR MICROBIOL, V25, P283, DOI 10.1007/BF01575863; DABBS ER, 1984, J BACTERIOL, V159, P770, DOI 10.1128/JB.159.2.770-772.1984; Davis R., 1980, ADV BACTERIAL GENETI; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; DUNCAN ML, 1987, J BACTERIOL, V169, P771, DOI 10.1128/jb.169.2.771-778.1987; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GLASS RE, 1988, EUR J BIOCHEM, V176, P403, DOI 10.1111/j.1432-1033.1988.tb14296.x; GLASS RE, 1986, MOL GEN GENET, V203, P492, DOI 10.1007/BF00422075; HALLING SM, 1977, J BIOL CHEM, V252, P9024; HEIL A, 1970, FEBS LETT, V11, P165, DOI 10.1016/0014-5793(70)80519-1; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; KASHLEV MV, 1989, GENETIKA+, V25, P396; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; Leighton T. J., 1971, J BIOL CHEM, V252, P268; LINN T, 1978, NATURE, V276, P33, DOI 10.1038/276033a0; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MEEK DW, 1986, MOL GEN GENET, V202, P500, DOI 10.1007/BF00333284; Miller J.H., 1972, EXPT MOL GENETICS; MILLER LP, 1994, ANTIMICROB AGENTS CH, V38, P805, DOI 10.1128/AAC.38.4.805; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; NEFF NF, 1980, BIOCHEMISTRY-US, V19, P3005, DOI 10.1021/bi00554a027; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PASSADOR L, 1989, J BACTERIOL, V171, P6234, DOI 10.1128/jb.171.11.6234-6242.1989; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perego Marta, 1993, P615; PIGGOT PJ, 1984, J GEN MICROBIOL, V130, P2123; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; PRICE CW, 1985, MOL GEN GENET, V210, P88; ROTHSTEIN DM, 1976, RNA POLYMERASE, P601; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; SCHAUS NA, 1981, ICN UCLA S MOL CELL, V22, P315; SCHULTZ W, 1981, NUCLEIC ACIDS RES, V24, P6889; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SHAABAN SA, 1995, MOL CELL BIOL, V75, P1467; SNYDER L, 1988, GENETICS, V118, P173; SNYDER M, 1985, HYBRIDOMA TECHNOLOGY, P397; SPARKOWSKI J, 1992, GENETICS, V130, P411; STEWARD KL, 1991, J MOL BIOL, V218, P23, DOI 10.1016/0022-2836(91)90870-C; SUH JW, 1986, J BACTERIOL, V168, P65, DOI 10.1128/jb.168.1.65-71.1986; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VARON D, 1993, J BACTERIOL, V175, P3964; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; YAMAMOTO M, 1978, P NATL ACAD SCI USA, V75, P3891, DOI 10.1073/pnas.75.8.3891; YANOFSKY C, 1981, J BACTERIOL, V145, P1334, DOI 10.1128/JB.145.3.1334-1341.1981	71	46	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20329	20336		10.1074/jbc.270.35.20329	http://dx.doi.org/10.1074/jbc.270.35.20329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657605	hybrid			2022-12-27	WOS:A1995RR58400018
J	CZAJA, C; LITWILLER, R; TOMLINSON, AJ; NAYLOR, S; TAVARES, P; LEGALL, J; MOURA, JJG; MOURA, I; RUSNAK, F				CZAJA, C; LITWILLER, R; TOMLINSON, AJ; NAYLOR, S; TAVARES, P; LEGALL, J; MOURA, JJG; MOURA, I; RUSNAK, F			EXPRESSION OF DESULFOVIBRIO-GIGAS DESULFOREDOXIN IN ESCHERICHIA-COLI - PURIFICATION AND CHARACTERIZATION OF MIXED-METAL ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; PLASMA EMISSION-SPECTROSCOPY; AMINO-ACID-SEQUENCE; HEME IRON PROTEIN; HILDENBOROUGH; MOSSBAUER; RESONANCE; GENES; RBO	The dsr gene from Desulfovibrio gigas encoding the nonheme iron protein desulforedoxin was cloned using the polymerase chain reaction, expressed in Escherichia coli, and purified to homogeneity. The physical and spectroscopic properties of the recombinant protein resemble those observed for the native protein isolated from D. gigas. These include an alpha(2) tertiary structure, the presence of bound iron, and absorbance maxima at 370 and 506 nm in the UV/visible spectrum due to ligand-to-iron charge transfer bands. Low temperature electron paramagnetic resonance studies confirm the presence of a high spin ferric ion with g values of 7.7, 5.7, 4.1, and 1.8. Interestingly, E. coli produced two forms of desulforedoxin containing iron. One form was identified as a dimer with the metal-binding sites of both subunits occupied by iron while the second form contained equivalent amounts of iron and zinc and represents a dimer with one subunit occupied by iron and the second with zinc.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOMED MASS SPECTROMETRY FACIL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602	Mayo Clinic; Mayo Clinic; Mayo Clinic; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; Tavares, Pedro/B-3654-2008	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Tavares, Pedro/0000-0002-7398-2661	NIGMS NIH HHS [GM46865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER M, 1995, IN PRESS J MOL BIOL, V251; BACHMAYE.H, 1967, P NATL ACAD SCI USA, V57, P122, DOI 10.1073/pnas.57.1.122; BRADDOCK WD, 1994, 42ND P ASMS C MASS S, P409; BRUMLIK MJ, 1990, J BACTERIOL, V172, P7289, DOI 10.1128/jb.172.12.7289-7292.1990; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; BRUSCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P596, DOI 10.1016/0006-291X(79)91277-4; CHORY J, 1990, CURRENT PROTOCOLS MO; DEBRUNNER PG, 1977, IRON SULFUR PROTEINS, V3, P381; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FASSEL VA, 1978, SCIENCE, V202, P183, DOI 10.1126/science.202.4364.183; LEE JC, 1974, ARCH BIOCHEM BIOPHYS, V165, P268, DOI 10.1016/0003-9861(74)90164-7; LOVENBERG W, 1969, BIOCHEMISTRY-US, V8, P141, DOI 10.1021/bi00829a020; LOVENBERG W, 1965, P NATL ACAD SCI USA, V54, P193, DOI 10.1073/pnas.54.1.193; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1978, BIOCHIM BIOPHYS ACTA, V533, P156, DOI 10.1016/0005-2795(78)90559-7; MOURA I, 1991, J INORG BIOCHEM, V44, P127, DOI 10.1016/0162-0134(91)84025-5; MOURA I, 1980, J BIOL CHEM, V255, P2493; MOURA I, 1990, J BIOL CHEM, V265, P21596; NIXON DE, 1986, CLIN CHEM, V32, P1660; PEISACH J, 1971, J BIOL CHEM, V246, P5877; PHILLIPS WD, 1970, NATURE, V227, P574, DOI 10.1038/227574a0; RUSNAK F, 1995, INORG CHEM, V34, P3833, DOI 10.1021/ic00118a037; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO; TAVARES P, 1994, J BIOL CHEM, V269, P10504; VERHAGEN MFJM, 1993, FEBS LETT, V336, P13, DOI 10.1016/0014-5793(93)81599-U; WILSON K, 1994, CURRENT PROTOCOLS MO; YACHANDRA VK, 1983, J AM CHEM SOC, V105, P6455, DOI 10.1021/ja00359a015	31	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20273	20277		10.1074/jbc.270.35.20273	http://dx.doi.org/10.1074/jbc.270.35.20273			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657596	Green Submitted, hybrid			2022-12-27	WOS:A1995RR58400009
J	GJERTSEN, BT; MELLGREN, G; OTTEN, A; MARONDE, E; GENIESER, HG; JASTORFF, B; VINTERMYR, OK; MCKNIGHT, GS; DOSKELAND, SO				GJERTSEN, BT; MELLGREN, G; OTTEN, A; MARONDE, E; GENIESER, HG; JASTORFF, B; VINTERMYR, OK; MCKNIGHT, GS; DOSKELAND, SO			NOVEL (RP)-CAMPS ANALOGS AS TOOLS FOR INHIBITION OF CAMP-KINASE IN CELL-CULTURE - BASAL CAMP-KINASE ACTIVITY MODULATES INTERLEUKTIN-1-BETA ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE LYMPHOMA-CELLS; ADENOSINE CYCLIC 3',5'-PHOSPHOROTHIOATE; ISOLATED RAT HEPATOCYTES; CATALYTIC SUBUNIT; BINDING-SITES; AMP; PHOSPHORYLATION; EXPRESSION; ACTIVATION	Novel (Rp)-cAMPS analogs differed widely in ability to antagonize cAMP activation of pure cAMP-dependent protein kinase I and II and to antagonize actions of cAMP on gene expression, shape change, apoptosis, DNA replication, and protein phosphorylation in intact cells. These differences were related to different abilities of the analogs to stabilize the holoenzyme form relative to the dissociated form of cAMP kinase type I and II. (Rp)-8-Br-cAMPS and (Rp)-8-Cl-cAMPS were the most potent cAMP antagonists for isolated type I kinase and for cells expressing mostly type I kinase, like IPC-81 leukemia cells, fibroblasts transfected with type I regulatory subunit (RI), and primary hepatocytes. It is proposed that (Rp)-8-Er-cAMPS or (Rp)-8-Cl-cAMPS should replace (Rp)-cAMPS as the first line cAMP antagonist, particularly for studies in cells expressing predominantly type I kinase. The phosphorylation of endogenous hepatocyte proteins was affected oppositely by (Rp)-8-Br-cAMPS and increased cAMP, indicating that (Rp)-8-Br-cAMPS inhibited basal cAMP-kinase activity. The inhibition of basal kinase activity was accompanied by enhanced DNA replication, an effect which could be reproduced by micro injected mutant cAMP subresponsive RI. It is concluded that the basal cAMP-kinase activity exerts a tonic inhibition of hepatocyte replication. (Rp)-8-Br-cAMPS and microinjected RI also desensitized hepatocytes toward inhibition of DNA synthesis by interleukin-1 beta. This indicates that basal cAMP-kinase activity can have a permissive role for the action of another (interleukin-1 beta) signaling pathway.	UNIV BERGEN,DEPT ANAT & CELL BIOL,N-5009 BERGEN,NORWAY; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; BIOLOG LIFE SCI INST,D-28071 BREMEN,GERMANY; UNIV BREMEN,INST ORGAN CHEM,D-28359 BREMEN,GERMANY	University of Bergen; University of Washington; University of Washington Seattle; University of Bremen			Mellgren, Gunnar/AAG-6573-2020; Gjertsen, Bjørn T/AAP-3281-2020; Maronde, Erik/J-1915-2019; Gjertsen, Bjorn T/O-1542-2015	Mellgren, Gunnar/0000-0001-6282-4986; Gjertsen, Bjørn T/0000-0001-9358-9704; Maronde, Erik/0000-0002-5574-6323; Gjertsen, Bjorn T/0000-0001-9358-9704; Doskeland, Stein Ove/0000-0002-4009-4756; Genieser, Hans-Gottfried/0000-0002-4904-5790	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32875] Funding Source: Medline; PHS HHS [ML 44948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BEEBE SJ, 1988, INITIATION TERMINATI, V159, P139; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BRUSTUGUN OT, 1995, EXP CELL RES, V219, P372, DOI 10.1006/excr.1995.1241; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CONNELLY PA, 1987, J BIOL CHEM, V262, P4324; COULSON R, 1983, LIFE SCI, V32, P1489, DOI 10.1016/0024-3205(83)90915-3; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1991, CELL SIGNALLING EXPT, V21, P103; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; EKANGER R, 1989, J BIOL CHEM, V264, P4374; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GENIESER HG, 1988, TETRAHEDRON LETT, V29, P2803, DOI 10.1016/0040-4039(88)85214-6; GENIESER HG, 1992, CARBOHYD RES, V234, P217, DOI 10.1016/0008-6215(92)85050-A; GJERTSEN BT, 1993, J BIOL CHEM, V268, P8332; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GWOSDOW AR, 1993, ENDOCRINOLOGY, V132, P710, DOI 10.1210/en.132.2.710; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HOHMANN P, 1993, CELL PROLIFERAT, V26, P195, DOI 10.1111/j.1365-2184.1993.tb00019.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KISS Z, 1985, FEBS LETT, V180, P207, DOI 10.1016/0014-5793(85)81072-3; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; OBRIAN CA, 1982, BIOCHEMISTRY-US, V21, P4371, DOI 10.1021/bi00261a028; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; ROSSI B, 1993, EUR CYTOKINE NETW, V4, P181; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P5294; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; ROTHERMEL JD, 1983, J BIOL CHEM, V258, P2125; SCHAFER C, 1994, CAN J PHYSIOL PHARM, V72, P1138, DOI 10.1139/y94-161; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STEINBERG RA, 1985, BIOCHEM J, V227, P987, DOI 10.1042/bj2270987; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STEINBERG RA, 1991, MOL CELL BIOL, V11, P705, DOI 10.1128/MCB.11.2.705; TAKAHASHI S, 1991, J BIOL CHEM, V266, P19894; TAYLOR SS, 1993, PHILOS T ROY SOC B, V340, P315, DOI 10.1098/rstb.1993.0073; VANHAASTERT PJM, 1983, EUR J BIOCHEM, V131, P659; VINTERMYR OK, 1993, J CELL PHYSIOL, V156, P160, DOI 10.1002/jcp.1041560122; WEITZMANN MN, 1993, BIOCHEM BIOPH RES CO, V190, P564, DOI 10.1006/bbrc.1993.1085	52	221	224	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20599	20607		10.1074/jbc.270.35.20599	http://dx.doi.org/10.1074/jbc.270.35.20599			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657638	hybrid			2022-12-27	WOS:A1995RR58400057
J	JARUZELSKA, J; ABADIE, V; DAUBENTONCARAFA, Y; BRODY, E; MUNNICH, A; MARIE, J				JARUZELSKA, J; ABADIE, V; DAUBENTONCARAFA, Y; BRODY, E; MUNNICH, A; MARIE, J			IN-VITRO SPLICING DEFICIENCY INDUCED BY A C-TO-T MUTATION AT POSITION--3 IN THE INTRON-10 ACCEPTOR SITE OF THE PHENYLALANINE-HYDROXYLASE GENE IN A PATIENT WITH PHENYLKETONURIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER RNA; MAMMALIAN INTRONS; POLYPYRIMIDINE TRACT; BETA-THALASSEMIA; ACTIVE-SITE; U6 SNRNA; SELECTION; SPLICEOSOME; SEQUENCES; INVITRO	A previous study has identified a C --> U mutation at position -3 in the 3' splice site of intron 10 of the phenylalanine hydroxylase pre-mRNA in a patient with phenylketonuria. In vivo, this mutation induces the skipping of the downstream exon. This result is puzzling because both CAG and UAG have been reported to function equally as 3' splice sites. In this report, we show that the C --> U mutation affects predominantly the first step of the splicing reaction and that it blocks spliceosome assembly at an early stage. The 3' region of the phenylalanine hydroxylase intron 10 has two unusual characteristic features: multiple potential branch sites and a series of four guanosine residues, which interrupt the polypyrimidine tract at positions -8 to -11 from the 3' splice site. We show that the mutation precludes the use of the proximal branch site, while having no effect on the remote one. We also show that in the UAG transcript, the four guanosine residues inhibit the splicing of intron 10. The substitution of these purine residues by one cytosine residue, regardless of the position, increases the splicing efficiency of the mutant UAG precursor while having no effect on the wild type CAG precursor. Substituting the four purine residues by four pyrimidines relieves the inhibition and rescues the use of the proximal branch site. These results demonstrate that according to the context, the C and U nucleotides preceding the AG are not equivalent for the splicing reaction.	UNIV PARIS 06,CNRS LAB,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; HOP ENFANTS MALAD,INSERM,U12,F-75015 PARIS,FRANCE; SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Jaruzelska, Jadwiga/0000-0003-2355-0729				ABADIE V, 1993, HUM MOL GENET, V2, P31, DOI 10.1093/hmg/2.1.31; ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BIENVENU T, 1994, HUM GENET, V94, P65, DOI 10.1007/BF02272843; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILELLA AG, 1986, BIOCHEMISTRY-US, V25, P743, DOI 10.1021/bi00352a001; DWORNICZAK B, 1991, GENOMICS, V11, P242, DOI 10.1016/0888-7543(91)90129-3; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HELFMAN DM, 1989, NUCLEIC ACIDS RES, P5633; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAWCZAK M, 1992, HUM GENET, V90, P41; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Maniatis T., 1982, MOL CLONING; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Moore M., 1993, RNA WORLD, P303; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; SOLNICK D, 1981, NATURE, V291, P508, DOI 10.1038/291508a0; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WONG C, 1989, BLOOD, V73, P914; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	47	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20370	20375		10.1074/jbc.270.35.20370	http://dx.doi.org/10.1074/jbc.270.35.20370			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657610	hybrid			2022-12-27	WOS:A1995RR58400023
J	NAGATA, Y; NAGAHISA, H; AIDA, Y; OKUTOMI, K; NAGASAWA, T; TODOKORO, K				NAGATA, Y; NAGAHISA, H; AIDA, Y; OKUTOMI, K; NAGASAWA, T; TODOKORO, K			THROMBOPOIETIN INDUCES MEGAKARYOCYTE DIFFERENTIATION IN HEMATOPOIETIC PROGENITOR FDC-P2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTORS; GENE-EXPRESSION; RECEPTOR GENE; GROWTH	Thrombopoietin (Tpo) is a cytokine that specifically regulates megakaryocyte maturation and platelet production. Little is known about the molecular and cellular mechanism of the Tpo-induced megakaryocyte maturation process including polyploidization and platelet release. To study Tpo-induced megakaryocyte differentiation, a mouse cell line FD-TPO, which responds and grows with Tpo, was established from a interleukin-3-dependent hematopoietic progenitor cell line FDC-P2, The FD-TPO cells, expressing endogenous Tpo receptor, grew with Tpo in a dose-dependent manner. Further, Tpo stimulation dramatically induced expression of megakaryocyte/erythroid-specific transcription factors GATA-1 and NF-EP in FD-TPO cells. Flow cytometry analysis demonstrated that expression of platelet-specific cell surface antigens including CD61 (GPIIIa) dramatically increased in Tpo-stimulated FD-TPO cells and that expression of myeloid-specific antigens, Gr-l and Mac-1, decreased. Therefore, we concluded that the binding of Tpo to FD-TPO cells induces not only cell growth but also differentiation into mature megakaryocyte-like cells, and thus this cell line was found to be useful for the study of Tpo receptor-mediated growth and differentiation signals.	RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST CLIN MED,DIV HEMATOL,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; University of Tsukuba								ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; METHIA N, 1993, BLOOD, V82, P1395; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ORKIN SH, 1992, BLOOD, V80, P575; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VISVADER JE, 1992, EMBO J, V12, P4557; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	16	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19673	19675		10.1074/jbc.270.34.19673	http://dx.doi.org/10.1074/jbc.270.34.19673			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649975	hybrid			2022-12-27	WOS:A1995RQ99100002
J	BOIE, Y; SAWYER, N; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M				BOIE, Y; SAWYER, N; SLIPETZ, DM; METTERS, KM; ABRAMOVITZ, M			MOLECULAR-CLONING AND CHARACTERIZATION OF THE HUMAN PROSTANOID DP RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; HIGH-AFFINITY; PROSTAGLANDIN-D2; EXPRESSION; CELLS; ANTAGONIST; SUBTYPE; PGD2; CDNA; STIMULATION	A cDNA encoding a functional human prostanoid DP (hDP) receptor has been constructed from a genomic clone and a fragment cloned by 3'-rapid amplification of cDNA ends-polymerase chain reaction. The hDP receptor consists of 359 amino acid residues with a predicted molecular mass of 40,276 and has the putative heptahelical transmembrane domains characteristic of G-protein-coupled receptors. The deduced amino acid sequence of the hDP receptor, when compared with ail other members of the prostanoid receptor family, shows the highest degree of identity with the hIP and hEP(2) receptors, followed by the hEP(4) receptor. Radioreceptor binding studies using membranes prepared from mammalian COS-M6 cells transiently transfected with an expression vector containing the DP receptor cDNA showed that the rank order of affinities for prostaglandins and prostaglandin analogs, in competition for [H-3]prostaglandin D-2 (PGD(2)) specific binding sites, was as predicted for the DP receptor, with PGD(2) >> PGE(2) > PGF(2 alpha) = iloprost > U46619. The signal transduction pathway of the cloned hDP receptor was studied by transfecting the hDP expression vector into HEK 293(EBNA) cells, Activation of the hDP receptor with PGD(2) resulted in an elevation of intracellular cAMP and in mobilization of Ca2+, but did not lead to generation of inositol 1,4,5-trisphosphate. Northern blot analysis of human tissues showed that the hDP receptor has a very discrete tissue distribution and was detectable only in retina and small intestine. In summary, we have cloned and expressed a functional cDNA for the hDP receptor.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company								ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; DARIUS H, 1994, EUR J PHARMACOL, V258, P207, DOI 10.1016/0014-2999(94)90482-0; DAVIES P, 1992, INFLAMMATION BASIC P, P123; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; FUNK CD, 1993, J BIOL CHEM, V268, P26767; GILES H, 1989, BRIT J PHARMACOL, V96, P291, DOI 10.1111/j.1476-5381.1989.tb11816.x; HAMIDBLOOMFIELD S, 1990, BRIT J PHARMACOL, V100, P761, DOI 10.1111/j.1476-5381.1990.tb14089.x; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; ITO S, 1990, BRIT J PHARMACOL, V99, P13, DOI 10.1111/j.1476-5381.1990.tb14645.x; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JOHNSTON SL, 1993, J ALLERGY CLIN IMMUN, V91, P903, DOI 10.1016/0091-6749(93)90348-J; KANTHA SS, 1994, PROSTAG LEUKOTR ESS, V51, P87, DOI 10.1016/0952-3278(94)90083-3; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; Kimura M., 1983, NEUTRAL THEORY MOL E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKE S, 1994, FEBS LETT, V355, P317, DOI 10.1016/0014-5793(94)01198-2; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MATSUMURA H, 1994, P NATL ACAD SCI USA, V91, P11998, DOI 10.1073/pnas.91.25.11998; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAKAJIMA M, 1991, GRAEF ARCH CLIN EXP, V229, P411, DOI 10.1007/BF00166301; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NEY P, 1991, EICOSANOIDS, V4, P21; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OKUDAASHITAKA E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P148, DOI 10.1016/0167-4889(93)90190-Z; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU T, 1982, J BIOL CHEM, V257, P13570; SUGAMA K, 1989, BIOCHIM BIOPHYS ACTA, V1011, P75, DOI 10.1016/0167-4889(89)90081-5; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; THIERAUCH KH, 1988, PROSTAGLANDINS, V35, P855, DOI 10.1016/0090-6980(88)90112-8; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; VIRGOLINI I, 1992, J BIOL CHEM, V267, P12700; WATSON S, 1993, TRENDS PHARM SCI S, P31; WHEELDON A, 1993, BRIT J PHARMACOL, V108, P1051, DOI 10.1111/j.1476-5381.1993.tb13504.x; WOODWARD DF, 1993, EUR J PHARMACOL, V230, P327, DOI 10.1016/0014-2999(93)90569-4; YOSHIMURA S, 1989, BIOCHIM BIOPHYS ACTA, V981, P69, DOI 10.1016/0005-2736(89)90083-7	53	286	307	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18910	18916		10.1074/jbc.270.32.18910	http://dx.doi.org/10.1074/jbc.270.32.18910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642548	hybrid			2022-12-27	WOS:A1995RN95400035
J	KRAEMER, DM; STRAMBIODECASTILLIA, C; BLOBEL, G; ROUT, MP				KRAEMER, DM; STRAMBIODECASTILLIA, C; BLOBEL, G; ROUT, MP			THE ESSENTIAL YEAST NUCLEOPORIN NUP159 IS LOCATED ON THE CYTOPLASMIC SIDE OF THE NUCLEAR-PORE COMPLEX AND SERVES IN KARYOPHERIN-MEDIATED BINDING OF TRANSPORT SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 STEPS; PROTEIN; SACCHAROMYCES; TRANSLOCATION; ENVELOPE; IMPORT	We have identified a new yeast nucleoporin of 159 kDa that me term NUP159. Immunofluorescence microscopy with a monospecific monoclonal antibody against NUP159 gave the punctate nuclear rim staining characteristic of nucleoporins, Immunogold electron microscopy with isolated yeast NEs yielded decoration of only the cytoplasmic side of the nuclear pore complex, The gene encoding NUP159 is essential, and, like some other nucleoporins, NUP159 contains a coiled-coil domain as well as a domain of repeated motifs, Five segments of NUP159, covering its entire length, were expressed in Escherichia coli, The repeat motif-containing segment was found to bind a nuclear transport substrate in the presence of vertebrate cytosolic extract containing nuclear transport factors, This segment also bound S-35-labeled mammalian karyopherin beta, one such transport factor that mediates the docking of substrates to the nuclear pore complex, These data establish a direct biochemical link between the repeat motif domain of a yeast nucleoporin, transport factors, (specifically karyopherin beta), and nuclear transport substrates. Its cytoplasmic aspect implies a role for NUP159 in nuclear import.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University			Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X; Strambio De Castillia, Caterina/0000-0002-1069-1816				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KILMARTIN JV, 1982, MICROTUBULES MICROOR, P157; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, IN PRESS P NATL ACAD; PEMBERTON LF, 1995, P NATL ACAD SCI USA, V92, P1187, DOI 10.1073/pnas.92.4.1187; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SHERMAN F, 1991, METHODS YEAST GENETI; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; WRAY BE, 1984, J HISTOCHEM CYTOCHEM, V32, P1117, DOI 10.1177/32.10.6481151; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209	35	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19017	19021		10.1074/jbc.270.32.19017	http://dx.doi.org/10.1074/jbc.270.32.19017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642562	hybrid			2022-12-27	WOS:A1995RN95400050
J	CHESNOKOV, IN; SCHMID, CW				CHESNOKOV, IN; SCHMID, CW			SPECIFIC ALU BINDING-PROTEIN FROM HUMAN SPERM CHROMATIN PREVENTS DNA METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; PURIFICATION; REPEATS; NUCLEI; CELLS	A protein from human sperm nuclei that specifically binds to Alu DNA repeats has been purified. The specific DNA binding site of this protein within the Alu sequence has been mapped by methylation interference and electrophoretic mobility shift assays. This sperm Alu binding protein selectively protects Alu elements from methylation in vitro and may be responsible for the unmethylated state of Alu sequences in the male germ line resulting in a parent-specific differential inheritance of Alu methylation.	UNIV CALIF DAVIS, MOLEC & CELLULAR BIOL PROGRAM, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis				Chesnokov, Igor/0000-0002-6659-2913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1994, CURRENT PORTOCOLS MO; BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHESNOKOV I, 1991, BIOCHEM BIOPH RES CO, V178, P613, DOI 10.1016/0006-291X(91)90152-W; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOCHANEK S, 1993, NUCLEIC ACIDS RES, V21, P2339, DOI 10.1093/nar/21.10.2339; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; PERELYGINA LM, 1987, MOL BIOL REP, V12, P111, DOI 10.1007/BF00368878; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RUBIN CM, 1994, NUCLEIC ACIDS RES, V22, P5121, DOI 10.1093/nar/22.23.5121; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, P323; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; ZALENSKY AO, 1993, MOL REPROD DEV, V36, P164, DOI 10.1002/mrd.1080360207	29	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18539	18542		10.1074/jbc.270.31.18539	http://dx.doi.org/10.1074/jbc.270.31.18539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629183	hybrid			2022-12-27	WOS:A1995RM64200061
J	FUKUTA, M; UCHIMURA, K; NAKASHIMA, K; KATO, M; KIMATA, K; SHINOMURA, T; HABUCHI, O				FUKUTA, M; UCHIMURA, K; NAKASHIMA, K; KATO, M; KIMATA, K; SHINOMURA, T; HABUCHI, O			MOLECULAR-CLONING AND EXPRESSION OF CHICK CHONDROCYTE CHONDROITIN 6-SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE SULFOTRANSFERASE; EMBRYO CHONDROCYTES; CULTURED CHONDROCYTES; MAST-CELLS; PROTEOGLYCAN; PURIFICATION; BIOSYNTHESIS; TIBIOTARSUS; TRANSLATION; SECRETION	Chondroitin 6-sulfotransferase (C6ST) catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phos-phosulfate to position 6 of the N-acetylgalactosamine residue of chondroitin. The enzyme has been purified previously to apparent homogeneity from the serum free culture medium of chick chondrocytes. The purified enzyme also catalyzed the sulfation of keratan sulfate. We have now cloned the cDNA of the enzyme. This cDNA contains a single open reading frame that predicts a protein composed of 458 amino acid residues. The protein predicts a Type II transmembrane topology similar to other glycosyltransferases and heparin/heparan sulfate N-sulfotransferase/N-deacetylases. Evidence that the predicted protein corresponds to the previously purified C6ST was the following: (a) the predicted sequence of the protein contains all of the known amino acid sequence, (b) when the cDNA was introduced in a eukaryotic expression vector and transfected in COS-7 cells, both the C6ST activity and the keratan sulfate sulfotransferase activity were overexpressed, (c) a polyclonal antibody raised against a fusion peptide, which was expressed from a cDNA containing the sequence coding for 150) amino acid residues of the predicted protein, cross-reacted to the purified C6ST, and (d) the predicted protein contained six potential sites for N-glycosylation, which corresponds to the observation that the purified C6ST is an N-linked glycoprotein. The aminoterminal amino acid sequence of the purified protein was found in the transmembrane domain, suggesting that the purified protein might be released from the chondrocytes after proteolytic cleavage in the transmembrane domain.	AICHI UNIV EDUC,DEPT LIFE SCI,KARIYA,AICHI 448,JAPAN; AICHI MED UNIV,INST MOLEC MED SCI,NAGAKUTE,AICHI 48011,JAPAN	Aichi University Education; Aichi Medical University			Uchimura, Kenji/C-9635-2014; Uchimura, Kenji/AFV-1802-2022	Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X				ADANY R, 1990, J BIOL CHEM, V265, P11389; ARUFFO A, 1991, CURRENT PROTOCOLS S, V14; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1985, J BIOL CHEM, V260, P3102; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HABUCHI O, 1995, J BIOL CHEM, V270, P4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KIM JJ, 1980, J BIOL CHEM, V255, P1586; KIM JJ, 1977, J BIOL CHEM, V252, P8292; KIM JJ, 1976, J BIOL CHEM, V251, P6210; KIM JJ, 1982, J BIOL CHEM, V257, P1670; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; KINGSTON RE, 1991, CURRENT PROTOCOLS S, V14; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; TSUKAHARA T, 1991, J CELL SCI, V100, P387; WLAD H, 1994, J BIOL CHEM, V269, P24538; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	42	120	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18575	18580		10.1074/jbc.270.31.18575	http://dx.doi.org/10.1074/jbc.270.31.18575			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629189	hybrid			2022-12-27	WOS:A1995RM64200067
J	YASUNAMI, M; SUZUKI, K; HOUTANI, T; SUGIMOTO, T; OHKUBO, H				YASUNAMI, M; SUZUKI, K; HOUTANI, T; SUGIMOTO, T; OHKUBO, H			MOLECULAR CHARACTERIZATION OF CDNA-ENCODING A NOVEL PROTEIN RELATED TO TRANSCRIPTIONAL ENHANCER FACTOR-I FROM NEURAL PRECURSOR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I TEF-1; GENE-EXPRESSION; ACTIVATION; MOUSE; EXTRACTION; CLONING; DOMAINS; MOTIF; BIND	We identified a novel cDNA related to that of transcriptional enhancer factor-1 (TEF-1) during the course of isolation and characterization of cDNAs, whose mRNAs are preferentially expressed in the mouse neural precursor cells. The putative polypeptide, termed embryonic TEA domain-containing factor (ETF), deduced from the nucleotide sequence contains 445 amino acids and shares 66% amino acid identity with mouse and human TEF-1 proteins, The primary structure of the TEA domain, a probable DNA-binding domain, and the specific DNA binding activity to the GT-IIC motif of ETF are indistinguishable from those of the known vertebrate TEF-1 proteins, However, the expression of the ETF gene is strictly regulated in developing embryos and is limited to certain tissues, such as the hindbrain of a 10-day-old mouse embryo, in contrast to the ubiquitous expression pattern of the TEF-1 gene, These results suggest that ETF is a novel mammalian member of the TEA domain containing transcription factor family and may be involved in the gene regulation of the neural development, We have discussed the possible existence of multiple subtypes of the mammalian TEF-1 family proteins, which may play different roles in cellular and developmental gene regulation.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN; KANSAI MED UNIV,DEPT ANAT,MORIGUCHI,OSAKA 570,JAPAN	Kumamoto University; Kansai Medical University								BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIGERIO JM, 1995, HUM MOL GENET, V4, P37, DOI 10.1093/hmg/4.1.37; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; KITANI H, 1991, IN VITRO CELL DEV B, V27, P615; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P1954, DOI 10.1093/nar/19.8.1954; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKUNAGA K, 1987, CANCER RES, V47, P5616; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	28	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18649	18654		10.1074/jbc.270.31.18649	http://dx.doi.org/10.1074/jbc.270.31.18649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629195	hybrid			2022-12-27	WOS:A1995RM64200077
J	FROELICHAMMON, SJ; OSHEROFF, N				FROELICHAMMON, SJ; OSHEROFF, N			TOPOISOMERASE POISONS - HARNESSING THE DARK SIDE OF ENZYME MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MEDIATED DNA CLEAVAGE; DRUG-INTERACTION DOMAINS; ESCHERICHIA-COLI; CAMPTOTHECIN; AGENTS; RESISTANCE; GYRASE; YEAST; CELLS; REPLICATION		VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; Beck W T, 1994, Adv Pharmacol, V29B, P145; BECK WT, 1994, CANCER CHEMOTH PHARM, V34, pS14, DOI 10.1007/BF00684858; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BJORNSTI MA, 1994, CANCER CHEMOTH PHARM, V34, pS1, DOI 10.1007/BF00684856; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BROWN GA, 1995, CANCER RES, V55, P78; BURKE TG, 1994, J MED CHEM, V37, P40, DOI 10.1021/jm00027a005; CAPRANICO G, 1992, EUR J CANCER, V12, P2055; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DANKS MK, 1994, BIOCHEM PHARMACOL, V48, P1785, DOI 10.1016/0006-2952(94)90465-0; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hooper D., 1993, QUINOLONE ANTIMICROB, Vsecond; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; ISHIDA R, 1995, CANCER RES, V55, P2299; KJELDSEN E, 1988, J BIOL CHEM, V263, P3912; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LETEURTRE F, 1994, J BIOL CHEM, V269, P28702; LIU LF, 1994, ADV PHARM, V29; LUTTINGER A, 1995, MOL MICROBIOL, V15, P601, DOI 10.1111/j.1365-2958.1995.tb02369.x; MADDEN KR, 1992, CANCER RES, V52, P525; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; NABIEV I, 1994, BIOCHEMISTRY-US, V33, P9013, DOI 10.1021/bi00196a020; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; NITISS JL, 1994, CANCER CHEMOTH PHARM, V34, pS6, DOI 10.1007/BF00684857; NITISS JL, 1993, CANCER RES, V53, P89; NITISS JL, 1992, CANCER RES, V52, P4467; OSHEROFF N, 1994, CANCER CHEMOTH PHARM, V34, pS19, DOI 10.1007/BF00684859; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; POMMIER Y, 1995, IN PRESS P NATL ACAD; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Potmesil M., 1991, DNA TOPOISOMERASES C; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIPLEY LS, 1994, MUTAT RES, V312, P67, DOI 10.1016/0165-1161(94)90011-6; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SHARMA A, 1995, CURR OPIN STRUC BIOL, V5, P39, DOI 10.1016/0959-440X(95)80007-N; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; STEVENSON RL, 1886, DR JEKYLL AND MR HYD; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMASHITA Y, 1991, BIOCHEMISTRY-US, V30, P5838, DOI 10.1021/bi00238a005; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZWELLING LA, 1991, BIOCHEMISTRY-US, V30, P4048, DOI 10.1021/bi00230a032	78	475	487	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21429	21432		10.1074/jbc.270.37.21429	http://dx.doi.org/10.1074/jbc.270.37.21429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665550	hybrid			2022-12-27	WOS:A1995RU75700001
J	KOIZUMI, T; ODANI, N; OKUYAMA, T; ICHIKAWA, A; NEGISHI, M				KOIZUMI, T; ODANI, N; OKUYAMA, T; ICHIKAWA, A; NEGISHI, M			IDENTIFICATION OF A CIS-REGULATORY ELEMENT FOR DELTA(12)-PROSTAGLANDIN J(2)-INDUCED EXPRESSION OF THE RAT HEME OXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; HEAT-SHOCK; ANTIPROLIFERATIVE ACTIVITY; INTRACELLULAR GLUTATHIONE; TRANSCRIPTIONAL CONTROL; STRESS PROTEIN; MESSENGER-RNA; INDUCTION; PROSTAGLANDINS; 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2	We recently reported that Delta(12)-prostaglandin (PG) J(2) caused various cells to synthesize heme oxygenase, HO-1 (Koizumi, T., Negishi, M., and Ichikawa, A. (1992) Prostaglandins 43, 121-131). Here we examined the molecular mechanism underlying the Delta 12-PGJ(2)-induced HO-1 synthesis. Delta(12)-PGJ(2) markedly stimulated the promoter activity of the 5'-flanking region of the rat HO-1 gene from -810 to +101 in rat basophilic leukemia cells. From functional analysis of various deletion mutant genes we found that the Delta 12-PGJ(2)-responsive element was localized in a region from -690 to -660, containing an E-box motif, which was essential for the Delta(12)-PGJ(2)-stimulated promoter activity. When the region containing the Delta(12)- PGJ(2)-responsive element was combined with a heterologous promoter, SV40 promoter, in the sense and antisense direction, the element showed an enhancer activity in response to Delta(12)-PGJ(2). Gel mobility shift assays demonstrated that Delta(12)-PGJ(2) specifically stimulated the binding of two nuclear proteins to the E-box motif of this region. These results indicate that Delta(12)-PGJ(2) induces the expression of the rat HO-1 gene through nuclear protein binding to a specific element having an E-box motif.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								ALAM J, 1994, J BIOL CHEM, V269, P1001; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BROCK TG, 1994, J BIOL CHEM, V269, P22069; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; ISHIZAWA S, 1983, J BIOL CHEM, V258, P4220; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; KIKUCHI G, 1983, MOL CELL BIOCHEM, V53-4, P163; KOIZUMI T, 1992, PROSTAGLANDINS, V43, P121, DOI 10.1016/0090-6980(92)90081-4; KOIZUMI T, 1993, BIOCHEM PHARMACOL, V45, P2457, DOI 10.1016/0006-2952(93)90227-N; KOIZUMI T, 1991, BIOCHEM PHARMACOL, V42, P777, DOI 10.1016/0006-2952(91)90036-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAVROVSKY Y, 1993, BIOCHEM BIOPH RES CO, V196, P336, DOI 10.1006/bbrc.1993.2253; LOPATA MA, 1983, NUCLEIC ACIDS RES, V11, P1475; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; OHNO K, 1988, J BIOL CHEM, V263, P19764; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SATO M, 1989, J BIOL CHEM, V264, P10251; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKETANI S, 1990, J BIOCHEM-TOKYO, V108, P28, DOI 10.1093/oxfordjournals.jbchem.a123156; TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090-6980(91)90001-V; TENHUNEN R, 1969, J BIOL CHEM, V24, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21779	21784		10.1074/jbc.270.37.21779	http://dx.doi.org/10.1074/jbc.270.37.21779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665598	hybrid			2022-12-27	WOS:A1995RU75700057
J	SHI, YW; LIU, HZ; VANDERBURG, G; SAMUEL, SJ; ISMAILBEIGI, F; JUNG, CY				SHI, YW; LIU, HZ; VANDERBURG, G; SAMUEL, SJ; ISMAILBEIGI, F; JUNG, CY			MODULATION OF GLUT1 INTRINSIC ACTIVITY IN CLONE-9 CELLS BY INHIBITION OF OXIDATIVE-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CYTOCHALASIN-B; PLASMA-MEMBRANE; BINDING; TRANSLOCATION; MECHANISM; PROTEINS; SITE	Brief (1-2 h) exposure of Clone 9 cells to inhibitors of oxidative phosphorylation such as azide is known to markedly increase glucose uptake. Clone 9 cells express GLUT1 but not GLUT2, -3, and -4, and the azide effect was not accompanied by any increase in cellular or plasma membrane GLUT1 level. To identify the molecular event underlying this apparent increase in GLUT1 intrinsic activity, we studied the acute effects of azide on the substrate binding activity of GLUT1 in Clone 9 cells by measuring glucose-sensitive cytochalasin B binding. The glucose-displaceable, cytochalasin B binding activity was barely detectable in membranes isolated from Clone 9 cells under control conditions but was readily detectable after a 60-min incubation of cells in the presence of 5 mM azide showing a 3-fold increase in binding capacity with no change in binding affinity. Furthermore, the cytochalasin B binding activity of purified human erythrocyte GLUT1 reconstituted in liposomes was significantly reduced in the presence of cytosol derived from azide-treated Clone 9 cells but not in the presence of cytosol from control cells; this effect was heat-labile and abolished by the presence of the peptide corresponding to the GLUT1 COOH-terminal sequence. These results suggest that a cytosolic protein in Clone 9 cells binds to GLUT1 at its COOH-terminal domain and inhibits its substrate binding and that azide-induced metabolic alteration releases GLUT1 from this inhibitory interaction. Studying the binding of cytosolic proteins derived from S-35-labeled Clone 9 cells to glutathione S-transferase fusion protein containing glucose transporter COOH-terminal sequences, we identified 28- and 70-kDa proteins that bind specifically to the cytoplasmic domain of GLUT1 and GLUT4 in vitro. We also found a P-32-labeled, 85-kDa protein that binds to GLUT4 but not to GLUT1 and only in cytosol derived from azide-treated cells, The roles, if any, of these glucose transporter-binding proteins in the azide-sensitive modulation of GLUT1 substrate binding activity in Clone 9 cells are yet to be determined.	VET ADM MED CTR, BIOPHYS LAB, BUFFALO, NY 14215 USA; SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA; CASE WESTERN RESERVE UNIV, DIV CLIN & MOLEC ENDOCRINOL, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005506, R01HD005506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376, R01DK045945] Funding Source: NIH RePORTER; NICHD NIH HHS [HD05506] Funding Source: Medline; NIDDK NIH HHS [DK13376, DK45945] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Battey, 1986, BASIC METHODS MOL BI; BELL GI, 1993, J BIOL CHEM, V268, P19161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DIAMOND DL, 1993, J BIOL CHEM, V268, P6437; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; INNIS MA, 1993, PCR PROTOCOL GUIDE M, P3; ISMAILBEIGI F, 1993, J MEMBRANE BIOL, V135, P1; JUNG CY, 1977, J BIOL CHEM, V252, P5456; KLEINZELLER A, 1965, MECANISMES REGULATIO, P371; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LIU HZ, 1995, J BIOL CHEM, V270, P7869, DOI 10.1074/jbc.270.14.7869; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19, DOI 10.1152/ajpcell.1989.257.1.C19; MORGAN HE, 1961, J BIOL CHEM, V236, P253; MORGAN HE, 1973, CURRENT TOPICS MEMBR, V4, P255; PASSONEAU J, 1962, BIOCHEM BIOPH RES CO, V7, P10, DOI 10.1016/0006-291X(62)90134-1; PINKOFSKY HB, 1978, J BIOL CHEM, V253, P4930; RANDLE PJ, 1958, BIOCHEM J, V70, P501, DOI 10.1042/bj0700501; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SHETTY M, 1993, AM J PHYSIOL, V265, pC1224, DOI 10.1152/ajpcell.1993.265.5.C1224; SOGIN DC, 1980, BIOCHEMISTRY-US, V19, P5417, DOI 10.1021/bi00564a041; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WOOD RE, 1969, J BIOL CHEM, V244, P1451	29	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21772	21778		10.1074/jbc.270.37.21772	http://dx.doi.org/10.1074/jbc.270.37.21772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665597	hybrid			2022-12-27	WOS:A1995RU75700056
J	ZHU, HY; RAMNARAYAN, K; ANCHIN, J; MIAO, WY; SERENO, A; MILLMAN, L; ZHENG, JH; BALAJI, VN; WOLFF, ME				ZHU, HY; RAMNARAYAN, K; ANCHIN, J; MIAO, WY; SERENO, A; MILLMAN, L; ZHENG, JH; BALAJI, VN; WOLFF, ME			GLU-96 OF BASIC FIBROBLAST GROWTH-FACTOR IS ESSENTIAL FOR HIGH-AFFINITY RECEPTOR-BINDING - IDENTIFICATION BY STRUCTURE-BASED SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; PROTEOLYTIC DEGRADATION; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; HEPARIN; RESOLUTION; INTERLEUKIN-1-BETA; LOCALIZATION; PROTECTS; CLONING	The importance of basic fibroblast growth factor (bFGF) in several pathophysiological processes has stimulated interest in the design of receptor antagonists to mitigate such effects. Of key importance in this connection is the characterization of the functional binding epitopes of the growth factor for its receptor. Based on peptide mapping and molecular dynamics calculations of the three-dimensional structure of basic fibroblast growth factor, we employed site-directed mutagenesis to investigate the effect of altering residues at positions 107, 109-114, and 96 on bFGF on receptor binding affinity. All muteins were cloned and expressed in Escherichia coli, purified to homogeneity employing heparin-Sepharose columns, and evaluated for receptor binding affinity. We found that replacement of residues at positions 107 and 109-114 by alanine or phenylalanine had little effect on receptor binding affinities compared with wild type bFGF, in agreement with previous evidence that bFGF residues 109-114 comprise a low affinity binding site. By contrast, substitution of Glu-96 with alanine yielded a molecule having about 0.1% of the affinity of the wild type bFGF. The affinity of the corresponding lysine and glutamine muteins was 0.3 and 10%, respectively, emphasizing the importance of a negative charge at this position. Our findings are consistent with the view that residues 106-115 on bFGF represent a low affinity binding site on bFGF. In addition, we identify Glu-96 as a crucial residue for binding to fibroblast growth factor receptor-1.			ZHU, HY (corresponding author), IMMUNOPHARMACEUT INC, SAN DIEGO, CA 92127 USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AGO H, 1991, J BIOCHEM-TOKYO, V110, P360, DOI 10.1093/oxfordjournals.jbchem.a123586; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GOSPODAROWICZ D, 1987, ENDOCRINOLOGY, V46, P187; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; MARICS I, 1989, ONCOGENE, V4, P335; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAMNARAYAN K, 1990, J CHEM PHYS, V92, P7057, DOI 10.1063/1.458246; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3; [No title captured]; [No title captured]	46	30	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21869	21874		10.1074/jbc.270.37.21869	http://dx.doi.org/10.1074/jbc.270.37.21869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665610	hybrid			2022-12-27	WOS:A1995RU75700070
J	CUNNINGHAM, SA; WAXHAM, MN; ARRATE, PM; BROCK, TA				CUNNINGHAM, SA; WAXHAM, MN; ARRATE, PM; BROCK, TA			INTERACTION OF THE FLT-1 TYROSINE KINASE RECEPTOR WITH THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE - MAPPING OF A NOVEL SITE INVOLVED IN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POINT MUTATION; SH2 DOMAIN; FAMILY; MITOGENESIS; ACTIVATION; SEQUENCE; SYSTEM	We have examined the interactions of the p85 regulatory subunit of phosphatidylinositol 3-kinase with the endothelium-specific Flt-1 receptor tyrosine kinase using the yeast two-hybrid system. We find that both the amino- and carboxyl-terminal SH2 domains of p85 bind to Flt-1. We have performed site-directed mutagenesis on the carboxyl-terminal tail of the Flt-1 receptor in order to identify the site(s) that is responsible for the p85 interactions. A single tyrosine to phenylalanine change at position 1213 inhibits the binding of both p85 SH2 domains. Phosphopeptide mapping of the wild type and mutant protein expressed in insect cells verifies that this amino acid is a target for autophosphorylation. The amino acids following this tyrosine are VNA and thus define a novel binding site for p85.	UNIV TEXAS, HLTH SCI CTR, DEPT PHYSIOL & CELL BIOL, HOUSTON, TX 77225 USA; UNIV TEXAS, HLTH SCI CTR, DEPT ANAT & NEUROBIOL, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	CUNNINGHAM, SA (corresponding author), TEXAS BIOTECHNOL CORP, DEPT PHARMACOL, SUITE 1920, 7000 FANNIN, HOUSTON, TX 77030 USA.			Waxham, M. Neal/0000-0003-4801-1190				CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM K, 1994, J BIOL CHEM, V269, P20648; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Miller J. H, 1972, EXPT MOL GENETICS; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TERMAN BI, 1991, ONCOGENE, V6, P1677; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20254	20257		10.1074/jbc.270.35.20254	http://dx.doi.org/10.1074/jbc.270.35.20254			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657594	hybrid			2022-12-27	WOS:A1995RR58400006
J	LAGARKOVA, MA; IAROVAIA, OV; RAZIN, SV				LAGARKOVA, MA; IAROVAIA, OV; RAZIN, SV			LARGE-SCALE FRAGMENTATION OF MAMMALIAN DNA IN THE COURSE OF APOPTOSIS PROCEEDS VIA EXCISION OF CHROMOSOMAL DNA LOOPS AND THEIR OLIGOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; INTERNUCLEOSOMAL FRAGMENTATION; CELL-DEATH; ENDONUCLEASE; MECHANISMS; CLEAVAGE	It has been shown recently that apoptotic degradation of genomic DNA in mammalian cells starts by excision of large DNA fragments ranging in size from 50 kilobases to more then 300 kilobases. Although it was suggested that the above fragments could represent chromosomal DNA loops, the supposition was not supported by direct experimental evidence. In present work, we have studied the specificity of nucleolar and euchromatic gene long-range fragmentation in mouse and human cells triggered to undergo apoptosis either by tumor necrosis factor or by serum deprivation. Separation of the excised large DNA fragments by pulsed field gel electrophoresis followed by Southern analysis has demonstrated that in all cases studied the above fragmentation proceeds in a specific way. Furthermore, the patterns of DNA long-range fragmentation in the cells undergoing apoptosis were indistinguishable from the patterns of DNA cleavage into chromosomal loops by the high salt-insoluble topoisomerase II of the nuclear matrix. These results suggest the conclusion that apoptotic degradation of chromosomal DNA starts by excision of DNA loops and their oligomers.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	International Center for Genetic Engineering & Biotechnology (ICGEB); Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Razin, Sergey V/M-6701-2015; Iarovaia, Olga/AAV-2321-2021; Lagarkova, Maria/A-3296-2014	Razin, Sergey V/0000-0003-1976-8661; Lagarkova, Maria/0000-0001-9594-1134				ARENDS MJ, 1990, AM J PATHOL, V136, P593; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAIN K, 1994, FEBS LETT, V349, P385, DOI 10.1016/0014-5793(94)80001-4; COHEN GM, 1994, J IMMUNOL, V153, P507; COHEN JJ, 1984, J IMMUNOL, V132, P38; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GROMOVA II, 1995, P NATL ACAD SCI USA, V92, P102, DOI 10.1073/pnas.92.1.102; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; REID TR, 1989, J BIOL CHEM, V264, P4583; RUGGIERO V, 1987, J IMMUNOL, V138, P2711; SUN XM, 1994, J BIOL CHEM, V269, P14857; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	18	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20239	20241		10.1074/jbc.270.35.20239	http://dx.doi.org/10.1074/jbc.270.35.20239			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657590	hybrid			2022-12-27	WOS:A1995RR58400002
J	LANKESTER, AC; VANSCHIJNDEL, GMW; VANLIER, RAW				LANKESTER, AC; VANSCHIJNDEL, GMW; VANLIER, RAW			HEMATOPOIETIC-CELL PHOSPHATASE IS RECRUITED TO CD22 FOLLOWING B-CELL ANTIGEN RECEPTOR LIGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; VIABLE MOTHEATEN; HUMAN CD5+; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; MICE; STIMULATION; DOMAINS; SUBSETS	Hematopoietic cell phosphatase is a nonreceptor protein tyrosine phosphatase that is preferentially expressed in hematopoietic cell lineages. Motheaten mice, which are devoid of (functional) hematopoietic cell phosphatase, have severe disturbances in the regulation of B cell activation and differentiation. Because signals transduced via the B cell antigen receptor are known to guide these processes, we decided to analyze molecular interactions between the hematopoietic cell phosphatase and the B cell antigen receptor. Ligation of the B cell antigen receptor induces moderate tyrosine phosphorylation of hema topoietic cell phosphatase and the formation of a multimolecular complex containing additional 68-70- and 135-kDa phosphoproteins. In resting B cells most of the hematopoietic cell phosphatase proteins reside in the cytosolic compartment, whereas after B cell antigen receptor cross-linking, a small fraction translocates toward the membrane where it specifically binds to the 135-kDa phosphoprotein. This 135-kDa glycoprotein was identified as CD22, a transmembrane associate of the B cell antigen receptor complex. Together these findings provide the first direct evidence that this cytoplasmic tyrosine phosphatase is involved in antigen receptor-mediated B cell activation, suggesting that in vivo B cell antigen receptor constituents or associated molecules may serve as substrate for its catalytic activity.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam	LANKESTER, AC (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			van Lier, Rene/0000-0002-3201-7144				ANTIN JH, 1986, J IMMUNOL, V136, P505; BHAT NM, 1992, INT IMMUNOL, V4, P243, DOI 10.1093/intimm/4.2.243; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREINER DL, 1986, J EXP MED, V164, P1129, DOI 10.1084/jem.164.4.1129; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1994, J BIOL CHEM, V269, P12310; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHULTZ LD, 1976, J IMMUNOL, V116, P936; Schultz Leonard D., 1993, Cell, V73, P1445; SCHWARTZALBIEZ R, 1989, LEUKOCYTE TYPING, V4, P65; SIDMAN CL, 1978, J IMMUNOL, V121, P2392; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SIDMAN CL, 1978, J IMMUNOL, V121, P2399; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZUPO S, 1991, EUR J IMMUNOL, V21, P351, DOI 10.1002/eji.1830210216	42	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20305	20308		10.1074/jbc.270.35.20305	http://dx.doi.org/10.1074/jbc.270.35.20305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657601	hybrid			2022-12-27	WOS:A1995RR58400014
J	LEE, JK; KAPLAN, S				LEE, JK; KAPLAN, S			TRANSCRIPTIONAL REGULATION OF PUC OPERON EXPRESSION IN RHODOBACTER-SPHAEROIDES - ANALYSIS OF THE CIS-ACTING DOWNSTREAM REGULATORY SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-SPHAEROIDES; PHOTOSYNTHETIC MEMBRANES; B800-850 COMPLEX; DNA-SEQUENCE; LIGHT; CAPSULATUS; CLONING; OXYGEN; GENES; PROTEINS	Both site-directed and spontaneous mutagenesis have been used to investigate the role of the cis-acting regulatory region between -92 and -1 base pair (bp) of the puc operon of Rhodobacter sphaeroides. The DNA sequence from -84 to -66 bp upstream of the 5' end of the start site of puc operon transcription is essential for normal puc operon expression. This regulatory effect was exerted irrespective of the presence or absence of additional upstream regulatory sequences extending from -629 to -93 bp. It is likely that this region is involved in activator binding. Additionally, two regions of dyad symmetry centered at -42 and -17 bp are shown to be involved in oxygen repression of puc operon expression. Mutations within these regions of dyad symmetry were further subdivided on the basis of whether or not the upstream regulatory region was required to observe the mutant phenotype. Based upon these observations we conclude that these regions of dyad symmetry possessing the motif TGT-N-12-ACA (where N represents any nucleotide) are involved in repressor binding with the puc operon promoter overlapping each of these dyad symmetries.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL & MOLEC GENET,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston					NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; CHORY J, 1983, J BACTERIOL, V153, P465, DOI 10.1128/JB.153.1.465-474.1983; CHORY J, 1984, J BACTERIOL, V159, P540, DOI 10.1128/JB.159.2.540-554.1984; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEHOFF BS, 1988, J BACTERIOL, V170, P4681, DOI 10.1128/jb.170.10.4681-4692.1988; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DONOHUE TJ, 1986, ENCY PLANT PHYSL, V19, P632; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; GICQUELSANZEY B, 1982, EMBO J, V1, P591, DOI 10.1002/j.1460-2075.1982.tb01213.x; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; KAPLAN S, 1983, J CELL BIOCHEM, V22, P15, DOI 10.1002/jcb.240220103; KAPLAN S, 1982, PHOTOSYNTHESIS, V1, P65; KILEY PJ, 1987, J BACTERIOL, V169, P3268, DOI 10.1128/jb.169.7.3268-3275.1987; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; LEE JK, 1993, J BIOL CHEM, V268, P24491; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Sambrook J, 1989, MOL CLONING LABORATO; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; Simon R., 1983, BIOTECHNOLOGY, V1, P37; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SUMMERTON J, 1983, ANAL BIOCHEM, V133, P79, DOI 10.1016/0003-2697(83)90224-5; TAI TN, 1988, PLASMID, V19, P175, DOI 10.1016/0147-619X(88)90037-6; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; YOUVAN DC, 1985, P NATL ACAD SCI USA, V82, P58, DOI 10.1073/pnas.82.1.58; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	30	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20453	20458		10.1074/jbc.270.35.20453	http://dx.doi.org/10.1074/jbc.270.35.20453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657621	hybrid			2022-12-27	WOS:A1995RR58400035
J	ARAGAY, AM; COLLINS, LR; POST, GR; WATSON, AJ; FERAMISCO, JR; BROWN, JH; SIMON, MI				ARAGAY, AM; COLLINS, LR; POST, GR; WATSON, AJ; FERAMISCO, JR; BROWN, JH; SIMON, MI			G(12) REQUIREMENT FOR THROMBIN-STIMULATED GENE-EXPRESSION AND DNA-SYNTHESIS IN 1321N1 ASTROCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATION; PROTEOLYTIC MECHANISM; CALCIUM MOBILIZATION; PERTUSSIS TOXIN; FIBROBLASTS; G-ALPHA-12; EVENTS; RAS; PROTEINS; CLONING	Thrombin stimulation of 1321N1 astrocytoma cells leads to Ras-dependent AP-1-mediated transcriptional activation and to DNA replication. In contrast to what has been observed in most cell systems, in 1321N1 cells these responses are pertussis toxin-insensitive. The pertussis toxin-insensitive G-protein G(12) has been implicated in cell growth and transformation in different cell systems. We have examined the potential role of this protein in AP-1-mediated transcriptional activation and DNA synthesis in 1321N1 cells. Transient expression of an activated (GTPase-deficient) mutant of G alpha(12) increased AP-1-dependent gene expression. This response was inhibited by co-expression of a dominant negative Ala-15 Ras protein. To determine whether the pertussis toxin-insensitive G(12) protein is involved in the thrombin-stimulated DNA synthesis, an inhibitory antibody against the C-terminal sequence of G alpha(12) subunit was microinjected into 1321N1 cells. Microinjection of the anti-G alpha(12) resulted in a concentration-dependent inhibition of thrombin-stimulated DNA synthesis. In contrast, microinjection of nonimmune IgG or an antibody directed against the C terminus of G alpha(0) did not reduce the mitogenic response to thrombin. Furthermore, microinjection of the anti-G alpha(12) antibody had no effect on fibroblast growth factor-stimulated DNA synthesis. These results demonstrate a specific role for G alpha(12) in the mitogenic response to thrombin in human astroglial cells.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	California Institute of Technology; University of California System; University of California San Diego			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NCI NIH HHS [CA50528] Funding Source: Medline; NIGMS NIH HHS [GM34236, GM36927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM036927, R56GM036927, R01GM034236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBAS J, 1993, J BIOL CHEM, V268, P22235; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BAFFY G, 1994, J BIOL CHEM, V269, P8483; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAURE M, 1994, J BIOL CHEM, V269, P7851; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONES LG, 1989, MOL PHARMACOL, V36, P142; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; NIETO M, 1994, MOL PHARMACOL, V46, P406; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1985, EMBO J, V4, P2927; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINITZ S, 1993, J BIOL CHEM, V268, P19196; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	30	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20073	20077		10.1074/jbc.270.34.20073	http://dx.doi.org/10.1074/jbc.270.34.20073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650024	Green Accepted, hybrid			2022-12-27	WOS:A1995RQ99100060
J	HOURCADE, DE; WAGNER, LM; OGLESBY, TJ				HOURCADE, DE; WAGNER, LM; OGLESBY, TJ			ANALYSIS OF THE SHORT CONSENSUS REPEATS OF HUMAN-COMPLEMENT FACTOR-B BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL PROTEIN MODULE; RECEPTOR TYPE-1; LIGAND-BINDING; FACTOR-H; C2; SUPERFAMILY; ACTIVATION; MECHANISMS; REJECTION; CLEAVAGE	Human factor B is required for the initiation and propagation of the complement alternative pathway, It also participates in the amplification of the complement classical pathway, Alone, factor B is a zymogen with Little known biochemical activity, but in the context of the alternative pathway convertases, the factor B serine protease is activated in a process that first involves the association with C3b and subsequently the cleavage of factor B into two fragments, Ba and Bb, Ba, the NH2-terminal fragment, is composed mainly of three tandem short consensus repeats, globular domains found in other complement proteins, It dissociates from the convertase during assembly, leaving the active C3 convertase, C3bBb, Previous reports suggest that the Ba region may be instrumental in convertase assembly, This hypothesis was tested using site-directed mutagenesis of recombinant factor B and monoclonal antibody epitope mapping to evaluate the relative importance of specific short consensus repeat amino acid residues, Three sites of interest were identified, Site 1 is a stretch of 19 contiguous amino acids in short consensus repeat 1 that form the epitope of a monoclonal antibody that effectively blocks factor B function. Site 2, composed of 6 contiguous amino acids in short consensus repeat 2, and site 3, consisting of 7 contiguous amino acids in short consensus repeat 3, were defined by mutations that reduce factor B hemolytic activity to 3% or less, Further analyses indicated that sites 2 and 3 contribute to factor B-C3b interactions.			HOURCADE, DE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,660 S EUCLID,BOX 8045,ST LOUIS,MO 63110, USA.							BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BORSOS T, 1967, J IMMUNOL, V99, P263; BRAUER RB, 1993, J IMMUNOL, V151, P7240; COLOMBATTI A, 1991, BLOOD, V77, P2305; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KATO Y, 1994, J IMMUNOL, V153, P4546; KRISTENSEN T, 1987, FASEB J, V46, P2463; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KRYCH M, 1994, J BIOL CHEM, V269, P13273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; Morgan B.P., 1990, COMPLEMENT; MULLEREBERHARD HJ, 1992, INFLAMMATION BASIC P, P33; NONAKA M, 1994, J IMMUNOL, V152, P2263; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGLESBY TJ, 1988, J IMMUNOL, V141, P926; PEELMAN LJ, 1991, IMMUNOGENETICS, V34, P192, DOI 10.1007/BF00205823; PERKINS SJ, 1993, BIOCHEM J, V295, P109, DOI 10.1042/bj2950109; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; UEDA A, 1987, J IMMUNOL, V138, P1143; VOLANAKIS JE, 1989, CURR TOP MICROBIOL I, V153, P1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Whaley K, 1985, METHODS COMPLEMENT C, P77	38	61	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19716	19722		10.1074/jbc.270.34.19716	http://dx.doi.org/10.1074/jbc.270.34.19716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649982	hybrid			2022-12-27	WOS:A1995RQ99100010
J	MCNALLY, AJ; MOTTER, K; JORDAN, F				MCNALLY, AJ; MOTTER, K; JORDAN, F			A LIBRARY OF MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI K-12 PYRUVATE-DEHYDROGENASE COMPLEX - A BIOCHEMICAL-ANALYSIS AND THEIR ABILITY TO INHIBIT THE ENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME COMPLEX; ACTIVE-SITE; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; BIFUNCTIONAL ARSENOXIDE; INACTIVATION; PROTEINS; BROMOPYRUVATE; PYROPHOSPHATE; COMPONENT	A library of monoclonal antibodies to K-12 Escherichia colt pyruvate dehydrogenase complex (PDHc) and its pyruvate decarboxylating (EC 1,2,4,1; El) subunit is reported, 21 monoclonal antibodies were generated, and 20 were investigated, of which 9 were elicited to PDHc and 11 to pure El subunit; 19 were of the IgG1 isotype and one of the IgG3 isotype. According to an enzyme immunoassay, all 20 of the monoclonal antibodies bound the PDHc, and 17 bound the El subunit, According to Western blot analysis, 14 of the 19 monoclonal antibodies bound to the El subunit, The monoclonal antibodies inhibited PDHc from 0 to > 98%. The six monoclonal antibodies that displayed greater than 30% inhibition off. colt PDHc were unable to inhibit porcine heart PDHc nor did they bind porcine heart PDHc according to dot blot analysis, Radiolabeling gave binding constants ranging from 5 to 10 x 10(8) M(-1) on these six monoclonal antibodies, with greater than 80% of maximal inhibition achieved in less than 1 min, One of the six, 18A9, gave > 98% inhibition, required two antibodies/E1 subunit for maximum inhibition, and was shown to be a non-competitive inhibitor, Monoclonal antibody 15A9 was shown to counteract GTP-induced inhibition, while 1F2 influenced the conformation of El, allowing two antibodies, which did not previously bind El, to bind to it, A new mechanism-based kinetic assay is presented that is specific for the El component of S-keto acid dehydrogenases. This assay confirmed that the three most strongly inhibitory monoclonal antibodies specifically inhibited the El function while antibody 1F2 led to enhanced activity, suggesting an induced conformational change in PDHc or in E1.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102; RUTGERS STATE UNIV,DEPT BIOL,NEWARK,NJ 07102; ROCHE DIAGNOST SYST INC,SOMERVILLE,NJ 08876	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50380] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SR, 1984, BIOCHEMISTRY-US, V23, P1269, DOI 10.1021/bi00301a039; ADAMSON SR, 1981, BIOCHEMISTRY-US, V20, P3418, DOI 10.1021/bi00515a018; ANGELIDES KJ, 1979, P NATL ACAD SCI USA, V76, P3279, DOI 10.1073/pnas.76.7.3279; ANNAN N, 1989, J AM CHEM SOC, V111, P8895, DOI 10.1021/ja00206a019; BISSWANGER H, 1971, EUR J BIOCHEM, V24, P376, DOI 10.1111/j.1432-1033.1971.tb19696.x; BISSWANGER H, 1980, BIOCHEM BIOPH RES CO, V95, P513, DOI 10.1016/0006-291X(80)90814-1; BJOERKLAND A, 1991, SCAND J IMMUNOL, V33, P749; BREMER J, 1969, EUR J BIOCHEM, V8, P535, DOI 10.1111/j.1432-1033.1969.tb00559.x; CRUMPTON MJ, 1986, CIBA F SYMP, V119, P93; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FLOURNOY DS, 1989, BIOCHEMISTRY-US, V28, P9594, DOI 10.1021/bi00451a007; GUNSALUS IC, 1954, MECHANISM ENZYME ACT, P545; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HUPE DJ, 1987, ANAL BIOCHEM, V161, P20, DOI 10.1016/0003-2697(87)90645-2; JACKSON RH, 1983, J BIOL CHEM, V258, P1857; KLUGER R, 1977, J AM CHEM SOC, V99, P4504, DOI 10.1021/ja00455a052; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOIKE M, 1960, J BIOL CHEM, V235, P1924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE PN, 1983, BIOCHEMISTRY-US, V22, P150, DOI 10.1021/bi00270a022; LOWE PN, 1984, BIOCHEMISTRY-US, V23, P91, DOI 10.1021/bi00296a015; MALDONADO ME, 1972, J BIOL CHEM, V247, P2711; Massy V, 1963, ENZYMES, V7, P275; MCNALLY A, 1992, BIOCHIM BIOPHYS ACTA, V1160, P179, DOI 10.1016/0167-4838(92)90005-X; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19744, DOI 10.1074/jbc.270.34.19744; MCNALLY AJ, 1992, THESIS RUTGERS U GRA; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; MULLER R, 1980, J IMMUNOL METHODS, V34, P345, DOI 10.1016/0022-1759(80)90107-6; OLIVER RM, 1982, ELECTRON MICROS, V1, P1; PALMER JL, 1964, BIOCHEMISTRY-US, V3, P863, DOI 10.1021/bi00894a024; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Reed LJ., 1969, METHOD ENZYMOL, P55; SCHONBRUNNHANEB.E, 1990, BIOCHEMISTRY-US, V29, P4880; SCHWARTZ ER, 1968, BIOCHEM BIOPH RES CO, V31, P495, DOI 10.1016/0006-291X(68)90504-4; SCHWARTZ ER, 1970, BIOCHEMISTRY-US, V9, P1434, DOI 10.1021/bi00808a019; SHEU KFR, 1984, J NEUROCHEM, V43, P1352, DOI 10.1111/j.1471-4159.1984.tb05394.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; SPECKHARD DC, 1975, BIOCHEM BIOPH RES CO, V62, P614, DOI 10.1016/0006-291X(75)90443-X; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; SURH CD, 1990, J IMMUNOL, V144, P2647; TSISELIUS A, 1956, ARCH BIOCHEM BIOPHYS, V65, P132; VANREGENMORTEL MHV, 1988, IMMUNOL LETT, V17, P95, DOI 10.1016/0165-2478(88)90076-4; VANREGENMORTEL MHV, 1986, CIBA F SYMP, V119, P76; YANG H, 1985, J BIOL CHEM, V260, P6049	49	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19736	19743		10.1074/jbc.270.34.19736	http://dx.doi.org/10.1074/jbc.270.34.19736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649983	hybrid			2022-12-27	WOS:A1995RQ99100013
J	MCNALLY, AJ; MATTSSON, L; JORDAN, F				MCNALLY, AJ; MATTSSON, L; JORDAN, F			A LIBRARY OF MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI K-12 PYRUVATE-DEHYDROGENASE COMPLEX - COMPETITIVE EPITOPE MAPPING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEINS; BINDING	Presented here are competitive epitope mapping studies on a monoclonal antibody library to K-12 Escherichia coli pyruvate dehydrogenase complex (PDHc) and its pyruvate decarboxylating (EC1.2.4.1) subunit (El). Several of the monoclonal antibodies had been found to inhibit PDHc from 0 to 98%, Of the 10 monoclonal antibodies that showed the greatest inhibition of PDHc, 4 were elicited by PDHc and 6 by El, Surface plasmon resonance was used for competitive epitope mapping and revealed that these 10 monoclonal antibodies had at least 6 separate binding regions on the PDHc. The three monoclonal antibodies that demonstrated the strongest inhibition appeared to bind the same region on the PDHc. Mapping studies with the El antigen using an additional five monoclonal antibodies demonstrated that the two strongest inhibitor mono clonal antibodies (18A9 and 21C3) shared the same binding region on El, whereas the third strongest inhibitor (15A9) displayed an epitope region that overlapped the previous two on the El subunit. Antibody 15A9 had been shown to counteract GTP regulation of PDHc. Simultaneous multiple site binding experiments confirmed that the defined epitope regions were indeed independent. Limited competitive epitope binding experiments using radiolabeled El confirmed the surface plasmon resonance results.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102; RUTGERS STATE UNIV,DEPT BIOL,NEWARK,NJ 07102; ROCHE DIAGNOST SYST INC,SOMERVILLE,NJ 08876; PHARM BIOSENSOR,PISCATAWAY,NJ 08854	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50380] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDRUP J, 1989, POLYM HDB, P469; BRICKER BJ, 1987, VIROLOGY, V161, P533, DOI 10.1016/0042-6822(87)90148-6; CULLEN DC, 1988, BIOSENSORS, V3, P211; DANIELS PB, 1988, SENSOR ACTUATOR, V15, P11, DOI 10.1016/0250-6874(88)85013-3; DUNN SD, 1985, J BIOL CHEM, V260, P418; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; HIRSCHFELD T, 1967, APPL OPTICS, V6, P715, DOI 10.1364/AO.6.000715; HOPFIELD JJ, 1958, PHYS REV, V112, P1555, DOI 10.1103/PhysRev.112.1555; JASTREBOFF MM, 1985, BIOCHEMISTRY-US, V24, P587, DOI 10.1021/bi00324a007; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOIKE M, 1960, J BIOL CHEM, V235, P1924; KRETSCHMANN E, 1968, Z NATURFORSCH, V230, P2135; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; OTTO A, 1968, Z PHYS, V216, P398, DOI 10.1007/BF01391532; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; Raether H, 1977, PHYS THIN FILMS, V9, P145; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; SYTKOWSKI AJ, 1987, J BIOL CHEM, V262, P1161; VANREGENMORTEL MHV, 1988, IMMUNOL LETT, V17, P95, DOI 10.1016/0165-2478(88)90076-4; WELFORD K, 1991, OPT QUANT ELECTRON, V23, P1, DOI 10.1007/BF00619516; WILSON JE, 1987, CHEM MODIFICATION EN, P171	25	6	7	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19744	19751		10.1074/jbc.270.34.19744	http://dx.doi.org/10.1074/jbc.270.34.19744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649984	hybrid			2022-12-27	WOS:A1995RQ99100014
J	PAPOV, VV; DIAMOND, TV; BIEMANN, K; WAITE, JH				PAPOV, VV; DIAMOND, TV; BIEMANN, K; WAITE, JH			HYDROXYARGININE-CONTAINING POLYPHENOLIC PROTEINS IN THE ADHESIVE PLAQUES OF THE MARINE MUSSEL MYTILUS-EDULIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-ANALYSIS; TANDEM MASS-SPECTROMETRY; PRECURSOR PROTEINS; HYDROXYPROLINE; HYDROLYSIS; ATTACHMENT; PEPTIDES; BYSSUS	An unusual polymorphic protein family of nine or more variants has been isolated from the byssal adhesive plaques and foot of the marine mussel Mytilus edulis. In accordance with established terminology, the family is referred to as IM. edulis foot protein 3 or simply Mefp-3. Variants of Mefp-S have molecular masses of about 6 kDa, isoelectric points greater than 10.5, and an amino acid composition dominated by six amino acids: glycine, asparagine, 3,4-dihydroxyphenylalanine (Dopa), tryptophan, arginine, and an unknown basic amino acid. The latter has been isolated and identified as 4-hydroxyarginine using fast atom bombardment mass spectrometry and appropriate standards. The primary structure of variant Mefp-3F has been determined by peptide mapping using automated Edman sequencing in combination with fast atom bombardment and matrix-assisted laser desorption ionization mass spectrometry: ADYYGPNYGPPRRYGGGNYNRYNRYGRRYGGYKGWNNGWNRGRRGKYW where Y represents Dopa, and R represents hydroxyarginine. Notably, the 4 occurrences of RY are marked by a resistance to trypsin digestion. Although the conversion of tyrosines to Dopa is essentially complete, hydroxylation of arginines varies between 40 and 80%. In contrast to other mussel adhesive proteins such as Mefp-1 and -2 which have large numbers of highly conserved, tandemly repeated peptide motifs, Mefp-3 has only short sporadic repeats. The specific function of Mefp-3 in byssal adhesion is unknown.	UNIV DELAWARE,COLL MARINE STUDIES,MARINE BIOL BIOCHEM PROGRAM,NEWARK,DE 19716; UNIV DELAWARE,DEPT CHEM,NEWARK,DE 19716; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	University of Delaware; University of Delaware; Massachusetts Institute of Technology (MIT)					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM005472, R37GM005472] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NIDCR NIH HHS [DE10042] Funding Source: Medline; NIGMS NIH HHS [GM05472] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER M, 1981, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39810000325; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BELL EA, 1964, BIOCHEM J, V91, P356, DOI 10.1042/bj0910356; BELL EA, 1963, NATURE, V197, P901, DOI 10.1038/197901a0; BENEDICT CV, 1986, J MORPHOL, V189, P261, DOI 10.1002/jmor.1051890305; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BORDERS CL, 1994, PROTEIN SCI, V3, P541; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DIAMOND TV, 1993, THESIS U DELAWARE NE; FILPULA DR, 1990, BIOTECHNOL PROGR, V6, P171, DOI 10.1021/bp00003a001; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; FUJITA Y, 1959, B CHEM SOC JPN, V32, P439, DOI 10.1246/bcsj.32.439; HANSEN DC, 1994, J COLLOID INTERF SCI, V168, P206, DOI 10.1006/jcis.1994.1410; HOLLECKER M, 1990, PROTEIN STRUCTURE PR, P145; INOUE K, 1995, J BIOL CHEM, V270, P6698, DOI 10.1074/jbc.270.12.6698; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LAURSEN RA, 1992, RESULTS PROBLEMS CEL, P55; LITWACK G, 1960, EXPT BIOCH LABORATOR; MAKISUMI S, 1961, J BIOCHEM-TOKYO, V49, P284, DOI 10.1093/oxfordjournals.jbchem.a127296; MEEK KM, 1979, BIOCHIM BIOPHYS ACTA, V587, P112, DOI 10.1016/0304-4165(79)90225-3; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; NOTTER MFD, 1988, EXP CELL RES, V177, P237, DOI 10.1016/0014-4827(88)90458-2; OLIVIERI MP, 1992, BIOMATERIALS, V13, P1000, DOI 10.1016/0142-9612(92)90150-M; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAZ MA, 1991, J BIOL CHEM, V266, P689; QIN XX, 1995, J EXP BIOL, V198, P633; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SATO K, 1987, ANAL CHEM, V59, P1652, DOI 10.1021/ac00140a016; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SULSER H, 1975, Lebensmittel-Wissenschaft and Technologie, V8, P161; TAMARIN A, 1976, J MORPHOL, V149, P199, DOI 10.1002/jmor.1051490205; TAYLOR SW, 1994, J AM CHEM SOC, V116, P10803, DOI 10.1021/ja00102a063; TOUS GI, 1989, ANAL BIOCHEM, V179, P50, DOI 10.1016/0003-2697(89)90198-X; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P; WAITE JH, 1981, SCIENCE, V212, P1038, DOI 10.1126/science.212.4498.1038; WAITE JH, 1985, BIOCHEMISTRY-US, V24, P5010, DOI 10.1021/bi00340a008; WAITE JH, 1992, MOL BIOCHEM PARASIT, V54, P143, DOI 10.1016/0166-6851(92)90107-U; WAITE JH, 1983, J BIOL CHEM, V258, P2911; WAITE JH, 1992, BIOCHEMISTRY-US, V31, P5733, DOI 10.1021/bi00140a007; WAITE JH, 1992, RESULTS PROBLEMS CEL, P27	42	270	293	6	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20183	20192		10.1074/jbc.270.34.20183	http://dx.doi.org/10.1074/jbc.270.34.20183			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650037	hybrid			2022-12-27	WOS:A1995RQ99100075
J	SCHMIDT, M; FASSELT, B; RUMENAPP, U; BIENEK, C; WIELAND, T; VANKOPPEN, CJ; JAKOBS, KH				SCHMIDT, M; FASSELT, B; RUMENAPP, U; BIENEK, C; WIELAND, T; VANKOPPEN, CJ; JAKOBS, KH			RAPID AND PERSISTENT DESENSITIZATION OF M3 MUSCARINIC ACETYLCHOLINE RECEPTOR-STIMULATED PHOSPHOLIPASE-D - CONCOMITANT SENSITIZATION OF PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL REGULATION; LYSOPHOSPHATIDIC ACID; PHOSPHATIDIC-ACID; GROWTH-FACTOR; PROTEIN; CELLS; FIBROBLASTS; ISOENZYMES; INHIBITION; ACTIVATION	Activation of muscarinic acetylcholine receptors (mAChR) in human embryonic kidney (HEK) cells stably expressing the human m3 subtype leads to stimulation of both phospholipase C (PLC) and D (PLD), mAChR-stimulated PLD was turned off after 2 min of receptor activation with either the full (carbachol) or partial agonist (pilocarpine) and remained completely suppressed for at least 4 h, Partial recovery was observed 24 h after agonist removal, This rapid arrest of PLD response was not due to a loss of cell surface receptors and was also not caused by negative feedback due to concomitant activation of protein kinase C, tyrosine phosphorylation, increase in cytosolic calcium, or activation of Gi proteins, Furthermore, PLD stimulation by directly activated protein kinase C and GTP-binding proteins was unaltered in carbachol-pretreated cells. Finally, neither prevention of PLD stimulation during carbachol pretreatment by genistein nor inhibition of protein synthesis by cycloheximide, added before or after carbachol challenge, resulted in recovery of mAChR-stimulated PLD, The short term carbachol pretreatment nearly completely abolished agonist-induced binding of guanosine 5'-O-(3-thiotriphosphate) to membranes or permeabilized adherent cells. Full recovery of this response was achieved after 4 h, Similar to transfected m3 mAChR, PLD stimulation by endogenously expressed purinergic receptors was also fully blunted after 2 min of agonist (ATP) treatment, Preexposure of HEK cells to either receptor agonist partially, but not completely, reduced PLD stimulation by the other agonist, In contrast to desensitization of PLD stimulation, 2 min of carbachol treatment led to a sensitization, by up to g-fold, of mAChR-stimulated inositol phosphate formation, This supersensitivity was also observed with pilocarpine, which acted as a full agonist on PLC. On the basis of these results, we conclude that the m3 mAChR stimulates PLD and PLC in HEK cells with distinct efficiencies and with very distinct durations of each response, The rapid and long lasting desensitization of the PLD response is apparently not due to a loss of cell surface receptors or PLD activation by GTP-binding proteins, but it may involve, at least initially, an uncoupling of receptors from GTP-binding proteins and most likely a loss of an as yet undefined essential transducing component.	UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY	University of Duisburg Essen			Schmidt, Martina/C-5339-2018; Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Schmidt, Martina/0000-0003-3075-0630; Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISCOE CP, 1994, BIOCHEM J, V298, P61, DOI 10.1042/bj2980061; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HA KS, 1993, J BIOL CHEM, V268, P10534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIANG H, 1994, MOL CELL BIOL, V14, P3676, DOI 10.1128/MCB.14.6.3676; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MOEHREN G, 1994, J BIOL CHEM, V269, P838; NIETO M, 1994, MOL PHARMACOL, V46, P406; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; THOMPSON NT, 1993, ADV PHARMACOL, V21, P199; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WIELAND T, 1995, N-S ARCH PHARMACOL, V351, P329, DOI 10.1007/BF00169072	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19949	19956		10.1074/jbc.270.34.19949	http://dx.doi.org/10.1074/jbc.270.34.19949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650010	hybrid			2022-12-27	WOS:A1995RQ99100043
J	FRANCOIS, JM; SHENG, ZL; SZCZESNA, D; POTTER, JD				FRANCOIS, JM; SHENG, ZL; SZCZESNA, D; POTTER, JD			THE FUNCTIONAL-ROLE OF THE DOMAINS OF TROPONIN-C INVESTIGATED WITH THROMBIN FRAGMENTS OF TROPONIN-C RECONSTITUTED INTO SKINNED MUSCLE-FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SR-2+ ACTIVATION PROPERTIES; CALCIUM-BINDING SITES; AMINO-ACID SEQUENCE; BIOLOGICAL-ACTIVITY; CENTRAL HELIX; AFFINITY; CONTRACTION; PROTEIN; CALMODULIN	Proteolysis of rabbit fast skeletal troponin-C (RSTnC) with thrombin produces four separate fragments containing the following Ca2+-binding site(s): TH1 (residues 1-120) sites I-III; TH2 (121-159) site IV; TH3 (1-100) sites I and II; and TH4 (101-120) site III. We studied the ability of these fragments 60 restore the steady state isometric force in TnC-depleted skinned skeletal muscle fibers, Interestingly, we found that all investigated fragments of RSTnC possessed some of the properties of native RSTnC, but none of them could fully regulate contraction in the fibers like intact RSTnC, TH1 was the most effective in the force restoration (65%) whereas the smaller fragments developed about 50% (TH3 and TH4) or 20% (TH2) of the initial force of unextracted fibers. Additionally, much higher concentrations of TH2, TH3, and TH4 compared to RSTnC or TH1 were necessary for force development suggesting a decreased affinity of these fragments to their binding site(s) in the fibers, Like intact RSTnC, TH1 was able to interact with the fibers in a Ca2+-independent (Mg2+-dependent) manner, indicating that at a minimum, Ca2+-binding site III is required for this type of binding, The initial binding of the other fragments to the TnC-depleted fibers occurred only in the presence of Ca2+, TH2 and TH4 appeared to bind to two different binding sites in the fibers, The binding to one of the sites caused partial force restoration, This binding of TH2 and TH4 was abolished when Ca2+ was removed, TH2 and TH4 binding to the second site required Ca2+ initially but was maintained in the presence of Mg2+. This interaction of TH2 and TH4 partially blocked the rebinding of RSTnC to the fibers, The latter results suggest that site III or IV in these small fragments, when removed from the constraints of the parent protein, may assume conformations that allow them to function, to a certain extent, like both the regulatory sites (I and II) and the Ca2+-Mg2+ sites (III and IV) of TnC.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040727, R01AR037701] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37701, AR40727] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPHLETT GW, 1976, FEBS LETT, V72, P163, DOI 10.1016/0014-5793(76)80836-8; BABU A, 1988, J BIOL CHEM, V30, P15485; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARSKAYA NV, 1982, BIOCHEM J, V207, P185, DOI 10.1042/bj2070185; COLLINS JH, 1991, BIOCHEMISTRY-US, V30, P702, DOI 10.1021/bi00217a017; COLLINS JH, 1976, NATURE, V259, P699, DOI 10.1038/259699a0; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DEDMAN JR, 1977, J BIOL CHEM, V252, P2437; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOPHEIDE TA, 1967, J BIOL CHEM, V242, P1833; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GUTH K, 1987, J BIOL CHEM, V262, P13627; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1975, CALCIUM TRANSPORT CO, P447; HOAR PE, 1988, J MUSCLE RES CELL M, V9, P165, DOI 10.1007/BF01773738; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; KERRICK WGL, 1985, J BIOL CHEM, V260, P5687; KERRICK WGL, 1975, J APPL PHYSIOL, V39, P1052, DOI 10.1152/jappl.1975.39.6.1052; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEAVIS PC, 1978, BIOCHIM BIOPHYS ACTA, V535, P281, DOI 10.1016/0005-2795(78)90094-6; MALIK NA, 1987, BIOCHIM BIOPHYS ACTA, V911, P221, DOI 10.1016/0167-4838(87)90011-2; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P812, DOI 10.1139/o85-103; MILLER T, 1992, BIOPHYS J, V61, P280; NEGELE JC, 1992, J BIOL CHEM, V267, P825; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; WALL CM, 1981, BIOCHEM J, V195, P307, DOI 10.1042/bj1950307; WANG CLA, 1986, EUR J BIOCHEM, V154, P225, DOI 10.1111/j.1432-1033.1986.tb09383.x; WANG CLA, 1983, J BIOL CHEM, V258, P9175; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1984, MET IONS BIOL SYST, V17, P381; ZOT HG, 1982, J BIOL CHEM, V257, P7678	49	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19287	19293		10.1074/jbc.270.33.19287	http://dx.doi.org/10.1074/jbc.270.33.19287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642603	hybrid			2022-12-27	WOS:A1995RP70300017
J	HAYWARD, CPM; FURMANIAKKAZMIERCZAK, E; CIEUTAT, AM; MOORE, JC; BAINTON, DF; NESHEIM, ME; KELTON, JG; COTE, G				HAYWARD, CPM; FURMANIAKKAZMIERCZAK, E; CIEUTAT, AM; MOORE, JC; BAINTON, DF; NESHEIM, ME; KELTON, JG; COTE, G			FACTOR-V IS COMPLEXED WITH MULTIMERIN IN RESTING PLATELET LYSATES AND COLOCALIZES WITH MULTIMERIN IN PLATELET ALPHA-GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; WEIBEL-PALADE BODIES; FACTOR-X ACTIVATION; BOVINE FACTOR-V; PROTHROMBINASE COMPLEX; FACTOR-VIII; PROCOAGULANT ACTIVITY; VONWILLEBRAND-FACTOR; MOLECULAR-WEIGHT; COMPLETE CDNA	Factor V stored in platelets is an important source of factor Va for the prothrombinase complex. Investigations of potential platelet factor Va-binding proteins, using factor Va light chain affinity chromatography, identified a disulfide-linked multimeric protein with a reduced mobility of 155 kDa in the column eluate, Immunodepletion and immunoblotting indicated that this protein was multimerin. Multimerin specifically bound factors V and Va and the isolated factor Va light chain, but not the heavy chain of factor Va. Factor V stored in platelets, but not plasma factor V, was found to be complexed with multimerin, Multimerin immunodepletion of resting platelet lysates was associated with the removal of factor V and the loss of factor V coagulant activity. Immunoelectron microscopic studies colocalized factor V with multimerin in the alpha-granules of resting platelets. With thrombin-induced platelet activation, we observed dissociation of factor Va-multimerin complexes, multimerin-independent membrane binding of factor Va, and prothrombinase activity that was not inhibitable by multimerin antibodies. This study indicates that platelet factor V is stored as a complex with multimerin and suggests a possible role for multimerin as a carrier protein for factor V stored in platelets.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143	McMaster University; Queens University - Canada; University of California System; University of California San Francisco				Hayward, Catherine/0000-0002-2843-0817	NHLBI NIH HHS [HL-31610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031610, R37HL031610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BARUCH D, 1986, EUR J BIOCHEM, V154, P213, DOI 10.1111/j.1432-1033.1986.tb09381.x; BLOOM JW, 1979, THROMB RES, V15, P595, DOI 10.1016/0049-3848(79)90169-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHESNEY CM, 1981, P NATL ACAD SCI-BIOL, V78, P5180, DOI 10.1073/pnas.78.8.5180; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; CRAMER EM, 1985, BLOOD, V66, P710; ESMON CT, 1979, J BIOL CHEM, V254, P964; GERWITZ AM, 1986, BLOOD, V67, P1639; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; HAYWARD CPM, 1991, J BIOL CHEM, V266, P7114; HAYWARD CPM, 1995, PLATELETS, V6, P1, DOI 10.3109/09537109509013255; HAYWARD CPM, 1993, J CLIN INVEST, V91, P2630, DOI 10.1172/JCI116502; HAYWARD CPM, 1991, BLOOD, V77, P2556; HORSEWOOD P, 1991, BLOOD, V77, P1019; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1980, J BIOL CHEM, V255, P1170; KANE WH, 1982, J BIOL CHEM, V257, P3963; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KELTON JG, 1990, BLOOD, V75, P2172; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; MANN KG, 1990, BLOOD, V76, P1; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILETECH JP, 1981, METHOD ENZYMOL, V80, P13137; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1979, BLOOD, V54, P1015, DOI 10.1182/blood.V54.5.1015.1015; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1993, THROMB HAEMOSTASIS, V70, P80; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1986, J CLIN INVEST, V77, P405, DOI 10.1172/JCI112318; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; ROSING J, 1985, BLOOD, V65, P319; ROSING J, 1980, J BIOL CHEM, V255, P274; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMITH JW, 1993, J IMMUNOL METHODS, V158, P77, DOI 10.1016/0022-1759(93)90260-E; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1984, J CLIN INVEST, V74, P1221, DOI 10.1172/JCI111531; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; TRACY PB, 1979, J BIOL CHEM, V254, P354; VANRIJN J, 1983, EUR J BIOCHEM, V133, P1; VISKUP RW, 1987, BLOOD, V69, P1188; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WENCELDRAKE JD, 1986, BLOOD, V68, P244; WILBOURN B, 1993, BRIT J HAEMATOL, V83, P608, DOI 10.1111/j.1365-2141.1993.tb04698.x; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	61	49	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19217	19224		10.1074/jbc.270.33.19217	http://dx.doi.org/10.1074/jbc.270.33.19217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642592	hybrid			2022-12-27	WOS:A1995RP70300006
J	ABEL, S; NGUYEN, MD; CHOW, W; THEOLOGIS, A				ABEL, S; NGUYEN, MD; CHOW, W; THEOLOGIS, A			ASC4, A PRIMARY INDOLEACETIC ACID-RESPONSIVE GENE ENCODING 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE IN ARABIDOPSIS-THALIANA - STRUCTURAL CHARACTERIZATION, EXPRESSION IN ESCHERICHIA-COLI, AND EXPRESSION CHARACTERISTICS IN RESPONSE TO AUXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA PISUM-SATIVUM; ETHYLENE BIOSYNTHESIS; MULTIGENE FAMILY; RAPID INDUCTION; MESSENGER-RNA; TOMATO; TRANSCRIPTION; TISSUE; FRUIT; IDENTIFICATION	1-Aminocyclopropane-1-carboxylic acid (ACC) synthase is the key regulatory enzyme in the biosynthetic pathway of the plant hormone ethylene. The enzyme is encoded by a divergent multigene family in Arabidopsis thaliana, comprising at least five genes, ACS1-5 (Liang, X., Abel, S., Keller, J. A., Shen, N. F., and Theologis, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11046-11050), In etiolated seedlings, ACS4 is specifically induced by indoleacetic acid (IAA), The response to IAA is rapid (within 25 min) and insensitive to protein synthesis inhibition, suggesting that the ACS4 gene expression is a primary response to IAA, The ACS4 mRNA accumulation displays a biphasic dose-response curve which is optimal at 10 mu M of IAA. However, IAA concentrations as low as 100 nM are sufficient to enhance the basal level of ACS4 mRNA. The expression of ACS4 is defective in the Arabidopsis auxin-resistant mutant lines axr1-12, axr2-1, and aux1-7, ACS4 mRNA levels are severely reduced in axr1-12 and axr2-1 but are only 1.5-fold lower in aux1-7, IAA inducibility is abolished in axr2-1. The ACS4 gene was isolated and structurally characterized. The promoter contains four sequence motifs reminiscent of functionally defined auxin-responsive cis-elements in the early auxin-inducible genes PS-IAA4/5 from pea and GH3 from soybean, Conceptual translation of the coding region predicts a protein with a molecular mass of 53,795 Da and a theoretical isoelectric point of 8.2, The ACS4 polypeptide contains the 11 invariant amino acid residues conserved between aminotransferases and ACC synthases from various plant species. An ACS4 cDNA was generated by reverse transcriptase-polymerase chain reaction, and the authenticity was confirmed by expression of ACC synthase activity in Escherichia coli.	CTR PLANT GENE EXPRESS, ALBANY, CA 94710 USA									Abeles F.B., 1992, PLANT BIOL ETHYL, P1, DOI [DOI 10.1016/B978-0-08-091628-6.50001-1, 10.1016/b978-0-08-091628-6.50001-1, DOI 10.1016/C2009-0-03226-7]; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BALLAS N, 1995, P NATL ACAD SCI USA, V92, P3483, DOI 10.1073/pnas.92.8.3483; BALLAS N, 1993, J MOL BIOL, V233, P580, DOI 10.1006/jmbi.1993.1537; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BOTELLA JR, 1993, GENE, V123, P249, DOI 10.1016/0378-1119(93)90132-M; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; HAGEN G, 1985, MOL CELL BIOL, V5, P1197, DOI 10.1128/MCB.5.6.1197; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HICKS GR, 1989, SCIENCE, V245, P52, DOI 10.1126/science.245.4913.52; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; HUANG PL, 1991, P NATL ACAD SCI USA, V88, P7021, DOI 10.1073/pnas.88.16.7021; JONES MD, 1993, METHOD ENZYMOL, V218, P413; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM WT, 1992, PLANT PHYSIOL, V100, P1126, DOI 10.1104/pp.100.3.1126; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LIANG XW, 1992, P NATL ACAD SCI USA, V89, P11046, DOI 10.1073/pnas.89.22.11046; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; LIU ZB, 1994, PLANT CELL, V6, P645, DOI 10.1105/tpc.6.5.645; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; NAKAGAWA N, 1991, PLANT CELL PHYSIOL, V32, P1153; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; TIMPTE C, 1994, GENETICS, V138, P1239; VAN DER STRAETEN D, 1992, P NATL ACAD SCI USA, V89, P9969, DOI 10.1073/pnas.89.20.9969; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491; ZAREMBINSKI TI, 1993, MOL BIOL CELL, V4, P363, DOI 10.1091/mbc.4.4.363	44	189	202	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19093	19099		10.1074/jbc.270.32.19093	http://dx.doi.org/10.1074/jbc.270.32.19093			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642574	hybrid			2022-12-27	WOS:A1995RN95400062
J	TSENG, MJ; DETJEN, K; STRUK, V; LOGSDON, CD				TSENG, MJ; DETJEN, K; STRUK, V; LOGSDON, CD			CARBOXYL-TERMINAL DOMAINS DETERMINE INTERNALIZATION AND RECYCLING CHARACTERISTICS OF BOMBESIN RECEPTOR CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; MOLECULAR-CLONING; PEPTIDE RECEPTOR; DOWN-REGULATION; MEMBRANE FORM; GROWTH-FACTOR; AGONIST	To investigate the role of the carboxyl terminus in the regulation of the bombesin (BN) receptor, we constructed two chimeric receptors with carboxyl termini transferred from either m3 muscarinic cholinergic (m3 ACh) (BMC) or cholecystokinin A (CCKA) (BCC) receptors and expressed them in Chinese hamster ovary cells, Previous studies showed that agonist treatment caused rapid internalization of CCKA but not m3 ACh receptors in these cells, In the current study we conducted separate analyses of ligand and receptor internalization and analyzed receptor recycling. Ligand internalization was assessed using acid washing. BN and CCKA receptors internalized ligand with 80 +/- 3 and 85 +/- 7% in an acid-resistant compartment at equilibrium, Ligand internalization of chimeric receptors generally assumed the properties of the donor receptors. Thus, BCC receptors internalized ligand to a similar extent as wild-type CCKA receptors (75 +/- 3%), whereas, BMC receptors showed reduced ligand internalization (38 +/- 1%), Receptor internalization was more directly assessed by determining agonist-induced loss of surface binding. BN and CCKA receptors were largely internalized (56 +/- 8 and 50 +/- 7%, respectively). BCC receptors were also extensively internalized (82 +/- 3%). In contrast, BMC receptors were minimally internalized (22 +/- 8%), Receptor recycling was assessed as recovery from agonist induced loss of binding, BN, CCKA, and BMC receptors showed rapid recycling, In contrast, BCC receptors did not recycle, These data indicate that carboxyl-terminal structures determine both internalization of ligand-receptor complexes and subsequent receptor recycling.	UNIV MICHIGAN, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK041225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41225, DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1994, MOL PHARMACOL, V46, P495; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARPENTIER JL, 1992, PROG HISTOCHEM CYTOC, V26, P77, DOI 10.1016/S0079-6336(11)80081-1; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMEH J, 1992, J BIOL CHEM, V267, P13406; MORO O, 1994, J BIOL CHEM, V269, P6651; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; YANG J, 1993, MOL PHARMACOL, V44, P1158; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	48	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18858	18864		10.1074/jbc.270.32.18858	http://dx.doi.org/10.1074/jbc.270.32.18858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642540	hybrid			2022-12-27	WOS:A1995RN95400027
J	BUSBY, TF; ARGRAVES, WS; BREW, SA; PECHIK, I; GILLILAND, GL; INGHAM, KC				BUSBY, TF; ARGRAVES, WS; BREW, SA; PECHIK, I; GILLILAND, GL; INGHAM, KC			HEPARIN-BINDING BY FIBRONECTIN MODULE-III-13 INVOLVES 6 DISCONTINUOUS BASIC RESIDUES BROUGHT TOGETHER TO FORM A CATIONIC CRADLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; ANTITHROMBIN-III; DOMAIN; PROTEIN; REGION; GLYCOSAMINOGLYCANS; IDENTIFICATION; ADHESION; EMBRYOS	The thirteenth type III domain of fibronectin binds heparin almost as well as fibronectin itself and contains a so-called heparin-binding consensus sequence, Arg(6)-Arg(7)-Ala(8)-Arg(9) (residues 1697-1700 in plasma fibronectin). Barkalow and Schwarzbauer (Barkalow, F. J., and Schwarzbauer, J. E. (1991) J. Biol. Chem. 266, 7812-7818) showed that mutation of Arg(6)-Arg(7) in domain III-13 of recombinant truncated fibronectins abolished their ability to bind heparin-Sepharose. However, synthetic peptides containing this sequence have negligible affinity for heparin (Ingham, K. C., Brew, S. A., Migliorini, M. M., and Busby, T. F. (1993) Biochemistry 32, 12548-12553). We generated a three dimensional model of fibronectin type III-13 based on the structure of a homologous domain from tenascin. The model places Arg(23), Lys(25), and Arg(54) parallel to and in close proximity to the Arg(6)-Arg(7)-Ala(8)-Arg(9) motif, suggesting that these residues may also contribute to the heparin-binding site. Domain III-13 and six single-site mutants containing Ser in place of each of the above-mentioned basic residues were expressed in Escherichia coli. All of the purified mutant domains melted reversibly with a Tm near that of the wild type indicating that they were correctly folded. When fluorescein-labeled heparin was titrated at physiological ionic strength, the wild type domain increased the anisotropy in a hyperbolic fashion with a K-d of 5-7 mu M, close to that of the natural domain obtained by proteolysis of fibronectin. The R54S mutant bound 3-fold weaker and the remaining mutants bound at least 10-fold weaker than wild type. The results point out that the Arg(6)-Arg(7)-Ala(8)-Arg(9) consensus sequence by itself has little affinity for heparin under physiological conditions, even when presented in the context of a folded domain. Thus, the heparin-binding site in fibronectin is more complex than previously realized. It is formed by a cluster of 6 positively charged residues that are remote in the sequence but brought together on one side of domain III-13 to form a ''cationic cradle'' into which the anionic heparin molecule could fit.	AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855; MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20855; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20855	American Red Cross; National Institute of Standards & Technology (NIST) - USA					NHLBI NIH HHS [HL21791, HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALBONA K, 1992, J BIOL CHEM, V267, P20120; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BRUNGER AT, 1992, X PLOR VERSION 3 1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DESIMONE DW, 1992, DEV BIOL, V149, P357, DOI 10.1016/0012-1606(92)90291-N; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DUFOUR S, 1991, EXP CELL RES, V193, P331, DOI 10.1016/0014-4827(91)90104-3; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; GUAN C, 1988, GENE, V67, P21; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HATA A, 1993, J BIOL CHEM, V268, P8447; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Hynes RO, 1990, FIBRONECTINS; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; MA YH, 1994, J LIPID RES, V35, P2049; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MANN DM, 1994, J BIOL CHEM, V269, P23661; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MAYO KH, 1992, BIOCHEMISTRY-US, V31, P12255, DOI 10.1021/bi00163a040; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; NOVOKHATNY V, 1992, J MOL BIOL, V227, P1182, DOI 10.1016/0022-2836(92)90530-W; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076	41	83	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18558	18562		10.1074/jbc.270.31.18558	http://dx.doi.org/10.1074/jbc.270.31.18558			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629186	hybrid			2022-12-27	WOS:A1995RM64200064
J	LIN, TA; KONG, XM; SALTIEL, AR; BLACKSHEAR, PJ; LAWRENCE, JC				LIN, TA; KONG, XM; SALTIEL, AR; BLACKSHEAR, PJ; LAWRENCE, JC			CONTROL OF PHAS-I BY INSULIN IN 3T3-L1 ADIPOCYTES - SYNTHESIS, DEGRADATION, AND PHOSPHORYLATION BY A RAPAMYCIN-SENSITIVE AND MITOGEN-ACTIVATED PROTEIN KINASE-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; GLUCOSE-TRANSPORT; CELLS; INITIATION; GROWTH; ACID; FACTOR-EIF-4E; STIMULATION; TRANSLATION; P70(S6K)	PHAS-I levels increased 8-fold as 3T3-L1 fibroblasts differentiated into adipocytes and acquired sensitivity to insulin. Insulin increased PHAS-I protein (3.3 fold after 2 days), the rate of PHAS-I synthesis (3-fold after 1 h), and the half-life of the protein (from 1.5 to 2.5 days). Insulin also increased the phosphorylation of PHAS-I and promoted dissociation of the PHAS-I eukaryotic initiation factor-4E (eIF-4E) complex, effects that were maximal within 10 min. With recombinant [H-6]PHAS-I as substrate, mitogen-activated protein (MAP) kinase was the only insulin-stimulated PHAS-I kinase detected after fractionation of extracts by Mono Q chromatography; however, MAP kinase did not readily phosphorylate [H-6]PHAS-I when the [H-6]PHAS-I . eIF-4E complex was the substrate. Thus, while MAP kinase may phosphorylate free PHAS-I, it is not sufficient to dissociate the complex. Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I . eIF-4E, without decreasing MAP kinase activity. Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70(S6K). The MAP kinase kinase inhibitor, PD 098059, markedly decreased MAP kinase activation by insulin, but it did not change PHAS-I phosphorylation or the association of PHAS-I with eIF-4E. In summary, insulin increases the expression of PHAS-I and promotes phosphorylation of multiple sites in the protein via multiple transduction pathways, one of which is rapamycin-sensitive and independent of MAP kinase. Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710	Washington University (WUSTL); Pfizer; Duke University; Duke University			Blackshear, Perry J./C-6206-2019; Saltiel, Alan/L-3632-2019	Blackshear, Perry J./0000-0002-9561-8529; Saltiel, Alan/0000-0002-9726-9828	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DENTON RM, 1981, DIABETOLOGIA, V21, P347; DEPHILIP RM, 1980, BIOCHEMISTRY-US, V19, P1662, DOI 10.1021/bi00549a022; DIGGLE TA, 1991, BIOCHEM J, V279, P545, DOI 10.1042/bj2790545; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; DUDLEY DT, 1995, IN PRESS P NAT ACAD; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FREDERICKSON RM, 1992, CELL BIOL, V3, P107; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KONG XM, 1994, J BIOL CHEM, V269, P12963; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1995, IN PRESS EXCERPTA ME; LAZARISKARATZAS A, 1990, NATURE, V235, P544; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; SMITH CJ, 1979, P NATL ACAD SCI USA, V76, P2725, DOI 10.1073/pnas.76.6.2725; SMITH M R, 1990, New Biologist, V2, P648; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; STJOHN TP, 1990, CURRENT PROTOCOLS MO; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WHITE MF, 1994, J BIOL CHEM, V269, P1	57	225	227	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18531	18538		10.1074/jbc.270.31.18531	http://dx.doi.org/10.1074/jbc.270.31.18531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629182	hybrid			2022-12-27	WOS:A1995RM64200060
J	MA, L; CONRAD, PJ; WEBB, DL; BLUE, ML				MA, L; CONRAD, PJ; WEBB, DL; BLUE, ML			ASPARTATE-698 WITHIN A NOVEL CATION-BINDING MOTIF IN ALPHA(4) INTEGRIN IS REQUIRED FOR CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; VLA-4 INTEGRIN; LYMPHOCYTES-T; FIBRONECTIN; SITE; DISTINCT; SUBUNIT; RECEPTOR; DOMAIN; VCAM-1	The interactions of alpha(4) beta(1) integrin with vascular cell adhesion molecule (VCAM) and fibronectin play important roles in many physiological and pathological processes, To understand the mechanism of alpha(1) beta(1) integrin-mediated cell adhesion, we made mutant alpha(4) constructs, Three aspartic acid (Asp) residues in alpha(4), Asp 489, Asp-698, and Asp-811, were replaced with glutamic acids (Glu), The wild-type and mutant alpha(4) constructs were transfected into K562 cells, and stable transfectants with similar levels of alpha(4) surface expression were established, The Asp --> Glu substitutions did not affect alpha(4) beta(1) association or heterodimer formation as demonstrated by immunoprecipitation analysis. However, the glutamate substitutions at Asp-489 and Asp-698 severely impaired cell adhesion to VCAM and fibronectin, whereas the substitution at Asp-811 had no detectable effect on cell adhesion. In contrast to these results, isolated alpha(4) beta(1), containing the D489E or D698E substitution, was able to bind to VCAM, suggesting that these two residues are not critical for ligand recognition. In searching for a mechanism to explain inhibition of adhesion by Asp-489 and Asp 698 mutations, we found that the sequences flanking Asp 698 resemble the DxxxxxD-S-Sx divalent cation/ligand binding motif in beta integrins and the I-domains of alpha integrins. This suggests that Asp-698 in the alpha(4) integrin, which does not possess an I-domain, may also be involved in cation binding and may be part of a sequence functionally similar to that found in the I-domains of other alpha integrins.	BAYER RES CTR,INST BONE & JOINT DISORDERS & CANC,W HAVEN,CT 06516	Bayer AG			Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BAO L, 1993, DIFFERENTIATION, V52, P239, DOI 10.1111/j.1432-0436.1993.tb00636.x; BLUE ML, 1993, IMMUNOLOGY, V78, P80; BURKLY LC, 1994, DIABETES, V43, P529, DOI 10.2337/diabetes.43.4.529; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG X, 1994, MOL BIOL CELL, V4, pA283; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; MARKAREM R, 1994, J BIOL CHEM, V269, P4005; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PULIDO R, 1991, J BIOL CHEM, V266, P10241; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEBB DL, 1993, BIOCHEM BIOPH RES CO, V197, P674, DOI 10.1006/bbrc.1993.2532; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	38	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18401	18407		10.1074/jbc.270.31.18401	http://dx.doi.org/10.1074/jbc.270.31.18401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629165	hybrid			2022-12-27	WOS:A1995RM64200041
J	OSTANIN, K; POKALSKY, C; WANG, S; VANETTEN, RL				OSTANIN, K; POKALSKY, C; WANG, S; VANETTEN, RL			CLONING AND CHARACTERIZATION OF A SACCHAROMYCES-CEREVISIAE GENE ENCODING THE LOW-MOLECULAR-WEIGHT PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; BOVINE HEART; CATALYTIC MECHANISM; CDC25 PROTEIN; FISSION YEAST; PURIFICATION; LIVER; GROWTH; DEPHOSPHORYLATION; EXPRESSION	The low molecular weight protein tyrosine phosphatase (low M(r) PTPase) is an 18-kDa cytoplasmic enzyme of unknown function that has been previously found in several vertebrates, Using an oligonucleotide probe derived from the active site sequence of the mammalian low M(r) PTPases, a Saccharomyces cerevisiae gene that encodes a homolog of this enzyme was cloned by low stringency hybridization, This gene, LTP1, together with a neighboring gene, TKL1, is shown to be located on the right arm of chromosome XVI. The deduced amino acid sequence of its 161-amino acid residue product shows a 39% average identity with that of the mammalian enzymes. The yeast Ltp1 protein was expressed in Escherichia coli, purified to homogeneity, and shown to possess PTPase activity. The recombinant Ltp1 efficiently hydrolyzes phosphotyrosine and a phosphotyrosine-containing peptide, Tyr(531)-fyn, but it shows low activity toward phosphoserine and phosphothreonine. The catalytic activity of Ltp1 toward a number of substrates was approximately 30-fold lower than the corresponding values measured for the bovine low M(r) PTPase. However, the yeast enzyme was markedly activated by adenine and some purine nucleosides and nucleotides, including cAMP and cGMP. In the case of adenine, the activity of Ltp1 was increased by approximately 30-fold. The high degree of evolutionary conservation of the low M(r) PTPases implies a significant role for this enzyme. However, neither the disruption of the LTP1 gene nor an approximately 10-fold overexpression of its product in S. cerevisiae caused any apparent phenotypic changes under the conditions tested. No proteins related to Ltp1 could be detected in extracts of the ltp1 null mutant, either by immunoblotting or by gelfiltration analysis accompanied by extended kinetic assays, consistent with the conclusion that LTP1 is the only low M(r) PTPase-encoding gene in S. cerevisiae.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Wang, Shuishu/0000-0002-0865-4522	NIGMS NIH HHS [GM 27003] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BAXTER JH, 1985, ARCH BIOCHEM BIOPHYS, V239, P29, DOI 10.1016/0003-9861(85)90808-2; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; BOIVIN P, 1987, INT J BIOCHEM, V19, P613, DOI 10.1016/0020-711X(87)90227-8; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CASELLI A, 1994, J PROTEIN CHEM, V13, P107, DOI 10.1007/BF01891998; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DAVIS JP, 1994, BIOCHEMISTRY-US, V33, P1278, DOI 10.1021/bi00171a031; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DIPIETRO DL, 1967, J BIOL CHEM, V242, P3391; DISSING J, 1992, BIOCHIM BIOPHYS ACTA, V1121, P261, DOI 10.1016/0167-4838(92)90155-7; DISSING J, 1993, BIOCHIM BIOPHYS ACTA, V1162, P275, DOI 10.1016/0167-4838(93)90291-X; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER EH, 1991, SCIENCE, V253, P401; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1992, J BIOL CHEM, V267, P10024; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNIG G, 1993, YEAST, V9, P1039, DOI 10.1002/yea.320091002; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAZARUK KDA, 1993, BIOCHEM BIOPH RES CO, V196, P440, DOI 10.1006/bbrc.1993.2269; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OAKADA M, 1986, BIOCHEM J, V239, P155; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; PANARA F, 1991, INT J BIOCHEM, V23, P1115, DOI 10.1016/0020-711X(91)90152-D; PANARA F, 1985, INT J BIOCHEM, V17, P1213, DOI 10.1016/0020-711X(85)90011-4; PANARA F, 1989, COMP BIOCHEM PHYS B, V92, P751, DOI 10.1016/0305-0491(89)90262-9; POKALSKY C, 1995, J BIOL CHEM, V270, P3809, DOI 10.1074/jbc.270.8.3809; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RILES L, 1993, GENETICS, V134, P81; Rose MD., 1990, METHODS YEAST GENETI; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Sambrook J, 1989, MOL CLONING LABORATO; SPURR NK, 1994, KCYTOGENET CELL GENE, V67, P215; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; TABOR S, 1990, CURRENT PROTOCOL S11, V2; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1990, MECHANISTIC KINETIC	67	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18491	18499		10.1074/jbc.270.31.18491	http://dx.doi.org/10.1074/jbc.270.31.18491			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629177	hybrid			2022-12-27	WOS:A1995RM64200054
J	TAIRIS, N; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR				TAIRIS, N; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR			ALTERATION IN THE RETINOID SPECIFICITY OF RETINOIC ACID RECEPTOR-BETA BY SITE-DIRECTED MUTAGENESIS OF ARG(269) AND LYS(220)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; DIFFERENTIAL PATTERN; GAMMA; MOUSE; IDENTIFICATION; LIGAND; ALPHA; EXPRESSION; ISOFORMS; TRANSCRIPTION	Retinoic acid receptor-beta (RAR-beta) specifically binds retinoic acid (RA) and functions as a RA-inducible transcriptional regulatory factor. Simultaneous mutation of Arg(269) and Lys(220) of RAR-beta to Ala results in a dramatic reduction in both transactivation and affinity for RA along with creating a RA concentration-dependent dominant negative mutant. In this report, we found that mutation of these two amino acid residues singly and simultaneously to Gin results in mutant RAR-beta s, each displaying a more dramatic reduction in transactivation and affinity for RA than their corresponding Ala mutant, with the R269Q more profoundly affected than K220Q. Furthermore, we examined both the Ala and Gin mutants for their ability to transactivate and bind two other retinoids with different functional end groups (all-trans-retinol and all-trans-retinal). Mutation of Lys(220) to either an Ala or a Gin favors transactivation and binding of retinal, while mutation of either Lys(220) or Arg(269) to Gin favors retinol transactivation and binding. Taken together, these results suggest that Arg(269) and Lys(220) lie within the ligand binding pocket of RAR-beta and that these two amino acid residues play an important role in determining retinoid specificity most likely by directly interacting with the carboxylate group of RA.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Tairis, Nikolaos/W-9326-2019		NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER; NCI NIH HHS [CA64945] Funding Source: Medline; NICHD NIH HHS [HD01076] Funding Source: Medline; NIDDK NIH HHS [DK44517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BENBROOK D, 1988, NATURE, V333, P444; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHENG L, 1991, J BIOL CHEM, V266, P24404; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GUDAS L, 1993, RETINOIDS, P443; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KNEGTEL RMA, 1993, BIOCHEM BIOPH RES CO, V192, P492, DOI 10.1006/bbrc.1993.1442; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MANGELSDORF DJ, 1993, RETINOIDS, P319; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1978, J BIOL CHEM, V253, P4551; ONG DE, 1993, RETINOIDS, P283; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCATCHARD G, 1946, ANN NY ACAD SCI, V51, P660; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOPRANO DR, 1993, TOXICOL APPL PHARM, V122, P159, DOI 10.1006/taap.1993.1183; STUMP DG, 1991, J BIOL CHEM, V266, P4622; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	45	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18380	18387		10.1074/jbc.270.31.18380	http://dx.doi.org/10.1074/jbc.270.31.18380			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629162	hybrid			2022-12-27	WOS:A1995RM64200038
J	GUO, B; PHILLIPS, JD; YU, Y; LEIBOLD, EA				GUO, B; PHILLIPS, JD; YU, Y; LEIBOLD, EA			IRON REGULATES THE INTRACELLULAR DEGRADATION OF IRON REGULATORY PROTEIN-2 BY THE PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; ACONITASE; FERRITIN; CLUSTER; PURIFICATION; TRANSLATION; EXPRESSION	Iron regulatory proteins (IRP1 and IRP2) are RNA-binding proteins that bind to specific structures, termed iron responsive elements (IREs), that are located in the 5'- or 3'-untranslated regions of mRNAs that encode proteins involved in iron homeostasis. IRP1 and IRP2 RNA binding activities are regulated by iron; IRP1 and IRP2 bind IREs with high affinity in iron-depleted cells and with low affinity in iron-repleted cells. The decrease in IRP1 RNA binding activity occurs by a switch between apoprotein and 4Fe-4S forms, without changes in IRP1 levels, whereas the decrease in IRP2 RNA binding activity reflects a reduction in IRP2 levels. To determine the mechanism by which iron decreases IRP2 levels, we studied IRP2 regulation by iron in rat hepatoma and human HeLa cells. The iron-dependent decrease in IRP2 levels was not due to a decrease in the amount of IRP2 mRNA or to a decrease in the rate of IRP2 synthesis. Pulse chase experiments demonstrated that iron resulted in a 3-fold increase in the degradation rate of IRP2. IRP2 degradation depends on protein synthesis, but not transcription, suggesting a requirement for a labile protein. IRP2 degradation is not prevented by lysosomal inhibitors or calpain II inhibitors, but is prevented by inhibitors that block proteasome function. These data suggest the involvement of the proteasome in iron-mediated IRP2 proteolysis.	UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NCI NIH HHS [CA4201] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1994, J BIOL CHEM, V270, P700; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1994, J BIOL CHEM, V268, P27327; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MCCONLOGUE L, 1986, MOL CELL BIOL, V6, P2865, DOI 10.1128/MCB.6.8.2865; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1993, BIOFACTORS, V4, P87; WALDEN WE, 1989, J BIOL CHEM, V26, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	42	256	259	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21645	21651		10.1074/jbc.270.37.21645	http://dx.doi.org/10.1074/jbc.270.37.21645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665579	hybrid			2022-12-27	WOS:A1995RU75700036
J	LUND, BO; LUND, J				LUND, BO; LUND, J			NOVEL INVOLVEMENT OF A MITOCHONDRIAL STEROID HYDROXYLASE (P450C11) IN XENOBIOTIC METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENOCORTICAL TOXICITY; MICE; 3-METHYLSULFONYL-DDE; PROTEIN; CORTEX; CELLS; DDT	Adrenocortical mitochondrial cytochrome P450 isozymes of the Cyp11 family normally synthesize steroids with a very strict substrate specificity. However, for the first time, P450c11 was additionally shown to metabolize and bioactivate the adrenotoxic environmental pollutant 3-methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene (MeSO(2)-DDE). This conclusion is based on a striking correlation between inductions of MeSO(2)DDE and deoxycorticosterone metabolism by forskolin in the adrenocortical cell lines Y1 and Kin-8, inhibition of P450c11-dependent activities in. Y1 cells by MeSO(2)-DDE, and metabolism of MeSO(2)-DDE by non-steroidogenic COS cells after transfection with a cDNA encoding P450c11. The interaction between xenobiotics and glucocorticoid synthesis should focus more attention to xenobiotic-induced hormonal disturbances.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED NUTR,NOVUM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	LUND, BO (corresponding author), SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT PHARMACOL TOXICOL,BOX 573,S-75123 UPPSALA,SWEDEN.							BAKER MT, 1984, BIOCHEM PHARMACOL, V33, P255, DOI 10.1016/0006-2952(84)90483-0; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; HARAGUCHI K, 1989, CHEMOSPHERE, V19, P487, DOI 10.1016/0045-6535(89)90356-1; HORNSBY PJ, 1989, FREE RADICAL BIO MED, V6, P103, DOI 10.1016/0891-5849(89)90163-9; JENSEN S, 1976, Ambio, V5, P257; JONSSON CJ, 1994, ENVIRON TOXICOL CHEM, V13, P1303, DOI [10.1897/1552-8618(1994)13[1303:TAIBOT]2.0.CO;2, 10.1002/etc.5620130812]; JONSSON CJ, 1994, PHARMACOL TOXICOL, V74, P58; JONSSON CJ, 1992, REPROD TOXICOL, V6, P233, DOI 10.1016/0890-6238(92)90178-V; JONSSON CJ, 1991, FUND APPL TOXICOL, V16, P365, DOI 10.1016/0272-0590(91)90121-J; JONSSON CJ, 1994, TOXICOL LETT, V71, P169, DOI 10.1016/0378-4274(94)90177-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND BO, 1988, CHEM-BIOL INTERACT, V65, P25, DOI 10.1016/0009-2797(88)90028-2; LUND BO, 1994, ENVIRON TOXICOL CHEM, V13, P911, DOI 10.1897/1552-8618(1994)13[911:IVABAA]2.0.CO;2; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; SZABO S, 1989, TOXICOL PATHOL, V17, P317, DOI 10.1177/019262338901700208; TALALAY P, 1953, J BIOL CHEM, V205, P823; WONG M, 1989, J BIOL CHEM, V264, P12867; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	18	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20895	20897		10.1074/jbc.270.36.20895	http://dx.doi.org/10.1074/jbc.270.36.20895			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673111	hybrid			2022-12-27	WOS:A1995RU05400007
J	MELCHIOR, GW; GREENLEE, KA; CASTLE, CK; PROUGH, MJ; MILNE, RW; MAROTTI, KR; KEZDY, FJ				MELCHIOR, GW; GREENLEE, KA; CASTLE, CK; PROUGH, MJ; MILNE, RW; MAROTTI, KR; KEZDY, FJ			EVIDENCE THAT CYNOMOLGUS MONKEY CHOLESTERYL ESTER TRANSFER PROTEIN HAS 2 NEUTRAL LIPID-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DEFICIENT PLASMA; HIGH-DENSITY LIPOPROTEINS; MONOCLONAL-ANTIBODY; MESSENGER-RNA; INHIBITION; EXCHANGE; SEQUENCE; RABBIT	Two inhibitors of cynomolgus monkey cholesteryl ester transfer protein were evaluated. One, a monoclonal antibody made against purified cynomolgus monkey cholesteryl ester transfer protein, was capable of severely inhibiting triglyceride transfer, but had a variable effect on cholesteryl ester transfer. At low antibody to antigen ratios, there was what appeared to be a stoichiometric inhibition of cholesteryl ester transfer, but at high antibody to antigen ratios the inhibition of cholesteryl ester transfer was completely relieved, even though triglyceride transfer remained blocked. Fab fragments of the antibody had no effect whatsoever on cholesteryl ester transfer, but were capable of completely blocking triglyceride transfer. The other inhibitor, 6-chloromecuric cholesterol, severely inhibited cholesteryl ester transfer with minimal inhibition of triglyceride transfer. When both inhibitors were added to the assay, both cholesteryl ester and triglyceride transfer were inhibited; an indication that the inhibitors did not compete for the same binding site on cholesteryl ester transfer protein. When the antibody was given subcutaneously to cynomolgus monkeys at a dose which inhibited triglyceride transfer in the plasma by more than 90%, there was no detectable effect on the high density lipoprotein (HDL) cholesterol level, but the HDL triglyceride levels decreased from 13 +/- 2 to 1 +/- 0 mol/mol of HDL (mean +/- S.D.); an indication that the antibody uncoupled cholesteryl ester and triglyceride transfer in vivo. The 6-chloromecuric cholesterol could not be evaluated in vivo because it is a potent lecithin:cholesterol acyltransferase inhibitor. The fact that cholesteryl ester transfer can be inhibited without effect on triglyceride transfer and, conversely, that triglyceride transfer can be inhibited without effect on cholesteryl ester transfer indicates that these two lipids are not transferred by a single, non-discriminatory process.	UNIV OTTAWA,OTTAWA CIVIC HOSP,INST HEART,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa Heart Institute	MELCHIOR, GW (corresponding author), UPJOHN CO,ENDOCRINE PHARMACOL & METAB,7250-209-4,KALAMAZOO,MI 49001, USA.							AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1980, J LIPID RES, V21, P238; BISGAIER CL, 1994, LIPIDS, V29, P811, DOI 10.1007/BF02536247; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CHAJEK T, 1978, P NATL ACAD SCI USA, V75, P3445, DOI 10.1073/pnas.75.7.3445; EPPS DE, 1995, IN PRESS CHEM PHYS L; EVANS GF, 1994, J LIPID RES, V35, P1634; FUKASAWA M, 1992, J BIOCHEM-TOKYO, V111, P696, DOI 10.1093/oxfordjournals.jbchem.a123821; GAYNOR BJ, 1994, ATHEROSCLEROSIS, V110, P101, DOI 10.1016/0021-9150(94)90073-6; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P67; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HAMILTON JA, 1991, P NATL ACAD SCI USA, V88, P251; HESLER CB, 1988, J BIOL CHEM, V263, P5020; IHM J, 1982, J LIPID RES, V23, P361; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KO KWS, 1994, J BIOL CHEM, V269, P28206; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; MARGULIES DH, 1992, CURRENT PROTOCOLS IM; MELCHIOR GW, 1994, J BIOL CHEM, V269, P8044; MIN X, 1992, NATURE, V358, P209; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1983, J BIOL CHEM, V258, P1751; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; RYE KA, 1992, STRUCTURE FUNCTION A, P401; SARCICH JL, 1994, J PROTEIN SCI, V14, P81; SCHUMAKER VN, 1973, ACCOUNTS CHEM RES, V6, P398, DOI 10.1021/ar50072a002; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; STEIN Y, 1990, BIOCHIM BIOPHYS ACTA, V1042, P138, DOI 10.1016/0005-2760(90)90068-9; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG SK, 1995, J BIOL CHEM, V270, P612, DOI 10.1074/jbc.270.2.612; WANG SK, 1993, J BIOL CHEM, V268, P1955; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YAMASHITA S, 1991, METABOLISM, V40, P756, DOI 10.1016/0026-0495(91)90097-G; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	37	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21068	21074		10.1074/jbc.270.36.21068	http://dx.doi.org/10.1074/jbc.270.36.21068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673135	hybrid			2022-12-27	WOS:A1995RU05400033
J	GUITON, M; GUNNMOORE, FJ; GLASS, DJ; GEIS, DR; YANCOPOULOS, GD; TAVARE, JM				GUITON, M; GUNNMOORE, FJ; GLASS, DJ; GEIS, DR; YANCOPOULOS, GD; TAVARE, JM			NATURALLY-OCCURRING TYROSINE KINASE INSERTS BLOCK HIGH-AFFINITY BINDING OF PHOSPHOLIPASE C-GAMMA AND SHC TO TRKC AND NEUROTROPHIN-3 SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; PROTEIN-KINASE; RAT TRKC; CELLS; PHOSPHORYLATION; ACTIVATION; ENCODES; AUTOPHOSPHORYLATION; IDENTIFICATION	Neurotrophin-3 binds to the receptor tyrosine kinase, TrkC. Several naturally occurring splice variants of TrkC exist including those with 14- and 39 amino acid inserts within the tyrosine kinase homology region. When expressed in fibroblasts, full-length TrkC, but not the kinase insert variants, mediated neurotrophin-3-stimulated cell proliferation. We investigated the molecular basis of this signaling defect. The kinase inserts blocked the ability of TrkC to mediate neurotrophin-3 stimulated c-myc and c-fos transcription and activation of the AP-1 transcriptional complex. In cells expressing full-length TrkC, neurotrophin-3 promoted a sustained activation of mitogen-activated protein kinase; TrkC containing kinase inserts only mediated transient activation of mitogen-activated protein kinase. The kinase inserts specifically blocked neurotrophin-3-stimulated autophosphorylation of the phospholipase C gamma binding site on TrkC (tyrosine 789) resulting in a severe reduction in phospholipase C gamma association with TrkC and its tyrosine phosphorylation. Neurotrophin-3-stimulated phosphorylation of the She binding site (tyrosine 485) on TrkC, and tyrosine phosphorylation of She itself, was unaffected by the kinase inserts; however, the kinase inserts blocked high affinity She association with TrkC. It is proposed that the lack of high affinity binding of Shc and/or phospholipase C gamma to the TrkC kinase insert variants may be responsible for the inability of these variants to bring about a full biological response in fibroblasts.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND; REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	University of Bristol; Regeneron			Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOZERI O, 1992, ONCOGENE, V7, P2259; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	40	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20384	20390		10.1074/jbc.270.35.20384	http://dx.doi.org/10.1074/jbc.270.35.20384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657612	hybrid			2022-12-27	WOS:A1995RR58400025
J	SANTOS, C; BALLESTA, JPG				SANTOS, C; BALLESTA, JPG			THE HIGHLY CONSERVED PROTEIN P0 CARBOXYL END IS ESSENTIAL FOR RIBOSOME ACTIVITY ONLY IN THE ABSENCE OF PROTEINS P1 AND P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; IMMUNE ELECTRON-MICROSCOPY; RAT-LIVER RIBOSOME; ACIDIC PHOSPHOPROTEINS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; ARTEMIA-SALINA; GTPASE DOMAIN; LARGE SUBUNIT; BINDING-SITE	Protein P0 together with proteins P1 and P2 form the stalk in eukaryotic ribosomes. P0 has a carboxyl-terminal domain about 100 amino acids long that has high sequence similar to the ribosomal proteins P1 and P2. By sequential deletion of this region, a series of Saccharomyces cerevisiae truncated P0 genes have been constructed that encode proteins lacking 21, 87, and 132 amino acids from the carboxyl terminus, respectively. These constructions have been used to transform yeast P0 conditional null mutants to test their capacity to restore cell growth. Removal of only the last 21 amino acids causes a small effect on cell growth in wild-type strains; however, this deletion is lethal in strains having P protein-deficient ribosomes. A P0 lacking 87 amino acids allows cell growth at a low rate, and ribosomes bind P proteins with much less affinity. Lastly, removal of 132 amino acids totally inactivates P0; this deleted protein is unable to bind to the particles, causing a deficiency in active 60 S subunits and making the cell nonviable. These results indicate that at least one out of the five protein P-like carboxyl termini present in the ribosome has to be firmly bound to the particle for protein synthesis and cell viability, and this structure can be provided by protein P0. The part of P0 from around positions 230-290 is important for the interaction of proteins P1/P2 with the ribosome, but it is not essential for protein synthesis. Finally, the region including from residues 185 to 230 is required for the interaction of P0 with the rRNA.	CSIC, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid			Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				BALLESTA JPG, 1993, PROTEIN SYNTHESIS TA, P67; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HIGHLAND JH, 1975, J BIOL CHEM, V250, P831; HORAK I, 1977, FEBS LETT, V82, P82, DOI 10.1016/0014-5793(77)80890-9; HORAK I, 1977, EUR J BIOCHEM, V79, P375, DOI 10.1111/j.1432-1033.1977.tb11818.x; ISSINGER OG, 1977, BIOCHIM BIOPHYS ACTA, V477, P185, DOI 10.1016/0005-2787(77)90234-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JU QD, 1994, YEAST, V10, P151, DOI 10.1002/yea.320100203; JUANVIDALES F, 1983, EUR J BIOCHEM, V136, P275, DOI 10.1111/j.1432-1033.1983.tb07738.x; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; KOPKE AKE, 1992, J BIOL CHEM, V267, P1382; KRUISWIJK T, 1978, BIOCHEM J, V175, P213, DOI 10.1042/bj1750213; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; LEADER DP, 1977, BIOCHEM J, V162, P199, DOI 10.1042/bj1620199; LILJAS A, 1991, INT REV CYTOL, V124, P103; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MACCONNELL WP, 1980, BIOCHEM BIOPH RES CO, V92, P46, DOI 10.1016/0006-291X(80)91517-X; MARQUIS DM, 1981, J MOL BIOL, V150, P121, DOI 10.1016/0022-2836(81)90327-2; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; MITSUI K, 1987, J BIOCHEM-TOKYO, V102, P1565, DOI 10.1093/oxfordjournals.jbchem.a122205; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3573, DOI 10.1093/nar/16.8.3573; Moller W., 1986, STRUCTURE FUNCTION G, P309; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; OLSON HM, 1986, J BIOL CHEM, V261, P6924; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1988, J BIOL CHEM, V263, P9094; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURUGI K, 1978, J BIOL CHEM, V253, P946; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; TSURUGI K, 1991, BIOCHEM BIOPH RES CO, V174, P1318, DOI 10.1016/0006-291X(91)91566-U; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; ZINKER S, 1976, J BIOL CHEM, V251, P1799	61	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20608	20614		10.1074/jbc.270.35.20608	http://dx.doi.org/10.1074/jbc.270.35.20608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657639	hybrid			2022-12-27	WOS:A1995RR58400058
J	KANAYA, E; KANAYA, S				KANAYA, E; KANAYA, S			RECONSTITUTION OF ESCHERICHIA-COLI RNASE HI FROM THE N-FRAGMENT WITH HIGH HELICITY AND THE C-FRAGMENT WITH A DISORDERED STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; RIBONUCLEASE-H; STAPHYLOCOCCAL NUCLEASE; PROTEIN; PEPTIDE; INTERMEDIATE; INITIATION; SUBSTITUTIONS; CONFORMATION	The Escherichia coli RNase HI variant with the Lys(86) --> Ala mutation is purified in two forms, as nicked and intact proteins. The nicked K86A protein, in which the N-fragment (Met(1)-Lys(87)) and the C-fragment (Arg(88)- Val(155)) remain associated, is enzymatically active. These N- and C-fragments were isolated and examined for reassociation. These peptides did not associate to form the nicked K86A protein at pH 3.0 in the absence of salt, but were associated, with a yield of 30-80%, when the pH was raised to 5.5 or when salt was added. Measurements of the CD spectra show that the alpha-helices are partially formed in the N-fragment at pH 3.0 in the absence of salt and are almost fully formed either at pH 5.5 or at pH 3.0 in the presence of 0.15 M NaCl. In contrast, the C-fragment remains almost fully disordered under these conditions. The N-fragment with this high (native-like) helicity shows the characteristics of a molten globule with respect to the content of the secondary and tertiary structures, the ability to bind a fluorescent probe (1-anilinonaphthalene-8-sulfonic acid), and the behavior on the thermal transition. These results suggest that the N-fragment contains an initial folding site, probably the alpha I-helix, and the completion of the folding in this site provides a surface that facilitates the folding of the C-fragment. This folding process may represent that of the intact RNase HI molecule.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEALS JM, 1991, BIOCHEMISTRY-US, V30, P7680, DOI 10.1021/bi00245a004; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; CHAFFOTTE A, 1991, BIOCHEMISTRY-US, V30, P8067, DOI 10.1021/bi00246a027; DABORA JM, 1994, PROTEIN SCI, V3, P1401, DOI 10.1002/pro.5560030906; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; FONTANA A, 1990, PEPTIDES CHEM STRUCT, P557; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GAY GD, 1994, P NATL ACAD SCI USA, V91, P10943, DOI 10.1073/pnas.91.23.10943; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; HARADA D, 1994, P NATL ACAD SCI USA, V81, P10325; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIPPEN AD, 1994, BIOCHEMISTRY-US, V33, P3778, DOI 10.1021/bi00178a039; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; SANCHO J, 1992, J MOL BIOL, V224, P741, DOI 10.1016/0022-2836(92)90558-2; SANCHO J, 1992, J MOL BIOL, V224, P749, DOI 10.1016/0022-2836(92)90559-3; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TANIUCHI H, 1971, J BIOL CHEM, V246, P2291; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; [No title captured]	54	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19853	19860		10.1074/jbc.270.34.19853	http://dx.doi.org/10.1074/jbc.270.34.19853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649997	hybrid			2022-12-27	WOS:A1995RQ99100029
J	KING, SC; FLEMING, SR; BRECHTEL, CE				KING, SC; FLEMING, SR; BRECHTEL, CE			LIGAND RECOGNITION PROPERTIES OF THE ESCHERICHIA-COLI 4-AMINOBUTYRATE TRANSPORTER ENCODED BY GABP - SPECIFICITY OF GAB PERMEASE FOR HETEROCYCLIC INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRATE; MELIBIOSE CARRIER; SUGAR; CLUSTER; GENE	4-aminobutyrate metabolism in Escherichia coli begins with transport across the cytoplasmic membrane via the GabP, which is encoded by gabP, Although GrabP is specific and exhibits poor affinity for many cellular constituents such as the alpha-amino acids, the range of compounds recognized with high affinity has yet to be investigated, In order to address this gap in knowledge, we developed a gabP-negative host strain, which permits evaluation of test compounds for inhibitory effects on cloned GabP (expression inducible by isopropyl-1-thio-beta-D-galactopyranoside). Using this inducible expression system, three structurally distinct categories of high affinity transport inhibitor were identified. The structural dissimilarity of these inhibitors significantly alters our view of ligand recognition by GabP, Any complete model must now account for the observation that inhibition of 4-aminobutyrate transport can be mediated either (i) by open chain analogs of 4-aminobutyrate, (ii) by cyclic amino acid analogs, or (iii) by planar heterocyclic compounds lacking a carboxyl group. Such results do not support a previously sustainable view of GabP that features a restrictive ligand recognition domain, unable to accommodate structures that differ very much from the native substrate, 4-aminobutyrate.			KING, SC (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,BASIC SCI BLDG,RTE F-41,GALVESTON,TX 77555, USA.				NINDS NIH HHS [5 RO1 NS31029-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031029] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; CHRISTENSEN HN, 1975, BIOL TRANSPORT, P346; HELLER KB, 1981, FEBS LETT, V129, P253, DOI 10.1016/0014-5793(81)80177-9; KAHANE S, 1978, J BACTERIOL, V135, P295, DOI 10.1128/JB.135.2.295-299.1978; KING SC, 1990, J BIOL CHEM, V265, P9638; METZER E, 1979, J BACTERIOL, V137, P1111, DOI 10.1128/JB.137.3.1111-1118.1979; METZER E, 1990, J BACTERIOL, V172, P3250, DOI 10.1128/jb.172.6.3250-3256.1990; NIEGEMANN E, 1993, ARCH MICROBIOL, V160, P454, DOI 10.1007/BF00245306; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; SHINE J, 1974, P NATL ACAD SCI USA, V72, P1342; WILSON DM, 1981, BIOCHIM BIOPHYS ACTA, V649, P377, DOI 10.1016/0005-2736(81)90427-2; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WRIGHT JK, 1986, ANNU REV BIOCHEM, V55, P225	14	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19893	19897		10.1074/jbc.270.34.19893	http://dx.doi.org/10.1074/jbc.270.34.19893			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650003	hybrid			2022-12-27	WOS:A1995RQ99100035
J	MURASAWA, S; MATSUBARA, H; KIJIMA, K; MARUYAMA, K; MORI, Y; INADA, M				MURASAWA, S; MATSUBARA, H; KIJIMA, K; MARUYAMA, K; MORI, Y; INADA, M			STRUCTURE OF THE RAT V1A VASOPRESSIN RECEPTOR GENE AND CHARACTERIZATION OF ITS PROMOTER REGION AND COMPLETE CDNA SEQUENCE OF THE 3'-END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTIDIURETIC-HORMONE; MOLECULAR-CLONING; MESSENGER-RNA; CHROMOSOMAL ASSIGNMENT; POTASSIUM CHANNEL; SUBSTANCE-P; EXPRESSION; ORGANIZATION; TRANSCRIPTION; LOCALIZATION	The gene encoding the rat Via arginine vasopressin (AVP) receptor was isolated, and its structural organization and 5'-flanking region were characterized, In addition, the complete cDNA sequence of the major transcript of the rat V1a receptor gene was determined, Southern blots demonstrated a single copy of the V1a receptor gene in the rat genome, spanning a region of 3.8 kilobases (kb) and consisting of two exons and one intron (1.8 kb). The location of the intron was unique among G protein coupled receptor genes in that the first exon encodes six of the seven transmembrane regions, the seventh region being encoded by the second exon, Primer extension, RNase protection, and rapid amplification of the 5'-end of the cDNA identified three transcriptional initiation sites (-405, -243, and -237), the major transcription initiation sites being mapped to positions -243 and -237 base pairs (bp) upstream of the ATG initiation codon (+1 bp), This portion of the 5'-flanking region has neither a TATA nor a CCAAT box, is GC-rich but has no GC box motif, and has features of promoters seen in housekeeping genes, Chimeras containing 2.2 kb of the 5'-flanking region and deletion analyses using the chloramphenicol acetyltransferase gene indicated that a ''minimal'' region, exhibiting promoter activity and tissue specificity, is located between nucleotides -296 and -221, when transfected into vascular smooth muscle cells, Gel mobility shift assay and Southwestern blotting suggested that similar to 30- and similar to 28-kDa nuclear proteins specifically bind to this region, Rapid amplification of the 3'-end of the cDNA showed that the major transcript terminates 442 bp downstream of the stop codon, in agreement with the mRNA size (2.1 kb), This study demonstrated a distinctive feature in the structural organization of the AVP-oxytocin receptor family genes, and characterization of the 5'-flanking region reported here will lead to a better understanding of the mechanism of transcriptional regulation of the rat Via AVP receptor gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								ARAI H, 1993, J BIOL CHEM, V268, P3463; AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HOSODA K, 1992, J BIOL CHEM, V267, P18797; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JARD S, 1986, MOL PHARMACOL, V30, P171; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; Michell R H, 1979, Biochem Soc Trans, V7, P861; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORI Y, 1993, J BIOL CHEM, V268, P26482; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; ROSEN F, 1995, P NATL ACAD SCI USA, V92, P200; SACHS A, 1993, J BIOL CHEM, V268, P22955; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; THIBONNIER M, 1988, KIDNEY INT S25, V34, P852; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	43	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20042	20050		10.1074/jbc.270.34.20042	http://dx.doi.org/10.1074/jbc.270.34.20042			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650021	hybrid			2022-12-27	WOS:A1995RQ99100056
J	BOOTH, JW; GUIDOTTI, G				BOOTH, JW; GUIDOTTI, G			AN ALLEGED YEAST POLYPHOSPHATE KINASE IS ACTUALLY DIADENOSINE-5',5'''-P-1,P-4-TETRAPHOSPHATE ALPHA,BETA-PHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PURIFICATION; PHOSPHATE; PHOSPHOTRANSFERASE; VACUOLES; CLEAVAGE; PROTEINS; GENE; PH	Polyphosphates are a major constituent of the yeast Saccharomyces cerevisiae. A purification of the enzyme polyphosphate kinase (E.C. 2.7.4.1) from this organism has been reported (Felter, S., and Stahl, A. J. C. (1973) Biochimie (Paris) 55, 245-251). The assay for activity used in this purification was the production of P-32-labeled nucleotide, presumed to be ATP, in the presence of [P-32]polyphosphate and ADP. We have found that this assay does not reflect the activity of a polyphosphate kinase but rather the combination of an exopolyphosphatase, releasing free [P-32]phosphate from the added [P-32]polyphosphate, and the ADP-[P-32]phosphate exchange activity of the enzyme diadenosine 5',5'''-P-1,P-4-tetraphosphate alpha,beta-phosphorylase (Ap(4)A phosphorylase). We also present direct evidence for the formation of an enzyme-AMP intermediate in the action of Ap(4)A phosphorylase.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; BOURNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1067, P81, DOI 10.1016/0005-2736(91)90028-7; DUNN T, 1994, J BIOL CHEM, V269, P7273; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; FELTER S, 1973, BIOCHIMIE, V55, P245, DOI 10.1016/S0300-9084(73)80122-1; FELTER S, 1970, B SOC CHIM BIOL, V52, P75; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; GREENFIELD NJ, 1987, BIOCHIM BIOPHYS ACTA, V926, P205, DOI 10.1016/0304-4165(87)90205-4; GURANOWSKI A, 1985, J BIOL CHEM, V260, P3542; GURANOWSKI A, 1986, J BIOL CHEM, V261, P5943; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KNLAEV IS, 1983, ADV MICROB PHYSL, V24, P83; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON SL, 1975, J GEN MICROBIOL, V88, P65, DOI 10.1099/00221287-88-1-65; LIHC, 1973, BIOCHEM BIOPH RES CO, V53, P875, DOI 10.1016/0006-291X(73)90174-5; LORENZ B, 1994, J BIOL CHEM, V269, P22198; LUSBY EW, 1980, MOL GEN GENET, V178, P69, DOI 10.1007/BF00267214; NICOLAY K, 1983, ARCH MICROBIOL, V134, P270, DOI 10.1007/BF00407801; PLATEAU P, 1989, J BACTERIOL, V171, P6437, DOI 10.1128/jb.171.12.6437-6445.1989; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; SCHUDDEMAT J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P191, DOI 10.1016/0167-4889(89)90160-2; SHABALIN YA, 1989, BIOCHEMISTRY-MOSCOW+, V54, P50; SHABALIN YA, 1977, BIOCHEMISTRY-MOSCOW+, V42, P1291; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; WEIMBERG R, 1975, J BACTERIOL, V121, P1122, DOI 10.1128/JB.121.3.1122-1130.1975; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WURST H, 1994, J BIOL CHEM, V269, P10996	36	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19377	19382		10.1074/jbc.270.33.19377	http://dx.doi.org/10.1074/jbc.270.33.19377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642617	hybrid			2022-12-27	WOS:A1995RP70300031
J	LABARRIERE, N; SELVAIS, PL; LEMAIGRE, FP; MICHEL, A; MAITER, DM; ROUSSEAU, GG				LABARRIERE, N; SELVAIS, PL; LEMAIGRE, FP; MICHEL, A; MAITER, DM; ROUSSEAU, GG			A NOVEL TRANSCRIPTIONAL ACTIVATOR ORIGINATING FROM AN UPSTREAM PROMOTER IN THE HUMAN GROWTH-HORMONE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING DOMAIN; ALTERNATIVE PROMOTER; SEQUENCE; DIMERIZATION; EXPRESSION; PITUITARY; PROTEINS; INVITRO	Transcription of the human growth hormone gene can start in vitro and in vivo 197 base pairs upstream from the cap site of growth hormone mRNA (Courtois, S. J., Lafontaine, D., and Rousseau, G. G. (1992) J. Biol. Chen. 267, 19736-19743). We have now characterized the mRNA that originates from this optional promoter and have found that it occurs in human hypophysis and placenta but not in 10 other tissues, This mRNA contains an open reading frame for a protein of 107 residues that shares sequence similarity with three domains of hepatic nuclear factor-1 alpha. With antibodies directed against a peptide corresponding to the C terminus of this protein, immunoreactive material was detected in a subset of cells of the adenohypophysis. When fused to the DNA-binding domain of the yeast transcription factor GALE, the protein stimulated transcription from a GAL4-sensitive reporter gene in transiently transfected pituitary and placental cells.	UNIV LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,DIABET & NUTR UNIT,B-1200 BRUSSELS,BELGIUM; UNIV MONS,BIOL CHEM LAB,B-7000 MONS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons			Labarriere, Nathalie/H-8876-2015	Labarriere, Nathalie/0000-0002-1407-6546; Lemaigre, Frederic/0000-0002-3609-434X				ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BAUMHUETER S, 1990, GENE DEV, V49, P372; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; COURTOIS SJ, 1992, J BIOL CHEM, V267, P19736; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Grant G, 1992, SYNTHETIC PEPTIDES; HSU DW, 1991, AM J PATHOL, V138, P897; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELVAIS PL, 1993, NEUROENDOCRINOLOGY, V58, P539, DOI 10.1159/000126588; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342	25	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19205	19208		10.1074/jbc.270.33.19205	http://dx.doi.org/10.1074/jbc.270.33.19205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642589	hybrid			2022-12-27	WOS:A1995RP70300003
J	ERIKSSON, S; XU, BJ; CLAYTON, DA				ERIKSSON, S; XU, BJ; CLAYTON, DA			EFFICIENT INCORPORATION OF ANTI-HIV DEOXYNUCLEOTIDES BY RECOMBINANT YEAST MITOCHONDRIAL-DNA POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; HUMAN THYMIDINE KINASE-1; SUBSTRATE-SPECIFICITY; NUCLEOSIDE ANALOGS; 3'->5' EXONUCLEASE; INSERTION FIDELITY; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; GAMMA; PURIFICATION	Saccharomyces cerevisiae mtDNA polymerase, isolated as a single 135-kDa recombinant polypeptide, showed high processivity and a capacity to use poly(dA). oligo(dT), poly(rA). oligo(dT), or primed bacteriophage M13 DNA as a template, In a primer extension assay, the enzyme exhibited an intrinsic 3'-5'-exonuclease activity, By optimizing the polymerization reaction conditions, apparent K-m and V-max values could be determined for the incorporation of dTTP, 2'-3'-dideoxy-TTP (ddTTP), 3'-azido-TTP (AZTTP), 3'-fluoro-TTP, dCTP, 2'-3'-dideoxy-CTP, and didehydro(d4)CTP, The yeast mtDNA polymerase used ddTTP, 3'-fluoro-TTP, and ddCTP almost as efficiently as natural deoxynucleoside triphosphates. Both 3'-AZTTP and d4CTP were each significantly less efficient as substrates. Overall, the kinetic data with mtDNA polymerase were very similar to those of the recombinant human immunodeficiency virus reverse transcriptase control, Terminally incorporated AZTTP or ddTTP was not removed by the 3'-5' exonuclease activity of mtDNA polymerase. This may explain the inhibition of mtDNA replication observed in anti-human immunodeficiency virus treatment with dideoxynucleoside analogs and suggests that screening of antiviral nucleosides for their effects on mtDNA polymerase could be of value in future rational drug design.	STANFORD UNIV,SCH MED,BECKMAN CTR MOLEC & GENET MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1991, MOL PHARMACOL, V39, P625; CHENG YC, 1987, J BIOL CHEM, V262, P2187; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590; DUBANSKY RM, 1989, MUSCLE NERVE, V12, P856; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FARAJ A, 1994, ANTIMICROB AGENTS CH, V28, P924; FICHL MA, 1987, NEW ENGL J MED, V317, P185; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GRAY H, 1992, J BIOL CHEM, V267, P5835; HERNIGA J, 1994, EVOLUTIONARY BIOL VI, P87; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; IZUTA S, 1991, BIOCHEM BIOPH RES CO, V179, P776, DOI 10.1016/0006-291X(91)91884-F; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MOSBAUGH DW, 1988, NUCLEIC ACIDS RES, V16, P5645, DOI 10.1093/nar/16.12.5645; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; OLSON MW, 1992, J BIOL CHEM, V267, P23136; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; UNGE T, 1990, AIDS RES HUM RETROV, V6, P1297, DOI 10.1089/aid.1990.6.1297; WANG LY, 1993, J BIOL CHEM, V268, P22847; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WINTERSBERGER U, 1970, EUR J BIOCHEM, V13, P20, DOI 10.1111/j.1432-1033.1970.tb00894.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18929	18934		10.1074/jbc.270.32.18929	http://dx.doi.org/10.1074/jbc.270.32.18929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642550	hybrid			2022-12-27	WOS:A1995RN95400038
J	GAMETT, DC; GREENE, T; WAGREICH, AR; KIM, HH; KOLAND, JG; CERIONE, RA				GAMETT, DC; GREENE, T; WAGREICH, AR; KIM, HH; KOLAND, JG; CERIONE, RA			HEREGULIN-STIMULATED SIGNALING IN RAT PHEOCHROMOCYTOMA CELLS - EVIDENCE FOR ERBB3 INTERACTIONS WITH NEU/ERBB2 AND P85	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU ONCOGENE; LIGAND	We have reported that overexpression of Neu leads to heregulin-stimulated neurite outgrowth and the tyrosine-phosphorylation of Neu and other cellular proteins in PC12 cells, Considering that Neu/ErbB2 alone is not able to functionally couple to heregulin, we looked for the possible involvement of ErbB3 in these neurite out-growth and tyrosine phosphorylation responses, We found that heregulin stimulates the tyrosine phosphorylation of endogenous ErbB3 protein in PC12 cells and that this phosphorylation, like that of Neu, is greatly enhanced in cells that overexpress Neu, Furthermore, overexpression of ErbB3 in PC12 cells led to heregulin-stimulated neurite extension, In addition to becoming tyrosine-phosphorylated, Neu/ErbB2 and ErbB3 associate with each other, and each associates with the 85-kDa regulatory subunit (p85) of phosphatidylinositol 3-kinase in a heregulin dependent manner, Thus, Neu/ErbB2 and ErbB3 appear to cooperate to mediate the heregulin signal in PC12 cells, Like heregulin, epidermal growth factor (EGF) also stimulates the tyrosine phosphorylation of both Neu and ErbB3, However, there are clear differences between the EGF- and heregulin-stimulated phosphorylations of ErbB3, In the heregulin response, two tyrosine phosphorylated forms of ErbB3 are detected, Of these, only the more quickly migrating form (on SDS-polyacrylamide gel electrophoresis) is found to be associated with Neu, whereas the other, more slowly migrating form is uniquely capable of forming stable complexes with p85, In the EGF response, at least two tyrosine-phosphorylated forms of ErbB3 are detected, but these phosphoproteins have distinctly fewer apparent molecular weights compared with the heregulin-stimulated ErbB3 phosphoproteins and do not complex with p85, Thus the formation of a stable ErbB3-p85 complex in PC12 cells is a unique outcome of heregulin signaling that correlates with the differences in cell morphology induced by the activated EGF receptor and the Neu tyrosine kinase.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	Cornell University; University of Iowa				Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KIM HH, 1994, J BIOL CHEM, V269, P24747; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	20	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19022	19027		10.1074/jbc.270.32.19022	http://dx.doi.org/10.1074/jbc.270.32.19022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642563	hybrid			2022-12-27	WOS:A1995RN95400051
J	GEMS, D; FERGUSON, CJ; ROBERTSON, BD; NIEVES, R; PAGE, AP; BLAXTER, ML; MAIZELS, RM				GEMS, D; FERGUSON, CJ; ROBERTSON, BD; NIEVES, R; PAGE, AP; BLAXTER, ML; MAIZELS, RM			AN ABUNDANT, TRANS-SPLICED MESSENGER-RNA FROM TOXOCARA-CANIS INFECTIVE LARVAE ENCODES A 26-KDA PROTEIN WITH HOMOLOGY TO PHOSPHATIDYLETHANOLAMINE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCRETORY-SECRETORY ANTIGENS; CDNA LIBRARY CONSTRUCTION; LIPID TRANSFER PROTEIN; BOVINE BRAIN CYTOSOL; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; 23-KDA PROTEIN; SURFACE; PURIFICATION; RNA	A full-length mRNA encoding a secreted 26-kDa antigen of infective larvae of the ascarid nematode parasite Toxocara canis has been identified. This was characterized as a 1,082-base pair clone highly abundant (0.8-1.9%) in cDNA prepared from infective stage larvae but absent from cDNA from adult male worms. Sequence analysis revealed an open reading frame corresponding to a hydrophilic 263-amino acid residue polypeptide with a 20-residue N-terminal signal peptide, indicating that it is secreted. The 5' end of the cDNA was isolated by polymerase chain reaction using a primer containing the nematode spliced leader sequence, SL1, showing that the mRNA is trans-spliced. The molecular mass of the putative protein with the signal peptide removed is 26.01 kDa, and antibody to the recombinant protein expressed in bacterial vectors reacts with a similarly sized protein in T. canis excretory/secretory (TES) products. An identical sequence was obtained from a genomic clone isolated by expression screening with mouse antibody to TES. The 72 amino acid residues adjacent to the signal peptide form two homologous 36 residue motifs containing 6 cysteine residues; this motif is found also in the T. canis-secreted glycoprotein TES-120 and in genes of Caenorhabditis elegans. Sequence data base searches revealed significant similarity to 7 other sequences in a newly recognized gene family of phosphatidylethanolamine binding proteins that includes yeast, Drosophila, rat, bovine, simian, and human genes and a representative from the filarial nematode Onchocerca volvulus. Assays with the T. canis recombinant 26-kDa protein expressed as a fusion with maltose-binding protein have confirmed phosphatidylethanolamine-binding specificity for this novel product.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, WELLCOME RES CTR PARASIT INFECT, DEPT BIOL, LONDON SW7 2BB, ENGLAND	Imperial College London			Blaxter, Mark/O-2535-2019; Blaxter, Mark L/B-4113-2010	Blaxter, Mark L/0000-0003-2861-949X; Robertson, Brian D./0000-0001-5785-5307; Gems, David/0000-0002-6653-4676	FIC NIH HHS [T37-TW00046] Funding Source: Medline; Wellcome Trust Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000046] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BADLEY JE, 1987, J PARASITOL, V73, P593, DOI 10.2307/3282142; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BEAVER PAUL C., 1962, BULL SOC PATHOL EXOT, V55, P555; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Savigny D.H., 1975, Journal Parasit, V61, P781, DOI 10.2307/3279492; DOMEC C, 1990, ANAL BIOCHEM, V188, P422, DOI 10.1016/0003-2697(90)90630-R; GILLESPIE SH, 1988, PARASITOL TODAY, V4, P180, DOI 10.1016/0169-4758(88)90156-1; Glickman L.T., 1986, P201; GLICKMAN LT, 1981, EPIDEMIOL REV, V3, P230, DOI 10.1093/oxfordjournals.epirev.a036235; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; HORI N, 1994, GENE, V140, P293; JONES R, 1991, BIOCHIM BIOPHYS ACTA, V1080, P78, DOI 10.1016/0167-4838(91)90114-F; KENNEDY MW, 1987, MOL BIOCHEM PARASIT, V22, P233, DOI 10.1016/0166-6851(87)90054-5; KENNEDY MW, 1993, TOXOCARA AND TOXOCARIASIS, P151; LINNESTAD C, 1991, PLANT PHYSIOL, V97, P841, DOI 10.1104/pp.97.2.841; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOBOS E, 1991, SCIENCE, V251, P1603, DOI 10.1126/science.2011741; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; MAIZELS RM, 1993, EXP PARASITOL, V77, P380, DOI 10.1006/expr.1993.1096; MAIZELS RM, 1984, PARASITE IMMUNOL, V6, P23, DOI 10.1111/j.1365-3024.1984.tb00779.x; MAIZELS RM, 1990, ACTA TROP, V47, P355, DOI 10.1016/0001-706X(90)90036-Y; MAIZELS RM, 1993, TOXOCARA AND TOXOCARIASIS, P141; MEGHJI M, 1986, MOL BIOCHEM PARASIT, V18, P155, DOI 10.1016/0166-6851(86)90035-6; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MOSER D, 1991, J BIOL CHEM, V266, P8447; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PAGE AP, 1992, PARASITOLOGY, V105, P297, DOI 10.1017/S0031182000074229; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1991, PARASITOLOGY, V103, P451, DOI 10.1017/S0031182000059977; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; RODRIGUEZPEREZ J, 1992, EXP PARASITOL, V74, P400, DOI 10.1016/0014-4894(92)90202-L; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; Sambrook J, 1989, MOL CLONING LABORATO; SCHANTZ P M, 1989, American Journal of Tropical Medicine and Hygiene, V41, P21; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SPRENT JFA, 1958, PARASITOLOGY, V48, P184, DOI 10.1017/S0031182000021168; SUGANE K, 1983, IMMUNOLOGY, V50, P113; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	47	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18517	18522		10.1074/jbc.270.31.18517	http://dx.doi.org/10.1074/jbc.270.31.18517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629180	hybrid			2022-12-27	WOS:A1995RM64200058
J	MILLER, VP; GOODIN, DB; FRIEDMAN, AE; HARTMANN, C; DEMONTELLANO, PRO				MILLER, VP; GOODIN, DB; FRIEDMAN, AE; HARTMANN, C; DEMONTELLANO, PRO			HORSERADISH-PEROXIDASE PHE(172)-]TYR MUTANT - SEQUENTIAL FORMATION OF COMPOUND-I WITH A PORPHYRIN RADICAL-CATION AND A PROTEIN RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SPERM WHALE MYOGLOBIN; LACTOPEROXIDASE-H2O2 COMPOUNDS; RIBONUCLEOTIDE REDUCTASE; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; ACID; SITE; PH	A gene coding for the F172Y mutant of horseradish peroxidase isozyme C (HRP) has been constructed and expressed in both Spodoptera frugiperda (SF-9) and Trichoplusia ni egg cell homogenate (HighFive(R)) cells. Homology modeling with respect to three peroxidases for which crystal structures are available places Phe(172) on the proximal side of the heme in the vicinity of porphyrin pyrrole ring C. The pH optimum and spectroscopic properties of the F172Y mutant are essentially identical to those of wild type HRP. V-max values show that the mutant protein retains most of the guaiacol oxidizing activity. Stopped flow studies indicate that Compound I is formed with H2O2 at the same rate (k(1) = 1.6 x 10(7) M(-1) s(-1)) at both pH 6.0 and 8.0 as it is with the wild type enzyme. This Compound I species decays rapidly at a rate k(2) = 1.01 s(-1), pH 7.0, to a second two-electron oxidized species that retains the ferryl (Fe-IV = O) absorption. EPR studies establish that a ferryl porphyrin radical cation is present in the initial Compound I, but electron transfer from the protein results in formation of a second Compound I species with an unpaired electron on the protein (presumably on Tyr(172)). The presence or absence of oxidizable amino acids adjacent to the heme is thus a key determinant of whether the second oxidation equivalent in Compound I is found as a porphyrin or protein radical cation.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; JOHNSON & JOHNSON CLIN DIAGNOST, RES LABS, ROCHESTER, NY 14650 USA	University of California System; University of California San Francisco; Scripps Research Institute; Johnson & Johnson			Friedman, Alan/Q-4858-2018	Friedman, Alan/0000-0002-4764-8168	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488, R37GM041049, R01GM041049, R29GM041049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41049, GM32488, R01 GM041049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUNSGAARD L, 1993, EUR J BIOCHEM, V213, P605, DOI 10.1111/j.1432-1033.1993.tb17800.x; BELFORD RL, 1979, 2UST EPR S ROCK MOUN; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; CHEN ZG, 1994, J AM CHEM SOC, V116, P8772, DOI 10.1021/ja00098a040; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; COURTIN F, 1982, EUR J BIOCHEM, V124, P603; DAVIES DM, 1976, BIOCHEM J, V157, P247, DOI 10.1042/bj1570247; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DEPILLIS GD, 1991, J BIOL CHEM, V266, P19334; DETTY MR, 1994, ORGANOMETALLICS, V13, P3338, DOI 10.1021/om00020a053; DOLMAN D, 1975, CAN J BIOCHEM CELL B, V53, P495, DOI 10.1139/o75-069; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Everse J., 1991, PEROXIDASES CHEM BIO, V2; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITZGERALD MM, 1994, BIOCHEMISTRY-US, V33, P3807, DOI 10.1021/bi00179a004; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HARTMANN C, 1992, ARCH BIOCHEM BIOPHYS, V297, P61, DOI 10.1016/0003-9861(92)90641-9; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HENDERSON WR, 1991, PEROXIDASES CHEM BIO, V1, P106; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MAGNUSSON RP, 1991, PEROXIDASES CHEM BIO, V1, P200; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; OZAKI S, 1995, IN PRESS J AM CHEM S; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; TEW D, 1988, J BIOL CHEM, V263, P17880; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; VIRION A, 1985, ARCH BIOCHEM BIOPHYS, V242, P41, DOI 10.1016/0003-9861(85)90477-1; WARNCKE K, 1994, J AM CHEM SOC, V116, P7332, DOI 10.1021/ja00095a042; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; WILKS A, 1992, J BIOL CHEM, V267, P8827	49	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18413	18419		10.1074/jbc.270.31.18413	http://dx.doi.org/10.1074/jbc.270.31.18413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629167	hybrid			2022-12-27	WOS:A1995RM64200043
J	RECZKOWSKI, RS; MARKHAM, GD				RECZKOWSKI, RS; MARKHAM, GD			STRUCTURAL AND FUNCTIONAL ROLES OF CYSTEINE-90 AND CYSTEINE-240 IN S-ADENOSYLMETHIONINE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; EXPRESSION; GENE; CDNA; SITE	Site-specific mutagenesis was performed on the structural gene for Escherichia coli S-adenosyhnethionine (AdoMet) synthetase to introduce mutations at cysteines 90 and 240, residues previously implicated by chemical modification studies to be catalytically and/or structurally important, The AdoMet synthetase mutants (i.e, MetK/C90A, MetK/C90S, and MetK/C240A) retained up to similar to 10% of wild type activity, demonstrating that neither sulfhydryl is required for catalytic activity. Mutations at Cys-90 produced a mixture of noninterconverting dimeric and tetrameric proteins, suggesting a structural significance for Cys-90, Dimeric Cys 90 mutants retained similar to 1% of wild type activity, indicating a structural influence on enzyme activity. Both dimeric and tetrameric MetK/C90A had up to a similar to 70-fold increase in K-m for ATP, while both dimeric and tetrameric MetK/C90S had K-m values for ATP similar to the wild type enzyme, suggesting a linkage between Cys-90 and the ATP binding site, MetK/C240A was isolated solely as a tetramer and differed from wild type enzyme only in its 10-fold reduction in specific activity, suggesting that the mutation affects the rate-limiting step of the reaction, which for the wild type enzyme is the joining of ATP and L-methionine to yield AdoMet and tripolyphosphate. Remarkably all of the mutants are much more thermally stable than the wild type enzyme.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-31186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BUKHARI AI, 1973, NATURE-NEW BIOL, V243, P238, DOI 10.1038/newbio243238a0; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; CHOU T, 1972, BIOCHEMISTRY-US, V11, P1065, DOI 10.1021/bi00756a019; Cleland W W, 1979, Methods Enzymol, V63, P103; DEVILLEBONNE D, 1991, EUR J BIOCHEM, V220, P747; DONCH J, 1969, GENETICS, V61, P363; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAFNER EW, 1977, J BACTERIOL, V132, P832, DOI 10.1128/JB.132.3.832-840.1977; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; HORIKAWA S, 1993, FEBS LETT, V312, P37; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN PB, 1991, PLANT PHYSIOL, V96, P997, DOI 10.1104/pp.96.3.997; MANIATUS T, 1982, MOL CLONING LABORATO, P432; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; MARKHAM GD, 1988, J BIOL CHEM, V263, P8666; MARKHAM GD, 1987, J AM CHEM SOC, V109, P599, DOI 10.1021/ja00236a057; MARKHAM GD, 1986, J BIOL CHEM, V261, P1507; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; MARKHAM GD, 1984, BIOCHEMISTRY-US, V23, P470, DOI 10.1021/bi00298a011; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MUDD SH, 1963, J BIOL CHEM, V238, P2156; PEACOCKE AR, 1986, ELECTROPHORESIS THEO; PELEMAN J, 1989, PLANT CELL, V1, P81, DOI 10.1105/tpc.1.1.81; PELEMAN J, 1989, GENE, V84, P359, DOI 10.1016/0378-1119(89)90510-6; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; RUAN KC, 1993, BIOCHEMISTRY-US, V32, P6295, DOI 10.1021/bi00075a025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATISHCHANDRAN C, 1993, MOL MICROBIOL, V9, P835, DOI 10.1111/j.1365-2958.1993.tb01742.x; SATISHCHANDRAN C, 1990, J BACTERIOL, V17, P4489; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; THOMAS D, 1987, J BIOL CHEM, V262, P16704; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	42	20	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18484	18490		10.1074/jbc.270.31.18484	http://dx.doi.org/10.1074/jbc.270.31.18484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629176	hybrid			2022-12-27	WOS:A1995RM64200053
J	DONG, Q; WANG, TSF				DONG, Q; WANG, TSF			MUTATIONAL STUDIES OF HUMAN DNA-POLYMERASE-ALPHA - LYSINE-950 IN THE 3RD MOST CONSERVED REGION OF ALPHA-LIKE DNA-POLYMERASES IS INVOLVED IN BINDING THE DEOXYNUCLEOSIDE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; ENZYMOLOGICAL CHARACTERIZATION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; IDENTIFICATION; MECHANISM; FIDELITY	The function of a lysine residue, Lys(950), of human DNA polymerase alpha located in the third most conserved region and conserved in all of the alpha-like polymerases was analyzed by site-directed mutagenesis. Lys(950) was mutagenized to Arg, Ala, or Asn, The mutant enzymes were expressed in insect cells infected with recombinant baculoviruses and purified to near homogeneity. The mutant enzymes had specific activities ranging from 8 to 22% of the wild type. All three Lys(950) mutants utilized Mn2+ as metal activator more effectively than the wild type enzyme and showed an increase in K-m values for deoxynucleoside triphosphate but not k(cat) values in reactions with either Mg2+ or Mn2+ as the metal activator. Although mutation of the Lys(950) residue caused an increase in K-m values for deoxynucleoside triphosphates, mutations of Lys(950) to Arg, Ala, or Asn did not alter the mutant enzymes' misinsertion efficiency in reactions with Mg2+ as a metal activator as compared with that of the wild type, suggesting that the base of the incoming deoxynucleoside triphosphate is not the structural feature interacting with the Lys(950) Side chain. In reaction with Mn2+ as a metal activator, all three Lys(950) mutants had an improved fidelity for deoxynucleotide misinsertion compared to wild type. Inhibition studies of the three Lys(950) mutant derivatives with an inhibitor, structural analogs of deoxynucleoside triphosphate, and pyrophosphate suggest that the deoxyribose sugar and beta-,gamma-phosphate groups are not the structural feature recognized by the Lys(950) side chain. Comparison of the mutant enzymes to the wild type enzyme for their affinities for dCTP alpha S versus deoxynucleoside triphosphate suggests that this highly conserved Lys(950) is involved in interacting either directly or indirectly with the oxygen moiety of the alpha-phosphate of the incoming deoxynucleoside triphosphate.	STANFORD UNIV,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; COPELAND WC, 1995, METHODS ENZYMOL, V262; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DONG Q, 1993, J BIOL CHEM, V268, P24163; DONG Q, 1993, J BIOL CHEM, V268, P24175; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; HERINGA J, 1992, EVOLUTIONARY BIOL VI, P87; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WANG TSF, 1995, IN PRESS METHODS ENZ, V262; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	30	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21563	21570		10.1074/jbc.270.37.21563	http://dx.doi.org/10.1074/jbc.270.37.21563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665569	hybrid			2022-12-27	WOS:A1995RU75700024
J	HAMALAINEN, ER; KEMPPAINEN, R; KUIVANIEMI, H; TROMP, G; VAHERI, A; PIHLAJANIEMI, T; KIVIRIKKO, KI				HAMALAINEN, ER; KEMPPAINEN, R; KUIVANIEMI, H; TROMP, G; VAHERI, A; PIHLAJANIEMI, T; KIVIRIKKO, KI			QUANTITATIVE POLYMERASE CHAIN-REACTION OF LYSYL OXIDASE MESSENGER-RNA IN MALIGNANTLY TRANSFORMED HUMAN CELL-LINES DEMONSTRATES THAT THEIR LOW LYSYL OXIDASE ACTIVITY IS DUE TO LOW QUANTITIES OF ITS MESSENGER-RNA AND LOW-LEVELS OF TRANSCRIPTION OF THE RESPECTIVE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MESSENGER-RNA; MOUSE CHROMOSOME-18; III PROCOLLAGEN; CDNA; MAPS; ASSIGNMENT; EXPRESSION; CLONING; CODON	Lysyl oxidase (EC 1.4.3.13), an extracellular copper amino oxidase, initiates the cross-linking of collagens and elastin by catalyzing oxidative deamination of the epsilon-amino group in certain lysine and hydroxylysine residues. We developed here a polymerase chain reaction (PCR) method for the quantification of lysyl oxidase mRNA in which a synthetic RNA is used as an internal standard for coamplification with the targeted mRNA. The amount of lysyl oxidase mRNA when studied by Northern blot analysis and the number of lysyl oxidase mRNA molecules when determined by the quantitative PCR method were found to be markedly low in various malignantly transformed cell lines relative to control cell fines, quantitative PCR indicating values of about 2-10% of those in the controls. No difference was found in the number of beta-actin mRNA molecules between the transformed cells and the controls. Nuclear runoff experiments indicated that most if not all of the decrease in the number of lysyl oxidase mRNA molecules can be explained by diminished transcription of the respective gene.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR,COLLAGEN RES UNIT,SF-90220 OULU,FINLAND; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; HELSINKI UNIV,DEPT VIROL,SF-00018 HELSINKI,FINLAND	University of Oulu; University of Oulu; Jefferson University; University of Helsinki			Vaheri, Antti/AAV-1523-2020; Kemppainen, Robert/X-9105-2019; Kuivaniemi, Helena/Q-8178-2019; Tromp, Gerard/B-2677-2017	Kuivaniemi, Helena/0000-0001-5753-8766; Tromp, Gerard/0000-0002-7761-0806; Pihlajaniemi, Taina/0000-0002-1664-9045				ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; CHANG YS, 1993, CYTOGENET CELL GENET, V63, P47, DOI 10.1159/000133500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CZSISAR K, 1993, GENOMICS, V16, P401; DANKS DM, 1992, CONNECTIVE TISSUE IT, P487; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1987, CONNECTIVE TISSUE DI, P263; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; LOSSIE AC, 1993, MAMM GENOME, V4, P177, DOI 10.1007/BF00352234; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MOCK BA, 1992, GENOMICS, V14, P822, DOI 10.1016/S0888-7543(05)80201-0; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Sambrook J, 1989, MOL CLONING LABORATO; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TROMP G, 1989, J BIOL CHEM, V264, P19313; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WU Y, 1992, J BIOL CHEM, V267, P24199	28	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21590	21593		10.1074/jbc.270.37.21590	http://dx.doi.org/10.1074/jbc.270.37.21590			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665572	hybrid			2022-12-27	WOS:A1995RU75700027
J	ZHOU, A; PAQUET, L; MAINS, RE				ZHOU, A; PAQUET, L; MAINS, RE			STRUCTURAL ELEMENTS THAT DIRECT SPECIFIC PROCESSING OF DIFFERENT MAMMALIAN SUBTILISIN-LIKE PROHORMONE CONVERTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATT-20 CELLS; PRO-REGION; SACCHAROMYCES-CEREVISIAE; SITE; KEX2; PC1; PROOPIOMELANOCORTIN; IDENTIFICATION; ENDOPROTEASE; MUTAGENESIS	PC1 and PC2 are two important subtilisin-like prohormone convertases (PC) that undergo differential endoproteolytic processing steps and sequentially mediate proopiomelanocortin (POMC) processing, To investigate the structural elements directing the processing of different PCs, we constructed a series of mutant and chimeric PC proteins and expressed them in cell lines with different patterns of expression of endogenous PCs: AtT-20, hEK293, and hLoVo cells. The COOH-terminally truncated PC1 underwent efficient proregion cleavage and rapid secretion in all three cell lines, while proregion cleavage and secretion were completely blocked in an active-site mutant of PC1. The truncated PC1 produced dramatic changes in POMC processing in AtT-20 cells. PC2 with the potential oxyanion hole Asp residue changed to Asn was processed and altered several aspects of POMC processing in a manner similar to that of wild-type PC2. PC1 protein with its proregion substituted with that of furin was cleaved after its proregion, producing active PC1 enzyme. A similar furin/PC2 fusion protein underwent proregion cleavage at low efficiency, By contrast, when the proregions of PC1 and PC2 were substituted with one another, both fusion proteins failed to cleave the foreign prosequences, were unable to undergo oligosaccharide maturation, and remained in the ER. Although inactive PC mutants could theoretically function as dominant negatives, none interfered with the processing of endogenous active PCs or with POMC processing. We conclude that the COOH-terminal of PC1 plays an important role in the routing or storage of PC1, the proregions of these PC proteins are replaceable in a molecule-specific manner, removal of proregion is essential for routing and for endoproteolytic activity, and the role of the potential oxyanion hole in PC2 is still unclear.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University				Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BLOOMQUIST BT, 1993, CELL PHYSIOL BIOCHEM, V3, P197, DOI 10.1159/000154684; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EGNELL P, 1992, MOL MICROBIOL, V6, P1115, DOI 10.1111/j.1365-2958.1992.tb01549.x; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LI YY, 1994, J BIOL CHEM, V269, P4169; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MITCHELL WM, 1971, NATURE-NEW BIOL, V231, P99, DOI 10.1038/newbio231099a0; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VINDROLA O, 1993, NEUROPEPTIDES, V25, P151, DOI 10.1016/0143-4179(93)90096-S; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	52	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21509	21516		10.1074/jbc.270.37.21509	http://dx.doi.org/10.1074/jbc.270.37.21509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665562	hybrid			2022-12-27	WOS:A1995RU75700017
J	BLAHOS, J; WHALIN, ME; KRUEGER, KE				BLAHOS, J; WHALIN, ME; KRUEGER, KE			IDENTIFICATION AND PURIFICATION OF A 10-KILODALTON PROTEIN ASSOCIATED WITH MITOCHONDRIAL BENZODIAZEPINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAZEPAM-BINDING INHIBITOR; STEROID-BIOSYNTHESIS; MOLECULAR-CLONING; DBI RECEPTOR; STEROIDOGENESIS; SITES; CHOLESTEROL; LIGANDS; CELLS; LOCALIZATION	The isoquinoline carboxamide photoaffinity probe PK14105, a ligand with selectivity for mitochondrial benzodiazepine receptors, has been established to photolabel an 18-kDa protein. When this radioactive probe is used to photolabel rat mitochondrial preparations, a protein of 10 kDa, in addition to the 18-kDa protein, is identified following electrophoretic separation and extended autoradiography. These proteins are referred to herein as pk10 and pk18, respectively. Both proteins exhibited the same specificity to a series of ligands used in competition photolabeling studies and are mutually present at apparently similar ratios across multiple tissues. Subcellular fractionation of rat adrenals indicated that pk10 and pk18 comigrated with the mitochondrial marker enzyme cytochrome c oxidase. In numerous paradigms examining specificity, photolabeling of pk18 invariably coincided with photolabeling of pk10. In detergent-solubilized extracts of rat adrenal mitochondria, pk18 and pk10 coimmunoprecipitated when using antisera raised against pk18. Furthermore, purification of the photolabeled proteins using nondenaturing conditions demonstrated that pk18 and pk10 copurify substantiating their intimate association. A set of three antisera, specific to different regions of pk18, did not recognize pk10 on Western blots. Likewise, partial amino acid sequence of peptide fragments indicate that pk10 is not derived from proteolytic cleavage of pk18. These data suggest that pk10 represents another component of mitochondrial benzodiazepine receptors whose identity is not apparent with any known protein.	GEORGETOWN UNIV,SCH MED,DEPT CELL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20007	Georgetown University; Georgetown University			Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061	NIMH NIH HHS [MH44284] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH044284] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANTKIEWICZMICHA.L, 1988, J BIOL CHEM, V263, P17317; ANTKIEWICZMICHA.L, 1988, MOL PHARMACOL, V34, P272; BARNEA ER, 1989, MOL CELL ENDOCRINOL, V64, P155, DOI 10.1016/0303-7207(89)90141-X; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; Bourguignon J.J., 1993, PERIPHERAL BENZODIAZ, P59; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVALLARO S, 1992, P NATL ACAD SCI USA, V89, P10598, DOI 10.1073/pnas.89.22.10598; COX DA, 1991, J PHARMACOL EXP THER, V258, P702; DEBROEUCQ MC, 1986, EUR J PHARMACOL, V128, P269; DOBLE A, 1987, MOL PHARMACOL, V31, P42; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; HIRSCH JD, 1989, MOL PHARMACOL, V35, P164; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; KRUEGER KE, 1992, ANNU REV PHARMACOL, V32, P211, DOI 10.1146/annurev.pa.32.040192.001235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SZ, 1988, PHARMACOL BIOCHEM BE, V29, P763, DOI 10.1016/0091-3057(88)90202-X; LEFUR G, 1983, LIFE SCI, V33, P449, DOI 10.1016/0024-3205(83)90794-4; LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; MUKHIN AG, 1990, BIOCHEM PHARMACOL, V40, P983, DOI 10.1016/0006-2952(90)90483-2; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAROLA AL, 1989, J PHARMACOL EXP THER, V250, P1149; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; ROMEO E, 1992, J PHARMACOL EXP THER, V262, P971; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958	38	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20285	20291		10.1074/jbc.270.35.20285	http://dx.doi.org/10.1074/jbc.270.35.20285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657598	hybrid			2022-12-27	WOS:A1995RR58400011
J	KOHOUT, TA; ROGERS, TB				KOHOUT, TA; ROGERS, TB			ANGIOTENSIN-II ACTIVATES THE NA+/HCO3- SYMPORT THROUGH A PHOSPHOINOSITIDE-INDEPENDENT MECHANISM IN CARDIAC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; RAT-HEART MYOCYTES; INTRACELLULAR PH; PURKINJE-FIBER; ARACHIDONIC-ACID; K+ CHANNELS; EXCHANGE; MUSCLE; STIMULATION; BETA	Angiotensin II (AngII) is a hormone that alters contractility as well as myocyte growth in heart. Since many hormones that regulate cardiac contractility have also been found to modulate intracellular pH (pH(i)) the goal of this study was to determine if AngII altered pH(i) in cultured neonatal rat ventricular myocytes. Changes in pH(i) were monitored in single cells using the fluorescent pH indicator carboxy-seminaphthorhodafluor-1. Application of 100 nM AngII resulted in a rapid, receptor-mediated alkalinization of 0.08 +/- 0.02 pH unit. The Na+/H+ exchanger was not involved since the response was HCO3--dependent and amiloride-insensitive. Ammonia rebound experiments showed AngII increased the initial rate of recovery from an imposed acid load by 3.15-fold and showed that the hormone led to the selective activation of the Na+/HCO3- symport. In contrast, phorbol ester activation of protein kinase C led to the selective activation of Na+/H+ antiport in these cells. Pharmacological studies showed that the alkalinization was independent of the AngII receptor subtype 1 (AT(1)) phosphoinositide signaling path. In contrast, AngII activation of the symport was blocked by nanomolar AT(2) receptor antagonist PD 123319. Superfusion of the myocytes with exogenous arachidonic acid (5 mu M) mimicked the AngII-mediated alkalinization, further suggesting that the AT(2) signaling pathway underlies the response. In summary, while most of the known actions of AngII in heart are mediated through AT(1) receptors, activation of the Na+/HCO3- symport occurs through a distinct alternative path that is likely related to fatty acid production.	UNIV MARYLAND,SCH MED,BIOMED RES FACIL,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028138, P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28138, HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-08181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BERK BC, 1990, J BIOL CHEM, V265, P19632; BLANK PS, 1992, AM J PHYSIOL, V263, pH276, DOI 10.1152/ajpheart.1992.263.1.H276; BOUNTRA C, 1989, J PHYSIOL-LONDON, V418, P163, DOI 10.1113/jphysiol.1989.sp017833; CANNELL MB, 1986, PFLUG ARCH EUR J PHY, V406, P536, DOI 10.1007/BF00583378; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DESILETS M, 1994, CIRC RES, V75, P862, DOI 10.1161/01.RES.75.5.862; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; ENGELMANN G L, 1990, Technique (Philadelphia), V2, P279; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GAMBASSI G, 1992, CIRC RES, V71, P870, DOI 10.1161/01.RES.71.4.870; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; IKENOUCHI H, 1994, J PHYSIOL-LONDON, V480, P203, DOI 10.1113/jphysiol.1994.sp020353; KEM DC, 1991, AM J PHYSIOL, V261, pC77, DOI 10.1152/ajpcell.1991.261.1.C77; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LAGADICGOSSMANN D, 1993, J PHYSIOL-LONDON, V464, P49, DOI 10.1113/jphysiol.1993.sp019624; LEAF A, 1994, P NATL ACAD SCI USA, V91, P9886; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; LOKUTA A, 1994, J CARDIOVASC ELECTR, V5, P50, DOI 10.1111/j.1540-8167.1994.tb01114.x; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PUCEAT M, 1995, J BIOL CHEM, V270, P1315, DOI 10.1074/jbc.270.3.1315; ROGERS TB, 1994, TRENDS CARDIOVAS MED, V4, P110, DOI 10.1016/1050-1738(94)90062-0; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TERZIC A, 1992, J PHYSIOL-LONDON, V447, P275, DOI 10.1113/jphysiol.1992.sp019002; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOBIAS LD, 1978, LIPIDS, V14, P181; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P83, DOI 10.1113/jphysiol.1979.sp012956; VAUGHANJONES RD, 1986, J PHYSIOL-LONDON, V379, P377, DOI 10.1113/jphysiol.1986.sp016259; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V425, P429, DOI 10.1113/jphysiol.1990.sp018112; WALLERT MA, 1989, AM J PHYSIOL, V257, pC207, DOI 10.1152/ajpcell.1989.257.2.C207; WALLERT MA, 1992, AM J PHYSIOL, V263, pC1096, DOI 10.1152/ajpcell.1992.263.5.C1096	43	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20432	20438		10.1074/jbc.270.35.20432	http://dx.doi.org/10.1074/jbc.270.35.20432			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657618	hybrid			2022-12-27	WOS:A1995RR58400032
J	RIVKEES, SA; LASBURY, ME; BARBHAIYA, H				RIVKEES, SA; LASBURY, ME; BARBHAIYA, H			IDENTIFICATION OF DOMAINS OF THE HUMAN A(1) ADENOSINE RECEPTOR THAT ARE IMPORTANT FOR BINDING-RECEPTOR SUBTYPE-SELECTIVE LIGANDS USING CHIMERIC A(1)/A(2A) ADENOSINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; ADENOSINE-A1-RECEPTOR CDNA; RAT-BRAIN; EXPRESSION; AGONIST; RADIOLIGAND; MODELS; HEART	To provide new insights into the regions of the human A(1) adenosine receptor (A(1)AR) involved in ligand binding, a series of chimeric human A(1) and rat A(2a) adenosine receptors (A(1)/A(2a)) were studied. Binding studies were initially performed on acutely transfected COS cells using fixed doses of the A(2a)AR agonist [H-3]CGS-21680, the A(1)AR agonist [H-3]2-chloro-N-6-cyclopentyladenosine (CCPA), and the A(1)AR antagonist [H-3]8-cyclopentyl-1,3-dipropylxanthine (DPCPX). When the region of the A(2a)AR from the amino terminus to the end of transmembrane (TM) 1 was replaced by the corresponding region of the A(1)AR (A(1)TM1/A(2a)), [H-3]CGS-21680 and [H-3]CCPA binding was detectable. When an A(1)TM1-2/A(2a) construct was studied, [H-3]CGS-21680 binding was lost and [H-3] DPCPX binding appeared. Saturation studies using [H-3]CCPA revealed that the A(1)TM1/A(2a) construct had low affinity. However, with the subsequent addition of A(1)AR TMs 2-4 receptor affinity improved markedly. Saturation studies using [H-3]DPCPX also revealed that the TMs 1-4 of the A(1)AR conferred wild-type receptor affinity. When the ligand binding properties of A(1)TM1-4/A(2a), A(1)TM1-6/A(2a), and wild type A(1)AR constructs were directly compared, no differences were found using 10 different compounds. When truncated A(1)ARs that extended from the amino terminus to shortly after TM4 were examined, no binding was detectable suggesting that the amino half of the receptor alone is not sufficient for ligand binding. Collectively, these data suggest that the important determinants for A(1)AR agonist and antagonist binding and ligand specificity are present in TMs 1-4.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, PROGRAM NEUROBIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	RIVKEES, SA (corresponding author), INDIANA UNIV, JAMES WHITCOMB RILEY HOSP CHILDREN, HERMAN B WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA.				NINDS NIH HHS [R01NS326224] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUNS RF, 1980, CAN J PHYSIOL PHARM, V58, P673, DOI 10.1139/y80-110; BRUNS RF, 1990, ANN NY ACAD SCI, V603, P211; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORI M, 1991, HYPERTENSION, V18, P565, DOI 10.1161/01.HYP.18.5.565; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; IJzerman A P, 1992, Drug Des Discov, V9, P49; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; JARVIS MF, 1990, ADENOSINE ADENOSINE, P423; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LOHSE MJ, 1988, N-S ARCH PHARMACOL, V337, P687; LOHSE MJ, 1987, N-S ARCH PHARMACOL, V336, P204, DOI 10.1007/BF00165806; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; MACKENZIE RG, 1993, FEBS LETT, V323, P59, DOI 10.1016/0014-5793(93)81448-9; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PLAH ME, 1994, J BIOL CHEM, V269, P18016; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RIVKEES SA, 1995, IN PRESS ENDOCRINE; SPARKS HV, 1986, CIRC RES, V58, P193, DOI 10.1161/01.RES.58.2.193; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; STILES GL, 1992, J BIOL CHEM, V267, P6451; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; Trivedi B. H., 1990, ADENOSINE ADENOSINE, P57; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; VANDERWENDEN EM, 1992, J MED CHEM, V35, P629, DOI 10.1021/jm00082a003; VANGALEN PJM, 1990, J MED CHEM, V33, P1708, DOI 10.1021/jm00168a027; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOUNG D, 1994, NEUROSCIENCE, V58, P245, DOI 10.1016/0306-4522(94)90032-9; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	43	32	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20485	20490		10.1074/jbc.270.35.20485	http://dx.doi.org/10.1074/jbc.270.35.20485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657625	hybrid			2022-12-27	WOS:A1995RR58400040
J	TERADA, K; MANCHIKALAPUDI, P; NOIVA, R; JAUREGUI, HO; STOCKERT, RJ; SCHILSKY, ML				TERADA, K; MANCHIKALAPUDI, P; NOIVA, R; JAUREGUI, HO; STOCKERT, RJ; SCHILSKY, ML			SECRETION, SURFACE LOCALIZATION, TURNOVER, AND STEADY-STATE EXPRESSION OF PROTEIN DISULFIDE-ISOMERASE IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROLYL 4-HYDROXYLASE; BETA-SUBUNIT; IDENTIFICATION; ANTIBODIES; SIGNAL; CELLS	Protein disulfide isomerase in isolated rat hepatocytes was present at a concentration of 7 mu g/mg cell protein, representing a similar to 2-fold enrichment compared to isolated hepatic non-parenchymal cells. Though localized mainly in microsomal fractions of hepatocyte, direct immunofluorescence and cell surface radioiodination followed by immunoprecipitation revealed the presence of M(r) 57,000 disulfide isomerase at the cell surface. Electrostatic interaction of the protein with the cell surface was suggested by susceptibility to carbonate washing. Metabolic radiolabeling and immunoprecipitation studies also indicated that some of the newly synthesized M(r) 57,000 disulfide isomerase was secreted. Treatment of cells with colchicine markedly reduced the recovery of disulfide isomerase from the media, indicating microtubular directed secretion of the protein. Partial staphlococcal V8 proteolytic digestion of the secreted protein revealed a peptide pattern similar to that of the cellular protein. Immunoprecipitation with antibody specific to the -KDEL peptide retention sequence confirmed the presence of this sequence in the secreted protein. Studies of the turnover of disulfide isomerase revealed a half-life of approximately 96 h. Treatment of cells with tunicamycin or heat shock resulted in an increased recovery of newly synthesized disulfide isomerase from cell lysates but diminished recovery from the media. The secretion and cell surface distribution of disulfide isomerase in hepatocytes may be important for the pathogenesis of immune mediated liver injury.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; NATL CTR STUDY WILSONS DIS INC,NEW YORK,NY 10019; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069; BROWN UNIV,RHODE ISL HOSP,DEPT PATHOL,PROVIDENCE,RI 02903	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of South Dakota; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NCI NIH HHS [CA61259] Funding Source: Medline; NIDDK NIH HHS [DK32972, DK41296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P30DK041296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1533, DOI 10.1177/36.12.3192937; BERG RA, 1980, BIOCHEM J, V189, P491, DOI 10.1042/bj1890491; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; FREEDMAN RB, 1994, TRENDS BIOL SCI, V19, P332; HONSCHA W, 1993, BIOCHIM BIOPHYS ACTA, V1153, P175, DOI 10.1016/0005-2736(93)90403-M; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; LAMBERT N, 1985, BIOCHEM J, V228, P635, DOI 10.1042/bj2280635; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; Leffert H L, 1979, Methods Enzymol, V58, P536; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MARTIN JL, 1993, HEPATOLOGY, V18, P858, DOI 10.1002/hep.1840180417; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Naik S, 1992, Cell Transplant, V1, P61; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OTSU M, 1994, J BIOL CHEM, V269, P6874; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; SATO M, 1990, J BIOL CHEM, V265, P2533; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; YOKOI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P339, DOI 10.1016/0304-4165(93)90033-5; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	24	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20410	20416		10.1074/jbc.270.35.20410	http://dx.doi.org/10.1074/jbc.270.35.20410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657616	hybrid			2022-12-27	WOS:A1995RR58400029
J	ZHUANG, SB; WANG, EZ; WANG, CLA				ZHUANG, SB; WANG, EZ; WANG, CLA			IDENTIFICATION OF THE FUNCTIONALLY RELEVANT CALMODULIN-BINDING SITE IN SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; ATPASE ACTIVITY; ACTOMYOSIN ATPASE; MOLECULAR-WEIGHT; THIN-FILAMENTS; CROSS-LINKING; H-CALDESMON; ACTIN; MYOSIN; TROPOMYOSIN	The C-terminal region of smooth muscle caldesmon (CaD) interacts with calmodulin (CaM) and reverses CaD's inhibitory effect on the actomyosin ATPase activity. me have previously shown that the major CaM-binding site (site A) in this region is within the segment from Met-658 to Ser-666 (Zhan, Q., Wong, S. S., and Wang, C.-L. A. (1991) J. Biol. Chem. 266, 21810-21814). Recently, another segment (site B), Asn-675 to Lys-695, was reported to bind CaM (Mezgueldi, M., Derancourt, J., Calas, B., Kassab, R., and Fattoum, A (1994) J. Biol. Chem. 269, 12824-12832). To assess the functional relevance of these two putative CaM-binding sites, we have examined three synthetic peptides regarding their effects on CaM's ability to reverse CaD-induced inhibition of actomyosin ATPase activity: GS17C (Gly-651 to Ser-667), VG29C (Val-685 to Gly-713), each containing one CaM-binding site, and MG56C (Met-658 to Gly-713), which contains both sites. We found that although VG29C did bind CaM, its affinity was weakened by GS17C, and it failed to compete with CaD for CaM under the conditions where GS17C effectively displaced CaD from CaM. MG56C had an effect similar to that of GS17C. These experiments demonstrated that site A for CaM binding is involved in regulating the inhibitory property of CaD.	BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114	Boston Biomedical Research Institute					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MABUCHI Y, 1995, BIOPHYS J, V68, P359; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	46	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19964	19968		10.1074/jbc.270.34.19964	http://dx.doi.org/10.1074/jbc.270.34.19964			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650012	hybrid			2022-12-27	WOS:A1995RQ99100045
J	CAI, K; SCHIRCH, D; SCHIRCH, V				CAI, K; SCHIRCH, D; SCHIRCH, V			THE AFFINITY OF PYRIDOXAL 5'-PHOSPHATE FOR FOLDING INTERMEDIATES OF ESCHERICHIA-COLI SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; GUANIDINE-HYDROCHLORIDE; TRYPTOPHAN SYNTHASE; COENZYME BINDING; BETA-2 SUBUNIT; PIG-HEART; DENATURATION; DISSOCIATION; PROTEINS; STEP	Escherichia coli serine hydroxymethyltransferase is a 94-kDa homodimer, Each subunit contains a covalently attached pyridoxal-P, which is required for catalytic activity, At which step pyridoxal-P binds in the folding pathway of E. coli serine hydroxymethyltransferase is addressed in this study, E. coli serine hydroxymethyltransferase is rapidly unfolded to an apparent random coil in 8 M urea, Removal of the urea initiates a complete refolding to the native holoenzyme in less than 10 min at 30 degrees C. Several intermediates on the folding pathway have been identified, The most important information was obtained during folding studies at 4 degrees C. At this temperature, the far-UV circular dichroism spectrum and the fluorescence spectrum of the 3 tryptophan residues become characteristic of the native apoenzyme in less than 10 min, Size exclusion chromatography shows that under these conditions the refolding enzyme is a mixture of monomeric and dimeric species. Continued incubation at 4 degrees C for 60 min results in the formation of only a dimeric species, Neither the monomer nor dimer formed at 4 degrees C bind pyridoxal phosphate. Raising the temperature to 30 degrees C results in the formation of a dimeric enzyme which rapidly binds pyridoxal phosphate forming active enzyme, These studies support the interpretation that pyridoxal phosphate binds only at the end of the folding pathway to a dimeric apoenzyme and plays no significant role in the folding mechanism.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BANIK U, 1995, J BIOL CHEM, V270, P7944, DOI 10.1074/jbc.270.14.7944; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Dempsey W., 1987, ESCHERICHIA COLI SAL, V1, P539; DEMPSEY WB, 1962, J BIOL CHEM, V237, P1113; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; FINK AL, 1988, FEBS LETT, V229, P123, DOI 10.1016/0014-5793(88)80810-X; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MCCORMICK DB, 1980, VITAMIN B6 METABOLIS, P1; PINEDA T, 1994, BBA-PROTEIN STRUCT M, V1207, P173, DOI 10.1016/0167-4838(94)00067-0; RAIBAUD O, 1976, J BIOL CHEM, V251, P2820; REYES AM, 1993, J BIOL CHEM, V268, P22281; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; WEST SM, 1989, BIOCHEM J, V261, P189, DOI 10.1042/bj2610189; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5	27	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19294	19299		10.1074/jbc.270.33.19294	http://dx.doi.org/10.1074/jbc.270.33.19294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642604	hybrid			2022-12-27	WOS:A1995RP70300018
J	STEFANSSON, S; CHAPPELL, DA; ARGRAVES, KM; STRICKLAND, DK; ARGRAVES, WS				STEFANSSON, S; CHAPPELL, DA; ARGRAVES, KM; STRICKLAND, DK; ARGRAVES, WS			GLYCOPROTEIN-330 LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2 MEDIATES ENDOCYTOSIS OF LOW-DENSITY LIPOPROTEINS VIA INTERACTION WITH APOLIPOPROTEIN B100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; LDL-RECEPTOR; IN-VITRO; BINDING; RABBIT; GP330; CELLS; RAT	The ability of glycoprotein 330/low density lipoprotein receptor-related protein-2 (LRP-2) to function as a lipoprotein receptor was investigated using cultured mouse F9 teratocarcinoma cells. Treatment with retinoic acid and dibutyryl cyclic AMP, which induces F9 cells to differentiate into endoderm-like cells, produced a 50-fold increase in the expression of LRP-2. Levels of the other members of the low density lipoprotein (LDL) receptor (LDLR) family, including LDLR, the very low density lipoprotein receptor, and LRP-1, were reduced, When LDL catabolism was examined in these cells, it was found that the treated cells endocytosed and degraded at 10-fold higher levels than untreated cells. The increased LDL uptake coincided with increased LRP-2 activity of the treated cells, as measured by uptake of both I-125-labeled monoclonal LRP-2 antibody and the LRP-2 ligand prourokinase. The ability of LDL to bind to LRP-2 was demonstrated by solid-phase binding assays. This binding was inhibitable by LRP-2 antibodies, receptor-associated protein (the antagonist of ligand binding for all members of the LDLR family), or antibodies to apoB100, the major apolipoprotein component of LDL. In cell assays, LRP-2 antibodies blocked the elevated I-125-LDL internalization and degradation observed in the retinoic acid/dibutyryl cyclic AMP treated F9 cells. A low level of LDL endocytosis existed that was likely mediated by LDLR since it could not be inhibited by LRP-2 antibodies, but was inhibited by excess LDL, receptor-associated protein, or apoB100 antibody. The results indicate that LRP-2 can function to mediate cellular endocytosis of LDL, leading to its degradation. LRP-2 represents the second member of the LDLR family identified as functioning in the catabolism of LDL.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	American Red Cross; University of Iowa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49264] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUCCARON MH, 1987, ANN INST PASTEUR IMM, V138, P707, DOI 10.1016/S0769-2625(87)80026-0; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Damjanov I, 1994, In Vivo, V8, P967; DIETSCHY JM, 1983, J LIPID RES, V24, P469; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GIANTURCO SH, 1987, PLASMA LIPOPROTEINS, P183; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; GUETHHALLONET C, 1994, DEVELOPMENT, V120, P3289; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	96	98	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19417	19421		10.1074/jbc.270.33.19417	http://dx.doi.org/10.1074/jbc.270.33.19417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642623	hybrid			2022-12-27	WOS:A1995RP70300037
J	SUN, B; LATHAM, KA; DODSON, ML; LLOYD, RS				SUN, B; LATHAM, KA; DODSON, ML; LLOYD, RS			STUDIES ON THE CATALYTIC MECHANISM OF 5 DNA GLYCOSYLASES - PROBING FOR ENZYME-DNA IMINO INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; COLI ENDONUCLEASE-III; ESCHERICHIA-COLI; PYRIMIDINE DIMER; PHYSICAL ASSOCIATION; T4-ENDONUCLEASE-V; NICKING; REPAIR; 8-OXOGUANINE; RESIDUES	DNA glycosylases catalyze scission of the N-glycosylic bond linking a damaged base to the DNA sugar phosphate backbone, Some of these enzymes carry out a concomitant abasic (apyrimidinic/apurinic (AP)) lyase reaction at a rate approximately equal to that of the glycosylase step. As a generalization of the mechanism described for T4 endonuclease V, a repair glycosylase/AP lyase that is specific for ultraviolet light-induced cis-syn pyrimidine dimers, a hypothesis concerning the mechanism of these repair glycosylases has been proposed, This hypothesis describes the initial action of all DNA glycosylases as a nucleophilic attack at the sugar C-1' of the damaged base nucleoside, resulting in scission of the N-glycosylic bond. It is proposed that the enzymes that are only glycosylases differ in the chemical nature of the attacking nucleophile from the glycosylase/AP lyases. Those DNA glycosylases, which carry out the AP lyase reaction at a rate approximately equal to the glycosylase step, are proposed to use an amino group as the nucleophile, resulting in an imino enzyme DNA intermediate. The simple glycosylases, lacking the concomitant AP lyase activity, are proposed to use some nucleophile from the medium, e.g. an activated water molecule, This paper reports experimental tests of this hypothesis using five representative enzymes, and these data are consistent with this hypothesis.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES04091, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CUNNINGHAM RP, 1994, DNA DAMAGE EFFECTS D, V726, P215; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; GROLLMAN AP, 1994, DNA DAMAGE EFFECTS D, V726, P208; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KOU CF, 1992, SCIENCE, V258, P434; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LATHAM KA, 1995, J BIOL CHEM, V270, P3765, DOI 10.1074/jbc.270.8.3765; LATHAM KA, 1994, DNA DAMAGE EFFECTS D, V726, P181; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LLOYD RS, 1993, NUCLEASES, V2, P263; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MCMILLAN S, 1981, P NATL ACAD SCI USA, V78, P2742; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PIERRE J, 1981, J BIOL CHEM, V256, P217; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WARNER HR, 1981, J VIROL, V77, P4602	38	144	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19501	19508		10.1074/jbc.270.33.19501	http://dx.doi.org/10.1074/jbc.270.33.19501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642635	hybrid			2022-12-27	WOS:A1995RP70300049
J	BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM				BHAT, GJ; THEKKUMKARA, TJ; THOMAS, WG; CONRAD, KM; BAKER, KM			ACTIVATION OF THE STAT PATHWAY BY ANGIOTENSIN-II IN T3CHO/AT(1A) CELLS - CROSS-TALK BETWEEN ANGIOTENSIN-II AND INTERLEUKIN-6 NUCLEAR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CARDIAC FIBROBLASTS; PROTEIN-SYNTHESIS; INTERFERON-GAMMA; GENE-EXPRESSION; RECEPTOR; BINDING; KINASE	We recently reported that angiotensin II (AII), acting through the STAT (Signal Transducers and Activators of Transcription) pathway, stimulated a delayed SIF (sis-inducing factor)-like DNA binding activity (maximal at 2-3 h) (Bhat, G. J., Thekkumkara, T. J., Thomas, W. G., Conrad, K. M., and Baker, K. M. (1994) J. Biol. Chem. 269, 31443-31449). Using a cell line transfected with the AT(1A) receptor (T3CHO/AT(1A)), we further characterized the AII-induced SIF response and explored the possible rea sons for the delay in stimulated SIF activity, In cells transfected with a chloramphenicol acetyltransferase reporter plasmid, under the control of a SIE (sis-inducing element), AII markedly stimulated chloramphenicol acetyltransferase activity. The delayed SIF activation by AII was not due to a requirement for the release of other SIF inducing factors into the medium and contrasts with the rapid (5 min) induction elicited by the cytokine, interleukin-6 (IL-6), Interestingly, both agents stimulated tyrosine phosphorylation of Stat92 and predominantly the formation of SIF complex A. We tested the hypothesis that AII initially activated an inhibitory pathway, which was responsible for delaying the maximal SIF stimulation until 2 h, Pretreatment of cells for 15 min with AII resulted in significant inhibition of the IL-6-induced nuclear SIF response (10 min) and Stat92 tyrosine phosphorylation, which was blocked by EXP3174, an AT(1) receptor antagonist. This inhibition was transient with return of the IL-6-induced SIF response at 2 h, suggesting that the delayed maximal activation of SIF by AII occurs following an initial transient inhibitory phase, Pretreatment of cells with phorbol 12-myristate 13-acetate for 15 min, to activate protein kinase C, resulted in inhibition of the IL-6-induced SIF response (10 min). However, down-regulation of protein kinase C activity prevented phorbol 12-myristate 13-acetate, but not AII mediated inhibition of the IL-6-induced SIF response. Although the mechanism is not clear, the results presented in this paper raise the interesting possibility that the activation of SIF/Stat92 by AII is characterized by an initial inhibitory phase, followed by the induction process. The observation that AII and IL-6 utilize similar components of the STAT pathway and that AII can cross-talk with IL-6 signaling through inhibition of IL-6-induced SIF/Stat92, implies a modulatory role for AII in cellular responses to cytokines.			BHAT, GJ (corresponding author), GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA.		Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952	NHLBI NIH HHS [HL-44883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOSTAL DE, 1993, TRENDS CARDIOVAS MED, V3, P67, DOI 10.1016/1050-1738(93)90039-9; DOSTAL DE, 1991, HORIZONS ENDOCRINOLO, P265; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; JOHNSON MC, 1992, ENDOCRINOLOGY, V131, P2404, DOI 10.1210/en.131.5.2404; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; LANDPAINTER K, 1994, CARDIAC RENIN ANGIOT; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; RAINEY WE, 1991, MOL CELL ENDOCRINOL, V81, P33, DOI 10.1016/0303-7207(91)90202-4; Raizada M.K., 1993, CELLULAR MOL BIOL RE; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCORB W, 1995, J MOL CELL CARDIOL, V27, P1151; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186	47	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19059	19065		10.1074/jbc.270.32.19059	http://dx.doi.org/10.1074/jbc.270.32.19059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642569	hybrid			2022-12-27	WOS:A1995RN95400057
J	BIRCH, OM; FUHRMANN, M; SHAW, NM				BIRCH, OM; FUHRMANN, M; SHAW, NM			BIOTIN SYNTHASE FROM ESCHERICHIA-COLI, AN INVESTIGATION OF THE LOW-MOLECULAR-WEIGHT AND PROTEIN-COMPONENTS REQUIRED FOR ACTIVITY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; PYRUVATE FORMATE-LYASE; BACILLUS-SPHAERICUS; MASS-SPECTROMETRY; BIOSYNTHESIS; DETHIOBIOTIN; SULFUR; ACID; BIOCONVERSION; ACTIVATION	We have developed a radiochemical method for the measurement of biotin synthase activity in vitro. A cell-free extract from an Escherichia coli strain containing a cloned bioB (biotin synthase) gene was incubated with [C-14]dethiobiotin, which was converted to [C-14]biotin, The assay was used to identify the low molecular weight compounds and two of the proteins that, in addition to the bioB gene product, are required for biotin synthase activity in vitro. The low molecular weight compounds are cysteine; S-adenosylmethionine thiamine pyrophosphate; Fe2+; a pyridine nucleotide (the most effective being NADPH); and one of the amino acids asparagine, aspartate, glutamine, or serine. The proteins are flavodoxin and ferredoxin (flavodoxin)-NADP(+) reductase (EC 1.18.1.2). A third thiamine pyrophosphate-dependent protein is also required for activity. When the cell-free extract was incubated with nonlabeled dethiobiotin and either [S-35]cysteine or [S-35]cystine, S-35 was incorporated into biotin, and we present further evidence that cysteine, and not S-adenosylmethionine or methionine, is the sulfur donor for the biotin synthase reaction.	LONZA AG,DEPT BIOTECHNOL,CH-3930 VISP,SWITZERLAND	Lonza Group								BALDET P, 1993, EUR J BIOCHEM, V217, P479, DOI 10.1111/j.1432-1033.1993.tb18267.x; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BAXTER RL, 1992, J CHEM SOC PERK T 1, P255, DOI 10.1039/p19920000255; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIRCH OM, 1994, Patent No. 08023; BOWMAN WC, 1993, J BACTERIOL, V175, P7702, DOI 10.1128/JB.175.23.7702-7704.1993; Brown S W, 1991, Biotechnol Genet Eng Rev, V9, P295; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; DEMOLL E, 1985, BIOCHEM BIOPH RES CO, V132, P217, DOI 10.1016/0006-291X(85)91010-1; DEMOLL E, 1983, BIOCHEM BIOPH RES CO, V110, P243, DOI 10.1016/0006-291X(83)91286-X; DEMOLL E, 1984, BIOCHEMISTRY-US, V23, P558, DOI 10.1021/bi00298a025; EISENBERG M, 1987, CELLULAR MOL BIOL, V1, P544; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FERREIRA RB, 1987, PLANT PHYSIOL, V83, P869, DOI 10.1104/pp.83.4.869; FLORENTIN D, 1994, CR ACAD SCI III-VIE, V317, P485; FRIEDRICH W, 1987, HDB VITAMINE, P220; FUJISAWA A, 1993, FEMS MICROBIOL LETT, V110, P1; GAUDRY M, 1992, CHROMATORG SCI, V60, P441; Goldberg M. W., 1949, [No title captured], Patent No. [2489238, US 2489238]; GOLDBERG MW, 1949, Patent No. 2489232; GOLDBERG MW, 1949, Patent No. 2489235; HUGHES GJ, 1990, BIOCHEM J, V271, P641, DOI 10.1042/bj2710641; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; IFUKU O, 1992, BIOSCI BIOTECH BIOCH, V56, P1780, DOI 10.1271/bbb.56.1780; IFUKU O, 1994, EUR J BIOCHEM, V220, P585, DOI 10.1111/j.1432-1033.1994.tb18659.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LEVYSCHIL S, 1993, APPL MICROBIOL BIOT, V38, P755, DOI 10.1007/BF00167141; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARQUET A, 1993, J AM CHEM SOC, V115, P2193; MARTI FB, 1983, THESIS EIDGENOSSISCH; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MCGARRITY J, 1989, Patent No. 4876350; OHSAWA I, 1992, J FERMENT BIOENG, V73, P121, DOI 10.1016/0922-338X(92)90475-A; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; REICHARD P, 1993, J BIOL CHEM, V268, P8383; ROLFE B, 1968, J BACTERIOL, V96, P515, DOI 10.1128/JB.96.2.515-524.1968; SAKURAI N, 1994, J FERMENT BIOENG, V77, P610, DOI 10.1016/0922-338X(94)90141-4; SANYAL I, 1994, J AM CHEM SOC, V116, P2637, DOI 10.1021/ja00085a061; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; ZHANG SG, 1994, ARCH BIOCHEM BIOPHYS, V309, P29, DOI 10.1006/abbi.1994.1079	48	91	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19158	19165		10.1074/jbc.270.32.19158	http://dx.doi.org/10.1074/jbc.270.32.19158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642583				2022-12-27	WOS:A1995RN95400071
J	KUMAGAI, H; CHUN, KT; SIMONI, RD				KUMAGAI, H; CHUN, KT; SIMONI, RD			MOLECULAR DISSECTION OF THE ROLE OF THE MEMBRANE DOMAIN IN THE REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-ENHANCED DEGRADATION; HMG-COA REDUCTASE; A REDUCTASE; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; ARABIDOPSIS-THALIANA; BOUND DOMAIN; ENZYME; CDNA; EXPRESSION	We have previously shown that the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase from hamster contains all of the sequences required for both localization to the endoplasmic reticulum and regulated degradation of the enzyme, It has been reported that the enzymatic activity and mRNA levels of HMG-CoA reductase from sea urchin embryos cultured in the presence of regulators were unchanged compared to levels in control embryos (Woodward, H. D., Alien, M. C., and Lennarz, W. J. (1988) J. Biol. Chem. 263, 18411-18418), This observation led us to investigate the possibility that the sea urchin enzyme is not subject to regulated protein turnover, Interestingly, the sea urchin enzyme shares 62% amino acid sequence identity with the hamster enzyme in the membrane domain and shares similar predicted topological features, In the current studies we have compared the degradation phenotypes of the sea urchin HMG-CoA reductase and the hamster HMG-CoA reductase in Chinese hamster ovary cells to further elucidate the role of the membrane domain in enzyme degradation in response to physiological regulators, To accomplish this, we constructed sea urchin HMGal (uHMGal), the structural equivalent of hamster HMGal (httMGal), which has the sea urchin HMG-CoA reductase membrane domain fused to Escherichia coli beta-galactosidase. The uHMGal was stably expressed in CHO cells, and we found that the degradation of uHMGal is not accelerated by sterols, and even in the absence of sterols, it is less stable than hHMGal. We also constructed chimeric hamster/sea urchin HMGal molecules to investigate which amino acid sequences from the hamster enzyme are sufficient to confer sterol-regulated degradation upon the sea urchin enzyme. Our results identify the second membrane-spanning domain of hamster enzyme as important for the regulated degradation of HMG-CoA reductase.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1985, J BIOL CHEM, V263, P8929; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V213, P233, DOI 10.1111/j.1432-1033.1993.tb17753.x; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411	26	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19107	19113		10.1074/jbc.270.32.19107	http://dx.doi.org/10.1074/jbc.270.32.19107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642576	hybrid			2022-12-27	WOS:A1995RN95400064
J	MCDONOUGH, VM; BUXEDA, RJ; BRUNO, MEC; OZIERKALOGEROPOULOS, O; ADELINE, MT; MCMASTER, CR; BELL, RM; CARMAN, GM				MCDONOUGH, VM; BUXEDA, RJ; BRUNO, MEC; OZIERKALOGEROPOULOS, O; ADELINE, MT; MCMASTER, CR; BELL, RM; CARMAN, GM			REGULATION OF PHOSPHOLIPID BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE BY CTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; ENZYME PHOSPHATIDYLSERINE SYNTHASE; CDP-DIACYLGLYCEROL SYNTHASE; COORDINATE REGULATION; ESCHERICHIA-COLI; PHOSPHATIDYLINOSITOL SYNTHASE; INOSITOL SYNTHESIS; SHUTTLE VECTORS; MESSENGER-RNA; YEAST MUTANT	In the yeast Saccharomyces cerevisiae, the major membrane phospholipid phosphatidylcholine is synthesized by the CDP-diacylglycerol and CDP-choline pathways. We examined the regulation of phosphatidylcholine synthesis by CTP. The cellular concentration of CTP was elevated (2.4-fold) by overexpressing CTP synthetase, the enzyme responsible for the synthesis of CTP. The overexpression of CTP synthetase resulted in a a-fold increase in the utilization of the CDP-choline pathway for phosphatidylcholine synthesis. The increase in CDP-choline pathway usage was not due to an increase in the expression of any of the enzymes in this pathway. CDP-choline, the product of the phosphocholine cytidylyltransferase reaction, was the limiting intermediate in the CDP-choline pathway. The apparent K-m of CTP (1.4 mM) for phosphocholine cytidylyltransferase was 2-fold higher than the cellular concentration of CTP (0.7 mM) in control cells. This provided an explanation of why the overexpression of CTP synthetase caused an increase in the cellular concentration of CDP-choline, Phosphatidylserine synthase activity was reduced in cells overexpressing CTP synthetase. This was not due to a transcriptional repression mechanism, Instead, the decrease in phosphatidylserine synthase activity was due, at least in part, to a direct inhibition of activity by CTP. These results show that CTP plays a role in the regulation of the pathways by which phosphatidylcholine is synthesized. This regulation includes the supply of CTP for the phosphocholine cytidylyltransferase reaction in the CDP-choline pathway and the inhibition of the phosphatidylserine synthase reaction in the CDP-diacylglycerol pathway.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; UNIV PARIS 06, CNRS, CTR GENET MOLEC, LAB PROPRE, F-91198 GIF SUR YVETTE, FRANCE; INST CHIM SUBST NAT, F-91198 GIF SUR YVETTE, FRANCE; DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA	Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Duke University				McMaster, Christopher/0000-0003-0822-5776	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20015, GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CARTER JR, 1966, J LIPID RES, V7, P678; CHRISTIANSEN K, 1979, BIOCHIM BIOPHYS ACTA, V574, P448, DOI 10.1016/0005-2760(79)90241-8; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; COVIELLA ILG, 1992, J NEUROCHEM, V59, P338, DOI 10.1111/j.1471-4159.1992.tb08909.x; CULBERTSON MR, 1975, GENETICS, V80, P23; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; HAID A, 1983, METHOD ENZYMOL, V96, P192; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; OVERMEYER JH, 1991, ARCH BIOCHEM BIOPHYS, V290, P511, DOI 10.1016/0003-9861(91)90574-3; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; STORER AC, 1976, BIOCHEM J, V159, P1; SUMMERS EF, 1988, GENETICS, V120, P909; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WU WI, 1994, J BIOL CHEM, V269, P29495; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	79	56	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18774	18780		10.1074/jbc.270.32.18774	http://dx.doi.org/10.1074/jbc.270.32.18774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642527				2022-12-27	WOS:A1995RN95400014
J	ROZANOWSKA, M; JARVISEVANS, J; KORYTOWSKI, W; BOULTON, ME; BURKE, JM; SARNA, T				ROZANOWSKA, M; JARVISEVANS, J; KORYTOWSKI, W; BOULTON, ME; BURKE, JM; SARNA, T			BLUE LIGHT-INDUCED REACTIVITY OF RETINAL AGE PIGMENT - IN-VITRO GENERATION OF OXYGEN-REACTIVE SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR DEGENERATION; HYDROPEROXIDES; LIPOFUSCIN; MELANINS; RADICALS; EYE	Exposure of the eye to intense light, particularly blue light, can cause irreversible, oxygen-dependent damage to the retina, However, no key chromophores that trigger such photooxidative processes have been identified yet, We have found that illumination of human retinal pigment epithelium (RPE) cells with light induces significant uptake of oxygen that is both wavelength- and age-dependent, Analysis of photoreactivity of RPE cells and their age pigment lipofuscin indicates that the observed photoreactivity in RPE cells is primarily due to the presence of lipofuscin, which, under aerobic conditions, generates several oxygen-reactive species including singlet oxygen, superoxide anion, and hydrogen peroxide, We have also found that lipofuscin-photosensitized aerobic reactions lead to enhanced lipid peroxidation as measured by accumulation of lipid hydroperoxides and malondialdehyde in illuminated pigment granules, Hydrogen peroxide is only a minor product of aerobic photoexcitation of lipofuscin, We postulate that lipofuscin is a potential photosensitizer that may increase the risk of retinal photodamage and contribute to the development of age related maculopathy.	JAGIELLONIAN UNIV, JAN ZURZYCKI INST MOLEC BIOL, DEPT BIOPHYS, PL-31120 KRAKOW, POLAND; UNIV MANCHESTER, DEPT OPHTHALMOL, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; MED COLL WISCONSIN, DEPT OPHTHALMOL & CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Jagiellonian University; University of Manchester; University of Manchester; Medical College of Wisconsin			Rozanowska, Malgorzata B/B-7860-2014; Rozanowska, Malgorzata/AAD-4806-2021	Rozanowska, Malgorzata B/0000-0003-2913-8954; Rozanowska, Malgorzata/0000-0003-2913-8954	NCRR NIH HHS [RR01008] Funding Source: Medline; NEI NIH HHS [P30EY01931, R01EY06664] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001931, R01EY006664] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIELSKI BHJ, 1991, INT J RADIAT BIOL, V59, P291, DOI 10.1080/09553009114550301; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784; DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S; ENOCHS WS, 1993, PIGM CELL RES, V6, P91, DOI 10.1111/j.1600-0749.1993.tb00587.x; FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195; FEENEYBURNS L, 1980, CURRENT TOPICS EYE R, P119; FOOTE CS, 1984, PORPHYRIN LOCALIZATI, P3; Fridovich, 1976, FREE RADICALS BIOLOG, V1, P239; GIROTTI AW, 1990, PHOTOCHEM PHOTOBIOL, V51, P497, DOI 10.1111/j.1751-1097.1990.tb01744.x; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; Gutteridge J M, 1983, J Appl Biochem, V5, P293; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; HALPERN HJ, 1990, J MAGN RESON, V90, P40, DOI 10.1016/0022-2364(90)90364-F; JAFFE GJ, 1988, OPHTHALMOLOGY, V95, P1130; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KORYTOWSKI W, 1987, PHOTOCHEM PHOTOBIOL, V45, P185, DOI 10.1111/j.1751-1097.1987.tb05362.x; KORYTOWSKI W, 1993, ANAL BIOCHEM, V213, P111, DOI 10.1006/abio.1993.1393; LERMAN S, 1989, PHOTOMEDICINE, V1, P79; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PRYOR WA, 1984, METHOD ENZYMOL, V105, P293; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SARNA T, 1994, NATO ADV SCI INST SE, V272, P125; SARNA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P140, DOI 10.1016/0003-9861(80)90340-9; SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R; Sarna T., 1993, ATMOSPHERIC OXIDATIO, VIII, P129; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; VINDING T, 1992, ACTA OPHTHALMOL, V70, P66; WEITER J, 1987, CLIN LIGHT DAMAGE EY, P79; WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145; Yannuzzi L A, 1987, Trans Am Ophthalmol Soc, V85, P120; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P265	35	346	350	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18825	18830		10.1074/jbc.270.32.18825	http://dx.doi.org/10.1074/jbc.270.32.18825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642534	hybrid			2022-12-27	WOS:A1995RN95400021
J	WOO, SK; LEE, JI; PARK, IK; YOO, YJ; CHO, CM; KANG, MS; HA, DB; TANAKA, K; CHUNG, CH				WOO, SK; LEE, JI; PARK, IK; YOO, YJ; CHO, CM; KANG, MS; HA, DB; TANAKA, K; CHUNG, CH			MULTIPLE UBIQUITIN C-TERMINAL HYDROLASES FROM CHICK SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; CELL CYCLE; HEAT-SHOCK; GENE; EXPRESSION; CLONING; ENZYME	A new method for assaying ubiquitin C-terminal hydrolases was developed using a I-125-labeled ubiquitin-alpha NH-MHISPPEPESEEEEEHYC as substrate, Since the peptide portion was almost exclusively radiolabeled, the enzymes could be assayed directly by simple measurement of the radioactivity released into acid-soluble products, Using this assay protocol, we identified at least 10 ubiquitin C-terminal hydrolase activities from the extract of chick skeletal muscle, which were tentatively named UCHs 1 through 10, Of these, UCH-B was purified to apparent homogeneity, Purified UCH-6 behaved as a dimer of 27-kDa subunits, The apparent molecular masses of the other partially purified UCHs ranged hom 35 to 810 kDa as determined under a nondenaturing condition, Muscle UCHs, except UCH-1, were activated dramatically by poly-L-Lys but with an unknown mechanism. Ah of the UCHs were sensitive to inhibition by sulfhydryl-blocking agents such as iodoacetamide. In addition, all of the UCHs were capable of releasing free ubiquitin from a ubiquitin-alpha NH-carboxyl extension protein of 80 amino acids and from ubiquitin-alpha NH-dihydrofolate reductase, Five of the enzymes, UCHs 1 through 5, were also capable of generating free ubiquitin from poly-His-tagged diubiquitin. In addition, UCH-1 and UCH-7 could remove ubiquitin that had been ligated covalently by an isopeptide linkage to a ubiquitin(RGA)-alpha NH-peptide, the peptide portion of which consists of the 20 amino acids of the calmodulin binding domain of myosin light chain kinase, These results suggest that the 10 UCH activities isolated from chick skeletal muscle appear to be distinct from each other at least in their chromatographic behavior, size, and substrate specificity.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; LUCKY BIOTECH LTD,TAEJON 305,SOUTH KOREA; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Seoul National University (SNU); Tokushima University			Yoo, Yung Joon/AAH-5002-2020					BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, UBIQUITIN, P173; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOSLIN G, 1991, J IMMUNOL, V147, P1614; KIM YM, 1994, PLANT PHYSIOL, V106, P791, DOI 10.1104/pp.106.2.791; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DH, 1993, BIOCHEM MOL BIOL INT, V30, P121; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MONIA BP, 1989, J BIOL CHEM, V264, P4093; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PICKART CM, 1988, UBIQUITIN, P77; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEOL JH, 1989, FEBS LETT, V247, P197, DOI 10.1016/0014-5793(89)81333-X; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YOO Y, 1989, J BIOL CHEM, V264, P17078	41	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18766	18773		10.1074/jbc.270.32.18766	http://dx.doi.org/10.1074/jbc.270.32.18766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642526	hybrid			2022-12-27	WOS:A1995RN95400013
J	GALLIANO, MF; ABERDAM, D; AGUZZI, A; ORTONNE, JP; MENEGUZZI, G				GALLIANO, MF; ABERDAM, D; AGUZZI, A; ORTONNE, JP; MENEGUZZI, G			CLONING AND COMPLETE PRIMARY STRUCTURE OF THE MOUSE LAMININ ALPHA-3 CHAIN - DISTINCT EXPRESSION PATTERN OF THE LAMININ ALPHA-3A AND ALPHA-3B CHAIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE ADHESION; A-CHAIN; SEQUENCE; HEMIDESMOSOMES; PROTEIN; GLYCOPROTEIN; KALININ	We have isolated and characterized overlapping cDNA clones encoding the alpha 3A and alpha 3B chains of mouse laminin 5. Sequence analysis of the cDNA for the alpha 3B predicts a polypeptide of 2541 amino acids (279,510 Da) comprising a truncated short arm and a carboxyl-terminal long arm common to the laminin a chains identified thus far. The short arm of the alpha 3B chain harbors two alternating epidermal growth factor-like domains and two globular domains. The amino-terminal globular domain, thought to mediate interactions with molecules of the extracellular matrix, shows no significant homology to any globular domain at the tips of the known laminin isoforms. The alpha 3A cDNA predicts a polypeptide of 1711 amino acids (186,230 Da) that substitutes a short sequence of 43 amino acids for the short arm seen in the alpha 3B isoform and displays 77% conservative homology to the alpha 3Ep chains of the adhesion ligand epiligrin. Northern and Western blot analyses of skin and lung epithelial cells demonstrated the tissue-specific expression of the laminin alpha 3A and alpha 3B isoforms, and in situ hybridization on mouse embryos revealed a focal localization of alpha 3B in areas of the central nervous system.	FAC MED NICE,INSERM,U385,F-06107 NICE 2,FRANCE; ETH ZURICH,INST NEUROPATHOL,CH-8093 ZURICH,SWITZERLAND; HOP LOUIS PASTEUR,SERV DERMATOL,F-06002 NICE 1,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Swiss Federal Institutes of Technology Domain; ETH Zurich; CHU Nice			Aberdam, Daniel/G-3299-2013; Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708; Aberdam, Daniel/0000-0002-4019-5418; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; BAUDOIN C, 1994, J CLIN INVEST, V93, P862, DOI 10.1172/JCI117041; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; JONES JCR, 1994, EXP CELL RES, V213, P1, DOI 10.1006/excr.1994.1166; KIVIRIKKO S, 1995, HUM MOL GENET, V4, P959, DOI 10.1093/hmg/4.5.959; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SANES JR, 1990, COLD SPRING HARB SYM, V55, P429; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VERRANDO P, 1991, LAB INVEST, V64, P85; VIDAL F, 1995, IN PRESS GENOMICS; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; YUSPA SH, 1980, CANCER RES, V40, P4694	33	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21820	21826		10.1074/jbc.270.37.21820	http://dx.doi.org/10.1074/jbc.270.37.21820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665604	hybrid			2022-12-27	WOS:A1995RU75700063
J	ORIAN, A; WHITESIDE, S; ISRAEL, A; STANCOVSKI, I; SCHWARTZ, AL; CIECHANOVER, A				ORIAN, A; WHITESIDE, S; ISRAEL, A; STANCOVSKI, I; SCHWARTZ, AL; CIECHANOVER, A			UBIQUITIN-MEDIATED PROCESSING OF NF-KAPPA-B TRANSCRIPTIONAL ACTIVATOR PRECURSOR P105 - RECONSTITUTION OF A CELL-FREE SYSTEM AND IDENTIFICATION OF THE UBIQUITIN-CARRIER PROTEIN, E2, AND A NOVEL UBIQUITIN-PROTEIN LIGASE, E3, INVOLVED IN CONJUGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53; DEGRADATION; BINDING; SUBUNIT; RESOLUTION; CLONING; E6-AP; E6	In most cases, the transcriptional factor NF-kappa B is a heterodimer consisting of two subunits, p50 and p65, which are encoded by two distinct genes of the Rel family. p50 is translated as a precursor of 105 kDa. The C-terminal domain of the precursor is rapidly degraded, forming the mature p50 subunit consisted of the N-terminal region of the molecule. The mechanism of generation of p50 is not known. It has been suggested that the ubiquitin-proteasome system is involved in the process; however, the specific enzymes involved and the mechanism of limited proteolysis, in which half of the molecule is spared, have been obscure. Palombella and colleagues (Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785) have shown that ubiquitin is required for the processing in a cell-free system of a truncated, artificially constructed, 60-kDa precursor. They have also shown that proteasome inhibitors block the processing both in vitro and in vivo. In this study, we demonstrate reconstitution of a cell-free processing system and demonstrate directly that: (a) the ubiquitin-proteasome system is involved in processing of the intact p105 precursor, (b) conjugation of ubiquitin to the precursor is an essential intermediate step in the processing, (c) the recently discovered novel species of the ubiquitin-carrier protein, E2-F1, that is involved in the coqjugation and degradation of p53, is also required for the limited processing of the p105 precursor, and (d) a novel, similar to 320-kDa species of ubiquitin protein ligase, is involved in the process. This novel enzyme is distinct from EG-AP, the p53 conjugating ligase, and from E3 alpha, the ''N-end rule'' ligase.	TECHNION ISRAEL INST TECHNOL,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; INST PASTEUR,UNITE BIOL MOLEC EXPRESS GEN,F-75724 PARIS 15,FRANCE; UNIV WASHINGTON,SCH MED,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Washington University (WUSTL); St. Louis Children's Hospital			Ciechanover, Aaron J/C-9166-2017					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1994, P NATL ACAD SCI USA, V269, P9582; COX JH, 1995, J IMMUNOL, V154, P511; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MICHALEK MT, 1993, NATURE, V3, P552; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REISS Y, 1988, J BIOL CHEM, V263, P2693; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	47	133	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21707	21714		10.1074/jbc.270.37.21707	http://dx.doi.org/10.1074/jbc.270.37.21707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665588	hybrid			2022-12-27	WOS:A1995RU75700046
J	WICE, BM; GORDON, JI				WICE, BM; GORDON, JI			A TETRASPAN MEMBRANE GLYCOPROTEIN PRODUCED IN THE HUMAN INTESTINAL EPITHELIUM AND LIVER THAT CAN REGULATE CELL DENSITY-DEPENDENT PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; DEGENERATION SLOW RDS; COLON CANCER-CELLS; MONOCLONAL-ANTIBODIES; ENTEROCYTIC DIFFERENTIATION; CD9 ANTIGEN; ANTIPROLIFERATIVE ANTIBODY; TRANSMEMBRANE PROTEINS; RETINITIS-PIGMENTOSA; SYNCYTIUM FORMATION	The human cell line HT-29 provides a model system for studying regulation of proliferation and differentiation in intestinal epithelial cell lineages: (i) HT-29 cells cultured in glucose resemble undifferentiated multipotent transit cells located in the lower half of intestinal crypts; (ii) proliferating HT-29 cells cultured in inosine resemble committed cells located in the upper half of the crypt; (iii) nonproliferating, confluent HT-29-inosine cells have features of differentiated enterocytes and goblet cells that overlie small intestinal villi. A cDNA library prepared from HT-29-inosine cells was screened with a series of subtracted cDNA probes to identify proteins that regulate proliferation/differentiation along the crypt-villus axis. A cDNA was recovered that encodes a 202-amino acid protein with four predicted membrane spanning domains and two potential sites for N-linked glycosylation. Levels of this new member of the superfamily of tetraspan membrane proteins (TMPs) increase dramatically as nondividing epithelial cells exit the proliferative compartment of the crypt-villus unit and migrate onto the villus. The protein is also produced in nondividing hepatocytes that have the greatest proliferative potential within liver acini. Three sets of observations indicate that in the appropriate cellular context, intestinal and liver (il)-TMP can mediate density-associated inhibition of proliferation. (i) Accumulation of il-TMP glycoforms precedes terminal differentiation of HT-29-inosine cells and occurs as they undergo density-dependent cessation of growth, il-TMP levels are lower and glycosylation less extensive in HT-29-glucose cells, which do not undergo growth arrest at confluence. (ii) HeLa cells normally do not produce il-TMP. Forced expression of il-TMP inhibits proliferation as cells approach confluence. The extent of il-TMP glycosylation in the transfected cells is similar to that observed in HT-29-inosine cells and greater than in HT-29-glucose cells, (iii) SW480 cells are derived from a human colon adenocarcinoma and do not express il-TMP. Like nontransfected HeLa cells, they do not stop dividing at confluence, whether grown in medium containing glucose or inosine. Expression of il-TMP has no effect on the growth properties of SW480 cells. The extent of il-TMP glycosylation in SW480 glucose cells is similar to that noted in HT-29-glucose cells, lending further support to the notion that il-TMP's activity is related to its state of N-glycosylation.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKEN KD, 1994, DEV DYNAM, V201, P63, DOI 10.1002/aja.1002010107; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Ausubel FM, 1988, MOL REPROD DEV; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BOLLAG DM, 1991, PROTEIN METHODS, P203; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CARROLL RC, 1990, BIOCHEM J, V266, P527, DOI 10.1042/bj2660527; CHANTRET I, 1988, CANCER RES, V48, P1936; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DULUC I, 1994, J CELL BIOL, V126, P211, DOI 10.1083/jcb.126.1.211; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GIL ML, 1992, J IMMUNOL, V148, P2826; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HATO T, 1990, BLOOD, V75, P1087; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HELLSTROM I, 1986, CANCER RES, V465, P3917; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIXSON DC, 1984, EXP CELL RES, V152, P402, DOI 10.1016/0014-4827(84)90641-4; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; IMAI T, 1992, J IMMUNOL, V149, P2879; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KALLIN B, 1992, MOL CELL BIOL, V11, P5338; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kellett M, 1992, Epithelial Cell Biol, V1, P147; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1987, LEUKOCYTE TYPING, V3, P339; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MATSUMOTO Y, 1992, HEPATOLOGY, V15, P1048, DOI 10.1002/hep.1840150613; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; OZAKI Y, 1991, EUR J BIOCHEM, V199, P347, DOI 10.1111/j.1432-1033.1991.tb16130.x; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; PAULUS U, 1993, J CELL SCI, V106, P473; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINTO M, 1982, BIOL CELL, V44, P193; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; Sambrook J, 1989, MOL CLONING LABORATO, P545; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; ULSHAFER RJ, 1986, INVEST OPHTH VIS SCI, V27, P1587; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; WICE BM, 1985, J BIOL CHEM, V260, P139; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; WICE BM, 1981, J BIOL CHEM, V256, P7812; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	78	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21907	21918		10.1074/jbc.270.37.21907	http://dx.doi.org/10.1074/jbc.270.37.21907			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665614	hybrid			2022-12-27	WOS:A1995RU75700075
J	EASTMAN, J; WILSON, EJ; CERVENANSKY, C; ROSENBERRY, TL				EASTMAN, J; WILSON, EJ; CERVENANSKY, C; ROSENBERRY, TL			FASCICULIN-2 BINDS TO THE PERIPHERAL SITE ON ACETYLCHOLINESTERASE AND INHIBITS SUBSTRATE HYDROLYSIS BY SLOWING A STEP INVOLVING PROTON-TRANSFER DURING ENZYME ACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED HYDROLYSIS; TORPEDO-CALIFORNICA; SPECIFICITY; LIGANDS; ESTERS; VENOM	The acetylcholinesterase active site consists of a gorge 20 Angstrom deep that is lined with aromatic residues, A serine residue near the base of the gorge defines an acylation site where an acyl enzyme intermediate is formed during the hydrolysis of ester substrates, Residues near the entrance to the gorge comprise a peripheral site where inhibitors like propidium and fasciculin 2, a snake neurotoxin, bind and interfere with catalysis, We report here the association and dissociation rate constants for fasciculin 2 interaction with the human enzyme in the presence of ligands that bind to either the peripheral site or the acylation site, These kinetic data confirmed that propidium is strictly competitive with fasciculin 2 for binding to the peripheral site, In contrast, edrophonium, N-methylacridinium, and butyrylthiocholine bound to the acylation site and formed ternary complexes with the fasciculin a-bound enzyme in which their affinities were reduced by about an order of magnitude from their affinities in the free enzyme. Steady state analysis of the inhibition of substrate hydrolysis by fasciculin 2 revealed that the ternary complexes had residual activity, For acetylthiocholine and phenyl acetate, saturating amounts of the toxin reduced the first-order rate constant k(cat) to 0.5-2% and the second-order rate constant k(cat)/K-app to 0.2-2% of their values with the uninhibited enzyme, To address whether fasciculin 2 inhibition primarily involved steric blockade of the active site or conformational interaction with the acylation site, deuterium oxide isotope effects on these kinetic parameters were measured, The isotope effect on k(cat)/K-app increased for both substrates when fasciculin 2 was bound to the enzyme, indicating that fasciculin 2 acts predominantly by altering the conformation of the active site in the ternary complex so that steps involving proton transfer during enzyme acylation are slowed,	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44120; INST INVEST BIOL,MONTEVIDEO 11600,URUGUAY	Case Western Reserve University; Instituto de Investigaciones Biologicas Clemente Estable Uruguay			Eastman, Joseph T./O-6150-2019	Eastman, Joseph T./0000-0003-3868-261X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK D, 1994, J BIOL CHEM, V269, P6296; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BERNHARD SA, 1968, STRUCTURE FUNCTION E, P83; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; HODGE AS, 1992, MOL PHARMACOL, V41, P937; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KRUPKA RM, 1961, J AM CHEM SOC, V83, P1454, DOI 10.1021/ja01467a043; LEDU MH, 1992, J BIOL CHEM, V267, P22122; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; NACHMANSOHN D, 1951, ADV ENZYMOL REL S BI, V12, P259; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RAO M, 1993, J AM CHEM SOC, V115, P11676, DOI 10.1021/ja00078a003; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROSENBERRY TL, 1979, BIOPHYS J, V26, P263, DOI 10.1016/S0006-3495(79)85249-2; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSENBERRY TL, 1975, P NATL ACAD SCI USA, V72, P3834, DOI 10.1073/pnas.72.10.3834; SCHALK I, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P117; SELWOOD T, 1993, J AM CHEM SOC, V115, P10477, DOI 10.1021/ja00076a002; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	34	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19694	19701		10.1074/jbc.270.34.19694	http://dx.doi.org/10.1074/jbc.270.34.19694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649979	hybrid			2022-12-27	WOS:A1995RQ99100007
J	MOYLE, WR; CAMPBELL, RK; RAO, SNV; AYAD, NG; BERNARD, MP; HAN, Y; WANG, YH				MOYLE, WR; CAMPBELL, RK; RAO, SNV; AYAD, NG; BERNARD, MP; HAN, Y; WANG, YH			MODEL OF HUMAN CHORIONIC-GONADOTROPIN AND LUTROPIN RECEPTOR INTERACTION THAT EXPLAINS SIGNAL-TRANSDUCTION OF THE GLYCOPROTEIN HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; LEUCINE-RICH REPEATS; ALPHA-SUBUNIT; HUMAN CHORIOGONADOTROPIN; MONOCLONAL-ANTIBODIES; HIGH-AFFINITY; LINKED OLIGOSACCHARIDES; EXTRACELLULAR DOMAIN; LUTEINIZING-HORMONE; ANTIGENIC STRUCTURE	The goal of these studies was to devise a model that explains how human chorionic gonadotropin (hCG) interacts with lutropin (LH) receptors to elicit a hormone signal. Here we show that alpha-subunit residues near the N terminus, the exposed surface of the cysteine knot, and portions of the first and third loops most distant from the beta-subunit interface were recognized by antibodies that bound to hCG-receptor complexes. These observations were combined with similar data obtained for the beta-subunit (Cosowsky, L., Rao, S. N. V,, Macdonald, G. J., Papkoff, H., Campbell, R K,, and Moyle, W. R. (1995) J. Biol. Chem. 270, 20011-20019), information on residues of hCG that can be changed without disrupting hormone function, the crystal structure of deglycosylated hCG, and the crystal structure of a leucine-repeat protein to devise a model of hCG-receptor interaction. This model suggests that the extracellular domain of the LH receptor is ''U-'' or ''J''-shaped and makes several contacts with the transmembrane domain. High affinity hormone binding results from interactions between residues in the curved portion of the extracellular domain of the receptor and the groove in the hormone formed by the apposition of the second cr subunit loop and the first and third P-subunit loops. Most of the remainder of the hormone is found in the large space between the arms of the extracellular domain and makes few, if any, additional specific contacts with the receptor needed for high affinity binding. Signal transduction is caused by steric or other influences of the hormone on the distance between the arms of the extracellular domain, an effect augmented by the oligosaccharides. Because the extracellular domain is coupled at multiple sites to the transmembrane domain, the change in conformation of the extracellular domain is relayed to the transmembrane domain and subsequently to the cytoplasmic surface of the plasma membrane. While the model does not require the hormone to contact the transmembrane domain to initiate signal transduction, small portions of both subunits may be near the transmembrane domain and assist in initiating the hormonal signal. This is the first model that is consistent with all known information on the activity of the gonadotropins including the amounts of the hormone that are exposed in the hormone-receptor complex, the apparent lack of specific contacts between much of the hormone and the receptor, and the roles of the oligosaccharides in signal transduction. This model differs from existing models of hormone action in that the extracellular domain has a much larger role in hormone action than serving as a high affinity hormone trap.			MOYLE, WR (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT OBSTET & GYNECOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.		Campbell, Robert/G-4112-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, P01HD015454, R01HD024650, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24650, HD15454, HD14907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG EG, 1986, BIOCHEM ACTION HORM, V13, P91; ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIDART JM, 1989, ENDOCRINOLOGY, V124, P923, DOI 10.1210/endo-124-2-923; BIRKEN S, 1986, J BIOL CHEM, V261, P719; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CAMPBELL RK, 1992, MOL CELL ENDOCRINOL, V83, P195, DOI 10.1016/0303-7207(92)90159-4; CHARLESWORTH MC, 1991, ENDOCRINOLOGY, V128, P2907, DOI 10.1210/endo-128-6-2907; CHARLESWORTH MC, 1990, ENDOCRINOLOGY, V127, P2977, DOI 10.1210/endo-127-6-2977; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN WY, 1991, J BIOL CHEM, V266, P9355; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; CRUZ RI, 1987, J CLIN ENDOCR METAB, V64, P433, DOI 10.1210/jcem-64-3-433; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; EHRLICH PH, 1983, METHOD ENZYMOL, V50, P638; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILIUS RP, 1983, P NATL ACAD SCI-BIOL, V80, P7375, DOI 10.1073/pnas.80.24.7375; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MOYLE WR, 1988, J RECEPTOR RES, V8, P419, DOI 10.3109/10799898809049002; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RAO SNV, 1994, TECHNIQUES PROTEIN C, V5, P413; REBOIS RV, 1984, J BIOL CHEM, V259, P8087; REBOIS RV, 1987, J BIOL CHEM, V262, P3891; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; VANDIJK S, 1993, ENDOCRINOLOGY, V132, P534, DOI 10.1210/en.132.2.534; WEARE JA, 1979, J BIOL CHEM, V254, P6972; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO JK, 1993, J BIOL CHEM, V268, P13034	51	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20020	20031		10.1074/jbc.270.34.20020	http://dx.doi.org/10.1074/jbc.270.34.20020			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650020	hybrid			2022-12-27	WOS:A1995RQ99100053
J	VENTURACLAPIER, R; KUZNETSOV, AV; DALBIS, A; VANDEURSEN, J; WIERINGA, B; VEKSLER, VI				VENTURACLAPIER, R; KUZNETSOV, AV; DALBIS, A; VANDEURSEN, J; WIERINGA, B; VEKSLER, VI			MUSCLE CREATINE KINASE-DEFICIENT MICE .1. ALTERATIONS IN MYOFIBRILLAR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GUANIDINOPROPIONIC ACID; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; CA-2+ SENSITIVITY; MYOSIN; FIBERS; ANALOG; TROPONIN; RATS; COMPARTMENTATION	The regulation of contractile activity in mice bearing a null mutation of the M-isoform of creatine kinase gene, has been investigated in tissue extracts and Triton X-100-treated preparations of ventricular, soleus, and gastrocnemius muscles of control and transgenic mice. Skinned fiber experiments did not evidence any statistical difference in the maximal force or the calcium sensitivity of either muscle type. Rigor tension development at a low MgATP concentration was greatly influenced by phosphocreatine in control but not in transgenic mice as should be expected. In calcium-activated ventricular preparations, although the force developed by each cross-bridge was the same in control and transgenic animals, the rate constant of tension changes appeared to be markedly slowed in transgenic animals. As the ventricular isomyosin pattern was not altered, we suggested that, in transgenic animals, cross-bridge cycling was hindered by a local decrease in the MgATP to MgADP ratio, due to lack of a local MgATP regenerating system. Myokinase activity was not significantly changed while activities of pyruvate kinase or glyceraldehyde-3-phosphate dehydrogenase were found to be increased in transgenic animals. These results show that no fundamental remodelling occurs in myofibrils of transgenic animals but that important adaptations modify the bioenergetic pathways including glycolytic metabolism.	UNIV PARIS 11, CNRS, URA 1131, F-91405 ORSAY, FRANCE; UNIV NIJMEGEN, FAC MED SCI, DEPT HISTOL & CELL BIOL, 6500 HB NIJMEGEN, NETHERLANDS; CARDIOL RES CTR, MOSCOW 121552, RUSSIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Radboud University Nijmegen; National Medical Research Center of Cardiology	VENTURACLAPIER, R (corresponding author), UNIV PARIS SUD, FAC PHARM, INSERM, CJF9211, CARDIOL CELLULAIRE & MOLEC LAB, F-92296 CHATENAY MALABRY, FRANCE.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				ARRIODUPONT M, 1992, EUR J BIOCHEM, V207, P951, DOI 10.1111/j.1432-1033.1992.tb17129.x; BESSMAN SP, 1980, BIOCHEM BIOPH RES CO, V96, P1414, DOI 10.1016/0006-291X(80)90108-4; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; D'ALBIS A, 1973, Febs Letters, V29, P292, DOI 10.1016/0014-5793(73)80042-0; DALBIS A, 1979, EUR J BIOCHEM, V99, P261, DOI 10.1111/j.1432-1033.1979.tb13253.x; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FOSSEL ET, 1987, AM J PHYSIOL, V252, pE124, DOI 10.1152/ajpendo.1987.252.1.E124; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; HOAR PE, 1987, PFLUG ARCH EUR J PHY, V410, P30, DOI 10.1007/BF00581892; HOH JFY, 1975, BIOCHEMISTRY-US, V14, P742, DOI 10.1021/bi00675a015; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; KAPELKO VI, 1988, J MOL CELL CARDIOL, V20, P465, DOI 10.1016/S0022-2828(88)80074-9; KUPRIYANOV VV, 1991, AM J PHYSIOL, V261, P45, DOI 10.1152/ajplung.1991.261.4.L45; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; MAUGHAN DW, 1989, BIOPHYS J, V56, P717, DOI 10.1016/S0006-3495(89)82719-5; MAYOUX E, 1994, AM J PHYSIOL, V266, pH2051, DOI 10.1152/ajpheart.1994.266.5.H2051; MEKHFI H, 1990, AM J PHYSIOL, V258, pH1151, DOI 10.1152/ajpheart.1990.258.4.H1151; MEKHFI H, 1988, PFLUG ARCH EUR J PHY, V411, P378, DOI 10.1007/BF00587716; MOERLAND TS, 1989, AM J PHYSIOL, V257, pC810, DOI 10.1152/ajpcell.1989.257.4.C810; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OTSU N, 1989, J HISTOCHEM CYTOCHEM, V37, P1465, DOI 10.1177/37.10.2778305; PAN BS, 1992, J BIOL CHEM, V267, P23052; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; SAKS VA, 1976, FEBS LETT, V62, P293, DOI 10.1016/0014-5793(76)80078-6; SAKS VA, 1984, BIOCHIM BIOPHYS ACTA, V803, P254, DOI 10.1016/0167-4889(84)90115-0; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; VANDEURSEN J, 1994, BBA-BIOENERGETICS, V1185, P327, DOI 10.1016/0005-2728(94)90248-8; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VENTURACLAPIER R, 1994, CIRC RES, V74, P920, DOI 10.1161/01.RES.74.5.920; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; VENTURACLAPIER R, 1987, AM J PHYSIOL, V253, pC444, DOI 10.1152/ajpcell.1987.253.3.C444; VENTURACLAPIER R, 1987, J GEN PHYSIOL, V89, P815, DOI 10.1085/jgp.89.5.815; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172; ZWEIER JL, 1991, J BIOL CHEM, V266, P20296	48	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19914	19920		10.1074/jbc.270.34.19914	http://dx.doi.org/10.1074/jbc.270.34.19914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650006	hybrid, Green Published			2022-12-27	WOS:A1995RQ99100038
J	LEHEL, C; OLAH, Z; JAKAB, G; SZALLASI, Z; PETROVICS, G; HARTA, G; BLUMBERG, PM; ANDERSON, WB				LEHEL, C; OLAH, Z; JAKAB, G; SZALLASI, Z; PETROVICS, G; HARTA, G; BLUMBERG, PM; ANDERSON, WB			PROTEIN-KINASE-C-EPSILON SUBCELLULAR-LOCALIZATION DOMAINS AND PROTEOLYTIC DEGRADATION SITES - A MODEL FOR PROTEIN-KINASE-C CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; PKC-EPSILON; CELLS; ASSOCIATION; ACTIVATION; ISOFORM; FIBROBLASTS; MORPHOLOGY	Protein kinase C (PKC) epsilon has been found to have unique properties among the PKC isozymes in terms of its membrane association, oncogenic potential, and substrate specificity, Recently we have demonstrated that PKC epsilon localizes to the Golgi network via its zinc finger domain and that both the holoenzyme and its zinc finger region modulate Golgi function. To further characterize the relationship between the domain organization and the subcellular localization of PKC epsilon, a series of NIH 3T3 cell lines were created, each overexpressing a different truncated version of PKC epsilon. The overexpressed proteins each were designed to contain an epsilon-epitope tag peptide at the COOH terminus to allow ready detection with an antibody specific for the tag. The subcellular localization of the recombinant proteins was analyzed by in vivo phorbol ester binding, immunocytochemistry, and cell fractionation followed by immunoblotting. Results revealed several regions of PKC epsilon that contain putative subcellular localization signals. The presence either of the hinge region or of a 33-amino-acid region including the pseudosubstrate sequence in the recombinant proteins resulted in association with the plasma membrane and cytoskeletal components. The catalytic domain was found predominantly in the cytosolic fraction. The accessibility and thus the dominance of these localization signals is likely to be affected by the overall conformation of the recombinant proteins. Regions with putative proteolytic degradation sites also were identified. The susceptibility of the overexpressed proteins to proteolytic degradation was dependent on the protein conformation. Based on these observations, a model depicting the interaction and hierarchy of the suspected localization signals and proteolytic degradation sites is presented.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NINCDS,EXPTL NEUROPATHOL LAB,BETHESDA,MD; NINCDS,CLIN NEUROSCI BRANCH,BETHESDA,MD; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Petrovics, Gyorgy/0000-0003-3732-284X; Szallasi, Zoltan/0000-0001-5395-7509				AKITA Y, 1994, J BIOL CHEM, V269, P4653; BAXTER G, 1992, J BIOL CHEM, V267, P1910; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; CACACE AM, 1993, ONCOGENE, V8, P2095; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MOSKALEWSKI S, 1992, J SUBMICR CYTOL PATH, V24, P359; NEWTON AC, 1994, J CELL BIOCHEM     S, V18, P68; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; SZALLASI Z, 1995, MOL PHARMACOL, V47, P285; THOMAS TP, 1988, CANCER RES, V48, P1910; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	38	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19651	19658		10.1074/jbc.270.33.19651	http://dx.doi.org/10.1074/jbc.270.33.19651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642654	hybrid			2022-12-27	WOS:A1995RP70300070
J	LIU, J; SCHONEBERG, T; VANRHEE, M; WESS, J				LIU, J; SCHONEBERG, T; VANRHEE, M; WESS, J			MUTATIONAL ANALYSIS OF THE RELATIVE ORIENTATION OF TRANSMEMBRANE HELIX-I AND HELIX-VII IN G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONIST BINDING; IDENTIFICATION; ACETYLCHOLINE; GENES; SELECTIVITY; EXPRESSION; RHODOPSIN; AGONIST; DOMAINS; DNA	Currently, detailed structural information about the arrangement of the seven transmembrane helices (TM I-VII) present in all G protein-coupled receptors is still lacking. We demonstrated previously that hybrid m2/m5 muscarinic acetylcholine receptors which contain m5 sequence in TRI I and m2 sequence in TM VII were unable to bind significant amounts of muscarinic radioligands (Pittel, Z., and Wess, J. (1994) Mol. Pharmacol. 45, 61-64). By using immunocytochemical and enzyme-linked immunosorbent assay techniques, we show in the present study that these pharmacologically inactive mutant receptors are present (at high levels) on the surface of transfected COS-7 cells. Strikingly, all misfolded m2/m5 hybrid receptors could be pharmacologically rescued by introduction of a single point mutation into either TM I (m5Thr(37) --> m2Ala(30)) or TM VII (m2Thr(423) --> m5His(478)). All experimental data are consistent with the notion that the two altered threonine residues face each other at the TM I/TM VII interface in the pharmacologically inactive m2/m5 hybrid receptors, thus interfering with proper helix-helix packing. Our data provide the first experimental evidence as to how TM I and TM VII are oriented relative to each other and also strongly suggest that the TM helices in G protein-coupled receptors are arranged in a counterclockwise fashion (as viewed from the extracellular membrane surface).	NIDDK, BIOORGAN CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P18870; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; Higuchi R., 1989, PCR TECHNOLOGY, P61; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MATSUI H, 1995, MOL PHARMACOL, V47, P88; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WATSON S, 1994, G PROTEIN LINKED REC, P1; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1992, MOL PHARMACOL, V41, P369; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	39	65	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19532	19539		10.1074/jbc.270.33.19532	http://dx.doi.org/10.1074/jbc.270.33.19532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642637	hybrid			2022-12-27	WOS:A1995RP70300053
J	NEWMYER, SL; DEMONTELLANO, PRO				NEWMYER, SL; DEMONTELLANO, PRO			HORSERADISH-PEROXIDASE HIS-42-]ALA, HIS-42-]VAL, AND PHE-41-]ALA MUTANTS - HISTIDINE CATALYSIS AND CONTROL OF SUBSTRATE ACCESS TO THE HEME IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; PROSTHETIC HEME; ABSOLUTE STEREOCHEMISTRY; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; LINKED IONIZATION; CRYSTAL-STRUCTURE; RADICAL SITE; SODIUM-AZIDE; COMPOUND-I	Polyhistidine-tagged horseradish peroxidase (hHRP) and its F41A, H42A, and H42V mutants have been expressed in an insect cell system. Kinetic studies show that the rates of Compound I formation and peroxidative catalysis are greatly decreased by the His-42 mutation, Furthermore, Compound II is not detected during turnover of the His-42 mutants, Compounds I and II are the two- and one-electron oxidized intermediates, respectively, of hHRP. In peroxygenative catalysis, the F41A and H42A mutants catalyze thioanisole sulfoxidation 100 and 10 times faster, respectively, than hHRP. Styrene epoxidation is catalyzed by both the Phe-41 and His-42 mutants but not by wild type hHRP. The higher peroxygenase activity of the mutants reflects increased accessibility of the ferryl species. This is indicated by the finding that, contrary to the reaction with wild-type hHRP, reaction of phenyldiazene with the F41A mutant yields a new and unidentified product, and the same reaction with the His-42 mutants yields phenyl iron complexes, Phe-41 and His-42 thus shield the iron-centered catalytic species, and His-42 plays a key catalytic role in the formation of Compound I. The peroxygenase activities of the Phe-41 and His-42 mutants approach those of cytochrome P450.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Newmyer, Sherri/0000-0003-1039-5416	NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAGGER S, 1971, ACTA CHEM SCAND, V25, P976, DOI 10.3891/acta.chem.scand.25-0976; BAYNTON KJ, 1994, BBA-PROTEIN STRUCT M, V1206, P272, DOI 10.1016/0167-4838(94)90218-6; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1995, BIOCHEM SOC T, V23, P223, DOI 10.1042/bst0230223; DEMONTELLANO PRO, 1995, IN PRESS BIOCH PARIS; DEMONTELLANO PRO, 1991, ANN REV PHARM TOXICO, V32, P89; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DOLPHIN D, 1974, P NATL ACAD SCI USA, V68, P614; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVERETT AJ, 1953, T FARADAY SOC, V49, P410, DOI 10.1039/tf9534900410; FARHANGRAZI ZS, 1994, BIOCHEMISTRY-US, V33, P5647, DOI 10.1021/bi00184a038; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FRUETEL J, 1994, J AM CHEM SOC, V116, P11643, DOI 10.1021/ja00105a003; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HENRISSAT B, 1990, PROTEINS, V8, P251, DOI 10.1002/prot.340080307; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KUNZE KL, 1983, J AM CHEM SOC, V105, P1380, DOI 10.1021/ja00343a057; MARKLUND S, 1973, ARCH BIOCHEM BIOPHYS, V154, P614, DOI 10.1016/0003-9861(73)90016-7; MILLER VP, 1992, J BIOL CHEM, V267, P8936; NAKAJIMA R, 1980, J BIOL CHEM, V255, P2067; OZAKI S, 1995, IN PRESS J AM CHEM S; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAMETTES RW, 1965, J AM CHEM SOC, V82, P5001; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SANDERS SA, 1995, IN PRESS BIOCH SOC T, V23; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]	46	129	130	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19430	19438		10.1074/jbc.270.33.19430	http://dx.doi.org/10.1074/jbc.270.33.19430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642625	hybrid			2022-12-27	WOS:A1995RP70300039
J	PALLANCK, L; ORDWAY, RW; RAMASWAMI, M; CHI, WY; KRISHNAN, KS; GANETZKY, B				PALLANCK, L; ORDWAY, RW; RAMASWAMI, M; CHI, WY; KRISHNAN, KS; GANETZKY, B			DISTINCT ROLES FOR N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN (NSF) SUGGESTED BY THE IDENTIFICATION OF A 2ND DROSOPHILA NSF HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								The N-ethylmaleimide-sensitive fusion protein (NSF) is a cytoplasmic protein implicated in the fusion of intracellular transport vesicles with their target membranes, NSF is thought to function in the fusion of essentially all types of vesicles, including endoplasmic reticulum, Golgi, and endocytic vesicles, as well as secretory vesicles undergoing regulated fusion (for review see Rothman, J. E. (1994) Nature 372, 55-63), However, little experimental evidence exists to address the possibility that organisms might have multiple NSF proteins serving distinct functions in the same or different cells, We previously cloned a neurally expressed Drosophila homolog, dNSF-1 (Ordway, R. W., Pallanck, L., and Ganetzky, B. (1994) Proc. Natl. Acad. Sci, U.S.A. 91, 5715-5719), and have subsequently identified mutations in this gene that confer an apparent failure of synaptic transmission at elevated temperature (Pallanck, L., Ordway, R. W., and Ganetzky, B. (1995) Nature, 376, 25; Siddiqi, O., and Benzer, S. (1976) Proc. Natl. Acad. Sci. U.S.A. 73, 3253-3257), Here we report that 1) Drosophila contains a second NSF homolog, termed dNSF-2, that exhibits 84% amino acid identity to dNSF-1, 2) dNSF-1 and dNSF-2 display overlapping but different temporal expression, and 3) multiple transcripts are derived from the dNSF-2 gene. These findings raise the possibility that different NSF gene products serve distinct or overlapping functions within the organism.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; TATA INST FUNDAMENTAL RES,MOLEC BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	University of Arizona; University of California System; University of California San Francisco; Tata Institute of Fundamental Research (TIFR)	PALLANCK, L (corresponding author), UNIV WISCONSIN,GENET LAB,MADISON,WI 53706, USA.			Ramaswami, Mani/0000-0001-7631-0468	NINDS NIH HHS [NS15390, NS09364, NS5927] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009364, R01NS015390] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; ORDWAY RW, 1994, P NATL ACAD SCI USA, V91, P5715, DOI 10.1073/pnas.91.12.5715; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; RAMASWAMI M, 1989, P NATL ACAD SCI USA, V86, P2079, DOI 10.1073/pnas.86.6.2079; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253	7	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18742	18744		10.1074/jbc.270.32.18742	http://dx.doi.org/10.1074/jbc.270.32.18742			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642522	hybrid			2022-12-27	WOS:A1995RN95400009
J	SEELY, BL; REICHART, DR; STAUBS, PA; JHUN, BH; HSU, D; MAEGAWA, H; MILARSKI, KL; SALTIEL, AR; OLEFSKY, JM				SEELY, BL; REICHART, DR; STAUBS, PA; JHUN, BH; HSU, D; MAEGAWA, H; MILARSKI, KL; SALTIEL, AR; OLEFSKY, JM			LOCALIZATION OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR-BINDING SITES FOR THE SH2 DOMAIN PROTEINS P85, SYP, AND GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; STIMULATES TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; INTACT-CELLS; PHOSPHOLIPASE-C; IRS-1; SUBSTRATE; KINASE; ASSOCIATION	Potential signaling substrates for the insulin like growth factor I (IGF-I) receptor are SH2 domain proteins including the p85 subunit of phosphatidylinositol 3-kinase, the tyrosine phosphatase Syp, GTPase activating protein (GAP), and phospholipase C-gamma (PLC-gamma), In this study, we demonstrate an association between the IGF-I receptor and p85, Syp, and GAP, but not with PLC-gamma in lysates of cells overexpressing the human IGF I receptor, We further investigated these interactions using glutathione S-transferase (GST) fusion proteins containing the amino terminal SH2 domains of p85 or GAP, or both SH2 domains of Syp or PLC-gamma to precipitate the IGF-I receptor from purified receptor preparations and from whole cell lysates, p85-, Syp-, and GAP-GSTs precipitated the IGF-I receptor, whereas the PLC-gamma-GST did not, Using phosphopeptides corresponding to IGF-I receptor phosphorylation sites, we determined that the p85- and Syp-GST association with the IGF-I receptor could be inhibited by a carboxyl-terminal peptide containing pY1316 and that the GAP-GST association could be inhibited by a NPXY domain peptide, The GAP-GST binding site was confirmed by showing that a mutant IGF-I receptor with a deletion of the NPXY domain including tyrosine 950 was poorly precipitated by the GAP-GST, We conclude that p85 and Syp may bind directly to the IGF I receptor at tyrosine 1316, and that GAP may bind to the IGF-I receptor at tyrosine 950, An association between the IGF I receptor and PLC-gamma was not evident, p85, Syp, and GAP are potential modulators of IGF-I receptor signal transduction.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA; VET ADM MED CTR, MED RES SERV, SAN DIEGO, CA 92161 USA; WHITTIER DIABET PROGRAM, LA JOLLA, CA 92037 USA; SHIGA UNIV MED SCI, SHIGA 52021, JAPAN; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Shiga University of Medical Science; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Maegawa, Hiroshi/0000-0002-4611-8149	NIDDK NIH HHS [DK 02162-02, DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, K08DK002162, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1985, J BIOL CHEM, V260, P9470; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	53	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19151	19157		10.1074/jbc.270.32.19151	http://dx.doi.org/10.1074/jbc.270.32.19151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642582				2022-12-27	WOS:A1995RN95400070
J	MOCK, WL; LIU, YY				MOCK, WL; LIU, YY			HYDROLYSIS OF PICOLINYLPROLINES BY PROLIDASE - A GENERAL MECHANISM FOR THE DUAL-METAL ION CONTAINING AMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS LEUCINE AMINOPEPTIDASE; HUMAN-ERYTHROCYTE PROLIDASE; CARBOXYPEPTIDASE-A; BOVINE LENS; PROLINE DIPEPTIDASE; PURIFICATION; INHIBITION; SUBSTITUTION; DEFICIENCY; BESTATIN	The velocity of enzymic cleavage of 4-substituted picolinylprolines by swine kidney prolidase approaches that of physiological; dipeptides, but depends substantially upon the nature of the pyridine-ring substituent. The pH dependence of k(cat)/K-m for picolinylproline is sigmoidal, with optimum activity on the acidic limb and a delimiting enzymic pK(alpha) of 6.6, unlike glycylproline (bell-shaped pH profile, maximum at pH 7.7). Productive chelation to an active site metal ion by the N terminus of substrates is indicated, with a water molecule ligated to that hyper(Lewis)acidic center prior to substrate binding supplying the pK(alpha) of 6.6. The rate-governing catalytic step differs according to the 4-substituent on the picolinyl residue; productive binding is slow in the case of electron-withdrawing groups, but subsequent nucleophilic addition to the metal ion-activated scissile linkage becomes controlling with more basic pyridine rings, Rate constants yield a Bronsted-type correlation with substrate pK(alpha), providing a gauge of active-site Lewis acidity. A mechanism is suggested involving the cooperative participation of two especially acidic metal ions positioned adjacently within the active site (situated as in an homologous and structurally characterized aminopeptidase), with both serving to stabilize a bridging carboxamide-hydrate intermediate.			MOCK, WL (corresponding author), UNIV ILLINOIS,DEPT CHEM,CHICAGO,IL 60607, USA.							ALLEN MP, 1983, BIOCHEMISTRY-US, V22, P3778, DOI 10.1021/bi00285a010; AULD DS, 1970, BIOCHEMISTRY-US, V9, P602, DOI 10.1021/bi00805a022; BIZZOZERO SA, 1975, FEBS LETT, V59, P105, DOI 10.1016/0014-5793(75)80351-6; BLACKBURN GM, 1968, J AM CHEM SOC, V90, P2638, DOI 10.1021/ja01012a031; BROWNE P, 1983, J BIOL CHEM, V258, P6147; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; BURLEY SK, 1991, P NATL ACAD SCI USA, V88, P6916, DOI 10.1073/pnas.88.16.6916; BZAN JF, 1994, P NATL ACAD SCI USA, V91, P2473; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Clemo GR, 1938, J CHEM SOC, P478, DOI 10.1039/jr9380000478; DAVIS NC, 1957, J BIOL CHEM, V224, P261; DEADY LW, 1971, AUST J CHEM, V24, P385, DOI 10.1071/CH9710385; DENSLOW ND, 1994, BIOCHEM BIOPH RES CO, V205, P1790, DOI 10.1006/bbrc.1994.2877; ENDO F, 1989, J BIOL CHEM, V264, P4476; ENDO F, 1982, PEDIATR RES, V16, P227, DOI 10.1203/00006450-198203000-00013; ENDO M, 1960, YAKUGAKU ZASSHI, V80, P875; FABRE JL, 1985, TETRAHEDRON LETT, V26, P5447, DOI 10.1016/S0040-4039(00)98232-7; HEINISCH G, 1985, ANGEW CHEM INT EDIT, V24, P692, DOI 10.1002/anie.198506921; KIM H, 1993, BIOCHEMISTRY-US, V32, P8465, DOI 10.1021/bi00084a011; KIM HD, 1993, P NATL ACAD SCI USA, V90, P5006, DOI 10.1073/pnas.90.11.5006; KING GF, 1986, BIOCHEMISTRY-US, V25, P1054, DOI 10.1021/bi00353a016; KING SW, 1983, BIOCHEMISTRY-US, V22, P3603, DOI 10.1021/bi00284a010; KUZNETSOVA EA, 1989, KHIM FARM ZH+, V23, P1425; LEUSSING DL, 1968, ANAL CHEM, V40, P575, DOI 10.1021/ac60259a019; LIN LN, 1979, BIOCHEMISTRY-US, V18, P43, DOI 10.1021/bi00568a007; MANAO G, 1972, PHYSIOL CHEM PHYS M, V4, P75; MOCK WL, 1991, J BIOL CHEM, V266, P6393; MOCK WL, 1990, J BIOL CHEM, V265, P19606; MOCK WL, 1993, BIOCHEM J, V289, P185, DOI 10.1042/bj2890185; MOCK WL, 1994, BIOCHEM J, V302, P57, DOI 10.1042/bj3020057; MOCK WL, 1992, BIOORG CHEM, V20, P377, DOI 10.1016/0045-2068(92)90047-7; MOCK WL, 1994, BIOORG CHEM, V22, P373, DOI 10.1006/bioo.1994.1031; MOCK WL, 1991, BIOCHEM BIOPH RES CO, V180, P401, DOI 10.1016/S0006-291X(05)81307-5; MOCK WL, 1990, J BIOL CHEM, V265, P19600; MOSHER HS, 1955, J ORG CHEM, V20, P283, DOI 10.1021/jo01121a002; MYARA I, 1994, INT J BIOCHEM, V26, P207, DOI 10.1016/0020-711X(94)90147-3; POSTMUS C, 1966, INORG CHEM, V5, P1154, DOI 10.1021/ic50041a017; RICHTER AM, 1989, BIOCHEM CELL BIOL, V67, P34, DOI 10.1139/o89-005; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Samvelyan V. M., 1992, Eksperimental'naya i Klinicheskaya Farmakologiya, V55, P11; SJOSTROM H, 1974, BIOCHIM BIOPHYS ACTA, V359, P177, DOI 10.1016/0005-2795(74)90141-X; TANOUE A, 1990, J BIOL CHEM, V265, P11306; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; THOMPSON GA, 1976, J BIOL CHEM, V251, P53; THOMPSON GA, 1976, J BIOL CHEM, V251, P1618; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; YOSHIMOTO T, 1983, J BIOCHEM, V94, P1889, DOI 10.1093/oxfordjournals.jbchem.a134542	48	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18437	18446		10.1074/jbc.270.31.18437	http://dx.doi.org/10.1074/jbc.270.31.18437			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629169	hybrid			2022-12-27	WOS:A1995RM64200046
J	WONG, JM; SHI, YB				WONG, JM; SHI, YB			COORDINATED REGULATION OF AND TRANSCRIPTIONAL ACTIVATION BY XENOPUS THYROID-HORMONE AND RETINOID-X RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; AMPHIBIAN METAMORPHOSIS; RESPONSE ELEMENTS; ACID RECEPTORS; BETA GENES; LAEVIS	Thyroid hormone (T-3) plays a causative role in amphibian metamorphosis, This regulation is thought to be mediated by heterodimers of T-3 receptors (TRs) and retinoid X receptors (RXRs). We report here that Xenopus TRs can indeed form strong heterodimers with Xenopus RXRs on the T-3 response element (TRE) present in Xenopus TRP beta genes. Using a T-3-responsive in vivo tran scription system established by introducing TRs and RXRs into Xenopus oocytes, we demonstrated that TR-RXR heterodimers repressed TR beta gene promoter in the absence of T-3 and activated the promoter in the presence of the hormone. Furthermore, by analyzing the expression of TR and RXR genes, we showed that TR and RXR genes were coordinately regulated in different tissues during metamorphosis. Thus high levels of their mRNAs are present in the limb during early stages of limb development when morphogenesis occurs and in the tail toward the end of metamorphosis when it is being resorbed. Such correlations coupled with our TRE-binding and in vivo transcriptional activation experiments provide strong evidence that TRs and RXRs function together to mediate the effects of T-3 during metamorphosis, These results further suggest a possible molecular basis for the temporal regulation of tissue-specific metamorphosis.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Dodd M.H.I., 1976, P467; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gilbert L, 1981, METAMORPHOSIS PROBLE; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1995, MOL ENDOCRINOL, V9, P96, DOI 10.1210/me.9.1.96; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; SHEPEL L A, 1988, Biofactors, V1, P71; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG Z, 1993, J BIOL CHEM, V268, P16270; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3	32	137	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18479	18483		10.1074/jbc.270.31.18479	http://dx.doi.org/10.1074/jbc.270.31.18479			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629175	hybrid			2022-12-27	WOS:A1995RM64200052
J	SINGH, A; HAYASHI, K				SINGH, A; HAYASHI, K			CONSTRUCTION OF CHIMERIC BETA-GLUCOSIDASES WITH IMPROVED ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLVIBRIO-GILVUS; RUMINOCOCCUS-ALBUS; GENE; ENZYMES; CELLULASE; SUBTILIS; CLONING; PURIFICATION; SEQUENCES	The amino acid sequences of beta-glucosidases from Cellvibrio gilvus and Agrobacterium tumefaciens show about 40% similarity. The pH/temperature optima and stabilities and substrate specificities of the two enzymes are quite different. C. gilvus beta-glucosidase exhibits an optimum pH of 6.2-6.4 and temperature of 35 degrees C, whereas the corresponding values for A. tumefaciens are 7.2- 7.4 and 60 degrees C, respectively. The substrate specificity of A. tumefaciens enzyme toward different aryl glycosides is broader than C. gilvus enzyme. To analyze these properties further, three chimeric beta-glucosidases were constructed by substituting segments from the C-terminal homologous region of C. gilvus beta-glucosidase gene with that of A. tumefaciens. The chimeric enzymes were characterized with respect to pH/temperature activity and stability and substrate specificity. Chimeric enzymes exhibited chromatographic behavior similar to that of C. gilvus enzyme. However, enzymatic properties of chimeras were admixtures of those of the two parents. The chimeric enzymes were optimally active at 45-50 degrees C and pH 6.6-7.0. K-m values of chimeric enzymes for the various saccharides were admixtures of both parental enzymes. These results suggest that the two domains of C. gilvus and A. tumefaciens enzymes probably can fold independently. The homologous C-terminal region in beta-glucosidase appears to play an important role in determining enzyme characteristics. Changes in the properties on substitution of segments in this region might be related to the enzyme specificity, and beta-glucosidases with improved properties can be prepared by manipulating this region.	NATL FOOD RES INST, BIOMAT CONVERS LAB, TSUKUBA, IBARAKI 305, JAPAN	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan								BEGUIN P, 1987, CRIT REV BIOTECHNOL, V6, P129, DOI 10.3109/07388558709113595; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; CASTLE LA, 1992, J BACTERIOL, V174, P1478, DOI 10.1128/jb.174.5.1478-1486.1992; FRANDSEN TP, 1994, BIOCHEMISTRY-US, V33, P13808, DOI 10.1021/bi00250a035; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLICK BR, 1989, BIOTECHNOL ADV, V7, P361, DOI 10.1016/0734-9750(89)90180-8; HAGA K, 1991, AGR BIOL CHEM TOKYO, V55, P1959, DOI 10.1080/00021369.1991.10870897; HENRISSAT B, 1990, COMPUT APPL BIOSCI, V6, P3; KANEKO T, 1989, J GEN MICROBIOL, V135, P3447; KASHIWAGI Y, 1991, AGR BIOL CHEM TOKYO, V55, P2553, DOI 10.1080/00021369.1991.10871004; KASHIWAGI Y, 1993, J FERMENT BIOENG, V75, P159, DOI 10.1016/0922-338X(93)90108-K; KASHIWAGI Y, 1993, GENETICS BIOCH ECOLO, P368; KUHAD RC, 1993, CRIT REV BIOTECHNOL, V13, P151, DOI 10.3109/07388559309040630; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOVE DR, 1987, BIO-TECHNOL, V5, P384, DOI 10.1038/nbt0487-384; MAS MT, 1986, SCIENCE, V233, P788, DOI 10.1126/science.3526552; MOLGAT GF, 1992, ARCH BIOCHEM BIOPHYS, V298, P238, DOI 10.1016/0003-9861(92)90118-G; NAKAMURA A, 1991, J BIOL CHEM, V266, P1579; NOSOH Y, 1990, TRENDS BIOTECHNOL, V8, P16, DOI 10.1016/0167-7799(90)90125-H; NUMATA K, 1995, PROTEIN ENG, V8, P39, DOI 10.1093/protein/8.1.39; OHMIYA K, 1991, J BACTERIOL, V173, P636, DOI 10.1128/jb.173.2.636-641.1991; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; PAAVILAINEN S, 1993, APPL ENVIRON MICROB, V59, P927, DOI 10.1128/AEM.59.3.927-932.1993; RYU DDY, 1980, ENZYME MICROB TECH, V2, P91, DOI 10.1016/0141-0229(80)90063-0; Sambrook J, 1989, MOL CLONING LABORATO; SHEWALE JG, 1982, INT J BIOCHEM, V14, P435, DOI 10.1016/0020-711X(82)90109-4; SIERKS MR, 1993, BIOCHEMISTRY-US, V32, P1113, DOI 10.1021/bi00055a017; SIERKS MR, 1994, PROTEIN ENG, V7, P1479, DOI 10.1093/protein/7.12.1479; SINGH A, 1995, BIOCHEM J, V305, P715, DOI 10.1042/bj3050715; STORVICK WO, 1960, J BIOL CHEM, V235, P303; TAKANO M, 1992, J FERMENT BIOENG, V73, P79, DOI 10.1016/0922-338X(92)90293-4; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; WALES ME, 1991, METHOD ENZYMOL, V202, P687; YAMANE K, 1984, J BIOCHEM-TOKYO, V96, P1849, DOI 10.1093/oxfordjournals.jbchem.a135019	35	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21928	21933		10.1074/jbc.270.37.21928	http://dx.doi.org/10.1074/jbc.270.37.21928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665615	hybrid			2022-12-27	WOS:A1995RU75700077
J	HIRSCH, HH; NAIR, APK; BACKENSTOSS, V; MORONI, C				HIRSCH, HH; NAIR, APK; BACKENSTOSS, V; MORONI, C			INTERLEUKIN-3 MESSENGER-RNA STABILIZATION BY A TRANS-ACTING MECHANISM IN AUTOCRINE TUMORS LACKING INTERLEUKIN-3 GENE REARRANGEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; ACUTE LYMPHOCYTIC-LEUKEMIA; A-PARTICLE TRANSPOSITION; C-MYC RETROVIRUS; HEMATOPOIETIC-CELLS; MAST-CELLS; MALIGNANT TRANSFORMATION; NUCLEOTIDE-SEQUENCE; EUKARYOTIC CELLS; RICH SEQUENCES	Tumors obtained from v-Ha-ras-transformed PB-3c cells are characterized by autocrine interleukin-3 (IL3) expression, which occurs either without (class I tumors) or with enhanced transcription (class II tumors). To address possible post-transcriptional mechanisms of IL3 expression, IL3 mRNA stability was examined in both tumor classes. Increased stability of IL3 mRNA was detected in class I tumor lines (t(1/2) > 3 h), whereas rapid decay of IL3 transcripts (t(1/2) < 0.5 h) was found in class II tumor lines. In both tumor classes, the c-myc and interleukin-6 transcripts were short-lived. Transcripts of a constitutively expressed IL3 reporter gene were stable in class I tumor cells but unstable in class II tumor cells, suggesting that IL3 mRNA stabilization involved a trans-acting mechanism. Rapid decay of IL3 reporter transcripts was observed in untransformed PB-3c as well as in v-Ha-ras expressing precursor cells linking transcript stabilization to the tumor stage. Reporter transcript stabilization in class I tumor cells correlated with increased IL3 production. Deletion of the AU-rich element from the IL3 reporter gene further augmented IL3 mRNA levels as well as IL3 production, suggesting that the stabilizing mechanism in class I tumor cells is not equivalent to AU-rich element deletion.			HIRSCH, HH (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ABRAMS JS, 1988, J IMMUNOL, V140, P131; ALGATE PA, 1993, ONCOGENE, V8, P1221; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARTER BZ, 1991, LAB INVEST, V65, P610; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; GRIMALDI JC, 1989, BLOOD, V73, P2081; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HENICS T, 1994, J BIOL CHEM, V269, P5377; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MEEKER TC, 1990, BLOOD, V76, P285; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; ROSS HJ, 1991, BLOOD, V77, P1787; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	45	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20629	20635		10.1074/jbc.270.35.20629	http://dx.doi.org/10.1074/jbc.270.35.20629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657642	hybrid			2022-12-27	WOS:A1995RR58400061
J	AZARANI, A; GOLTZMAN, D; ORLOWSKI, J				AZARANI, A; GOLTZMAN, D; ORLOWSKI, J			PARATHYROID-HORMONE AND PARATHYROID HORMONE-RELATED PEPTIDE INHIBIT THE APICAL NA+/H+ EXCHANGER NHE-3 ISOFORM IN RENAL-CELLS (OK) VIA A DUAL SIGNALING CASCADE INVOLVING PROTEIN-KINASE-A AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; EPIDERMAL GROWTH-FACTOR; OPOSSUM KIDNEY-CELLS; MOLECULAR-CLONING; PHEOCHROMOCYTOMA CELLS; FUNCTIONAL-PROPERTIES; OSTEOSARCOMA CELLS; PHORBOL ESTERS; BRUSH-BORDER; GENE FAMILY	Parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) interact with a common G protein-coupled receptor and stimulate production of diverse second messengers (i.e, cAMP, diacylglycerol, and inositol 1,4,5-trisphosphate) that varies depending on the target cell, In renal proximal tubule OK cells, PTH inhibits the activity of the apical membrane Na+H+ exchanger, although it is unclear whether the signal is transmitted through protein kinase A (PKA) and/or protein kinase C (PKC). To delineate the signaling circuitry, a series of synthetic PTH and PTHRP fragments were used that stimulate the adenylate cyclase-cAMP-PKA and/or phospholipase C-diacylglycerol-PHC pathways, Human PTH-(1-34) and PTHRP-(1-34) stimulated adenylate cyclase and PHC activity, whereas the PTH analogues, PTH-(3-34), PTH-(28-42), and PTH-(28-48), selectively enhanced only PI(C activity, However, each peptide fragment inhibited Na+/H+ exchanger activity by 40-50%, suggesting that PHC and possibly PRA were capable of transducing the PTH/PTHRP signal to the transporter, This was corroborated when forskolin and phorbol 12-myristate 13-acetate (PMA), direct agonists of adenylate cyclase and PKC, respectively, both inhibited the Na+/H+ exchanger. The specific PW antagonist, H-89, abolished the forskolin-mediated suppression of Na+/H+ exchanger activity, but did not prevent the inhibitory effects of PTH-(1-34) or PMA In comparison, the potent PKC inhibitor, chelerythrine chloride, prevented the inhibition of Na+/H+ exchanger activity mediated by PTH-(28-48) and PMA. but did not avert the negative regulation caused by PTH-(1-34) or forskolin, However, inhibition of both PKA and PRC prevented PTH-(1-34)-mediated suppression of Na+/H+ exchanger activity, indicating that PTH-(1-34) acted through both signaling pathways, In addition, Northern blot analysis revealed the presence of only the NHE-3 isoform of the Na+/H+ exchanger in OR cells, In summary, these results demonstrated that NHE-3 is expressed in OR cells and that activation of the PTH receptor can stimulate both the PKA and PKC pathways, each of which can independently lead to inhibition of NHE-3 activity.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital				Orlowski, John/0000-0001-7371-175X				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MRKIC B, 1992, J MEMBRANE BIOL, V130, P205; MRKIC B, 1993, PFLUG ARCH EUR J PHY, V424, P377, DOI 10.1007/BF00374897; MUFF R, 1992, ANNU REV PHYSIOL, V54, P67, DOI 10.1146/annurev.physiol.54.1.67; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1994, J BIOL CHEM, V269, P1563; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU FH, 1993, J BIOL CHEM, V268, P25536	50	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20004	20010		10.1074/jbc.270.34.20004	http://dx.doi.org/10.1074/jbc.270.34.20004			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650018	hybrid			2022-12-27	WOS:A1995RQ99100051
J	CHADEE, DN; TAYLOR, WR; HURTA, RAR; ALLIS, CD; WRIGHT, JA; DAVIE, JR				CHADEE, DN; TAYLOR, WR; HURTA, RAR; ALLIS, CD; WRIGHT, JA; DAVIE, JR			INCREASED PHOSPHORYLATION OF HISTONE H1 IN MOUSE FIBROBLASTS TRANSFORMED WITH ONCOGENES OR CONSTITUTIVELY ACTIVE MITOGEN-ACTIVATED PROTEIN-KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; CHROMOSOME CONDENSATION; METASTATIC PHENOTYPE; CHROMATIN STRUCTURE; GENE-EXPRESSION; CELLS; DNA; H-1; TRANSCRIPTION; ORGANIZATION	We compared the nucleosomal organization, histone H1 subtypes, and histone H1 phosphorylated isoforms of ras-transformed and parental 10T1/2 mouse fibroblasts. In agreement with previous studies, we found that ras-transformed mouse fibroblasts have a less condensed chromatin structure than normal fibroblasts. ras-transformed and parental 10T1/2 cells had similar amounts of H1 subtypes, proteins that have a key role in the compaction of chromatin. However, labeling studies with P-32 and Western blot experiments with an antiphosphorylated H1 antibody show that interphase ras-transformed cells have higher levels of phosphorylated H1 isoforms than parental cells. G(1)/S phase-arrested ras-transformed cells had higher amounts of phosphorylated H1 than G(1)/S phase-arrested parental cells. Mouse fibroblasts transformed with fes, mos, raf, myc, or constitutively active mitogen-activated protein (MAP) kinase kinase had increased levels of phosphorylated H1. These observations suggest that increased phosphorylation of H1 is one of the consequences of the persistent activation of the mitogen-activated protein kinase signal transduction pathway. Indirect immunofluorescent studies show that phosphorylated H1b is localized in centers of RNA splicing in the nucleus, suggesting that this modified H1 subtype is complexed totranscriptionally active chromatin.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244	University of Manitoba; University of Manitoba; Syracuse University				Davie, James/0000-0002-0420-6888	NIGMS NIH HHS [GM 40922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashihara T, 1979, Methods Enzymol, V58, P248; AUBERT D, 1991, J CELL BIOL, V113, P497, DOI 10.1083/jcb.113.3.497; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BASSIMHASSAN A, 1994, J CELL SCI, V107, P425; BELIKOV SV, 1993, NUCLEIC ACIDS RES, V21, P1031, DOI 10.1093/nar/21.4.1031; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BLOSMANIS R, 1987, CANCER RES, V47, P1273; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRENEMAN JW, 1993, EXP CELL RES, V206, P16, DOI 10.1006/excr.1993.1115; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DAVIE JR, 1991, BIOCHEM J, V280, P491, DOI 10.1042/bj2800491; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; DAVIE JR, 1987, CANCER RES, V47, P5407; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FILMUS J, 1994, ONCOGENE, V9, P3627; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GORKA C, 1993, EXP CELL RES, V205, P152, DOI 10.1006/excr.1993.1069; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAPLAN LJ, 1984, J BIOL CHEM, V259, P8777; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAITINEN J, 1995, J CELL BIOCHEM, V57, P1, DOI 10.1002/jcb.240570102; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1983, J BIOL CHEM, V258, P262; LENNOX RW, 1988, BIOCHEM CELL BIOL, V66, P636, DOI 10.1139/o88-073; LENNOX RW, 1988, HISTONE GENES GENE E, P375; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; LU MJ, 1994, CHROMOSOMA, V103, P111; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCCLARTY GA, 1990, J BIOL CHEM, V265, P7539; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NAGARAJA S, 1995, BBA-GENE STRUCT EXPR, V1260, P207, DOI 10.1016/0167-4781(94)00201-D; NEVINS JR, 1992, NATURE, V357, P375; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PARSEGHIAN MH, 1994, CHROMOSOMA, V103, P198, DOI 10.1007/BF00368013; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; Parseghian MH, 1993, CHROMOSOME RES, V1, P127, DOI 10.1007/BF00710036; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; TAN KB, 1982, J BIOL CHEM, V257, P5337; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028	70	96	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20098	20105		10.1074/jbc.270.34.20098	http://dx.doi.org/10.1074/jbc.270.34.20098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650028	hybrid			2022-12-27	WOS:A1995RQ99100064
J	GREGORI, L; FUCHS, C; FIGUEIREDOPEREIRA, ME; VANNOSTRAND, WE; GOLDGABER, D				GREGORI, L; FUCHS, C; FIGUEIREDOPEREIRA, ME; VANNOSTRAND, WE; GOLDGABER, D			AMYLOID BETA-PROTEIN INHIBITS UBIQUITIN-DEPENDENT PROTEIN-DEGRADATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; POLYACRYLAMIDE-GEL ELECTROPHORESIS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MULTIUBIQUITIN CHAIN; PRECURSOR PROTEIN; LYSOSOMAL SYSTEM; DOWNS-SYNDROME; TAU; COMPLEX	Intraneuronal accumulation of ubiquitin conjugates in inclusion bodies and neurofibrillary tangles is a pathological feature of neurodegenerative disorders such as Alzheimer's disease and Down's syndrome and of normal aging of the brain, Amyloid beta-protein (A beta) and its precursor are found in neurofibrillary tangle-containing neurons. A beta is the major component of extracellular plaques, We showed that A beta acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro. We examined the effect of A beta on the steps of this proteolytic pathway that contribute to the level of ubiquitin conjugates in the cell, Neither conjugate formation nor conjugate deubiquitination was affected by the presence of A beta. However, A beta significantly reduced the rate of conjugate degradation. Our results indicate that A beta interacts with the proteolytic step of the ubiquitin degradative pathway, Since this step is performed by the 26 S proteasome, the effect of A beta on the catalytic core of this proteolytic complex, the 20 S proteasome, was determined, We found that A beta selectively inhibits the chymotrypsin-like activity of the 20 S proteasome. Under pathological conditions in the affected neuron, A beta could interfere with ubiquitin-dependent degradation by inhibiting the 26 S proteasome activity, This finding may explain the origin of the accumulation of ubiquitin conjugates.	SUNY STONY BROOK,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NEW YORK,NY 11794; CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine	GREGORI, L (corresponding author), SUNY STONY BROOK,SCH MED,CTR HLTH SCI,DEPT PSYCHIAT & BEHAV SCI,T-10,STONY BROOK,NY 11794, USA.							BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BHASIN R, 1994, AMYLOID, V1, P221, DOI 10.3109/13506129409146113; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COLE GM, 1987, NEUROSCI LETT, V79, P207, DOI 10.1016/0304-3940(87)90698-7; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICE JF, 1982, J BIOL CHEM, V257, P4624; DICKSON DW, 1988, AM J PATHOL, V132, P86; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FIGUEIREDOPEREIRA, 1994, J NEUROCHEM, V63, P1578; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GREGORI L, 1994, BIOCHEM BIOPH RES CO, V203, P1731, DOI 10.1006/bbrc.1994.2386; GROPPER R, 1991, J BIOL CHEM, V266, P3602; GRUNDKEIQBAL I, 1989, P NATL ACAD SCI USA, V86, P2853, DOI 10.1073/pnas.86.8.2853; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1982, J BIOL CHEM, V258, P8206; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; LOWE J, 1990, NEUROPATHOL APPL NEU, V1, P281; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTIACE LA, 1991, J NEUROPATH EXP NEUR, V50, P547, DOI 10.1097/00005072-199109000-00003; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASH.M, 1993, NEURON, V10, P1151; MURPHY GM, 1994, AM J PATHOL, V144, P1082; NIXON RA, 1992, ANN NY ACAD SCI, V674, P65; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REFOLO LM, 1991, J NEUROSCI, V11, P3888; RIPELLINO JA, 1994, J NEUROSCI RES, V39, P211, DOI 10.1002/jnr.490390211; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHAW G, 1988, P NATL ACAD SCI USA, V85, P2854, DOI 10.1073/pnas.85.8.2854; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAMAGUCHI H, 1990, BRAIN RES, V537, P318, DOI 10.1016/0006-8993(90)90377-N	63	175	179	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19702	19708		10.1074/jbc.270.34.19702	http://dx.doi.org/10.1074/jbc.270.34.19702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649980	hybrid			2022-12-27	WOS:A1995RQ99100008
J	RAO, MJ; IYER, KS; ACHARYA, AS				RAO, MJ; IYER, KS; ACHARYA, AS			POLYMERIZATION OF HEMOGLOBIN-S - QUINARY INTERACTIONS OF GLU-43(BETA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; CARBOXYL GROUPS; FIBERS; REACTIVITY; SOLUBILITY	Hemoglobin S (HbS) Hoshida and three substituted forms of HbS Hoshida (the substituents being on the amide nitrogen of Gln-43(beta)) have been prepared by the amidation of Glu-43(beta) of HbS with ammonia, methylamine, glycine ethyl ester, and galactosamine. The O-2 affinity of HbS is increased slightly on amidation of Glu-43(beta). All the four amidated derivatives exhibited nearly the same oxygen affinity. On the other hand, the influence of amidation on the solubility exhibits some sensitivity to the chemical nature of the substituent on the Gln-43(beta). The solubility of HbS Hoshida (a case with no substitution on Gln-43(beta)), and the methyl-substituted derivatives are about 33 and 36% higher than that of HbS. The solubility of the HbS modified with the glycine ethyl ester or galactosamine is increased to 41 and 47%, respectively. The first derivative UV spectra of HbS Hoshida and its methyl derivative reflect very little perturbations in their alpha(1) beta(2) interface as compared with that of HbS, whereas the amidated derivatives with larger substituents on Gln-43(beta) reflected noticeable differences. Thus, the increase in the solubility and the oxygen affinity of HbS on the amidation of Glu-43(beta) is primarily a consequence of the loss of the negative charge at 43(beta), a residue proximal to the alpha 1 beta(2) interface. The copolymerization studies of amidated HbS with HbA and HbS with amidated HbA demonstrate that cis Glu-43(beta) is the ''active'' residue. This assignment is discrepant with the earlier implication of a trans configuration for this residue in the polymer (Edelstein, S. J. (1981) J. Mol. Biol. 150, 557-575). However, it is consistent with the solution studies of Nagel ct al. (Nagel, R. L., Bookchin, R. M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W. A., Honig, G. R., Schiliro, G., Crookstan, J. H., and Matsutomo, K. (1979) Proc. Not. Acad. Sci. U. S. A. 76, 670-672) and McCurdy ct al. (McCurdy, P. R., Lorkin, P. A., Casey, R., Lehmann, H., Uddin, D. E., and Dickson, L. G. (1974) Am. J. Med. 57, 665-760).	ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL38655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA AS, 1985, BIOCHEMISTRY-US, V24, P4885, DOI 10.1021/bi00339a024; ACHARYA AS, 1991, MOL CONFORMATION BIO, P269; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1977, NATURE, V269, P526, DOI 10.1038/269526a0; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BOOKCHIN RM, 1970, BIOCHIM BIOPHYS ACTA, V221, P373, DOI 10.1016/0005-2795(70)90279-5; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; BOWMAN BH, 1964, BLOOD, V23, P193, DOI 10.1182/blood.V23.2.193.193; CABURIMARTIN J, 1986, BIOCHIM BIOPHYS ACTA, V874, P82, DOI 10.1016/0167-4838(86)90105-6; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; EDELSTEIN SJ, 1981, J MOL BIOL, V150, P557, DOI 10.1016/0022-2836(81)90381-8; IUCHI I, 1978, HEMOGLOBIN, V2, P235, DOI 10.3109/03630267809007069; MCCURDY PR, 1974, AM J MED, V57, P665, DOI 10.1016/0002-9343(74)90021-7; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; Nagel R L, 1981, Methods Enzymol, V76, P760; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; RAO MJ, 1992, BIOCHEMISTRY-US, V31, P7231, DOI 10.1021/bi00147a004; RAO MJ, 1994, METHOD ENZYMOL, V231, P246; RAO MJ, 1991, J PROTEIN CHEM, V10, P129, DOI 10.1007/BF01024663; SEETHARAM R, 1983, J BIOL CHEM, V258, P4810; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	28	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19250	19255		10.1074/jbc.270.33.19250	http://dx.doi.org/10.1074/jbc.270.33.19250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642597	hybrid			2022-12-27	WOS:A1995RP70300011
J	SCHOONJANS, K; WATANABE, M; SUZUKI, H; MAHFOUDI, A; KREY, G; WAHLI, W; GRIMALDI, P; STAELS, B; YAMAMOTO, T; AUWERX, J				SCHOONJANS, K; WATANABE, M; SUZUKI, H; MAHFOUDI, A; KREY, G; WAHLI, W; GRIMALDI, P; STAELS, B; YAMAMOTO, T; AUWERX, J			INDUCTION OF THE ACYL-COENZYME-A SYNTHETASE GENE BY FIBRATES AND FATTY-ACIDS IS MEDIATED BY A PEROXISOME PROLIFERATOR RESPONSE ELEMENT IN THE C-PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; BETA-OXIDATION PATHWAY; ENOYL-COA HYDRATASE; ACTIVATED RECEPTOR; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; RAT-LIVER; 3-HYDROXYACYL-COA DEHYDROGENASE; LIPOPROTEIN-LIPASE; CLOFIBRIC ACID	The long-chain acyl coenzyme A synthetase (ACS) gene gives rise to three transcripts containing different first exons preceded by specific regulatory regions A, B, and C. Exon-specific oligonucleotide hybridization indicated that only A-ACS mRNA is expressed in rat liver. Fibrate administration induced liver C-ACS strongly and A-ACS mRNA to a lesser extent. B-ACS mRNA remained undetectable. In primary rat hepatocytes and Fa-32 hepatoma cells C-ACS mRNA increased after treatment with fenofibric acid, alpha-bromopalmitate, tetradecylthioacetic acid, or alpha-linolenic acid. Nuclear run-on experiments indicated that fenofibric acid and alpha-bromopalmitate act at the transcriptional level. Transient transfections showed a 3.4-, 2.3-, and 2.2-fold induction of C-ACS promoter activity after fenofibric acid, alpha-bromopalmitate, and tetradecylthioacetic acid, respectively. Unilateral deletion and site-directed mutagenesis identified a peroxisome proliferator activator receptor (PPAR)-responsive element (PPRE) mediating the responsiveness to fibrates and fatty acids. This ACS PPRE contains three imperfect half sites spaced by 1 and 3 oligonucleotides and binds PPAR retinoid X receptor heterodimers in gel retardation assays. In conclusion, the regulation of C-ACS mRNA expression by fibrates and fatty acids is mediated by PPAR retinoid X receptor heterodimers interacting through a PPRE in the C-ACS promoter. PPAR therefore occupies a key position in the transcriptional control of a pivotal enzyme controlling the channeling of fatty acids into various metabolic pathways.	INST PASTEUR,BIOL REGULAT EUCARYOTES LAB,F-59019 LILLE,FRANCE; TOHOKU UNIV,GENE RES CTR,SENDAI,MIYAGI 981,JAPAN; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; CTR BIOCHIM,BIOL DEV TISSU ADIPEUX LAB,CNRS,UNITE MIXTE RECH 134,F-06108 NICE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Tohoku University; University of Lausanne; Centre National de la Recherche Scientifique (CNRS)			Wahli, Walter/I-3194-2019; Staels, Bart/N-9497-2016; Auwerx, Johan/ABE-9307-2021; Wahli, Walter/B-1398-2009	Staels, Bart/0000-0002-3784-1503; Wahli, Walter/0000-0002-5966-9089; Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393				ALVARES K, 1994, CANCER RES, V54, P2303; APERLO C, 1995, IN PRESS GEN AMST; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CHATTERJEE B, 1987, EUR J BIOCHEM, V166, P273, DOI 10.1111/j.1432-1033.1987.tb13511.x; CHATTERJEE B, 1983, BIOCHEM J, V214, P879, DOI 10.1042/bj2140879; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Groot P H, 1976, Adv Lipid Res, V14, P75; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MCQUAID S, 1987, CANCER LETT, V37, P115, DOI 10.1016/0304-3835(87)90152-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; OSUMI T, 1984, J BIOL CHEM, V259, P2031; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SANGER TD, 1981, P NATL ACAD SCI USA, V78, P243; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVOBODA DJ, 1966, J CELL BIOL, V30, P442, DOI 10.1083/jcb.30.2.442; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WU PF, 1993, BIOCHIM BIOPHYS ACTA, V1170, P118, DOI 10.1016/0005-2760(93)90060-M; YAMAMOTO T, 1990, PROG OBESITY RES, P219; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	62	332	344	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19269	19276		10.1074/jbc.270.33.19269	http://dx.doi.org/10.1074/jbc.270.33.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642600	hybrid			2022-12-27	WOS:A1995RP70300014
J	TOTH, I; BRIDGES, KR				TOTH, I; BRIDGES, KR			ASCORBIC-ACID ENHANCES FERRITIN MESSENGER-RNA TRANSLATION BY AN IRP/ACONITASE SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; FE-S CLUSTER; RNA-BINDING; MESSENGER-RNA; ESCHERICHIA-COLI; PROTEIN; METABOLISM; ACONITASE; ANTIOXIDANT	Replenishment of ascorbate in cultured cells, which are almost uniformly vitamin-deficient, increases ferritin mRNA translation in response to iron by 20-fold (Toth, I., Rogers, J. T., McPhee, J. A., Elliott, S, M., Abramson, S. L., and Bridges, K. R. (1995) J. Biol, Chem. 270, 2846-2852). We now demonstrate that ascorbate increases cytosolic aconitase activity. The iron-responsive element-binding protein (IRP-1) exists in three states: bound to mRNA without aconitase activity, free in the cytosol without aconitase activity, and free in the cytosol with aconitase activity. Ascorbate converts free IRP-1 to the enzymatically active form. Enhanced ferritin synthesis with subsequent iron stimulation is due to the altered equilibrium of the free IRP-1. The cellular biology of iron is closely intertwined with that of ascorbate.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45794] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BRIDGES KR, 1986, J BIOL CHEM, V261, P14273; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOFFMAN KE, 1991, AM J CLIN NUTR, V54, pS1188, DOI 10.1093/ajcn/54.6.1188s; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LIPSCHITZ DA, 1971, BRIT J HAEMATOL, V20, P155, DOI 10.1111/j.1365-2141.1971.tb07024.x; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Moser U., 1991, HDB VITAMINS, P195; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TANG CK, 1992, J BIOL CHEM, V267, P24466; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	36	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19540	19544		10.1074/jbc.270.33.19540	http://dx.doi.org/10.1074/jbc.270.33.19540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642638	hybrid			2022-12-27	WOS:A1995RP70300054
J	WAGGONER, DW; MARTIN, A; DEWALD, J; GOMEZMUNOZ, A; BRINDLEY, DN				WAGGONER, DW; MARTIN, A; DEWALD, J; GOMEZMUNOZ, A; BRINDLEY, DN			PURIFICATION AND CHARACTERIZATION OF A NOVEL PLASMA-MEMBRANE PHOSPHATIDATE PHOSPHOHYDROLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; HUMAN NEUTROPHILS; 2ND MESSENGER; NADPH OXIDASE	An N-ethylmaleimide-insensitive phosphatidate phosphohydrolase, which also hydrolyzes lysophosphatidate, was isolated from the plasma membranes of rat liver. The specific activity of an anionic form of the enzyme (53 kDa, pI < 4) was increased 2700-fold, A cationic form of the enzyme (51 kDa, pI = 9) was purified to homogeneity, but the fold purification was low because the activity of the highly purified enzyme was unstable. Immunoprecipitating antibodies raised against the homogeneous protein confirmed the identity of the cationic protein as the phosphohydrolase and were used to identify the anionic enzyme, Both forms are integral membrane glycoproteins that were converted to 28-kDa proteins upon treatment with N-glycanase F. Treatment of the anionic form with neuraminidase allowed it to be purified in the same manner as the cationic enzyme and yielded an immunoreactive protein with a molecular mass identical to the cationic protein, Thus, the two ionic forms most likely represent different sialated states of the protein. An immunoreactive 51-53-kDa protein was detected in rat liver, heart, kidney, skeletal muscle, testis, and brain. Little immunoreactive 51-53-kDa protein was detected in rat thymus, spleen, adipose, or lung tissue. This work provides the tools for determining the regulation and function of the phosphatidate phosphohydrolase in signal transduction and cell activation.	UNIV ALBERTA, SIGNAL TRANSDUCT LAB, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AKASAKI K, 1990, CHEM PHARM BULL, V38, P2766, DOI 10.1248/cpb.38.2766; AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CALLAGHAN JM, 1992, BIOCHEM J, V283, P63, DOI 10.1042/bj2830063; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; COLEMAN R, 1967, BIOCHIM BIOPHYS ACTA, V135, P573, DOI 10.1016/0005-2736(67)90089-2; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; DAY CP, 1993, CLIN SCI, V85, P281, DOI 10.1042/cs0850281; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FLEMING LN, 1995, BIOCHIM BIOPHYS ACTA, V1254, P161; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GODING JW, 1986, MONOCLONAL ANTIBODIE, P281; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAMES BD, 1990, GEL ELECTROPHORESIS, P136; Harlow E. L, 1988, ANTIBODIES LABORATOR, P100; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JAMAL Z, 1992, INT J OBESITY, V16, P789; JAMDAR SC, 1994, BIOCHEM J, V301, P793, DOI 10.1042/bj3010793; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; KAWAMURA S, 1991, JPN J CANCER RES, V82, P758, DOI 10.1111/j.1349-7006.1991.tb02699.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1994, EUR J BIOCHEM, V220, P919, DOI 10.1111/j.1432-1033.1994.tb18695.x; LIN YP, 1989, J BIOL CHEM, V264, P8641; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MITSUYAMA T, 1993, FEBS LETT, V328, P67, DOI 10.1016/0014-5793(93)80967-Y; MOEHREN G, 1994, J BIOL CHEM, V269, P838; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PERRY DK, 1993, J BIOL CHEM, V268, P25302; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; SWARTS HGP, 1992, BIOCHIM BIOPHYS ACTA, V1107, P143, DOI 10.1016/0005-2736(92)90340-R; TAYLOR GS, 1993, BIOCHIM BIOPHYS ACTA, V1175, P219, DOI 10.1016/0167-4889(93)90026-L; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VERMEULEN PS, 1994, THESIS U UTRECHT HOL; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P21309	76	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19422	19429		10.1074/jbc.270.33.19422	http://dx.doi.org/10.1074/jbc.270.33.19422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642624	hybrid			2022-12-27	WOS:A1995RP70300038
J	CARMAN, GM; DEEMS, RA; DENNIS, EA				CARMAN, GM; DEEMS, RA; DENNIS, EA			LIPID SIGNALING ENZYMES AND SURFACE DILUTION KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE-C; MIXED MICELLAR ANALYSIS; MEMBRANE-BOUND ENZYME; ESCHERICHIA-COLI; TRITON X-100; SN-1,2-DIACYLGLYCEROL KINASE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4-KINASE; PHOSPHATIDYLSERINE SYNTHASE; PHOSPHATIDATE PHOSPHATASE		REVELLE COLL,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903	University of California System; University of California San Diego; Rutgers State University New Brunswick			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140, R01GM035655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35655, GM-28140, GM-20501] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BELL RM, 1991, J BIOL CHEM, V266, P4661; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS E A, 1974, Journal of Supramolecular Structure, V2, P682, DOI 10.1002/jss.400020513; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; DENNIS EA, 1974, ARCH BIOCHEM BIOPHYS, V165, P764, DOI 10.1016/0003-9861(74)90305-1; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; JONES GA, 1993, J BIOL CHEM, V268, P20845; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1990, J BIOL CHEM, V265, P166; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NICKELS JTJ, 1994, J BIOL CHEM, V268, P11018; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; ROBSON RJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P513, DOI 10.1016/0005-2736(78)90096-2; ROBSON RJ, 1977, J PHYS CHEM-US, V81, P1075, DOI 10.1021/j100526a010; ROBSON RJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P489, DOI 10.1016/0005-2760(79)90223-6; SANDERMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P235, DOI 10.1016/0005-2736(91)90130-Z; Segel I.H., 1975, ENZYME KINETICS; SUNDLER R, 1978, J BIOL CHEM, V253, P4175; TANFORD C, 1980, HYDROPHOBIC EFFECT; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1990, J BIOL CHEM, V265, P4374; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WARNER TG, 1975, J BIOL CHEM, V250, P8004; WISSING JB, 1994, PLANT PHYSIOL, V105, P903, DOI 10.1104/pp.105.3.903; WU WI, 1993, J BIOL CHEM, V268, P13830; YU L, 1992, J AM CHEM SOC, V114, P8757, DOI 10.1021/ja00049a001; Yu Lin, 1992, Bioorganic and Medicinal Chemistry Letters, V2, P1343	52	261	266	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18711	18714		10.1074/jbc.270.32.18711	http://dx.doi.org/10.1074/jbc.270.32.18711			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642515	Green Submitted, hybrid			2022-12-27	WOS:A1995RN95400001
J	CHEN, SG; TEPLOW, DB; PARCHI, P; TELLER, JK; GAMBETTI, P; AUTILIOGAMBETTI, L				CHEN, SG; TEPLOW, DB; PARCHI, P; TELLER, JK; GAMBETTI, P; AUTILIOGAMBETTI, L			TRUNCATED FORMS OF THE HUMAN PRION PROTEIN IN NORMAL BRAIN AND IN PRION DISEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOINOSITOL PHOSPHOLIPID ANCHOR; SCRAPIE-ASSOCIATED FORM; MOLECULAR-CLONING; CULTURED-CELLS; AGENT PROTEIN; HAMSTER BRAIN; PRP 27-30; MOUSE; CONVERSION; ACID	The cellular form of the prion protein (PrPc) is a glycoprotein anchored to the cell membrane by a glycosylphosphatidylinositol moiety. An aberrant form of PrPc that is partially resistant to proteases, PrPres, is a hallmark of prion diseases, which in humans include Creutzfeldt Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia. We have characterized the major forms of PrP in normal and pathological human brains. A COOH-terminal fragment of PrPc, designated C1, is abundant in normal and CJD brains as well as in human neuroblastoma cells. Sequence analysis revealed that C1 contains alternative NH2 termini starting at His-111 or Met-112. Like PrPc, C1 is glycosylated, anchored to the cell membrane, and is heat stable. Consistent with the lack of the NH2-terminal region of PrPc, C1 is more acidic than PrPc and does not bind heparin. An additional fragment longer than C1, designated C2, is present in substantial amounts in CJD brains. Like PrPres, C2 is resistant to proteases and is detergent-insoluble. Our data indicate that C1 is a major product of normal PrPc metabolism, generated by a cleavage that disrupts the neurotoxic and amyloidogenic region of PrP comprising residues 106-126. This region remains intact in C2, suggesting a role for C2 in prion diseases.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; HARVARD UNIV,SCH MED,DEPT NEUROL NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115	Case Western Reserve University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Parchi, Piero/L-9833-2015; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021; Chen, Shu/Z-2943-2019	Parchi, Piero/0000-0002-9444-9524; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; 	NATIONAL INSTITUTE ON AGING [R35AG008992, R37AG008155] Funding Source: NIH RePORTER; NIA NIH HHS [AG08155, AG08992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BULER H, 1992, NATURE, V356, P577; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P634; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DEEG MA, 1992, J BIOL CHEM, V267, P18573; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HOPE J, 1994, BIOCHEM SOC T, V22, P159, DOI 10.1042/bst0220159; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARINI F, 1991, MOL BRAIN RES, V10, P343, DOI 10.1016/0169-328X(91)90093-D; LIAO YCJ, 1986, SCIENCE, V233, P364, DOI 10.1126/science.3014653; MANSON J, 1992, DEVELOPMENT, V115, P117; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAURY CPJ, 1995, LAB INVEST, V72, P4; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; PUCKETT C, 1991, AM J HUM GENET, V49, P320; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHINAGAWA M, 1986, J GEN VIROL, V67, P1745, DOI 10.1099/0022-1317-67-8-1745; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WION D, 1988, INT J DEV NEUROSC, V64, P387	60	438	447	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19173	19180		10.1074/jbc.270.32.19173	http://dx.doi.org/10.1074/jbc.270.32.19173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642585	hybrid			2022-12-27	WOS:A1995RN95400073
J	LEVINGER, L; VASISHT, V; GREENE, V; BOURNE, R; BIRK, A; KOLLA, S				LEVINGER, L; VASISHT, V; GREENE, V; BOURNE, R; BIRK, A; KOLLA, S			SEQUENCE AND STRUCTURE REQUIREMENTS FOR DROSOPHILA TRANSFER-RNA 5'-END AND 3'-END PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; XENOPUS-LAEVIS; ENDONUCLEOLYTIC CLEAVAGE; RIBONUCLEASE-P; RIBOSOMAL-RNA; 3' END; COMPONENT; TRANSCRIPTION; POLYMERASE; SELECTION	Eukaryotic tRNAs are processed at their 5'- and 3'-ends by the endonucleases RNase P and 3'-tRNase, respectively, We have prepared substrates for both enzymes, separated the activities from a Drosophila extract, and designed variant tRNAs to assess the effects of sequence and structure on processing. Mutations affect these reactions in similar ways; thus, RNase P and 3'-tRNase probably require similar substrate structures to maintain the catalytic fit. RNase P is more sensitive to substrate substitutions than 3'-tRNase. In three of the four stems, one substitution prevents both processing reactions while the opposite one has less effect; anticodon stem substitutions hardly affect processing, and double substitutions intended to restore base pairing also restore processing to the wild type rate. Structure probing suggests that tRNA misfolding sometimes coincides with reduced processing. In other cases, processing inhibition probably results from specific unfavorable stem appositions leading to local helix deformation. A single T loop substitution disrupts the tertiary D-T loop interaction and reduces processing. We have thus begun mapping tRNA processing determinants on the global, local, and tertiary structure levels.			LEVINGER, L (corresponding author), CUNY YORK COLL,DEPT NAT SCI BIOL,JAMAICA,NY 11451, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM008498, S06GM008153] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15 GM04603, S06 GM08153, T34 GM08498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; Bjork Glenn R., 1995, P165; BRUNEL C, 1990, J MOL BIOL, V215, P103, DOI 10.1016/S0022-2836(05)80099-3; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CIESIOLKA J, 1994, EUR J BIOCHEM, V219, P49, DOI 10.1111/j.1432-1033.1994.tb19913.x; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; Deutscher Murray P., 1995, P51; DICHTL B, 1993, NUCLEIC ACIDS RES, V21, P531, DOI 10.1093/nar/21.3.531; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3908; Dirheimer G., 1995, P93; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARDT WD, 1993, BIOCHEMISTRY-US, V32, P13046, DOI 10.1021/bi00211a014; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; McClain William H., 1995, P335; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Westaway Shawn K., 1995, P79; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZENNARO E, 1989, NUCLEIC ACIDS RES, V17, P5741	33	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18903	18909		10.1074/jbc.270.32.18903	http://dx.doi.org/10.1074/jbc.270.32.18903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642547	hybrid			2022-12-27	WOS:A1995RN95400034
J	YAN, BF; YANG, DF; BULLOCK, P; PARKINSON, A				YAN, BF; YANG, DF; BULLOCK, P; PARKINSON, A			RAT SERUM CARBOXYLESTERASE - CLONING, EXPRESSION, REGULATION, AND EVIDENCE OF SECRETION FROM LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MICROSOMAL CYTOCHROME-P-450; NUCLEOTIDE-SEQUENCE; BETA-GLUCURONIDASE; RETENTION SIGNAL; HDEL RECEPTOR; PROTEIN; CDNA; MOUSE; CELLS	Multiple forms of carboxylesterase have been identified in rat liver, and five carboxylesterases (designated hydrolases A, B, C, S, and egasyn) have been cloned, Hydrolases A, B, C and egasyn all have a C-terminal consensus sequence (HXEL) for retaining proteins in the endoplasmic reticulum, and these carboxylesterases are found in rat liver microsomes, In contrast, hydrolase S lacks this C-terminal consensus sequence and is presumed to be secreted. In order to test this hypothesis, a polyclonal antibody was raised against recombinant hydrolase S from cDNA-directed expression in Escherichia coli. In addition to hydrolases A, B, and C (57-59 kDa), this antibody recognized a 67-kDa protein in rat liver microsomes and a 71-kDa protein in rat serum, The 71-kDa protein detected in rat serum was also detected in the extracellular medium from primary cultures of rat hepatocytes. Non-denaturing gel electrophoresis with staining for esterase activity showed that a serum carboxylesterase comigrated with the 71-kDa protein. Immunoprecipitation of the 71-kDa enzyme from rat serum decreased esterase activity toward 1-naphthylacetate and para-nitrophenylacetate. The 71-kDa protein immunoprecipitated from rat serum had an N-terminal amino acid sequence identical to that predicted from the cDNA encoding hydrolase S, providing further evidence that hydrolase S is synthesized in and secreted by the liver. The levels of the 67-kDa protein in rat liver microsomes and the levels of the 71-kDa protein in rat serum were co-regulated. Deglycosylation of microsomes and serum converted the 67- and 71-kDa proteins to a 58-kDa peptide, which matches the molecular mass calculated from the cDNA for hydrolase S. These results suggest that the 67-kDa protein in liver microsomes is a precursor form of hydrolase S that undergoes further glycosylation before being secreted into serum. In rats, liver appears to be the only source of hydrolase S because no mRNA encoding hydrolase S could be detected in several extrahepatic tissues. Serum carboxylesterases have been found to play an important role in lipid metabolism and detoxication of organophosphates, therefore, the secretion of hydrolase S and the modulation of its expression by xenobiotics may have physiological as well as toxicological significance.	UNIV KANSAS, MED CTR, CTR ENVIRONM & OCCUPAT HLTH, DEPT PHARMACOL TOXICOL & THERAPEUT, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NIEHS NIH HHS [ES 04996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDER S, 1989, METHOD ENZYMOL, V179, P505; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; ARLOTTO MP, 1987, BIOCHEM PHARMACOL, V36, P3859, DOI 10.1016/0006-2952(87)90450-3; BERNAL DL, 1992, INT J VITAM NUTR RES, V62, P186; BOYER CS, 1992, J PHARMACOL EXP THER, V260, P939; HALBAN PA, 1994, BIOCHEM J, V299, P1; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; KADNER SS, 1992, ARCH BIOCHEM BIOPHYS, V296, P435, DOI 10.1016/0003-9861(92)90594-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINWEBER FJ, 1987, DRUG METAB REV, V18, P379, DOI 10.3109/03602538708994129; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LU AYH, 1972, BIOCHEM BIOPH RES CO, V46, P1334, DOI 10.1016/S0006-291X(72)80121-9; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; MEDDA S, 1986, BIOCHEM GENET, V24, P229, DOI 10.1007/BF00502791; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MENTLEIN R, 1986, J BIOL CHEM, V261, P7816; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P495, DOI 10.1006/abbi.1994.1531; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P513, DOI 10.1006/abbi.1994.1532; MURAKAMI K, 1993, J BIOCHEM-TOKYO, V113, P61, DOI 10.1093/oxfordjournals.jbchem.a124004; NAKAMURA M, 1993, OPHTHALMIC RES, V25, P46, DOI 10.1159/000267220; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; ROBBI M, 1987, BIOCHEM J, V248, P545, DOI 10.1042/bj2480545; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; ROBBI M, 1994, BIOCHEM BIOPH RES CO, V203, P1404, DOI 10.1006/bbrc.1994.2341; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SEGLEN PO, 1983, METHOD CELL BIOL, V29, P1767; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; SONDERFAN AJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P208, DOI 10.1016/0003-9861(88)90386-4; SULTATOS LG, 1986, TOXICOL APPL PHARM, V86, P105, DOI 10.1016/0041-008X(86)90403-5; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TSUJITA T, 1990, PROG CLIN BIOL RES, V334, P915; VERONESI B, 1993, TOXICOL APPL PHARM, V120, P240, DOI 10.1006/taap.1993.1108; WATSON AM, 1994, TOXICOL LETT, V71, P217, DOI 10.1016/0378-4274(94)90108-2; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WILSON DW, 1993, J BIOL CHEM, V268, P7465; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V317, P222, DOI 10.1006/abbi.1995.1157; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V316, P899, DOI 10.1006/abbi.1995.1121; YAN BF, 1994, J BIOL CHEM, V269, P29688; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	49	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19128	19134		10.1074/jbc.270.32.19128	http://dx.doi.org/10.1074/jbc.270.32.19128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642579	hybrid			2022-12-27	WOS:A1995RN95400067
J	LU, XY; XU, L; MEISSNER, G				LU, XY; XU, L; MEISSNER, G			PHOSPHORYLATION OF DIHYDROPYRIDINE RECEPTOR II-III LOOP PEPTIDE REGULATES SKELETAL-MUSCLE CALCIUM-RELEASE CHANNEL FUNCTION - EVIDENCE FOR AN ESSENTIAL ROLE OF THE BETA-OH GROUP OF SER(687)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SARCOPLASMIC-RETICULUM; ADENINE-NUCLEOTIDE; BLOCKERS; CA-2+; ACTIVATION; CALMODULIN; SUBUNITS; MG-2+; SITE	In vertebrate skeletal muscle, excitation-contraction coupling may occur by a mechanical coupling mechanism involving protein-protein interactions between the dihydropyridine receptor (DHPR) of the transverse tubule membrane and the ryanodine receptor (RYR)/Ca2+ release channel of the sarcoplasmic reticulum membrane. We have previously shown that the cytoplasmic II-III loop peptides of the skeletal and cardiac muscle DHPR alpha 1 subunits (SDCL and CDCL, respectively) activate the skeletal muscle RYR. We now report that cyclic AMP dependent protein kinase mediated phosphorylation of Ser(687) of SDCL yields a peptide that fails to activate the RYR, as determined in [H-3]ryanodine binding and single channel measurements. The phosphorylated SDCL bound to the skeletal muscle but not cardiac muscle RYR, and the binding could be displaced by the unphosphorylated SDCL. A mutant SDCL with a Ser687 --> Ala substitution failed to activate the RYR, but was still able to bind. Similarly, a Ser(813) --> Ala substitution in CDCL yielded a peptide that failed to activate the skeletal RYR. Use of three smaller overlapping peptides within the SDCL region identified an amino acid region from 666 to 726 including Ser687, which bound to and activated the skeletal muscle RYR. These results suggest that cyclic AMP-dependent protein kinase-mediated phosphorylation of the DHPR cu, subunit may play a role in the functional interaction of the DHPR and RYR in skeletal muscle.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1994, AM J PHYSIOL, V266, pC462, DOI 10.1152/ajpcell.1994.266.2.C462; BRANDT NR, 1992, FEBS LETT, V299, P57, DOI 10.1016/0014-5793(92)80100-U; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FRANZINIARMSTRO.C, 1994, ANNU REV PHYSIOL, V56, P509; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEE HB, 1994, J BIOL CHEM, V269, P13305; LU XY, 1994, J BIOL CHEM, V269, P6511; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MUNDINAWEILENMA.C, 1991, BIOPHYS J, V60, P902; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467	25	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18459	18464		10.1074/jbc.270.31.18459	http://dx.doi.org/10.1074/jbc.270.31.18459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629172	hybrid			2022-12-27	WOS:A1995RM64200049
J	MUSIAL, A; MANDAL, A; CORONEOS, E; KESTER, M				MUSIAL, A; MANDAL, A; CORONEOS, E; KESTER, M			INTERLEUKIN-1 AND ENDOTHELIN STIMULATE DISTINCT SPECIES OF DIGLYCERIDES THAT DIFFERENTIALLY REGULATE PROTEIN-KINASE-C IN MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FIBROBLAST GROWTH-FACTOR; INOSITOL LIPID TURNOVER; PHOSPHOLIPASE-D; DIACYLGLYCEROL PRODUCTION; PHOSPHATIDYLCHOLINE HYDROLYSIS; CULTURED FIBROBLASTS; SIGNAL TRANSDUCTION; LINKED DIGLYCERIDES; NEUROBLASTOMA-CELLS	Diglycerides are phospholipid-derived second messengers that serve as cofactors for protein kinase C activation. We have previously shown that, in rat glomerular mesangial cells, the cytokine, interleulrin-1 alpha, and the vasoactive peptide, endothelin, generate diglycerides from unique phospholipid precursors. However, neither the molecular species of these diglycerides nor their biological actions were determined. It is now hypothesized that interleukin-1- and endothelin-treated mesangial cells form distinct molecular species of diglycerides which may serve different roles as intracellular signaling molecules. Diglyceride molecular species were resolved and quantified by TLC and high performance liquid chromatography as diglyceride-[C-14]acetate derivatives. Endothelin stimulates predominantly ester linked species (diacylglycerols) in contrast to interleukin-1 which stimulates only ether-linked species (alkyl, acyl- and alkenyl,acylglycerols). In support of these data, interleukin-1-treated mesangial cells hydrolyze ethanolamine plasmalogens, vinyl ether-linked phospholipids. It has been reported that ether-linked, in contrast to ether-linked, diglyceride species do not activate protein kinase C activity. Thus, we next assessed membrane protein kinase C activity in endothelin- or interleukin-1-treated mesangial cells. Even though interleukin-1 has no effect upon basal protein kinase C activity, this cytokine, through the formation of ether-linked diglyceride second messengers, inhibits endothelin, platelet-activating factor, or arginine vasopressin-stimulated protein kinase C activity. We further demonstrate that ether-linked diacylglycerols but not alkyl,acyl- or alkenyl,acylglycerols substitute for phorbol esters in a cell-free protein kinase C assay, In addition, alkenyl,acylglycerols inhibit diacylglycerol-stimulated immunoprecipitated protein kinase C alpha activity in vitro and total protein kinase C activity in permeabilized mesangial cells ex vivo. Taken together, these data suggest that interleukin-1-induced formation of ether-linked diglycerides may physiologically serve to down-regulate receptor-mediated protein kinase C activity and that individual molecular species of diglycerides may serve different roles as intracellular signaling molecules.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NIAMS NIH HHS [AR40225] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040225] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARTHUR G, 1985, BIOCHIM BIOPHYS ACTA, V833, P189, DOI 10.1016/0005-2760(85)90189-4; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BEASLEY D, 1990, AM J PHYSIOL, V259, pR38, DOI 10.1152/ajpregu.1990.259.1.R38; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P9069; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CARLSON RO, 1993, EXP CELL RES, V207, P340, DOI 10.1006/excr.1993.1201; CHAUDHORY GG, 1993, AM J PHYSIOL, V265, pF634; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; CORONEOS E, 1995, IN PRESS J BIOL CHEM; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; ENG LF, 1968, LIPIDS, V3, P157, DOI 10.1007/BF02531734; FORD DA, 1989, J BIOL CHEM, V264, P13818; GALLELA G, 1992, BIOCHEM PHARMACOL, V44, P715; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GARCIA JGN, 1992, J LAB CLIN MED, V120, P929; GRIENDLING KK, 1989, J BIOL CHEM, V264, P8237; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P5339; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSE C, 1990, CELL SIGNAL, V2, P187, DOI 10.1016/0898-6568(90)90022-3; HULKOWER KI, 1992, EUR J BIOCHEM, V209, P81, DOI 10.1111/j.1432-1033.1992.tb17263.x; HUWILER A, 1993, EXP NEPHROL, V1, P19; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; JURKOWITZALEXAN.M, 1989, BIOCHIM BIOPHYS ACTA, V1002, P203; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KESTER M, 1994, J BIOL CHEM, V269, P22574; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEE TS, 1989, BIOCHEM BIOPH RES CO, V162, P381, DOI 10.1016/0006-291X(89)92008-1; LELI U, 1993, J NEUROCHEM, V60, P289, DOI 10.1111/j.1471-4159.1993.tb05850.x; LELI U, 1989, MOL PHARMACOL, V37, P286; LIGANGE M, 1992, BIOCHEM J, V283, P781; LIN PY, 1992, BIOCHEM J, V287, P325, DOI 10.1042/bj2870325; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MAHONEY CW, 1993, FASEB J, V7, pA1118; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NANBERG E, 1990, J CELL PHYSIOL, V143, P232, DOI 10.1002/jcp.1041430206; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; RAPPORT MM, 1955, J BIOL CHEM, V217, P199; RIDER LG, 1988, J IMMUNOL, V140, P200; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SEDOR JR, 1992, KIDNEY INT, V41, P595, DOI 10.1038/ki.1992.89; SHIBATA M, 1990, AM J PHYSIOL, V259, pH1486, DOI 10.1152/ajpheart.1990.259.5.H1486; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIMONSON MS, 1991, ADV NEPHROL, V21, P155; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; STEVENSON FT, 1993, J AM SOC NEPHROL, V4, pA636; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; THOMAS CP, 1991, AM J PHYSIOL, V260, pF347, DOI 10.1152/ajprenal.1991.260.3.F347; THOMAS TP, 1992, ENDOCRINOLOGY, V131, P1985, DOI 10.1210/en.131.4.1985; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; WRIGHT TM, 1988, P NATL ACAD SCI USA, V85, P1869, DOI 10.1073/pnas.85.6.1869; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	76	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21632	21638		10.1074/jbc.270.37.21632	http://dx.doi.org/10.1074/jbc.270.37.21632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665577	hybrid			2022-12-27	WOS:A1995RU75700034
J	MLINAR, B; BIAGI, BA; ENYEART, JJ				MLINAR, B; BIAGI, BA; ENYEART, JJ			LOSARTAN-SENSITIVE AII RECEPTORS LINKED TO DEPOLARIZATION-DEPENDENT CORTISOL SECRETION THROUGH A NOVEL SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; GATED TRANSIENT CURRENTS; ANGIOTENSIN-II; FASCICULATA CELLS; ARACHIDONIC-ACID; CALCIUM CHANNELS; K+ CURRENT; RAT; STIMULATION; INHIBITION	In bovine adrenal zona fasciculata (AZF) cells, angiotensin II (AII) may stimulate depolarization-dependent Ca2+ entry and cortisol secretion through inhibition of a novel potassium channel (I-AC), which appears to set the resting potential of these cells, Aspects of the signaling pathway, which couples AII receptors to membrane depolarization and secretion, were characterized in patch clamp and membrane potential recordings and in secretion studies. AII mediated inhibition of I-AC, membrane depolarization, and cortisol secretion were all blocked by the AII type I (AT(1)) receptor antagonist losartan, These responses were unaffected by the AT(2) antagonist PD123319, Inhibition of I-AC by AII was prevented by intracellular application of guanosine 5'-O-2-(thio)diphosphate but was not affected by pre-incubation of cells with pertussis toxin, Although mediated through an AT(1) receptor, several lines of evidence indicated that AII inhibition of I-AC occurred through an unusual phospholipase C (PLC)-independent pathway. Acetylcholine, which activates PLC in AZF cells, did not inhibit I-AC. Neither the PLC antagonist neomycin nor PLC-generated second messengers prevented I-AC expression or mimicked the inhibition of this current by AII, I-AC expression and inhibition by AII were insensitive to variations in intracellular or extracellular Ca2+ concentration. AII-mediated inhibition of I-AC was markedly reduced by the non-hydrolyzable ATP analog adenosine 5'-(beta,gamma-imino)triphosphate and by the non-selective protein kinase inhibitor staurosporine. The protein phosphatase antagonist okadaic acid reversibly inhibited I-AC in whole cell recordings, These findings indicate that AII-stimulated effects on I-AC current, membrane voltage, and cortisol secretion are linked through a common AT(1) receptor, Inhibition of I-AC in AZF cells appears to occur through a novel signaling pathway, which may include a losartan-sensitive AT(1) receptor coupled through a pertussis-insensitive G protein to a staurosporine-sensitive protein kinase, Apparently, the mechanism linking AT(1) receptors to I-AC inhibition and Ca2+ influx in adrenocortical cells is separate from that involving inositol trisphosphate-stimulated Ca2+ release from intracellular stores, AII-stimulated cortisol secretion may occur through distinct parallel signaling pathways.	OHIO STATE UNIV, COLL MED, DEPT PHARMACOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, DEPT PHYSIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, NEUROSCI PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Mlinar, Boris/A-7034-2008	Mlinar, Boris/0000-0001-9082-0827	NIDDK NIH HHS [DK-40131] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BREGESTOVSKI P, 1986, NATURE, V319, P776, DOI 10.1038/319776a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; GOSPODAROWICZ D, 1977, ENDOCRINOLOGY, V100, P1080; HADJIAN AJ, 1984, BIOCHIM BIOPHYS ACTA, V804, P427, DOI 10.1016/0167-4889(84)90070-3; HADJIAN AJ, 1982, BIOCHIM BIOPHYS ACTA, V714, P157; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P1260, DOI 10.1006/bbrc.1993.1552; HAJNOCZKY G, 1992, BIOCHEM PHARMACOL, V43, P1009, DOI 10.1016/0006-2952(92)90606-J; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIRKWOOD A, 1991, NEURON, V6, P1009, DOI 10.1016/0896-6273(91)90240-Z; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1985, J BIOL CHEM, V260, P9171; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; MARRION NV, 1991, NEURON, V6, P533, DOI 10.1016/0896-6273(91)90056-6; MCCARTHY RT, 1989, J GEN PHYSIOL, V94, P669, DOI 10.1085/jgp.94.4.669; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROBBINS J, 1993, J PHYSIOL-LONDON, V469, P153, DOI 10.1113/jphysiol.1993.sp019809; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	40	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20942	20951		10.1074/jbc.270.36.20942	http://dx.doi.org/10.1074/jbc.270.36.20942			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673118	hybrid			2022-12-27	WOS:A1995RU05400015
J	BARRY, FP; ROSENBERG, LC; GAW, JU; GAW, JU; KOOB, TJ; NEAME, PJ				BARRY, FP; ROSENBERG, LC; GAW, JU; GAW, JU; KOOB, TJ; NEAME, PJ			N-LINKED AND O-LINKED KERATAN SULFATE ON THE HYALURONAN-BINDING REGION OF AGGRECAN FROM MATURE AND IMMATURE BOVINE CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR-CARTILAGE; PROTEOGLYCAN; PROTEINS; OLIGOSACCHARIDES; SEQUENCE; CLEAVAGE; DOMAINS; CHROMATOGRAPHY; CATABOLISM	In the hyaluronan binding region (HABR) peptide of aggrecan, there is a marked increase in the level of keratan sulfate (KS) during aging. To determine the sites of RS attachment, KS containing peptides were prepared from HABRs from immature and mature bovine articular cartilage by digestion with trypsin or papain followed by carbohydrate analysis and peptide sequencing. KS is attached to Thr(42) within loop A in mature, but not in immature, HABR. Within loop B KS is N-linked to Asn(220) in both HABRs, but in the immature HABR the chains are shorter. Asn(314) in loop B' of mature HABR is substituted either with a KS chain or with an oligosaccharide of the complex type. In immature HABR this site does not carry KS. In the interglobular domain, 2 threonine residues within the sequence TIQTVT are substituted in both calf and steer, and in steer further substitution occurs within the sequence NITEGEA, which contains a major catabolic cleavage site (Sandy, J., Neame, P. J., Boynton, R., and Flannery, C. R. (1991) J. Biol. Chem. 266, 8683-8685). The extreme polydispersity of mature HABR was investigated by preparing four subfractions of increasing molecular size which had essentially the same protein core, i.e. Val(1)-Arg(367) or Val(1)-Arg(375). The smaller species lacked the KS chains attached to loop A. These results show that KS substitution occurs within each of the disulfide-bonded loops of the HABR, that the KS may be either N- or O-linked, and that variations in the addition of KS are responsible for the polydispersity of mature HABR.	UNIV S FLORIDA, COLL MED, SHRINERS HOSP CRIPPLED CHILDREN, TAMPA, FL 33612 USA; UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; MONTEFIORE MED CTR, ORTHOPED RES LAB, NEW YORK, NY 10467 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Montefiore Medical Center			Barry, Frank P/K-5960-2013		NIAMS NIH HHS [1526 AR35322] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035322] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BONNET F, 1986, BIOCHIM BIOPHYS ACTA, V873, P152, DOI 10.1016/0167-4838(86)90202-5; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HEINEGARD D, 1979, BIOCHIM BIOPHYS ACTA, V581, P122, DOI 10.1016/0005-2795(79)90228-9; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MEYER K, 1953, J BIOL CHEM, V205, P611; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; NILSSON B, 1982, J BIOL CHEM, V257, P920; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; ROSENBERG L, 1993, T ORTHOP RES SOC, V39, P362; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SENO N, 1965, J BIOL CHEM, V240, P1005; Stuhlsatz H.W., 1989, KERATAN SULPHATE PRO, P1; SWANN DA, 1984, J BIOL CHEM, V259, P7693; TAI GH, 1991, BIOCHEM J, V273, P307, DOI 10.1042/bj2730307; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; THORNTON DJ, 1989, BIOCHEM J, V260, P277, DOI 10.1042/bj2600277; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	27	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20516	20524		10.1074/jbc.270.35.20516	http://dx.doi.org/10.1074/jbc.270.35.20516			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657627	hybrid			2022-12-27	WOS:A1995RR58400045
J	HARDIKAR, W; ANANTHANARAYANAN, M; SUCHY, FJ				HARDIKAR, W; ANANTHANARAYANAN, M; SUCHY, FJ			DIFFERENTIAL ONTOGENIC REGULATION OF BASOLATERAL AND CANALICULAR BILE-ACID TRANSPORT PROTEINS IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; POSTNATAL CHANGES; TAUROCHOLATE TRANSPORT; ECTO-ATPASE; EXPRESSION; SYSTEM; GLYCOPROTEINS; CLONING; BINDING; CELLS	The hepatic transport systems mediating bile acid uptake and excretion undergo independent, stage-specific expression during development in the rat. In this study, the mechanisms underlying ontogenic regulation of both the Na+-dependent basolateral bile acid transporter and canalicular bile acid transporter/ecto-ATPase were examined. Steady state mRNA levels for the basolateral transporter were less than 20% of adult values prior to birth, increased to 35% on the first postnatal day, and reached adult levels by 1 week of age. This was paralleled by transcription rates, which were low prior to birth, reached 47% by day 1, and were maximal by 1 week of age. Steady state mRNA levels for ecto-ATPase were 12% of adult values prior to birth and showed a a fold increase by the first day of life. Thereafter, there was a gradual increase in mRNA for this transporter, with adult levels being reached at 4 weeks of age. Transcription rates paralleled this increment, although adult levels were reached earlier. Surprisingly, for both transporters, the full complement of protein was present well before adult levels of mRNA were reached. The basolateral protein was expressed at 82% of adult levels on the first day of life but was of lower apparent molecular mass (39 kDa), a difference that persisted until 4 weeks of age. N-Glycanase digestion suggested that this difference could be fully accounted for by N-linked glycosylation. The ecto-ATPase protein was present at 33% of adult levels prior to birth, 77% by 1 day, and 84% of adult levels by 1 week of age. Unlike the basolateral transporter, the apparent molecular weight of this protein did not change during development, In summary, the ontogeny of bile acid transporters on the plasma membrane of the hepatocyte is complex and appears to be regulated at transcriptional, translational, and post-translational levels.	YALE UNIV, SCH MED, DEPT PEDIAT, GASTROENTEROL HEPATOL SECT, NEW HAVEN, CT 06520 USA	Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020632, R01HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [DK34989] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; BLITZER BL, 1984, J BIOL CHEM, V259, P9295; BOYER JL, 1971, AM J PHYSIOL, V221, P1156, DOI 10.1152/ajplegacy.1971.221.4.1156; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMOND DJ, 1985, J MOL BIOL, V181, P41, DOI 10.1016/0022-2836(85)90323-7; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; KATO S, 1988, BIOCHEM J, V253, P59, DOI 10.1042/bj2530059; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; MULLER M, 1991, J BIOL CHEM, V266, P18920; NOVAK DA, 1991, AM J PHYSIOL, V260, pG743, DOI 10.1152/ajpgi.1991.260.5.G743; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; ODATAMAI S, 1991, BIOCHEM J, V280, P179, DOI 10.1042/bj2800179; ODATAMAI S, 1989, BIOCHEM J, V261, P371, DOI 10.1042/bj2610371; PANDAK WM, 1992, J LIPID RES, V33, P659; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAFRITZ DA, 1988, SEMIN LIVER DIS, V8, P285, DOI 10.1055/s-2008-1040550; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SUCHY FJ, 1986, AM J PHYSIOL, V251, pG655, DOI 10.1152/ajpgi.1986.251.5.G665; SUCHY FJ, 1987, SEMIN LIVER DIS, V7, P77, DOI 10.1055/s-2008-1040567; SUCHY FJ, 1981, GASTROENTEROLOGY, V80, P1037; SUCHY FJ, 1985, AM J PHYSIOL, V248, pG648, DOI 10.1152/ajpgi.1985.248.6.G648; YAMAZAKI M, 1992, J HEPATOL, V14, P54, DOI 10.1016/0168-8278(92)90131-8	34	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20841	20846		10.1074/jbc.270.35.20841	http://dx.doi.org/10.1074/jbc.270.35.20841			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657669	hybrid			2022-12-27	WOS:A1995RR58400090
J	FRASER, IDC; MARSTON, SB				FRASER, IDC; MARSTON, SB			IN-VITRO MOTILITY ANALYSIS OF SMOOTH-MUSCLE CALDESMON CONTROL OF ACTIN-TROPOMYOSIN FILAMENT MOVEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; THIN-FILAMENTS; BINDING FRAGMENT; ATPASE ACTIVITY; PHOSPHORYLATION; CALMODULIN; INHIBITION; SUBFRAGMENT-1; DISSOCIATION; ACTOMYOSIN	We have used the in vitro motility assay to investigate the effect of caldesmon on the movement of actin-tropomyosin filaments over thiophosphorylated smooth muscle myosin and skeletal muscle heavy meromyosin. Using either motor, incorporation of up to 8 nM caldesmon inhibited filament movement by decreasing the proportion of filaments motile from >85% to <30%. There was a minimal effect on filament attachment and a modest decrease in motile filament velocity in this concentration range. The reduction in the proportion of filaments motile could be completely reversed by incorporation of an excess of calmodulin at pCa 4.5. The expressed C-terminal fragment, 606C, which retains caldesmon's inhibitory capacity but does not bind to myosin, decreased the proportion of filaments motile but had no effect on velocity. We conclude that the velocity reduction by whole caldesmon is due to actin-myosin cross-linking. A significant decrease in filament attachment was observed when caldesmon was added to an excess over actin (>10 nM). In the absence of tropomyosin, addition of an excess of caldesmon caused a similar decrease in the filament density, but there was no effect on the proportion of filaments that were motile. Our results demonstrate that caldesmon can switch actin-tropomyosin from motile to non-motile states without controlling velocity of movement or weak binding affinity and show the inhibitory action of caldesmon in the motility assay to be functionally indistinguishable from that reported for troponin.	NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907; Marston, Steven/0000-0001-6054-6070				BARANY M, 1993, ARCH BIOCHEM BIOPHYS, V305, P202, DOI 10.1006/abbi.1993.1412; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; KHALIL RA, 1995, BIOPHYS J, V68, P75; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MOODY CJ, 1985, FEBS LETT, V191, P107, DOI 10.1016/0014-5793(85)81003-6; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; NGAI PK, 1984, J BIOL CHEM, V259, P3656; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022	40	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19688	19693		10.1074/jbc.270.34.19688	http://dx.doi.org/10.1074/jbc.270.34.19688			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649978	hybrid			2022-12-27	WOS:A1995RQ99100006
J	CHEN, ZQ; CHAKRABORTY, S; BANERJEE, R				CHEN, ZQ; CHAKRABORTY, S; BANERJEE, R			DEMONSTRATION THAT MAMMALIAN METHIONINE SYNTHASES ARE PREDOMINANTLY COBALAMIN-LOADED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL-TUBE DEFECTS; SYNTHETASE; MECHANISM; OXIDATION; FOLATE	Methionine synthase is an important cellular housekeeping enzyme and is dependent on the cofactor cobalamin, a derivative of vitamin B-12, for activity, It functions in two major metabolic pathways including the tetrahydrofolate-dependent one-carbon cycle and the salvage pathway for methionine, Its dysfunction has several physiological ramifications and leads to the development of megaloblastic anemia. In addition, it is suspected to be involved in the pathogenesis of neural tube defects. An issue that is central in weighing therapeutic options for methionine synthase-related disorders is the extent to which the enzyme exists as apoenzyme in vivo and, thus, can be potentially responsive to vitamin B-12 therapy. Despite the importance of this issue, the extent of holo- versus apoenzyme in mammalian tissue is controversial and unresolved. To address this question, we have developed a convenient anaerobic assay that employs titanium citrate to deliver low potential electron equivalents. The reductive activation of this enzyme is essential under in vitro assay conditions. We find that both the human placental and porcine liver methionine synthases exist predominantly in the holoenzyme form (90-100%) in the crude homogenate. In addition, the activity of the pure enzyme measured in the titanium citrate assay is also independent of exogenous cofactor, revealing that the cobalamin is tightly bound to the active site.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln					NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; CLARKE R, 1991, NEW ENGL J MED, V324, P114; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; Fujii K, 1979, BIOCH ASPECTS NUTRIT, P173; GIANNOTTI C, 1982, ELECTRONIC SPECTRA B, P394; GREEN R, 1995, FOLATE HLTH DIS, P75; JACOBSEN DW, 1993, J INORG BIOCHEM, V50, P47, DOI 10.1016/0162-0134(93)80013-Y; KERWAR SS, 1971, ARCH BIOCHEM BIOPHYS, V142, P231, DOI 10.1016/0003-9861(71)90279-7; KIRKE PN, 1993, Q J MED, V86, P703; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; LOUGHLIN RE, 1964, J BIOL CHEM, V239, P2888; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; PEEL JL, 1963, BIOCHEM J, V88, P296, DOI 10.1042/bj0880296; TAYLOR RT, 1967, J BIOL CHEM, V242, P1509; TAYLOR RT, 1967, J BIOL CHEM, V242, P1502; TAYLOR RT, 1974, ARCH BIOCHEM BIOPHYS, V165, P787, DOI 10.1016/0003-9861(74)90308-7; UTLEY CS, 1985, J BIOL CHEM, V260, P3656; WHITMAN WB, 1985, J BACTERIOL, V164, P164; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	27	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19246	19249		10.1074/jbc.270.33.19246	http://dx.doi.org/10.1074/jbc.270.33.19246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642596	hybrid			2022-12-27	WOS:A1995RP70300010
J	TRAN, H; TANAKA, A; LITVINOVICH, SV; MEDVED, LV; HAUDENSCHILD, CC; ARGRAVES, WS				TRAN, H; TANAKA, A; LITVINOVICH, SV; MEDVED, LV; HAUDENSCHILD, CC; ARGRAVES, WS			THE INTERACTION OF FIBULIN-1 WITH FIBRINOGEN - A POTENTIAL ROLE IN HEMOSTASIS AND THROMBOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; DOMAIN-STRUCTURE; CALCIUM-BINDING; PROTEIN; GLYCOPROTEIN; FIBRONECTIN; PLASMA; POLYMERIZATION; SEQUENCE; LIGANDS	The fibulins are an emerging family of extracellular matrix and blood proteins presently having two members designated fibulin-1 and -2. Fibulin-1 is the predominant fibulin in blood, present at a concentration of 30-40 mu g/ml (similar to 1000-fold higher than fibulin-2). During the course of isolating fibulin-1 from plasma by immunoaffinity chromatography, a 340-kDa polypeptide was consistently found to co-purify. This protein was identified as fibrinogen (Fg) based on its electrophoretic behavior and reactivity with Fg monoclonal antibodies. Radioiodinated fibulin-1 was shown to bind to Fg transferred onto nitrocellulose filters after SDS-polyacrylamide gel electrophoresis. In enzyme-linked immunosorbent assay, fibulin-1 bound to Fg (and fibrin) adsorbed onto microtiter well plastic, and conversely, Fg bound to fibulin-1-coated wells. The binding of Fg to fibulin-1 was also observed in surface plasmon resonance assays, and a dissociation constant (K-d) of 2.9 +/- 1.6 mu M was derived. In addition, fluorescence anisotropy experiments demonstrated that the interaction was also able to occur in fluid phase, which suggests that complexes of fibulin-1 and Fg could exist in the blood. To localize the portion of Fg that is responsible for interacting with fibulin-1, proteolytic fragments of Fg were evaluated for their ability to promote fibulin-1 binding. Fragments containing the carboxyl-terminal region of the B beta chain (residues 216-468) were able to bind to fibulin-1. In addition, it was found that fibulin-1 was able to incorporate into fibrin clots formed in vitro and was immunologically detected within newly formed fibrin-containing thrombi associated with human atherectomy specimens. The interaction between fibulin-1 and Fg highlights potential new roles for fibulin-1 in hemostasis as well as thrombosis.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; AMER RED CROSS,JEROME H HOLLAND LAB,DEPT EXPTL PATHOL,ROCKVILLE,MD 20855	American Red Cross; American Red Cross				Medved, Leonid/0000-0002-3665-9849	NIGMS NIH HHS [GM42912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RJ, 1984, BIOCHEM J, V217, P67, DOI 10.1042/bj2170067; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BALE MD, 1985, J BIOL CHEM, V260, P7502; BALE MD, 1986, J BIOL CHEM, V261, P862; BROWN JC, 1994, J CELL SCI, V107, P329; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; DOOLITTLE RF, 1980, PROTIDES BIOL FLUIDS, V28, P311; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; Godyna S., 1994, Molecular Biology of the Cell, V5, p55A; GODYNA S, 1994, MATRIX BIOL, V14, P467; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; GREEN AA, 1955, METHOD ENZYMOL, V1, P67, DOI 10.1016/0076-6879(55)01014-8; Ham TH, 1938, MEDICINE, V17, P413, DOI 10.1097/00005792-193812000-00002; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; LENDRUM AC, 1962, J CLIN PATHOL, V15, P401, DOI 10.1136/jcp.15.5.401; LITVINOVICH SV, 1995, EUR J BIOCHEM, V229, P605, DOI 10.1111/j.1432-1033.1995.tb20504.x; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MEDVED LV, 1993, FEBS LETT, V320, P239, DOI 10.1016/0014-5793(93)80594-K; MEDVED LV, 1988, FEBS LETT, V232, P56, DOI 10.1016/0014-5793(88)80385-5; MEDVED LV, 1986, FEBS LETT, V202, P298, DOI 10.1016/0014-5793(86)80705-0; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOESSON MW, 1983, ANN NY ACAD SCI, V408, P97; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	36	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19458	19464		10.1074/jbc.270.33.19458	http://dx.doi.org/10.1074/jbc.270.33.19458			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642629	hybrid			2022-12-27	WOS:A1995RP70300043
J	DUCKETT, CS; PERKINS, ND; LEUNG, K; AGRANOFF, AB; NABEL, GJ				DUCKETT, CS; PERKINS, ND; LEUNG, K; AGRANOFF, AB; NABEL, GJ			CYTOKINE INDUCTION OF NUCLEAR FACTOR KAPPA-B IN CYCLING AND GROWTH-ARRESTED CELLS - EVIDENCE FOR CELL CYCLE-INDEPENDENT ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; HUMAN IMMUNODEFICIENCY VIRUS; RECEPTOR-ALPHA-GENE; TRANSCRIPTIONAL ACTIVATION; C-MYC; MOUSE FIBROBLASTS; G0/G1 TRANSITION; 3T3 CELLS; PROTEIN-KINASE	Nuclear factor kappa B (NF-kappa B) is a pleiotropic transcription factor which regulates the expression of a large number of cellular and viral genes. Induction of NF-kappa B has been shown previously to occur during cell cycle transition from G(0) to G(1), but the relationship of cytokine induction of this transcription factor to cell cycling has not been directly addressed. Here we examine the induction of NF-kappa B in serum-deprived and cycling cells in response to tumor necrosis factor-alpha (TNF-alpha). In 3T3 fibroblasts deprived of serum, and in the temperature-sensitive G(2) phase mutant carcinoma line FT210, we find that NF-kappa B DNA binding activity is rapidly induced upon addition of TNF-alpha. In addition, NF-kappa B induction in cycling cells occurs without a significant change in cell cycle distribution. These data reveal that NF-kappa B is rapidly induced by TNF-alpha in both proliferating and arrested cells and suggest that distinct activation pathways can lead to cell cycle-dependent or -independent induction of NF-kappa B.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Duckett, Colin/0000-0001-9413-2263	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAMBROOK JJ, 1994, LABORATORY MANUAL; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; VOLLAND S, 1994, INT J CANCER, V56, P696; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	62	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18836	18840		10.1074/jbc.270.32.18836	http://dx.doi.org/10.1074/jbc.270.32.18836			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642536	hybrid			2022-12-27	WOS:A1995RN95400023
J	FURMAN, I; COOK, O; KASIR, J; LOW, W; RAHAMIMOFF, H				FURMAN, I; COOK, O; KASIR, J; LOW, W; RAHAMIMOFF, H			THE PUTATIVE AMINO-TERMINAL SIGNAL PEPTIDE OF THE CLONED RAT-BRAIN NA+-CA2+ EXCHANGER GENE (RBE-1) IS NOT MANDATORY FOR FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; CLONING; SEQUENCE; CLEAVAGE; CELLS	The rat brain Na+-Ca2+ exchanger (RBE) gene, as well as other isoforms of this protein family, can be organized into 12 transmembrane alpha helices, the first of which was proposed by Durkin et al. (14) to constitute a cleavable signal peptide. We have prepared three amino-terminal mutants, in which 21, 26, and 31 amino acids beyond the initiating methionine were deleted. The deletions include the hydrophobic core of the putative signal peptide (N21), the entire putative signal peptide and parts of the putative signal peptidase cleavage site (N26), and the entire putative signal peptide and putative signal peptidase cleavage site (N31). Ah three mutant clones were transiently expressed in HeLa cells. The average Na+ gradient-dependent Ca2+ transport activity of the mutant exchangers was 108% (N21), 37.2% (N26), and 60.06% (N31) of the wild-type clone. Mutation of the putative cleavage site by an exchange of Ala-32 --> Asp, resulted in a decrease in Na+-Ca2+ exchange activity to 7.7%, relative to the wild-type exchanger. Functional reconstitution of the proteins that were expressed in the transfected cells, resulted in transport activities of: 60.1% (N21), 26.75% (N26), 85.36% (N31), and 31% (Ala-32 --> Asp) relative to the wild-type exchanger. Western blot analysis of the protein profile of RBE-I, N21, N26, N31 and Ala-32 --> Asp-transfected HeLa cells was carried out by using an antipeptide antibody directed against a pentadecapeptide segment derived from the large putative cytoplasmic loop of the cloned rat exchanger gene. In the total cell extract and in the plasma membrane-enriched fraction, in addition to a major protein band of about 125 kDa, which corresponds to the molecular mass of the mature fully processed Na+-Ca2+ exchanger, an additional protein of about 135 kDa is revealed in the profile of N21- and N26-transfected cells. This band is not detected in the protein profile of RBE-1, N31, or Ala-32 --> Asp. The amino-terminal truncated mutants of the cloned Na+-Ca2+ exchanger could be expressed and processed also in a reticulocyte lysate supplemented with dog microsomes. Our results suggest that the putative signal peptide of the cloned Na+-Ca2+ exchanger gene does not play a mandatory role in functional expression of the protein in HeLa cells.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; ANDREWS D, 1987, PROMEGA NOTES, V11, P3; BARZILAI A, 1987, BIOCHEMISTRY-US, V26, P6113, DOI 10.1021/bi00393a025; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; JAIN RG, 1994, J BIOL CHEM, V269, P16305; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOW W, 1992, FEBS LETT, V316, P63; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAM LY, 1994, J BIOL CHEM, V269, P32542; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	31	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19120	19127		10.1074/jbc.270.32.19120	http://dx.doi.org/10.1074/jbc.270.32.19120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642578	hybrid			2022-12-27	WOS:A1995RN95400066
J	SAMOKHIN, GP; LORAND, L				SAMOKHIN, GP; LORAND, L			CONTACT WITH THE N-TERMINI IN THE CENTRAL E-DOMAIN ENHANCES THE REACTIVITIES OF THE DISTAL D-DOMAINS OF FIBRIN TO FACTOR-XIII(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; THROMBIN-CATALYZED ACTIVATION; ALPHA-CHAIN; GAMMA-CHAIN; POLYMERIZATION SITES; PLASMIC DEGRADATION; STABILIZING FACTOR; BINDING-SITES; LOCALIZATION; PROMOTION	The reaction of Factor XIII(a) with fibrin is the last enzyme-catalyzed step on the coagulation cascade, leading to the formation of a normal blood clot. The finding that fibrin is preferred by the cross-linking enzyme about 10-fold over the circulating fibrinogen suggests the operation of a unique substrate-level control for the orderly functioning of the physiological process in the forward direction. An important task is to elucidate the molecular mechanism for the transmission of the signal generated by the thrombin catalyzed cleavage in the central E domain of fibrin to the distant Factor XIII(a)-reactive glutamine residues. By focusing on the substrate sites present in gamma chain remnants of D type domains of fibrinogen and by employing the approach of fragment complementation with the regulatory E domain, which represents the thrombin-modified portion of fibrin, we have now succeeded in reconstructing in solution the phenomenon of kinetic enhancement for the reaction with Factor XIII(a). Two D type preparations (truncated fibrinogen, similar to 250 kDa and D', similar to 105 kDa) were obtained by digestion of human fibrinogen with endo Lys-C. Neither product could be cross-linked by Factor XIII(a), but as shown by the incorporation of dansylcadaverine, both were acceptor substrates for the enzyme. The plasmin-derived D (similar to 105-kDa) product, however, could be cross-linked into DD dimers. In all cases, the admixture of E fragments exerted a remarkable boosting effect on the reactions with Factor XIII(a). Even with native fibrinogen as substrate, cross-linking of gamma chains was enhanced in the presence of E. Nondenaturing electrophoresis was used to demonstrate the complex forming potential of E fragments with fibrinogen, truncated fibrinogen, D', or D, The GPRP tetrapeptide mimic of the GPRV N-terminal sequence of the alpha chains in the E fragments, abolished both complex formation and the kinetic boosting effect of E on the reactions of substrates with Factor XIII(a). Thus, the N-terminal alpha chain sequences seem to act as organizing templates for spatially orienting the D domains, probably during the protofibrillar assembly of the fibrin units, for favorable reaction with Factor XIII(a).	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC & CELL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016346, R01HL016346] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16346, HL02212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIL RE, 1973, BIOL REPROD, V8, P613, DOI 10.1093/biolreprod/8.5.613; BRUNERLORAND J, 1966, NATURE, V210, P1273; Chen R, 1971, Biochemistry, V10, P4487; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CIERNIEWSKI CS, 1986, J BIOL CHEM, V261, P9116; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; CREDO RB, 1981, BIOCHEMISTRY-US, V20, P3770, DOI 10.1021/bi00516a016; Curtis C G, 1976, Methods Enzymol, V45, P177; DERANLEA.DA, 1966, BIOCHEMISTRY-US, V5, P1413, DOI 10.1021/bi00868a040; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EHRLICH PH, 1983, BIOCHEMISTRY-US, V22, P4184, DOI 10.1021/bi00287a004; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; FRETTO LJ, 1978, J BIOL CHEM, V253, P2184; FURLAN M, 1972, BIOCHIM BIOPHYS ACTA, V263, P631, DOI 10.1016/0005-2795(72)90044-X; Hart R G, 1970, Biol Reprod, V3, P347; HART RG, 1968, J REPROD FERTIL, V17, P223; HENRIKSSON P, 1974, PEDIATR RES, V8, P789, DOI 10.1203/00006450-197409000-00002; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P6269, DOI 10.1021/bi00295a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LORAND L, 1981, METHOD ENZYMOL, V80, P333; LORAND L, 1969, J CLIN INVEST, V48, P1054, DOI 10.1172/JCI106061; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; LORAND L, 1962, NATURE, V195, P911, DOI 10.1038/195911b0; LORAND L, 1969, P NATL ACAD SCI USA, V63, P1247, DOI 10.1073/pnas.63.4.1247; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1966, BIOCHEMISTRY-US, V5, P1747, DOI 10.1021/bi00869a043; Lorand L, 1980, Prog Hemost Thromb, V5, P245; LORAND L, 1972, ANN NY ACAD SCI, V202, P165; Lorand L., 1970, METHOD ENZYMOL, V19, P770; Lorand L., 1994, ANTICOAGULANTS PHYSL, P169; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MATSUEDA GR, 1988, FIBRINOGEN, V3, P133; MILLS DA, 1972, BIOCHIM BIOPHYS ACTA, V263, P619, DOI 10.1016/0005-2795(72)90043-8; MOCKROS LF, 1974, BIOPHYS CHEM, V2, P164, DOI 10.1016/0301-4622(74)80037-2; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; PIZZO SV, 1972, J BIOL CHEM, V247, P636; POZDNYAKOVA T M, 1987, Biokhimiya, V52, P592; POZDNYAKOVA TM, 1985, UKR BIOKHIM ZH+, V57, P3; POZDNYAKOVA TM, 1986, UKR BIOKHIM ZH+, V58, P10; POZDNYAKOVA TM, 1983, UKR BIOKHIM ZH+, V55, P614; PROCYK R, 1991, BLOOD, V77, P1469; RADEK JT, 1993, BIOCHEMISTRY-US, V32, P3527, DOI 10.1021/bi00065a002; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROBERTS W W, 1973, Biorheology, V10, P29; ROZENFEL'D M A, 1988, Molekulyarnaya Biologiya (Moscow), V22, P923; RYBACHUK VN, 1986, UKR BIOKHIM ZH+, V58, P3; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SHIMIZU A, 1992, P NATL ACAD SCI USA, V89, P2888, DOI 10.1073/pnas.89.7.2888; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VARADI A, 1984, BIOCHEMISTRY-US, V23, P2108, DOI 10.1021/bi00304a036; WILLIAMSASHMAN HG, 1977, BIOCHEM BIOPH RES CO, V79, P1192, DOI 10.1016/0006-291X(77)91132-9; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893	65	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21827	21832		10.1074/jbc.270.37.21827	http://dx.doi.org/10.1074/jbc.270.37.21827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665605	hybrid			2022-12-27	WOS:A1995RU75700064
J	TRAIANEDES, K; FINDLAY, DM; MARTIN, TJ; GILLESPIE, MT				TRAIANEDES, K; FINDLAY, DM; MARTIN, TJ; GILLESPIE, MT			MODULATION OF THE SIGNAL RECOGNITION PARTICLE 54-KDA SUBUNIT (SRP54) IN RAT PREOSTEOBLASTS BY THE EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALKALINE-PHOSPHATASE; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; RETINOIC ACID; 54K SUBUNIT; CELL; PROTEIN; RNA; OSTEOPONTIN; SUBSTRATUM	Rat preosteoblastic cells, UMI201, develop a more mature phenotype when subcultured onto a type I collagen gel when compared with their growth on plastic. Basal osteopontin mRNA expression is up-regulated, whereas retinoic acid-induced alkaline phosphatase expression is reduced in cells on collagen when compared with cells plated onto plastic, We have used differential display polymerase chain reaction (PCR) of mRNA to identify other mRNA species that are regulated by collagen and/or retinoic acid in UMR201 cells. A number of differentially expressed PCR products were isolated, whose sequences did not correspond to known sequences in the data bank, However, one species which was up-regulated by growth on collagen showed 95 and 94% homology to the murine and canine 54-kDa subunit of the signal recognition particle (SRP54), respectively. In time course experiments, using reverse transcription PCR, it was found that SRP54 mRNA was up-regulated in UMR201 cells as early as 1 h after subculture onto collagen, when compared with cells subcultured onto plastic, and levels remained elevated after 48 h, The increased expression of SRP54 paralleled the increased expression of a known secreted protein, osteopontin, SRP54 recognizes signal sequences of proteins destined for secretion and retards them for further elongation in the endoplasmic reticulum, The increased expression may correlate with the synthesis of specific extracellular matrix molecules in differentiating osteoblasts.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; UNIV MELBOURNE,ST VINCENTS HOSP,DEPT MED,FITZROY,VIC 3065,AUSTRALIA	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne				Gillespie, Matthew/0000-0001-6543-8909				AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4772; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HADLEY MA, 1988, IN VITRO CELL DEV, V29, P943; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, CURRENT PROTOCOLS MO; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; NG KW, 1988, J BONE MINER RES, V3, P53; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREULI CH, 1990, J CELL BIOL, V110, P1405; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEINREB M, 1990, J BONE MINER RES, V5, P831; ZHANG LX, 1993, MOL CARCINOGEN, V8, P123, DOI 10.1002/mc.2940080209	32	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20891	20894		10.1074/jbc.270.36.20891	http://dx.doi.org/10.1074/jbc.270.36.20891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673110	hybrid			2022-12-27	WOS:A1995RU05400006
J	HEEGAARD, CW; SIMONSEN, ACW; OKA, K; KJOLLER, L; CHRISTENSEN, A; MADSEN, B; ELLGAARD, L; CHAN, L; ANDREASEN, PA				HEEGAARD, CW; SIMONSEN, ACW; OKA, K; KJOLLER, L; CHRISTENSEN, A; MADSEN, B; ELLGAARD, L; CHAN, L; ANDREASEN, PA			VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BINDS AND MEDIATES ENDOCYTOSIS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR-TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; PROTEIN; DEGRADATION; FORMS; LOCALIZATION; RECOGNITION; EXPRESSION; AFFINITY; REGION	Very low density lipoprotein receptor (VLDL-R) was found to be expressed in bovine mammary gland and the human breast carcinoma cell line MCF-7 as an M(r) 105,000 variant, and in Chinese hamster ovary (CHO) cells transfected with human VLDL-R cDNA as an M(r) 130,000 variant. The receptor was purified by ligand affinity chromatography with immobilized M(r) 40,000 receptor-associated protein (RAP). The purified receptor was found to bind urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex (u-PA . PAI-1), while there was no or very weak binding of active site blocked u-PA (DFP-u-PA), PAI-1 or u-PA-type-2 plasminogen activator inhibitor complex. The binding of u-PA . PAI-1 was blocked by RAP. The transfected CHO cells had an efficient, RAP sensitive endocy tosis of u-PA . PAI-1, severalfold higher than non-transfected parental CHO cells. u-PA . PAI-1 endocytosis was partially inhibited by DFP-u-PA, which blocks binding of the complex to the u-PA receptor. RAP and DFP-u-PA sensitive u-PA . PAI-1 endocytosis was also observed in MCF-7 cells, which were without detectable levels of other RAP-binding endocytosis receptors. These results show that VLDL-R represents a novel endocytosis mechanism for u-PA receptor-bound u-PA . PAI-1.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; AARHUS UNIV,GENE EXPRESS LAB,DK-8000 AARHUS C,DENMARK	Aarhus University; Baylor College of Medicine; Baylor College of Medicine; Aarhus University			Ellgaard, Lars/I-9034-2014; Heegaard, Christian W/A-4814-2019	Ellgaard, Lars/0000-0002-7018-0137; Wurtz Heegaard, Christian/0000-0002-7989-2624	NHLBI NIH HHS [HL16512, HL27341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027341, R37HL016512, P60HL027341, R01HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ASTEDT B, 1986, THROMB HAEMOSTASIS, V56, P63; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; HEEGAARD CW, 1994, BBA-MOL CELL RES, V1222, P45, DOI 10.1016/0167-4889(94)90023-X; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KEIJER J, 1990, BLOOD, V78, P401; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KJOLLER L, 1995, MOL CELL ENDOCRINOL, V109, P209, DOI 10.1016/0303-7207(95)03504-Z; KNUDSEN H, 1994, EUR J BIOCHEM, V220, P63, DOI 10.1111/j.1432-1033.1994.tb18599.x; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1994, ANN NY ACAD SCI, V737, P483, DOI 10.1111/j.1749-6632.1994.tb44346.x; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9552; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WILNOW TE, 1994, J BIOL CHEM, V269, P15827	43	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20855	20861		10.1074/jbc.270.35.20855	http://dx.doi.org/10.1074/jbc.270.35.20855			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657671	hybrid			2022-12-27	WOS:A1995RR58400092
J	OWENSGRILLO, JK; HOFFMANN, K; HUTCHISON, KA; YEM, AW; DEIBEL, MR; HANDSCHUMACHER, RE; PRATT, WB				OWENSGRILLO, JK; HOFFMANN, K; HUTCHISON, KA; YEM, AW; DEIBEL, MR; HANDSCHUMACHER, RE; PRATT, WB			THE CYCLOSPORINE A-BINDING IMMUNOPHILIN CYP-40 AND THE FK506-BINDING IMMUNOPHILIN HSP56 BIND TO A COMMON SITE ON HSP90 AND EXIST IN INDEPENDENT CYTOSOLIC HETEROCOMPLEXES WITH THE UNTRANSFORMED GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; UTERINE PROGESTIN RECEPTOR; 59-KILODALTON PROTEIN; POLYCLONAL ANTIBODY; ESTROGEN-RECEPTOR; COMPLEXES; COMPONENT; IDENTIFICATION; ASSOCIATION; P59	We have recently shown that hsp56, the FKBOG-binding immunophilin component of both the heat shock protein (hsp90 . hsp70 . hsp56) heterocomplex and the untransformed glucocorticoid receptor heterocomplex, is bound directly to hsp90 (Czar, M. J., Owens-Grillo, J. K., Dittmar, K. D., Hutchison, K. A., Zacharek, A. M., Leach, K. L., Deibel, M. R., and Pratt, W. B. (1994) J. Biol. Chem. 269, 11155-11161). In this work, we show that both untransformed glucocorticoid receptor and hsp90 heterocomplexes contain CyP-40, a 40-kDa immunophilin of the cyclosporin A-binding class. CyP-40 is present in both native glucocorticoid receptor heterocomplexes and receptor heterocomplexes reconstituted with rabbit reticulocyte lysate, and the presence of CyP-40 in the receptor heterocomplex is stabilized by molybdate. Immunoadsorption of hsp90 from cell lysate yields coimmunoadsorption of both hsp56 and CyP-40, showing that both immunophilins are in native heterocomplex with hsp90. However, immunoadsorption of hsp56 does not yield coimmunoadsorption of CyP-40; thus, the two immunophilins do not exist in the same heterocomplex with hsp90. Both purified CyP-40 and hsp56 bind directly to purified hsp90, and excess CyP-40 blocks the binding of hsp56, consistent with the presence of a common immunophilin binding site on hsp90. Our data also suggest that there are at least two types of untransformed glucocorticoid receptor-hsp90 heterocomplexes, one that contains hsp56 and another that contains CyP-40. The role played by the immunophilins in steroid receptor action is unknown, but it is clear that the peptidylprolyl isomerase activity of immunophilins is not required for glucocorticoid receptor-hsp90 heterocomplex assembly and proper folding of the hormone binding domain by the hsp90-associated protein folding system of reticulocyte lysate.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	University of Michigan System; University of Michigan; Pfizer; Yale University					NCI NIH HHS [T32 CA09676, CA28010] Funding Source: Medline; NIGMS NIH HHS [GM49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010, T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; JOHNSON JL, 1994, J CELL BIOCHEM, V18, P344; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANDHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	44	161	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20479	20484		10.1074/jbc.270.35.20479	http://dx.doi.org/10.1074/jbc.270.35.20479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657624	hybrid			2022-12-27	WOS:A1995RR58400039
J	RADIC, Z; QUINN, DM; VELLOM, DC; CAMP, S; TAYLOR, P				RADIC, Z; QUINN, DM; VELLOM, DC; CAMP, S; TAYLOR, P			ALLOSTERIC CONTROL OF ACETYLCHOLINESTERASE CATALYSIS BY FASCICULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICHOLINESTERASE TOXINS; ANIONIC SITE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE; IDENTIFICATION; SPECIFICITY; BINDING; LIGANDS; VENOM	The interaction of fasciculin 2 was examined with wild-type and several mutant forms of acetylcholinesterase (AChE) where Trp(86), which lies at the base of the active center gorge, is replaced by Tyr, Phe, and Ala. The fasciculin family of peptides from snake venom bind to a peripheral site near the rim of the gorge, but at a position which still allows substrates and other inhibitors to enter the gorge. The interaction of a series of charged and uncharged carboxyl esters, alkyl phosphoryl esters, and substituted trifluoroacetophenones were analyzed with the wild-type and mutant AChEs in the presence and absence of fasciculin. We show that Trp(86) is important for the alignment of carboxyl ester substrates in the AChE active center. The most marked influence of Trp(86) substitution in inhibiting catalysis is seen for carboxyl esters that show rapid turnover. The extent of inhibition achieved with bound fasciculin is also greatest for efficiently catalyzed, charged substrates. When Ala is substituted for Trp(86), fasciculin becomes an allosteric activator instead of an inhibitor for certain substrates. Analysis of the kinetics of acylation by organophosphates and conjugation by trifluoroacetophenones, along with deconstruction of the kinetic constants for carboxyl esters, suggests that AChF inhibition by fasciculin arises from reductions of both the commitment to catalysis and diffusional entry of substrate into the gorge. The former is reflected in the ratio of the rate constant for substrate acylation to that for dissociation of the initial complex. The action of fasciculin appears to be mediated allosterically from its binding site at the rim of the gorge to affect the orientation of the side chain of Trp(86) which lies at the gorge base.			RADIC, Z (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN WW, 1949, P SOC EXP BIOL MED, V72, P1; ALDRIDGE WN, 1972, ENZYME INHIBITORS SU, P1; ASHANI Y, 1995, J BIOL CHEM, V270, P6370, DOI 10.1074/jbc.270.11.6370; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BARAK D, 1994, J BIOL CHEM, V269, P6296; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BUCHT G, 1994, BBA-PROTEIN STRUCT M, V1209, P265, DOI 10.1016/0167-4838(94)90195-3; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; EPSTEIN DJ, 1979, BIOCHEMISTRY-US, V18, P4749, DOI 10.1021/bi00588a040; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; Hansch C, 1979, SUBSTITUENT CONSTANT, P1; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HAREL M, 1995, IN PRESS ENZYMES CHO; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KARLSSON E, 1985, PHARMACOL THERAPEUT, V30, P259, DOI 10.1016/0163-7258(85)90051-8; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LINDERMAN RJ, 1988, PESTIC BIOCHEM PHYS, V31, P187, DOI 10.1016/0048-3575(88)90021-1; LOEWENSTEIN Y, 1993, J MOL BIOL, V234, P289, DOI 10.1006/jmbi.1993.1584; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; NAIR HK, 1993, BIOORG MED CHEM LETT, V3, P2619, DOI 10.1016/S0960-894X(01)80727-7; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSENBERRY TL, 1995, IN PRESS ENZYMES CHO; SHAFFERMAN A, 1994, EMBO J, V13, P3448, DOI 10.1002/j.1460-2075.1994.tb06650.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VANDENBORN HKL, 1995, PROTEIN SCI, V4, P703; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003	37	87	89	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20391	20399		10.1074/jbc.270.35.20391	http://dx.doi.org/10.1074/jbc.270.35.20391			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657613	hybrid			2022-12-27	WOS:A1995RR58400026
J	TENG, KK; LANDER, H; FAJARDO, JE; HANAFUSA, H; HEMPSTEAD, BL; BIRGE, RB				TENG, KK; LANDER, H; FAJARDO, JE; HANAFUSA, H; HEMPSTEAD, BL; BIRGE, RB			V-CRK MODULATION OF GROWTH FACTOR-INDUCED PC12 CELL-DIFFERENTIATION INVOLVES THE SRC HOMOLOGY-2 DOMAIN OF V-CRK AND SUSTAINED ACTIVATION OF THE RAS/MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION; SH3 DOMAINS; NEURONAL DIFFERENTIATION; MAP KINASE; RAS; ONCOGENE; GRB2; PHOSPHOTYROSINE	Nerve growth factor (NGF) and epidermal growth factor (EGF) elicit contrasting actions on PC12 pheochromocytoma cells; NGF causes neuronal differentiation, and EGF induces proliferation. However, ectopic expression of the Src homology 2 (SH2) and SH3-containing onco genic adaptor protein v-Crk in PC12 cells results in EGF-inducible neuronal differentiation (Hempstead, B. L., Birge, R. B., Fajardo, J. E., Glassman, R., Mahadeo, D., Kraemer, R., and Hanafusa, H. (1994) Mol. Cell. Biol. 14, 1964-1971). Here we show that v-Crk complexes with both the tyrosine-phosphorylated EGF receptor and the Pas guanine nucleotide exchange factor SOS in PC12 cells and is involved in an pathway analogous to that of Grb2. Expression of v-Crk results in an enhanced and sustained activation of Pas and mitogen-activated protein (MAP) kinase following EGF or NGF stimulation, implying that v-Crk can couple divergent tyrosine kinase pathways to Pus. To investigate the causal relationship between EGF receptor binding, MAP kinase activation, and neurite outgrowth, we stably expressed two v-Crk SH2 point mutants, v-Crk(R273N) and v-Crk(H294R) in PC12 cells. Mutations within the SH2 domain of v-Crk block binding of v-Crk to the tyrosine phosphorylated EGF receptor, compromise v-Crk's ability to cause EGF-dependent neurite outgrowth, and act in a dominant negative manner for NGF-induced neurite outgrowth. However, the kinetics of MAP kinase activation in EGF- or NGF-treated v-Crk(R273N)PC12 cells was comparable with that in v-CrkPC12 cells. These data are consistent with a model in which v-Crk regulates the strength of a tyrosine kinase signal leading to prolonged activation of Pas and MAP kinase. However, the experiments with the SH2 mutants suggest that sustained activation, by itself, may not be sufficient to switch the fate of v-CrkPC12 cells from proliferation toward differentiation.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; CORNELL UNIV MED COLL,NEW YORK HOSP,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY; CORNELL UNIV MED COLL,NEW YORK HOSP,DEPT BIOCHEM,NEW YORK,NY	Rockefeller University; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital					NCI NIH HHS [CA09673, CA44356] Funding Source: Medline; NIGMS NIH HHS [GM51446] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051446] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1991, NATURE, V246, P719; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	54	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20677	20685		10.1074/jbc.270.35.20677	http://dx.doi.org/10.1074/jbc.270.35.20677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657647	hybrid			2022-12-27	WOS:A1995RR58400067
J	IMLAY, JA				IMLAY, JA			A METABOLIC ENZYME THAT RAPIDLY PRODUCES SUPEROXIDE, FUMARATE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE-OXIDASE; UBIQUINONE OXIDOREDUCTASE; NADH DEHYDROGENASE; ELECTRON-TRANSPORT; DISMUTASE MUTANTS; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; BOUND FLAVIN; ANION; QUINONES	Aerobic organisms synthesize superoxide dismutases in order to escape injury from endogenous superoxide, An earlier study of Escherichia coli indicated that intracellular superoxide is formed primarily by autoxidation of components of the respiratory chain, In order to identify those components, inverted respiratory vesicles were incubated with five respiratory substrates, In most cases, essentially all of the superoxide was formed through autoxidation of fumarate reductase, despite the paucity of this anaerobic terminal oxidase in the aerobic cells from which the vesicles were prepared, In contrast, most dehydrogenases, the respiratory quinones, and the cytochrome oxidases did not produce any detectable superoxide, The propensity of fumarate reductase to generate superoxide could conceivably deluge cells with superoxide when anaerobic cells, which contain abundant fumarate reductase, enter an aerobic habitat, In fact, deletion or overexpression of the frd structural genes improved and retarded, respectively, the outgrowth of superoxide dismutase-attenuated cells when they were abruptly aerated, suggesting that fumarate reductase is a major source of superoxide in vivo, Steric inhibitors that bind adjacent to the flavin completely blocked superoxide production, indicating that the flavin, rather than an iron-sulfur cluster, is the direct electron donor to oxygen, Since the turnover numbers for superoxide formation by other flavoenzymes are orders of magnitude lower than that of fumarate reductase (1600 min(-1)), additional steric or electronic factors must accelerate its autoxidation.			IMLAY, JA (corresponding author), UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA.				NIGMS NIH HHS [GM49640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; AU DCT, 1984, J BACTERIOL, V157, P122, DOI 10.1128/JB.157.1.122-125.1984; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CHANG EC, 1991, J BIOL CHEM, V266, P4417; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GAUDU P, 1994, J BIOL CHEM, V269, P8182; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; HILLE R, 1981, J BIOL CHEM, V256, P9090; IMLAY J, 1992, ARCH BIOCHEM BIOPHYS, V296, P337, DOI 10.1016/0003-9861(92)90581-G; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IUCHI S, 1985, J BACTERIOL, V161, P1023, DOI 10.1128/JB.161.3.1023-1028.1985; KARGALIOGLU Y, 1994, J BACTERIOL, V176, P7653, DOI 10.1128/JB.176.24.7653-7658.1994; KITA K, 1989, J BIOL CHEM, V264, P2672; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V234, P34, DOI 10.1016/0005-2728(71)90126-5; LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P201; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASSEY V, 1994, J BIOL CHEM, V36, P22458; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; MIKI T, 1992, J BIOL CHEM, V267, P18695; Miller J.H., 1972, EXPT MOL GENETICS; MISRA HP, 1972, J BIOL CHEM, V247, P3170; POOLE RK, 1975, BIOCHEM J, V152, P537, DOI 10.1042/bj1520537; POOLE RK, 1987, ESCHERICHIA COLI SAL, V1, P170; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; SIX S, 1994, J BACTERIOL, V176, P6470, DOI 10.1128/JB.176.21.6470-6478.1994; TURRENS JF, 1987, MOL BIOCHEM PARASIT, V25, P55, DOI 10.1016/0166-6851(87)90018-1; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6	49	113	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19767	19777						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649986				2022-12-27	WOS:A1995RQ99100017
J	BALDWIN, MA; COHEN, FE; PRUSINER, SB				BALDWIN, MA; COHEN, FE; PRUSINER, SB			PRION PROTEIN ISOFORMS, A CONVERGENCE OF BIOLOGICAL AND STRUCTURAL INVESTIGATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CREUTZFELDT-JAKOB-DISEASE; GERSTMANN-STRAUSSLER SYNDROME; FATAL FAMILIAL INSOMNIA; SCRAPIE PRION; TRANSGENIC MICE; CONFORMATIONAL TRANSITIONS; SECONDARY STRUCTURE; PRP 27-30; GENE; INFECTIVITY		UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BAJDUSEK DC, 1990, BIOMEDICAL ADV AGING, P3; BARTZ JC, 1994, J GEN VIROL, V75, P2947, DOI 10.1099/0022-1317-75-11-2947; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BELLINGERKAWAHA.CG, 1988, VIROLOGY, V164, P537; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GAJDUSEK DC, 1990, VIROLOGY, P2289; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Gibbs C.J., 1979, SLOW TRANSMISSIBLE D, V1, P87; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GOLDFARB LG, 1993, NEUROLOGY, V43, P2392, DOI 10.1212/WNL.43.11.2392; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1989, LANCET, V1, P51; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PATTISON IH, 1967, VET REC, V80, P1; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; WILESMITH JW, 1992, PRION DISEASES HUMAN, P243	80	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19197	19200		10.1074/jbc.270.33.19197	http://dx.doi.org/10.1074/jbc.270.33.19197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642588	hybrid			2022-12-27	WOS:A1995RP70300001
J	GEREZ, L; ARAD, G; EFRAT, S; KETZINEL, M; KAEMPFER, R				GEREZ, L; ARAD, G; EFRAT, S; KETZINEL, M; KAEMPFER, R			POSTTRANSCRIPTIONAL REGULATION OF HUMAN INTERLEUKIN-2 GENE-EXPRESSION AT PROCESSING OF PRECURSOR TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; LYMPHOCYTES-T; GROWTH-FACTOR; C-FOS; INDUCTION; SUPERINDUCTION; INTERFERON; STABILITY	Interleukin-2 (IL-2) regulates the clonal expansion of activated T cells and is produced in limited amounts during an immune response. Mitogenic induction of human IL-2 gene expression elicits a transient wave of unstable mRNA. We show here that transcription continues unabated during and well beyond the time when the wave is subsiding, yet few, if any, new mRNA molecules are generated once the wave has reached its maximum, Instead, IL-2 precursor transcripts accumulate, becoming the majority of expressed IL-2 RNA molecules. The flow of precursor transcripts into mature mRNA becomes inhibited in the course of induction. When translation is blocked (e.g. by cycloheximide), expression of IL-2 mRNA can be superinduced by 2 orders of magnitude. This superinduction is completely dependent upon transcription, yet is not accompanied by any significant increase in the rate of primary transcription or in mRNA stability. Instead, the processing of nuclear IL-2 precursor transcripts is greatly facilitated, resulting in pronounced superinduction of cytoplasmic mRNA Once its transcription has been induced, therefore, expression of the IL-2 gene is down-regulated extensively at the level of precursor RNA processing.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC VIROL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Kaempfer, Raymond/0000-0002-5865-4619				AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ARAD G, 1995, CELL IMMUNOL, V160, P240, DOI 10.1016/0008-8749(95)80034-G; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0; EFRAT S, 1984, BIOCHEM BIOPH RES CO, V123, P842, DOI 10.1016/0006-291X(84)90307-3; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GULLBERG M, 1982, J IMMUNOL, V128, P746; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; JARROUS N, 1994, J BIOL CHEM, V269, P23141; KETZINEL M, 1991, SCAND J IMMUNOL, V33, P593, DOI 10.1111/j.1365-3083.1991.tb02531.x; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LEBENDIKER MA, 1987, EMBO J, V6, P585, DOI 10.1002/j.1460-2075.1987.tb04794.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHWARTZ JL, 1983, MUTAT RES, V107, P413, DOI 10.1016/0027-5107(83)90180-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	31	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19569	19575		10.1074/jbc.270.33.19569	http://dx.doi.org/10.1074/jbc.270.33.19569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642643	hybrid			2022-12-27	WOS:A1995RP70300059
J	WU, DH; AHMED, SN; LIAN, W; HERSH, LB				WU, DH; AHMED, SN; LIAN, W; HERSH, LB			ACTIVATION OF RAT CHOLINE-ACETYLTRANSFERASE BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; INHIBITION; EXPRESSION; ENZYME	In the past, purification of choline acetyltransferase (ChAT, EC 2.3.1.6), the enzyme responsible for the biosynthesis of the neurotransmitter acetylcholine, has yielded fragmented species of the enzyme. The nature and possible function of these forms of ChAT are not well understood, Using a bacterial expression system, recombinant rat ChAT in its active form has been purified to homogeneity. The purified enzyme was found to be activated to >25-fold when assayed at low ionic strength and >5-fold when assayed at high ionic strength by limited proteolysis with either trypsin or chymotrypsin, but not with proteinase K. The activated ChAT shows an increased K-m for both substrates, diminished sensitivity to salt activation and a pH optimum that is shifted approximately 1 pH unit, On a denaturing SDS-polyacrylamide gel, the activated ChAT is composed of three to four polypeptides; however, it migrates as an intact 68-kDa protein species on gel filtration, In order to delineate the site of cleavage by proteolysis, the newly generated fragments have been subjected to N-terminal sequencing, By comparing cleavage sites between trypsin and chymotrypsin, the putative activation sites were identified.			WU, DH (corresponding author), UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,800 ROSE ST,LEXINGTON,KY 40536, USA.				NIA NIH HHS [AG05893] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R55AG005893, R01AG005893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENECKE S, 1993, J NEUROCHEM, V61, P804, DOI 10.1111/j.1471-4159.1993.tb03590.x; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; BRUCE G, 1989, NEUROCHEM RES, V14, P613, DOI 10.1007/BF00964869; BRUCE G, 1985, J NEUROCHEM, V45, P611, DOI 10.1111/j.1471-4159.1985.tb04030.x; CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x; CHAO LP, 1975, J NEUROCHEM, V25, P261, DOI 10.1111/j.1471-4159.1975.tb06963.x; Cleland W W, 1979, Methods Enzymol, V63, P103; COZZARI C, 1983, BRAIN RES, V276, P109, DOI 10.1016/0006-8993(83)90552-8; CURRIER SF, 1974, P NATL ACAD SCI USA, V71, P3355, DOI 10.1073/pnas.71.9.3355; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GLOVER VAS, 1971, J NEUROCHEM, V18, P571, DOI 10.1111/j.1471-4159.1971.tb11987.x; HAHN M, 1992, P NATL ACAD SCI USA, V89, P4387, DOI 10.1073/pnas.89.10.4387; HERSH LB, 1978, J NEUROCHEM, V30, P1077, DOI 10.1111/j.1471-4159.1978.tb12401.x; HERSH LB, 1982, J BIOL CHEM, V257, P2820; HERSH LB, 1984, J BIOL CHEM, V259, P1253; HERSH LB, 1978, J BIOL CHEM, V254, P11988; IBANEZ CF, 1991, P NATL ACAD SCI USA, V88, P3676, DOI 10.1073/pnas.88.9.3676; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUTNER HG, 1977, CRC CR REV BIOCH MOL, V4, P341, DOI 10.3109/10409237709105460; MAUTNER HG, 1986, NEUROTRANSMITTER ENZ, V5, P273; MCGEER PL, 1984, LIFE SCI, V34, P2319, DOI 10.1016/0024-3205(84)90419-3; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; ROSSIER J, 1977, INT REV NEUROL, V28, P283; RYAN RL, 1979, BIOCHEMISTRY-US, V18, P5357, DOI 10.1021/bi00591a016; SALVATERRA PM, 1985, J NEUROSCI, V5, P903; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY BVR, 1981, J PHARMACOL EXP THER, V216, P378; SCHUBERTH J, 1966, BIOCHIM BIOPHYS ACTA, V122, P470, DOI 10.1016/0926-6593(66)90039-7; TUCEK S, 1988, HDB EXPT PHARM, V86, P129; WHITE HL, 1970, BIOCHIM BIOPHYS ACTA, V206, P343, DOI 10.1016/0005-2744(70)90151-8; WU DH, 1994, J NEUROCHEM, V62, P1653	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19395	19401		10.1074/jbc.270.33.19395	http://dx.doi.org/10.1074/jbc.270.33.19395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642620	hybrid			2022-12-27	WOS:A1995RP70300034
J	HOLLIDAY, LS; DEAN, AD; GREENWALD, JE; GLUCK, SL				HOLLIDAY, LS; DEAN, AD; GREENWALD, JE; GLUCK, SL			C-TYPE NATRIURETIC PEPTIDE INCREASES BONE-RESORPTION IN 1,25-DIHYDROXYVITAMIN D-3 STIMULATED MOUSE BONE-MARROW CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; MICROBIAL ORIGIN; CELL-LINE; RAT; INHIBITION; DIFFERENTIATION; RECEPTORS; CNP; OSTEOCLASTS; EXPRESSION	Most agents that regulate osteoclast bone resorption exert their effects indirectly, through the osteoblast, Nitric oxide, which stimulates soluble guanylyl cyclase, has been reported to inhibit osteoclast bone resorption directly, by a cGMP-independent mechanism (1). In this report, we demonstrate that C-type natriuretic peptide (CNP), an activator of membrane-bound guanylyl cyclase, stimulates bone resorption by osteoclast-containing 1,25-dihydroxyvitamin D-3 (1,2 5-(OH)(2)D-3)-stimulated mouse bone marrow cultures. Quantitative reverse transcription polymerase chain reaction assays and anti-CNP immunocytochemistry were used to demonstrate that CNP is expressed in mouse marrow cells cultured in the presence, but not the absence, of 1,25-(OH)(2)D-3. mRNA for guanylyl cyclase type B, the receptor for CNP, was expressed in cultures independent of 1,25-(OH)(2)D-3, CNP (1 and 10 mu M) elevated cGMP production in marrow cultures to 350 and 870%, respectively, of control values, 10 mu M CNP increased osteoclast bone resorptive activity, measured by the resorption area on whale dentine wafers, or by the NH4Cl-inhibitable release of [H-3]proline from radiolabeled bone chips, to 214 and 557% of control, respectively, without affecting osteoclast formation, Bone resorption by the marrow cultures was inhibited by 7F9.1, a monoclonal antibody raised against CNP, but not by control antibodies. These results indicate that CNP is a potent activator of osteoclast activity and may be a novel local regulator of bone remodeling.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RENAL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63108 USA; WASHINGTON UNIV, SCH MED, GEORGE M OBRIEN KIDNEY & UROL DIS CTR, ST LOUIS, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK09976, DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976, R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUI T, 1992, ENDOCRINOLOGY, V130, P2487, DOI 10.1210/en.130.5.2487; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOYDE A, 1985, SCANNING ELECTRON MI, V3, P1259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DEAN AD, 1994, AM J PHYSIOL, V266, pF491, DOI 10.1152/ajprenal.1994.266.3.F491; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P670; FLETCHER AE, 1986, FEBS LETT, V208, P263, DOI 10.1016/0014-5793(86)81029-8; FUKUSHIMA O, 1991, J HISTOCHEM CYTOCHEM, V39, P529, DOI 10.1177/39.4.1672318; GARBERS DL, 1993, ADV SEC MESS PHOSPH, V28, P91; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Humphreys G K, 1981, J Immunoassay, V2, P137, DOI 10.1080/15321818108056973; IMURA R, 1992, MOL PHARMACOL, V42, P982; ISHIZAKA Y, 1992, BIOCHEM BIOPH RES CO, V189, P697, DOI 10.1016/0006-291X(92)92257-X; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; MARTIN TJ, 1993, OSTEOPOROSIS INT, V3, pS121, DOI 10.1007/BF01621884; MINAMINO N, 1993, BIOCHEM BIOPH RES CO, V197, P326, DOI 10.1006/bbrc.1993.2479; MUNDY GR, 1993, J CELL BIOCHEM, V53, P296, DOI 10.1002/jcb.240530405; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; MUNDY GR, 1993, OSTEOPOROSIS INT, V3, pS126; MUNDY GR, 1992, INT J CELL CLONING, V10, P215, DOI 10.1002/stem.5530100404; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; OHYAMA Y, 1993, LIFE SCI, V52, pPL153, DOI 10.1016/0024-3205(93)90071-A; RODAN GA, 1975, SCIENCE, V189, P467, DOI 10.1126/science.168639; SANO T, 1992, J PHARMACOL EXP THER, V260, P825; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; STERN PH, 1992, RES COMMUN CHEM PATH, V75, P19; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDA T, 1989, P SOC EXP BIOL MED, V191, P214; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1993, ENDOCRINOLOGY, V133, P3038, DOI 10.1210/en.133.6.3038; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARGAS SJ, 1989, ENDOCRINOLOGY, V125, P2527, DOI 10.1210/endo-125-5-2527; WANG ZQ, 1992, AM J PHYSIOL, V263, pF277, DOI 10.1152/ajprenal.1992.263.2.F277; WILKINS MR, 1990, J CLIN INVEST, V85, P1274, DOI 10.1172/JCI114564	47	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18983	18989		10.1074/jbc.270.32.18983	http://dx.doi.org/10.1074/jbc.270.32.18983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642558				2022-12-27	WOS:A1995RN95400046
J	CRATER, DL; VANDERIJN, I				CRATER, DL; VANDERIJN, I			HYALURONIC-ACID SYNTHESIS OPERON (HAS) EXPRESSION IN GROUP-A STREPTOCOCCI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; TYPE-12 M-PROTEIN; MOLECULAR CHARACTERIZATION; ESCHERICHIA-COLI; MESSENGER-RNA; GENE; PYOGENES; VIRULENCE; LOCUS; IDENTIFICATION	The has operon is composed of three genes, hasA, hasB, and hasC that encode hyaluronate synthase. UDP-glucose dehydrogenase, and presumptively UDP-glucose pyrophosphorylase, respectively. Expression of the has operon was shown to be required for the synthesis of the hyaluronic acid capsule in group A streptococci. Previous studies indicated that some group A and group C streptococcal strains produce the hyaluronic acid capsule, while others do not. In addition, it was observed that encapsulated strains cultured in stationary phase of growth lose the hyaluronic acid capsule. Therefore, the molecular mechanisms controlling the expression of the hyaluronic acid capsule in group A streptococci was investigated. In this study, it was determined that all encapsulated and unencapsulated strains of group A streptococci as well as encapsulated group C streptococci analyzed possess the has operon locus. The acapsular phenotype was accounted for by the absence of hyaluronate synthase activity in the membrane and not the production of extracellular hyaluronidase. A has operon mRNA transcript was not expressed by unencap sulated strains of group A streptococci, whereas encapsulated strains of group A streptococci grown to mid to late exponential phase produced the hyaluronate capsule, as well as has operon mRNA. However, as the streptococci entered the stationary phase of growth, they became acapsular and this was concomitant with the loss of has operon mRNA transcript. These results were confirmed by primer extension analyses of RNA isolated from encapsulated and unencapsulated strains of group A streptococci as well as RNA prepared from encapsulated strains cultured in exponential and stationary phases of growth. Thus, the loss of has operon mRNA in unencapsulated group A streptococci, as well as growth phase regulation occurs at the previously mapped has operon promoter. These data suggested that the synthesis of the hyaluronic acid capsule for group A streptococci may be controlled by transcriptional mechanisms.	WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401, R01AI037320] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [T32-AI-07401, AI37320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BOYLE MDP, 1994, INFECT IMMUN, V62, P1336, DOI 10.1128/IAI.62.4.1336-1347.1994; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CAPARON MG, 1987, P NATL ACAD SCI USA, V84, P8677, DOI 10.1073/pnas.84.23.8677; CHITNIS CE, 1993, MOL MICROBIOL, V8, P583, DOI 10.1111/j.1365-2958.1993.tb01602.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DERETIC V, 1994, J BACTERIOL, V176, P2773, DOI 10.1128/JB.176.10.2773-2780.1994; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; HOTEZ PJ, 1992, INFECT IMMUN, V60, P1018, DOI 10.1128/IAI.60.3.1018-1023.1992; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; KELLY T, 1994, INFECT IMMUN, V62, P1813, DOI 10.1128/IAI.62.5.1813-1819.1994; Krause RM, 1972, STREPTOCOCCI STREPTO, P3; KROLL JS, 1992, J INFECT DIS, V165, pS93, DOI 10.1093/infdis/165-Supplement_1-S93; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MELIN L, 1990, MOL MICROBIOL, V4, P1881, DOI 10.1111/j.1365-2958.1990.tb02037.x; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; PODBIELSKI A, 1993, MOL GEN GENET, V237, P287, DOI 10.1007/BF00282810; ROBBINS JC, 1987, J BACTERIOL, V169, P5633, DOI 10.1128/jb.169.12.5633-5640.1987; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON WJ, 1990, J BACTERIOL, V172, P696, DOI 10.1128/jb.172.2.696-700.1990; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994	34	101	113	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18452	18458		10.1074/jbc.270.31.18452	http://dx.doi.org/10.1074/jbc.270.31.18452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629171	hybrid			2022-12-27	WOS:A1995RM64200048
J	GILBERT, GE; ARENA, AA				GILBERT, GE; ARENA, AA			PHOSPHATIDYLETHANOLAMINE INDUCES HIGH-AFFINITY BINDING-SITES FOR FACTOR-VIII ON MEMBRANES CONTAINING PHOSPHATIDYL-L-SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBIN-CONVERTING ACTIVITY; COAGULATION FACTOR-V; PHOSPHOLIPID-VESICLES; ENZYMATIC-SYNTHESIS; HUMAN-PLATELETS; C2 DOMAIN; SURFACE; SEQUENCES; PROTEINS; RELEASE	Synthetic membranes of phosphatidylcholine require inclusion of at least 5% phosphatidylserine (Ptd-L-Ser) to form binding sites for factor VIII. The relatively high requirement for Ptd-L-Ser suggests that stimulated platelets may contain another membrane constituent that enhances expression of factor VIII-binding sites. We report that phosphatidylethanolamine (PE), which is exposed in concert with Ptd-L-Ser in the course of platelet stimulation, induces high affinity binding sites for factor VIII on synthetic membranes containing 1-15% Ptd-L-Ser. The affinity of factor VIII for binding sites on membranes of Ptd-L-Ser/PE/phosphatidylcholine in a 4:20:76 ratio was 10.2 +/- 3.5 nM with 180 +/- 33 phospholipid molecules/site. PE did not induce binding sites on membranes of 4% Ptd-D-Ser, indicating that the induced binding sites require the correct stereochemistry of Ptd-L-Ser as well as PE. Egg PE and dimyristoyl-PE were equivalent for inducing factor VIII-binding sites, indicating that hexagonal phase-inducing properties of PE are not important. We conclude that PE induces high affinity factor VIII-binding sites on membranes with physiologic mole fractions of Ptd-L-Ser, possibly including those of stimulated platelets.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GILBERT, GE (corresponding author), BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, 1400 VFW PKWY, BOSTON, MA 02132 USA.							BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; COMFURIUS P, 1990, J LIPID RES, V31, P1719; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cullis P, 1983, CONCEPTS MEMBRANE ST, P39; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER PA, 1990, BLOOD, V75, P1999; GAESTEL M, 1983, BIOCHIM BIOPHYS ACTA, V732, P405, DOI 10.1016/0005-2736(83)90057-3; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GILBERT GE, 1993, BLOOD, V82, pA60; GILBERT GE, 1994, THROMBOSIS HEMORRHAG, P37; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HINDERLITER AK, 1994, BIOPHYS J, V67, P1906, DOI 10.1016/S0006-3495(94)80673-3; KANE WH, 1988, BLOOD, V71, P539; LUBIN B, 1981, J CLIN INVEST, V67, P1643, DOI 10.1172/JCI110200; MANN KG, 1990, BLOOD, V76, P1; MARCUS AJ, 1969, J LIPID RES, V10, P108; MARINETTI GV, 1977, BIOCHIM BIOPHYS ACTA, V465, P198, DOI 10.1016/0005-2736(77)90074-8; MONCELLI MR, 1994, BIOPHYS J, V66, P1969, DOI 10.1016/S0006-3495(94)80990-7; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; PUSSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SCHICK PK, 1976, J CLIN INVEST, V57, P1221, DOI 10.1172/JCI108390; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x	39	56	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18500	18505		10.1074/jbc.270.31.18500	http://dx.doi.org/10.1074/jbc.270.31.18500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629178	hybrid			2022-12-27	WOS:A1995RM64200055
J	CREASY, CL; CHERNOFF, J				CREASY, CL; CHERNOFF, J			CLONING AND CHARACTERIZATION OF A HUMAN PROTEIN-KINASE WITH HOMOLOGY TO STE20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; SKELETAL-MUSCLE; YEAST; EXPRESSION; PHOSPHORYLATION; COMPLEMENTATION; ELECTROPHORESIS; ACTIVATOR	A human protein kinase (termed MST1) has been cloned and characterized. The MST1 catalytic domain is most homologous to Ste20 and other Ste20-like kinases (62-65% similar). MST1 is expressed ubiquitously, and the MST1 protein is present in all human cell lines examined. Biochemical characterization of MST1 catalytic activity demonstrates that it is a serine/threonine kinase, and that it can phosphorylate an exogenous substrate as well as itself in an in vitro kinase assay. Further characterization of the protein indicates MST1 activity increases approximately 3-4-fold upon treatment with PP2A, suggesting that MST1 is negatively regulated by phosphorylation. MST1 activity decreases approximately 2-fold upon treatment with epidermal growth factor; however, overexpression of MST1 does not affect extracellular signal-regulated kinase-1 and -2 activation. MST1 is unaffected by heat shock or high osmolarity, indicating that it is not involved in the stress-activated or high osmolarity glycerol signal transduction pathways. Thus MST1, although homologous to a member of a yeast MAPK cascade, is not involved in the regulation of a known mammalian MAPK pathway and potentially regulates a novel signaling cascade.			CREASY, CL (corresponding author), FOX CHASE CANC CTR, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [R01CA058836] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58836, CA-09035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; EVAN GL, 1985, MOL CELL BIOL, V8, P551; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HATZ P, 1994, J BIOL CHEM, V269, P16802; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KURJAN J, 1993, ANNU REV GENET, V27, P147; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SETH A, 1991, J BIOL CHEM, V266, P23521; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	42	171	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21695	21700		10.1074/jbc.270.37.21695	http://dx.doi.org/10.1074/jbc.270.37.21695			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665586	hybrid			2022-12-27	WOS:A1995RU75700044
J	GORSHKOVA, I; MOORE, JL; MCKENNEY, KH; SCHWARZ, FP				GORSHKOVA, I; MOORE, JL; MCKENNEY, KH; SCHWARZ, FP			THERMODYNAMICS OF CYCLIC-NUCLEOTIDE BINDING TO THE CAMP RECEPTOR PROTEIN AND ITS T127L MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI; CONFORMATIONAL STATES; HEAT-CAPACITY; AMP; DNA; EQUILIBRIUM; COMPLEX; CAP	The thermodynamics of the binding of cyclic adenosine monophosphate (cAMP) and its non-functional analog, cyclic guanosine monophosphate (cGMP), to cyclic AMP receptor protein (CRP) and its T127L mutant were investigated by isothermal titration calorimetry (ITC) in 0.2 and 0.5 M KCl phosphate buffer (pH 7.0) at 24 and 39 degrees C. Although, the binding of the first cAMP molecule to CRP is exothermic with an enthalpy change (Delta H-b) of -6 kJ mol(-1), a heat capacity change (Delta C-p) of -0.300 kJ mol(-1) K-1, and an entropy increase (Delta S-b) of 72 J mol(-1) K-1, the overall binding of cAMP to CRP is endothermic and positively cooperative: binding of the first cAMP molecule increases the affinity for the second one by more than an order of magnitude at 24 degrees C. The binding of the second cAMP molecule is accompanied by large changes of 48.1 kJ mol(-1) in Delta H-b, of -1.4 kJ mol(-1) K-1 in Delta C-p, and of 255 J mol(-1) K-1 in Delta S-b at 24 degrees C and 0.5 M KCl phosphate buffer. In contrast, the overall binding of cGMP to CRP is exothermic and non-cooperative with Delta H-b, Delta C-p, and Delta S-b, values close to the those values for binding of the first cAMP molecule to CRP. The point mutation, T127L, switches off the cooperativity between the cAMP ligated binding sites without affecting the binding constant of cAMP and changes the specificity of the protein so that transcription is now activated only upon cGMP binding. All the binding reactions to CRP and the mutant are mainly entropically driven at 24 degrees C.	NIST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; RUSSIAN ACAD SCI,INST BIOORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA	National Institute of Standards & Technology (NIST) - USA; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences								DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; EILEN E, 1977, BIOCHIM BIOPHYS ACTA, V493, P115, DOI 10.1016/0005-2795(77)90264-1; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KUMAR SA, 1980, FEBS LETT, V109, P121, DOI 10.1016/0014-5793(80)81324-X; LANG L, 1966, ABSORPTION SPECTRA U, V1, P326; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; MOORE JL, 1993, THESIS G WASHINGTON; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1988, THERMOCHIM ACTA, V128, P267, DOI 10.1016/0040-6031(88)85371-1; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TAN GS, 1991, BIOCHEMISTRY-US, V30, P5076, DOI 10.1021/bi00234a034; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66	22	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21679	21683		10.1074/jbc.270.37.21679	http://dx.doi.org/10.1074/jbc.270.37.21679			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665583	hybrid			2022-12-27	WOS:A1995RU75700041
J	ASAHI, M; FUJII, J; SUZUKI, K; SEO, HG; KUZUYA, T; HORI, M; TADA, M; FUJII, S; TANIGUCHI, N				ASAHI, M; FUJII, J; SUZUKI, K; SEO, HG; KUZUYA, T; HORI, M; TADA, M; FUJII, S; TANIGUCHI, N			INACTIVATION OF GLUTATHIONE-PEROXIDASE BY NITRIC-OXIDE - IMPLICATION FOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT RAT-LIVER; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ADP-RIBOSYLATION; S-NITROSYLATION; APOPTOSIS; DEATH	S-nitro-N-acetyl-DL-penicillamine (SNAP), a nitric oxide (NO) donor, inactivated bovine glutathione peroxidase (GPx) in a dose- and time-dependent manner. The IC50 of SNAP for GPx was 2 mu M at 1 h of incubation and was 20% of the IC50 for another thiol enzyme, glyceraldehyde-3-phosphate dehydrogenase, in which a specific cysteine residue is known to be nitrosylated, Incubation of the inactivated GPx with 5 mM dithiothreitol within 1 h restored about 50% of activity of the start of the SNAP incubation. A longer exposure to NO donors, however, irreversibly inactivated the enzyme, The similarity of the inactivation with SNAP and reactivation with dithiothreitol of GPx to that of glyceraldehyde-3-phosphate dehydrogenase, suggested that NO released from SNAP modified a cysteine-like essential residue on GPx, When U937 cells were incubated with 100 mu M SNAP for 1 h, a significant decrease in GPx activity was observed although the change was less dramatic than that with the purified enzyme, and intracellular peroxide levels increased as judged by flow cytometric analysis using a peroxide-sensitive dye, Other major antioxidative enzymes, copper/zinc superoxide dismutase, manganese superoxide dismutase, and catalase, were not affected by SNAP, which suggested that the increased accumulation of peroxides in SNAP-treated cells was due to inhibition of GPx activity by NO. Moreover, stimulation with lipopolysaccharide significantly decreased intracellular GPx activity in RAW 264.7 cells, and this effect was blocked by NO synthase inhibitor N-omega-methyl-L-arginine. This indicated that GPx was also inactivated by endogenous NO, This mechanism may at least in part explain the cytotoxic effects of NO on cells and NO-induced apoptotic cell death.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOPHYSIOL, SUITA, OSAKA 565, JAPAN; KANSAI MED UNIV, CHEM LAB, HIRAKATA, OSAKA 573, JAPAN	Osaka University; Osaka University; Osaka University; Kansai Medical University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Aebi H., 1974, METHODS ENZYMATIC AN, Vsecond, P673, DOI [DOI 10.1016/B978-0-12-091302-2.50032-3, 10.1016/B978-0-12-091302-2.50032-3]; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ALBINA JE, 1993, J IMMUNOL, V150, P5080; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BASS DA, 1983, J IMMUNOL, V130, P1910; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KORSMEYER SJ, 1992, BLOOD, V80, P879; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Matsuda Y, 1991, Protein Expr Purif, V2, P170, DOI 10.1016/1046-5928(91)90067-S; MONCADA S, 1991, PHARMACOL REV, V43, P109; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUEMIZU H, 1992, HYBRIDOMA, V11, P795, DOI 10.1089/hyb.1992.11.795; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	277	286	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21035	21039		10.1074/jbc.270.36.21035	http://dx.doi.org/10.1074/jbc.270.36.21035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673130	hybrid			2022-12-27	WOS:A1995RU05400027
J	FIRE, E; GUTMAN, O; ROTH, MG; HENIS, YI				FIRE, E; GUTMAN, O; ROTH, MG; HENIS, YI			DYNAMIC OR STABLE INTERACTIONS OF INFLUENZA HEMAGGLUTININ MUTANTS WITH COATED PITS - DEPENDENCE ON THE INTERNALIZATION SIGNAL BUT NOT ON AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; RECEPTOR-MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEIN TRAFFICKING; LYSOSOMAL ACID-PHOSPHATASE; LOW-DENSITY LIPOPROTEIN; CYTOPLASMIC DOMAIN; VIRUS HEMAGGLUTININ; ASIALOGLYCOPROTEIN RECEPTOR; LATERAL MOBILITY; INVITRO BINDING	Measurements of the lateral mobility of native and mutated membrane proteins, combined with treatments that alter clathrin lattice structure, are capable of characterizing their interactions with coated pits in live cells (Fire, E., Zwart, D. E., Roth, M. G., and Henis, Y. I. (1991) J. Cell Biol. 115, 1585-1594). To explore the dependence of these interactions on the internalization signal and the aggregation state of the protein, we have extended this approach to investigate the interactions between coated pits and several influenza hemagglutinin (HA) mutants, which differ in the internalization signals in their short cytoplasmic tails. The lack of internalization signals in the trimeric wild-type HA enables a direct comparison between specific internalization signals introduced singly in each mutant. We have selected for these studies HA mutants that showed different internalization rates and varied in their tendency to aggregate into complexes larger than trimers. Our results indicate that the mode of interaction with coated pits (transient association-dissociation versus stable entrapment) depends on the internalization signal and affects the internalization efficiency. Mutants that contain a strong internalization signal and undergo fast endocytosis were entrapped in coated pits for the entire duration of the lateral mobility measurement, suggesting stable association with (slow dissociation from) coated pits. A mutant with a suboptimal internalization signal, which was internalized 10-fold slower, exhibited transient interactions with coated pits. Both types of interactions disappeared or were significantly reduced upon disruption of the clathrin lattices under hypertonic conditions, and were modulated following the ''freezing'' of coated pits by cytosol acidification. Unlike the dependence on the cytoplasmic internalization signal, the interactions with coated pits did not depend on the aggregation state (measured by sucrose gradient centrifugation after solubilization in n-octylglucoside) of the mutants.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Tel Aviv University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X; Henis, Yoav/0000-0002-1408-3877	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRANDTZAEG P, 1973, SCAND J IMMUNOL, V2, P273, DOI 10.1111/j.1365-3083.1973.tb02037.x; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELSON EL, 1979, J SUPRAMOL STR CELL, V12, P481, DOI 10.1002/jss.400120408; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KATZIR Z, 1994, J BIOL CHEM, V269, P21568; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZWART DE, 1995, IN PRESS J BIOL CHEM	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21075	21081		10.1074/jbc.270.36.21075	http://dx.doi.org/10.1074/jbc.270.36.21075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673136	hybrid			2022-12-27	WOS:A1995RU05400034
J	SHEN, WJ; KIM, HS; TSAI, SY				SHEN, WJ; KIM, HS; TSAI, SY			STIMULATION OF HUMAN INSULIN-RECEPTOR GENE-EXPRESSION BY RETINOBLASTOMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; SUSCEPTIBILITY GENE; FUNCTIONAL-ANALYSIS; TUMOR SUPPRESSOR; PROMOTER REGION; FACTOR-BINDING; PROTEIN; GROWTH	Multiple cis-acting elements have been defined to be important for the transcriptional regulation of the human insulin receptor (hIR) gene expression. We report here that one of these elements also mediated the stimulation of hIR promoter activity by the retinoblastoma gene product (Rb). The cis-element responsible for Rb stimulation was localized to the GA and GC boxes situated between -643 to -607 of the hIR gene. We have previously demonstrated that these GA and GC boxes bind Sp1 with high affinity and are responsible for E1a activation of hIR promoter activity. Mutation of these sequences completely abolished Rb-dependent enhancement of hIR promoter activity. In addition, we localized three regions in the N-terminal domain of Rb to be involved in stimulation of hIR promoter activity. Our results represent one of the first studies to demonstrate a functional importance assigned to the multiple phosphorylation sites in the N terminus of Rb. Finally, the mechanism by which Rb activates the hIR promoter are presented.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044988] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44988] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAKI E, 1991, J BIOL CHEM, V266, P3944; ARAKI E, 1987, J BIOL CHEM, V262, P16186; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMERON KE, 1992, J BIOL CHEM, V267, P17375; CHELLAPPAN SP, 1991, CELL, V65, P1058; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAHN CR, 1985, ANNU REV MED, V36, P429; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; KIM HS, 1994, MOL ENDOCRINOL, V9, P178; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STRAUS DS, 1984, ENDOCR REV, V5, P356, DOI 10.1210/edrv-5-2-356; SUMEGI J, 1990, CELL GROWTH DIFFER, V2, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHYTE P, 1988, NATURE, V34, P471; XU J, 1993, J BIOL CHEM, V268, P16065; YU DH, 1992, J BIOL CHEM, V267, P10203	58	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20525	20529		10.1074/jbc.270.35.20525	http://dx.doi.org/10.1074/jbc.270.35.20525			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657628	hybrid			2022-12-27	WOS:A1995RR58400046
J	VEMU, S; REICHEL, RR				VEMU, S; REICHEL, RR			CELL-CYCLE REGULATION OF A NOVEL DNA-BINDING COMPLEX IN SACCHAROMYCES-CEREVISIAE WITH E2F-LIKE PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; GROWTH-REGULATION; GENE-EXPRESSION; S-PHASE; PROTEIN; YEAST; PHOSPHORYLATION; ACTIVATION; SITE; SWI4	Using a biochemical approach, we have detected an activity in Saccharomyces cerevisiae extract that displays the same DNA binding specificity as the mammalian E2F transcription factor and interacts with TTTCGCGC promoter elements. Additional studies revealed that this factor, termed SCELA (S. cerevisiae E2F-like activity), also binds to the closely related SCB promoter sequences. SCB sites (consensus: TTTCGTG) are involved in the cell cycle regulation of several S. cerevisae cyclin genes and have been shown to interact with the heterodimeric yeast Swi4-Swi6 complex. However, genetic studies clearly demonstrate that SCELA is not related to Swi4 or Swi6. These experiments imply that SCB sites are able to interact with at least two activities: Swi4-Swi6 and SCELA. Because SCB sites are critical for the periodic activation of cell cycle genes, we asked whether SCELA is regulated during yeast cell cycle. Employing a temperature-sensitive strain, we were able to demonstrate that the DNA binding activity of SCELA oscillates during the cell cycle and reaches its maximum at the transition between the G(1) and S phases. Preliminary studies suggest that this fluctuation is mediated by phosphorylation/dephosphorylation events. Further characterization of SCELA by UV cross-licking experiments indicate a molecular mass of 47 kDa for this activity. In addition, we present evidence strongly suggesting that SCELA is actually the DNA binding moiety of a large 300-kDa protein complex. Together, these studies firmly indicate that SCELA (as part of a larger complex) plays a critical role in cell cycle regulation of SCB-containing genes, such as CLN cyclins and HO endonuclease. This hypothesis is consistent with other studies that conclude that the SCB-mediated cell cycle oscillation of CLN cyclins and HO requires activities that are distinct from Swi4-Swi6. Finally, it is worth mentioning that the similarities between SCELA and E2F, which is a crucial component in mammalian cell cycle regulation, extend well beyond the DNA binding specificity. In analogy to E2F, SCELA oscillates during the cell cycle, interacts with other cellular activities, and binds to promoter elements that are known mediators of cell cycle control. We will discuss possible functions for SCELA in yeast cell cycle regulation and its relationship to E2F.	CHICAGO MED SCH,DEPT PHARMACOL & MOLEC BIOL,N CHICAGO,IL 60064	Chicago Medical School								ANDREWS BJ, 1992, BIOCHEM CELL BIOL, V70, P1073, DOI 10.1139/o92-152; ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BREEDEN L, 1994, GENETICS, V138, P1015; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MAI B, 1993, FEBS LETT, V321, P153, DOI 10.1016/0014-5793(93)80098-F; MALHOTRA P, 1993, J BIOL CHEM, V268, P20392; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Murray A, 1993, CELL CYCLE INTRO; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Reichel Ronald R., 1992, Gene Expression, V2, P259; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STRUHL K, 1987, CELL, V20, P269	33	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20724	20729		10.1074/jbc.270.35.20724	http://dx.doi.org/10.1074/jbc.270.35.20724			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657654	hybrid			2022-12-27	WOS:A1995RR58400074
J	CAMERON, HS; SZCZEPANIAK, D; WESTON, BW				CAMERON, HS; SZCZEPANIAK, D; WESTON, BW			EXPRESSION OF HUMAN-CHROMOSOME 19P ALPHA(1,3)-FUCOSYL-TRANSFERASE GENES IN NORMAL-TISSUES - ALTERNATIVE SPLICING, POLYADENYLATION, AND ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; HUMAN-PAROTID SALIVA; SIALYL LEWIS-X; FUCOSYL-TRANSFERASE; EMBRYONIC ANTIGEN; E-SELECTIN; DETERMINES EXPRESSION; MOLECULAR-CLONING; CELL-ADHESION	The human alpha(1,3)-fucosyltransferase genes FUT3, FUT5, and FUT6 form a cluster on chromosome 19p13.3. Expression was studied using reverse transcriptase-polymerase chain reaction, rapid amplification of cDNA ends, and Northern analyses, FUT3 and FUT6 were expressed at high levels, while FUT5 expression was lower and restricted to fewer cell types. Alternatively spliced transcripts were identified for FUT3 and FUT6 in kidney, Liver, and colon. A 2.37-kilobase pair (kb) FUT3 transcript, detected at high levels in kidney and colon, was absent in liver. FUT6 expression was characterized by a 3.5-kb transcript present in kidney and liver, and a 2.5-kb transcript in colon and liver. Two polyadenylation sites were shown for FUT5, but absence of consensus sequences suggests reduced efficiency for cleavage and polyadenylation. Two polyadenylation sites were also shown for FUT6, with the alternatively spliced downstream signal in tissues expressing high levels of FUT6. In these tissues, additional splicing results in isoforms with catalytic domain deletions, No detectable alpha(1,3)- or alpha(1,4)-fucosyltransferase activity was found in assays of cells transfected with FUT6 isoform cDNAs, Thus, tissue-specific post-transcriptional modifications are associated with expression patterns of FUT3, FUT5, and FUT6.	UNIV N CAROLINA, DEPT PEDIAT, DIV PEDIAT HEMATOL ONCOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			/L-2667-2019		NATIONAL CANCER INSTITUTE [K08CA001758] Funding Source: NIH RePORTER; NCI NIH HHS [CA01758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOULARAND S, 1995, J BIOL CHEM, V270, P3748, DOI 10.1074/jbc.270.8.3748; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; CANDELIER JJ, 1993, LAB INVEST, V69, P449; DOHI T, 1994, CANCER, V73, P1552, DOI 10.1002/1097-0142(19940315)73:6<1552::AID-CNCR2820730605>3.0.CO;2-6; DOMINSKI Z, 1994, J BIOL CHEM, V269, P23590; FEIZI T, 1987, BIOCHEM J, V245, P1; FLEMING S, 1986, HISTOCHEM J, V18, P61, DOI 10.1007/BF01675358; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JEZEQUELCUER M, 1992, LIVER, V12, P140; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUIJPERS TW, 1993, BLOOD, V81, P873; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LANGKILDE NC, 1991, BRIT J HAEMATOL, V79, P493, DOI 10.1111/j.1365-2141.1991.tb08061.x; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MANDEL U, 1991, VOX SANG, V61, P205, DOI 10.1111/j.1423-0410.1991.tb00947.x; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MESSNER HA, 1981, BLOOD, V58, P402; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, TRANSFUS CLIN BIOL, V1, P91, DOI 10.1016/S1246-7820(94)80002-2; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NAH HD, 1994, J BIOL CHEM, V269, P16443; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OKADA Y, 1990, J HEPATOL, V10, P1, DOI 10.1016/0168-8278(90)90065-Y; OKADA Y, 1994, CANCER, V73, P1811, DOI 10.1002/1097-0142(19940401)73:7<1811::AID-CNCR2820730707>3.0.CO;2-4; ORNTOFT TF, 1991, BLOOD, V77, P1389; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PENG SB, 1994, J BIOL CHEM, V269, P17262; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI M, 1994, HEPATOLOGY, V19, P138, DOI 10.1016/0270-9139(94)90065-5; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TAMAGAWA H, 1987, J DENT RES, V66, P756, DOI 10.1177/00220345870660031001; TAMAGAWA H, 1987, J DENT RES, V66, P72, DOI 10.1177/00220345870660011601; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAGO K, 1993, CANCER RES, V53, P5559	60	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20112	20122		10.1074/jbc.270.34.20112	http://dx.doi.org/10.1074/jbc.270.34.20112			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650030	hybrid			2022-12-27	WOS:A1995RQ99100066
J	GUSTAFSSON, CM; FALKENBERG, M; SIMONSSON, S; VALADI, H; ELIAS, P				GUSTAFSSON, CM; FALKENBERG, M; SIMONSSON, S; VALADI, H; ELIAS, P			THE DNA LIGANDS INFLUENCE THE INTERACTIONS BETWEEN THE HERPES-SIMPLEX VIRUS-1 ORIGIN-BINDING PROTEIN AND THE SINGLE-STRAND DNA-BINDING PROTEIN, ICP-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL INTERACTION; UL42 PROTEIN; C-TERMINUS; TYPE-1; POLYMERASE; REPLICATION; HELICASE; DOMAIN; PURIFICATION; UL9	The herpes simplex virus type 1 (HSV-1) origin binding protein, OBP, is a DNA helicase specifically stimulated by the viral single strand DNA-binding protein, ICP-8. The stimulation is dependent on direct protein-protein interactions between the C-terminal domain of OBP,Delta OBP, and ICP 8 (Boehmer, P, E,, Craigie, M, C,, Stow, N, D,, and Lehman, I.R. (1994) J. Biol. Chem, 269, 29329-29334). We have now observed that this interaction is dramatically influenced by the nature of the DNA ligand, Stable complexes between Delta OBP, ICP 8, and double stranded DNA,presented either as a specific duplex oligonucleotide or a restriction fragment containing the HSV-1 origin of replication, oriS, can be detected by gel chromatography and gel electrophoresis, In contrast, a single-stranded oligonucleotide, oligo(dT)(65), will completely disrupt the complex between Delta OBP and ICP 8, We therefore suggest that the interaction between Delta OBP and ICP 8 serves to position the single strand DNA-binding protein with high precision onto single-stranded DNA at a replication fork or at an origin of DNA replication.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg			Valadi, Hadi/ABH-9766-2020; Simonsson, Stina/R-2699-2016	Valadi, Hadi/0000-0003-3482-2451; Simonsson, Stina/0000-0001-9020-3714; Gustafsson, Claes/0000-0003-3531-8468				ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BURKE RL, 1985, J BIOL CHEM, V260, P1711; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DIGARD P, 1990, J BIOL CHEM, V265, P17393; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; ELIAS P, 1990, J BIOL CHEM, V267, P17424; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GAO M, 1988, VIROLOGY, V163, P319, DOI 10.1016/0042-6822(88)90272-3; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUPTE SS, 1991, J BIOL CHEM, V266, P11413; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P17424; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kornberg A., 1992, DNA REPLICATION; LEINBACH SS, 1989, BIOCHIM BIOPHYS ACTA, V1008, P281, DOI 10.1016/0167-4781(89)90017-1; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1993, PROTEIN EXPRES PURIF, V4, P32, DOI 10.1006/prep.1993.1005; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; MONAHAN SJ, 1993, J VIROL, V67, P5922, DOI 10.1128/JVI.67.10.5922-5931.1993; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RUYCHEAN WT, 1983, J VIROL, V46, P661; RUYCHEAN WT, 1992, J VIROL, V66, P6273; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; TENNEY DJ, 1993, J VIROL, V67, P534; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990	42	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19028	19034		10.1074/jbc.270.32.19028	http://dx.doi.org/10.1074/jbc.270.32.19028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642564	hybrid			2022-12-27	WOS:A1995RN95400052
J	HIROTA, J; MICHIKAWA, T; MIYAWAKI, A; FURUICHI, T; OKURA, I; MIKOSHIBA, K				HIROTA, J; MICHIKAWA, T; MIYAWAKI, A; FURUICHI, T; OKURA, I; MIKOSHIBA, K			KINETICS OF CALCIUM-RELEASE BY IMMUNOAFFINITY-PURIFIED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN RECONSTITUTED LIPID VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; FUNCTIONAL-CHARACTERIZATION; PERMEABILIZED HEPATOCYTES; ADENINE-NUCLEOTIDES; MOUSE CEREBELLUM; RAT HEPATOCYTES; INSP3 RECEPTOR; SMOOTH-MUSCLE; PURKINJE-CELL; TRISPHOSPHATE	The kinetics of inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release of the immunoaffinity-purified IP3 receptor (IP(3)R), reconstituted into lipid vesicles, was investigated using the fluorescent Ca2+ indicator fluo-3. IP(3)R was purified from mouse cerebellar microsomal fraction by using an immunoaffinity column conjugated with an anti-IP(3)R type 1 (IP(3)R1) antibody. The immunoblotting analysis using monoclonal antibodies against each IP(3)R type showed that the purified IP(3)R is almost homogeneous, composed of IP(3)R1. Ca2+ efflux from the proteoliposomes was monitored as fluorescence changes of 10 mu M fluo-3, whose concentration was high enough to buffer released Ca2+ and to keep deviations of extravesicular free Ca2+ concentration within 30 nM, excluding the possibility of Ca2+-mediated regulation of IP3-induced Ca2+ release. We also examined IP3-induced Ca2+ release using 1 mu M fluo-3, where the deviations of free Ca2+ concentration were within 300 nM. At both fluo-3 concentrations, IP3-induced Ca2+ release showed similar kinetic properties, i.e. little Ca2+ regulation of Ca2+ release was observed in this system. IP3-induced Ca2+ release of the purified IP(3)R exhibited positive cooperativity; the Hill coefficient was 1.8 +/- 0.1. The half-maximal initial rate for Ca2+ release occurred at 100 nM IP3. At the submaximal concentrations of IP3, the purified IP(3)R showed quantal Ca2+ release, indicating that a single type of IP(3)R is capable of producing the phenomenon of quantal Ca2+ release. The profiles of the IP3-induced Ca2+ release of the purified IP(3)R were found to be biexponential with the fast and slow rate constants (k(fast) = 0.3 similar to 0.7 s(-1), k(slow) = 0.03 similar to 0.07 s(-1)), indicating that IP(3)R has two states to release Ca2+. The amount of released Ca2+ by the slow phase was constant over the range of 10-5000 nM IP3 concentrations, whereas that by the fast phase increased in proportion to added IP3. This provides evidence to support the view that the fast phase of Ca2+ release is mediated by the low affinity state and the slow phase by the high affinity state of the IP(3)R. This also suggests that the fast component of Ca2+ release is responsible for the process of quantal Ca2+ release.	TOKYO INST TECHNOL, DEPT BIOENGN, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC NEUROBIOL LAB, TSUKUBA, IBARAKI 305, JAPAN	Tokyo Institute of Technology; RIKEN	HIROTA, J (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.		Hirota, Junji/O-9315-2019; Hirota, Junji/G-1357-2019; Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015; Miyawaki, Atsushi/K-3569-2014	Hirota, Junji/0000-0002-5741-0655; Hirota, Junji/0000-0002-5741-0655; Furuichi, Teiichi/0000-0002-9676-1888; Miyawaki, Atsushi/0000-0002-2329-3235				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1994, SCIENCE, V265, P813, DOI 10.1126/science.8047889; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1994, BIOCHEM J, V300, P81, DOI 10.1042/bj3000081; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PIETRI F, 1990, GASTROEN CLIN BIOL, V14, P710; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	41	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19046	19051		10.1074/jbc.270.32.19046	http://dx.doi.org/10.1074/jbc.270.32.19046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642567				2022-12-27	WOS:A1995RN95400055
J	DAVIS, RE; HARDWICK, C; TAVERNIER, P; HODGSON, S; SINGH, H				DAVIS, RE; HARDWICK, C; TAVERNIER, P; HODGSON, S; SINGH, H			RNA TRANSSPLICING IN FLATWORMS - ANALYSIS OF TRANS-SPLICED MESSENGER-RNAS AND GENES IN THE HUMAN PARASITE, SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; TRYPANOSOMA-BRUCEI; TRIMETHYLGUANOSINE CAP; LEADER SEQUENCE; TRANSCRIPTS; INFORMATION; EXPRESSION; MATURE	Characteristics of trans-splicing in Schistosoma mansoni were examined to explore the significance and determinants of spliced leader (SL) addition in flatworms. Only a small subset of mRNAs acquire the SL. Analysis of 30 trans-spliced mRNAs and four genes revealed no discernable patterns or common characteristics in the genes, mRNAs, or their encoded proteins that might explain the functional significance of SL addition. While the mRNA encoding the glycolytic enzyme enolase is trans-spliced, mRNAs encoding four other glycolytic enzymes are not, indicating trans-splicing is not prevalent throughout this metabolic pathway. Although the 3' end of flatworm SLs contribute an AUG to mRNAs, the SL AUG does not typically serve to provide a methionine for translation initiation of reading frames in recipient mRNAs. SL RNA expression exhibits no apparent sex, tissue, or cell specificity. Trans-spliced genes undergo both cis- and trans-splicing, and the sequence contexts for these respective acceptor sites are very similar. These results suggest trans-splicing in flatworms is most Likely associated either with some property conferred on recipient mRNAs by SL addition or related to some characteristic of the primary transcripts or transcription of trans-spliced genes.	UNIV CALIF SAN FRANCISCO, DEPT BIOL, SAN FRANCISCO, CA 94132 USA; BETHEL COLL, DEPT CHEM, ST PAUL, MN 55112 USA	University of California System; University of California San Francisco					NIAID NIH HHS [AI 32709] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI032709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAHIAN N, 1990, CELL, V61, P1157; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; CONRAD R, 1993, NUCLEIC ACIDS RES, V21, P913, DOI 10.1093/nar/21.4.913; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; CRAIG SP, 1989, NUCLEIC ACIDS RES, V17, P1635, DOI 10.1093/nar/17.4.1635; DAVIS RE, 1988, MOL CELL BIOL, V8, P4745, DOI 10.1128/MCB.8.11.4745; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; Davis Richard E., 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P299; DOSREIS MG, 1993, MOL BIOCHEM PARASIT, V59, P235, DOI 10.1016/0166-6851(93)90221-I; EMMERT DB, 1994, NUCLEIC ACIDS RES, V22, P3445, DOI 10.1093/nar/22.17.3445; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; ROTHER RP, 1992, BIOTECHNIQUES, V13, P524; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STURROCK SS, 1993, BIOCOMPUTING RES UNI; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; Tschudi Christian, 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P255; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WILLMER P, 1980, INVERTEBRATE RELATIO; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	57	56	65	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21813	21819		10.1074/jbc.270.37.21813	http://dx.doi.org/10.1074/jbc.270.37.21813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665603	hybrid			2022-12-27	WOS:A1995RU75700062
J	ROSS, LH; FREEDMAN, JH; RUBIN, CS				ROSS, LH; FREEDMAN, JH; RUBIN, CS			STRUCTURE AND EXPRESSION OF NOVEL SPLICED LEADER RNA GENES IN CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; CASEIN KINASE-II; C-ELEGANS; MESSENGER-RNA; DEVELOPMENTAL REGULATION; TRIMETHYLGUANOSINE CAP; TRANSSPLICING INVITRO; SPLICEOSOMAL SNRNAS; SEQUENCE; CLONING	Approximately 25% of Caenorhabditis elegans genes are organized as operons. Polycistronic transcripts are converted to monocistronic mRNAs by 3' cleavage/polyadenylation and 5' trans-splicing with untranslated, 5'-terminal exons called spliced leaders, (SLs). The 5' termini of mRNAs encoded by downstream genes in operons are accepters for greater than or equal to 7 recently discovered ''novel'' SLs and a classical SL (SL2). Diversity in SL exons is now partly explained by the discovery and characterization of five novel genes that encode C. elegans SL RNAs. These novel SL RNAs contain a 22- or 23-nucleotide SL followed by conserved splice donor and downstream sequences that are essential for catalysis of trans-splicing reactions. The SL3 alpha, SL4, and SL5 RNA genes are tightly clustered on chromosome III; their 114-nucleotide transcripts deliver three distinct SLs to mRNAs. The SL3 beta and SL3 gamma RNA genes are on chromosome I, but are not tightly linked. SL RNAs 3 alpha, 3 beta, and 3 gamma provide identical 5' leader exons, although their 3' sequences diverge. Transcription of SL 3-5 RNA genes appears to be driven by flanking DNA elements that are homologous with segments of promoters for the C. elegans SL2 RNA and small nuclear RNA genes. RNase protection assays demonstrated that novel SL RNAs are transcribed in vivo and accumulate in the poly(A(-)) RNA pool. SL3 exons are transferred to mRNAs as frequently as SL2 exons. In contrast, SL4 is appended to mRNAs 10% as frequently as SL3. The abundance of SL4 RNA increased 6-fold during postembryonic development, and the SL4 RNA gene promoter is active principally in hypodermal cells.			ROSS, LH (corresponding author), ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOLEC PHARMACOL,BRONX,NY 10461, USA.				NIDDK NIH HHS [DK44597] Funding Source: Medline; NIGMS NIH HHS [GM7288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK044597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; Patel Nipam H., 1992, P377; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUL HS, 1984, J BIOL CHEM, V259, P1201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thein SI., 1986, HUMAN GENETIC DIS PR, P33; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	53	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22066	22075		10.1074/jbc.270.37.22066	http://dx.doi.org/10.1074/jbc.270.37.22066			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665629	hybrid			2022-12-27	WOS:A1995RU75700095
J	ELLIS, JA; LUZIO, JP				ELLIS, JA; LUZIO, JP			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PROTEIN (P137) WHICH TRANSCYTOSES BIDIRECTIONALLY IN CACO-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; CANINE KIDNEY-CELLS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PLASMA-MEMBRANE; EPITHELIAL-CELLS; MDCK CELLS; DIFFERENTIAL SOLUBILIZATION; PHASE-SEPARATION; GROWTH-FACTOR; TRANSPORT	Antisera raised against detergent-extracted membrane fractions from the human intestinal epithelial cell line Caco-2 were used to screen a human colon cDNA library in a bacteriophage expression vector. This led to the identification, molecular cloning, and sequencing of a novel plasma membrane protein (p137) which was present in approximately equal amounts on the basolateral and apical surfaces of the cell. The pattern of extraction of p137 from membranes by Triton X-114 and its release from membranes after incubation with phosphatidylinositol-specific phospholipase C were consistent with it being a glycosylphosphatidylinositol-anchored membrane protein. Using antibodies raised against bacterial fusion proteins, it was shown that p137 was present on the cell surface as a reducible homodimer of 137 kDa subunits. There was constitutive release of p137 into the culture medium as a non-reducible 280-kDa entity. Pulse-chase experiments showed that newly synthesized p137 appeared at the basolateral side of a Caco-2 cell layer before appearing at the apical domain. Domain-specific surface biotinylation of Caco-2 cells at 4 degrees C, followed by chasing at 37 degrees C, demonstrated that p137 is capable of transcytosing in both directions across Caco-2 cells. The unusual plasma membrane domain distribution of this glycosylphosphatidylinositol-linked protein and its transcytosis characteristics demonstrate the existence of a previously uncharacterized apical to basolateral transcytotic pathway in Caco-2 cells.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Eckhardt, Erik/G-1567-2010					ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; APODACA G, 1993, J BIOL CHEM, V268, P23712; BANTING G, 1989, FEBS LETT, V254, P171; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BELL GI, 1993, HUM MOL GENET, V2, P1793; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAKE B, 1990, BIOCHEM J, V267, P631, DOI 10.1042/bj2670631; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAN N, 1994, J BIOL CHEM, V269, P18849; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; FOOD MR, 1994, J BIOL CHEM, V269, P3034; Fritz B. A., 1994, Molecular Biology of the Cell, V5, p71A; GILBRAT JF, 1987, J MOL BIOL, V198, P425; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HASTEWELL J, 1991, ADV DRUG DELIVER REV, V7, P119, DOI 10.1016/0169-409X(91)90050-M; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HOOPER NM, 1991, BIOCHEM J, V273, P301, DOI 10.1042/bj2730301; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Hopkins C.R., 1986, SITE SPECIFIC DRUG D, P27; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL S, 1994, J BIOL CHEM, V269, P16993; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; JACKMAN MR, 1994, J CELL SCI, V107, P2547; JESSUP JM, 1988, CANCER RES, V48, P1689; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V304, P80; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEBIVIC A, 1993, J BIOL CHEM, V268, P6909; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LUZIO JP, 1995, GENE PROBES PRACTICA, V2, P77; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; METZ CN, 1994, EMBO J, V13, P1741, DOI 10.1002/j.1460-2075.1994.tb06438.x; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEREZ JH, 1988, BIOCHEM J, V251, P763, DOI 10.1042/bj2510763; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SIMINOSKI K, 1986, J CELL BIOL, V103, P1979, DOI 10.1083/jcb.103.5.1979; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P551, DOI 10.1093/nar/12.1Part2.551; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; SZTUL E, 1993, J BIOL CHEM, V268, P1876; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	62	31	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20717	20723		10.1074/jbc.270.35.20717	http://dx.doi.org/10.1074/jbc.270.35.20717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657653	hybrid			2022-12-27	WOS:A1995RR58400073
J	ESCHENBRENNER, M; COVES, J; FONTECAVE, M				ESCHENBRENNER, M; COVES, J; FONTECAVE, M			THE FLAVIN REDUCTASE-ACTIVITY OF THE FLAVOPROTEIN COMPONENT OF SULFITE REDUCTASE FROM ESCHERICHIA-COLI - A NEW MODEL FOR THE PROTEIN-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; PROSTHETIC GROUPS; HEMOFLAVOPROTEIN; ENTEROBACTERIA; OXIDOREDUCTASE; SEQUENCE; PARAMETERS; GENERATION; IRON	Sulfite reductase (SiR) from Escherichia coli has a alpha(8) beta(4) subunit structure, where alpha(8) is a flavoprotein (SiR-FP) containing both FAD and FMN as prosthetic groups. It also exhibits a NADPH:flavin oxidoreductase activity with exogenous riboflavin, FMN, and FAD serving as substrates. The flavin reductase activity may function during activation of ribonucleotide reductase or during ferrisiderophore reduction. A plasmid containing cysJ gene, coding for the alpha subunit, overexpresses flavin reductase activity by 100-fold, showing that a is the site of free flavin reduction. The overproducer allows a fast and simple preparation of large amounts of the flavoprotein. Kinetic studies of its flavin reductase activity demonstrates a ping-pong bisubstrate-biproduct reaction mechanism. NADP(+) inhibition studies show that both substrates, NADPH and free flavins, bind to the same site. While the FAD cofactor mediates the electron transfer between NADPH and free flavins, the FMN cofactor is not essential since a FMN-depleted SiR-FP retains a large proportion of activity. In contradiction with previous reports, SiR-FP is found to contain 1.6-1.7 flavin per alpha subunit. This result, together with the sequence homology between SiR-FP and NADPH-cytochrome P-450 reductase, suggests a new model for the structure of the protein with one FMN and one FAD prosthetic group per a subunit.	UNIV GRENOBLE 1,ETUD DYNAM & STRUCT SELECT LAB,CNRS,URA 332,F-38041 GRENOBLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)								BEINERT H, 1960, ENZYMES, V2, P339; BRADFORD MM, 1970, ANAL BIOCHEM, V72, P248; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; COVES J, 1993, BIOCHEM BIOPH RES CO, V192, P1403, DOI 10.1006/bbrc.1993.1572; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; FAEDER EJ, 1974, J BIOL CHEM, V249, P1599; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1993, BIOMETALS, V7, P3; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; JABLONSKI E, 1977, BIOCHEMISTRY-US, V16, P2932, DOI 10.1021/bi00632a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1971, FLAVINS FLAVOPROTEIN, P523; TANNER J, 1994, J MOL BIOL, V241, P283, DOI 10.1006/jmbi.1994.1501; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; ZENNO S, 1994, J BACTERIOL, V176, P3544, DOI 10.1128/JB.176.12.3544-3551.1994	24	41	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20550	20555		10.1074/jbc.270.35.20550	http://dx.doi.org/10.1074/jbc.270.35.20550			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657631	hybrid			2022-12-27	WOS:A1995RR58400050
J	QUELLE, FW; THIERFELDER, W; WITTHUHN, BA; TANG, B; COHEN, S; IHLE, JN				QUELLE, FW; THIERFELDER, W; WITTHUHN, BA; TANG, B; COHEN, S; IHLE, JN			PHOSPHORYLATION AND ACTIVATION OF THE DNA-BINDING ACTIVITY OF PURIFIED STAT1 BY THE JANUS PROTEIN-TYROSINE KINASES AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; MOUSE-LIVER	The activation of Janus protein-tyrosine kinases (Jaks) and the subsequent phosphorylation and activation of latent signal transducers and activators of transcription (Stats) are common elements in signal transduction through the cytokine receptor superfamily. To assess the role and specificity of Jaks in Stat activation, we have utilized baculovirus expression systems to produce Stat1 and the Jaks. Co-expression of Stat1 with Tyk2, Jak1, or Jak2 resulted in the specific tyrosine phosphorylation of Stat1 at Tyr(701), the residue phosphorylated in mammalian cells stimulated with interferon gamma. Alternatively, Stat1, purified to apparent homogeneity from insect cell extracts, was phosphorylated at Tyr(701) Jak immune complex kinase reactions. Phosphorylation of purified Stat1 was necessary and sufficient for the acquisition of DNA binding activity. The specificity in both systems was indicated by the inability of a Jak2 catalytically inactive mutant (Jak2-Glu(882)) or the Tec protein-tyrosine kinase to phosphorylate Stat1. However, immune complex purified epidermal growth factor receptor was capable of phosphorylating purified Stat1 at Tyr(701) and activating its DNA binding activity in in vitro reactions.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TENNESSEE, SCH MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center			witthuhn, bruce/GSE-3193-2022	Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK/HL42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MANO H, 1990, ONCOGENE, V5, P1781; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	28	142	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20775	20780		10.1074/jbc.270.35.20775	http://dx.doi.org/10.1074/jbc.270.35.20775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657660	hybrid			2022-12-27	WOS:A1995RR58400081
J	GUALBERTO, A; BALDWIN, AS				GUALBERTO, A; BALDWIN, AS			P53 AND SP1 INTERACT AND COOPERATE IN THE TUMOR NECROSIS FACTOR-INDUCED TRANSCRIPTIONAL ACTIVATION OF THE HIV-1 LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NF-KAPPA-B; MONOCLONAL-ANTIBODIES; CELL-PROLIFERATION; EXPRESSION; PROMOTER; PROTEIN; GENE; LYMPHOCYTES; MODULATION; ELEMENT	Tumor necrosis factor alpha (TNF) is a potent activator of transcription directed by the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). We have recently reported that the p53 tumor suppressor gene product binds to a site within the Spl binding region of the HIV-1 LTR and contributes to the TNF induction of this promoter. In this study Re show that the transcription factor Spl cooperates with p53 in the transcriptional activation directed by the HIV-1 LTR. The presence of Spl increased p53 binding to its recognition sequence in the HIV-1 LTR, and experiments in Drosophila cells show that Spl is necessary for full transactivation by mutant p53. Importantly, TNF induced the association between p53 and Spl in Jurkat T cells. These data demonstrate a synergistic role for these proteins in the mechanism of TNF induction of HIV-1 LTR-mediated transcription and suggest that Spl may play an important role in modulating certain functions of p53.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Gualberto, Antonio/0000-0002-6590-839X	NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AZIZKHAN J, 1994, CRIT REV EUCARYOTIC, V3, P229; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V3, P3415; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V60, P5100; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	34	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19680	19683		10.1074/jbc.270.34.19680	http://dx.doi.org/10.1074/jbc.270.34.19680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649977	Green Published, hybrid			2022-12-27	WOS:A1995RQ99100004
J	RAMAN, B; RAMAKRISHNA, T; RAO, CM				RAMAN, B; RAMAKRISHNA, T; RAO, CM			RAPID REFOLDING STUDIES ON THE CHAPERONE-LIKE ALPHA-CRYSTALLIN - EFFECT OF ALPHA-CRYSTALLIN ON REFOLDING OF BETA-CRYSTALLIN AND GAMMA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RED-EDGE-EXCITATION; B-CRYSTALLIN; FLUORESCENCE SPECTROSCOPY; MOLECULAR CHAPERONE; QUATERNARY STRUCTURE; PLASMA-MEMBRANES; LENS; TISSUES; LOCALIZATION	alpha-Crystallin, a multimeric protein present in the eye lens, is shown to have chaperone-like activity in preventing thermally induced aggregation of enzymes and other crystallins, We have studied the rapid refolding of alpha-crystallin, and compared it with other calf eye lens proteins, namely beta- and gamma-crystallins, alpha-Crystallin forms a clear solution upon rapid refolding from 8 M urea, The refolded alpha-crystallin has native-like secondary, tertiary, and quaternary structures as revealed by circular dichroism and fluorescence characteristics as well as gel filtration and sedimentation velocity measurements. On rapid refolding, beta- and gamma-crystallins aggregate and form turbid solutions, The presence of alpha-crystallin in the refolding buffer marginally increases the recovery of beta-and gamma-crystallins in the soluble form, However, unfolding of these crystallins together with alpha-crystallin using 8 M urea and subsequent refolding significantly increases the recovery of these proteins in the soluble form, These results indicate that an intermediate of alpha-crystallin formed during refolding is more effective in preventing the aggregation of beta- and gamma-crystallins, This supports our earlier hypothesis (Raman, B., and Rao, C.M. (1994) J. Biol. Chem. 269, 27264-27268) that the chaperone-like activity of alpha-crystallin is more pronounced in its structurally perturbed state.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								ADAMSKA I, 1991, EUR J BIOCHEM, V198, P375, DOI 10.1111/j.1432-1033.1991.tb16025.x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1975, NATURE, V255, P426, DOI 10.1038/255426a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BYRON CM, 1991, J CHEM EDUC, V68, P433, DOI 10.1021/ed068p433; CHATTOPADHYAY A, 1993, BIOCHEMISTRY-US, V32, P3804, DOI 10.1021/bi00065a037; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEMCHENKO AP, 1988, EUR BIOPHYS J BIOPHY, V16, P121, DOI 10.1007/BF00255522; DEMCHENKO AP, 1982, BIOPHYS CHEM, V15, P101, DOI 10.1016/0301-4622(82)80022-7; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IFEANYI F, 1990, CURR EYE RES, V9, P259, DOI 10.3109/02713689009044521; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUMAR TKS, 1994, INT J BIOL MACROMOL, V16, P171; LAKOWICZ JR, 1984, BIOCHEMISTRY-US, V23, P3013, DOI 10.1021/bi00308a026; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LIM L, 1984, BIOCHEM J, V224, P677, DOI 10.1042/bj2240677; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MASCAGNI P, 1991, FEBS LETT, V286, P201, DOI 10.1016/0014-5793(91)80973-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MULDERS JWM, 1985, EUR J BIOCHEM, V152, P721, DOI 10.1111/j.1432-1033.1985.tb09253.x; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO CM, 1989, PHOTOCHEM PHOTOBIOL, V50, P399, DOI 10.1111/j.1751-1097.1989.tb04176.x; RAO CM, 1991, BIOCHEM BIOPH RES CO, V176, P1351, DOI 10.1016/0006-291X(91)90435-A; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RAO SC, 1994, FEBS LETT, V337, P269, DOI 10.1016/0014-5793(94)80206-8; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1984, BIOPHYS CHEM, V19, P49, DOI 10.1016/0301-4622(84)85005-X; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; TANDON S, 1989, J BIOL CHEM, V264, P9859; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; WALSH MT, 1991, J BIOL CHEM, V266, P20079; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	54	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19888	19892		10.1074/jbc.270.34.19888	http://dx.doi.org/10.1074/jbc.270.34.19888			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650002	hybrid			2022-12-27	WOS:A1995RQ99100034
J	TAKENAKA, IM; LEUNG, SM; MCANDREW, SJ; BROWN, JP; HIGHTOWER, LE				TAKENAKA, IM; LEUNG, SM; MCANDREW, SJ; BROWN, JP; HIGHTOWER, LE			HSC70-BINDING PEPTIDES SELECTED FROM A PHAGE DISPLAY PEPTIDE LIBRARY THAT RESEMBLE ORGANELLAR TARGETING SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; KARYOPHILIC PROTEINS; BINDING-SPECIFICITY; UNFOLDED PROTEINS; HSP70; LIGANDS; INVITRO; ATPASE; HSC70; FORM	A 15-mer phage display random peptide library was screened with purified bovine Hsc70, and nucleotide sequence analysis of the selected clones showed a large enrichment for peptides containing basic sequences with at least KR, RR, or RR, Binding affinity for Hsc70 of representative peptides increased dramatically for heptamers compared with hexamers, The peptide RIVRKKK, had the highest affinity for Hsc70, and substitution analyses showed that hydrophobic residues followed by basic residues play important roles in maintaining this affinity, In contrast, NIVRKKK was a weaker stimulator of the Hsc70 ATPase activity compared with pigeon cytochrome c peptide and FYQLALT, a peptide optimized for binding to Hsc70, FYQLALT effectively blocked the binding of NIVRKKK to Hsc70, possibly by causing a conformational change that masked Hsc70's binding site for the basic peptide, Two hypotheses are offered to explain the two different peptide motifs, First, it is proposed that Hsc70 recognizes two different amino acid sequence motifs in its dual roles of chaperoning proteins to organelles (NIVRKKK-like sequences) and facilitating protein folding (FYQLALT-like sequences), Second, the NIVRKKK motif may be used to bind certain folded proteins with which Hsc70 interacts, such as itself, p53, and Dnaj2.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; PATHOGENESIS INC,SEATTLE,WA 98119	University of Connecticut	TAKENAKA, IM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,POB 4000,PRINCETON,NJ 08543, USA.							BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KEIBLER M, 1993, CELL, V74, P483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROBERTS D, 1993, GENE, V128, P67, DOI 10.1016/0378-1119(93)90154-U; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG TF, 1993, J BIOL CHEM, V268, P26049	32	102	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19839	19844		10.1074/jbc.270.34.19839	http://dx.doi.org/10.1074/jbc.270.34.19839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649995	hybrid			2022-12-27	WOS:A1995RQ99100027
J	WONG, CI; KELCE, WR; SAR, M; WILSON, EM				WONG, CI; KELCE, WR; SAR, M; WILSON, EM			ANDROGEN RECEPTOR ANTAGONIST VERSUS AGONIST ACTIVITIES OF THE FUNGICIDE VINCLOZOLIN RELATIVE TO HYDROXYFLUTAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUTAMIDE WITHDRAWAL SYNDROME; LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; MUTATION; CELLS; SPECIFICITY; HYDROLYSIS; STEROIDS; HORMONE; CANCER	The mechanism of antiandrogenic activity of vinclozolin (3-(3,5-dichlorophenyl)-5-methyl-5-vinyloxazolidine-2,4-dione), a dicarboximide fungicide under investigation for its potential adverse effects on human male reproduction, was investigated using recombinant human androgen receptor (AR). The two primary metabolites of vinclozolin in plants and mammals are Mi (2-[[3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid) and M2 (3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide). Both metabolites, in a dose-dependent manner, target AR to the nucleus and inhibit androgen-induced transactivation mediated by the mouse mammary tumor virus promoter. M2 is a 50-fold more potent inhibitor than M1 and only 2-fold less than hydroxyflutamide. In the presence of dihydrotestosterone (50 nM), M2 (0.2-10 mu M) inhibits androgen-induced AR binding to androgen response element DNA. In the absence of dihydrotestosterone, concentrations of 10 mu M M2 Or hydroxyflutamide promote AR binding to androgen response element DNA and activation of transcription. Agonist activities of M2 and hydroxyflutamide occur at 10-fold lower concentrations with the mutant AR (Thr(877) to Ala) endogenous to LNCaP human prostate cancer cells. The results indicate that androgen antagonists can act as agonists, depending on ligand binding affinity, concentration, and the presence of competing natural ligands.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; US EPA,NATL HLTH & ENVIRONM EFFECTS RES LAB,DIV DEV TOXICOL,RES TRIANGLE PK,NC 27711	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency					NICHD NIH HHS [HD16910, P30-HD18968] Funding Source: Medline; NINDS NIH HHS [NS17479] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, P30HD018968, R37HD016910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BELANI CP, 1989, ARCH INTERN MED, V149, P449, DOI 10.1001/archinte.149.2.449; EDWARDS DP, 1994, 9TH INT C HORM STER, P65; French F S, 1990, Recent Prog Horm Res, V46, P1; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GARCIA T, 1992, MOL ENDOCRINOL, V6, P2071, DOI 10.1210/me.6.12.2071; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; GRAY LE, 1993, BIOL REPROD S1, V48, P97; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; HAWKINS DR, 1990, MRID41824307 BASF CO; JIANG SY, 1992, MOL ENDOCRINOL, V6, P2167, DOI 10.1210/me.6.12.2167; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; KELLY WK, 1993, J UROLOGY, V149, P607; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SZETO SY, 1989, J AGR FOOD CHEM, V37, P1103, DOI 10.1021/jf00088a064; SZETO SY, 1989, J AGR FOOD CHEM, V37, P523, DOI 10.1021/jf00086a055; SZETO SY, 1989, J AGR FOOD CHEM, V37, P529, DOI 10.1021/jf00086a056; TAN JA, 1992, J BIOL CHEM, V267, P4456; VANRAVENZWAAY B, 1992, MRID42581302 BASF CO; VELDSCHOLTE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P187, DOI 10.1016/0167-4889(90)90075-O; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WONG CI, 1993, J BIOL CHEM, V268, P19004; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115; 1993, EEULEXIN MED EC DATA, P2185	29	288	300	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19998	20003		10.1074/jbc.270.34.19998	http://dx.doi.org/10.1074/jbc.270.34.19998			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650017	hybrid			2022-12-27	WOS:A1995RQ99100050
J	YOUNGMAN, KM; SPENCER, DB; BREMS, DN; DEFELIPPIS, MR				YOUNGMAN, KM; SPENCER, DB; BREMS, DN; DEFELIPPIS, MR			KINETIC-ANALYSIS OF THE FOLDING OF HUMAN GROWTH-HORMONE - INFLUENCE OF DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRIUM DENATURATION; SECONDARY STRUCTURE; CROSS-LINK; INTERMEDIATE; PROTEINS; PATHWAY; STATE	We report the results of a stopped-Bow kinetic evaluation of the folding of human growth hormone (hGH). The results are compared with those obtained for a disulfide-modified analog in which the four cysteine residues have been reduced and alkylated to form tetra-S-carbamidomethylated hGH in order to elucidate the role of disulfide bonds in the folding reaction, Multiple detection techniques were applied to monitor both refolding and unfolding processes initiated by guanidine hydrochloride concentration jumps. Using far-UV circular dichroism (CD) detection to monitor folding of hGH, we find that 70% of the secondary structure forms in a burst phase occurring within the stopped-flow dead time, Two slower phases were identified in the observable portion of the CD signal. Multiple kinetic phases were resolved when folding was monitored by intrinsic tryptophan fluorescence or near-UV absorbance as probes of tertiary structure, and the number of time constants required to fit the data depended on the hGH concentration and nature of the denaturant jump. The associated amplitudes also displayed strong dependence on the final denaturant concentration. Results obtained from the tetra-S-carbamidomethylated hGR studies demonstrate that the folding reactions of hGH are remarkably similar in the presence and absence of the disulfide bonds. Disulfide bond reduction in hGH is proposed to affect folding primarily by increasing the population of self-associated intermediate states in the folding pathway.	ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,INDIANAPOLIS,IN 46285	Eli Lilly								BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BASTIRAS S, 1992, BIOCHEMISTRY-US, V31, P9304, DOI 10.1021/bi00153a025; BEWLEY TA, 1969, BIOCHEMISTRY-US, V8, P4701, DOI 10.1021/bi00840a007; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; BREMS DN, 1985, BIOCHEMISTRY-US, V24, P7662, DOI 10.1021/bi00347a025; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; BREMS DN, 1990, J BIOL CHEM, V265, P5504; BREMS DN, 1987, J BIOL CHEM, V262, P2590; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P4303, DOI 10.1021/bi00132a022; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; DEFELIPPIS MR, 1993, BIOCHEMISTRY-US, V32, P1555, DOI 10.1021/bi00057a021; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; HAVEL HA, 1986, BIOCHEMISTRY-US, V25, P6533, DOI 10.1021/bi00369a029; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LIN SH, 1985, BIOCHEMISTRY-US, V24, P2680, DOI 10.1021/bi00332a013; MAYR LM, 1994, PROTEIN SCI, V3, P227; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; Nozaki Y, 1972, Methods Enzymol, V26, P43; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P10371, DOI 10.1021/bi00090a012; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; Utiyama H, 1986, Methods Enzymol, V131, P51	31	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19816	19822		10.1074/jbc.270.34.19816	http://dx.doi.org/10.1074/jbc.270.34.19816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649991	hybrid			2022-12-27	WOS:A1995RQ99100023
J	TECTOR, M; SALTER, RD				TECTOR, M; SALTER, RD			CALNEXIN INFLUENCES FOLDING OF HUMAN CLASS-I HISTOCOMPATIBILITY PROTEINS BUT NOT THEIR ASSEMBLY WITH BETA(2)-MICROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; ANTIGEN; MOLECULES; BETA-2-MICROGLOBULIN; PEPTIDE	Class I major histocompatibility complex heavy chains bind to calnexin before associating with beta(2)-microglobulin (beta(2)m) and peptides. Calnexin has been shown to retain in the endoplasmic reticulum those class I heavy chains which have not assembled properly and, thus, to serve as a quality control mechanism. In addition, calnexin may direct the folding of class I subunits or their subsequent assembly. We asked whether calnegin plays a role in the initial folding of HLA-B*0702 heavy chains by assessing disulfide bond formation in vivo. Our results show that class I heavy chains form intrachain disulfide bonds very soon after translation, and that calnexin is bound to both reduced and oxidized forms during this process. When a cell-permeable reducing agent, dithiothreitol, was added to cells, disulfide bond formation in newly synthesized heavy chains was substantially blocked, as was their association with calnexin. The reducing agent appeared to affect calnexin directly, since binding was similarly abolished to a subset of proteins which do not contain internal disulfide bonds. Addition of the glucosidase inhibitor castanospermine to cells, shown previously to disrupt calnexin binding to ligands, slowed formation of disulfide bonds but did not decrease the amount of assembled heavy chain-beta(2)m complexes that formed. Our data suggest that calnexin can promote disulfide bond formation in class I heavy chains but does not directly facilitate subsequent binding to beta(2)m.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Salter, Russell/0000-0003-4553-2986				ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARUNACHALAM B, 1994, INT IMMUNOL, V6, P439, DOI 10.1093/intimm/6.3.439; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LAMB CA, 1992, J IMMUNOL, V148, P3478; LE AQ, 1994, J BIOL CHEM, V269, P7514; LOO TW, 1994, J BIOL CHEM, V269, P28683; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; NOBNER E, 1994, J EXP MED, V181, P3257; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P343; PIND S, 1995, J BIOL CHEM, V269, P2784; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TRAPANI JA, 1989, IMMUNOGENETICS, V29, P25, DOI 10.1007/BF02341610; WADA I, 1994, J BIOL CHEM, V269, P7464; WANG H, 1994, J BIOL CHEM, V269, P22276; WARBURTON RJ, 1994, HUM IMMUNOL, V34, P261; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WQU WJ, 1993, NATURE, V364, P771; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	38	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19638	19642		10.1074/jbc.270.33.19638	http://dx.doi.org/10.1074/jbc.270.33.19638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642652	hybrid			2022-12-27	WOS:A1995RP70300068
J	MENON, SD; GUY, GR; TAN, YH				MENON, SD; GUY, GR; TAN, YH			INVOLVEMENT OF A PUTATIVE PROTEIN-TYROSINE-PHOSPHATASE AND I-KAPPA-B-ALPHA SERINE PHOSPHORYLATION IN NUCLEAR FACTOR KAPPA-B ACTIVATION BY TUMOR-NECROSIS-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CELLS; KINASE; INTERLEUKIN-1; INHIBITOR; RECEPTORS; VANADATE; ADIPOCYTES	Inhibitors of phosphotyrosyl protein phosphatases, pervanadate and phenylarsine oxide, abrogate tumor necrosis factor (TNF)-induced nuclear factor kappa B (NF-kappa B) nuclear translocation in transformed cell lines (U-937 and Jurkat) and primary fibroblasts (MRC-5 and REF). The inhibitors also abrogate NF-kappa B activation by the phosphoseryl/threonyl protein phosphatase inhibitor okadaic acid in U-937 cells, Inhibition of NF-kappa B activation is not due to a general inhibitory effect since neither pervanadate nor phenylarsine oxide treatment affected the constitutive DNA-binding activity of the transcription factors octamer-1 and cAMP response element-binding protein in U-937 cells, nor did these compounds inhibit the TNF-induced phosphorylation of proteins, viz, hsp 27, eukaryotic initiation factor 4e, and pp19, in MRC-5 fibroblasts, Overexpression of the protein-tyrosine phosphatase HPTP alpha resulted in a constitutive nuclear NF-kappa B-like DNA-binding activity in REF cells, Conversely, treatment of human protein-tyrosine phosphatase alpha-overexpressing cells with phenylarsine oxide led to a loss of the constitutive NF-kappa B activity, The presence of a tyrosine phosphorylation site on the inhibitor of NF-kappa B (I kappa B-alpha) suggested that it could be a target for TNF/okadaic acid-induced tyrosine dephosphorylation. However, no tyrosine phosphorylation was detected on I kappa B-alpha from unstimulated cells, while TNF/okadaic acid-treated cells showed increased phosphorylation of I kappa B-alpha exclusively at serine residue(s), Treatment of cells with pervanadate inhibited TNF-induced I kappa B-alpha phosphorylation and degradation, whereas the serine protease inhibitors tosylphenylalanyl chloro methyl ketone and N-alpha-p-tosyl-L-lysine chloromethyl ketone prevented TNF-induced I kappa B-alpha degradation and NF-kappa B nuclear translocation, but not the TNF-induced phosphorylation of I kappa B-alpha. The data suggest that TNF and okadaic acid induce the activation of a putative protein-tyrosine phosphatase(s), leading to IKB-alpha serine phosphorylation and degradation and NF-kappa B nuclear translocation.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAUR A, 1994, J IMMUNOL, V152, P976; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROXMEYER HE, 1991, J EXP MED, V174, P447, DOI 10.1084/jem.174.2.447; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOONG AC, 1994, CANCER RES, V54, P1425; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MENON SD, 1993, J BIOL CHEM, V268, P26805; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PORTER AG, 1991, TRENDS BIOTECHNOL, V9, P158, DOI 10.1016/0167-7799(91)90053-K; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLINT J, 1992, J BIOL CHEM, V267, P25916; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18881	18887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642544				2022-12-27	WOS:A1995RN95400031
J	GROMOVA, II; NIELSEN, OF; RAZIN, SV				GROMOVA, II; NIELSEN, OF; RAZIN, SV			LONG-RANGE FRAGMENTATION OF THE EUKARYOTIC GENOME BY EXOGENOUS AND ENDOGENOUS NUCLEASES PROCEEDS IN A SPECIFIC FASHION VIA PREFERENTIAL DNA CLEAVAGE AT MATRIX ATTACHMENT SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TOPOISOMERASE-II; INTERNUCLEOSOMAL FRAGMENTATION; CHROMATIN; LOCALIZATION; BREAKPOINTS; BREAKAGE; DOMAINS; REGIONS; CELLS	Small cell lung cancer cells (OC-NYH-VM) were permeabilized and treated with different nucleases. The long-range distribution of DNA cleavage sites in the amplified c-myc gene locus was then analyzed by pulsed field gel electrophoretic separation of the released 50-kilobase to 1-megabase DNA fragments followed by indirect end labeling. Exogenous DNase I and nucleases specific for the single stranded DNA were found to generate similar nonrandom patterns of large DNA fragments. The cleavage sites were located close to or even colocalized with matrix attachment regions, which were mapped independently using a recently developed procedure for DNA loop excision by DNA topoisomerase II-mediated DNA cleavage. Endogenous acidic nuclease with the properties of DNase II also digested DNA preferentially in proximity to the matrix attachment regions, generating characteristic patterns of excised DNA loops and their oligomers. A similar, although less specific, pattern of DNA fragmentation was observed after incubation of permeabilized cells under conditions favoring the activity of endogenous neutral Ca2+- and Mg2+-dependent nucleases, These findings are discussed in the context of the current model of the spatial domain organization of eukaryotic genome.	RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	GROMOVA, II (corresponding author), AARHUS UNIV,DEPT MOLEC BIOL,CF MOLLERS ALLE 130,DK-8000 AARHUS,DENMARK.		Razin, Sergey V/M-6701-2015	Razin, Sergey V/0000-0003-1976-8661; Gromova, Irina/0000-0003-4357-5958				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P1442; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CLARK RW, 1987, EXP CELL RES, V169, P296, DOI 10.1016/0014-4827(87)90192-3; COHEN GM, 1994, J IMMUNOL, V153, P507; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GASSER SM, 1986, J MOL BIOL, V186, P613; GENG JP, 1993, LEUKEMIA, V7, P20; GEORGIEV GP, 1991, EUR J BIOCHEM, V200, P613, DOI 10.1111/j.1432-1033.1991.tb16224.x; GROMOVA II, 1995, P NATL ACAD SCI USA, V92, P102, DOI 10.1073/pnas.92.1.102; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; JACKSON DA, 1992, CELL BIOL INT REP, V16, P687, DOI 10.1016/S0309-1651(05)80013-X; JENSEN PB, 1993, BIOCHEM PHARMACOL, V45, P2025, DOI 10.1016/0006-2952(93)90013-M; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; MOREAU J, 1982, NATURE, V295, P260, DOI 10.1038/295260a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; RAZIN SV, 1992, CELL BIOL INT REP, V16, P697, DOI 10.1016/S0309-1651(05)80014-1; RAZIN SV, 1995, BIOESSAYS, V17, P443, DOI 10.1002/bies.950170512; RECILLASTARGA F, 1994, P NATL ACAD SCI USA, V91, P4422; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SUN XM, 1994, J BIOL CHEM, V269, P14857; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	33	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18685	18690		10.1074/jbc.270.31.18685	http://dx.doi.org/10.1074/jbc.270.31.18685			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629201	hybrid			2022-12-27	WOS:A1995RM64200083
J	PARNESS, J; PALNITKAR, SS				PARNESS, J; PALNITKAR, SS			IDENTIFICATION OF DANTROLENE BINDING-SITES IN PORCINE SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMIA SUSCEPTIBLE SWINE; HUMAN-MALIGNANT HYPERTHERMIA; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTORS; CALCIUM RELEASE; CHARGE MOVEMENT; AZUMOLENE; SODIUM; INHIBITION; CHANNEL	Dantrolene, an intracellularly acting skeletal muscle relaxant, inhibits Ca2+ release from the sarcoplasmic reticulum during excitation-contraction coupling by an unknown mechanism. The drug is used to treat malignant hyperthermia, a genetic sensitivity to volatile anesthetics which results in the massive release of intra cellular Ca2+ from affected skeletal muscle. We hypothesize that determination of the site of action of dantrolene will lead to further understanding of the regulation of sarcoplasmic reticulum calcium release. We report the identification of specific dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum using a rapid filtration binding assay for [H-3]dantrolene. The binding isotherm in the heavy sarcoplasmic reticulum fraction indicates a single binding site with a K-d of 277 +/- 25 nM and a B-max of 13.1 +/- 1.5 pmol/mg of protein, Pharmacological specificity is characterized by inhibition of [H-3]dantrolene binding with unlabeled dantrolene, or azumolene, a physiologically active congener, but not with aminodantrolene, which is physiologically inactive. Drug binding is maximal at pH 6.5-7.5, requires no Ca2+ or Mg2+, and is inhibited by salt concentrations above 100 mM. [H-3]Dantrolene binding is greatest in the sarcoplasmic reticulum, which contains the ryanodine receptor, the primary calcium release channel. No binding is detected in the fractions enriched for sarcolemma or transverse tubules. We suggest that dantrolene inhibits calcium release from the sarco plasmic reticulum by either direct or indirect interaction with the ryanodine receptor.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,NEW BRUNSWICK,NJ 08901; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,NEW BRUNSWICK,NJ 08901	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	PARNESS, J (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ANESTHESIA,CLIN ACAD BLDG,NEW BRUNSWICK,NJ 08901, USA.							ALLEN PD, 1992, ANESTHESIOLOGY, V76, P132, DOI 10.1097/00000542-199201000-00019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CASWELL AH, 1989, J BIOENERG BIOMEMBR, V21, P149, DOI 10.1007/BF00812067; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHU A, 1990, MOL PHARMACOL, V37, P735; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; CUATRECASAS P, 1975, RECENT PROGR HORMONE, P37; DEHPOUR AR, 1982, BIOCHEM PHARMACOL, V31, P965, DOI 10.1016/0006-2952(82)90328-8; DERSHWITZ M, 1990, ANESTH ANALG, V70, P253; DHILLON DS, 1992, DRUG DEVELOP RES, V25, P161, DOI 10.1002/ddr.430250208; ELHAYEK R, 1992, BIOCHEM BIOPH RES CO, V187, P894, DOI 10.1016/0006-291X(92)91281-T; ELLIS KO, 1978, N-S ARCH PHARMACOL, V301, P237, DOI 10.1007/BF00507042; ELLIS KO, 1973, J PHARM SCI, V62, P948, DOI 10.1002/jps.2600620619; FOSTER PS, 1991, CLIN EXP PHARMACOL P, V18, P489, DOI 10.1111/j.1440-1681.1991.tb01482.x; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GRONERT GA, 1976, ANESTHESIOLOGY, V44, P488, DOI 10.1097/00000542-197606000-00005; HARRISON GG, 1975, BRIT J ANAESTH, V47, P62, DOI 10.1093/bja/47.1.62; HARRISON GG, 1988, BRIT J ANAESTH, V60, P279, DOI 10.1093/bja/60.3.279; HUI CS, 1983, J PHYSIOL-LONDON, V337, P509, DOI 10.1113/jphysiol.1983.sp014639; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; KOLB ME, 1982, ANESTHESIOLOGY, V56, P254, DOI 10.1097/00000542-198204000-00005; LIVERTOUX MH, 1988, TALANTA, V35, P613, DOI 10.1016/0039-9140(88)80142-5; LOPEZ JR, 1988, MUSCLE NERVE, V11, P82; LOPEZ JR, 1990, ANESTHESIOLOGY, V73, P109, DOI 10.1097/00000542-199007000-00016; LOPEZ JR, 1992, ANESTHESIOLOGY, V76, P711, DOI 10.1097/00000542-199205000-00008; LU XY, 1994, J BIOL CHEM, V269, P6511; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; NELSON T, 1995, BIOPHYS J, V68, P173; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PONG SF, 1989, PHARMACOLOGIST, V31, P161; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROED A, 1991, EUR J PHARMACOL, V209, P33, DOI 10.1016/0014-2999(91)90007-D; ROSENBERG H, 1989, CLIN ANESTH, P459; SALATA JJ, 1982, J PHARMACOL EXP THER, V220, P157; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SENGUPTA C, 1980, FEBS LETT, V117, P37, DOI 10.1016/0014-5793(80)80908-2; SNYDER HR, 1967, J MED CHEM, V10, P807, DOI 10.1021/jm00317a011; VALDIVIA H, 1988, CALCIUM CHANNEL STRU, P252; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; VALDIVIA HH, 1990, BIOPHYS J, V58, P471, DOI 10.1016/S0006-3495(90)82392-4; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; WHITE MD, 1983, BIOCHEM J, V212, P399, DOI 10.1042/bj2120399; WHITE RL, 1987, J MED CHEM, V30, P263, DOI 10.1021/jm00385a006; WUIS EW, 1982, J CHROMATOGR, V231, P401, DOI 10.1016/S0378-4347(00)81864-2; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	53	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18465	18472		10.1074/jbc.270.31.18465	http://dx.doi.org/10.1074/jbc.270.31.18465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629173	hybrid			2022-12-27	WOS:A1995RM64200050
J	PANDEY, A; DUAN, H; DIFIORE, PP; DIXIT, V				PANDEY, A; DUAN, H; DIFIORE, PP; DIXIT, V			THE RET RECEPTOR PROTEIN-TYROSINE KINASE ASSOCIATES WITH THE SH2-CONTAINING ADAPTER PROTEIN GRB10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ZINC FINGER PROTEIN; TRANSFORMING GENE; ACTIVATION; CARCINOMAS; ONCOGENE; ENCODES; SUBUNIT; FUSION; ALPHA	Ret is a receptor protein tyrosine kinase that has been implicated in the development of the enteric nervous, endocrine, and renal systems, Mutations associated with multiple endocrine neoplasia types 2A and 2B (MEN 2A and 2B) have been shown to activate the intrinsic kinase and transforming ability of ret (Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, IM. H., and Paolo DiFiore, P. (1995) Science 267, 381-383), Using the cytoplasmic domain of Ret as bait in a yeast two-hybrid screen of a mouse embryonic library, it was discovered that the src homology 2 (SH2) domain containing protein Grb10 bound Ret, Grb10 belongs to an emerging family of SH2 containing adapter proteins, the prototypical member being Grb7. Using glutathione S-transferase fusion proteins, it was demonstrated that the SH2 domain of Grb10 specifically interacted with Ret, Additionally, using an EGFR/Ret chimera, it was shown that Grb10 bound Ret in an activation dependent manner in vivo. This is the first description of a receptor protein tyrosine kinase that utilizes Grb10 as a signaling intermediate.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY	University of Michigan System; University of Michigan; IRCCS European Institute of Oncology (IEO)			Di Fiore, Pier Paolo/K-2130-2012; Pandey, Akhilesh/B-4127-2009	Di Fiore, Pier Paolo/0000-0002-2252-0950; Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAI N, 1995, MOL CELL BIOL, V15, P1613; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HU HM, 1994, J BIOL CHEM, V269, P30069; IWAMOTO T, 1993, ONCOGENE, V8, P1087; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; OOI J, 1995, ONCOGENE, V10, P1621; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PANDEY A, 1994, J BIOL CHEM, V269, P30154; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	33	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21461	21463		10.1074/jbc.270.37.21461	http://dx.doi.org/10.1074/jbc.270.37.21461			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665556	hybrid			2022-12-27	WOS:A1995RU75700009
J	SHIEH, SY; STELLRECHT, CMM; TSAI, MJ				SHIEH, SY; STELLRECHT, CMM; TSAI, MJ			MOLECULAR CHARACTERIZATION OF THE RAT INSULIN ENHANCER-BINDING COMPLEX 3B2 - CLONING OF A BINDING-FACTOR WITH PUTATIVE HELICASE MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PANCREATIC ALPHA-CELLS; RICH ACTIVATION MOTIF; TRANSCRIPTION FACTOR; BETA-CELLS; II GENE; 5'-FLANKING REGION; DNA; PROTEIN; SEQUENCES	Cell-specific expression of the rat insulin II gene is in part mediated through an element located in the 5'-flanking region, The element, termed RIPE3b (-126 to -101), confers P-cell-specific expression in conjunction with an adjacent element RTPE3a (-110 to -86), Here we report the characterization of one of the RIPE3b-binding complexes, 3b2. UV cross-linking analysis demonstrated that it is composed of at least three polypeptides: p58, p62, and p110. Furthermore, a cDNA was isolated via expression screening for binding to RIPE3b. Sequence analysis reveals that the encoded protein, designated Rip-1, possessed putative helicase motifs and a potential transcription activation domain, Overexpression of Rip-1 in cells greatly enhances the 3b2 binding complex, suggesting that Rip-1 is involved in the binding of 3b2.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine			Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017379, R01HD017379] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17379] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FUKITA Y, 1993, J BIOL CHEM, V268, P17463; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KERR D, 1991, J BIOL CHEM, V266, P15876; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAYA FJ, 1995, GENE DEV, V8, P1009; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J, 1989, MOL CLONING LABORATO; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHIASAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P314; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; STELLRECHT CMM, 1993, J BIOL CHEM, V268, P4078; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423	47	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21503	21508		10.1074/jbc.270.37.21503	http://dx.doi.org/10.1074/jbc.270.37.21503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665561	hybrid			2022-12-27	WOS:A1995RU75700016
J	WANG, J; SUN, LZ; MYEROFF, L; WANG, XF; GENTRY, LE; YAN, JH; LIANG, JR; ZBOROWSKA, E; MARKOWITZ, S; WILLSON, JKV; BRATTAIN, MG				WANG, J; SUN, LZ; MYEROFF, L; WANG, XF; GENTRY, LE; YAN, JH; LIANG, JR; ZBOROWSKA, E; MARKOWITZ, S; WILLSON, JKV; BRATTAIN, MG			DEMONSTRATION THAT MUTATION OF THE TYPE-II TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR INACTIVATES ITS TUMOR-SUPPRESSOR ACTIVITY IN REPLICATION ERROR-POSITIVE COLON-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; TGF-BETA; DIFFERENTIAL SENSITIVITY; INHIBITORY RESPONSES; EXPRESSION CLONING; COLORECTAL-CANCER; LINES; FACTOR-BETA-1; STIMULATION; HOMOLOG	Escape from negative growth regulation by transforming growth factor beta (TGF-beta) as a result of the loss of TGF-beta type II receptor (RII) expression has been found to be associated with the replication error (RER) colorectal cancer genotype, which is characteristic of hereditary nonpolyposis colorectal cancers. The RER-positive HCT 116 colon carcinoma cell line was examined for RII mutations. A 1-base deletion was found within a sequence of 10 repeating adenines (nucleotides 709-718), which resulted in a frameshift mutation. Although it is reasonable to predict that the loss of RII function would be an important determinant of malignancy, the large number of potential mutations in cells of this phenotype raises the possibility that an RII mutation may not be a key event in the tumorigenic phenotype of these cells. One way to test directly the importance of RII mutations in determining the malignant phenotype would be to restore its expression. If restoration of expression leads to diminished tumorigenicity, it would indicate that RII mutation is an important determinant of malignancy in the RER phenotype. To determine whether restoration of RII would lead to reversal of malignancy in RER colon cancers, an RII expression vector was transfected into the HCT 116 cell line. RII stable clones showed mRNA and protein expression of transfected RII. The fibronectin mRNA level was increased by exogenous TGF-beta(1) treatment in a dose-dependent manner in RII-positive clones, whereas the control cells remained insensitive. The RII transfectants showed reduced clonogenicity in both monolayer culture and soft agarose. They were growth arrested at a lower saturation density than control cells. TGF-beta(1)-neutralizing antibody stimulated the proliferation of RII-transfected but not control cells, indicating that the alterations in the growth parameters of the transfected cells were due to the acquisition of autocrine-negative activity. Tumorigenicity in athymic mice was reduced and delayed in RII transfectants. These results indicate that reconstitution of TGF-beta autocrine activity by reexpression of RII can reverse malignancy in RER colon cancers, thus verifying that the malignancy of hereditary nonpolyposis colorectal cancer can be directly associated with the loss of RII expression.	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43699; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106	Duke University; Case Western Reserve University			Liang, Carol Jiurong/AAI-4963-2021; , LuZhe/AAW-4095-2021		NCI NIH HHS [CA50457, CA38173, CA60848] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038173, R01CA060848, R01CA050457, R37CA038173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHEN JS, 1995, CANCER RES, V55, P174; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAGAN KW, 1995, MOL CELL BIOL, V15, P8009; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SUN LZ, 1994, J BIOL CHEM, V269, P26449; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P186	51	321	338	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22044	22049		10.1074/jbc.270.37.22044	http://dx.doi.org/10.1074/jbc.270.37.22044			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665626	hybrid			2022-12-27	WOS:A1995RU75700092
J	PHILIPHOLLINGSWORTH, S; ORGAMBIDE, GG; BRADFORD, JJ; SMITH, DK; HOLLINGSWORTH, RI; DAZZO, FB				PHILIPHOLLINGSWORTH, S; ORGAMBIDE, GG; BRADFORD, JJ; SMITH, DK; HOLLINGSWORTH, RI; DAZZO, FB			MUTATION OR INCREASED COPY NUMBER OF NODE HAS NO EFFECT ON THE SPECTRUM OF CHITOLIPOOLIGOSACCHARIDE NOD FACTORS MADE BY RHIZOBIUM-LEGUMINOSARUM BV TRIFOLII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFIC NODULATION; WHITE CLOVER; MELILOTI; GENES; ACID; LIPOOLIGOSACCHARIDES; LIPOPOLYSACCHARIDE; RECOGNITION; EXPRESSION; SYMBIOSIS	The bacterial gene nodE is the key determinant of host specificity in the Rhizobium leguminosarum-legume symbiosis and has been proposed to determine unique polyunsaturated fatty acyl moieties in chitolipooligosaccharides (CLOS) made by the bacterial symbiont, We evaluated nodE function by examining CLOS structures made by wild-type R, leguminosarum by. trifolii ANU843, an isogenic nodE::Tn5 mutant, and a recombinant strain containing multiple copies of the pSym nod region of ANU843, H-1-NMR, electrospray ionization mass spectrometry, fast atom bombardment mass spectrometry, flame ionization detection-gas chromatography, gas chromatography/mass spectrometry, and high performance liquid chromatography/UV photodiode array analyses revealed that these bacterial strains made the same spectrum of CLOS species. We also found that ions in the mass spectra which were originally assigned to nodE-dependent CLOS species containing unique polyunsaturated fatty acids (Spaink, H, P., Bloemberg, G, V,, van Brussel, A A, N., Lugtenberg, B, J, J,, van der Drift, K.M.G.M., Haverkamp, J,, and Thomas-Gates, J, E, (1995) Mol, Plant-Microbe Interact, 8, 155-164) were actually due to sodium adducts of the major nodE-independent CLOS species, No evidence for nodE-dependent CLOSs was found for these strains. These results indicate a need to revise the current model to explain how nodE determines host range in the R, leguminosarum-legume symbiosis.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University; Michigan State University					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004750] Funding Source: NIH RePORTER; NCRR NIH HHS [1-S10-RR04750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; CEDERGREN RA, 1995, BIOCHEMISTRY-US, V34, P4467, DOI 10.1021/bi00013a040; Dazzo F. B., 1982, Experimental microbial ecology, P431; DAZZO FB, 1979, CURR MICROBIOL, V2, P15, DOI 10.1007/BF02601726; DEMONT N, 1993, J BIOL CHEM, V268, P20134; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DJORDJEVIC MA, 1985, MOL GEN GENET, V200, P463, DOI 10.1007/BF00425732; DJORDJEVIC MA, 1991, AUST J PLANT PHYSIOL, V18, P543, DOI 10.1071/PP9910543; DJORDJEVIC MA, 1982, J BACTERIOL, V151, P560, DOI 10.1128/JB.151.2.560-568.1982; ESPUNY MR, 1987, J APPL BACTERIOL, V63, P13, DOI 10.1111/j.1365-2672.1987.tb02412.x; FISHER RF, 1985, APPL ENVIRON MICROB, V49, P1432, DOI 10.1128/AEM.49.6.1432-1435.1985; HIRSCH AM, 1992, NEW PHYTOL, V122, P211, DOI 10.1111/j.1469-8137.1992.tb04227.x; HOLLINGSWORTH RI, 1988, J MICROBIOL METH, V7, P295, DOI 10.1016/0167-7012(88)90024-3; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; HRABAK EM, 1981, J BACTERIOL, V148, P697, DOI 10.1128/JB.148.2.697-711.1981; HUNTER SW, 1985, BIOCHEMISTRY-US, V24, P2798, DOI 10.1021/bi00332a030; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MCKAY IA, 1993, APPL ENVIRON MICROB, V59, P3385, DOI 10.1128/AEM.59.10.3385-3392.1993; ORGAMBIDE GG, 1992, CARBOHYD RES, V233, P151, DOI 10.1016/S0008-6215(00)90927-3; ORGAMBIDE GG, 1995, BIOCHEMISTRY-US, V34, P3832, DOI 10.1021/bi00011a041; ORGAMBIDE GG, 1993, LIPIDS, V28, P975, DOI 10.1007/BF02537117; OSTERHOUT GJ, 1991, J CLIN MICROBIOL, V29, P1822, DOI 10.1128/JCM.29.9.1822-1830.1991; PETERS NK, 1985, SCIENCE, V233, P977; POUPOT R, 1995, J BIOL CHEM, V270, P6050, DOI 10.1074/jbc.270.11.6050; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; REDMOND JW, 1986, NATURE, V323, P632, DOI 10.1038/323632a0; ROLFE B, 1982, PLANT SCI LETT, V19, P277; SALZWEDEL JL, 1993, MOL PLANT MICROBE IN, V6, P127, DOI 10.1094/MPMI-6-127; SCHOFIELD PR, 1984, PLANT MOL BIOL, V3, P3, DOI 10.1007/BF00023410; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1995, MOL PLANT MICROBE IN, V8, P155, DOI 10.1094/MPMI-8-0155; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; Williams D.H., 1966, SPECTROSCOPIC METHOD, P6	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20968	20977		10.1074/jbc.270.36.20968	http://dx.doi.org/10.1074/jbc.270.36.20968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673121	hybrid			2022-12-27	WOS:A1995RU05400018
J	ASH, J; DOMINGUEZ, M; BERGERON, JJM; THOMAS, DY; BOURBONNAIS, Y				ASH, J; DOMINGUEZ, M; BERGERON, JJM; THOMAS, DY; BOURBONNAIS, Y			THE YEAST PROPROTEIN CONVERTASE ENCODED BY YAP3 IS A GLYCOPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN THAT LOCALIZES TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE GAS1 PROTEIN; SACCHAROMYCES-CEREVISIAE; ASPARTYL PROTEASE; SECRETORY VESICLES; MF-ALPHA; GENE; ENZYME; GLYCOSYLATION; PURIFICATION; COMPARTMENT	The yeast YAP3 gene encodes an aspartyl endoprotease that cleaves precursor proteins at selected pairs of basic amino acids and after single arginine residues. Biosynthetic studies of this proprotein processing enzyme indicate that Yap3 is predominantly cell-associated and migrates as a similar to 160-kDa protein on SDS-polyacrylamide gel electrophoresis. Nearly equal amounts of Yap3 are immunodetected in alpha-haploid, alpha-haploid, and a/alpha-diploid yeast, demonstrating that the expression of YAP3 is not mating type-specific. As shown by endoglycosidase H treatment, which drastically reduces both the estimated molecular mass and the heterogeneity of the protein on SDS polyacrylamide gel electrophoresis (68 versus 160 kDa), the oligosaccharides N-linked to the protein are subjected to extensive outer chain mannosylation. Outer chain sugar mannosylation takes place in the Golgi apparatus and is commonly found on yeast secreted glycoproteins and/or cell wall mannoproteins. Treatment of the total yeast membranes with chemical agents known to disrupt protein-protein and protein-lipid interactions reveal that Yap3 is membrane-associated. Based upon the release of the membrane bound form by bacterial phosphatidylinositol phospholipase C digestion and metabolic labeling of the protein with myo-[H-3]inositol, Yap3 owes its association with the membrane to the addition of a glycophosphatidylinositol anchor. The cellular localization of Yap3 has been addressed by subcellular fractionation studies. In both differential centrifugation of intracellular organelles and sucrose density gradients, the bulk of Yap3 at steady state co-localizes with the plasma membrane azide-insensitive ATPase. Furthermore, consistent with the transport of Yap3 to the plasma membrane, the endoprotease sediments with secretory vesicles which accumulate at restrictive temperature in the late secretory mutant sec1-1. We therefore conclude that the endoprotease encoded by YAP3 is a glycophosphatidylinositol-anchored protein, which can process substrates both intracellularly and at the cell surface.	UNIV LAVAL, DEPT BIOCHIM, QUEBEC CITY, PQ G1K 7P4, CANADA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, EUKARYOT GENET GRP, MONTREAL, PQ H4P 2R2, CANADA; MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL, PQ H3A 2B2, CANADA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 2B2, CANADA	Laval University; National Research Council Canada; McGill University; McGill University			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X; Bourbonnais, Yves/0000-0002-8130-6612				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BOURBONNAIS Y, 1994, BIOCHIMIE, V76, P226, DOI 10.1016/0300-9084(94)90150-3; BOURBONNAIS Y, 1991, ENZYME, V45, P244, DOI 10.1159/000468899; BOURBONNAIS Y, 1991, J BIOL CHEM, V266, P13203; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HORVATH A, 1994, EMBO J, V13, P2789; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P187, DOI 10.1093/oxfordjournals.jbchem.a131434; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LOH YP, 1985, J BIOL CHEM, V260, P7194; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; Sherman F., 1986, METHODS YEAST GENETI; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STEINER DF, 1992, J BIOL CHEM, V267, P23435; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554	40	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20847	20854		10.1074/jbc.270.35.20847	http://dx.doi.org/10.1074/jbc.270.35.20847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657670	hybrid			2022-12-27	WOS:A1995RR58400091
J	SVENSSON, L; HEINEGARD, D; OLDBERG, A				SVENSSON, L; HEINEGARD, D; OLDBERG, A			DECORIN-BINDING SITES FOR COLLAGEN TYPE-I ARE MAINLY LOCATED IN LEUCINE-RICH REPEATS 4-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN-II; CORE PROTEIN; FIBROMODULIN; EXPRESSION; CDNA; CARTILAGE; SEQUENCE; BIGLYCAN; HOMOLOGY; BONE	Decorin and biglycan are structurally related interstitial proteoglycans synthesized in connective tissues like skin, tendon, and cartilage. Despite the conspicuous sequence similarities, where about 55% of the amino acid residues in decorin and biglycan are located in identical positions, the two proteoglycans show differences in their interaction with collagen. Decorin binds to collagen type I, whereas biglycan in several assay systems shows no affinity for this collagen type. Here we have made use of these structural similarities and affinity differences in studies of the collagen binding properties of decorin. Recombinant biglycan/decorin chimeras were produced in mammalian cells and analyzed for their capacity to bind collagen. In the chimeras, biglycan contributes sequences crucial for synthesis and export from the mammalian cells, and decorin provides potential collagen-binding properties. By using this approach we show that decorin binds to the collagen primarily via leucine-rich repeats 4-5 composed of some 40 amino acid residues. Proteoglycan chimeras containing decorin sequences from the N terminus to leucine-rich repeat 3 or sequences from leucine rich repeat 6 to the C terminus do not show any detectable binding to collagen. A proteoglycan chimera containing decorin leucine rich repeats 4-5 flanked by biglycan sequences binds to collagen. However, this chimera binds to collagen with somewhat lower affinity than wild type decorin, suggesting that additional low affinity binding sites may be located in other parts of decorin. Alternatively, the conformation of the collagen binding leucine-rich repeats 4-5 are different in decorin and in the biglycan/decorin chimera, leading to a lower collagen affinity for the latter.	LUND UNIV, DEPT CELL & MOLEC BIOL, S-22100 LUND, SWEDEN	Lund University								ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; YOUNG JM, 1988, GENE, V62, P171, DOI 10.1016/0378-1119(88)90556-2	20	197	201	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20712	20716		10.1074/jbc.270.35.20712	http://dx.doi.org/10.1074/jbc.270.35.20712			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657652	hybrid			2022-12-27	WOS:A1995RR58400072
J	VAGNER, S; WAYSBORT, A; MARENDA, M; GENSAC, MC; AMALRIC, F; PRATS, AC				VAGNER, S; WAYSBORT, A; MARENDA, M; GENSAC, MC; AMALRIC, F; PRATS, AC			ALTERNATIVE TRANSLATION INITIATION OF THE MOLONEY MURINE LEUKEMIA-VIRUS MESSENGER-RNA CONTROLLED BY INTERNAL RIBOSOME ENTRY INVOLVING THE P57/PTB SPLICING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; HUMAN RHINOVIRUS RNA; MESSENGER-RNA; PROTEIN-SYNTHESIS; PICORNAVIRUS RNA; CIS ELEMENTS; NONTRANSLATED REGION; INVITRO TRANSLATION; SECONDARY STRUCTURE; BINDING PROTEIN	Moloney murine leukemia virus (Mo-MuLV) genomic mRNA codes for two gag precursors by alternative initiations of translation. An AUG codon governs the synthesis of the retroviral capsid proteins precursor, whereas a CUG codon directs the synthesis of a glycosylated cell surface antigen, the gross cell surface antigen. Control of the relative synthesis of the two precursors is crucial for MuLV infectivity and pathology. Furthermore, the MuLV mRNA leader sequence is very long and should inhibit translation according to the classical scanning model. This suggests a different translation initiation mechanism allowing gag efficient expression. We demonstrate, by using bicistronic vectors expressed in COS-7 cells, that the Mo-MuLV mRNA leader drives translation initiation by internal ribosome entry. We have localized the internal ribosome entry site (IRES) between the two initiation codons. This 126 nucleotide long IRES implies an oligopyrimidine tract located 45 nucleotides upstream of AUG codon. UV crosslinking and affinity chromatography experiments show that the PTB/p57 splicing factor specifically interacts with this oligopyrimidine tract. The MuLV IRES controls alternative translation initiation by activating the capsid protein precursor expression. This gag translational enhancer could exist in other retroviruses.	CHU RANGUEIL, INST LOUIS BUGNARD,INSERM,U397, UNITE ENDOCRINOL & COMMUN CELLULAIRE, F-31054 TOULOUSE, FRANCE; CNRS, BIOL MOLEC EUCARYOTES LAB, F-31062 TOULOUSE, FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Prats, Anne-Catherine/E-5051-2016; Vagner, Stephan/G-3664-2013	Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164; MARENDA, MARC/0000-0001-6778-1110				AGOL VI, 1991, ADV VIRUS RES, V40, P103; ANGEL RMD, 1989, P NATL ACAD SCI USA, V86, P8292; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; CORBIN A, 1994, J VIROL, V68, P3857, DOI 10.1128/JVI.68.6.3857-3867.1994; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EDWARDS SA, 1979, J VIROL, V30, P551, DOI 10.1128/JVI.30.2.551-563.1979; GLASS MJ, 1993, VIROLOGY, V193, P842, DOI 10.1006/viro.1993.1193; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MOUGEL M, 1993, NUCLEIC ACIDS RES, V21, P4677, DOI 10.1093/nar/21.20.4677; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; PILLEMER EA, 1986, J VIROL, V57, P413, DOI 10.1128/JVI.57.2.413-421.1986; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; PRATS AC, 1989, J MOL BIOL, V205, P363, DOI 10.1016/0022-2836(89)90347-1; PRATS AC, 1988, THESIS U P SABATIER; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; TOYODA H, 1994, ARCH VIROL, V138, P1, DOI 10.1007/BF01310034; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WEISS R, 1984, RNA TUMOR VIRUSES; WITHERELL GW, 1994, J VIROL, V68, P3183, DOI 10.1128/JVI.68.5.3183-3192.1994	49	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20376	20383		10.1074/jbc.270.35.20376	http://dx.doi.org/10.1074/jbc.270.35.20376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657611	hybrid			2022-12-27	WOS:A1995RR58400024
J	AZROLAN, N; ODAKA, H; BRESLOW, JL; FISHER, EA				AZROLAN, N; ODAKA, H; BRESLOW, JL; FISHER, EA			DIETARY-FAT ELEVATES HEPATIC APOA-I PRODUCTION BY INCREASING THE FRACTION OF APOLIPOPROTEIN-A-I MESSENGER-RNA IN THE TRANSLATING POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MESSENGER-RNA; PROTEIN-SYNTHESIS; TRANSPORT RATES; GENE-REGULATION; PLASMA-LEVELS; APOPROTEIN-B; CHOLESTEROL; POLYSOMES; EXPRESSION	Elevated plasma high density lipoprotein cholesterol (HDL-C) levels are associated with a decreased risk for coronary heart disease, Ironically, diets enriched in saturated fat and cholesterol (HF/HC diets), which tend to accelerate atherosclerotic processes by increasing LDL cholesterol levels, also raise HDL-C, We have recently reported, using a human apoA-I (hapoA-1) transgenic mouse model, that the elevation of HDL-C by a HF/HC diet is attributable, in part, to an increase in the hepatic production of hapoA-1, To further define the hepatocellular processes associated with this induction, we have prepared primary hepatocytes from hapoA-1 transgenic mice. Rates of hapoA-1 secretion were 40% greater from cells prepared from animals fed the HF/HC relative to a low fat-low cholesterol (LF/LC) control diet, The abundance of hapoA-1 mRNA in these cells was similar between hepatocytes prepared from the HF/HC and LF/LC diet fed animals, suggesting a post-transcriptional mechanism that does not involve mRNA stability, Inhibition of secretion using brefeldin A revealed an increase in cellular hapoA-1 accumulation, Thus, the HF/HC diet apparently affects hepatic hapoA-1 production via a mechanism that is manifest prior to the exit of newly synthesized hapoA-1 from the Golgi, Pulse-chase experiments revealed a 39% greater peak hapoA-1 synthesis, with no difference in the degradation of total labeled hapoA-1 protein, as a result of the HF/HC diet feeding, Finally, resolution of liver S10 extracts via sucrose density sedimentation and metrizamide density equilibrium gradient centrifugation analyses both revealed similar increases (31 and 24%, respectively) in the relative percentage of hapoA-1 mRNA associated with the translating polysomal fractions as a result of the HF/HC feeding, Together, these data suggest that the HF/HC diet affects hepatic hapoA-1 production via a specific modulation in the relative amount of hapoA-1 mRNA in the polysomal pool, These observations provide an opportunity to explore a new mechanism regulating apoA-1 production and might lead to the development of novel therapies to elevate plasma HDL-C levels.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; MED COLL PENN,PHILADELPHIA,PA 19129	Rockefeller University; Drexel University			Breslow, Jan L/B-7544-2008	Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL33714, HL32435, HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032435, R01HL033714, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZROLAN N, 1990, J LIPID RES, V31, P1141; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; CHEN XL, 1993, J BIOL CHEM, V268, P21007; DIXON JL, 1993, J LIPID RES, V34, P167; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GO MF, 1988, J CLIN INVEST, V81, P1615, DOI 10.1172/JCI113496; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; Munro HN, 1989, CURR OPIN CELL BIOL, V1, P1154, DOI 10.1016/S0955-0674(89)80066-3; NELSON EM, 1987, J BIOL CHEM, V262, P11501; ORCI L, 1991, CELL, V64, P1183; REA TJ, 1994, J LIPID RES, V35, P1274; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYZANOV AG, 1991, FEBS LETT, V285, P170; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	29	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19833	19838		10.1074/jbc.270.34.19833	http://dx.doi.org/10.1074/jbc.270.34.19833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649994	hybrid			2022-12-27	WOS:A1995RQ99100026
J	CHAUHAN, S; OBRIAN, MR				CHAUHAN, S; OBRIAN, MR			A MUTANT BRADYRHIZOBIUM-JAPONICUM DELTA-AMINOLEVULINIC-ACID DEHYDRATASE WITH AN ALTERED METAL REQUIREMENT FUNCTIONS IN-SITU FOR TETRAPYRROLE SYNTHESIS IN SOYBEAN ROOT-NODULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PORPHOBILINOGEN SYNTHASE; BINDING DOMAIN; HEMB GENE; EXPRESSION; SYMBIOSIS; PURIFICATION; YEAST; ZINC; RNA	The tetrapyrrole synthesis enzyme S-aminolevulinic acid (ALA) dehydratase requires Mg2+ for catalytic activity in photosynthetic organisms and in Bradyrhizobium japonicum, a bacterium that can reside symbiotically within plant cells of soybean root nodules or as a free-living organism. ALA dehydratase from animals and other non-photosynthetic organisms is a Zn2+-dependent enzyme. A modified B. japonicum ALA dehydratase, ALAD, was constructed by site-directed mutagenesis of hemB in which three proximal amino acids conserved in plant dehydratases were changed to cysteine residues as is found in the Zn2+-dependent enzyme of animals. These substitutions resulted in an enzyme that required Zn2+ rather than Mg2+ for catalytic activity, and therefore a region of the ALA dehydratase from B. japonicum, and probably from plants, was identified that is involved in Mg2+ dependence. In addition, the data show that a change in only a few residues is sufficient to change a Mg2+-dependent ALA dehydratase to a Zn2+-dependent one. B. japonicum strains were constructed that contained a single copy of either hemB or the altered gene hemB integrated into the genome of a hemB(-) mutant. Cultures of the hemB strain KPZn3 had Zn2+-dependent ALA dehydratase activity that functioned in vivo as discerned by its heme prototrophy and expression of wild type levels of cellular hemes. Strain KPZn3 elicited root nodules on soybean that contained viable bacteria and exhibited traits of normally developed nodules, and the symbiotic bacteria expressed nearly wild type levels of cellular hemes. We conclude that the Zn2+-dependent ALAD can function and support bacterial tetrapyrrole synthesis within the plant milieu of root nodules.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214; SUNY BUFFALO,CTR ADV MOLEC BIOL & IMMUNOL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BOESE QF, 1991, J BIOL CHEM, V266, P17060; BORRALHO LM, 1990, YEAST, V6, P319, DOI 10.1002/yea.320060405; CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; CHAUHAN S, 1993, J BACTERIOL, V175, P7222, DOI 10.1128/JB.175.22.7222-7227.1993; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; FRUSTACI JM, 1991, J BACTERIOL, V173, P1145, DOI 10.1128/jb.173.3.1145-1150.1991; FRUSTACI JM, 1993, APPL ENVIRON MICROB, V59, P2347, DOI 10.1128/AEM.59.8.2347-2351.1993; FRUSTACI JM, 1995, J BIOL CHEM, V270, P7387, DOI 10.1074/jbc.270.13.7387; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GUERINOT ML, 1986, P NATL ACAD SCI USA, V83, P1837, DOI 10.1073/pnas.83.6.1837; JAFFE EK, 1984, J BIOL CHEM, V259, P5032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JONES MC, 1994, PLANT MOL BIOL, V24, P435, DOI 10.1007/BF00024112; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KACZOR CM, 1994, PLANT PHYSIOL, V104, P1411, DOI 10.1104/pp.104.4.1411; LI JM, 1988, J BACTERIOL, V170, P1021, DOI 10.1128/jb.170.2.1021-1025.1988; LI JM, 1989, GENE, V75, P177, DOI 10.1016/0378-1119(89)90394-6; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MADSEN O, 1993, PLANT MOL BIOL, V23, P35, DOI 10.1007/BF00021417; MATTERS GL, 1995, PLANT MOL BIOL, V27, P607, DOI 10.1007/BF00019326; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; OBRIAN MR, 1987, P NATL ACAD SCI USA, V84, P8390, DOI 10.1073/pnas.84.23.8390; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; SANGWAN I, 1991, SCIENCE, V251, P1220, DOI 10.1126/science.251.4998.1220; SANGWAN I, 1993, PLANT PHYSIOL, V102, P829, DOI 10.1104/pp.102.3.829; SCHAUMBURG A, 1992, Z NATURFORSCH C, V47, P77; SPENCER P, 1994, BIOCHEM J, V300, P373, DOI 10.1042/bj3000373; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703	34	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19823	19827		10.1074/jbc.270.34.19823	http://dx.doi.org/10.1074/jbc.270.34.19823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649992	hybrid			2022-12-27	WOS:A1995RQ99100024
J	SACCO, PA; MCGRANAHAN, TM; WHEELOCK, MJ; JOHNSON, KR				SACCO, PA; MCGRANAHAN, TM; WHEELOCK, MJ; JOHNSON, KR			IDENTIFICATION OF PLAKOGLOBIN DOMAINS REQUIRED FOR ASSOCIATION WITH N-CADHERIN AND ALPHA-CATENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL PLAQUE PROTEIN; CELL-ADHESION MOLECULES; AMINO-ACID-SEQUENCE; BETA-CATENIN; EPITHELIAL-CELLS; CYTOPLASMIC DOMAIN; UVOMORULIN; DROSOPHILA; DISTINCT; HOMOLOG	Cadherins are calcium-dependent, cell surface glycoproteins involved in cell cell adhesion. To function in cell-cell adhesion, the transmembrane cadherin molecule must be associated with the cytoskeleton via cytoplasmic proteins known as catenins. Three catenins, alpha-catenin, beta-catenin, and gamma-catenin (also known as plakoglobin), have been identified, The domain of the cadherin molecule important for its interaction with the catenins has been mapped to the COOH-terminal 70 amino acids, but less is known about regions of the catenins that allow them to associate with one another or with the cadherin molecule, In this study we have transfected carboxyl-terminal deletions of plakoglobin into the human fibrosarcoma HT-1080 and used immunofluorescence localization and co-immunoprecipitation to map the regions of plakoglobin that allow it to associate with N-cadherin and with alpha-catenin. Plakoglobin is an armadillo family member containing 13 weakly similar internal repeats. These data show that the alpha-catenin-binding region maps within the first repeat and the N-cadherin binding region maps within repeats 7 and 8.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University System of Ohio; University of Toledo					NIGMS NIH HHS [GM51188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FOUQUET B, 1992, DIFFERENTIATION, V51, P187, DOI 10.1111/j.1432-0436.1992.tb00695.x; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Geiger B., 1985, CELL CONTACT ADHESIO, P461; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHORE EM, 1991, J BIOL CHEM, V266, P19672; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049	41	132	133	4	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20201	20206		10.1074/jbc.270.34.20201	http://dx.doi.org/10.1074/jbc.270.34.20201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650039	hybrid			2022-12-27	WOS:A1995RQ99100077
J	YUK, MH; LODISH, HF				YUK, MH; LODISH, HF			ENHANCED FOLDING AND PROCESSING OF A DISULFIDE MUTANT OF THE HUMAN ASIALOGLYCOPROTEIN RECEPTOR H2B SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; BINDING PROTEINS; BOND FORMATION; PRE-GOLGI; SEQUENCE; CALCIUM; POLYPEPTIDES; SECRETION	Unfolded forms of the H2b subunit of the human asialoglycoprotein receptor, a galactose-specific C-type lectin, are degraded in the endoplasmic reticulum (ER), whereas folded forms of the protein can mature to the cell surface (Wikstrom, L., and Lodish, H. F. (1993) J. Biol. Chem. 268, 14412-14416). There are eight cysteines in the exoplasmic domain of the protein, forming four disulfide bonds in the folded protein. We have constructed double cysteine to alanine mutants for each of the four disulfide bonds and examined the folding and metabolic fate of each of the mutants in transfected 3T3 fibroblasts. We find that mutation of the two cysteines nearest to the transmembrane region (C1) does not prevent proper folding of the protein, whereas mutations of the other three disulfides prevent proper folding of the protein and all of the mutant proteins are degraded in the ER, A normal (similar to 20%) fraction of the C1 mutant protein exits the endoplasmic reticulum and is processed in the Golgi complex, and it does so at a faster rate compared to the wild-type. Furthermore, the folded form of this mutant protein is more resistant to unfolding by dithiothreitol than the wild-type. The CI mutant protein is expressed on the cell surface and can form a functional receptor with the H1 subunit with similar binding affinities for natural ligands as that of the wild-type receptor. The same fraction of newly made mutant and wild-type proteins (similar to 80%) remain in the ER, but the mutant protein is degraded more quickly. Thus, the presence of the C1 disulfide bond in the wild-type receptor both reduces the rate of protein folding and exit to the Golgi and slows the rate of ER degradation of the portion (similar to 80%) of the receptor that never folds properly.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; GIGA Y, 1987, J BIOL CHEM, V262, P6197; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HUTH JR, 1992, J BIOL CHEM, V267, P8570; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAJI EH, 1993, J BIOL CHEM, V268, P22188; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; NG NFL, 1992, J BIOL CHEM, V267, P16069; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; YOUNG J, 1993, J BIOL CHEM, V268, P19810; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	41	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20169	20176		10.1074/jbc.270.34.20169	http://dx.doi.org/10.1074/jbc.270.34.20169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650036	hybrid			2022-12-27	WOS:A1995RQ99100073
J	URBATSCH, IL; SANKARAN, B; WEBER, J; SENIOR, AE				URBATSCH, IL; SANKARAN, B; WEBER, J; SENIOR, AE			P-GLYCOPROTEIN IS STABLY INHIBITED BY VANADATE-INDUCED TRAPPING OF NUCLEOTIDE AT A SINGLE CATALYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; ATP HYDROLYSIS; GIZZARD MYOSIN; RECONSTITUTION; SUBFRAGMENT-1; PURIFICATION; DIPHOSPHATE; BINDING	P-glycoprotein (Pgp or multidrug-resistance protein) shows drug-stimulated ATPase activity, The catalytic sites are known to be of low affinity and specificity for nucleotides, From the sequence, two nucleotide sites are predicted per Pgp molecule. Using plasma membranes from a multidrug-resistant Chinese hamster ovary cell line, which are highly enriched in Pgp, we show that vanadate-induced trapping of nucleotide at a single catalytic site produces stably inhibited Pgp, with t(1/2) for reactivation of ATPase activity of 84 min at 37 degrees C and >30 h at 4 degrees C. Reactivation of ATPase correlated with release of trapped nucleotide. Concentrations of MgATP and MgADP required to produce 50% inhibition were 9 and 15 mu M, respectively, thus the apparent affinity for nucleotide is greatly increased by vanadate-trapping. The trapped nucleotide species was ADP, Divalent cation was required, with magnesium, manganese, and cobalt all effective; cobalt yielded a very stable inhibited species, t(1/2) at 37 degrees C = 18 h, No photocleavage of Pgp was observed after vanadate trapping with MgATP, nor was UV-induced photolabeling of Pgp by trapped adenine nucleotide observed, Vanadate-trapping with 8-azido-ATP followed by UV irradiation caused permanent inactivation and specific labeling of Pgp, Vanadate-induced inhibition was also shown with pure, reconstituted Pgp, with similar characteristics to those in plasma membranes, Vanadate trapping overcomes technical difficulties posed by lack of high affinity nucleotide-binding site(s) or a covalent enzyme-phosphate catalytic intermediate in Pgp. The finding that vanadate trapping of nucleotide at just one site/Pgp is sufficient to give full inhibition of ATPase activity shows that the two pre dieted nucleotide sites can not function independently as catalytic sites.			URBATSCH, IL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARABEDIAN TE, 1991, BIOCHEMISTRY-US, V30, P10126, DOI 10.1021/bi00106a008; GARABEDIAN TE, 1990, J BIOL CHEM, V265, P22547; GIBBONS IR, 1987, J BIOL CHEM, V265, P2780; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RINGEL I, 1990, BIOCHEMISTRY-US, V29, P9091, DOI 10.1021/bi00490a029; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	26	364	367	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19383	19390		10.1074/jbc.270.33.19383	http://dx.doi.org/10.1074/jbc.270.33.19383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642618	hybrid			2022-12-27	WOS:A1995RP70300032
J	GONG, QQ; PITAS, RE				GONG, QQ; PITAS, RE			SYNERGISTIC EFFECTS OF GROWTH-FACTORS ON THE REGULATION OF SMOOTH-MUSCLE CELL SCAVENGER RECEPTOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN MONOCYTE-MACROPHAGES; CHOLESTEROL DEPOSITION; INTERFERON-GAMMA; LYSINE RESIDUES; E-APOPROTEIN; FOAM CELLS; C-FMS; ATHEROSCLEROSIS; EXPRESSION	Rabbit smooth muscle cells (SMC) express types I and II scavenger receptors (ScR) that are up-regulated by platelet secretion products. In the current studies we investigated the effect of growth factors secreted by platelets on ScR activity in rabbit and human SMC. Platelet-derived growth factor (PDGrF BB) and transforming growth factor beta(1) (TGF-beta(1)) at 10 ng/ml increased ScR activity in rabbit SMC (by approximately 4- and 2-fold, respectively) but not in human SMC. Epidermal growth factor (EGF) or insulin-like growth factor I (IGF-I) alone had little effect on SMC ScR activity. The growth factors had synergistic effects on ScR activity and on types I and Il ScR mRNA expression. In rabbit SMC, PDGF BB, EGF, and TGF-beta(1) together stimulated ScR activity 12-fold. In human SMC, EGF and TGF-beta(1), together with either IGF-I or PDGF BB, stimulated receptor activity approximately 7-fold. Growth factor-mediated induction of ScR activity in rabbit and human SMC was blocked by the tyrosine kinase inhibitor tyrphostin 47, whereas the induction of ScR activity in rabbit but not human SMC was blocked by the protein kinase C inhibitor MDL.29,152. Studies using neutralizing antibodies demonstrated that TGF-beta(1) is the predominant factor in in vitro preparations of platelet secretory products which regulates ScR activity. The growth factors that act synergistically in regulating ScR activity in vitro are all present in atherosclerotic lesions, where they are produced by macrophages, endothelial cells, SMC, and platelets. The data suggest that these growth factors may regulate ScR activity in SMC in vivo and contribute to foam cell formation.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1991, J LIPID RES, V32, P1699; AVIRAM M, 1989, METABOLISM, V38, P425, DOI 10.1016/0026-0495(89)90192-3; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CLINTON SK, 1992, AM J PATHOL, V140, P301; CLINTON SK, 1992, ARCH PATHOL LAB MED, V116, P1292; DEJAGER S, 1993, J CLIN INVEST, V92, P894, DOI 10.1172/JCI116664; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FONG LG, 1990, J BIOL CHEM, V265, P11751; FOWLER S, 1979, LAB INVEST, V41, P372; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FUHRMAN B, 1991, J LIPID RES, V32, P1113; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUTSTEIN WH, 1973, LAB INVEST, V29, P134; HABERLAND ME, 1987, AM HEART J, V113, P573, DOI 10.1016/0002-8703(87)90635-1; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HOLMSEN H, 1989, ANN MED, V21, P23, DOI 10.3109/07853898909149178; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; INABA T, 1995, J CLIN INVEST, V95, P1133, DOI 10.1172/JCI117761; Innerarity T L, 1986, Methods Enzymol, V129, P542; JAAKKOLA O, 1990, AM J PATHOL, V137, P457; Kawakami M, 1993, Nihon Rinsho, V51, P2010; KRAEMER FB, 1990, ARTERIOSCLEROSIS, V10, P8, DOI 10.1161/01.ATV.10.1.8; KURATSU J, 1990, J NEUROSURG, V73, P436, DOI 10.3171/jns.1990.73.3.0436; LEWIS JC, 1977, SCIENCE, V196, P1007, DOI 10.1126/science.860128; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LI ZH, 1994, INT J EXP PATHOL, V75, P169; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MAHLEY RW, 1979, P NATL ACAD SCI USA, V76, P1746, DOI 10.1073/pnas.76.4.1746; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASOLIVA J, 1994, J BIOL CHEM, V269, P10177; MUNRO JM, 1988, LAB INVEST, V58, P249; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; PITAS RE, 1992, ARTERIOSCLER THROMB, V12, P1235, DOI 10.1161/01.ATV.12.11.1235; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1995, IN PRESS P MEXICAN B; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTH M, 1991, P NATL ACAD SCI USA, V88, P1888, DOI 10.1073/pnas.88.5.1888; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tamamoto T, 1994, Rinsho Byori, V42, P971; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	58	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21672	21678		10.1074/jbc.270.37.21672	http://dx.doi.org/10.1074/jbc.270.37.21672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665582	hybrid			2022-12-27	WOS:A1995RU75700040
J	LAMPHEAR, BJ; KIRCHWEGER, R; SKERN, T; RHOADS, RE				LAMPHEAR, BJ; KIRCHWEGER, R; SKERN, T; RHOADS, RE			MAPPING OF FUNCTIONAL DOMAINS IN EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4G (EIF4G) WITH PICORNAVIRAL PROTEASES - IMPLICATIONS FOR CAP-DEPENDENT AND CAP-INDEPENDENT TRANSLATIONAL INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; MESSENGER-RNA TRANSLATION; BINDING-PROTEIN; FACTOR-III; POLIOVIRUS INFECTION; P220 COMPONENT; INTERNAL INITIATION; COMPLEX; CLEAVAGE; VIRUS	Cap-dependent binding of mRNA to the 40 S ribosomal subunit during translational initiation requires the association of eukaryotic initiation factor 4G (eIF4G; formerly eIF-4 gamma and p220) with other initiation factors, notably eIF4E, eIF4A, and eIF3. Infection of cells by picornaviruses results in proteolytic cleavage of eIF4G and generation of a cap-independent translational state. Rhinovirus 2A protease and foot-and-mouth-disease virus L protease were used to analyze the association of eIF4G with eIF4A, eIF4E, and eIF3. Both proteases bisect eIF4G into N- and C-terminal fragments termed cp(N) and cp(C). cp(N) was shown to contain the eIF4E-binding site, as judged by retention on m(7)GTP-Sepharose, whereas cp(C) was bound to eIF3 and eIF4A, based on ultracentrifugal co-sedimentation. Further proteolysis of cp(N) by L protease produced an 18-kDa polypeptide termed cp(N2) which retained eIF4E binding activity and corresponded to amino acid residues 319-479 of rabbit eIF4G. Further proteolysis of cp(C) yielded several smaller fragments. cp(C2) (similar to 887-1402) contained the eIF4A binding site, whereas cp(C3) (similar to 480-886) contained the eIF3 binding site. These results suggest that cleavage by picornaviral proteases at residues 479-486 separates eIF4G into two domains, one required for recruiting capped mRNAs and one for attaching mRNA to the ribosome and directing helicase activity. Only the latter would appear to be necessary for internal initiation of picornaviral RNAs.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71130 USA; UNIV VIENNA, FAK MED, INST BIOCHEM, A-1030 VIENNA, AUSTRIA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Vienna			Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SD, 1968, ARCH BIOCHEM BIOPHYS, V125, P671, DOI 10.1016/0003-9861(68)90625-5; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BENNE R, 1978, J BIOL CHEM, V253, P3078; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; BUCKLEY B, 1986, VIROLOGY, V152, P497, DOI 10.1016/0042-6822(86)90155-8; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN R, 1983, J BIOL CHEM, V258, P7236; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HANSEN J, 1982, J VIROL, V42, P200, DOI 10.1128/JVI.42.1.200-207.1982; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHI B, 1994, J BIOL CHEM, V269, P2048; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; LLOYD RE, 1986, VIROLOGY, V150, P299, DOI 10.1016/0042-6822(86)90291-6; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUECKERT R R, 1990, P507; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SEAL SN, 1983, J BIOL CHEM, V258, P859; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Trachsel H., 1991, TRANSLATION EUKARYOT; VANHEUGTEN HAA, 1991, J BIOL CHEM, V266, P7279; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; WYCKOFF EE, 1990, BIOCHEMISTRY-US, V29, P10055, DOI 10.1021/bi00495a007; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226	65	478	485	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21975	21983		10.1074/jbc.270.37.21975	http://dx.doi.org/10.1074/jbc.270.37.21975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665619	hybrid			2022-12-27	WOS:A1995RU75700083
J	SHIH, HM; LIU, ZR; TOWLE, HC				SHIH, HM; LIU, ZR; TOWLE, HC			2 CACGTG MOTIFS WITH PROPER SPACING DICTATE THE CARBOHYDRATE REGULATION OF HEPATIC GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; MAJOR LATE PROMOTER; FACTOR BINDS; RAT-LIVER; S14 GENE; RESPONSE ELEMENT; THYROID-HORMONE; GLUCOSE; EXPRESSION; UPSTREAM	Regulatory sequences involved in the transcriptional induction of the rat S-14 gene in response to increased glucose metabolism in the hepatocyte were investigated and compared with those of the liver-type pyruvate kinase (L-PK) gene. The carbohydrate response element (ChoRE) of the S-14 gene was found to consist of two motifs related to the consensus binding site for the c-myc family of transcription factors, CACGTG. These two motifs are separated by five base pairs, a similar arrangement to that found in the L-PK ChoRE. In its natural context, the S-14 ChoRE requires a novel accessory factor to support the full response to glucose. This factor, as well as the factor hepatic nuclear factor-4, are both capable of binding to the L-PK gene to enhance its carbohydrate regulation. The need for an accessory factor for supporting the glucose response can be overcome in two ways. First, multimers of the ChoREs of either the L-PK or S-14 genes can function independently to support the glucose response. Second, mutations in the S-14 ChoRE that create a perfect match to the consensus CACGTG motif at each locus no longer require an accessory factor site. The spacing of the two CACGTG motifs, but not the nature of the bases within the spacer, are critical for control. These observations suggest that a carbohydrate responsive factor binds to both motifs in a highly specific spatial orientation to confer the response to increased carbohydrate metabolism.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018					BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BOL CHEM, V269, P17023; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEFRANCOISMARTI.AM, 1995, J BIOL CHEM, V270, P2640; LEFRANCOISMARTI.AM, 1994, FASEB J, V8, P89; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1983, METABOLISM, V33, P545; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STROBL W, 1989, J BIOL CHEM, V264, P1190; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WANG LH, 1989, NATURE, V340, P168	33	177	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21991	21997		10.1074/jbc.270.37.21991	http://dx.doi.org/10.1074/jbc.270.37.21991			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665621	hybrid			2022-12-27	WOS:A1995RU75700085
J	ZHANG, R; CAI, HQ; FATIMA, N; BUCZKO, E; DUFAU, ML				ZHANG, R; CAI, HQ; FATIMA, N; BUCZKO, E; DUFAU, ML			FUNCTIONAL GLYCOSYLATION SITES OF THE RAT LUTEINIZING-HORMONE RECEPTOR REQUIRED FOR LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; PURIFICATION; MUTAGENESIS	The contribution of N-linked glycosylation to the ligand binding activity of the rat luteinizing hormone receptor (LHR) was studied in wild-type and mutant LHR expressed in mammalian (COS1) cells and overexpressed in insect (Sf9) cells. The binding affinities of the holoreceptor and its truncated splice variant (form B) lacking the transmembrane domain were equivalent in both cell lines. Tunicamycin-treated transfected Sf9 cells expressed a carbohydrate-free LH receptor that lacked hormone binding activity. Functional carbohydrate chains essential for binding activity were localized to glycosylation sites at Asn-173 and Asn-152. Glycosidase treatment of the double mutant N173Q/N152Q revealed the presence of at least one additional carbohydrate chain at Asn-269, Asn-277, or Asn-291 that does not contribute to hormone binding. Asn-77 was not glycosylated, but its mutation to Gln reduced hormone binding. LHR expressed in insect cells contained only high mannose carbohydrate chains, and those located at Asn-173 and Asn-152 were sufficient for high-affinity hormone binding. Enzymatic cleavage of glycosyl chains indicated that only the proximal N-acetylglucosamine residue, which is common to high mannose and complex carbohydrate forms, is necessary for acquisition of the high affinity conformation of the receptor. The carbohydrate chains of the LHR appear to be involved in intramolecular folding of the nascent receptor rather than in its interaction with the hormone.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC ENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								CATT KJ, 1976, METHODS RECEPTOR RES, V1, P175; CHEN WY, 1993, MOL CELL ENDOCRINOL, V91, P35, DOI 10.1016/0303-7207(93)90252-F; DANIELSON EM, 1992, BIOCHEMISTRY-US, V31, P226; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; JI L, 1990, ENDOCRINOLOGY, V127, P494; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KEINANEN KP, 1988, BIOCHEM J, V256, P719, DOI 10.1042/bj2560719; KETELSLEGERS JM, 1975, BIOCHEMISTRY-US, V14, P3075, DOI 10.1021/bi00685a006; KOH YC, 1993, J BIOL CHEM, V268, P18267; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KUSUDA S, 1988, J BIOL CHEM, V263, P3046; KUSUDA S, 1986, J BIOL CHEM, V261, P6161; LIU XB, 1993, J BIOL CHEM, V268, P1513; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; MINEGISHI T, 1987, J BIOL CHEM, V262, P17138; PETAJAREPO UE, 1994, BIOCHEM J, V298, P361, DOI 10.1042/bj2980361; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; ZHANG R, 1991, BIOCHEM BIOPH RES CO, V181, P804, DOI 10.1016/0006-291X(91)91261-A	21	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21722	21728		10.1074/jbc.270.37.21722	http://dx.doi.org/10.1074/jbc.270.37.21722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665591	hybrid			2022-12-27	WOS:A1995RU75700049
J	BRIAND, JP; GUICHARD, G; DUMORTIER, H; MULLER, S				BRIAND, JP; GUICHARD, G; DUMORTIER, H; MULLER, S			RETRO-INVERSO PEPTIDOMIMETICS AS NEW IMMUNOLOGICAL PROBES - VALIDATION AND APPLICATION TO THE DETECTION OF ANTIBODIES IN RHEUMATIC DISEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDES; HEXAPEPTIDE; RECOGNIZE; HISTONES; PROTEIN	Retro-inverso peptides which contain NH-CO bonds instead of CO-NH peptide bonds are much more resistant to proteolysis than L-peptides. Moreover, they have been shown recently to be able to mimic natural L-peptides with respect to poly- and monoclonal antibodies (Guichard, G., Benkirane, N., Zeder-Lutz, G., Van Regenmortel, M. H. V., Briand, J. P., and Muller, S. (1994b) Proc. Natl. Acad. Sci. U.S.A. 91, 9765-9769). We have further tested the capacity of retro-inverso peptidomimetics to serve as possible targets for antibodies produced by lupus mice and by patients with rheumatic autoimmune diseases. Several retro-inverso peptides corresponding to sequences known to be recognized by autoantibodies were synthesized, namely peptides 28-45 and 130-135 of H3, 277-291 of the Ro/SSA 52-kDa protein, and 304-324 of the Ro/SSA 60-kDa protein, and tested with autoimmune sera by enzyme-linked immunosorbent assay. We have found that retro-inverso peptides are recognized as well as or even better than natural peptides by antibodies from autoimmune patients and lupus mice. This new approach may lead to important progress in the future development of immunodiagnostic assays, particularly in the case of diseases characterized by inflammatory reactions in the course of which the level of degradative enzymes is increased.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9021, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Muller, Sylviane/J-5319-2014; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502				BARAKAT S, 1992, CLIN EXP IMMUNOL, V89, P38; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; CHOREV M, 1983, J MED CHEM, V26, P129, DOI 10.1021/jm00356a003; ELKON KB, 1992, MOL BIOL REP, V16, P207, DOI 10.1007/BF00464709; GOODMAN M, 1979, ACCOUNTS CHEM RES, V12, P1, DOI 10.1021/ar50133a001; GRASMASSE HS, 1986, MOL IMMUNOL, V23, P1391, DOI 10.1016/0161-5890(86)90025-8; GUICHARD G, 1994, PEPTIDE RES, V7, P308; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LEVINSON SS, 1994, J CLIN IMMUNOASSAY, V17, P72; LOUDON GM, 1981, J AM CHEM SOC, V103, P4508, DOI 10.1021/ja00405a036; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; MULLER S, 1982, EMBO J, V1, P421, DOI 10.1002/j.1460-2075.1982.tb01185.x; MULLER S, 1994, CLIN IMMUNOL IMMUNOP, V73, P187, DOI 10.1006/clin.1994.1187; MULLER S, 1995, PEPTIDE RES, V8, P138; MULLER S, 1994, AUTOIMMUNITY EXPT AS, P76; MULLER S, 1988, SYNTHETIC POLYPEPTID, P95; MULLER S, 1993, STRUCTURE ANTIGENS, P149; NEIMARK J, 1993, PEPTIDE RES, V6, P219; RICCHIUTI V, 1994, CLIN EXP IMMUNOL, V95, P397; RICCHIUTI V, 1994, AUTOIMMUNE DISEASES, P101; SHEMYAKIN MM, 1969, ANGEW CHEM INT EDIT, V8, P492, DOI 10.1002/anie.196904921; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6	27	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20686	20691		10.1074/jbc.270.35.20686	http://dx.doi.org/10.1074/jbc.270.35.20686			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657648	hybrid			2022-12-27	WOS:A1995RR58400068
J	HSIUNG, YC; ELSEA, SH; OSHEROFF, N; NITISS, JL				HSIUNG, YC; ELSEA, SH; OSHEROFF, N; NITISS, JL			A MUTATION IN YEAST TOP2 HOMOLOGOUS TO A QUINOLONE-RESISTANT MUTATION IN BACTERIA - MUTATION OF THE AMINO-ACID HOMOLOGOUS TO SER(83) OF ESCHERICHIA-COLI GYRA ALTERS SENSITIVITY TO EUKARYOTIC TOPOISOMERASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; ANTITUMOR DRUGS; ENZYME; COMPLEX; CELLS; SITE; FLUOROQUINOLONES; ENHANCEMENT; BINDING; SHARE	In prokaryotic type II topoisomerases (DNA gyrases), mutations that result in resistance to quinolones frequently occur at Ser(83) or Ser(84) of the gyrA subunit. Mutations to Trp, Ala, and Leu have been identified, all of which confer high levels of quinolone resistance. Extensive segments of DNA gyrase are homologous to eukaryotic topoisomerase II, and Ser(741) of yeast TOP2 is homologous to Ser(83) of prokaryotic DNA gyrA. Introduction of the Ser(741) --> Trp mutation into yeast TOP2 confers resistance to 6,8-difluoro 7-(4'-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3 carboxylic acid (CP 115,953), a fluoroquinolone with substantial activity against eukaryotic topoisomerase II, whereas changing Ser(741) to either Leu or Ala does not change sensitivity to quinolones. Interestingly, Ser(741) --> Trp in the yeast TOP2 also confers hypersensitivity to etoposide. Sensitivity to intercalating anti topoisomerase II agents such as amsacrine is not changed by any of the three mutations. The topoisomerase II protein carrying the Ser(741) --> Trp mutation was overexpressed and purified. The purified mutant enzyme had enhanced levels of etoposide stabilized covalent complex as compared with the wild type enzyme and reduced cleavage with CP-115,953. Unlike the wild type enzyme, etoposide-stabilized cleavage is not readily reversible by heat. We suggest that Ser(741) is near a binding site for both quinolones and etoposide and that the Ser(741) --> Trp mutation leads to a more stable ternary complex between etoposide, DNA, and the mutant enzyme.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38101 USA; CHILDRENS HOSP LOS ANGELES, DIV HEMATOL ONCOL, DEV THERAPEUT SECT, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90089 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	St Jude Children's Research Hospital; Children's Hospital Los Angeles; University of Southern California; Vanderbilt University; Vanderbilt University			Nitiss, John/E-9974-2010	Elsea, Sarah/0000-0002-1400-8519; Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [T32CA009582, R01CA052814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09582, CA52814] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck W T, 1991, Semin Cancer Biol, V2, P235; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIUNG YH, 1989, J BIOL CHEM, V264, P9713; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; KAWADA SZ, 1991, CANCER RES, V51, P2922; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU YX, 1994, CANCER RES, V54, P2943; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Neu H C, 1994, Adv Pharmacol, V29A, P227; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHILD D, 1983, CURR GENET, V7, P85, DOI 10.1007/BF00365631; Sherman F, 1979, METHODS YEAST GENETI; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	34	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20359	20364		10.1074/jbc.270.35.20359	http://dx.doi.org/10.1074/jbc.270.35.20359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657608	hybrid			2022-12-27	WOS:A1995RR58400021
J	ULLU, E; TSCHUDI, C				ULLU, E; TSCHUDI, C			ACCURATE MODIFICATION OF THE TRYPANOSOME SPLICED LEADER CAP STRUCTURE IN A HOMOLOGOUS CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; M3G CAP; BRUCEI; TRANSCRIPTION; REQUIREMENT; METHYLATION; TRANSPORT; INVITRO; SIGNAL; INVIVO	During RNA maturation in trypanosomatid protozoa, trans-splicing transfers the spliced leader (SL) sequence and its cap from the SL RNA to the 5' end of all mRNAs. In Trypanosoma brucei and Crithidia fasciculata the SL RNA has an unusual cap structure with four methylated nucleotides following the 7-methylguanosine residue (cap 4). Since modification of the 5' end of the SL RNA is a pre-requisite for trans-splicing activity in T. brucei, we have begun to characterize the enzyme(s) involved in this process. Here we report the development of a T. brucei cell-free system for modification of the cap of the SL RNA. Analysis of the nucleotide composition of the in vitro generated cap structure by two-dimensional thin layer chromatography established that the in vitro reaction is accurate. Cap 4 formation requires the SL RNA to be in a ribonucleoprotein particle and can be inhibited by annealing a complementary 2'-O-methyl RNA oligonucleotide to nucleotides 7-18 of the SL RNA. Methylation of the 5' end of the SL RNA is also required for trans-splicing in T. cruzi and Leishmania amazonensis and cell-free extracts from C. fasciculata and L. amazonensis are capable of modifying the cap structure on the T. brucei SL ribonucleoprotein particle.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028798, R37AI028798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BANGS JD, 1992, J BIOL CHEM, V267, P9805; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HARRIS KA, 1995, RNA, V1, P351; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; PATTON JR, 1991, MOL CELL BIOL, V11, P5998, DOI 10.1128/MCB.11.12.5998; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; ULLU E, 1993, J BIOL CHEM, V268, P13068	26	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20365	20369		10.1074/jbc.270.35.20365	http://dx.doi.org/10.1074/jbc.270.35.20365			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657609	hybrid			2022-12-27	WOS:A1995RR58400022
J	MURAI, N; TAGUCHI, H; YOSHIDA, M				MURAI, N; TAGUCHI, H; YOSHIDA, M			KINETIC-ANALYSIS OF INTERACTIONS BETWEEN GROEL AND REDUCED ALPHA-LACTALBUMIN - EFFECT OF GROES AND NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; ESCHERICHIA-COLI; CHAPERONIN GROE; HYDROLYSIS; ABSENCE; BARNASE; BINDING; CELL; ATP	The real-time analysis of the association and dissociation of chaperonin with respect to its substrate protein was carried out using the BIAcore(TM) system, We immobilized alpha-lactalbumin (LA) as a substrate protein on the sensor chip and the GroEL solution was passed over it. Whereas GroEL did not bind to the immobilized native LA, it associated with the immobilized Ca2+-depleted, disulfide bond-reduced form of LA (rLA) rapidly (k(on) = 1.96 x 10(5) M(-1) s(-1)) and dissociated extremely slowly (k(off) = 2.08 x 10(-4) s(-1)), giving a low dissociation constant (K-D = 1.06 nM). MgATP greatly accelerated the dissociation (k(off) = 0.15 +/- 0.02 s(-1)). The K-D value remained almost unchanged when GroES and/or 10 mu M ADP was included in the GroEL solution, However, when 1 mM ADP was included, the K-D value of GroEL increased by 2 orders of magnitude solely due to the change in k(off). When GroES and 1 mM ADP were included, no interaction with rLA was detected due to changes in both k(on) and k(off). These results indicate that GroEL/ES has high and low affinity ADP binding sites and that occupation of the low affinity sites by ADP was responsible for the loss of ability to interact with the substrate protein, The effect of excess GroES on the preformed GroEL rLA and GroELIES rLA complexes was also examined. With increasing GroES, the dissociation of GroEL and GroEL/ES from rLA was accelerated, and thus the possibility is suggested that the substrate protein and GroES compete for the same site on GroEL.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021; MURAI, NORIYUKI/V-5747-2018	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339; MURAI, NORIYUKI/0000-0002-1552-5104				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAIKEN I, 1991, ANAL BIOCHEM, V201, P197; CULLEN DC, 1988, BIOSENSORS, V3, P211; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FARGERSTAM LG, 1992, J CHROMATOGR, V597, P397; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KUBO T, 1993, J BIOL CHEM, V268, P19346; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MARTIN J, 1991, NATURE, V352, P39; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TAGUCHI H, 1995, FEBS LETT, V359, P159; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VIITANEN PV, 1992, PROTEIN SCI, V1, P361; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; ZHAN R, 1994, J MOL BIOL, V242, P150	40	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19957	19963		10.1074/jbc.270.34.19957	http://dx.doi.org/10.1074/jbc.270.34.19957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650011	hybrid			2022-12-27	WOS:A1995RQ99100044
J	SERRA, EC; KRAPP, AR; OTTADO, J; FELDMAN, MF; CECCARELLI, EA; CARRILLO, N				SERRA, EC; KRAPP, AR; OTTADO, J; FELDMAN, MF; CECCARELLI, EA; CARRILLO, N			THE PRECURSOR OF PEA FERREDOXIN-NADP(+) REDUCTASE SYNTHESIZED IN ESCHERICHIA-COLI CONTAINS BOUND FAD AND IS TRANSPORTED INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; NADP+ OXIDOREDUCTASE; COMPETENT PRECURSOR; SPINACH FERREDOXIN; STEP PURIFICATION; PROTEIN IMPORT; SMALL SUBUNIT; TRANSLOCATION; CARBOXYLASE; BINDING	The precursor of the chloroplast flavoprotein ferredoxin-NADP(+) reductase hom pea was expressed in Escherichia coli as a carboxyl-terminal fusion to glutathione S-transferase. The fused protein was soluble, and the precursor could be purified in a few steps involving affinity chromatography on glutathione-agarose, cleavage of the transferase portion by protease Xa, and ion exchange chromatography on DEAE-cellulose. The purified prereductase contained bound FAD but displayed marginally low levels of activity, Removal of the transit peptide by limited proteolysis rendered a functional protease-resistant core exhibiting enzymatic activity, The FAD-containing precursor expressed in E. coli was readily transported into isolated pea chloroplasts and was processed to the mature size, both inside the plastid and by incubation with stromal extracts in a plastid-free reaction. import was dependent on the presence of ATP and was stimulated severalfold by the addition of plant leaf extracts.	UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT CIENCIAS BIOL,MOLEC BIOL SECT,RA-2000 ROSARIO,ARGENTINA	National University of Rosario			Feldman, Mario/A-2637-2014; Ceccarelli, Eduardo A./M-8699-2014; Ceccarelli, Eduardo A./V-2600-2019	Feldman, Mario/0000-0003-4497-0976; Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306				ALTIERI F, 1989, J BIOL CHEM, V264, P4782; AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bar-Nun S, 1980, METHOD ENZYMOL, V69, P363; CARRILLO N, 1985, EUR J BIOCHEM, V150, P469, DOI 10.1111/j.1432-1033.1985.tb09045.x; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EVANS A, 1992, PROTEIN EXPRES PURIF, V3, P178, DOI 10.1016/1046-5928(92)90013-M; FELIPO V, 1983, EUR J BIOCHEM, V133, P641, DOI 10.1111/j.1432-1033.1983.tb07511.x; FERNANDEZ MD, 1991, J BIOL CHEM, V266, P7220; GADDA G, 1990, J BIOL CHEM, V265, P11955; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; NAGAO M, 1992, J BIOL CHEM, V267, P17925; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OBLONG JE, 1992, J BIOL CHEM, V267, P14328; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; OTTADO J, 1994, EUR J BIOCHEM, V225, P677, DOI 10.1111/j.1432-1033.1994.00677.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROBINSON SP, 1979, ARCH BIOCHEM BIOPHYS, V196, P319, DOI 10.1016/0003-9861(79)90584-8; SCHREIER PH, 1988, PLANT MOL BIOL MANUA, P1; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SERRA EC, 1993, PROTEIN EXPRES PURIF, V4, P539, DOI 10.1006/prep.1993.1071; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; TARONI F, 1991, J BIOL CHEM, V266, P13267; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; YUAN JG, 1994, J BIOL CHEM, V269, P18463	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19930	19935		10.1074/jbc.270.34.19930	http://dx.doi.org/10.1074/jbc.270.34.19930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650008	hybrid			2022-12-27	WOS:A1995RQ99100040
J	KENNEDY, MW; BRITTON, C; PRICE, NC; KELLY, SM; COOPER, A				KENNEDY, MW; BRITTON, C; PRICE, NC; KELLY, SM; COOPER, A			THE DVA-1 POLYPROTEIN OF THE PARASITIC NEMATODE DICTYOCAULUS-VIVIPARUS - A SMALL HELIX-RICH LIPID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ANALOG; PHOSPHOGLYCERATE MUTASE; 3-DIMENSIONAL STRUCTURE; DIROFILARIA-IMMITIS; MAJOR ALLERGEN; ASCARIS; ANTIGENS; ALBUMIN	DNA encoding a single unit of the DvA-1 polyprotein of the parasitic nematode Dictyocaulus viviparus was isolated and the polypeptide (''rDvA-1L'') expressed in Escherichia coli, to give a protein showing high binding affinity for fatty acids and retinoids, Fluorescent fatty acid probes show substantial changes in emission spectrum in the presence of rDvA-1L, which can be reversed by fatty acids (oleic, palmitic, stearic, arachidonic) and retinoids, but not by tryptophan, squalene, or cholesterol. Moreover, changes in intrinsic fluorescence of retinol or retinoic acid confirm a retinoid binding activity, Fluorescence titration experiments indicate stoichiometric binding to a single protein site per monomer unit with affinities (K-d) in the range 3 x 10(-8) M for 11-((5-dimethylaminonaphthalene-1-sulfonyl)amino)undecanoic acid, and, by competition, 5 x 10(-8) RI for oleic acid, The extreme blue shift of bound fluorescent fatty acid suggests an unusually low polarity for the protein binding site. The emission spectrum of the single tryptophan of rDvA-1L indicates that it is deeply buried in a nonpolar environment, and its spectrum is unaffected by ligand binding, Far UV circular dichroism of rDvA-1L reveals a high alpha-helix content (53%). Differential scanning calorimetry studies indicate that rDvA-1L is highly stable (T-m approximate to 98 degrees C), refolding efficiently following thermal denaturation, DvA-1 therefore represents an example of a new class of lipid binding protein, and is the first product of a polyprotein with this activity to be described.	UNIV GLASGOW,WELCOME LABS EXPTL PARASITOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT CHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV STIRLING,DEPT BIOL & MOLEC SCI,STIRLING FK9 4LA,SCOTLAND	University of Glasgow; University of Glasgow; University of Stirling			Kelly, Sharon/K-4611-2013; Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387; Britton, Collette/0000-0002-5165-312X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRITTON C, 1995, IN PRESS MOL BIOCH P; CHRISTIE JF, 1990, IMMUNOLOGY, V69, P596; Cooper A, 1994, Methods Mol Biol, V22, P109; CULPEPPER J, 1992, MOL BIOCHEM PARASIT, V54, P51, DOI 10.1016/0166-6851(92)90094-Z; EFTINK MR, 1984, BIOCHEMISTRY-US, V23, P3891, DOI 10.1021/bi00312a016; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FRAPIN D, 1993, J PROTEIN CHEM, V12, P443, DOI 10.1007/BF01025044; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JOHNSON CM, 1987, BIOCHEM J, V245, P525, DOI 10.1042/bj2450525; KENNEDY MW, 1986, IMMUNOLOGY, V58, P515; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MCREYNOLDS LA, 1993, PARASITOL TODAY, V9, P403, DOI 10.1016/0169-4758(93)90046-I; MOORE JD, 1993, BIOCHEM J, V295, P277, DOI 10.1042/bj2950277; Nozaki Y, 1972, Methods Enzymol, V26, P43; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; POOLE CB, 1992, P NATL ACAD SCI USA, V89, P5986, DOI 10.1073/pnas.89.13.5986; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1989, J MOL BIOL, V208, P827; SPENCE HJ, 1993, MOL BIOCHEM PARASIT, V7, P339; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TOMLINSON LA, 1989, J IMMUNOL, V143, P2349; TWEEDIE S, 1993, EXP PARASITOL, V76, P156, DOI 10.1006/expr.1993.1018; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419; WILTON DC, 1990, BIOCHEM J, V270, P163, DOI 10.1042/bj2700163; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	33	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19277	19281		10.1074/jbc.270.33.19277	http://dx.doi.org/10.1074/jbc.270.33.19277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642601				2022-12-27	WOS:A1995RP70300015
J	SHA, M; FERREDAMARE, AR; BURLEY, SK; GOSS, DJ				SHA, M; FERREDAMARE, AR; BURLEY, SK; GOSS, DJ			ANTI-COOPERATIVE BIPHASIC EQUILIBRIUM BINDING OF TRANSCRIPTION FACTOR UPSTREAM STIMULATORY FACTOR TO ITS COGNATE DNA MONITORED BY PROTEIN FLUORESCENCE CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; SYNTHESIS INITIATION FACTOR-4E; FACTOR USF; COMPONENT; ELEMENT; REGION; RNA	Upstream stimulatory factor USF is a human transcriptional activation factor, which uses a basic/helix-loop-helix/leucine zipper (b/HLH/Z) motif to homodimerize and recognize specific sequences in the promoter region of both nuclear and viral genes transcribed by RNA polymerase II, Steady state fluorescence spectroscopy demonstrated that the basic/helix-loop-helix/leucine zipper domain of USF binds its DNA targets with high affinity and specificity, whereas removal of the leucine zipper yielding the basic/helix-loop-helix minimal DNA binding region reduces both affinity and specificity. Stopped flow method provided kinetic evidence for a two-step binding process involving rapid formation of a protein-DNA intermediate followed by a slow isomerization step, which is consistent with the basic region undergoing a random coil to a-helix folding transition on specific DNA recognition. The leucine zipper is also necessary for USF to function as a bivalent homotetramer, capable of binding two distinct recognition sites simultaneously and mediating DNA looping under physiologic conditions. Titration studies revealed that the first binding event has a equilibrium constant K-eq = (2.2 +/- 2.0) x 10(9) M(-1) for major late promoter DNA, whereas the second binding event occurs with a remarkably reduced affinity, K-eq = (1.2 +/- 0.8) x 10(8) M(-1). This anticooperative feature of DNA binding by the homotetramer suggests that USF stimulates transcription by mediating DNA looping between nearby recognition sites located in class II nuclear and viral gene promoters,	CUNY HUNTER COLL,DEPT CHEM,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LABS,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; Rockefeller University				Burley, Stephen K./0000-0002-2487-9713				BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; ISHIDA T, 1983, BIOCHEM BIOPH RES CO, V115, P849, DOI 10.1016/S0006-291X(83)80012-6; LAWACZECK R, 1974, BIOPOLYMERS, V13, P2003, DOI 10.1002/bip.1974.360131006; LESHKOWITZ D, 1992, DNA CELL BIOL, V11, P549, DOI 10.1089/dna.1992.11.549; MARTIN KA, 1994, GENE, V142, P275, DOI 10.1016/0378-1119(94)90274-7; MEISTERERNST M, 1985, P NATL ACAD SCI USA, V87, P9153; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHA M, 1994, J BIOL CHEM, V269, P14872	21	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19325	19329		10.1074/jbc.270.33.19325	http://dx.doi.org/10.1074/jbc.270.33.19325			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642609	hybrid			2022-12-27	WOS:A1995RP70300023
J	SUZUKI, K; YAMAGUCHI, T; TANAKA, T; KAWANISHI, T; NISHIMAKIMOGAMI, T; YAMAMOTO, K; TSUJI, T; IRIMURA, T; HAYAKAWA, T; TAKAHASHI, A				SUZUKI, K; YAMAGUCHI, T; TANAKA, T; KAWANISHI, T; NISHIMAKIMOGAMI, T; YAMAMOTO, K; TSUJI, T; IRIMURA, T; HAYAKAWA, T; TAKAHASHI, A			ACTIVATION INDUCES DEPHOSPHORYLATION OF COFILIN AND ITS TRANSLOCATION TO PLASMA-MEMBRANES IN NEUTROPHIL-LIKE DIFFERENTIATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-KINASE-C; NADPH OXIDASE; SUPEROXIDE GENERATION; GUANINE-NUCLEOTIDES; PHOSPHORYLATION; ACTIN; COMPONENTS; STAUROSPORINE	We suggested that a cytosolic 21-kDa phosphoprotein played an important role in opsonized zymosan-triggered activation of superoxide-generating enzyme in neutrophil-like HL-60 cells through dephosphorylation (Suzubi, K., Yamaguchi, T., Oshizawa, T., Yamamoto, Y., Nishimaki-Mogami, T., Hayakawa, T., and Takahashi, A (1995) Biochim, Biophys, Acta 1266, 261-267). In the present study, we characterized the phosphoprotein and studied changes in its localization upon activation of phagocytes. The 21-kDa phosphoprotein was rapidly dephosphorylated upon activation not only with opsonized zymosan but also with formyl-Met-Leu-Phe and arachidonic acid. The peptide fragments derived from the 21-kDa phosphoprotein were found to have the same amino acid sequences as those of cofilin, an actin-binding protein. The phosphoprotein reacted exclusively with anti cofilin antibody on two dimensional immunoblots. Accordingly, together with its apparent molecular weight, isoelectric point, and detection of phosphoserine as a phosphoamino acid, we concluded that the 21-kDa phosphoprotein was a phosphorylated form of cofilin. The amount of cofilin in membranous fractions was increased upon activation. Furthermore, confocal laser scanning microscopy showed that cofilin existed diffusely in the cytosol and nuclear region of the resting cells, while in the activated cells, it was accumulated at the plasma membrane area, forming ruffles or endocytic vesicles on which O-2(radical) (anion) should be produced. These results suggested that in resting cells cofilin exists as a soluble phosphoprotein in the cytosol and nuclei, while upon stimulation a large portion of cofilin is dephosphorylated and translocated to the plasma membrane regions.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	SUZUKI, K (corresponding author), NATL INST HLTH SCI,SETAGAYA KU,18-1 KAMIYOGA 1 CHOME,TOKYO 158,JAPAN.		Kawanishi, Tetsuya/V-3860-2019					ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ANDREWS PC, 1983, BLOOD, V61, P333; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KONAMI Y, 1992, J BIOCHEM-TOKYO, V112, P366, DOI 10.1093/oxfordjournals.jbchem.a123907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONO S, 1994, J BIOL CHEM, V269, P15280; PARK JW, 1992, J BIOL CHEM, V267, P19901; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RETROSEN D, 1990, J BIOL CHEM, V265, P19910; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROSALES C, 1994, NEUTROPHIL, P23; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SMITH RM, 1991, BLOOD, V77, P673; SUZUKI K, 1995, BBA-MOL CELL RES, V1266, P261, DOI 10.1016/0167-4889(95)00029-R; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	42	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19551	19556		10.1074/jbc.270.33.19551	http://dx.doi.org/10.1074/jbc.270.33.19551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642640	hybrid			2022-12-27	WOS:A1995RP70300056
J	AKASHI, M; HACHIYA, M; OSAWA, Y; SPIRIN, K; SUZUKI, G; KOEFFLER, HP				AKASHI, M; HACHIYA, M; OSAWA, Y; SPIRIN, K; SUZUKI, G; KOEFFLER, HP			IRRADIATION INDUCES WAF1 EXPRESSION THROUGH A P53-INDEPENDENT PATHWAY IN KG-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; FACTOR GENE-EXPRESSION; LONG TERMINAL REPEAT; FACTOR-KAPPA-B; WILD-TYPE P53; IONIZING-RADIATION; FREQUENT MUTATIONS; OXYGEN RADICALS; SUPPRESSOR GENE	WAF1 binds to cyclin-Cdk complexes and inhibits their activity, causing cell cycle arrest. Previous studies have shown that expression of WAF1 is induced through the p53-dependent pathway; WAF1 is induced in cells with functional p53 but not in cells with either mutant p53 or no p53. Human myeloblastic leukemia cells KG-1 had no constitutive expression of p53, and irradiation did not induce p53. However, irradiation increased WAF1 expression in KG-1 cells and other cell lines containing mutant p53. The KG-1 cells constitutively produced low levels of tumor necrosis factor (TNF); irradiation markedly increased the production of TNF. Notably, induction of WAF1 mRNA by irradiation was blocked by anti-TNF antibody, Furthermore, exogenously added TNF increased levels of WAF1 mRNA in these cells. Irradiation increased the rate of WAF1 transcription 3-fold, and the half-life (t(1/2)) of WAF1 mRNA in these cells increased from <1 h in unirradiated cells to >4 h in irradiated cells. These findings indicate that increased levels of WAF1 transcripts occur, at least in part, through a pathway of TNF production and that the increase in WAF1 mRNA observed after irradiation is regulated by both transcriptional and posttranscriptional mechanisms. Our present study strongly suggests that an alternative pathway of induction of WAF1 occurs independent of activation by p53.	UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI RES INST, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	AKASHI, M (corresponding author), NATL INST RADIOL SCI, DIV RADIAT HLTH, INAGE KU, 4-9-1 ANAGAWA, CHIBA 263, JAPAN.				NCI NIH HHS [CA43277, CA33936, CA26038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026038, U01CA043277, R01CA033936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; AKASHI M, 1989, BLOOD, V74, P2383; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CAVARD C, 1990, J CLIN INVEST, V86, P1369, DOI 10.1172/JCI114849; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CLARK IA, 1985, MED RES REV, V5, P297, DOI 10.1002/med.2610050303; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DENEKAMP J, 1986, INT J RADIAT BIOL, V49, P357, DOI 10.1080/09553008514552591; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HACHIYA M, 1994, EXP CELL RES, V214, P343, DOI 10.1006/excr.1994.1266; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P10; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KASTAN M, CANCER RES, V51, P6304; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Maniatis T, 1982, MOL CLONING LABORATO, P194; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MICHIELI P, 1994, CANCER RES, V54, P3391; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; XLONG Y, 1993, NATURE, V366, P701; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	79	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19181	19187		10.1074/jbc.270.32.19181	http://dx.doi.org/10.1074/jbc.270.32.19181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642586				2022-12-27	WOS:A1995RN95400074
J	HUANG, CC; SPRINGER, TA				HUANG, CC; SPRINGER, TA			A BINDING INTERFACE ON THE I-DOMAIN OF LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 (LFA-1) REQUIRED FOR SPECIFIC INTERACTION WITH INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; MEDIATED CYTOLYSIS; COUNTER-RECEPTOR; DISTINCT; INTEGRIN; CLONING; EXPRESSION	Previous studies have shown that lymphocyte function-associated antigen-1 (LFA-1) molecules containing the human alpha (CD11a) and human beta (CD18) subunits but not the murine a and human beta subunits can bind to human intercellular adhesion molecule 1 (ICAM-1). Using human/mouse LFA-1 alpha subunit chimeras, we mapped regions required for binding to ICAM-1 N-terminal to amino acid (aa) residue 359. Ligand binding sites were mapped in greater detail by scanning this region with murine sequences from 56 down to 17 aa in length and finally by introducing single or few murine aa residue replacements into the human sequence. Replacement of two non-contiguous regions of aa residues 119-153 and 218-248 in the I domain with the corresponding mouse sequences abolished most binding to human ICAM-1, without affecting alpha beta subunit association or expression on the surface of transfected COS cells. Specific residues within the I domain found to be important were Met-140, Glu-146, Thr-243, and Ser-245. Using the recently solved structure of the Mac-1 (CD11b) I domain as a model (Lee, J.-O., Rieu, P., Aznaout, M. A., and Liddington, R. (1995) Cell 80, 631-638), these residues are shown to be located on the surface of the I domain surrounding the site to which Mg2+ is chelated, and define a ligand binding interface. Mapping of the epitopes of a panel of mouse anti-human and rat anti-mouse monoclonal antibodies gave concordant results. Epitopes were mapped to two different regions in the N-terminal domain, four regions within the I domain, and two regions between the I domain and the EF handlike repeats. Monoclonal antibodies to epitopes within the mid- to C-terminal portion of the I domain and the N-terminal portion of the region between the I domain and the EF hand-like repeats gave good inhibition of LFA-1-dependent homotypic aggregation with cells that express either ICAM-1 or ICAM-3 as the major LFA-1 ligand.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FISCHER A, 1986, LANCET, V2, P1058; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAUFMANN Y, 1991, J IMMUNOL, V147, P369; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MORIMOTO C, 1987, NATURE, V330, P479, DOI 10.1038/330479a0; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NAKAMURA Y, 1989, P NATL ACAD SCI USA, V86, P1318, DOI 10.1073/pnas.86.4.1318; OHASHI Y, 1992, TOHOKU J EXP MED, V167, P297, DOI 10.1620/tjem.167.297; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WARE CF, 1983, J IMMUNOL, V131, P1182; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	53	156	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19008	19016		10.1074/jbc.270.32.19008	http://dx.doi.org/10.1074/jbc.270.32.19008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642561	hybrid			2022-12-27	WOS:A1995RN95400049
J	KAPOOR, M; ZHANG, LW; RAMACHANDRA, M; KUSUKAWA, J; EBNER, KE; PADMANABHAN, R				KAPOOR, M; ZHANG, LW; RAMACHANDRA, M; KUSUKAWA, J; EBNER, KE; PADMANABHAN, R			ASSOCIATION BETWEEN NS3 AND NS5 PROTEINS OF DENGUE VIRUS TYPE-2 IN THE PUTATIVE RNA REPLICASE IS LINKED TO DIFFERENTIAL PHOSPHORYLATION OF NS5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; ADENOVIRUS DNA-POLYMERASE; SV40 T-ANTIGEN; NF-KAPPA-B; STRUCTURAL PROTEINS; NONSTRUCTURAL PROTEIN; POLYPROTEIN PRECURSOR; VIRAL POLYPROTEIN; NUCLEAR TRANSPORT; INVITRO SYNTHESIS	Dengue virus type 2, a member of the family Flaviviridae, encodes a single polyprotein precursor consisting of 3391 amino acid residues that is processed to at least 10 mature proteins by host and viral proteases. The NS3 protein contains a domain commonly found in cellular serine proteinases that in cooperation with NS2B is involved in polyprotein processing. In addition, NS3 and NS5 proteins contain conserved motifs found in several RNA helicases and RNA-dependent RNA polymerases, respectively. Both enzymatic activities have been suggested to be involved in viral RNA replication. In this report, we demonstrate that the NS3 and NS5 proteins interact in vivo in dengue virus type 2-infected monkey kidney (CV-1) cells and in HeLa cells coinfected with recombinant vaccinia viruses encoding these proteins as shown by coimmunoprecipitations and immunoblotting methods. We also show by immunofluorescence, metabolic labeling, and two-dimensional peptide mapping that NS5 is a nuclear phosphoprotein and that phosphorylation occurs on serine residues at multiple sites. Furthermore, NS5 exists in differentially phosphorylated states in the nuclear and the cytoplasmic fractions, and only the cytoplasmic form of NS5 is found to coimmunoprecipitate with NS3, suggesting that differential phosphorylation may control the interaction between these proteins and its function in the viral RNA replicase.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Ramachandra, Murali/0000-0003-4039-1491	NIAID NIH HHS [AI 32078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTHOLOMEUSZ AI, 1993, ARCH VIROL, V128, P111, DOI 10.1007/BF01309792; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; Earl P, 1991, CURRENT PROTOCOLS MO; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRUN JB, 1987, J VIROL, V61, P3641, DOI 10.1128/JVI.61.11.3641-3644.1987; GRUN JB, 1986, J VIROL, V60, P1113, DOI 10.1128/JVI.60.3.1113-1124.1986; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KNUSUKAWA J, 1994, J BIOL CHEM, V269, P2189; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBINIEC.AS, 1974, P SOC EXP BIOL MED, V145, P1165; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; RANSONE LJ, 1989, J VIROL, V63, P4563, DOI 10.1128/JVI.63.11.4563-4568.1989; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Rice CM., 1986, TOGAVIRIDAE FLAVIVIR, P279, DOI 10.1007/978-1-4757-0785-4_10; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RUIZLINARES A, 1989, J VIROL, V63, P4199, DOI 10.1128/JVI.63.10.4199-4209.1989; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; Schlesinger, 1986, TOGAVIRIDAE FLAVIVIR, P327; STOLLAR V, 1967, VIROLOGY, V33, P650, DOI 10.1016/0042-6822(67)90065-7; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; TAKEGAMI T, 1989, VIRUS RES, V13, P337; TRENT DW, 1969, J VIROL, V3, P385, DOI 10.1128/JVI.3.4.385-394.1969; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1978, VIROLOGY, V89, P423, DOI 10.1016/0042-6822(78)90185-X; WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4; WESTAWAY EG, 1985, INTERVIROLOGY, V24, P183, DOI 10.1159/000149642; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	58	267	276	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19100	19106		10.1074/jbc.270.32.19100	http://dx.doi.org/10.1074/jbc.270.32.19100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642575	hybrid			2022-12-27	WOS:A1995RN95400063
J	KHARBANDA, S; SALEEM, A; SHAFMAN, T; EMOTO, Y; TANEJA, N; RUBIN, E; WEICHSELBAUM, R; WOODGETT, J; AVRUCH, J; KYRIAKIS, J; KUFE, D				KHARBANDA, S; SALEEM, A; SHAFMAN, T; EMOTO, Y; TANEJA, N; RUBIN, E; WEICHSELBAUM, R; WOODGETT, J; AVRUCH, J; KYRIAKIS, J; KUFE, D			IONIZING-RADIATION STIMULATES A GRB2-MEDIATED ASSOCIATION OF THE STRESS-ACTIVATED PROTEIN-KINASE WITH PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MYELOID-LEUKEMIA CELLS; C-JUN GENE; SH3 DOMAINS; GRB2; BINDS; PHOSPHORYLATION; EXPRESSION	The stress-activated protein (SAP) kinases are induced by tumor necrosis factor, oncoproteins, and UV light. The present studies demonstrate that ionizing radiation (IR) activates p54 SAP kinase. IR-induced activation of SAP kinase is associated with binding to the SH2/SH3-containing adaptor protein Grb2, This interaction is mediated by the SH3 domains of Grb2 and the proline-rich sequence PPPKIP in the carboxyl terminal region of SAP kinase, We also demonstrate that SAP kinase and the p85 alpha-subunit of phosphatidylinositol (PI) 3-kinase form a complex in irradiated cells, The results indicate that this complex involves binding of the p85 alpha subunit of PI 3-kinase to the SH2 domain of Grb2. The functional role of linking SAP kinase to PI 3-kinase is further supported by the finding that wortmannin, an inhibitor of PI 3-kinase, stimulates SAP kinase activity. These results suggest that the cellular response to IR may include regulation of SAP kinase by a PI 3-kinase-dependent signaling pathway.	HARVARD UNIV,DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,DIABET RES LAB,MED SRV,BOSTON,MA 02129; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; University of Chicago; University of Toronto; University Toronto Affiliates; University Health Network Toronto	KHARBANDA, S (corresponding author), HARVARD UNIV,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBIN E, 1991, MOL PHARMACOL, V39, P697; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Wymann M. P., 1993, BIOCHEM J, V296, P297; YAN MH, 1994, NATURE, V372, P798; YANO H, 1993, J BIOL CHEM, V268, P25846	33	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18871	18874		10.1074/jbc.270.32.18871	http://dx.doi.org/10.1074/jbc.270.32.18871			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642542	Green Submitted, hybrid			2022-12-27	WOS:A1995RN95400029
J	XIA, Y; ZWEIER, JL				XIA, Y; ZWEIER, JL			SUBSTRATE CONTROL OF FREE-RADICAL GENERATION FROM XANTHINE-OXIDASE IN THE POSTISCHEMIC HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPERFUSION INJURY; MYOCARDIAL ISCHEMIA; INFARCT SIZE; ALLOPURINOL; MECHANISM; TISSUES; DAMAGE; ENZYME	While the free radical-generating enzyme xanthine oxidase is a central mechanism of injury in postischemic tissues, questions remain regarding how xanthine oxidase-mediated radical generation is triggered during ischemia and reperfusion. There is controversy regarding whether radical generation is caused by enzyme formation or that of its substrates xanthine and hypo xanthine. Therefore, studies were performed in isolated rat hearts correlating the magnitude and time course of radical generation with alterations in xanthine oxidase and its substrates. Radical generation was measured by electron paramagnetic resonance spectroscopy and correlated with spectrophotometric assays of tissue xanthine oxidase activity and chromatographic measurement of tissue and effluent concentrations of xanthine oxidase substrates and products. Xanthine oxidase was present in preischemic hearts and slightly increased during 30-min global ischemia. Hypoxanthine and xanthine were not present prior to ischemia but accumulated greatly during ischemia due to ATP degradation. These substrate concentrations rapidly declined over the first 5 min of reperfusion matching the observed time course of radical generation, whereas xanthine oxidase activity was largely unchanged. Both substrates were also observed in the coronary effluent during the first 5 min of reflow along with the product uric acid. Thus, the burst of xanthine oxidase-mediated free radical generation upon reperfusion is triggered and its time course controlled by a large increase in substrate formation that occurs secondary to the degradation of ATP during ischemia.	JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD 21224 USA; JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELFATTAH AS, 1988, CIRCULATION, V78, P224; ABDELFATTAH AS, 1990, CIRCULATION, V82, P341; ABDELFATTAH AS, 1987, CARDIOVASC DRUG THER, V1, P210; ACKERMAN E, 1962, BIOCHIM BIOPHYS ACTA, V56, P397, DOI 10.1016/0006-3002(62)90591-7; ADKISON D, 1986, ACTA PHYSIOL SCAND, V126, P101; AMBROSIO G, 1986, CIRCULATION, V74, P1424, DOI 10.1161/01.CIR.74.6.1424; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CHAMBERS DJ, 1987, ANN THORAC SURG, V44, P291, DOI 10.1016/S0003-4975(10)62076-0; COUDRAY C, 1992, BASIC RES CARDIOL, V87, P478; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; ENGERSON TD, 1989, FASEB J, V3, P628; FREDERIKS WM, 1993, INT J EXP PATHOL, V74, P21; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOUSSON B, 1983, ENZYME, V29, P32, DOI 10.1159/000469601; ONTYD J, 1984, J CHROMATOGR, V307, P404, DOI 10.1016/S0378-4347(00)84113-4; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PISARENKO OI, 1994, BIOCHEM MED METAB B, V51, P16, DOI 10.1006/bmmb.1994.1002; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL, P1; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	37	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18797	18803		10.1074/jbc.270.32.18797	http://dx.doi.org/10.1074/jbc.270.32.18797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642530	hybrid			2022-12-27	WOS:A1995RN95400017
J	KOIKETAKESHITA, A; KOYAMA, T; OBATA, S; OGURA, K				KOIKETAKESHITA, A; KOYAMA, T; OBATA, S; OGURA, K			MOLECULAR-CLONING AND NUCLEOTIDE-SEQUENCES OF THE GENES FOR 2 ESSENTIAL PROTEINS CONSTITUTING A NOVEL ENZYME-SYSTEM FOR HEPTAPRENYL DIPHOSPHATE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAPRENYL PYROPHOSPHATE SYNTHETASE; MICROCOCCUS-LUTEUS B-P-26; 2 ESSENTIAL COMPONENTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SYNTHASE; PRENYLTRANSFERASE; PURIFICATION; FARNESYLTRANSFERASE; SEPARATION	The genes encoding two dissociable components essential for Bacillus stearothermophilus heptaprenyl diphosphate synthase (all-trans-hexaprenyl-diphosphate:isopentenyl-diphosphate hexaprenyl-trans-transferase, EC 2.5.1.30) were cloned, and their nucleotide sequences were determined. Sequence analyses revealed the presence of three open reading frames within 2,350 base pairs, designated as ORF-1, ORF-2, and ORF-3 in order of nucleotide sequence, which encode proteins of 220, 234, and 323 amino acids, respectively. Deletion experiments have shown that expression of the enzymatic activity requires the presence of ORF-1 and ORF-3, but ORF-2 is not essential. As a result, this enzyme was proved genetically to consist of two different protein components with molecular masses of 25 kDa (Component I) and 36 kDa (Component II), encoded by two of the three tandem genes. The protein encoded by ORF-1 has no similarity to any protein so far registered. However, the protein encoded by ORF-3 shows a 32% similarity to the farnesyl diphosphate synthase of the same bacterium and has seven highly conserved regions that have been shown typical in prenyltransferases (Koyama, T., Obata, S., Osabe, M., Takeshita, A., Yokoyama, K., Uchida, M., Nishino, T., and Ogura, K. (1993) J. Biochem. (Tokyo) 113, 355-363).	TOYOTA MOTOR CO LTD,BIORES LAB,TOYOTA,AICHI 47171,JAPAN; TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Toyota Motor Corporation; Tohoku University								ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJII H, 1983, FEBS LETT, V161, P257, DOI 10.1016/0014-5793(83)81020-5; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; HESS A, 1979, J GEN MICROBIOL, V115, P247, DOI 10.1099/00221287-115-1-247; ISHII K, 1986, BIOCHEM J, V233, P733; KOYAMA T, 1994, BIOCHEMISTRY-US, V33, P12644, DOI 10.1021/bi00208a015; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1985, METHOD ENZYMOL, V110, P153; MUTH JD, 1984, ARCH BIOCHEM BIOPHYS, V230, P49, DOI 10.1016/0003-9861(84)90085-7; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, V1, P161; REISS Y, 1991, J BIOL CHEM, V266, P10672; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TORAYA T, 1974, BIOCHEMISTRY-US, V13, P3895, DOI 10.1021/bi00716a012; YOSHIDA I, 1987, BIOCHEMISTRY-US, V26, P6840, DOI 10.1021/bi00395a038; YOSHIDA I, 1989, BIOCHEM BIOPH RES CO, V160, P448, DOI 10.1016/0006-291X(89)92453-4	32	54	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18396	18400		10.1074/jbc.270.31.18396	http://dx.doi.org/10.1074/jbc.270.31.18396			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629164	hybrid			2022-12-27	WOS:A1995RM64200040
J	STURCHLERPIERRAT, C; HUBERT, N; TOTSUKA, T; MIZUTANI, T; CARBON, P; KROL, A				STURCHLERPIERRAT, C; HUBERT, N; TOTSUKA, T; MIZUTANI, T; CARBON, P; KROL, A			SELENOCYSTEYLATION IN EUKARYOTES NECESSITATES THE UNIQUELY LONG AMINOACYL ACCEPTOR STEM OF SELENOCYSTEINE TRNA(SEC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; TRANSFER RNA(SEC); ESCHERICHIA-COLI; SERINE; GENE	Selenocysteine synthesis is achieved on a specific tRNA, tRNA(Sec), which is first charged with serine to yield seryl-tRNA(Sec). Eukaryotic tRNA(Sec) exhibits an aminoacyl acceptor stem with a unique length of 9 base pairs. Within this stem, two base pairs, G5a.U67b and U6.U67, drew our attention, whose non-Watson-Crick status is maintained in the course of evolution either through U6.U67 base conservation or base covariation at G5a.U67b. Single or double point mutations were performed, which modified the identity of either or both of the base pairs. Serylation by seryl-tRNA synthetase was unaffected by substitutions at either G5a.U67b or U6.U67. Instead, and quite surprisingly, changing G5a.U67b and U6.U67 to G5a-C67b/U6.G67 or G5a-C67b/C6-G67 gave rise to a tRNA(Sec) mutant exhibiting a gain of function in serylation. This finding sheds light on the negative influence born by a few base pairs in the acceptor stem of tRNA(Sec) on its serylation abilities. The tRNA(Sec) capacities to support selenocysteylation were next examined with regard to a possible role played by the two non-Watson-crick base pairs and the unique length of the acceptor stem. It first emerges from our study that tRNA(Sec) transcribed in vitro is able to support selenocysteylation. Second, none of the point mutations engineered at G5a.U67b and/or U6.U67 significantly modified the selenocysteylation level. In contrast, reduction of the acceptor stem length to 8 base pairs led tRNA(Sec) to lose its ability to efficiently support selenocysteylation. Thus, our study provides strong evidence that the length of the acceptor stem is of prime importance for the serine to selenocysteine conversion step.	INST BIOL MOLEC & CELLULAIRE,CNRS,UPR 9002,F-67084 STRASBOURG,FRANCE; AICHI PREFECTURAL COLONY HANDICAPPED,INST DEV RES,KASUGAI,AICHI 48003,JAPAN; NAGOYA CITY UNIV,FAC PHARMACEUT SCI,NAGOYA,AICHI 467,JAPAN	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Nagoya City University								AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; BARON C, 1991, J BIOL CHEM, V266, P20375; BARON C, 1993, J MOL BIOL, V231, P274, DOI 10.1006/jmbi.1993.1282; BARON C, 1995, TRNA STRUCTURE BIOSY, P524; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; DIETRICH A, 1976, EUR J BIOCHEM, V70, P147, DOI 10.1111/j.1432-1033.1976.tb10965.x; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GELPI C, 1992, P NATL ACAD SCI USA, V89, P9739, DOI 10.1073/pnas.89.20.9739; JUNG JE, 1994, J BIOL CHEM, V269, P29739; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; MIZUTANI T, 1989, FEBS LETT, V250, P142, DOI 10.1016/0014-5793(89)80707-0; MIZUTANI T, 1984, EUR J BIOCHEM, V143, P9, DOI 10.1111/j.1432-1033.1984.tb08331.x; MIZUTANI T, 1992, BIOCHEM J, V284, P827, DOI 10.1042/bj2840827; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; OHAMA T, 1994, ARCH BIOCHEM BIOPHYS, V315, P293, DOI 10.1006/abbi.1994.1503; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; STURCHLER C, 1993, NUCLEIC ACIDS RES, V21, P1073, DOI 10.1093/nar/21.5.1073; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YAMADA K, 1994, FEBS LETT, V347, P137, DOI 10.1016/0014-5793(94)00523-0; ZADOWSKI V, 1991, NUCLEIC ACIDS RES, V19, P1948	24	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18570	18574		10.1074/jbc.270.31.18570	http://dx.doi.org/10.1074/jbc.270.31.18570			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629188	hybrid			2022-12-27	WOS:A1995RM64200066
J	BROCK, TG; MCNISH, RW; PETERSGOLDEN, M				BROCK, TG; MCNISH, RW; PETERSGOLDEN, M			TRANSLOCATION AND LEUKOTRIENE SYNTHETIC CAPACITY OF NUCLEAR 5-LIPOXYGENASE IN RAT BASOPHILIC LEUKEMIA-CELLS AND ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; ARACHIDONIC-ACID; HUMAN-LEUKOCYTES; PROTEIN; INHIBITION; STIMULATION; CALCIUM; ENZYME	Leukotriene (LT) synthesis involves the translocation of enzymatically active 5-lipoxygenase (5-LO) from a soluble site to a bound site, where it interacts with 5-lipoxygenase-activating protein (FLAP). In human polymorphonuclear leukocytes (PMNs), 5-LO moves from the cytosol to the nuclear envelope (NE) to interact with FLAP. However, 5-LO has recently been found within the nucleus, as well as the cytosol, of rat basophilic leukemia (RBL) cells and alveolar macrophages (AMs). To assess whether nuclear 5-LO can contribute to LT synthesis in these cells, we investigated whether this enzyme pool 1) translocates upon cell activation, 2) colocalizes with FLAP, and 3) is enzymatically active. By cell fractionation followed by immunoblotting, both cytosolic and nuclear soluble 5-LO decreased dramatically in RBL cells following activation with the calcium ionophore A23187. Concurrently, 5-LO increased in the pelletable nuclear pool, where FLAP was also detected. The loss of both cytosolic and nuclear soluble 5-LO, with concomitant increase exclusively at the NE, as well as co-localization with FLAP, were confirmed by indirect immunofluorescent and confocal microscopy. In AMs, the nuclear soluble pool of 5-LO moved to the NE, where FLAP was also found; however, the cytosolic 5-LO pool did not translocate. Application of these methods to PMNs confirmed that cytosolic 5-LO moved to the nuclear envelope and co-localized with FLAP. By cell-free assay, nuclear soluble proteins from both RBL cells and AMs, but not PMNs, were able to generate 5-LO products from arachidonate, and this was inhibited by the direct 5-LO inhibitor zileuton. Cytosolic proteins from all cell types also showed cell-free 5-LO activity. These results demonstrate three distinct patterns of 5-LO translocation that are specific for each cell type: translocation of only a cytosolic pool in PMNs, of only a nuclear pool in AMs, and of both cytosolic and nuclear pools in RBL cells. By virtue of its enzymatic activity and ability to translocate, nuclear 5-LO has the potential to contribute to LT synthesis in RBL cells and AMs. Finally, these results provide a foundation for considering the individual functions of discrete pools of 5-LO in future studies.			BROCK, TG (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046487, R01HL047391, T32HL007749] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07749, P50 HL46487, R01 HL47391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; COFFEY M, 1992, J BIOL CHEM, V267, P570; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; GUIDOT DM, 1994, P NATL ACAD SCI USA, V91, P8156, DOI 10.1073/pnas.91.17.8156; HATZELMANN A, 1994, BIOCHEM PHARMACOL, V48, P31, DOI 10.1016/0006-2952(94)90220-8; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; REID GK, 1990, J BIOL CHEM, V265, P19818; ROTMAN EI, 1992, BIOCHEM J, V282, P487, DOI 10.1042/bj2820487; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SOLIVEN B, 1993, AM J PHYSIOL, V264, pC632, DOI 10.1152/ajpcell.1993.264.3.C632; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	33	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21652	21658		10.1074/jbc.270.37.21652	http://dx.doi.org/10.1074/jbc.270.37.21652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665580	hybrid			2022-12-27	WOS:A1995RU75700037
J	DELAROSA, J; OSTROWSKI, J; HRYNIEWICZ, MM; KREDICH, NM; KOTB, M; LEGROS, HL; VALENTINE, M; GELLER, AM				DELAROSA, J; OSTROWSKI, J; HRYNIEWICZ, MM; KREDICH, NM; KOTB, M; LEGROS, HL; VALENTINE, M; GELLER, AM			CHROMOSOMAL LOCALIZATION AND CATALYTIC PROPERTIES OF THE RECOMBINANT ALPHA-SUBUNIT OF HUMAN LYMPHOCYTE METHIONINE ADENOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; N-TERMINAL METHIONINE; RAT-LIVER; ESCHERICHIA-COLI; MOLECULAR-CLONING; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; PARTIAL-PURIFICATION; NUCLEOTIDE-SEQUENCE; AMINO-ACID	Human lymphocyte methionine adenosyltransferase (HuLy MAT) consists of heterologous subunits alpha and beta. The cDNA sequence of the alpha subunit of HuLy MAT from Jurkat leukemic T cells was identical to that of the human kidney alpha subunit and highly homologous to the sequence of the extrahepatic MAT from other sources, The 3'-untranslated sequence was found to be highly conserved, suggesting that it may be important in regulating the expression of MAT. The extrahepatic alpha subunit of MAT was found to be expressed also in human liver, and no differences were found in the sequence of the alpha subunit from normal and malignant T cells, The sequence of two unspliced introns found in the cDNA clones from the Jurkat library enabled us to isolate genomic clones harboring the human extrahepatic alpha subunit gene and to localize it to the centromere on chromosome arm 2p, an area that corresponds to band 2p11.2. Expression of the alpha subunit cDNA in Escherichia coli yielded two peptides with the immunoreactivity and mobilities of authentic alpha/alpha' subunits from HuLy, The K-m of the recombinant alpha subunit was 80 mu M, which is 20-fold higher than found for the (alpha alpha')(x) beta(y) holoenzyme purified from leukemic lymphocytes and 4-10-fold higher than found for the normal lymphocyte enzyme. The data suggest that the alpha/alpha' subunits mediate the enzyme catalytic activity and that the beta subunit may be a regulatory subunit of extrahepatic MAT.	VET ADM MED CTR, RES SERV 151, MEMPHIS, TN 38104 USA; POLISH ACAD SCI, INST BIOCHEM & BIOPHYS, WARSAW, POLAND; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; UNIV TENNESSEE, DEPT SURG, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Duke University; Duke University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital					NIDDK NIH HHS [DK-12828] Funding Source: Medline; NIGMS NIH HHS [GM-38530] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE T, 1982, Journal of Biochemistry (Tokyo), V91, P1081; AKERMAN K, 1991, BIOCHIM BIOPHYS ACTA, V1097, P140, DOI 10.1016/0925-4439(91)90098-T; ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BAHNAK BR, 1987, BLOOD, V69, P224; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERO C, 1988, BIOCHIM BIOPHYS ACTA, V952, P277, DOI 10.1016/0167-4838(88)90127-6; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1957, J BIOL CHEM, V225, P1033; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; DALBOGE H, 1990, FEBS LETT, V266, P1, DOI 10.1016/0014-5793(90)90001-B; DELAROSA J, 1991, BIOCHIM BIOPHYS ACTA, V1077, P225, DOI 10.1016/0167-4838(91)90062-5; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1992, CANCER RES, V52, P3361; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GELLER AM, 1986, EXP EYE RES, V43, P997, DOI 10.1016/0014-4835(86)90077-1; GELLER AM, 1988, EXP EYE RES, V47, P197, DOI 10.1016/0014-4835(88)90003-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KAPPLER F, 1987, J MED CHEM, V30, P1599, DOI 10.1021/jm00392a013; KAPPLER F, 1988, J MED CHEM, V31, P384, DOI 10.1021/jm00397a020; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; KOTB M, 1987, J IMMUNOL, V139, P202; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LIAU MC, 1977, CANCER RES, V37, P427; LIAU MC, 1979, CANCER RES, V39, P162; LIAU MC, 1979, CANCER RES, V39, P2113; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; MANIATIS T, 1992, MOL CLONING; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Maxam A M, 1980, Methods Enzymol, V65, P499; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1958, J BIOL CHEM, V231, P481; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; ODEN KL, 1983, BIOCHIM BIOPHYS ACTA, V760, P270, DOI 10.1016/0304-4165(83)90173-3; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PELEMAN J, 1989, GENE, V84, P359, DOI 10.1016/0378-1119(89)90510-6; PETERSON GL, 1986, BIOCHEMISTRY-US, V25, P3189, DOI 10.1021/bi00359a017; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUSSELL DR, 1982, GENE, V20, P231, DOI 10.1016/0378-1119(82)90042-7; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; SUFRIN JR, 1982, MOL PHARMACOL, V22, P752; SUFRIN JR, 1980, FED PROC, V39, P1908; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; THOMAS D, 1987, J BIOL CHEM, V262, P16704	68	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21860	21868						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665609				2022-12-27	WOS:A1995RU75700069
J	HUANG, KX; FUJII, I; EBIZUKA, Y; GOMI, K; SANKAWA, U				HUANG, KX; FUJII, I; EBIZUKA, Y; GOMI, K; SANKAWA, U			MOLECULAR-CLONING AND HETEROLOGOUS EXPRESSION OF THE GENE ENCODING DIHYDROGEODIN OXIDASE, A MULTICOPPER BLUE ENZYME FROM ASPERGILLUS-TERREUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; RESOLUTION; TRANSFORMATION; NIDULANS; SEQUENCE; FUNGUS; IDENTIFICATION; PURIFICATION; BIOSYNTHESIS	Aspergillus terreus dihydrogeodin oxidase (DHGO) is an enzyme catalyzing the stereospecific phenol oxidative coupling reaction converting dihydrogeodin to (+)-geodin, We previously reported the purification of DHGO from A. terreus and raised polyclonal antibody against DHGO. From the first cDNA library constructed in lambda gt11 using mRNA from 3-day-old mycelium of A. terreus, four clones were identified using anti-DHGO antibody, but all contained partial cDNA inserts around 280 base pairs. This cDNA fragment was used as a probe to clone the genomic DNA and cDNA for dihydrogeodin oxidase from A. terreus. The sequence of the cloned DHGO genomic DNA and cDNA predicted that the DHGO polypeptide consists of 605 amino acids showing significant homology with multicopper blue proteins such as laccase and ascorbate oxidase. Four potential copper binding domains exist in DHGO polypeptide, The DHGO gene consists of seven exons separated by six short introns. Expression of the DHGO gene in Aspergillus nidulans under the starch or maltose-inducible Taka-amylase A promoter as an active enzyme established the functional identity of the gene. Also, introduction of the genomic DNA for DHGO into Penicillium frequentans led to the production of DHGO polypeptide as judged by Western blot analysis.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN; NATL RES INST BREWING,KITA KU,TOKYO 114,JAPAN	University of Tokyo								Barton D. H. R., 1957, FESTSCHRIFT A STOLL, P117; BIEL SW, 1986, ANAL BIOCHEM, V154, P21, DOI 10.1016/0003-2697(86)90489-6; BROWN BR, 1967, OXIDATIVE COUPLING P, P109; BROWN BR, 1967, OXIDATIVE COUPLING P, P1; CHANG PK, 1992, CURR GENET, V21, P231, DOI 10.1007/BF00336846; CHEN ZG, 1992, ARCH MICROBIOL, V158, P29, DOI 10.1007/BF00249062; CHEN ZG, 1995, PHYTOCHEMISTRY, V38, P373; CHOI GH, 1992, MOL PLANT MICROBE IN, V5, P119, DOI 10.1094/MPMI-5-119; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; DAVIN LB, 1991, PHYTOCHEMISTRY, V31, P3869; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJII I, 1991, BIOCHEM INT, V25, P1043; FUJII I, 1987, J BIOCHEM, V101, P11, DOI 10.1093/oxfordjournals.jbchem.a121881; FUJII I, 1988, J BIOCHEM-TOKYO, V103, P878, DOI 10.1093/oxfordjournals.jbchem.a122365; GERMANN UA, 1988, J BIOL CHEM, V263, P885; GOMI K, 1987, AGR BIOL CHEM TOKYO, V51, P2549; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; GUSS JM, 1988, SCIENCE, V241, P806, DOI 10.1126/science.3406739; GUSS JM, 1983, J MOL BIOL, V169, P521; HUANG K, 1995, IN PRESS CURR GENET; KIMURA N, 1993, J BACTERIOL, V175, P4427, DOI 10.1128/JB.175.14.4427-4435.1993; KOJIMA Y, 1990, J BIOL CHEM, V265, P15224; KOMATSU E, 1958, NIPPON NOGEIKAGAKU K, V31, P564; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P3; MAYER AM, 1987, PHYTOCHEMISTRY, V26, P11; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MUSSO H, 1963, ANGEW CHEM INT EDIT, V75, P965, DOI 10.1002/ange.19630752004; NORDLOV H, 1982, ARCH MICROBIOL, V131, P208, DOI 10.1007/BF00405880; NORRIS GE, 1983, J MOL BIOL, V165, P501, DOI 10.1016/S0022-2836(83)80216-2; OHKAWA J, 1989, P NATL ACAD SCI USA, V86, P1239, DOI 10.1073/pnas.86.4.1239; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PROUDFOOT N, 1984, NATURE, V307, P412, DOI 10.1038/307412a0; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT AI, 1965, Q REV CHEM SOC, V19, P1, DOI 10.1039/qr9651900001; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADLER R, 1993, J BIOL CHEM, V268, P823; TADA S, 1991, AGR BIOL CHEM TOKYO, V55, P1939, DOI 10.1080/00021369.1991.10870884; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZENK MH, 1989, J CHEM SOC CHEM COMM, P1725, DOI 10.1039/c39890001725	48	64	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21495	21502		10.1074/jbc.270.37.21495	http://dx.doi.org/10.1074/jbc.270.37.21495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665560	hybrid			2022-12-27	WOS:A1995RU75700015
J	RAY, K; KUNSCH, C; BONNER, LM; ROBISHAW, JD				RAY, K; KUNSCH, C; BONNER, LM; ROBISHAW, JD			ISOLATION OF CDNA CLONES ENCODING 8 DIFFERENT HUMAN G-PROTEIN GAMMA-SUBUNITS, INCLUDING 3 NOVEL FORMS DESIGNATED THE GAMMA(4), GAMMA(10), AND GAMMA(11) SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; SIGNAL TRANSDUCTION; 3RD FORM; SEQUENCE; RHODOPSIN; IDENTIFICATION; TRANSLATION; DIVERSITY; RECEPTORS; COMPLEX	With the growing awareness that the G protein beta and gamma subunits directly regulate the activities of various enzymes and ion channels, the importance of identifying and characterizing these subunits is underscored. In this paper, we report the isolation of cDNA clones encoding eight different human gamma subunits, including three novel forms designated gamma(4), gamma(10), and gamma(11). The predicted protein sequence of gamma(4) shares the most identity (60-77%) with gamma(2), gamma(3), and gamma(7) and the least identity (38%) with gamma(1). The gamma(4) is modified by a geranylgeranyl group and is capable of interacting with both beta(1) and beta(2) but not with beta(3). The predicted protein sequence of gamma(10) shows only modest to low identity (35-53%) with the other known gamma subunits, with most of the differences concentrated in the N-terminal region, suggesting gamma(10) may interact with a unique subclass of alpha. The gamma(10) is modified by a geranylgeranyl group and is capable of interacting with beta(1) and beta(2) but not with beta(3). Finally, the predicted protein sequence of gamma(11) shows the most identity to gamma(1) (76% identity) and the least identity to the other known gamma (33-44%). Unlike most of the other known gamma subunits, gamma(11) is modified by a farnesyl group and is not capable of interacting with beta(2). The close resemblance of gamma(11) to gamma(1) raises intriguing questions regarding its function since the mRNA for gamma(11) is abundantly expressed in all tissues tested except for brain, whereas the mRNA for gamma(1) is expressed only in the retina where the protein functions in phototransduction.	WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	GlaxoSmithKline; Human Genome Sciences Inc								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRMBAUMER L, 1992, CELL, V71, P1069; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; RAY K, 1992, J BIOL CHEM, V267, P6086; RAY K, 1994, GENE, V149, P337, DOI 10.1016/0378-1119(94)90172-4; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	46	139	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21765	21771		10.1074/jbc.270.37.21765	http://dx.doi.org/10.1074/jbc.270.37.21765			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665596	hybrid			2022-12-27	WOS:A1995RU75700055
J	HIDALGO, E; BOLLINGER, JM; BRADLEY, TM; WALSH, CT; DEMPLE, B				HIDALGO, E; BOLLINGER, JM; BRADLEY, TM; WALSH, CT; DEMPLE, B			BINUCLEAR [2FE-2S] CLUSTERS IN THE ESCHERICHIA-COLI SOXR PROTEIN AND ROLE OF THE METAL CENTERS IN TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; NITRIC-OXIDE; NUCLEASE ACTIVITY; STRESS REGULON; SUPEROXIDE; ACTIVATION; DNA; GENES; MERR; MACROPHAGES	SoxR protein of Escherichia coli is activated by super oxide-generating agents or nitric oxide as a powerful transcription activator of the soxS gene, whose product activates similar to 10 other promoters, SoxR contains non heme iron essential for abortive initiation of transcription in vitro, Here we show that this metal dependence extends to full-length transcription in vitro, In the presence off. coli sigma(70) RNA polymerase, iron-containing SoxR mediates open complex formation at the soxS promoter, as determined using footprinting with Cu-5-phenyl-1,10-phenanthroline. We investigated the nature of the SoxR iron center by chemical analyses and electron paramagnetic resonance spectroscopy. Dithionite-reduced Fe-SoxR exhibited an almost axial paramagnetic signature with g values of 2.01 and 1.93 observable up to 100 g. These features, together with quantitation of spin, iron, and S2-, and hydrodynamic evidence that SoxR is a homodimer in solution, indicate that (SoxR)(2) contains two [2Fe-2S] clusters. Treatment of Fe-SoxR with high concentrations of dithiothreitol caused subtle changes in the visible absorption spectrum and blocked transcriptional activity without generating reduced [2Fe-2S] centers, but was also associated with the loss of iron from the protein, However, lowering the thiol concentration by dilution allowed spontaneous regeneration of active Fe-SoxR.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Bollinger, Joseph/C-1425-2016; Hidalgo, Elena/K-2919-2014	Hidalgo, Elena/0000-0002-3768-6785	NCI NIH HHS [CA37831] Funding Source: Medline; NIGMS NIH HHS [GM20011, GM15477] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; Freifelder D, 1973, Methods Enzymol, V27, P140; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GONZALEZFLECHA B, 1994, J BACTERIOL, V176, P2293; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GREEN J, 1993, FEBS LETT, V329, P55, DOI 10.1016/0014-5793(93)80192-W; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1994, ENCY INORGANIC CHEM, V4, P1896; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; RUSSELL DR, 1981, NUCLEIC ACIDS RES, V9, P2517, DOI 10.1093/nar/9.11.2517; Sambrook J, 1989, MOL CLONING LABORATO; Sies H., 1991, OXIDATIVE STRESS OXI, pxv; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992	41	147	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20908	20914		10.1074/jbc.270.36.20908	http://dx.doi.org/10.1074/jbc.270.36.20908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673113	hybrid			2022-12-27	WOS:A1995RU05400010
J	BETHIN, KE; CIMATO, TR; ETTINGER, MJ				BETHIN, KE; CIMATO, TR; ETTINGER, MJ			COPPER-BINDING TO MOUSE-LIVER S-ADENOSYLHOMOCYSTEINE HYDROLASE AND THE EFFECTS OF COPPER ON ITS LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; L-HOMOCYSTEINE HYDROLASE; MENKES DISEASE; CANDIDATE GENE; CU,ZN-SUPEROXIDE DISMUTASE; TRANSPORTING ATPASE; DEFICIENT MICE; PRIMARY DEFECT; RAT-LIVER; PROTEIN	The dissociation constant and stoichiometry of copper binding to mouse liver S-adenosylhomocysteine hydrolase (SAHH) was determined as part of characterizing the possible roles of SAHH in copper metabolism. Copper (Cu-64(II)) binding was measured by an ultrafiltration method in the presence of EDTA as a competing ligand. The K-D was 3.9 +/- 0.7 x 10(-16) M, and the stoichiometry was one g atom of copper per 48-kDa subunit. Western blots indicated that the liver contains approximate to 12 times more SAHH than the kidney, which in turn contains approximate to 5 times more SAHH than the brain. The high concentration and copper affinity of SAHH in the liver may contribute to the liver's ability to preferentially accumulate copper, and the low levels of SAHH in the brain may contribute to the sensitivity of the brain to copper deficiency. The effects of genetic defects of copper metabolism and copper deficiency on SAHH were also determined. Normal SAHH levels were detected in brindled mouse liver, kidney, and brain. However, SAHH from brindled mouse liver eluted abnormally from phenyl Superose columns implying an effect of the brindled mouse defect on SAHH protein structure. Hepatic cytosols from the toxic milk mouse contained approximate to 42% the amount of SAHH detected in controls, and hepatic levels of SAHH were also decreased by approximate to 45% in copper-deficient mice. The binding properties of SAHH and the effects of abnormal states of copper metabolism on its levels are consistent with significant roles for SAHH in normal and abnormal copper metabolism. SAHH may have roles in regulating tissue copper levels and the distribution of intracellular copper.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Bethin, Kathleen/L-8904-2019	Bethin, Kathleen/0000-0002-6100-4983; Cimato, Thomas/0000-0001-9230-4463				ARREDONDOVEGA FX, 1989, ANN HUM GENET, V53, P157, DOI 10.1111/j.1469-1809.1989.tb01780.x; BEARN AG, 1954, P SOC EXP BIOL MED, V85, P44; BETHIN KE, 1995, J BIOL CHEM, V270, P20698, DOI 10.1074/jbc.270.35.20698; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DARWISH HM, 1983, J BIOL CHEM, V258, P3621; DAS S, 1995, AM J HUM GENET, V56, P570; Dawson R.M.C., 1986, DATA BIOCH RES, P399; ETTINGER MJ, 1984, LIFE CHEM REPORTS, V5, P169; FINKELSTEIN JD, 1974, METABOLISM, V23, P387, DOI 10.1016/0026-0495(74)90057-2; FINKELSTEIN JD, 1973, ARCH BIOCHEM BIOPHYS, V159, P160, DOI 10.1016/0003-9861(73)90440-2; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; HASOBE M, 1989, MOL PHARMACOL, V36, P490; HERSHFIELD MS, 1982, SCIENCE, V216, P739, DOI 10.1126/science.7079734; HUNT DM, 1974, NATURE, V249, P852, DOI 10.1038/249852a0; KOEPKE JA, 1984, LABORATORY HEMATOLOG, V2, P868; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU SJ, 1971, J BIOL CHEM, V246, P5938; LEVINSON B, 1994, NAT GENET, V6, P369, DOI 10.1038/ng0494-369; MANN JR, 1979, BIOCHEM J, V180, P605, DOI 10.1042/bj1800605; MARCEAU N, 1970, AM J PHYSIOL, V218, P377, DOI 10.1152/ajplegacy.1970.218.2.377; MATSUDA I, 1974, PEDIATR RES, V8, P821, DOI 10.1203/00006450-197410000-00001; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1994, NAT GENET, V6, P374, DOI 10.1038/ng0494-374; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MICHAEL CK, 1979, COMPUT BIOMED RES, V12, P461; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; OWEN CA, 1965, AM J PHYSIOL, V209, P900, DOI 10.1152/ajplegacy.1965.209.5.900; OWEN CA, 1981, COPPER DEFICIENCY TO; PALIDA FA, 1991, J BIOL CHEM, V266, P4586; PETROVIC N, 1993, THESIS STATE U NEW Y; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PILZ A, 1992, MAMM GENOME, V3, P633, DOI 10.1007/BF00352480; PROHASKA JR, 1991, J NUTR, V121, P355, DOI 10.1093/jn/121.3.355; RAUCH H, 1984, HEPATOLOGY, V4, P1072; RAUCH H, 1983, J HERED, V74, P141, DOI 10.1093/oxfordjournals.jhered.a109751; Sass-Kortsak A, 1965, Adv Clin Chem, V8, P1; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; SEO HC, 1993, J BIOL CHEM, V268, P1151; SEO HC, 1993, J BIOL CHEM, V268, P1160; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SQUIBB KS, 1977, BIOCHEM J, V164, P223, DOI 10.1042/bj1640223; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WALDROP GL, 1990, BIOCHEM J, V267, P417, DOI 10.1042/bj2670417; WALDROP GL, 1990, AM J PHYSIOL, V259, pG219, DOI 10.1152/ajpgi.1990.259.2.G219; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	54	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20703	20711		10.1074/jbc.270.35.20703	http://dx.doi.org/10.1074/jbc.270.35.20703			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657651	hybrid			2022-12-27	WOS:A1995RR58400071
J	TRIANAALONSO, FJ; CHAKRABURTTY, K; NIERHAUS, KH				TRIANAALONSO, FJ; CHAKRABURTTY, K; NIERHAUS, KH			THE ELONGATION-FACTOR-3 UNIQUE IN HIGHER FUNGI AND ESSENTIAL FOR PROTEIN-BIOSYNTHESIS IS AN E-SITE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-BINDING; ALLOSTERIC 3-SITE MODEL; ESCHERICHIA-COLI RIBOSOMES; FACTOR-III EF-3; SACCHAROMYCES-CEREVISIAE; FACTOR REQUIREMENTS; SEQUENCE-ANALYSIS; MESSENGER-RNA; YEAST; CYCLE	Two elongation factors drive the ribosomal elongation cycle; elongation factor 1 alpha (EP-1 alpha) mediates the binding of an aminoacyl-tRNA to the ribosomal A site, whereas elongation factor 2 (EF-2) catalyzes the translocation reaction. Ribosomes from yeast and other higher fungi require a third elongation factor (EF-3) which is essential for the elongation process, but the step affected by EF-3 has not yet been identified. Here we demonstrate that the first and the third tRNA binding site (A and E sites, respectively) of yeast ribosomes are reciprocally linked; if the A site is occupied the E site has lost its binding capability, and vice versa, if the E site is occupied the A site has a low affinity for tRNAs. EF-3 is essential for EF-1 alpha-dependent A site binding of amino acyl-tRNA only when the E site is occupied with a deacylated tRNA. The ATP-dependent activity of EF-3 is required for the release of deacylated tRNA from the E site during A site occupation.	AG RIBOSOMEN, MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY; MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Max Planck Society; Medical College of Wisconsin					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029795] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER D, 1994, J BIOL CHEM, V269, P30713; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; CHAKRABURTTY K, 1988, INT J BIOCHEM, V20, P581, DOI 10.1016/0020-711X(88)90096-1; Chakraburtty K., 1992, New approaches for antifungal drugs., P114; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P5; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P9999; DIDOMENICO BJ, 1992, YEAST, V8, P337, DOI 10.1002/yea.320080502; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GRUMMT F, 1974, EUR J BIOCHEM, V43, P343, DOI 10.1111/j.1432-1033.1974.tb03418.x; HAPKE B, 1976, J MOL BIOL, V105, P97, DOI 10.1016/0022-2836(76)90196-0; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; HUTCHISON JS, 1984, BIOCHEMISTRY-US, V23, P3055, DOI 10.1021/bi00308a032; KAMATH A, 1986, J BIOL CHEM, V261, P2596; KAMATH A, 1989, J BIOL CHEM, V264, P15423; LEGON S, 1976, J MOL BIOL, V106, P37, DOI 10.1016/0022-2836(76)90299-0; MARTIN TE, 1971, METHOD ENZYMOL, V20, P417; MIYAZAKI M, 1988, J BIOCHEM-TOKYO, V104, P445, DOI 10.1093/oxfordjournals.jbchem.a122487; MIYAZAKI M, 1990, J BIOCHEM-TOKYO, V108, P1001, DOI 10.1093/oxfordjournals.jbchem.a123298; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; QIN SL, 1990, J BIOL CHEM, V265, P1903; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; RODNINA MV, 1992, J MOL BIOL, V228, P450, DOI 10.1016/0022-2836(92)90834-7; SANDBAKEN MG, 1990, J BIOL CHEM, V265, P15838; SARUYAMA H, 1986, MOL GEN GENET, V204, P221, DOI 10.1007/BF00425502; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SKOGERSON L, 1977, J BIOL CHEM, V252, P1471; SKOGERSON L, 1976, P NATL ACAD SCI USA, V73, P73, DOI 10.1073/pnas.73.1.73; TRIANA F, 1994, BIOCHEM MOL BIOL INT, V33, P909; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	36	129	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20473	20478		10.1074/jbc.270.35.20473	http://dx.doi.org/10.1074/jbc.270.35.20473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657623	hybrid			2022-12-27	WOS:A1995RR58400038
J	COSOWSKY, L; RAO, SNV; MACDONALD, GJ; PAPKOFF, H; CAMPBELL, RK; MOYLE, WR				COSOWSKY, L; RAO, SNV; MACDONALD, GJ; PAPKOFF, H; CAMPBELL, RK; MOYLE, WR			THE GROOVE BETWEEN THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF HORMONES WITH LUTROPIN (LH) ACTIVITY APPEARS TO CONTACT THE LH RECEPTOR, AND ITS CONFORMATION IS CHANGED DURING HORMONE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN CHORIOGONADOTROPIN-BETA; FOLLICLE-STIMULATING-HORMONE; LUTEINIZING-HORMONE; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; PITUITARY GONADOTROPINS; GLYCOPROTEIN HORMONES; SYNTHETIC PEPTIDES; CDNA	Gonadotropins are heterodimeric glycoprotein hormones that control vertebrate fertility through their actions on gonadal lutropin (luteinizing hormone, LH) and follitropin (follicle-stimulating hormone, FSH) receptors, The beta-subunits of these hormones control receptor binding specificity; however, the region of the beta-subunit that contacts the receptor has not been identified, By a process of elimination we show this contact to be the portions of beta-subunit loops one and three found in a hormone groove created by the juxtaposition of the alpha- and beta-subunits. Most other regions of the beta-subunit can be recognized by antibodies that bind to human chorionic hormone (hCG)-receptor complexes or replaced without disrupting hormone function, Using a series of bovine LH/hCG and human FSH/hCG beta-subunit chimeras we identified key hCG beta-subunit residues in the epitopes of two antibodies that bind to hCG-receptor complexes, These epitopes include the surfaces of beta-subunit loops one and three near residue 74 on the outside of the hormone groove and parts of the C-terminal end of the ''seat belt'' that holds the two subunits together, The antibody that recognized residue 74 bound to receptor complexes containing most mammalian lutropins better than to the free hormones, an indication that the outside surface of the beta-subunit groove is altered during hormone binding, This region of the beta-subunit is furthest from the alpha-subunit and is recognized equally well in the free beta-subunit and in the heterodimer, Thus, the receptor associated increase in antibody binding appears due to an interaction of this portion of the beta-subunit with the receptor and not to an effect of the receptor on the relative positions of the alpha- and beta-subunits, Unlike most previous studies designed to identify portions of the beta-subunit likely to contact the LH receptor, this indirect approach provides data that are more easily interpreted because it does not rely on the use of mutations that disrupt hormone function, The approach described here should be valuable for studying the receptor interactions of other complex ligands.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT OBSTET GYNECOL, PISCATAWAY, NJ 08854 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, PISCATAWAY, NJ 08854 USA; UNIV CALIF DAVIS, DEPT ANIM SCI, DAVIS, CA 95616 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Davis			Campbell, Robert/G-4112-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R01HD024650, R01HD005722, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD05722, HD14907, HD24650] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BIDART JM, 1989, ENDOCRINOLOGY, V124, P923, DOI 10.1210/endo-124-2-923; BOUSFIELD GR, 1988, J BIOL CHEM, V263, P12602; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHARLESWORTH MC, 1991, ENDOCRINOLOGY, V128, P2907, DOI 10.1210/endo-128-6-2907; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLOMA TAS, 1990, BIOCHEMISTRY-US, V29, P1194, DOI 10.1021/bi00457a015; CRAWFORD RJ, 1986, GENE, V46, P161, DOI 10.1016/0378-1119(86)90400-2; CRUZ RI, 1987, J CLIN ENDOCR METAB, V64, P433, DOI 10.1210/jcem-64-3-433; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANGELOBERNARD G, 1990, NUCLEIC ACIDS RES, V18, P2175, DOI 10.1093/nar/18.8.2175; Gordon WL, 1985, LUTEINIZING HORMONE, P173; HAGEVANNOORT M, 1992, P NATL ACAD SCI USA, V89, P3922, DOI 10.1073/pnas.89.9.3922; HAGEVANNOORT M, 1993, P NATL ACAD SCI USA, V90, P12056; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KATO Y, 1989, MOL CELL ENDOCRINOL, V62, P47, DOI 10.1016/0303-7207(89)90112-3; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LICHT P, 1979, J ENDOCRINOL, V83, P311, DOI 10.1677/joe.0.0830311; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Maniatis T, 1989, MOL CLONING; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V174, P940, DOI 10.1016/0006-291X(91)91509-B; MATTERI RL, 1987, DOMEST ANIM ENDOCRIN, V4, P157, DOI 10.1016/0739-7240(87)90011-7; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MAURER RA, 1985, J BIOL CHEM, V260, P4684; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MOYLE WR, 1988, J RECEPTOR RES, V8, P419, DOI 10.3109/10799898809049002; MOYLE WR, 1988, ICSU SHORT REP, V8, P116; NOCE T, 1989, J MOL ENDOCRINOL, V3, P129, DOI 10.1677/jme.0.0030129; PAPKOFF H, 1982, GEN COMP ENDOCR, V48, P181, DOI 10.1016/0016-6480(82)90016-8; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROSER JF, 1984, BIOL REPROD, V30, P1253, DOI 10.1095/biolreprod30.5.1253; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SANTACOLOMA TA, 1991, MOL CELL ENDOCRINOL, V78, P197, DOI 10.1016/0303-7207(91)90123-A; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SMITH PL, 1993, J BIOL CHEM, V268, P795; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; WOLF DL, 1987, NUCLEIC ACIDS RES, V15, P10602, DOI 10.1093/nar/15.24.10602; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337	54	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20011	20019		10.1074/jbc.270.34.20011	http://dx.doi.org/10.1074/jbc.270.34.20011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650019	hybrid			2022-12-27	WOS:A1995RQ99100052
J	COX, KH; ADAIRKIRK, TL; COX, JV				COX, KH; ADAIRKIRK, TL; COX, JV			4 VARIANT CHICKEN ERYTHROID AE1 ANION-EXCHANGERS - ROLE OF THE ALTERNATIVE N-TERMINAL SEQUENCES IN INTRACELLULAR TARGETING IN TRANSFECTED HUMAN ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING SITE; TRANSCRIPTIONAL INITIATION; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; MESSENGER-RNAS; BAND-3; PROTEIN; GENE; ORGANIZATION; LOCALIZATION	Four variant AE1 anion exchangers with predicted molecular masses of similar to 99, similar to 102, similar to 104, and similar to 108 kDa are expressed in chicken erythroid cells. These variant polypeptides differ in sequence only at the N terminus of their cytoplasmic domains, Molecular analyses have shown that transcripts derived from both of the erythroid-specific promoters, P1 and P2, encode all four of these AE1 anion exchanger variants. However, quantitative RNase protection analyses have shown that the transcripts derived from the P1 promoter are much more prevalent than those derived from the P2 promoter, Reverse transcriptase polymerase chain reaction studies have indicated that the extensive diversity in the transcripts derived from the AE1 gene occurs both in primitive and definitive lineage erythroid cells, Transient transfection analyses using human erythroleukemia cells have investigated the functional significance of the alternative sequences at the N terminus of these variant exchangers, These studies have shown that the erythroid AE1 variants are sorted to different membrane compartments in these cells, The similar to 99- and similar to 102-kDa variants are primarily sorted to the plasma membrane, whereas the similar to 108-kDa variant is retained in a perinuclear compartment. These results suggest that the alternative N-terminal cytoplasmic sequences of these polypeptides may serve as signals to direct these variant transporters to different membrane compartments within cells.	UNIV TENNESSEE,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BECK KA, 1993, J CELL BIOL, V5, pA240; BENNETT V, 1980, NATURE, V280, P468; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; COX KH, 1995, AM J PHYSIOL-RENAL, V268, pF503, DOI 10.1152/ajprenal.1995.268.3.F503; DAVIS L, 1989, J BIOL CHEM, V264, P9665; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KELLOKUMPU S, 1988, SCIENCE, V264, P1308; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KIM HRC, 1989, MOL CELL BIOL, V9, P5198, DOI 10.1128/MCB.9.11.5198; Knauf P.A, 1979, CURR TOP MEMBR TRANS, V12, P249, DOI 10.1016/S0070-2161(08)60259-2; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LINN SC, 1992, J BIOL CHEM, V267, P7927; MORGANS CW, 1993, J CELL SCI, V105, P1137; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J, 1989, MOL CLONING LABORATO; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WONG SH, 1993, J BIOL CHEM, V268, P22853	31	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19752	19760		10.1074/jbc.270.34.19752	http://dx.doi.org/10.1074/jbc.270.34.19752			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649985	hybrid			2022-12-27	WOS:A1995RQ99100015
J	JUUL, B; TURC, H; DURAND, ML; DEGRACIA, AG; DENOROY, L; MOLLER, JV; CHAMPEIL, P; LEMAIRE, M				JUUL, B; TURC, H; DURAND, ML; DEGRACIA, AG; DENOROY, L; MOLLER, JV; CHAMPEIL, P; LEMAIRE, M			DO TRANSMEMBRANE SEGMENTS IN PROTEOLYZED SARCOPLASMIC-RETICULUM CA2+-ATPASE RETAIN THEIR FUNCTIONAL CA2+ BINDING-PROPERTIES AFTER REMOVAL OF CYTOPLASMIC FRAGMENTS BY PROTEINASE-K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; EXTENSIVE TRYPTIC DIGESTION; CHARGED AMINO-ACIDS; TRANSPORT SITES; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MEMBRANE-PROTEINS; CATION OCCLUSION; CALCIUM-BINDING; CONFORMATIONAL-CHANGES	The present study was undertaken to investigate the Ca2+ binding properties of sarcoplasmic reticulum Ca2+-ATPase after removal of the cytoplasmic regions by treatment with proteinase K. One of the proteolysis cleavage sites (at the end of M6) was found unexpectedly close to the predicted membrane-water interphase, but otherwise the cleavage pattern was consistent with the presence of 10 transmembrane ATPase segments, C-terminal membranous peptides containing the putative transmembrane segments M7 to M10 accumulated after prolonged proteolysis, as well as large water-soluble fragments containing most of the phosphorylation and ATP-binding domain. Ca2+ binding was intact after cleavage of the polypeptide chain in the N-terminal region, but cuts at other locations disrupted the high affinity binding and sequential dissociation properties characteristic of native sarcoplasmic reticulum, leaving the translocation sites with only weak affinity for Ca2+ High affinity Ca2+ binding could only be maintained when proteolysis and subsequent manipulations took place in the presence of a Ca2+ concentration high enough to ensure permanent occupation of the binding sites with Ca2+. We conclude that in the absence of Ca2+ the complex of membrane-spanning segments in proteolyzed Ca2+-ATPase is labile, probably because of relatively free movement or rearrangement of individual segments. Our study, which is discussed in relation to results obtained on Na+,K+-ATPase and H+,K+-ATPase, emphasizes the importance of the cytosolic segments of the main polypeptide chain in exerting constraints on the intramembranous domain of a P-type ATPase.	CTR ETUD SACLAY, CEA,DEPT BIOL CELLULAIRE & MOLEC, BIOPHYS PROT & MEMBRANES SECT,CNRS, URA 1290, F-91191 GIF SUR YVETTE, FRANCE; AARHUS UNIV, DEPT BIOPHYS, DK-8000 AARHUS C, DENMARK; CNRS, SERV CENT ANALYSE, F-69390 VERNAISON, FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS); Aarhus University; Centre National de la Recherche Scientifique (CNRS)								ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEFORESTA B, 1994, EUR J BIOCHEM, V223, P359; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1108, P247, DOI 10.1016/0005-2736(92)90032-H; FAMBROUGH DM, 1994, CURR TOP MEMBR, V41, P45, DOI 10.1016/S0070-2161(08)60453-0; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORGE V, 1993, J BIOL CHEM, V268, P10953; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeGendre N., 1989, PRACTICAL GUIDE PROT, P52; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LONDON E, 1978, ANAL BIOCHEM, V88, P203, DOI 10.1016/0003-2697(78)90412-8; LOO TW, 1994, J BIOL CHEM, V269, P7750; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MATA AM, 1992, BIOCHEM J, V286, P567, DOI 10.1042/bj2860567; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MERINO JM, 1994, FEBS LETT, V343, P155, DOI 10.1016/0014-5793(94)80309-9; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; MOLLER JV, 1993, SODIUM PUMP, P131; NING G, 1993, FEBS LETT, V330, P19, DOI 10.1016/0014-5793(93)80910-M; OR E, 1993, J BIOL CHEM, V268, P16929; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RABON EC, 1993, J BIOL CHEM, V268, P8012; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHMALZING G, 1994, CELL PHYSIOL BIOCHEM, V4, P96, DOI 10.1159/000154715; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAGUCHI M, 1988, METHOD ENZYMOL, V157, P233; YAMANAKA N, 1976, BIOCHIM BIOPHYS ACTA, V426, P132, DOI 10.1016/0005-2736(76)90435-1	78	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20123	20134		10.1074/jbc.270.34.20123	http://dx.doi.org/10.1074/jbc.270.34.20123			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650031	hybrid			2022-12-27	WOS:A1995RQ99100067
J	YANO, M; ELHAYEK, R; IKEMOTO, N				YANO, M; ELHAYEK, R; IKEMOTO, N			ROLE OF CALCIUM FEEDBACK IN EXCITATION-CONTRACTION COUPLING IN ISOLATED TRIADS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG SKELETAL-MUSCLE; CUT TWITCH FIBERS; SARCOPLASMIC-RETICULUM; CHARGE MOVEMENT; HUMP COMPONENT; CA-2+ RELEASE; FOOT PROTEIN; FURA-2; DEPOLARIZATION; INACTIVATION	There is a considerable controversy in the literature concerning the effects of higher concentrations of calcium chelators (e.g. BAPTA (1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid) or fura-2) on the intracellular Ca2+ transients in muscle, We induced calcium release from sarcoplasmic reticulum (SR) in the triad preparation by chemical depolarization of the T-tubule in the presence of various concentrations of BAPTA-calcium buffer ([Ca2+] = 0.1 mu M) and investigated the effects of the BAPTA concentration on the time courses of conformational changes in the junctional foot protein (JFP) and calcium release hem SR Upon stimulation, the JFP underwent biphasic conformational changes, as determined by stopped-now fluorometry of the JFP-bound conformational probe, The first phase of protein conformational change, which preceded calcium release from SR, was virtually unaffected by the BAPTA concentration However, the magnitude of the second phase increased in an inversely proportional fashion to the BAPTA concentration, An abrupt increase in [Ca2+] from 0.1 mu M up to 1.0 mu M (Delta Ca2+), concurrently with T-tubule depolarization, produced biphasic protein conformational changes: a Delta Ca2+-independent first phase and a Delta Ca2+ dependent second phase, Similar Ca2+ jump experiments under non-depolarizing conditions produced a slow monophasic conformational change equivalent to the second phase described above, These results suggest that the first phase of protein conformational change represents the activation of JFP by T-tubule depolarization to induce calcium release, and the second phase the secondary activation by the released Ca2+, Activation of the JFP by the released Ca2+ resulted in an acceleration of both (i) the rate of initial calcium release, and (ii) the subsequent attenuation of calcium release, The acceleration of both was suppressed by higher concentrations of BAPTA These results provide a reasonable explanation for both of the apparently contradictory views in the Literature; high concentrations of calcium buffer (a) suppress the initial activation and (b) prevent the subsequent attenuation of calcium release.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR 16822] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; CSERNOCH L, 1992, ADV EXP MED BIOL, V311, P137; CSERNOCH L, 1991, J GEN PHYSIOL, V97, P845, DOI 10.1085/jgp.97.5.845; CSERNOCH L, 1993, J GEN PHYSIOL, V101, P297, DOI 10.1085/jgp.101.2.297; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; GARCIA J, 1991, J GEN PHYSIOL, V97, P885, DOI 10.1085/jgp.97.5.885; HOLLINGWORTH S, 1992, BIOPHYS J, V63, P224, DOI 10.1016/S0006-3495(92)81599-0; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; JACQUEMOND V, 1991, BIOPHYS J, V60, P867, DOI 10.1016/S0006-3495(91)82120-8; JONG DS, 1993, J GEN PHYSIOL, V102, P333, DOI 10.1085/jgp.102.2.333; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; OHKUSA T, 1991, J BIOCHEM-TOKYO, V109, P609, DOI 10.1093/oxfordjournals.jbchem.a123428; PALADE P, 1987, J BIOL CHEM, V262, P6149; PAPE PC, 1993, J GEN PHYSIOL, V102, P295, DOI 10.1085/jgp.102.2.295; PIZARRO G, 1991, J GEN PHYSIOL, V97, P913, DOI 10.1085/jgp.97.5.913; PIZARRO G, 1992, J PHYSIOL-LONDON, V457, P525, DOI 10.1113/jphysiol.1992.sp019392; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1993, J GEN PHYSIOL, V102, P449, DOI 10.1085/jgp.102.3.449; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SCHNEIDER MF, 1987, J PHYSIOL-LONDON, V392, P167, DOI 10.1113/jphysiol.1987.sp016775; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SHIROKOVA N, 1994, J GEN PHYSIOL, V104, P449, DOI 10.1085/jgp.104.3.449; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; SIMON BJ, 1992, BIOPHYS J, V61, P1109, DOI 10.1016/S0006-3495(92)81920-3; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SZUCS G, 1991, J GEN PHYSIOL, V97, P897, DOI 10.1085/jgp.97.5.897; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017; YANO M, 1994, FEBS LETT, V351, P349, DOI 10.1016/0014-5793(94)00869-8	42	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19936	19942		10.1074/jbc.270.34.19936	http://dx.doi.org/10.1074/jbc.270.34.19936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650009	hybrid			2022-12-27	WOS:A1995RQ99100041
J	BOAM, DSW; DAVIDSON, I; CHAMBON, P				BOAM, DSW; DAVIDSON, I; CHAMBON, P			A TATA-LESS PROMOTER CONTAINING BINDING-SITES FOR UBIQUITOUS TRANSCRIPTION FACTORS MEDIATES CELL-TYPE-SPECIFIC REGULATION OF THE GENE FOR TRANSCRIPTION ENHANCER FACTOR-I (TEF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I TEF-1; SV40 ENHANCER; AUTO-REGULATION; RECEPTOR GENE; DNA; EXPRESSION; SEQUENCE; INITIATOR; PROTEINS; ELEMENTS	TEF-1 is a tissue-specific human transcription factor which binds to and activates transcription from the SV40 early promoter and the HPV-16 E6/E7 promoter and may be involved in regulation of muscle-specific and placenta-specific gene expression, To investigate the mechanism of its tissue-specific expression, we have isolated up to 3 kilobase pairs of 8'-flanking DNA and characterized the promoter of the gene for TEF-1, Multiple transcription start sites centering on a motif similar to the initiator element (Inr) were identified. A minimal promoter, which contains no recognizable TATA element but contains an Inr, delimited at -137 base pairs had full transcriptional activity both in vivo in HeLa cells and in vitro in HeLa cell extracts, This promoter is also highly active in vitro in lymphoid cell extracts, but not in vivo in lymphoid cell lines, which do not express the endogenous TEF-1 gene. The minimal promoter, which is sufficient to direct tissue-specific expression of the TEF-1 gene in vivo, contains multiple sites which bind the ubiquitous transcription factors Sp1 and ATF-1. Mutation of the Inr completely abolished transcription from the major start site while transcription from the minor sites was slightly augmented. Inactivation of the proximal Sp1 site abolished transcription from the principle start site and increased transcription from a 5' minor start site. Insertion of a TATA box element did not qualitatively alter the pattern of start site usage which seemed to be dependent upon integrity of the upstream Sp1 site. These observations suggest a ''cross-talk'' between the Inr and a proximal element to fix transcription start sites, which is independent of spacing and the presence of a TATA element.	INST GENET & BIOL MOLEC & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Davidson, Irwin/0000-0001-5533-1171				BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BONNEROT C, 1991, NUCLEIC ACIDS RES, V19, P7251, DOI 10.1093/nar/19.25.7251; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUNKEL TA, 1985, METHOD ENZYMOL, V154, P387; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM A, 1978, METHOD ENZYMOL, V65, P499; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	46	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19487	19494		10.1074/jbc.270.33.19487	http://dx.doi.org/10.1074/jbc.270.33.19487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642633	hybrid			2022-12-27	WOS:A1995RP70300047
J	WAWRZYNOW, A; BANECKI, B; WALL, D; LIBEREK, K; GEORGOPOULOS, C; ZYLICZ, M				WAWRZYNOW, A; BANECKI, B; WALL, D; LIBEREK, K; GEORGOPOULOS, C; ZYLICZ, M			ATP HYDROLYSIS IS REQUIRED FOR THE DNAJ-DEPENDENT ACTIVATION OF DNAK CHAPERONE FOR BINDING TO BOTH NATIVE AND DENATURED PROTEIN SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; LAMBDA-P-PROTEIN; REPLICATION PROTEIN; GRPE; PURIFICATION; HOMOLOG; COMPLEX	Using two independent experimental approaches to monitor protein-protein interactions (enzyme-linked immunosorbent assay and size exclusion high performance liquid chromatography) we describe a general mechanism by which DnaJ modulates the binding of the DnaK chaperone to various native protein substrates, e.g. lambda P, lambda O, sigma(32), P1, RepA, as well as permanently denatured alpha-carboxymethylated lactalbumin, The presence of DnaJ promotes the DnaK for efficient DnaK-substrate complex formation, ATP hydrolysis is absolutely required for such DnaJ-dependent activation of DnaK for binding to both native and denatured protein substrates. Although ADP can stabilize such an activated DnaK-protein complex, it cannot substitute for ATP in the activation reaction, Ln the presence of DnaJ and ATP, DnaK possesses the affinity to different substrates which correlates well with the affinity of DnaJ alone for these protein substrates, Only when the affinity of the DnaJ chaperone for its protein substrate is relatively high (e.g. sigma(32), RepA) can a tertiary complex DnaK-substrate-DnaJ be detected. In the case that DnaJ binds weakly to its substrate (lambda P, alpha-carboxymethylated lactalbumin), DnaJ is only transiently associated with the DnaK-substrate complex, but the DnaK activation reaction still occurs, albeit less efficiently,	UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Utah System of Higher Education; University of Utah; University of Geneva	WAWRZYNOW, A (corresponding author), UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,24 KLADKI,PL-80822 GDANSK,POLAND.		Liberek, Krzysztof/F-5812-2011	Zylicz, Alicja/0000-0003-4174-3073; Liberek, Krzysztof/0000-0002-7532-9279; Wall, Daniel/0000-0002-0273-1371				BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PANAGIOTIDIS CA, 1994, J BIOL CHEM, V269, P16643; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, NATURE, V350, P165; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	30	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19307	19311		10.1074/jbc.270.33.19307	http://dx.doi.org/10.1074/jbc.270.33.19307			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642606	hybrid			2022-12-27	WOS:A1995RP70300020
J	FUKUCHI, JI; KASHIWAGI, K; YAMAGISHI, M; ISHIHAMA, A; IGARASHI, K				FUKUCHI, JI; KASHIWAGI, K; YAMAGISHI, M; ISHIHAMA, A; IGARASHI, K			DECREASE IN CELL VIABILITY DUE TO THE ACCUMULATION OF SPERMIDINE IN SPERMIDINE ACETYLTRANSFERASE-DEFICIENT MUTANT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE-REQUIRING MUTANTS; RIBOSOME MODULATION FACTOR; ORNITHINE DECARBOXYLASE; PROTEIN-SYNTHESIS; MESSENGER-RNA; GROWTH; STIMULATION; INHIBITION; ABSENCE; GENE	Physiological functions of spermidine acetyltransferase in Escherichia coli have been studied using the spermidine acetyltransferase (speG) gene deficient mutant CAG2242 and the cloned speG gene, The growth of E. coli CAG2242 in the defined M9 medium was normal in the presence and absence of 0.5 mM spermidine. How ever, cell viability of E. coli CAG2242 at 48 h after the onset of growth decreased greatly by the addition of 0.5 mM spermidine. The amount of spermidine accumulated in the cells was approximately 3-fold that in the cells grown in the absence of spermidine. Transformation of the cloned speG gene to E. coli CAG2242 recovered the cell viability, Decrease in cell viability of E. coli CAG2242 was observed even when 0.5 mM spermidine was added at 24 h after the onset of growth. The results indicate that accumulated spermidine functions at the late stationary phase of growth. The accumulation of spermidine caused a decrease in protein synthesis but not in DNA and RNA synthesis at 28 h after the onset of growth, The synthesis of several kinds of proteins was particularly inhibited, They included ribosome modulation factor and OmpC protein, Since the ribosome modulation factor is essential for cell viability at the stationary phase of growth (Yamagishi, M., Matsushima, H., Wada, A., Sakagami, Ri,, Fujita, N., and Ishihama, A. (1993) EMBO J. 12, 625-630), the decrease in the protein was thought to be one of the reasons for the decrease in cell viability, The decrease in the ribosome modulation factor mainly occurred at the translational level.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN	Chiba University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan				Igarashi, Kazuei/0000-0003-3751-3187				CARPER SW, 1991, J BIOL CHEM, V266, P12439; CASERO RA, 1993, FASEB J, V656, P653; DUBIN DT, 1960, J BIOL CHEM, V235, P776; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HE Y, 1994, EUR J BIOCHEM, V221, P391, DOI 10.1111/j.1432-1033.1994.tb18751.x; HE Y, 1993, EUR J BIOCHEM, V217, P89, DOI 10.1111/j.1432-1033.1993.tb18222.x; HERSHEY JWB, 1977, ARCH BIOCHEM BIOPHYS, V182, P626, DOI 10.1016/0003-9861(77)90543-4; IGARASHI K, 1981, EUR J BIOCHEM, V114, P127; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO K, 1990, J BIOL CHEM, V265, P13036; KASHIWAGI K, 1987, BIOCHIM BIOPHYS ACTA, V911, P180, DOI 10.1016/0167-4838(87)90007-0; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P440; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NEILSEN PJ, 1982, J BIOL CHEM, V257, P12316; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEGG AE, 1988, CANCER RES, V48, P759; PERSSON L, 1984, J BIOL CHEM, V259, P2364; POULIN R, 1993, J BIOL CHEM, V268, P4690; SATO T, 1981, J BACTERIOL, V145, P88, DOI 10.1128/JB.145.1.88-96.1981; TABOR CW, 1970, J BIOL CHEM, V245, P2086; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; WADA A, 1987, J BIOCHEM, V101, P817, DOI 10.1093/jb/101.3.817; WADA A, 1990, P NATL ACAD SCI USA, V87, P2657, DOI 10.1073/pnas.87.7.2657; WATANABE S, 1991, J BIOL CHEM, V266, P20803; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718	35	62	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18831	18835		10.1074/jbc.270.32.18831	http://dx.doi.org/10.1074/jbc.270.32.18831			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642535				2022-12-27	WOS:A1995RN95400022
J	WEINER, KXB; CIESLA, J; JAFFE, AB; KETRING, R; MALEY, F; MALEY, GF				WEINER, KXB; CIESLA, J; JAFFE, AB; KETRING, R; MALEY, F; MALEY, GF			CHROMOSOMAL LOCATION AND STRUCTURAL ORGANIZATION OF THE HUMAN DEOXYCYTIDYLATE DEAMINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DCMP DEAMINASE; TRIPHOSPHATE POOL; HAMSTER-CELLS; DNA; THYMIDYLATE; IMBALANCES	Deoxycytidylate deaminase is an allosteric enzyme whose impairment can lead to deoxynucleotide imbalances that affect the fidelity of DNA synthesis, A DNA fragment encompassing the gene for deoxycytidylate deaminase has been isolated from a human lung fibroblast genomic library and sequenced in both directions through 26,764 base pairs, The previously isolated cDNA, which was used to establish the amino acid sequence for this enzyme (Weiner, K. X. B., Weiner, R. S., Maley, F., and Maley, G. F. (1993) J. Biol. Chem. 268, 12983-12989) was instrumental in isolating this gene. The gene consists of five exons of about 100 base pairs each, separated by four introns, The most striking feature of the genomic structure is that the second and third exons are separated by an intron of about 20 kilobases, The chromosomal location of the deaminase gene was determined by fluorescence in situ hybridization as 4q35, which is the extreme end of this chromosome, The position of this gene on chromosome 4, in addition to the role of its product in limiting potentially detrimental mutations, suggests that the normal operation of both the gene and its product is important to the well being of the organism.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center			Cieśla, Joanna/F-8445-2011; Cieśla, Joanna/D-7918-2015	Cieśla, Joanna/0000-0002-0115-5595	NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; MALEY F, 1960, J BIOL CHEM, V235, P2968; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; MALEY F, 1972, CURR TOP CELL REGUL, V5, P177; MALEY GF, 1959, J BIOL CHEM, V234, P2975; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEINER KXB, 1990, MOL ENDOCRINOL, V4, P1249, DOI 10.1210/mend-4-8-1249; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	20	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18727	18729		10.1074/jbc.270.32.18727	http://dx.doi.org/10.1074/jbc.270.32.18727			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642519	hybrid			2022-12-27	WOS:A1995RN95400005
J	CASCIO, M; KUMAR, NM; SAFARIK, R; GILULA, NB				CASCIO, M; KUMAR, NM; SAFARIK, R; GILULA, NB			PHYSICAL CHARACTERIZATION OF GAP JUNCTION MEMBRANE CONNEXONS (HEMI-CHANNELS) ISOLATED FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; CIRCULAR-DICHROISM; SECONDARY STRUCTURE; MOLECULAR-WEIGHT; PROTEIN; DIFFRACTION; DETERGENT; SIZE; CELLS; CHROMATOGRAPHY	Enriched subcellular fractions of double membrane gap junctions (plaques) from rat livers were treated under reducing conditions with high salt and non-ionic detergent concentrations at high pH to obtain a preparation of structural 80-90 Angstrom complexes of oligomers (connexons). The isolated oligomers were chromatographically purified, and subsequently characterized immunologically, morphologically by electron microscopy, hydrodynamically by gel filtration and ultracentrifugation, spectroscopically by circular dichroism, and chemically via cross-linking studies. The physical characteristics of these isolated gap junction complexes were compared to those of native membrane-bound gap junctions in rat liver. These analyses indicate that the isolated complex (connexon) principally contains a hexameric arrangement of gap junction protein to form a single membrane hemi channel.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037904, R01GM041449, R37GM037904] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06884] Funding Source: Medline; NIGMS NIH HHS [GM 37904, GM 41449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CASCIO M, 1990, J BIOL CHEM, V265, P2358; CASCIO M, 1988, PROTEINS, V4, P89, DOI 10.1002/prot.340040203; CASCIO M, 1995, ANAL BIOCHEM, V227, P90, DOI 10.1006/abio.1995.1257; CASCIO M, 1994, PROTEIN PEPTIDE LETT, V1, P136; CASPAR DLD, 1977, J CELL BIOL, V74, P605, DOI 10.1083/jcb.74.2.605; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GOODENOUGH DA, 1972, J CELL BIOL, V54, P646, DOI 10.1083/jcb.54.3.646; GORDON DJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P481, DOI 10.1016/0003-9861(71)90511-X; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; HERTZBERG EL, 1984, J BIOL CHEM, V259, P9936; Kumar N M, 1992, Semin Cell Biol, V3, P3; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; LAEMMLI UK, 1970, NATURE, V224, P149; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEMAIRE M, 1989, J BIOCHEM-TOKYO, V106, P814, DOI 10.1093/oxfordjournals.jbchem.a122936; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; REYNOLDS JA, 1985, METHOD ENZYMOL, V117, P41; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHNEIDER AS, 1976, BIOCHEMISTRY-US, V15, P4158, DOI 10.1021/bi00664a004; SMITH AP, 1978, BIOCHEMISTRY-US, V17, P1761, DOI 10.1021/bi00602a029; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; TIBBITTS TT, 1990, BIOPHYS J, V57, P1025, DOI 10.1016/S0006-3495(90)82621-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WALLACE BA, 1984, P NATL ACAD SCI-BIOL, V81, P1406, DOI 10.1073/pnas.81.5.1406; Warner A., 1992, Seminars in Cell Biology, V3, P81; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	48	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18643	18648		10.1074/jbc.270.31.18643	http://dx.doi.org/10.1074/jbc.270.31.18643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629194	hybrid			2022-12-27	WOS:A1995RM64200076
J	KAZANIETZ, MG; WANG, S; MILNE, GWA; LEWIN, NE; LIU, HL; BLUMBERG, PM				KAZANIETZ, MG; WANG, S; MILNE, GWA; LEWIN, NE; LIU, HL; BLUMBERG, PM			RESIDUES IN THE 2ND CYSTEINE-RICH REGION OF PROTEIN-KINASE-C-DELTA RELEVANT TO PHORBOL ESTER BINDING AS REVEALED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; REGULATORY DOMAIN; UNC-13 GENE; RAT-BRAIN; DIACYLGLYCEROL; ZINC; EXPRESSION; INHIBITORS; CHIMAERIN; AFFINITY	Phorbol esters bind with high affinity to protein kinase C (PKC) isozymes as well as to two novel receptors, n-chimaerin and Unc-13, The cysteine-rich regions present in these proteins were identified as the binding sites for the phorbol ester tumor promoters and the lipophilic second messenger sn-diacylglycerol. A 50-amino-acid peptide comprising the second cysteine-rich region of PKC delta, expressed in Escherichia coli as a glutathione S-transferase (GST)-fusion protein, bound [H-3]phorbol 12,13-dibutyrate (PDBu) with high affinity (K-d =0.8 nM). Using the cDNA of that cysteine-rich region as a template, a series of 37 point mutations was generated by site-directed mutagenesis, and the mutated proteins were analyzed quantitatively for binding of [H-3]PDBu and, as appropriate, for binding of the ultrapotent analog [3H]bryostatin 1. Mutants displayed one of three patterns of behavior: phorbol ester binding was completely abolished, binding affinity was reduced, or binding was not significantly modified, As expected, five of the six cysteines as well as the two histidines involved in Zn2+ coordination are critical for the interaction of the protein with the phorbol esters. In addition, mutations in several positions, including phenylalanine 3, tyrosine 8, proline 11, leucines 20, 21, and 24, tryptophan 21, glutamine 27, and valine 38 drastically reduced the interaction with the ligands, The effect of these mutations can be rationalized from the three-dimensional (NMR) structure of the cysteine-rich region. In particular, the C-terminal portion of the protein does not appear to be essential, and the loop comprising amino acids 20 to 28 is implicated in the binding activity.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BETHESDA,MD 20892; NCI,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Wang, Shaomeng/0000-0002-8782-6950				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ARECES LB, 1994, J BIOL CHEM, V269, P19553; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LEWIN NE, 1991, CANCER COMMUN, V3, P6770; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARKEY NA, 1985, CANCER RES, V45, P19; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WENDER PA, 1995, P NATL ACAD SCI USA, V92, P239, DOI 10.1073/pnas.92.1.239; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	34	158	162	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21852	21859		10.1074/jbc.270.37.21852	http://dx.doi.org/10.1074/jbc.270.37.21852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665608	hybrid			2022-12-27	WOS:A1995RU75700068
J	WAGNER, PD; VU, ND				WAGNER, PD; VU, ND			PHOSPHORYLATION OF ATP-CITRATE LYASE BY NUCLEOSIDE DIPHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; TUMOR-METASTASIS; SEQUENCE-ANALYSIS; BINDING PROTEINS; MELANOMA-CELLS; BREAST-CANCER; NM23; EXPRESSION; GENE; AUTOPHOSPHORYLATION	Rat liver nucleoside diphosphate kinase (NDPK) and PC12 cell cytosol were used to determine whether NDPK could function as a protein kinase. NDPK was phosphorylated on its catalytic histidine using [gamma-P-32]ATP, and the phosphorylated NDPK separated from [gamma-P-32]ATP, The addition of phosphorylated NDPK to dialyzed PC12 cell cytosol resulted in the phosphorylation of a protein with a subunit molecular mass of about 120 kDa, This phosphorylation appeared to occur by a direct transfer of a phosphoryl group from the catalytic histidine of NDPK to a histidine on the 120-kDa protein. The 120-kDa protein was partially purified and shown by peptide sequencing to be ATP-citrate lyase, ATP-citrate lyase is the primary source of cytosolic acetyl-CoA. NDPK phosphorylated the histidine at the catalytic site of ATP-citrate lyase, This histidine can also be phosphorylated by ATP, and its phosphorylation is the first step in the conversion of citrate and CoA to oxaloacetate and acetyl-CoA by ATP-citrate lyase. The level of phosphorylation of PC12 cell ATP-citrate lyase by phosphorylated NDPK was comparable with that by ATP. Thus, in addition to its nucleoside diphosphate kinase activity, NDPK can function as a protein kinase.			WAGNER, PD (corresponding author), NCI, BIOCHEM LAB, BLDG 37, RM 4C24, 37 CONVENT DR MSC 4255, BETHESDA, MD 20892 USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; BRIDGER WA, 1984, CURR TOP CELL REGUL, V24, P345; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUCZYNSKI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P296, DOI 10.1016/0167-4838(90)90288-Q; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; FRANCIS B, 1989, MOL CARCINOGEN, V2, P168, DOI 10.1002/mc.2940020310; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUE H, 1967, BIOCHEM BIOPH RES CO, V26, P602, DOI 10.1016/0006-291X(67)90108-8; KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S; KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LINN TC, 1979, J BIOL CHEM, V254, P1691; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OHTSUKI K, 1986, BIOCHIM BIOPHYS ACTA, V882, P322, DOI 10.1016/0304-4165(86)90254-0; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SINGH M, 1976, J BIOL CHEM, V251, P5242; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SRERE PA, 1975, ADV ENZYMOLOGY, V43, P85; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VU ND, 1993, BIOCHEM J, V296, P169, DOI 10.1042/bj2960169; WAGNER PD, 1989, J BIOL CHEM, V264, P19614; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WELLS TNC, 1991, EUR J BIOCHEM, V199, P163, DOI 10.1111/j.1432-1033.1991.tb16105.x; WILLIAMS SP, 1985, BIOCHEMISTRY-US, V24, P5527, DOI 10.1021/bi00341a037	56	162	164	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21758	21764		10.1074/jbc.270.37.21758	http://dx.doi.org/10.1074/jbc.270.37.21758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665595	hybrid			2022-12-27	WOS:A1995RU75700054
J	ENGELENDER, S; WOLOSKER, H; DEMEIS, L				ENGELENDER, S; WOLOSKER, H; DEMEIS, L			THE CA2+-ATPASE ISOFORMS OF PLATELETS ARE LOCATED IN DISTINCT FUNCTIONAL CA2+ POOLS AND ARE UNCOUPLED BY A MECHANISM DIFFERENT FROM THAT OF SKELETAL-MUSCLE CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; HUMAN-BLOOD PLATELETS; TRANSMEMBRANE CHANNEL; HYDROPHOBIC MOLECULES; CALCIUM RELEASE; ATP SYNTHESIS; CA-2+ ATPASE; TRANSPORT; VESICLES; MEMBRANE	Vesicles derived from the dense tubular system of platelets possess a Ca2+-ATPase that can use either ATP or acetyl phosphate as a substrate. In the presence of phosphate as a precipitating anion, the maximum amount of Ca2+ accumulated by the vesicles with the use of acetyl phosphate was only one-third of that accumulated with the use of ATP. Vesicles derived from the sarcoplasmic reticulum of skeletal muscle accumulated equal amounts of Ca2+ regardless of the substrate used. When acetyl phosphate was used in platelet vesicles, the transport of Ca2+ was inhibited by Na+, Li+, and K+; in sarcoplasmic reticulum vesicles, only Na+ caused inhibition. When ATP was used as substrate, the different monovalent cation had no effect on either sarcoplasmic reticulum or platelet vesicles. The catalytic cycle of the Ca2+-ATPase is reversed when a Ca2+ gradient is formed across the vesicle membrane, The stoichiometry between active Ca2+ efflux and ATP synthesis was one in platelet vesicles and two in sarcoplasmic reticulum vesicles. The coupling between ATP synthesis and Ca2+ efflux in sarcoplasmic reticulum vesicles was abolished by arsenate regardless of whether the vesicles were loaded with Ca2+ using acetyl phosphate or ATP. In platelets, uncoupling was observed only when the vesicles were loaded using acetyl phosphate. In both sarcoplasmic reticulum and platelet vesicles, the effect of arsenate was antagonized by thapsigargin (2 mu M), micromolar Ca2+ concentrations, P-i (5-20 mM), and MgATP (10-100 mu M). Trifluoperazine also uncoupled the platelet Ca2+ pump but, different from arsenate, this drug was effective in vesicles that were loaded using either ATP or acetyl phosphate. Trifluoperazine enhanced Ca2+ efflux from both sarcoplasmic reticulum and platelet vesicles; thapsigargin, Ca2+, Mg2+, or K+ antagonized this effect in sarcoplasmic reticulum but not in platelet vesicles. The data indicate that the Ca2+-transport isoforms found in sarcoplasmic reticulum and in platelets have different kinetic properties.	FED UNIV RIO DE JANEIRO, DEPT BIOQUIM, INST CIENCIAS BIOMED, BR-21941590 RIO DE JANEIRO, BRAZIL					Wolosker, Herman/0000-0001-5508-9194; Engelender, Simone/0000-0001-7401-6855				ADUNYAH SE, 1986, J BIOL CHEM, V261, P3071; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BENECH JC, 1995, BIOCHEM J, V306, P35, DOI 10.1042/bj3060035; BOBE R, 1994, J BIOL CHEM, V269, P1417; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CHIESI M, 1979, J BIOL CHEM, V254, P370; CUTLER L, 1978, J GEN PHYSIOL, V61, P463; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DEAN WL, 1983, J BIOL CHEM, V259, P7343; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1988, EUR J BIOCHEM, V171, P343; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENOUF J, 1989, BIOCHEM J, V263, P547, DOI 10.1042/bj2630547; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; GOSH TK, 1988, J BIOL CHEM, V263, P11075; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; INESI G, 1989, J BIOL CHEM, V264, P5929; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; KASERGLANZMANN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P1, DOI 10.1016/0005-2736(78)90213-4; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MENASHI S, 1982, FEBS LETT, V140, P298, DOI 10.1016/0014-5793(82)80918-6; PICK U, 1982, EUR J BIOCHEM, V131, P393; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SAXENA S P, 1991, FASEB Journal, V5, pA902; SCHWARTZENBACH G, 1957, HELV CHIM ACTA, V40, P1186; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; WHITE GC, 1982, BIOCHEM BIOPH RES CO, V104, P1066, DOI 10.1016/0006-291X(82)91358-4; WOLOSKER H, 1994, AM J PHYSIOL, V266, pC1376, DOI 10.1152/ajpcell.1994.266.5.C1376; WOLOSKER H, 1990, EUR J BIOCHEM, V193, P873, DOI 10.1111/j.1432-1033.1990.tb19411.x; WOLOSKER H, 1992, J BIOL CHEM, V267, P5785; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	48	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21050	21055		10.1074/jbc.270.36.21050	http://dx.doi.org/10.1074/jbc.270.36.21050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673132	hybrid			2022-12-27	WOS:A1995RU05400030
J	GERGEL, D; MISIK, V; ONDRIAS, K; CEDERBAUM, AI				GERGEL, D; MISIK, V; ONDRIAS, K; CEDERBAUM, AI			INCREASED CYTOTOXICITY OF 3-MORPHOLINOSYDNONIMINE TO HEPG2 CELLS IN THE PRESENCE OF SUPEROXIDE-DISMUTASE - ROLE OF HYDROGEN-PEROXIDE AND IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; CYTO-TOXICITY; FREE-RADICALS; URIC-ACID; PEROXYNITRITE; HYDROXYL; COMPLEXES; OXYGEN; CARDIOPROTECTION	3-Morpholinosydnonimine (SIN-1) is widely used to generate nitric oxide (NOx.) and superoxide radical (Oa. The effect of SOD on the toxicity of SIN-1 is complex, depending on what is the ultimate species responsible for toxicity. SIN-1 (<1 mM) was only slightly toxic to HepG2 cells, Copper,zinc superoxide dismutase (Cu,Zn-SOD) or manganese superoxide dismutase (Mn-SOD) increased the toxicity of SIN-1. Catalase abolished, while sodium azide potentiated, this toxicity, suggesting a key role for H2O2 in the overall mechanism. Depletion of GSH from the HepG2 cells also potentiated the toxicity of SIN-1 plus SOD, Although Me(2)SO, sodium formate, and mannitol had no protective effect, iron chelators, thiourea and urate protected the cells against the SIN-1 plus Cu,Zn-SOD-mediated cytotoxicity. The cytotoxic effect of Cu,Zn-SOD but not Mn-SOD, showed a biphasic dose response being most pronounced at lower concentrations (10-100 units/ml). In the presence of SIN-1, Mn-SOD increased accumulation of H2O2 in a concentration-dependent manner. In contrast, Cu,Zn-SOD increased H2O2 accumulation from SIN-1 at low but not high concentrations of the enzyme, suggesting that high concentrations of the Cu,Zn-SOD interacted with the H2O2. EPR spin trapping studies demonstrated the formation of hydroxyl radical from the decomposition of H2O2 by high concentrations of the Cu,Zn-SOD. The cytotoxic effect of the NO donors SNAP and DEA/NO was only slightly enhanced by SOD; catalase had no effect, Thus, the oxidants responsible for the toxicity of SIN-1 and SNAP or DEA\NO to HepG2 cells under these conditions are different, with H2O2 derived from O-2-radical-anion dismutation playing a major role with SIN-1, These results suggest that the potentiation of SIN-1 toxicity by SOD is due to enhanced production of H2O2, followed by site-specific damage of critical cellular sites by a transition metal-catalyzed reaction, These results also emphasize that the role of SOD as a protectant against oxidant damage is complex and dependent, in part, on the subsequent fate and reactivity of the generated H2O2.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; NCI,BETHESDA,MD 20892	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Ondrias, Karol/0000-0001-8329-3563	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA009460, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-09460, AA-03312] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BARNIER M, 1989, AM J PHYSIOL, V256, pH1344; BECKMAN JS, 1990, P NATL ACAD SCI USA, V84, P1620; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CEDERBAUM AI, 1979, BIOCHEMISTRY-US, V18, P1187, DOI 10.1021/bi00574a011; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V14, P19; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; DEGROOT H, 1992, FEBS LETT, V315, P139; DIMASCIO P, 1994, FEBS LETT, V335, P287; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; FEELISCH M, 1989, J CARDIOVASC PHA S11, V14, P313; FOSSATI P, 1980, CLIN CHEM, V26, P227; FUNG KP, 1994, LIFE SCI, V54, pPL491, DOI 10.1016/0024-3205(94)00722-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; GUTTERIDGE JMC, 1984, BIOCHEM J, V224, P761, DOI 10.1042/bj2240761; HADDAD IY, 1994, AM J PHYSIOL, V264, pL242; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HERSHKO C, 1988, CRIT REV CLIN LAB SC, V76, P303; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; HOGG N, 1992, BIOCHEM J, V28, P419; HORTON RA, 1994, BIOCHEM J, V299, P735, DOI 10.1042/bj2990735; ILAN YA, 1977, BIOCHIM BIOPHYS ACTA, V498, P386, DOI 10.1016/0304-4165(77)90277-X; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KRONCKE KD, 1993, BIOCHIM BIOPHYS ACTA, V1182, P221, DOI 10.1016/0925-4439(93)90144-P; KUKIELKA E, 1989, ARCH BIOCHEM BIOPHYS, V275, P540, DOI 10.1016/0003-9861(89)90400-1; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAO GD, 1993, J BIOL CHEM, V268, P416; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; ROSEN GM, 1984, P NATL ACAD SCI USA, V81, P7268; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SCHULZ W, 1991, BASIC RES CARDIOL, V86, P233; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STIEF CG, 1992, J UROLOGY, V148, P1437, DOI 10.1016/S0022-5347(17)36931-8; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WINK DA, 1994, NEUROBIOLOGY NO OH, P765; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	61	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20922	20929		10.1074/jbc.270.36.20922	http://dx.doi.org/10.1074/jbc.270.36.20922			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673115	hybrid			2022-12-27	WOS:A1995RU05400012
J	KOTENKO, SV; IZOTOVA, LS; POLLACK, BP; MARIANO, TM; DONNELLY, RJ; MUTUKUMARAN, G; COOK, JR; GAROTTA, G; SILVENNOINEN, O; IHLE, JN; PESTKA, S				KOTENKO, SV; IZOTOVA, LS; POLLACK, BP; MARIANO, TM; DONNELLY, RJ; MUTUKUMARAN, G; COOK, JR; GAROTTA, G; SILVENNOINEN, O; IHLE, JN; PESTKA, S			INTERACTION BETWEEN THE COMPONENTS OF THE INTERFERON-GAMMA RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY FACTOR; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; GENE; IDENTIFICATION; PROTEINS; CHROMOSOME-21; INDUCTION; SYSTEM; CELLS	Interferon gamma (IFN-gamma) signals through a multimeric receptor complex consisting of two different chains: the IFN-gamma receptor binding subunit (IFN-gamma R, IFN-gamma R1), and a transmembrane accessory factor (AF-1, IFN-gamma R2) necessary for signal transduction. Using cell lines expressing different cloned components of the IFN-gamma receptor complex, we examined the function of the receptor components in signal transduction upon IFN-gamma treatment. A specific IFN-gamma R2:IFN-gamma cross-linked complex was observed in cells expressing both IFN-gamma R1 and IFN-gamma R2 indicating that IFN-gamma R2 (AF-1) interacts with IFN-gamma and is closely associated with IFN-gamma R1. We show that the intracellular domain of IFN-gamma R2 is necessary for signaling. Cells coexpressing IFN-gamma R1 and truncated IFN-gamma R2, lacking the COOH-terminal 51 amino acids (residues 286-337), or cells expressing IFN-gamma R1 alone were unresponsive to IFN-gamma treatment as measured by MHC class I antigen induction. Jak1, Jak2, and Stat1 alpha were activated, and IFN-gamma R1 was phosphorylated only in cells expressing both IFN-gamma R1 and IFN-gamma R2. Jak2 kinase was shown to associate with the intracellular domain of the LFN-gamma R2.	HUMAN GENOME SCI, ROCKVILLE, MD 20850 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	GlaxoSmithKline; Human Genome Sciences Inc; St Jude Children's Research Hospital	KOTENKO, SV (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MOLEC GENET & MICROBIOL, PISCATAWAY, NJ 08854 USA.				NCI NIH HHS [P30 CA21765, R01 CA46465] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA046465] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MARIANO TM, 1991, CYTOKINES PRACTICAL, P95; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	47	137	147	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20915	20921		10.1074/jbc.270.36.20915	http://dx.doi.org/10.1074/jbc.270.36.20915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673114	hybrid			2022-12-27	WOS:A1995RU05400011
J	SUN, ZM; MEANS, AR				SUN, ZM; MEANS, AR			AN INTRON FACILITATES ACTIVATION OF THE CALSPERMIN GENE BY THE TESTIS-SPECIFIC TRANSCRIPTION FACTOR CREM-TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING PROTEIN; SV40 ENHANCER; SEQUENCE; EXPRESSION; ELEMENTS	Calspermin is a high affinity Ca2+/calmodulin binding protein that is found only in postmeiotic male germ cells, Our previous studies have shown that the calspermin transcript is produced by utilization of a testis-specific promoter located within an intron of the calmodulin kinase IV gene. This promoter contains two cAMP response element-like motifs that bind the testis-specific transcription factor CREM tau. This interaction is required for transcriptional activation. Here we describe a novel regulatory element, the 111-base pair first intron of the calspermin gene, which is also required for enhancement of transcription by CREM tau via the cAMP response element motifs, Deletion or inversion of this intron results in loss of CREM tau-mediated stimulation of transcription. However, CREM tau stimulates calspermin promoter activity when the intron is moved upstream of the promoter but only when inserted in the proper orientation. Footprint, linker scanning, and deletion analyses were used to identify regulatory elements in the intron. We suggest that the intron functions as an orientation-dependent but position-independent regulatory element to activate the calspermin promoter by facilitating the stimulatory effect of CREM tau on transcription.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NICHD NIH HHS [HD-07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; IMAI E, 1993, J BIOL CHEM, V268, P5353; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; LEFRANC G, 1990, BIOCHIMIE, V72, P7, DOI 10.1016/0300-9084(90)90167-F; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1993, RECENT PROG HORM RES, V48, P79; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS BJ, 1992, J HYPERTENS, V10, P337, DOI 10.1097/00004872-199204000-00003; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; ONO T, 1989, J BIOL CHEM, V264, P2081; PETERLIN BM, 1991, RES IMMUNOL, V142, P393, DOI 10.1016/0923-2494(91)90037-J; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561	22	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20962	20967		10.1074/jbc.270.36.20962	http://dx.doi.org/10.1074/jbc.270.36.20962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673120	hybrid			2022-12-27	WOS:A1995RU05400017
J	BETHIN, KE; PETROVIC, N; ETTINGER, MJ				BETHIN, KE; PETROVIC, N; ETTINGER, MJ			IDENTIFICATION OF A MAJOR HEPATIC COPPER-BINDING PROTEIN AS S-ADENOSYLHOMOCYSTEINE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; BRINDLED MOUSE MODEL; WILSON DISEASE GENE; MENKES DISEASE; RAT-LIVER; CANDIDATE GENE; CU,ZN-SUPEROXIDE DISMUTASE; TRANSPORTING ATPASE; PRIMARY DEFECT; METABOLISM	The properties of a mouse liver copper binding protein (CuBP) and human placental S-adenosylhomocysteine hydrolase (SAHH) were compared to test the hypothesis that CuBP is SAHH. CuBP and SAHH migrated identically on SDS-polyacrylamide gel electrophoresis gels, and their 48-kDa monomers both self-associate to tetramers. Human placental SAHH cross-reacted with polyclonal antibodies to mouse liver CuBP, and CuBP from mouse liver cross-reacted with two monoclonal antibodies to human placental SAHH. A third monoclonal antibody to human placenta SAHH reacted weakly with the mouse liver protein but well with CuBP from human lymphoblasts. NAD(+)-activated CuBP has high SAHH enzymatic activity. Moreover, human placental SAHH, like mouse liver CuBP, has a single high affinity copper binding site per 48-kDa subunit. Thus, the data confirm that CuBP is SAHH, and SAHH is proposed to be a bifunctional protein with roles in sulfur-amino acid metabolism and copper metabolism. The copper binding activity of SAHH is proposed to play a significant role in the intracellular distribution of copper, and SAHH enzymatic activity may influence copper metabolism through its role in cysteine biosynthesis from methionine.	SUNY BUFFALO, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Bethin, Kathleen/L-8904-2019	Bethin, Kathleen/0000-0002-6100-4983				ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; ARREDONDOVEGA FX, 1989, ANN HUM GENET, V53, P157, DOI 10.1111/j.1469-1809.1989.tb01780.x; BEARN AG, 1954, P SOC EXP BIOL MED, V85, P44; BETHIN KE, 1995, J BIOL CHEM, V270, P20703, DOI 10.1074/jbc.270.35.20703; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DARWISH HM, 1983, J BIOL CHEM, V258, P3621; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DELAHABA G, 1986, BIOCHEMISTRY-US, V25, P8337, DOI 10.1021/bi00373a031; DOSKELAND SO, 1982, BIOCHIM BIOPHYS ACTA, V708, P185, DOI 10.1016/0167-4838(82)90219-9; ETTINGER MJ, 1984, LIFE CHEM REPORTS, V5, P169; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; GOMI T, 1985, J BIOL CHEM, V260, P2789; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1990, J BIOL CHEM, V265, P16102; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; HUNT DM, 1974, NATURE, V249, P852, DOI 10.1038/249852a0; KAGI JHR, 1979, METALLOTHIONEIN, V2, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU SJ, 1971, J BIOL CHEM, V246, P5938; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; MANN JR, 1979, BIOCHEM J, V180, P605, DOI 10.1042/bj1800605; MARCEAU N, 1970, AM J PHYSIOL, V218, P377, DOI 10.1152/ajplegacy.1970.218.2.377; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; METZLER DE, 1977, BIOCHEMISTRY-US, P846; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALIDA FA, 1991, J BIOL CHEM, V266, P4586; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PEGG AE, 1988, CANCER RES, V48, P759; PETROVIC N, 1993, THESIS STATE U NEW Y; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; SEO HC, 1993, J BIOL CHEM, V268, P1151; SEO HC, 1993, J BIOL CHEM, V268, P1160; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SQUIBB KS, 1977, BIOCHEM J, V164, P223, DOI 10.1042/bj1640223; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WALDROP GL, 1990, BIOCHEM J, V267, P417, DOI 10.1042/bj2670417; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	52	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20698	20702		10.1074/jbc.270.35.20698	http://dx.doi.org/10.1074/jbc.270.35.20698			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657650	hybrid			2022-12-27	WOS:A1995RR58400070
J	GALISTEO, ML; DIKIC, I; BATZER, AG; LANGDON, WY; SCHLESSINGER, J				GALISTEO, ML; DIKIC, I; BATZER, AG; LANGDON, WY; SCHLESSINGER, J			TYROSINE PHOSPHORYLATION OF THE C-CBL PROTOONCOGENE PROTEIN PRODUCT AND ASSOCIATION WITH EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR UPON EGF STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							V-CBL; BINDING-SITE; DOMAIN; TRUNCATION; KINASES; GRB2; SH2	The murine retroviral oncogene v-cbl induces pre-B cell lymphomas and myelogenous leukemias. The protein product of the mammalian c-cbl proto-oncogene is a widely expressed cytoplasmic 120-kDa protein (p120(cbl)) whose normal cellular function has not been deter mined. Here we show that upon stimulation of human epidermal growth factor (EGF) receptor, p120(cbl) becomes strongly tyrosine-phosphorylated and associates with activated EGF receptor in vivo. A GST fusion protein containing amino acids 1-486 of p120(cbl), including a region highly conserved in nematodes, binds directly to the autophosphorylated carboxyl-terminal tail of the EGF receptor. Platelet derived growth factor (PDGF), fibroblast growth factor (FGF), or nerve growth factor (NGF) stimulation also results in tyrosine phosphorylation of p120(cbl). Recent genetic studies in Caenorhabditis elegans indicate that Sli-1, a p120(cbl) homologue, plays a negative regulatory role in control of the Ras signaling pathway initiated by the C. elegans EGF receptor homologue. Our results indicate that p120(cbl) is involved in an early step in the EGF signaling pathway that is conserved from nematodes to mammals.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	New York University; University of Western Australia			Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; PAWSON T, 1994, CURR BIOL, V3, P434; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RON D, 1992, BIOTECHNIQUES, V13, P866; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; YOON CH, 1995, IN PRESS SCIENCE	27	180	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20242	20245		10.1074/jbc.270.35.20242	http://dx.doi.org/10.1074/jbc.270.35.20242			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657591	hybrid			2022-12-27	WOS:A1995RR58400003
J	NORMANT, E; GROS, C; SCHWARTZ, JC				NORMANT, E; GROS, C; SCHWARTZ, JC			CARBOXYPEPTIDASE-A ISOFORMS PRODUCED BY DISTINCT GENES OR ALTERNATIVE SPLICING IN BRAIN AND OTHER EXTRAPANCREATIC TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL CARBOXYPEPTIDASE; DIRECTED MUTAGENESIS; RAT CARBOXYPEPTIDASE; MOLECULAR-CLONING; FAMILY; PURIFICATION; INHIBITORS; MECHANISM; SEQUENCE; SITE	The presence of carboxypeptidase A (EC 3.4.17.1; CPA) gene transcripts and corresponding catalytic activity was investigated in brain and other extradigestive rat tissues in which presence of the pancreatic enzyme had not been reported so far. Transcripts of two known CPA genes, CPA1 and CPA2, were identified in extremely low abundance in brain and several other extrapancreatic tissues using Northern blot and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Whereas the CPA1 gene transcripts in brain, heart, stomach, or colon had a size similar to that in pancreas (1.35 kilobases), the CPA2 gene transcripts in brain, testis, or lung were of a smaller size (1.1 kilobases). Northern blot analysis using various probes, RT-PCR, and 5'-rapid amplification of cDNA 5'-end (5' RACE analysis) all indicated that this smaller size of the brain transcript was attributable to production by alternative splicing of the pro-mRNA. This process corresponds to deletion of the first four exons, leading to a mRNA encoding a protein in which the signal peptide and activation peptide of prepro-CPA2 are absent but the active site remains. The prediction that the shorter CPA2 isoform, designated CPA2(S), should correspond to a cytoplasmic metallopeptidase that does not require tryptic activation was verified by characterization of the recombinant protein and comparing it with the native CPA-like activity in brain. Both recombinant CPA2(S) generated in Escherichia coli and a soluble protein from brain displayed similar sizes on Western blots (32 kDa to be compared to 34 kDa for pancreatic CPA2). Recombinant CPA2(S) and a soluble CPA-like activity from brain displayed similar sensitivity to a series of inhibitors, contrasting with that of the pancreatic enzyme. It is concluded that alternative splicing produces a truncated CPA2 with distinct subcellular localization and modified catalytic activity. In spite of the presence of the CPA1 mRNA, no corresponding CPA activity could be detected in brain extracts, even after tryptic activation. This apparent discrepancy seems attributable to the presence of an endogenous peptide inhibitor which remains to be identified.			NORMANT, E (corresponding author), CTR PAUL BROCA,INSERM,UNITE NEUROBIOL & PHARMACOL,2TER RUE ALESIA,F-75014 PARIS,FRANCE.							Anson ML, 1937, J GEN PHYSIOL, V20, P663, DOI 10.1085/jgp.20.5.663; AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1985, P NATL ACAD SCI USA, V82, P6840, DOI 10.1073/pnas.82.20.6840; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GARDELL SJ, 1987, J BIOL CHEM, V262, P576; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; GUASH A, 1991, J MOL BIOL, V224, P141; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HASS GM, 1979, PLANT PHYSIOL, V64, P1022, DOI 10.1104/pp.64.6.1022; HUI KS, 1983, HDB NEUROCHEMISTRY, V1, P1; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANEHISA R, 1987, NUCLEIC ACIDS RES, V12, P203; LINDER D, 1993, BIOMED CHROMATOGR, V7, P143, DOI 10.1002/bmc.1130070308; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; Makinen M W, 1984, Adv Inorg Biochem, V6, P1; Maniatis T., 1982, MOL CLONING; ONDETTI MA, 1979, BIOCHEMISTRY-US, V18, P1427, DOI 10.1021/bi00575a006; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; URATA H, 1993, J BIOL CHEM, V268, P24318; WALDSCHMIDTLEIT, 1929, BER CHEM GES, V62, P2217	33	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20543	20549		10.1074/jbc.270.35.20543	http://dx.doi.org/10.1074/jbc.270.35.20543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657630	hybrid			2022-12-27	WOS:A1995RR58400049
J	SPRECHER, H; BARR, HM; SLOTKY, JI; TZUKERMAN, M; EYTAN, GD; ASSARAF, YG				SPRECHER, H; BARR, HM; SLOTKY, JI; TZUKERMAN, M; EYTAN, GD; ASSARAF, YG			ALTERATION OF MITOCHONDRIAL GENE-EXPRESSION AND DISRUPTION OF RESPIRATORY-FUNCTION BY THE LIPOPHILIC ANTIFOLATE PYRIMETHAMINE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; HAMSTER OVARY CELLS; DIHYDROFOLATE-REDUCTASE; HELA-CELLS; FLOW-CYTOMETRY; METHOTREXATE; RESISTANCE; DRUG; TRANSPORT; ACID	To clone the mammalian gene(s) associated with a novel lipophilic antifolate resistance provoked by the antiparasitic drug pyrimethamine (Assaraf, Y. G., and Slotky, J. I. (1993) J. Biol. Chem. 268, 4556-4566), differential screening of a cDNA library from pyrimethamine-resistant (Pyr(R100)) cells was used. This library was screened with total cDNA from wild-type and Pyr(R100) cells. Surprisingly, several differentially overexpressed cDNA clones were isolated from Pyr(R100) cells, many of which mapped to the mitochondrial genome. Several lines of evidence establish mitochondria as a new target for the cytotoxic activity of pyrimethamine. (a) At greater than or equal to 10 mu M, pyrimethamine inhibited mitochondrial respiration in viable wild-type cells. (b) Electron microscopy revealed degenerated mitochondrial membrane cristae in Pyr(R100) cells. (c) Some mitochondrially encoded transcripts were prominently elevated, whereas the normally stable 12 S/16 S rRNA was decreased in Pyr(R100) cells. (d) Metabolic pulse chase labeling suggested an increased turnover rate of mitochondrially synthesized proteins in Pyr(R100) cells. (e) The specific activity of the key respiratory enzymatic complex cytochrome c oxidase was reduced by 6-fold in Pyr(R100) cells. (f) Consequently, the rate of respiration in intact Pyr(P100) cells was reduced by 3-fold. We conclude that pyrimethamine and possibly lipophilic analogues of methotrexate possess a folinic acid nonrescuable toxicity involving disruption of mitochondrial inner membrane structure and respiratory function, thereby establishing a new organellar target for the cytotoxic effect elicited by lipid-soluble antifolates.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology				Assaraf, Yehuda G./0000-0001-6692-8221				ALT FW, 1978, J BIOL CHEM, V253, P1357; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; ASSARAF YG, 1993, ANTI-CANCER DRUG, V4, P535, DOI 10.1097/00001813-199310000-00002; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CAVALLITO JC, 1978, DRUG METAB DISPOS, V6, P329; CHABNER BA, 1990, CANCER CHEMOTHERAPY; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CONOVER TE, 1981, J BIOL CHEM, V256, P402; COWAN KH, 1984, J BIOL CHEM, V259, P793; DAGA A, 1993, J BIOL CHEM, V268, P8123; DUCH DS, 1982, CANCER RES, V42, P3987; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERBRICH U, 1982, HISTOCHEMISTRY, V74, P1, DOI 10.1007/BF00495046; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; GILMAN AG, 1990, PHARMACOL BASIS THER, P985; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V6, P385; HABER DA, 1981, J BIOL CHEM, V256, P9501; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LIN JT, 1987, J CLIN ONCOL, V5, P2032, DOI 10.1200/JCO.1987.5.12.2032; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; LU X, 1992, CANCER RES, V52, P3718; MALCZEWSKI RM, 1984, J BIOL CHEM, V259, P1103; MELERA PW, 1988, J BIOL CHEM, V263, P1978; MUUS P, 1991, BRIT J CANCER, V64, P29, DOI 10.1038/bjc.1991.234; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NARDELLI M, 1994, FEBS LETT, V344, P10, DOI 10.1016/0014-5793(94)00342-4; PIZZORNO G, 1988, CANCER RES, V48, P2149; RAGO RP, 1994, CANCER, V73, P1954, DOI 10.1002/1097-0142(19940401)73:7<1954::AID-CNCR2820730729>3.0.CO;2-H; RAIKHINSTEIN M, 1993, P NATL ACAD SCI USA, V90, P10509, DOI 10.1073/pnas.90.22.10509; ROOS DS, 1987, P NATL ACAD SCI USA, V84, P4860, DOI 10.1073/pnas.84.14.4860; ROTTELE J, 1993, CELL MOL BIOL, V39, P739; SCNEIDER K, 1994, HISTOCHEMISTRY, V101, P135; SHARMA RC, 1991, CANCER RES, V51, P2949; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; WHITFIELD CD, 1990, J BIOL CHEM, V265, P18852	49	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20668	20676		10.1074/jbc.270.35.20668	http://dx.doi.org/10.1074/jbc.270.35.20668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657646	hybrid			2022-12-27	WOS:A1995RR58400066
J	KIRKPATRICK, RB; GANGULY, S; ANGELICHIO, M; GRIEGO, S; SHATZMAN, A; SILVERMAN, C; ROSENBERG, M				KIRKPATRICK, RB; GANGULY, S; ANGELICHIO, M; GRIEGO, S; SHATZMAN, A; SILVERMAN, C; ROSENBERG, M			HEAVY-CHAIN DIMERS AS WELL AS COMPLETE ANTIBODIES ARE EFFICIENTLY FORMED AND SECRETED FROM DROSOPHILA VIA A BIP-MEDIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; LUMINAL ER PROTEINS; BINDING-PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; GENE; EXPRESSION; MELANOGASTER; COMPARTMENT; ENCODES; MEMBER	We have constructed a stable Drosophila cell line coexpressing heavy chain (HC) and Light chain (LC) immunoglobulins of a humanized monoclonal antibody (mAb) that recognizes the F antigen of respiratory syncytial virus Tempest, P. R, Bremmer, P., Lambert, M., Taylor, G., Furze, J. M, Carr, F. J., and Harris, W. J. (1991) Bio/Technology 9, 266-271. These cells efficiently secrete antibody with substrate binding activity indistinguishable from that produced from vertebrate cell lines. Significantly, the Drosophila homologue of the immunoglobulin binding chaperone protein (BiP), hsc72, was found to interact specifically with the immunoglobulin HC in an ATP-dependent fashion, similar to the BiP-HC interaction known to occur in vertebrate cells. This is, in fact, the first substrate ever shown to interact specifically with Drosophila hsc72. Most surprisingly, expression of heavy chains in the absence of LC led to the efficient secretion of heavy chain dimers. Moreover, this secretion occurred in association with hsc72. This dramatically contrasts with what is seen in vertebrate cells where in the absence of LC, HC remains sequestered inside the cell in stable association with BiP. Our results clearly suggest that Drosophila Hip can substitute for its mammalian counterpart and chaperone the secretion of active IgG. However, the finding that Drosophila Hip can also uniquely chaperone heavy chain dimers indicates mechanistic differences that may relate to the evolved need for retaining immature IgGs in vertebrates.	SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC VIROL & HOST DEF,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline	KIRKPATRICK, RB (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOLE DG, 1986, J CELL BIOL, V102, P1588; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; DACKOWSKI W, 1981, P NATL ACAD SCI-BIOL, V78, P7091, DOI 10.1073/pnas.78.11.7091; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; FRANKLIN EC, 1975, CONT TOPICS MOL IMMU, P89; GARBE JC, 1993, DEVELOPMENT, V119, P1237; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V365, P33; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAINS PE, 1982, J BIOL CHEM, V258, P5027; MARCHALONIS JJ, 1994, PRIMORDIAL IMMUNITY, P1; MARONI G, 1986, GENETICS, V112, P493; MCCUNE JM, 1981, J IMMUNOL, V127, P2609; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MORRISON SL, 1975, J IMMUNOL, V114, P655; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RUBIN DM, 1993, GENE, V128, P155, DOI 10.1016/0378-1119(93)90558-K; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; SHIELDS G, 1977, DROSOPHILA INF SERVI, V52, P161; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19800	19805		10.1074/jbc.270.34.19800	http://dx.doi.org/10.1074/jbc.270.34.19800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649989	hybrid			2022-12-27	WOS:A1995RQ99100021
J	PTASZNIK, A; TRAYNORKAPLAN, A; BOKOCH, GM				PTASZNIK, A; TRAYNORKAPLAN, A; BOKOCH, GM			G-PROTEIN-COUPLED CHEMOATTRACTANT RECEPTORS REGULATE LYN TYROSINE KINASE-CENTER-DOT-SHC ADAPTER PROTEIN SIGNALING COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN NEUTROPHILS; ACTIVATED NEUTROPHILS; SUPEROXIDE PRODUCTION; PHOSPHORYLATION; ASSOCIATION; TRANSDUCTION; STIMULATION; PATHWAY	Receptors for chemoattractants that direct the migration of phagocytic leukocytes to sites of injury/infection also modulate many other leukocyte functions that are critical to the inflammatory response, These chemoattractant receptors, members of the G protein-coupled heptahelical receptor family, have been classically linked to cell activation via phospholipase C, calcium, and protein kinase C. We show here that activation of the N-formyl peptide chemoattractant receptor stimulates an additional protein kinase C-independent pathway through the Src-related tyrosine kinase, Lyn, in human neutrophils. We demonstrate that activation of Lyn is associated with binding to the She adapter protein, which becomes phosphorylated on tyrosine residues. This interaction appears to be mediated via the She SH2 domain, Complexes of phosphorylated Lyn and She with phosphatidylinositol 3-kinase are rapidly formed in stimulated neutrophils, correlating with phosphatidylinositol 1,4,5-trisphosphate formation and cell activation. This signaling pathway involving a Src-related kinase and the She adapter protein provides a potential mechanism linking chemoattractant receptors to downstream events involving Rac activation and NADPH oxidase, Regulation of She by G protein-coupled receptors may also allow these receptors to modulate the activity of the Ras/mitogen-activated protein kinase cascade.	Scripps Res Inst, DEPT IMMUNOL IMM14, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego					NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, P65; BOLEN JB, 1993, ONCOGENE, V8, P2025; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DORSEUIL O, 1995, IN PRESS J LEUKOCYTE; EBERLE M, 1990, J BIOL CHEM, V265, P16726; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NACCACHE PH, 1990, BLOOD, V76, P2098; NOBES CD, 1995, J CELL SCI, V108, P225; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKADA T, 1994, J BIOL CHEM, V269, P3563; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	48	168	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19969	19973		10.1074/jbc.270.34.19969	http://dx.doi.org/10.1074/jbc.270.34.19969			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650013	hybrid			2022-12-27	WOS:A1995RQ99100046
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO TRANSLOCASE ACTIVITY OF LAMBDA-TERMINASE AND ITS SUBUNITS - KINETIC AND BIOCHEMICAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; DNA PACKAGING ENZYME; BACTERIOPHAGE-LAMBDA; COS DNA; ESCHERICHIA-COLI; ATPASE ACTIVITY; GENE PRODUCTS; EARLY EVENTS; INVITRO; SYSTEM	The terminase holoenzyme of bacteriophage lambda is a multifunctional protein composed of two subunits, gpNu1 and gpA In vitro, under certain conditions, terminase can render DNAs from various sources, of varying lengths and termini, resistant to degradation by high concentrations of DNase I. This reaction is completely dependent on the presence of terminase, proheads, a hydrolyzable triphosphate, and a divalent metal ion, and we propose that it is the result of translocation of DNA into proheads by terminase. This reaction is stoichiometric with respect to terminase, DNA, and proheads and can be supported by all deoxyriboand ribonucleoside triphosphates, but not by the corresponding diphosphates or nonhydrolyzable ATP analogs. Mg2+ and Ca2+ promote the reaction, but Mn2+ and Zn2+ do not. In the absence of spermidine, translocase activity is low, but addition of the Escherichia coli protein integration host factor (IHF) promotes specific translocation of only those DNA fragments containing the terminase-binding site, cosB. When spermidine is present, nonspecific translocation of DNA from any source is stimulated. Under these conditions IHF no longer promotes specificity, but translocation of only cosB-containing DNA fragments can be restored by addition of small amounts of a dialyzed and RNase-treated E. coli extract, suggesting that additional host factor(s) may be involved in determination of packaging specificity. To a limited extent, gpA alone can promote translocation, but gpNu1, which has no translocase activity on its own, must be added to approach the holoenzyme-like activity levels. Formation of viable phage cannot be accomplished by gpA in the absence of gpNu1.	UNIV TORONTO,FAC MED,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto								BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BEHNISCH W, 1985, VIROLOGY, V144, P310, DOI 10.1016/0042-6822(85)90273-9; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CAMPBELL A, 1961, VIROLOGY, V14, P22, DOI 10.1016/0042-6822(61)90128-3; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; CUE D, 1993, P NATL ACAD SCI USA, V90, P9290, DOI 10.1073/pnas.90.20.9290; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; Georgopoulos C., 1983, LAMBDA 2, P279; GOLD M, 1983, J BIOL CHEM, V258, P4619; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAMADA K, 1986, VIROLOGY, V151, P110, DOI 10.1016/0042-6822(86)90108-X; HASHIMOTO C, 1988, VIROLOGY, V166, P432, DOI 10.1016/0042-6822(88)90514-4; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; LOW B, 1968, P NATL ACAD SCI USA, V60, P160, DOI 10.1073/pnas.60.1.160; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; MURIALDO H, 1988, MOL GEN GENET, V213, P42, DOI 10.1007/BF00333396; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; PARRIS W, 1994, J BIOL CHEM, V269, P13564; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; PTASHNE M, 1967, P NATL ACAD SCI USA, V57, P306, DOI 10.1073/pnas.57.2.306; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; ROSENBERG SM, 1985, GENE, V38, P165, DOI 10.1016/0378-1119(85)90215-X; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SHIBATA H, 1987, VIROLOGY, V159, P250, DOI 10.1016/0042-6822(87)90462-4; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SHINDER G, 1989, NUCLEIC ACIDS RES, V17, P2005, DOI 10.1093/nar/17.5.2005; SON M, 1992, VIROLOGY, V190, P824, DOI 10.1016/0042-6822(92)90920-K; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STERNBERG N, 1977, GENE, V1, P255, DOI 10.1016/0378-1119(77)90049-X; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; XU SY, 1991, J MOL BIOL, V220, P293, DOI 10.1016/0022-2836(91)90014-W; YANOFSKY C, 1966, J MOL BIOL, V21, P313, DOI 10.1016/0022-2836(66)90102-1	43	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20059	20066		10.1074/jbc.270.34.20059	http://dx.doi.org/10.1074/jbc.270.34.20059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650023	hybrid			2022-12-27	WOS:A1995RQ99100058
J	BANDYOPADHYAY, SK; LEONARD, GT; BANDYOPADHYAY, T; STARK, GR; SEN, GC				BANDYOPADHYAY, SK; LEONARD, GT; BANDYOPADHYAY, T; STARK, GR; SEN, GC			TRANSCRIPTIONAL INDUCTION BY DOUBLE-STRANDED-RNA IS MEDIATED BY INTERFERON-STIMULATED RESPONSE ELEMENTS WITHOUT ACTIVATION OF INTERFERON-STIMULATED GENE FACTOR-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; INDUCIBLE GENES; MESSENGER-RNA; HUMAN-CELLS; IFN-BETA; EXPRESSION; IRF-1; BINDING; PROTEIN; ALPHA	Many genes induced by type I interferons (IFNs) are also induced by double stranded (ds) RNA. In this study, we investigated the mechanism of this induction process. Using cell lines from which the type I IFN genes have been deleted, we established that induction by dsRNA of the IFN-inducible 561 gene is direct and not mediated by the intermediate synthesis of IFN. Unlike 561 mRNA, the IFN-inducible 6-16 mRNA was induced poorly by dsRNA. Transfection studies demonstrated that the sequence difference between the core IFN-stimulated response elements (ISREs) of these two genes is not responsible for their differential inducibility by dsRNA. A point mutation in the 561 ISRE that abolished its response to IFN-alpha also made it unresponsive to dsRNA, thus demonstrating that the ISRE is the relevant cis acting element for dsRNA signaling. The roles of different known ISRE-binding protein and tyrosine kinases in transducing the signal elicited by dsRNA were evaluated in genetically altered cell lines, dsRNA failed to induce 561 mRNA in cells expressing an antisense RNA for interferon regulatory factor 1, whereas it was induced strongly in cells expressing the corresponding sense mRNA, 561 mRNA was also induced strongly by dsRNA, but not by IFN-alpha, in mutant cell lines that do not express functional tyrosine kinases Tyk2 or JAK1 or ISRE binding protein, p48, or STATE, all of which are required for LFN-alpha signaling. However, in cells devoid of functional STAT1, which is also required for IFN-alpha signaling, the induction of 561 mRNA by dsRNA was very low. Expression of transfected STAT1 alpha protein, but not of STAT1 beta protein, in these cells greatly enhanced the dsRNA inducibility of the 561 gene. These studies indicate that the major ISRE-mediated signaling pathway used by dsRNA requires interferon regulatory factor 1 and STAT1 alpha. This pathway, however, does not require the other known cytoplasmic components used for IFN-alpha signaling.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University			Li, Chia Cheng/D-9906-2015		NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDYOPADHYAY SK, 1992, J BIOL CHEM, V267, P6389; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PARRINGTON J, 1994, EUR J BIOCHEM, V214, P617; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SAMBROOK J, 1989, MOL CLONING LABORATO, P1639; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4278; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x	35	117	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19624	19629		10.1074/jbc.270.33.19624	http://dx.doi.org/10.1074/jbc.270.33.19624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642650	hybrid			2022-12-27	WOS:A1995RP70300066
J	MAXWELL, SE; RAMALINGAM, S; GERBER, LD; BRINK, L; UDENFRIEND, S				MAXWELL, SE; RAMALINGAM, S; GERBER, LD; BRINK, L; UDENFRIEND, S			AN ACTIVE CARBONYL FORMED DURING GLYCOSYLPHOSPHATIDYLINOSITOL ADDITION TO A PROTEIN IS EVIDENCE OF CATALYSIS BY A TRANSAMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PI-G)-ANCHORED MEMBRANE-PROTEINS; TERMINAL SIGNAL PEPTIDE; PLACENTAL ALKALINE-PHOSPHATASE; ACID-REQUIREMENTS ADJACENT; DECAY-ACCELERATING FACTOR; CLEAVAGE ATTACHMENT SITE; CELL-FREE SYSTEMS; PHOSPHOLIPASE-C; PI-G; BACILLUS-CEREUS	Glycosylphosphatidylinositol (GPI) substitution is now recognized to be a ubiquitous method of anchoring a protein to membranes in eukaryotes. The structure of GPI and its biosynthetic pathways are known and the signals in a nascent protein for GPI addition have been elucidated. The enzyme(s) responsible for GPI addition with release of a COOH-terminal signal peptide has been considered to be a transamidase but has yet to be isolated, and evidence that it is a transamidase is indirect. The experiments reported here show that hydrazine and hydroxylamine, in the presence of rough microsomal membranes, catalyze the conversion of the pro form of the engineered protein miniplacental alkaline phosphatase (prominiPLAP) to mature forms from which the COOH-terminal signal peptide has been cleaved, apparently at the same site but without the addition of GPI. The products, presumably the hydrazide or hydroxamate of miniPLAP, have yet to be characterized definitively. However, our demonstration of enzyme-catalyzed cleavage of the signal peptide in the presence of the small nucleophiles, even in the absence of an energy source, is evidence of an activated carbonyl intermediate which is the hallmark of a transamidase.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCHANAN JM, 1973, ADV ENZYMOL RAMB, V39, P91; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1993, LIPID MODIFICATIONS, P83; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HERELD D, 1988, POST TRANSLATIONAL M, P9; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LOW MG, 1977, FEBS LETT, V82, P143, DOI 10.1016/0014-5793(77)80905-8; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MCCOMB RB, 1972, CLIN CHEM, V18, P97; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; SUNDLER R, 1978, J BIOL CHEM, V253, P4175; TAGUCHI R, 1980, BIOCHIM BIOPHYS ACTA, V619, P48; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3320; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; WELLNER VP, 1966, BIOCHEMISTRY-US, V5, P872, DOI 10.1021/bi00867a010	43	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19576	19582		10.1074/jbc.270.33.19576	http://dx.doi.org/10.1074/jbc.270.33.19576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642644				2022-12-27	WOS:A1995RP70300060
J	MILOSO, M; MAZZOTTI, M; VASS, WC; BEGUINOT, L				MILOSO, M; MAZZOTTI, M; VASS, WC; BEGUINOT, L			SHC AND GRB-2 ARE CONSTITUTIVELY ACTIVATED BY AN EPIDERMAL GROWTH-FACTOR RECEPTOR WITH A POINT MUTATION IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EGF RECEPTOR; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; ONCOGENIC FORMS; PHOSPHORYLATION; TRANSFORMATION; SUBSTITUTION; GENE	A single point mutation, Glu(627) --> Val, equivalent to the activating mutation in the Neu oncogene, was inserted in the transmembrane domain of the human epidermal growth factor (EGF) receptor. Unlike the wild type, Glu(627)-EGF receptor, transfected in NIH3T3 cells, gave rise to focal transformation and growth in agar even in the absence of EGF. Constitutive activity of mutant EGF receptor amounted to 20% of that of wild type receptor stimulated by EGF. In addition, the mutant receptor was more sensitive to EGF, reaching maximum transforming activity at 5 ng/ml EGF, NIH3T3 cells expressing Glu(627)-EGF receptor showed a transformed phenotype and were not arrested in G(0) upon serum deprivation, The mutant receptor was constitutively autophosphorylated. and several other cellular proteins were phosphorylated on tyrosine in absence of the ligand. Among these, the SHC adaptor protein was phosphorylated in absence of EGF, the other adaptor, GRB-2, was constitutively associated with the Glu(627)-EGF receptor in vivo and in vitro, and mitogen-activated protein kinase was constitutively phosphorylated. In contrast, other EGF receptor substrates, like phospholipase C gamma, were not phosphorylated in absence of EGF. The mutant receptor showed a higher sensitivity to cleavage by calpain both in absence and presence of EGF, appeared as a 170- and 150-kDa doublet in cell extracts, and a specific calpain inhibitor blocked the appearance of the 150-kDa form. Since the calpain cleavage site is located in the receptor cytoplasmic tail, this finding suggests that the Glu(627) mutation induces a slightly different conformation in the EGF receptor intracellular domain. In conclusion, our data show that a point mutation in the EGF receptor transmembrane domain was able to constitutively activate the receptor and to induce transformation via constitutive activation of the Ras pathway.	HOSP SAN RAFFAELE,DIBIT,MOLEC ONCOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY; NIH,MOLEC ONCOL LAB,BETHESDA,MD 20892	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA			Miloso, Mariarosaria/AAC-7373-2021					ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P488; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BERTICS PJ, 1987, J BIOL CHEM, V263, P3610; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1990, J BIOL CHEM, V265, P616; CARPENTER G, 1993, FORUM, V3, P613; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HELIN K, 1991, ONCOGENE, V6, P3610; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LONGO N, 1992, J BIOL CHEM, V267, P12416; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROUSSEL MF, CELL, V55, P979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SOLER C, 1994, ONCOGENE, V9, P2207; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOOLWORD JM, 1988, CELL, V5, P965; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	41	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19557	19562		10.1074/jbc.270.33.19557	http://dx.doi.org/10.1074/jbc.270.33.19557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642641	hybrid			2022-12-27	WOS:A1995RP70300057
J	PUGLIELLI, L; RIGOTTI, A; GRECO, AV; SANTOS, MJ; NERVI, F				PUGLIELLI, L; RIGOTTI, A; GRECO, AV; SANTOS, MJ; NERVI, F			STEROL CARRIER PROTEIN-2 IS INVOLVED IN CHOLESTEROL TRANSFER FROM THE ENDOPLASMIC-RETICULUM TO THE PLASMA-MEMBRANE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR-TRANSPORT; GOLGI-APPARATUS; EXPRESSION	The cellular mechanism of cholesterol transport from the endoplasmic reticulum to the plasma membrane is currently unknown. To assess the possibility that sterol carrier protein-2 (SCP-2) is involved in this transport, we studied the time course of newly synthesized cholesterol incorporation in the plasma membrane of normal and SCP-2 deficient (Zellweger syndrome) human fibroblasts. Cholesterol transfer was rapid, cytoskeleton-independent, and Golgi independent in normal cells, but it was slower, cytoskeleton dependent, and Golgi-dependent in SCP-2-deficient cells. After SCP-2 antisense oligonucleotides treatment of normal fibroblasts, the rapid transport was reduced by 81% with a simultaneous increase of the slower one. These results suggest that in normal fibroblasts the major fraction of newly synthesized cholesterol is trans ported to the plasma membrane by a SCP-2-dependent mechanism. In contrast, in SCP-2-deficient cells, newly synthesized cholesterol leaves the endoplasmic reticulum by a cytoskeleton/Golgi-dependent mechanism.	PONTIFICIA UNIV CATOLICA CHILE, FAC MED, DEPT GASTROENTEROL, SANTIAGO, CHILE; PONTIFICIA UNIV CATOLICA CHILE, FAC MED, CTR PARA PREVENT & TRATAMIENTO CANC DIGEST, SANTIAGO, CHILE; PONTIFICIA UNIV CATOLICA CHILE, FAC CIENCIAS BIOL, DEPT BIOL CELULAR & MOLEC, SANTIAGO, CHILE; UNIV CATTOLICA SACRO CUORE, FAC MED & CHIRURG, IST MED INTERNA, I-00198 ROME, ITALY	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli				Nervi, Flavio/0000-0002-6642-7985				BAUM CL, 1993, J LIPID RES, V34, P729; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1974, J BIOL CHEM, V249, P7306; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1991, J BIOL CHEM, V266, P2439; LISCUM L, 1992, J LIPID RES, V33, P1239; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; OSSENDORP BC, 1994, CURR TOP MEMBR, V40, P217, DOI 10.1016/S0070-2161(08)60983-1; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SCHRODER F, 1991, P SOC EXP BIOL MED, V193, P235; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	26	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18723	18726		10.1074/jbc.270.32.18723	http://dx.doi.org/10.1074/jbc.270.32.18723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642518	hybrid			2022-12-27	WOS:A1995RN95400004
J	WANG, Y; KENT, C				WANG, Y; KENT, C			IDENTIFICATION OF AN INHIBITORY DOMAIN OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPASE-C TREATMENT; MEMBRANE-ASSOCIATED CTP; HEP G2 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MAMMALIAN-CELLS; FATTY-ACIDS; HELA-CELLS; BACILLUS-SUBTILIS	The function of the putative amphipathic helices between residues 236 and 314 of CTP:phosphocholine cytidylyltransferase was examined by constructing two truncation mutants; CT314 was missing the entire phosphorylation segment, whereas CT236 was missing both the region with the putative amphipathic helices and the phosphorylation segment. Stable cells lines expressing these truncation mutants in Chinese hamster ovary 58 cells were isolated and characterized. CT314 was predominantly soluble in control cells but became membrane-associated in cells treated with oleate, which also causes translocation of wild type cytidylyltransferase. CT236 was found to be soluble both in control cells and in cells treated to cause translocation. These results strongly suggest that the membrane-binding site is located within residues 237-314. When assayed for activity in vitro, the mutant forms were catalytically active in the presence of exogenous lipids, CT236, moreover, was as active in the absence of lipids as in their presence, whereas CT314 required lipids for activity. The rate of phosphatidylcholine synthesis in cells expressing CT236 was considerably higher than in wild-type cells, consist ent with the enzyme being constitutively active in the cells. These results indicate that residues 237-314 constitute an inhibitory segment; when this segment is removed from the catalytic domain by truncation or by binding to membranes, an inhibitory constraint is removed and cytidylyltransferase is activated.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NCI NIH HHS [CA64159] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CRAIG L, 1994, J BIOL CHEM, V269, P3311; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1980, BIOCHIM BIOPHYS ACTA, V620, P603, DOI 10.1016/0005-2760(80)90152-6; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KRUG EL, 1984, ARCH BIOCHEM BIOPHYS, V231, P400, DOI 10.1016/0003-9861(84)90403-X; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PARK YS, 1993, J BIOL CHEM, V268, P16648; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9	40	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18948	18952		10.1074/jbc.270.32.18948	http://dx.doi.org/10.1074/jbc.270.32.18948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642553	hybrid			2022-12-27	WOS:A1995RN95400041
J	TOLLEFSBOL, TO; HUTCHISON, CA				TOLLEFSBOL, TO; HUTCHISON, CA			MAMMALIAN DNA (CYTOSINE-5-)-METHYLTRANSFERASE EXPRESSED IN ESCHERICHIA-COLI, PURIFIED AND CHARACTERIZED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; FRAGILE-X-SYNDROME; CPG DINUCLEOTIDE; METHYLATION PATTERNS; SEQUENCE SPECIFICITY; DENOVO METHYLATION; MISMATCH REPAIR; METHYLTRANSFERASE; GENE; 5-METHYLCYTOSINE	Besides modulating specific DNA-protein interactions, methylated cytosine, frequently referred to as the fifth base of the genome, also influences DNA structure, recombination, transposition, repair, transcription, imprinting, and mutagenesis, DNA (cytosine-5-)-methyl transferase catalyzes cytosine methylation in eukaryotes. We have cloned and expressed this enzyme in Escherichia coli, purified it to apparent homogeneity, characterized its properties, and we have shown that it hemimethylates DNA. The cDNA for murine maintenance methyltransferase was reconstructed and cloned for direct expression in native form. Immunoblotting revealed a unique protein (M(r) = 190,000) not present in control cells. The mostly soluble overexpressed protein was purified by DEAE, Sephadex, and DNA cellulose chromatography. Peak methylating activity correlated with methyltransferase immunoblots. The purified enzyme preferentially transferred radioactive methyl moieties to hemimethylated DNA in assays and on autoradiograms. All of the examined properties of the purified recombinant DNA methyltransferase are consistent with the enzyme purified from mammalian cells. Further characterization revealed enhanced in vitro methylation of premethylated oligodeoxynucleotides. The cloning of hemimethyltransferase in E. coli should allow facilitated structure-function mutational analysis of this enzyme, studies of its biological effects in prokaryotes, and potential large scale methyltransferase production for crystallography, and it may have broad applications in maintaining the native methylated state of cloned DNA.			TOLLEFSBOL, TO (corresponding author), UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CB 7290, 804 FLOB, CHAPEL HILL, NC 27599 USA.			Tollefsbol, Trygve/0000-0002-0284-1511	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021313] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08998] Funding Source: Medline; NIGMS NIH HHS [GM21313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLETTA J, 1992, ANTIVIR RES, V18, P1, DOI 10.1016/0166-3542(92)90002-M; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DOERFLER W, 1990, FEBS LETT, V268, P329, DOI 10.1016/0014-5793(90)81280-2; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; PFEIFER GP, 1983, BIOCHIM BIOPHYS ACTA, V740, P323, DOI 10.1016/0167-4781(83)90141-0; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RIGGS AD, 1990, PHILOS T R SOC B, V326, P285, DOI 10.1098/rstb.1990.0012; Sambrook J, 1989, MOL CLONING LABORATO; SANO H, 1983, EUR J BIOCHEM, V135, P181, DOI 10.1111/j.1432-1033.1983.tb07635.x; SCHEIDT G, 1994, NUCLEIC ACIDS RES, V22, P953, DOI 10.1093/nar/22.6.953; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SMITH SS, 1987, NUCLEIC ACIDS RES, V15, P6899, DOI 10.1093/nar/15.17.6899; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TOLLEFSBOL TO, 1993, MED HYPOTHESES, V41, P83, DOI 10.1016/0306-9877(93)90040-W; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; TURKER MS, 1990, SOMAT CELL MOLEC GEN, V16, P331, DOI 10.1007/BF01232461; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; ZUCKER KE, 1985, J CELL BIOCHEM, V29, P337, DOI 10.1002/jcb.240290407	60	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18543	18550		10.1074/jbc.270.31.18543	http://dx.doi.org/10.1074/jbc.270.31.18543			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629184	hybrid, Green Published			2022-12-27	WOS:A1995RM64200062
J	GOLDSMITH, MA; LAI, SY; XU, W; AMARAL, MC; KUCZEK, ES; PARENT, LJ; MILLS, GB; TARR, KL; LONGMORE, GD; GREENE, WC				GOLDSMITH, MA; LAI, SY; XU, W; AMARAL, MC; KUCZEK, ES; PARENT, LJ; MILLS, GB; TARR, KL; LONGMORE, GD; GREENE, WC			GROWTH SIGNAL-TRANSDUCTION BY THE HUMAN INTERLEUKIN-2 RECEPTOR REQUIRES CYTOPLASMIC TYROSINES OF THE BETA-CHAIN AND NONTYROSINE RESIDUES OF THE GAMMA(C) CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IL-2 RECEPTOR; KINASE-ACTIVITY; ACTIVATION; BINDING; DOMAIN; REGION; PHOSPHORYLATION; PROTEIN; COMPLEX; ANTIGEN	To evaluate the possible role for receptor-based tyrosine phosphorylation in growth signaling induced by interleukin-2 (IL-2), a series of substitution tyrosine mutants of the IL-2 receptor beta and gamma(c) chains was prepared and analyzed. Concurrent mutation of all six of the cytoplasmic tyrosines present in the beta chain markedly inhibited IL-2-induced growth signaling in both pro-B and T cell lines. Growth signaling in a pro-B cell line was substantially reconstituted when either of the two distal tyrosines (Tyr-392, Tyr-510) was selectively restored in the tyrosine-negative beta mutant, whereas reconstitution of the proximal tyrosines (Tyr-338, Tyr-355, Tyr-358, Tyr-361) did not restore this signaling function. Furthermore, at least one of the two cytoplasmic tyrosines that is required for beta chain function was found to serve as a phosphate acceptor site upon induction with IL-2. Studies employing a chimeric receptor system revealed that tyrosine residues of the beta chain likewise were important for growth signaling in T cells. In contrast, although the gamma(c) subunit is a target for tyrosine phosphorylation in vivo, concurrent substitution of all four cytoplasmic tyrosines of this chain produced no significant effect on growth signaling by chimeric IL-2 receptors. However, deletion of either the Box 1, Box 2, or intervening (V-Box) regions of gamma(c) abrogated receptor function. Therefore, tyrosine residues of beta but not of gamma(c) appear to play a pivotal role in regulating growth signal transduction through the IL-2 receptor, either by influencing cytoplasmic domain folding or by serving as sites for phosphorylation and subsequent association with signaling intermediates. These findings thus highlight a fundamental difference in the structural requirements for IL-2R beta and gamma(c) in receptor-mediated signal transduction.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94141; PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; TORONTO GEN HOSP,TORONTO,ON M4X 1K9,CANADA; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Washington University (WUSTL); Washington University (WUSTL)	GOLDSMITH, MA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141, USA.			Lai, Stephen/0000-0001-8301-7286; Parent, Leslie/0000-0002-0431-9049; Kuczek, Elizabeth/0000-0002-5412-5509				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS MO; ASAO H, 1990, J EXP MED, V171, P2183; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FUNG MR, 1991, J IMMUNOL, V147, P1253; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1994, CYTOKINE HDB, P57; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ISHII N, 1994, J IMMUNOL, V153, P1310; KAWAHARA A, 1994, MOL CELL BIOL, V4, P5433; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MERIDA I, 1991, J IMMUNOL, V147, P2202; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	60	61	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21729	21737		10.1074/jbc.270.37.21729	http://dx.doi.org/10.1074/jbc.270.37.21729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665592	hybrid			2022-12-27	WOS:A1995RU75700050
J	LOPEZCABRERA, M; MUNOZ, E; BLAZQUEZ, MV; URSA, MA; SANTIS, AG; SANCHEZMADRID, F				LOPEZCABRERA, M; MUNOZ, E; BLAZQUEZ, MV; URSA, MA; SANTIS, AG; SANCHEZMADRID, F			TRANSCRIPTIONAL REGULATION OF THE GENE ENCODING THE HUMAN C-TYPE LECTIN LEUKOCYTE RECEPTOR AIM/CD69 AND FUNCTIONAL-CHARACTERIZATION OF ITS TUMOR NECROSIS FACTOR-ALPHA-RESPONSIVE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELL ACTIVATION; NATURAL-KILLER-CELLS; LYMPHOCYTE-ACTIVATION; INDUCER MOLECULE; ANTIGEN CD69; EXPRESSION; PROLIFERATION; BINDING; ANTIBODIES	The human activation antigen CD69 is a member of the C-type animal lectin superfamily that functions as a signal-transmitting receptor. Although the expression of CD69 can be induced in vitro on cells of most hematopoietic lineages with a wide variety of stimuli, in vivo it is mainly expressed by T-lymphocytes located in the inflammatory infiltrates of several human diseases. To elucidate the mechanisms that regulate the constitutive and inducible expression of CD69 by leukocytes, we isolated the promoter region of the CD69 gene and carried out its functional characterization. Sequence analysis of the 5'-flanking region of the CD69 gene revealed the presence of a potential TATA element 30 base pairs upstream of the major transcription initiation site and several putative binding sequences for inducible transcription factors (NF-kappa B, Egr-1, AP-1), which might mediate the inducible expression of this gene, Transient expression of CD69 promoter-based reporter gene constructs in K562 cells indicated that the proximal promoter region spanning positions -78 to +16 contained the cis-acting sequences necessary for basal and phorbol 12-myristate 13-acetate-inducible transcription of the CD69 gene. Removal of the upstream sequences located between positions -78 and -38 resulted in decreased promoter strength and abolished the response to phorbol 12-myristate 13-acetate. We also found that tumor necrosis factor-alpha (TNF-alpha) is capable of inducing the surface expression of the CD69 molecule as well as the promoter activity of fusion plasmids that contain 5'-flanking sequences of the CD69 gene, suggesting that this cytokine may regulate in vivo the expression of CD69. In addition, cotransfection experiments demonstrated that the CD69 gene promoter can be activated by the NF-kappa B/Rel family members c-Rel and RelA. The deletion of the sequence spanning positions -255 to -170 abolished both the response to TNF-alpha and the transactivation by NF-kappa B. These results indicate that the NF-kappa B-binding site located at position -223 is necessary for the TNF-alpha-induced expression of the CD69 gene. Mobility shift assays showed that the two NF-kappa B motifs located in the proximal promoter region (positions -223 and -160) bind various NF-kappa B-related complexes, in eluding the heterodimers p50/RelA and p50/c-Rel and homodimers of p50 (KBF-1) and RelA. Our findings help to explain the regulated synthesis of CD69 in vivo and suggest that TNF-alpha has a key role in the expression of this molecule at sites of chronic inflammation.	UNIV AUTONOMA MADRID,HOSP PRINCESA,SERV IMMUNOL,E-28006 MADRID,SPAIN; UNIV AUTONOMA MADRID,HOSP PRINCESA,UNIDAD BIOL MOLEC,E-28006 MADRID,SPAIN; UNIV CORDOBA,FAC MED,DEPT FISIOL & INMUNOL,E-14004 CORDOBA,SPAIN	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Universidad de Cordoba			Munoz, Eduardo/I-5225-2012; Cabrera, Manuel López/AAA-5463-2019; Sanchez-Madrid, Francisco/M-7889-2016	Munoz, Eduardo/0000-0001-8478-5842; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Lopez Cabrera, Manuel/0000-0002-0976-9719				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GARCIAMONZON C, 1990, GASTROENTEROLOGY, V98, P1029, DOI 10.1016/0016-5085(90)90030-5; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; NAKAMURA S, 1989, J EXP MED, V169, P677, DOI 10.1084/jem.169.3.677; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUEDA A, 1993, J BIOL CHEM, V268, P19305; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; SANTIS AG, 1995, IN PRESS EUR J IMMUN; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TESTI R, 1989, J IMMUNOL, V143, P1123; TUGORES A, 1992, J IMMUNOL, V148, P2300; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; YOKOYAMA WM, 1993, CURR OPIN IMMUNOL, V5, P67, DOI 10.1016/0952-7915(93)90083-5; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	38	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21545	21551		10.1074/jbc.270.37.21545	http://dx.doi.org/10.1074/jbc.270.37.21545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665567	hybrid			2022-12-27	WOS:A1995RU75700022
J	HAMANAKA, R; SMITH, MR; OCONNOR, PM; MALOID, S; MIHALIC, K; SPIVAK, JL; LONGO, DL; FERRIS, DK				HAMANAKA, R; SMITH, MR; OCONNOR, PM; MALOID, S; MIHALIC, K; SPIVAK, JL; LONGO, DL; FERRIS, DK			POLO-LIKE KINASE IS A CELL-CYCLE-REGULATED KINASE ACTIVATED DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; CDC2 PROTEIN-KINASE; PHOSPHORYLATION SITES; DEPENDENT KINASES; MESSENGER-RNA; IDENTIFICATION; DROSOPHILA; DEPHOSPHORYLATION; CHECKPOINTS; DIVISION	Previously, we demonstrated that expression of polo-like kinase (PLK) is required for cellular DNA synthesis and that overexpression of PLK is sufficient to induce DNA synthesis. We now report that the endogenous levels of PLK, its phosphorylation status, and protein kinase activity are tightly regulated during cell cycle progression. PLK protein is low in G(1), accumulates during S and G(2)M, and is rapidly reduced after mitosis. During mitosis, PLK is phosphorylated on serine, and its serine threonine kinase function is activated at a time close to that of p34(cdc2). The phosphorylated form of PLK migrates with reduced mobility on SDS-polyacrylamide gel electrophoresis, and dephosphorylation by purified protein phosphatase 2A converts it to the more rapidly migrating form and reduces the total amount of PLK kinase activity. Purified p34(cdc2)-cyclin B complex can phosphorylate PLK protein in vitro but causes little increase in PLK kinase activity.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DIV HEMATOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University			Longo, Dan L./F-6022-2011					BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HANKS S, 1991, METHOD ENZYMOL, V200, P3862; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1973, GENETICS, V74, P267; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KATO J, 1993, GENE DEV, V7, P331; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KREK W, 1992, NEW BIOL, V4, P323; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NIGG EA, 1991, SEMIN CELL BIOL, V2, P251; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1990, New Biologist, V2, P389; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SUNKEL CE, 1988, J CELL SCI, V89, P25; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	41	160	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21086	21091		10.1074/jbc.270.36.21086	http://dx.doi.org/10.1074/jbc.270.36.21086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673138	hybrid			2022-12-27	WOS:A1995RU05400036
J	RAIMO, G; MASULLO, M; BOCCHINI, V				RAIMO, G; MASULLO, M; BOCCHINI, V			STUDIES ON THE POLYPEPTIDE ELONGATION-FACTOR-2 FROM SULFOLOBUS-SOLFATARICUS - INTERACTION WITH GUANOSINE NUCLEOTIDES AND GTPASE ACTIVITY STIMULATED BY RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; ARCHAEBACTERIAL RIBOSOMES; STRUCTURAL-PROPERTIES; PROTEIN-SYNTHESIS; BINDING	The elongation factor 2 from the thermoacidophilic archaeon Sulfolobus solfataricus (SsEF-2) binds [H-3]GDP at 1:1 molar ratio. The bound [H-3]GDP is displaced by GTP or its nonhydrolyzable analogue guanyl-5'-yl imidodiphosphate (Gpp(NH)p) but not by ATP, thus indicating that only the two guanosine nucleotides compete for the same binding site. The affinity of SsEF-2 for [H-3]GDP is higher than that for GTP and Gpp(NH)p. On the contrary, in the presence of ribosomes the affinity of SsEF-2 for GDP is lower than that for Gpp(NH)p. SsEF-2 is endowed with an intrinsic hardly detectable GTPase activity that is stimulated by ribosomes up to 2000-fold. The ribosome-stimulated SsEF-2 GTPase (GTPase(r)) reaches a maximum at pH 7.8 and is not affected by ATP but is competitively inhibited by either GDP or Gpp(NH)p. Both K-m for [gamma-P-32]GTP and k(cat) of GTPase(r) increase with increasing temperature, and the highest catalytic efficiency is reached at 80 degrees C. The ADP-ribosylation of SsEF-2 does not significantly affect either the binding of GDP and GTP or the kinetics of the GTPase(r). A hypothesis on the stimulation by ribosome of SsEF-2 GTPase is proposed.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	University of Naples Federico II			Raimo, Gennaro/F-4651-2012; Masullo, Mariorosario/H-4884-2016	Masullo, Mariorosario/0000-0003-4485-7383; Raimo, Gennaro/0000-0003-0365-7430				ARAI N, 1977, J BIOCHEM-TOKYO, V82, P687, DOI 10.1093/oxfordjournals.jbchem.a131744; BEAUCLERK AAD, 1985, EUR J BIOCHEM, V151, P245, DOI 10.1111/j.1432-1033.1985.tb09095.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMARANO P, 1985, EMBO J, V4, P811, DOI 10.1002/j.1460-2075.1985.tb03702.x; DEVENDITTIS E, 1986, J BIOL CHEM, V261, P4445; DEVENDITTIS E, 1993, GENE, V136, P41; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Klink F., 1985, BACTERIA, V8, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASULLO M, 1991, EUR J BIOCHEM, V199, P529, DOI 10.1111/j.1432-1033.1991.tb16151.x; MASULLO M, 1989, BIOCHEM J, V261, P725, DOI 10.1042/bj2610725; MASULLO M, 1994, J BIOL CHEM, V239, P20376; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MIZUMOTO K, 1974, J BIOCHEM-TOKYO, V76, P1269, DOI 10.1093/oxfordjournals.jbchem.a130680; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NURTEN R, 1980, EUR J BIOCHEM, V103, P551, DOI 10.1111/j.1432-1033.1980.tb05979.x; NYGARD O, 1990, J BIOL CHEM, V265, P6030; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; RAIMO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P127, DOI 10.1016/0167-4781(92)90002-H; RAIMO G, 1993, ITAL J BIOCHEM, V42, P11; ROHRBACH MS, 1976, BIOCHEMISTRY-US, V15, P4565, DOI 10.1021/bi00666a003; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x	22	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21082	21085		10.1074/jbc.270.36.21082	http://dx.doi.org/10.1074/jbc.270.36.21082			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673137	hybrid			2022-12-27	WOS:A1995RU05400035
J	WATERS, SB; HOLT, KH; ROSS, SE; SYU, LJ; GUAN, KL; SALTIEL, AR; KORETZKY, GA; PESSIN, JE				WATERS, SB; HOLT, KH; ROSS, SE; SYU, LJ; GUAN, KL; SALTIEL, AR; KORETZKY, GA; PESSIN, JE			DESENSITIZATION OF RAS ACTIVATION BY A FEEDBACK DISASSOCIATION OF THE SOS-GRB2 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; PROTEIN; KINASES; P21RAS; RECEPTOR; EXCHANGE; INSULIN; RAF-1	Activation of Ras by the exchange of bound GDP for GTP is predominantly catalyzed by the guanylnucleotide exchange factor SOS. Receptor tyrosine kinases increase Ras-GTP loading by targeting SOS to the plasma membrane location of Ras through the small adaptor protein Grb2. However, despite the continuous stimulation of receptor tyrosine kinase activity, Ras activation is transient and, in the case of insulin, begins returning to the GDP-bound state within 5 min. We report here that the cascade of serine kinases activated directly by Ras results in a mitogen-activated protein kinase kinase (MEK)-dependent phosphorylation of SOS and subsequent disassociation. of the Grb2-SOS complex, thereby interrupting the ability of SOS to catalyze nucleotide exchange on Ras. These data demonstrate a molecular feedback mechanism accounting for the desensitization of Ras-GTP loading following insulin stimulation.	UNIV IOWA,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48104	University of Iowa; University of Iowa; Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019; Koretzky, Gary/AAU-5381-2021	Saltiel, Alan/0000-0002-9726-9828				ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; DUDLEY DT, 1995, IN PRESS P NATL ACAD; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	20	135	138	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20883	20886		10.1074/jbc.270.36.20883	http://dx.doi.org/10.1074/jbc.270.36.20883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673108	hybrid			2022-12-27	WOS:A1995RU05400004
J	BREUER, O; BJORKHEM, I				BREUER, O; BJORKHEM, I			USE OF AN O-18(2) INHALATION TECHNIQUE AND MASS ISOTOPOMER DISTRIBUTION ANALYSIS TO STUDY OXYGENATION OF CHOLESTEROL IN RAT - EVIDENCE FOR IN-VIVO FORMATION OF 7-OXOCHOLESTEROL, 7-BETA-HYDROXYCHOLESTEROL, 24-HYDROXYCHOLESTEROL, AND 24-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; STEROL SYNTHESIS; 25-HYDROXYCHOLESTEROL; DERIVATIVES; INHIBITION; REDUCTASE; MECHANISM; INVIVO; CELLS	Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol. This constitutes a considerable risk of quantitation errors, since even a minor oxidation of cholesterol during sample processing would yield a substantial increase of oxysterol levels. It has therefore been suggested that some of the oxysterols do not occur in vivo and their detection in tissues merely are artifacts produced in vitro. In the present work, an O-18(2), inhalation technique was developed in order to clarify which oxysterols are produced in vivo, Rats were exposed for 3 h to an atmosphere with a composition similar to normal air, except that it contained O-18(2), instead of O-16(2). Control rats were kept in O-16(2)-containing atmosphere throughout the experiment. The O-18(2) enrichment of oxysterols in plasma and liver was determined by gas/liquid chromatography-mass spectrometry and mass isotopomer distribution analysis. In vivo formation of oxysterols, indicated by enrichment in O-18(2), was established for cholest-5-ene-3 beta,7 alpha-diol, cholest-5-ene-3 beta,7 beta-diol, 7-oxocholesterol, cholest-5-ene-3 beta,24-diol, cholest-5-ene-3 beta,25-diol, and cholest-5-ene-3 beta,27-diol. Additionally, it seems likely that cholest-5-ene-3 beta,4 beta-diol is formed in vivo. The O-18(2) labeling pattern suggests that there is incomplete equilibration between the liver and plasma pools of cholest-5-ene-3 beta,27-diol. No evidence for the in vivo formation of 5,6-oxygenated oxysterols was obtained.			BREUER, O (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN.			Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1979, J BIOL CHEM, V254, P5252; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ERICKSON SK, 1978, J BIOL CHEM, V253, P4159; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Halliwell B., 1989, FREE RADICAL BIO MED, P214; JOHANSSON G, 1971, EUR J BIOCHEM, V21, P68, DOI 10.1111/j.1432-1033.1971.tb01441.x; JOHNSON KA, 1994, J LIPID RES, V35, P2241; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KANDUTSCH AA, 1978, LIPIDS, V13, P704, DOI 10.1007/BF02533749; KUDO K, 1989, J LIPID RES, V30, P1097; LUND E, 1992, J BIOL CHEM, V267, P12462; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; MAYEVSKY A, 1973, BIOCHEM BIOPH RES CO, V51, P746, DOI 10.1016/0006-291X(73)91379-X; REISS AB, 1994, J LIPID RES, V35, P1026; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; Smith, 1981, CHOLESTEROL AUTOXIDA; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; SMITH LL, 1967, J CHROMATOGR, V26, P509, DOI 10.1016/S0021-9673(01)98913-7; TENG JI, 1976, BIOORG CHEM, V5, P99, DOI 10.1016/0045-2068(76)90017-1; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205	30	73	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20278	20284		10.1074/jbc.270.35.20278	http://dx.doi.org/10.1074/jbc.270.35.20278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657597	hybrid			2022-12-27	WOS:A1995RR58400010
J	HENSTRAND, JM; AMRHEIN, N; SCHMID, J				HENSTRAND, JM; AMRHEIN, N; SCHMID, J			CLONING AND CHARACTERIZATION OF A HETEROLOGOUSLY EXPRESSED BIFUNCTIONAL CHORISMATE SYNTHASE FLAVIN REDUCTASE FROM NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYDALIS-SEMPERVIRENS PERS; AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MOLECULAR-CLONING; PURIFICATION; PLANT; ENZYME; GENES	Activities of all chorismate synthases (CS) so far analyzed are absolutely dependent upon reduced flavin. For monofunctional CSs, which represent the only class of CSs that have yet been cloned, the flavin must be reduced either (photo-)chemically or by a separable flavin reductase (FR) for in vitro activity. Neurospora crassa CS, in contrast, possesses an intrinsic FR activity and represents the only firmly established member of a bifunctional class of CSs. To better understand this bifunctional protein, a cDNA from an N. crassa expression library encoding a 46.4-kDa protein was cloned by complementation of the CS-deficient Escherichia coli strain AB2849. The deduced amino acid sequence was highly similar (79%) to a previously isolated Saccharomyces cerevisiae CS. The N. crassa sequence was unequivocally shown to encode the bifunctional CS/FR by analysis of the purified protein expressed in E. coli. Based on sequence comparisons with known monofunctional CSs, two regions of 18 internal residues and 29 C-terminal residues unique to N. crassa CS were deleted, and the constructs were also expressed in E. coli. The presence of these regions was found not essential for complementation of the CS- phenotype of E. coli strain AB2849. Although a 3.5-fold decline in specific activity of the purified CS from cells expressing the C-terminal deletion construct was observed, bifunctional activity was not eliminated. These data strongly suggest that the domain(s) responsible for reduction of flavin lie(s) within regions in which homology is also shared among monofunctional CSs.	ETH ZURICH, INST PLANT SCI, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BORNEMANN S, 1995, BIOCHEM J, V305, P707, DOI 10.1042/bj3050707; CHARLES IG, 1990, J GEN MICROBIOL, V136, P353, DOI 10.1099/00221287-136-2-353; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; FLOSS HG, 1972, J BIOL CHEM, V247, P736; GANEM B, 1978, TETRAHEDRON, V34, P3353, DOI 10.1016/0040-4020(78)80222-1; HASAN N, 1978, J BIOL CHEM, V253, P4993; HASAN N, 1978, J BIOL CHEM, V253, P4987; HAWKES TR, 1990, BIOCHEM J, V265, P899, DOI 10.1042/bj2650899; HAWKINS AR, 1991, EUR J BIOCHEM, V196, P717, DOI 10.1111/j.1432-1033.1991.tb15870.x; HENSTRAND JM, 1995, IN PRESS PLANT PHYSL; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; RAMJEE MN, 1992, J AM CHEM SOC, V114, P3151, DOI 10.1021/ja00034a079; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER A, 1991, PLANT PHYSIOL, V97, P1271, DOI 10.1104/pp.97.4.1271; SCHALLER A, 1991, J BIOL CHEM, V266, P21434; SCHALLER A, 1990, ARCH BIOCHEM BIOPHYS, V282, P437, DOI 10.1016/0003-9861(90)90141-K; SCHLOSS JV, 1991, FLAVINS AND FLAVOPROTEINS 1990, P907; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	24	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20447	20452		10.1074/jbc.270.35.20447	http://dx.doi.org/10.1074/jbc.270.35.20447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657620	hybrid			2022-12-27	WOS:A1995RR58400034
J	MAEDA, M; TAFT, CS; BUSH, EW; HOLDER, E; BAILEY, WM; NEVILLE, H; PERRYMAN, MB; BIES, RD				MAEDA, M; TAFT, CS; BUSH, EW; HOLDER, E; BAILEY, WM; NEVILLE, H; PERRYMAN, MB; BIES, RD			IDENTIFICATION, TISSUE-SPECIFIC EXPRESSION, AND SUBCELLULAR-LOCALIZATION OF THE 80-KDA AND 71-KDA FORMS OF MYOTONIC-DYSTROPHY KINASE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							UNSTABLE CTG REPEAT; MESSENGER-RNA; MUSCULAR-DYSTROPHY; TRIPLET REPEAT; GENE; TRANSCRIPT; ANTIBODIES; DROSOPHILA; EXPANSION; MUTATION	The protein product of the myotonic dystrophy (DM) gene is a putative serine-threonine protein kinase (DM kinase). Previous reports have characterized the DM gene product as various 50-62-kDa proteins. The predicted protein size from DM cDNA sequence is 69 kDa. We therefore expressed a full-length recombinant human DM kinase protein and compared its size and expression to heart, cardiac Purkinje fibers, and skeletal muscle from normal and DM subjects. Recombinantly expressed DM kinase and endogenous DM kinase in human heart, displayed two immunoreactive DM kinase proteins with apparent molecular sizes of 71 and 80 kDa, suggesting that these prior reports are incorrect. In cardiac Purkinje fibers the 71-kDa protein was the major form, and in skeletal muscle the 80-kDa protein was the major form. Immunostaining showed DM kinase localized to neuromuscular junctions in skeletal muscle and intercalated discs in heart and Purkinje fibers. DM subjects showed low abundance of DM kinase in heart and skeletal muscle, suggesting haplotype insufficiency as a potential mechanism for disease expression. These studies describe differential expression of two protein forms of DM kinase, which are localized to specialized cellular structures associated with impulse transmission.	UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,TEMPLE HOYNE BUELL LABS,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DIV NEUROMUSCULAR,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DENVER GEN HOSP,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [R01HL50715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050715] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNANE D, 1994, CIRCULATION, V90, P2629, DOI 10.1161/01.CIR.90.6.2629; ASTROW SH, 1992, J NEUROSCI, V12, P1605; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BIES RD, 1992, CIRCULATION, V86, P147, DOI 10.1161/01.CIR.86.1.147; BREWSTER BS, 1993, BIOCHEM BIOPH RES CO, V194, P1256, DOI 10.1006/bbrc.1993.1958; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; Engel AG, 1994, MYOLOGY, P1192; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GEIGER B, 1990, J CELL SCI, V97, P607; GREEN CR, 1983, TISSUE CELL, V15, P17, DOI 10.1016/0040-8166(83)90030-7; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; LEGATO MJ, 1973, MYOCARDIAL CELL CLIN, P131; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MELACINI P, 1995, J AM COLL CARDIOL, V25, P239, DOI 10.1016/0735-1097(94)00351-P; OHIENDIECH K, 1991, NEURON, V7, P499; PERRYMAN MB, 1993, TRENDS CARDIOVAS MED, V3, P82, DOI 10.1016/1050-1738(93)90028-5; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SOMMER JR, 1968, J CELL BIOL, V37, P570, DOI 10.1083/jcb.37.2.570; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; WARMKE JW, 1989, GENETICS, V122, P139	29	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20246	20249		10.1074/jbc.270.35.20246	http://dx.doi.org/10.1074/jbc.270.35.20246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657592	hybrid			2022-12-27	WOS:A1995RR58400004
J	DOUVILLE, K; PRICE, A; EICHLER, J; ECONOMOU, A; WICKNER, W				DOUVILLE, K; PRICE, A; EICHLER, J; ECONOMOU, A; WICKNER, W			SECYEG AND SECA ARE THE STOICHIOMETRIC COMPONENTS OF PREPROTEIN TRANSLOCASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; PRECURSOR PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; TRIGGER FACTOR; ACIDIC PHOSPHOLIPIDS; INNER MEMBRANE; COAT PROTEIN	The transport of large preproteins across the Escherichia coli plasma membrane is catalyzed by preprotein translocase, comprised of the peripherally bound SecA subunit and an integrally bound heterotrimeric domain consisting of the SecY, SecE, and SecG subunits. me have now placed the secY, secE, and secG genes under the control of an arabinose-inducible promoter on a multicopy plasmid. Upon induction, all three of the proteins are strongly overexpressed and recovered in the plasma membrane fraction. These membranes show a strong enhancement of 1) translocation ATPase activity, 2) preprotein translocation, 3) capacity for SecA binding, and 4) formation of the membrane-inserted form of Seek These data establish that SecY, SecE, and SecG constitute the integral membrane domain of preprotein translocase.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE	Dartmouth College; University of Crete			Economou, Anastassios/P-8292-2017; EICHLER, JERRY/F-2351-2012	Economou, Anastassios/0000-0002-1770-507X; EICHLER, JERRY/0000-0001-9409-8026				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HABERLAND ME, 1989, J IMMUNOL, V142, P855; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1992, MOL MICROBIOL, V6, P2423; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1994, PHOSPHATE IN MICROORGANISMS, P251; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RENSING SA, 1994, MOL PHYLOGENET EVOL, V3, P187, DOI 10.1006/mpev.1994.1021; Sambrook J, 1989, MOL CLONING LABORATO; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	65	114	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20106	20111		10.1074/jbc.270.34.20106	http://dx.doi.org/10.1074/jbc.270.34.20106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650029	hybrid			2022-12-27	WOS:A1995RQ99100065
J	HIRANO, K; ITO, M; HARTSHORNE, DJ				HIRANO, K; ITO, M; HARTSHORNE, DJ			INTERACTION OF THE RIBOSOMAL-PROTEIN, L5, WITH PROTEIN PHOSPHATASE TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; RAT-LIVER RIBOSOMES; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SKELETAL-MUSCLE; YEAST; RNA; PHOSPHORYLATION; IDENTIFICATION; TRANSFORMATION	The two-hybrid system was used to screen for binding proteins of type 1 protein phosphatase. Two plasmids were constructed, one containing the cDNA of the delta isoform of the type 1 catalytic subunit and the other containing a chicken gizzard cDNA library. Yeast (Y190) were transformed with the plasmids and screened for interacting species. 35 positive clones were categorized into 19 gene groups. Most of these were not identified. One clone, however, contained a sequence identical to the C-terminal portion of the chicken ribosomal protein L5 and corresponded to nucleotide residues 606-975. L5 was isolated from rat liver ribosomes as the L5 . 5 S RNA complex. This activated phosphatase activity of a myosin-bound phosphatase and the isolated type 1 catalytic subunit using phosphorylated myosin light chains and phosphorylase a as substrates. In addition, it was found that phosphatase sedimented with ribosomal subunits containing L5 but did not sediment with those deficient in L5. These data indicate that L5 binds to the catalytic subunit of the type 1 protein phosphatase and may act as a target molecule for phosphatase in ribosomal function or other cell mechanisms.	UNIV ARIZONA, MUSCLE BIOL GRP, TUCSON, AZ 85721 USA; MIE UNIV, SCH MED, DEPT INTERNAL MED 1, TSU, MIE 514, JAPAN	University of Arizona; Mie University			Hirano, Katsuya/B-2785-2008	Hirano, Katsuya/0000-0003-0164-1283	NHLBI NIH HHS [HL 20984, HL 23615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023615, P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHU YF, 1994, BBA-PROTEIN STRUCT M, V1208, P45, DOI 10.1016/0167-4838(94)90158-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; HARPER JW, 1993, CELL, V75, P805; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUBBARD MJ, 1991, METHOD ENZYMOL, V201, P414; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KENMOCHI N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P445, DOI 10.1016/0167-4781(91)90142-9; KNIGHT E, 1967, J MOL BIOL, V28, P491, DOI 10.1016/S0022-2836(67)80099-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN BI, 1994, PROTEIN EXPRES PURIF, V5, P211, DOI 10.1006/prep.1994.1033; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; MEEK DW, 1992, BIOCHEM J, V287, P1; NORGARD MV, 1980, J BIOL CHEM, V255, P7665; OGATA K, 1994, BBA-GENE STRUCT EXPR, V1218, P388, DOI 10.1016/0167-4781(94)90192-9; OGATA K, 1991, J BIOCHEM-TOKYO, V110, P1030, DOI 10.1093/oxfordjournals.jbchem.a123673; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Spedding G., 1990, RIBOSOMES PROTEIN SY; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; TAKAHASHI Y, 1981, J BIOCHEM-TOKYO, V90, P1549, DOI 10.1093/oxfordjournals.jbchem.a133624; TERAO K, 1975, BIOCHIM BIOPHYS ACTA, V402, P230, DOI 10.1016/0005-2787(75)90042-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRECO DA, 1993, CURRENT PROTOCOLS MO, V2; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W	49	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19786	19790		10.1074/jbc.270.34.19786	http://dx.doi.org/10.1074/jbc.270.34.19786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649987	hybrid			2022-12-27	WOS:A1995RQ99100019
J	HSU, HY; NICHOLSON, AC; POMERANTZ, KB; KANER, RJ; HAJJAR, DP				HSU, HY; NICHOLSON, AC; POMERANTZ, KB; KANER, RJ; HAJJAR, DP			ALTERED CHOLESTEROL TRAFFICKING IN HERPESVIRUS-INFECTED ARTERIAL CELLS - EVIDENCE FOR VIRAL PROTEIN KINASE-MEDIATED CHOLESTEROL ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; SIMPLEX VIRUS-INFECTION; RECEPTOR GENE; GROWTH-FACTOR; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CULTURED FIBROBLASTS; CYTOKINE REGULATION; LIPID-ACCUMULATION; TRANSFORMED-CELLS	Herpesvirus infection of arterial smooth muscle cells has been shown to cause cholesteryl ester (CE) accumulation. However, the effects of human herpes simplex virus type 1 (HSV-1) infection on cholesterol binding and internalization, intracellular metabolism, and efflux have not been evaluated. In addition, the effects of viral infection on signal transduction pathways that impact upon cholesterol metabolism have not been studied. We show in studies reported herein that HSV-1 infection of arterial smooth muscle cells enhances low density lipoprotein (LDL) binding and uptake which parallels an increase in LDL receptor steady state mRNA levels and transcription of the LDL receptor gene. HSV-1 also increases CE synthesis and 5-hydroxy-3-methylglutaryl-CoA reductase activity but concomitantly reduces CE hydrolysis and cholesterol efflux. Interestingly, this viral infection was associated with a time-dependent decrease in protein kinase A activity and an increase in viral-induced protein kinase (VPK) activity commensurate with the accumulation of esterified cholesterol. The relationship between increased VPK activity and alterations in CE accumulation in virally infected cells was explored using an HSV-1 VPK- mutant in which the portion of the HSV-1 genome encoding VPK had been deleted. Cholesteryl ester accumulation was significantly increased (>50-fold) in HSV-1-infected cells compared to uninfected cells. However, the HSV-1 VPK- mutant had no significant effect on CE accumulation. The relationship between VPK activity and these alterations in cholesterol metabolism was further supported by the observation that staurosporine and calphostin C (protein kinase inhibitors) reduced protein kinase activity in HSV-l-infected cells. These results suggest several potential mechanisms by which alterations in kinase activities in response to HSV-1 infection of vascular cells may alter cholesterol trafficking processes that eventually lead to CE accumulation.	CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center				Pomerantz, Kenneth/0000-0001-9443-5301	NHLBI NIH HHS [HL-45343, HL-07423, HL-46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL045343, T32HL007423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht T, 1989, Subcell Biochem, V15, P157; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; Battey, 1986, BASIC METHODS MOL BI; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; COLBRAN RJ, 1986, FEBS LETT, V201, P257, DOI 10.1016/0014-5793(86)80619-6; CUNNINGHAM C, 1992, J GEN VIROL, V73, P303, DOI 10.1099/0022-1317-73-2-303; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETINGIN OR, 1990, J LIPID RES, V31, P299; EVERETT RD, 1985, EMBO J, V4, P1973, DOI 10.1002/j.1460-2075.1985.tb03880.x; GARCIN D, 1990, EUR J BIOCHEM, V194, P279, DOI 10.1111/j.1432-1033.1990.tb19454.x; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J LIPID RES, V32, P1889; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HAJJAR DP, 1986, ARCH BIOCHEM BIOPHYS, V247, P49, DOI 10.1016/0003-9861(86)90531-X; HALEY NJ, 1980, J LIPID RES, V21, P961; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; HSU HY, 1994, J BIOL CHEM, V269, P9213; KEMP LM, 1986, NUCLEIC ACIDS RES, V14, P9261, DOI 10.1093/nar/14.23.9261; LANGELAND N, 1986, BIOCHEM J, V237, P707, DOI 10.1042/bj2370707; LEADER DP, 1988, TRENDS BIOCHEM SCI, V13, P244, DOI 10.1016/0968-0004(88)90157-0; LENG L, 1993, CANCER RES, V53, P5554; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNAB JCM, 1985, EMBO J, V4, P3223, DOI 10.1002/j.1460-2075.1985.tb04069.x; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MELNICK JL, 1983, LANCET, V2, P644; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MIDDLETON B, 1992, BIOCHEM J, V282, P853, DOI 10.1042/bj2820853; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; OFFORD EA, 1989, J VIROL, V63, P2388, DOI 10.1128/JVI.63.5.2388-2391.1989; POMERANTZ KB, 1990, BIOCHEMISTRY-US, V29, P1892, DOI 10.1021/bi00459a033; PURVES FC, 1992, J VIROL, V66, P4295, DOI 10.1128/JVI.66.7.4295-4303.1992; PURVES FC, 1991, J VIROL, V65, P5757, DOI 10.1128/JVI.65.11.5757-5764.1991; PURVES FC, 1992, P NATL ACAD SCI USA, V89, P7310, DOI 10.1073/pnas.89.16.7310; PURVES FC, 1986, J GEN VIROL, V67, P1049, DOI 10.1099/0022-1317-67-6-1049; PURVES FC, 1987, J VIROL, V61, P2896, DOI 10.1128/JVI.61.9.2896-2901.1987; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUT RW, 1983, ATHEROSCLEROSIS, V46, P13, DOI 10.1016/0021-9150(83)90159-4; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423	62	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19630	19637		10.1074/jbc.270.33.19630	http://dx.doi.org/10.1074/jbc.270.33.19630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642651	hybrid			2022-12-27	WOS:A1995RP70300067
J	NAKAI, H; KRUKLITIS, R				NAKAI, H; KRUKLITIS, R			DISASSEMBLY OF THE BACTERIOPHAGE-MU TRANSPOSASE FOR THE INITIATION OF MU DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO TRANSPOSITION; ESCHERICHIA-COLI; B-PROTEIN; PHAGE-MU; ENZYMATIC REPLICATION; STRAND CLEAVAGE; COMPLEXES; TRANSPOSOSOMES; AMPLIFICATION; PURIFICATION	Upon catalyzing strand transfer, the Mu transposase (MuA) remains tightly bound to the resulting transposition intermediate, the strand transfer complex (STC), and poses an impediment to host replication proteins. Additional host factors, which can be resolved into two fractions (Mu Replication Factor alpha and beta; MRF alpha and MRF beta), are required to disassemble the MuA complex and initiate DNA synthesis. MRF alpha modifies the protein content of the STC, removing MuA from the DNA in the process. The MRF beta promotes initiation of Mu DNA synthesis on the STC altered by the MRF alpha. These host factors cannot promote initiation of Mu DNA synthesis if the STC is damaged by partial proteolysis. Moreover, the mutant protein MuA211 cannot be removed from the STC by MRF alpha, blocking initiation of DNA synthesis. These results indicate that MuA in the STC plays a critical function in beginning a sequence of events leading to the establishment of a Mu replication fork.			NAKAI, H (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007, USA.				NIGMS NIH HHS [GM49649] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1994, CELL, V39, P387; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; KOCH C, 1987, PHAGE MU, P75; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAKI H, 1988, J BIOL CHEM, V263, P6570; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAI H, 1993, J BIOL CHEM, V268, P23997; RESIBOIS A, 1984, PROTEINS INVOLVED DN, P69; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9	34	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19591	19598		10.1074/jbc.270.33.19591	http://dx.doi.org/10.1074/jbc.270.33.19591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642646	hybrid			2022-12-27	WOS:A1995RP70300062
J	OGASAWARA, Y; VOELKER, DR				OGASAWARA, Y; VOELKER, DR			THE ROLE OF THE AMINO-TERMINAL DOMAIN AND THE COLLAGENOUS REGION IN THE STRUCTURE AND THE FUNCTION OF RAT SURFACTANT PROTEIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LUNG; PHOSPHATIDYLINOSITOL; PURIFICATION; CONGLUTININ; SPECIFICITY; CP4	Surfactant protein D (SP-D) is a member of the C-type lectin superfamily with four distinct structural domains: an amino terminus involved in forming intermolecular disulfides, a collagen-like domain, a neck region, and a carbohydrate recognition domain, A collagen domain deletion mutant (CDM) of SP-D was created by site-directed mutagenesis, A second variant lacking both the amino-terminal region and the collagen-like domain was generated by collagenase treatment and purification of the collagenase-resistant fragment (CRF), The CDM expressed in CHO-K1 cells formed the covalent trimers, but not the noncovalent dodecamers, typical of native SP-D, The CRF derived from recombinant SP-D formed only monomers. The CDM bound mannose-Sepharose and phosphatidylinositol (PI) as well as SP-D, but the binding to mannosyl bovine serum albumin and glucosylceramide was diminished by approximately 60%. The CRF displayed weak binding to mannose-Sepharose and PI and essentially no binding to mannosyl bovine serum albumin and glucosylceramide. Both SP-D and CDM altered the self-aggregation of PI-containing liposomes. SP-D reduced the density and the light scattering properties of PI aggregates. These results demonstrate that the collagen-like domain is required for dodecamer but not covalent trimer formation of SP-D and plays an important, but not essential, role in the interaction of SP-D with PI and GlcCer. Removal of the amino-terminal domain of SP-D along with the collagen-like domain diminishes PI binding and effectively eliminates GlcCer binding.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,ANNA PERAHIA ADATTO CLIN RES CTR,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R01HL045286, R37HL029891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29891, HL45286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1994, J BIOL CHEM, V269, P15808; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINLE JE, 1993, J BIOL CHEM, V268, P364; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853	27	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19052	19058		10.1074/jbc.270.32.19052	http://dx.doi.org/10.1074/jbc.270.32.19052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642568	hybrid			2022-12-27	WOS:A1995RN95400056
J	ROEBUCK, KA; RAHMAN, A; LAKSHMINARAYANAN, V; JANAKIDEVI, K; MALIK, AB				ROEBUCK, KA; RAHMAN, A; LAKSHMINARAYANAN, V; JANAKIDEVI, K; MALIK, AB			H2O2 AND TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) GENE-TRANSCRIPTION THROUGH DISTINCT CIS-REGULATORY ELEMENTS WITHIN THE ICAM-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; PEROXIDE-INDUCED INCREASE; YA SUBUNIT GENE; NF-KAPPA-B; HYDROGEN-PEROXIDE; BINDING-ACTIVITY; INTACT-CELLS; NEUTROPHILS; INDUCTION; INVITRO	We investigated the mechanisms by which H2O2 increases intercellular adhesion molecule 1 (ICAM-1; CD54) expression in endothelial cells. The H2O2-induced increase in ICAM-1 mRNA was inhibited by actinomycin D, by the antioxidant N-acetylcysteine, and by 3-aminobenzamide (which blocks oxidant-induced AP-1 activity), but not by pyrrolidine dithiocarbamate (which blocks oxidant-induced NF-kappa B activity). Nuclear run-on and transient transfections of ICAM-1 promoter constructs indicated that H2O2 stimulated ICAM-1 gene transcription by activation of a distinct region of the ICAM-1 promoter. The H2O2-responsive element was localized to sequences between -981 and -769 (relative to the start codon). Located within this region are two 16-base pair repeats, each containing binding sites for the transcription factors AP-1 and Ets. A similar composite AP-1/Ets element isolated from the macrophage scavenger receptor gene conferred H2O2 responsiveness to a minimal promoter. Mutation of the 16-base pair repeats within the ICAM-1 promoter prevented H2O2-induced DNA binding activity, and their deletion abrogated the H2O2-induced transcriptional activity. In contrast, TNF alpha induced ICAM-1 transcription via activation of promoter sequences between -393 and -176, a region with C/EBP and NF-kappa B binding sites. The results indicate that H2O2 activates ICAM-1 transcription through AP-1/Ets elements within the ICAM-1 promoter, which are distinct from NF-kappa B-mediated ICAM-1 expression induced by TNF alpha.	RUSH MED COLL,RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612; ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208	Rush University; Albany Medical College	ROEBUCK, KA (corresponding author), RUSH MED COLL,RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PHARMACOL,1750 W HARRISON ST,CHICAGO,IL 60612, USA.			Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL45638, HL46350, HL27016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046350, R37HL027016, R01HL045638, R01HL027016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMSTAD PA, 1992, CANCER RES, V52, P3952; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BERGELSON S, 1994, CANCER RES, V54, P36; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; DUSTIN ML, 1988, J IMMUNOL, V137, P245; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IKEDA M, 1994, J INVEST DERMATOL, V103, P791, DOI 10.1111/1523-1747.ep12413176; KUKIELKA GL, 1993, J CLIN INVEST, V92, P1504, DOI 10.1172/JCI116729; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LO SK, 1993, AM J PHYSIOL, V264, pL406; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; NAKAMURA K, 1993, ONCOGENE, V6, P3133; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOURSHARGH S, 1990, ENDOTHELIUM INTRO CU, P171; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; ROEBUCK KA, 1993, J CLIN INVEST, V92, P1336, DOI 10.1172/JCI116707; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SELLAK H, 1994, BLOOD, V83, P2669; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIFLINGERBIRNBO.A, 1992, LAB INVEST, V67, P24; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12020; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P60330; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	45	237	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18966	18974		10.1074/jbc.270.32.18966	http://dx.doi.org/10.1074/jbc.270.32.18966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642556	hybrid			2022-12-27	WOS:A1995RN95400044
J	SMITH, ER; MERRILL, AH				SMITH, ER; MERRILL, AH			DIFFERENTIAL ROLES OF DE-NOVO SPHINGOLIPID BIOSYNTHESIS AND TURNOVER IN THE BURST OF FREE SPHINGOSINE AND SPHINGANINE, AND THEIR 1-PHOSPHATES AND N-ACYL-DERIVATIVES, THAT OCCURS UPON CHANGING THE MEDIUM OF CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; LONG-CHAIN BASES; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPASE-D; RAT-LIVER; HUMAN-NEUTROPHILS; PHOSPHATIDATE PHOSPHOHYDROLASE; STEREOSELECTIVE SYNTHESIS; SUBCELLULAR-LOCALIZATION	Long-chain (sphingoid) bases are highly bioactive intermediates of sphingolipid metabolism, yet relatively little is known about how the amounts of these compounds are regulated, This study used J774A.1 cells to characterize the ''burst'' of sphinganine and sphingosine, or the transient increase of up to 10-fold in long-chain base mass, that occurs when cells in culture are changed to fresh medium, The increase in sphinganine was attributable to de novo sphingolipid biosynthesis because: 1) there is increased incorporation of [H-3]serine and [H-3]palmitate into sphinganine; 2) the incorporation of [H-3]serine was equivalent to the increase in sphinganine mass; 3) beta-F-alanine, an inhibitor of serine palmitoyltransferase, blocked the sphinganine burst; 4) the magnitude of the burst depended on the concentration of serine in the medium, which is known to affect long chain base biosynthesis; and 5) the appearance of sphinganine was relatively unaffected by lyso-osmotrophic agents (NH4Cl and chloroquine) that blocked sphingolipid hydrolysis in these cells, In contrast, the sphingosine burst arose mainly from turnover of complex sphingolipids because no incorporation of [H-3]serine or [H-3]palmitate into sphingosine was detected; sphingosine mass was not affected by beta-F-alanine or the serine concentration; and, the burst could be followed by the release of sphingosine and ceramide from complex sphingolipids (especially sphingomyelin) in a process that was inhibited by NH4Cl and chloroquine, Additionally, the fate of these long-chain bases differed: sphinganine was mostly (80-85%) acylated and incorporated into dihydroceramide and complex sphingolipids, whereas most of the sphingosine (70%) was phosphorylated and degraded, with incorporation of the resulting ethanolamine phosphate into phosphatidylethanolamine. Sphinganine, however, could be diverted toward degradation by adding an inhibitor of N-acylation (fumonisin B-1), In accounting for the elevation in sphingosine and sphinganine after cells are changed to new medium, these studies have provided fundamental information about long-chain base metabolism. The existence of differential changes in sphinganine and sphingosine, as well as their 1-phosphates and N-acyl-derivatives, should be considered when evaluating the roles of sphingolipid metabolites in cell regulation,	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM46368, GM08367, GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM033369, R01GM046368] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1967, J BIOL CHEM, V242, P1895; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BRAUN PE, 1970, J BIOL CHEM, V245, P335; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO R, 1992, J BIOL CHEM, V267, P23459; COOKE JWB, 1993, TETRAHEDRON, V49, P7955, DOI 10.1016/S0040-4020(01)88019-4; DECKER L, 1972, WORTHINGTON ENZYME M; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DIMARI SJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P553, DOI 10.1016/0003-9861(71)90240-2; FUTERMAN AH, 1994, CURR TOP MEMBR, V40, P93, DOI 10.1016/S0070-2161(08)60978-8; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P295; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P301; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIRSCHBERG CB, 1970, J BIOL CHEM, V245, P3084; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KISS Z, 1991, EUR J BIOCHEM, V197, P785, DOI 10.1111/j.1432-1033.1991.tb15972.x; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; KISS Z, 1991, LIPIDS, V26, P321, DOI 10.1007/BF02537144; KOBAYASHI T, 1988, EUR J BIOCHEM, V171, P747; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1994, CURR TOP MEMBR, V40, P361, DOI 10.1016/S0070-2161(08)60988-0; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1992, POLYUNSATURATED FATT, V28, P41; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MORRELL P, 1970, J BIOL CHEM, V245, P342; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OISHI K, 1990, J BIOL CHEM, V265, P70; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONG DE, 1973, J BIOL CHEM, V248, P3884; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SARMIENTOS F, 1985, EUR J BIOCHEM, V146, P59, DOI 10.1111/j.1432-1033.1985.tb08619.x; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH ER, 1993, FASEB J, V7, pA173; SMITH ER, 1992, FASEB J, V6, pA968; SMITH ER, 1994, THESIS EMORY U ATLAN; SMITH ER, 1991, FASEB J, V5, pA1836; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; SU Y, 1994, J BIOL CHEM, V269, P16512; SWEELEY CC, 1991, BIOCH LIPIDS LIPOPRO, P327; Thudichum J.L.W., 1884, TREATISE CHEM CONSTI; VANDENEIJNDEN DH, 1971, Z PHYSIOL CHEM, V352, P1601; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; WANG E, 1991, J BIOL CHEM, V266, P14486; WARDEN LA, 1990, FASEB J, V4, pA1910; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WU WI, 1993, J BIOL CHEM, V268, P13830; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	76	132	135	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18749	18758		10.1074/jbc.270.32.18749	http://dx.doi.org/10.1074/jbc.270.32.18749			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642524	hybrid			2022-12-27	WOS:A1995RN95400011
J	BUTKERAIT, P; ZHENG, YJ; HALLAK, H; GRAHAM, TE; MILLER, HA; BURRIS, KD; MOLINOFF, PB; MANNINGS, DR				BUTKERAIT, P; ZHENG, YJ; HALLAK, H; GRAHAM, TE; MILLER, HA; BURRIS, KD; MOLINOFF, PB; MANNINGS, DR			EXPRESSION OF THE HUMAN 5-HYDROXYTRYPTAMINE(1A) RECEPTOR IN SF9 CELLS - RECONSTITUTION OF A COUPLED PHENOTYPE BY COEXPRESSION OF MAMMALIAN G-PROTEIN SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; INFECTED INSECT CELLS; TERNARY COMPLEX MODEL; GTP-BINDING PROTEINS; ALPHA-SUBUNITS; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; 5-HT1A RECEPTOR; GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION	The possibility that Spodoptera frugiperda (Sf9) cells can provide an intact cell setting for reconstitution of the human 5-hydroxytryptamine(1A) (5-HT1A) receptor with mammalian G protein subunits was explored. The 5-HT1A receptor was found to assume an uncoupled phenotype when expressed alone in Sf9 cells at relatively high levels (5-34 pmol of receptor/mg of membrane protein), i.e. agonist-binding to the receptor was characterized by a relatively high K-d and an insensitivity to GTP, Go-expression of the receptor with members of the alpha(i) ''family'' together with various combinations of beta(1) and gamma subunits increased the affinity for agonists to that ob served for the coupled form of receptor in mammalian cells, concomitant with conferrance of guanosine 5'-(beta,gamma-imino)triphosphate sensitivity. The agonists employed were [H-3]8-hydroxy-N,N-dipropyl-2-aminotetralin ([H-3] 8-OH-DPAT) and [I-125]R(+)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin ([I-125]8-OH-PI-PAT), The binding of an antagonist, [I-125]4-(2'-methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido]ethyl] piperazine ([I-125]p-MPPI), was unaffected by co-expression of G protein subunits. Both alpha and beta gamma subunits were required for optimal coupling. No differences were evident among alpha(i1), alpha(i2), alpha(i3), alpha(o), and alpha(z) when expressed with beta(1) gamma(2) in this regard, nor among most permutations of beta(1) gamma subunits when expressed with alpha(i1), (beta(1) gamma(2) approximate to beta(1) gamma(3) approximate to beta(1) gamma(5) > beta(1) gamma(2)). alpha(s) and alpha(q) expressed with beta(1) gamma(2) did not participate in coupling, These data support the conclusion that normal interactions between a mammalian receptor and a select array of G proteins can be established in intact Sf9 cells, and extend previous observations of 5-HT1A receptor coupling to G(o) and the pertussis toxin-insensitive G protein G(z).	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009245] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH48125] Funding Source: Medline; NINDS NIH HHS [NS09245] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOUNDY VA, 1993, J PHARMACOL EXP THER, V264, P1002; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHAMBERLAIN J, 1993, J PHARMACOL EXP THER, V266, P618; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEMONTIGNY C, 1984, NEUROPHARMACOLOGY, V23, P1511, DOI 10.1016/0028-3908(84)90095-9; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HALL MD, 1985, J NEUROCHEM, V44, P1685, DOI 10.1111/j.1471-4159.1985.tb07155.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HINTON DR, 1990, J NEUROSCI, V10, P2763; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; INNIS RB, 1987, EUR J PHARMACOL, V143, P195, DOI 10.1016/0014-2999(87)90533-4; INNIS RB, 1988, BRAIN RES, V459, P27, DOI 10.1016/0006-8993(88)90282-X; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KARSCHIN A, 1991, P NATL ACAD SCI USA, V88, P5694, DOI 10.1073/pnas.88.13.5694; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KUNG HF, 1994, LIFE SCI, V55, P1459, DOI 10.1016/0024-3205(94)00686-5; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAW SF, 1991, J BIOL CHEM, V266, P17885; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YF, 1991, J BIOL CHEM, V266, P23689; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NENONENE EK, 1994, J NEUROCHEM, V62, P1822; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1994, EUR J PHARM-MOLEC PH, V268, P43, DOI 10.1016/0922-4106(94)90118-X; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RAYMOND JR, 1994, BIOCHEMISTRY-US, V32, P11064; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLEGEL JR, 1986, BIOCHEM PHARMACOL, V35, P1943, DOI 10.1016/0006-2952(86)90725-2; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; UEDA N, 1994, J BIOL CHEM, V269, P4388; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WOOLKALIS MJ, 1986, J BIOL CHEM, V261, P3408; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; YOCCA FD, 1994, ANN NY ACAD SCI, V600, P212; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484; ZHUANG ZP, 1994, J MED CHEM, V37, P1406, DOI 10.1021/jm00036a003; ZHUANG ZP, 1993, J MED CHEM, V36, P3161, DOI 10.1021/jm00073a016	66	147	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18691	18699		10.1074/jbc.270.31.18691	http://dx.doi.org/10.1074/jbc.270.31.18691			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629202	hybrid			2022-12-27	WOS:A1995RM64200084
J	OGATA, Y; ITOH, Y; NAGASE, H				OGATA, Y; ITOH, Y; NAGASE, H			STEPS INVOLVED IN ACTIVATION OF THE PRO-MATRIX METALLOPROTEINASE-9 (PROGELATINASE-B)-TISSUE INHIBITOR OF METALLOPROTEINASES-1 COMPLEX BY 4-AMINOPHENYLMERCURIC ACETATE AND PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 72-KDA GELATINASE; 72 KDA PROGELATINASE; C-TERMINAL DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; INTERSTITIAL COLLAGENASE; ENZYMATIC-PROPERTIES; FIBROSARCOMA CELLS; CYSTEINE SWITCH; TIMP-2	The precursor of matrix metalloproteinase 9 (pro-MMP-9, progelatinase B) noncovalently binds to tissue inhibitor of metalloproteinases (TIMP)-1 through the C-terminal domain of each molecule. We have isolated the proMMP-9 . TIMP-1 complex from the medium of human fibrosarcoma HT-1080 cells and investigated the activation processes of the complex by 4-aminophenylmercuric acetate, trypsin, and matrix metalloproteinase 3 (MMP-3, stromelysin 1). The treatment of the proMMP-9 . TIMP-1 complex with 4-aminophenylmercuric acetate or trypsin converts proMMP-9 to lower molecular weight species corresponding to active forms, but no gelatinolytic activity is detected. The lack of enzymic activity results from binding of TIMP-1 to the activated MMP-9. The treatment of the proMMP-9 . TIMP-1 complex with a possible physiological proMMP-9 activator, MMP-3, does not reveal any gelatinolytic activity unless the molar ratio of MMP-3 to the complex exceeds 1. This is due to the inhibition of MMP-3 by TIMP-1 forming a ternary proMMP-9 . TIMP-1 . MMP-3 complex. The formation of the ternary complex weakens the interaction between proMMP-9 and TIMP-1, resulting in partial dissociation of the complex into proMMP-9 and the TIMP-1 . MMP-3 complex. When MMP-3 is in excess, the propeptide is completely processed, and the full activity of MMP-9 is detected. Similarly, the proMMP-9 . TIMP-1 complex inhibits MMP-1 (interstitial collagenase) and in turn renders the proMMP-9 activable by a catalytic amount of MMP-3. These results suggest that formation of the proMMP-9 . TIMP-1 complex regulates extracellular matrix breakdown in tissue by switching the predominant MMP activity from one type to another.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center				Itoh, Yoshifumi/0000-0002-2128-2823	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994, R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994, AR39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CURRY VA, 1992, BIOCHEM J, V285, P143, DOI 10.1042/bj2850143; DAVIS GE, 1991, ARCH BIOCHEM BIOPHYS, V286, P551, DOI 10.1016/0003-9861(91)90078-W; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; KOLKENBROCK H, 1994, BIOL CHEM H-S, V375, P589; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; MOLL UM, 1990, CANCER RES, V50, P6162; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1993, J BIOL CHEM, V268, P15453; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEI DQ, 1994, J BIOL CHEM, V269, P25849; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STETLERSTEVENSO.WG, 1993, FASEB J, V7, P14334; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	169	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18506	18511		10.1074/jbc.270.31.18506	http://dx.doi.org/10.1074/jbc.270.31.18506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629179	hybrid			2022-12-27	WOS:A1995RM64200056
J	DUNCAN, PI; HOWELL, BW; MARIUS, RM; DRMANIC, S; DOUVILLE, EMJ; BELL, JC				DUNCAN, PI; HOWELL, BW; MARIUS, RM; DRMANIC, S; DOUVILLE, EMJ; BELL, JC			ALTERNATIVE SPLICING OF STY, A NUCLEAR DUAL-SPECIFICITY KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; SIGNAL TRANSDUCTION; SKELETAL-MUSCLE; MESSENGER-RNA; RECEPTOR; THREONINE; GENE; PHOSPHOTYROSINE; VARIANTS	The LAMMER subfamily of kinases has been conserved throughout evolution, and its members are thought to play important roles in the regulation of cellular growth and differentiation programs. STY is a murine LAMMER kinase which has been implicated in the control of PC12 cell differentiation. Multiple transcripts are derived from the Sty gene, and their relative abundance is developmentally regulated, Alternative splicing of the primary Sty transcript generates mRNAs encoding full-length catalytically active (STY) and truncated, kinase-deficient polypeptides. Both STY and its truncated isoform, STYT, are localized in the nucleus and are capable of heterodimerizing. We also demonstrate that STY functions as a dual specificity kinase in mammalian cells.	OTTAWA REG CANC CTR,CANC RES GRP,OTTAWA,ON K1H 8L6,CANADA	University of Ottawa; Ottawa Hospital Research Institute				Howell, Brian/0000-0002-0204-0773				BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LEWIN B, 1987, GENES; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT REM, 1990, MOL ENDOCRINOL, V4, P812, DOI 10.1210/mend-4-6-812; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160	32	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21524	21531		10.1074/jbc.270.37.21524	http://dx.doi.org/10.1074/jbc.270.37.21524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665564	hybrid			2022-12-27	WOS:A1995RU75700019
J	KOJIMA, T; OHEDA, M; HATTORI, K; TANIGUCHI, Y; TAMURA, M; OCHI, N; YAMAGUCHI, N				KOJIMA, T; OHEDA, M; HATTORI, K; TANIGUCHI, Y; TAMURA, M; OCHI, N; YAMAGUCHI, N			MOLECULAR-CLONING AND EXPRESSION OF MEGAKARYOCYTE POTENTIATING FACTOR CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; HUMAN INTERFERON-GAMMA; AMINO-ACID-SEQUENCE; GROWTH-FACTOR; PRECURSOR; PROTEIN; CELLS	The human megakaryocyte potentiating factor (hMPF) has been previously purified from a culture supernatant of human pancreatic cancer cells HPC-Y5 (Yamaguchi, N., Hattori, K., Oh-eda, M., Kojima, T., Imai, N., and Ochi, N. (1994) J. Biol. Chem. 269, 805-808). We have now isolated hMPF cDNA from a HPC-Y5 cDNA library using polymerase chain reaction and plaque hybridization methods. The hMPF cDNA encodes a polypeptide consisting of 622 amino acids, including a signal peptide of 33 amino acids, and with a deduced molecular mass of 68 kDa, although HPC-Y5 cells secrete a 33-kDa form of hMPF. Human MPF does not show any significant homology with other previously described sequences. The cDNA was expressed in COS-7 and Chinese hamster ovary (CHO) cells, and megakaryocyte potentiating activity was detected in their culture supernatant. The COS-7 cells secreted only a 33-kDa recombinant hMPF, whereas an additional 30-kDa form was detected in the culture medium of CHO cells. The 33-kDa rhMPF purified from CHO cells showed megakaryocyte potentiating activity, but not the purified 30-kDa rhMPF. The difference in structure and activity between the 33- and 30-kDa forms of hMPF was ascribed to the existence in the 33-kDa form of the C-terminal 25 amino acid residues.	KYOTO PREFECTURAL UNIV MED,NEUROL DIS & GERIAT RES INST,DEPT CELL BIOL,KAMIGYO KU,KYOTO 602,JAPAN; CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,SHIZUOKA 412,JAPAN	Kyoto Prefectural University of Medicine; Chugai Pharmaceutical Co., Ltd.; Roche Holding								BENDIG MM, 1992, Patent No. 19759; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; GORDON MS, 1992, BLOOD, V80, P302; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1993, J BIOL CHEM, V268, P22414; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; METCALF D, 1975, P NATL ACAD SCI USA, V72, P1744, DOI 10.1073/pnas.72.5.1744; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAN YCE, 1987, EUR J BIOCHEM, V166, P145, DOI 10.1111/j.1432-1033.1987.tb13494.x; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SLODOWSKI O, 1991, EUR J BIOCHEM, V202, P1133, DOI 10.1111/j.1432-1033.1991.tb16481.x; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILLIAMS N, 1981, BLOOD, V57, P157; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	24	97	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21984	21990		10.1074/jbc.270.37.21984	http://dx.doi.org/10.1074/jbc.270.37.21984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665620	hybrid			2022-12-27	WOS:A1995RU75700084
J	OSHIMA, H; SZAPARY, D; SIMONS, SS				OSHIMA, H; SZAPARY, D; SIMONS, SS			THE FACTOR-BINDING TO THE GLUCOCORTICOID MODULATORY ELEMENT OF THE TYROSINE AMINOTRANSFERASE GENE IS A NOVEL AND UBIQUITOUS HETEROMERIC COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-A; TISSUE-SPECIFIC EXTINGUISHER; SEQUENCE-SPECIFIC BINDING; HEPATOMA-CELL LINES; TRANSCRIPTION FACTOR; AGONIST ACTIVITY; PROGESTERONE-RECEPTOR; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; RESPONSIVE ELEMENTS	Glucocorticoid induction of the tyrosine aminotransferase gene deviates from that of many glucocorticoid-responsive genes by having a lower EC(50) and displaying more agonist activity with a given antiglucocorticoid. A cis acting element, located 3646 base pairs upstream of the start of tyrosine aminotransferase gene transcription, has been found to be sufficient to reproduce these variations with heterologous genes and promoters (Oshima, H., and Simons, S. S., Jr. (1992) Mol. Endocrinol. 6, 416-428). This element has been called a glucocorticoid modulatory element, or GME. Others have called this sequence a cyclic AMP-responsive element (CRE) due to the binding of the cyclic AMP response element binding protein (CREB). We now report the partial purification and characterization of two new proteins (GMEB1 and -2) of 88 and 67 kDa that bind to the GME/ CRE as a heteromeric complex. This purification was followed by the formation of a previously characterized, biologically relevant band in gel shift assays. By several biochemical criteria, the GMEBs differed from many of the previously described CREB/CREM/ATF family members. Partial peptide sequencing revealed that the sequences of these two proteins have not yet been described. Size exclusion chromatography and molecular weight measurements of the gel-shifted band demonstrated that the GMEBs bound to the GME as a macromolecular complex of about 550 kDa that could be dissociated by deoxycholate. Similar experiments showed that CREB bound to the GME as heteromeric complexes of about 310 and 360 kDa. As determined from gel shift assays, GMEB1 and -2 are not restricted to rat liver cells but appear to be ubiquitous. Thus, these novel GMEBs may participate in a similar modulation of other glucocorticoid-inducible genes in a variety of cells.	NIDDK,CELLULAR & MOLEC BIOL LAB,STEROID HORMONES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1993, TRANSCRIPTION FACTOR, P49; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HARRISON SC, 1991, NATURE, V358, P715; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAZMI SMI, 1993, ENDOCRINOLOGY, V133, P1230, DOI 10.1210/en.133.3.1230; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LALLI E, 1994, J BIOL CHEM, V269, P17359; Maniatis T, 1989, DECONTAMINATION DILU; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MILLER PA, 1988, ENDOCRINOLOGY, V122, P2990, DOI 10.1210/endo-122-6-2990; MIYASHITA Y, 1993, J STEROID BIOCHEM, V46, P309, DOI 10.1016/0960-0760(93)90220-Q; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NING YM, 1993, J BIOL CHEM, V268, P6073; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; REIK A, 1994, MOL ENDOCRINOL, V8, P490, DOI 10.1210/me.8.4.490; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1988, J STEROID BIOCHEM, V31, P1, DOI 10.1016/0022-4731(88)90198-7; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1987, STEROID STEROL HORMO, P251; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WASNER G, 1987, MOL ENDOCRINOL, V1, P109, DOI 10.1210/mend-1-1-109; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437	53	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21893	21901		10.1074/jbc.270.37.21893	http://dx.doi.org/10.1074/jbc.270.37.21893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665613	hybrid			2022-12-27	WOS:A1995RU75700073
J	SHAW, LC; LEWIN, AS				SHAW, LC; LEWIN, AS			PROTEIN-INDUCED FOLDING OF A GROUP-I INTRON IN CYTOCHROME-B PRE-MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC RNA MOLECULE; RIBOSOMAL-RNA; NEUROSPORA MITOCHONDRIA; TETRAHYMENA RIBOZYME; MESSENGER-RNA; SEQUENCE; GENE; EXCISION; BINDING; CORE	Some group I introns have been shown to be self-splicing in vitro, but perhaps all require proteins for splicing in vivo, Sequence differences affect the stability of secondary structures and may explain why some group I introns function efficiently without protein cofactors while others require them. The terminal intron of the cytochrome b pre-mRNA from yeast mitochondria needs a nucleus encoded protein for splicing, even though it splices autocatalytically in high salt in vitro. This system has the advantage that the protein is specific for this intron, and yet the structure of the catalytically active RNA can be studied in its absence, We have modified the intron by chemical and enzymatic treatment in the presence and absence of the protein to determine the impact of the protein on the secondary and tertiary structures of the intron, We found protein-induced formation of secondary and tertiary structures within the intron, and the same structures also form in high salt autocatalytic conditions, We have also studied UV cross-links to determine those bases of the intron that interact directly with the protein and found that the protein contacts the intron most intimately at the structures denoted P1, L2, P4, and P6a.	UNIV FLORIDA, COLL MED, DEPT MOLEC GENET & MICROBIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida				Lewin, Alfred/0000-0002-4192-9727	NIGMS NIH HHS [R01 GM12228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CHRISTIANSEN J, 1988, METHOD ENZYMOL, V164, P456; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; GUO QB, 1991, J BIOL CHEM, V266, P1809; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HILL J, 1985, J BIOL CHEM, V260, P3235; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PUGLISI JD, 1992, STRUCTURAL TOOLS ANA, P269; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; STERN S, 1988, METHOD ENZYMOL, V164, P481; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERHORST G, 1985, CELL, V40, P759, DOI 10.1016/0092-8674(85)90335-6; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WILLIAMS GJB, 1977, J AM CHEM SOC, V99, P3150, DOI 10.1021/ja00451a047	32	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21552	21562		10.1074/jbc.270.37.21552	http://dx.doi.org/10.1074/jbc.270.37.21552			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665568	hybrid			2022-12-27	WOS:A1995RU75700023
J	TAIT, JF; ENGELHARDT, S; SMITH, C; FUJIKAWA, K				TAIT, JF; ENGELHARDT, S; SMITH, C; FUJIKAWA, K			PROUROKINASE-ANNEXIN-V CHIMERAS - CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; SINGLE-CHAIN UROKINASE; ESCHERICHIA-COLI; PLASMINOGEN-ACTIVATOR; PLATELET-AGGREGATION; PHOSPHOLIPID BINDING; CLOT LYSIS; PHOSPHATIDYLSERINE; EXPOSURE; CONJUGATION	Annexin V is a human protein that binds with high affinity to the abundant phosphatidylserine molecules exposed on activated platelets and accumulates selectively in thrombi after intravenous administration in animal models of arterial thrombosis. We designed two chimeras that use annexin V as a means to target thrombolytic agents to platelet-containing thrombi: prourokinase (1-411)-annexin V (1-320); and prourokinase (144-411)-annexin V (1-320) (amino acid numbers of parent proteins given in parentheses). Chimeras were produced by cytoplasmic expression in Escherichia coli, refolded, and purified in single-chain form. Both chimeras had the same specific activity as annexin V in binding to cell membranes containing exposed phosphatidylserine. After activation with plasmin, both chimeras had specific amidolytic activity similar to that of urokinase. Both chimeras activated plasminogen in vitro with kinetic parameters similar to those for urokinase, and both showed full activity compared to urokinase in an assay of clot lysis in vitro. This study shows the feasibility of producing chimeric plasminogen activators in which annexin V provides the thrombus-targeting component; although not yet tested in vivo, such chimeras may have advantages over antibody-based targeting agents.	UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	TAIT, JF (corresponding author), UNIV WASHINGTON, DEPT LAB MED, HLTH SCI RM NW-120, BOX 357110, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [HL-47151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BEVERS EM, 1991, BLOOD REV, V5, P147; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BODE C, 1991, CIRCULATION, V84, P805, DOI 10.1161/01.CIR.84.2.805; BODE C, 1990, CIRCULATION, V81, P1974, DOI 10.1161/01.CIR.81.6.1974; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; COOKSON BT, 1994, GENOMICS, V20, P463, DOI 10.1006/geno.1994.1201; DEBONO D, 1994, HAEMOSTASIS THROMBOS, P1459; DEWERCHIN M, 1991, BLOOD, V78, P1005; FADOK VA, 1992, J IMMUNOL, V148, P2207; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOLVOET P, 1993, BLOOD, V81, P696; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; LIJNEN HR, 1994, HAEMOSTASIS THROMBOS, P625; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUNGE MS, 1991, P NATL ACAD SCI USA, V88, P10337, DOI 10.1073/pnas.88.22.10337; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sambrook J, 1989, MOL CLONING LABORATO; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; STRATTON JR, 1995, IN PRESS CIRCULATION; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGIMURA M, 1994, BLOOD COAGUL FIBRIN, V5, P365; TAIT JF, 1994, THROMB RES, V75, P491, DOI 10.1016/0049-3848(94)90224-0; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; TAIT JF, 1994, J LAB CLIN MED, V123, P741; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008	41	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21594	21599		10.1074/jbc.270.37.21594	http://dx.doi.org/10.1074/jbc.270.37.21594			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665573	hybrid			2022-12-27	WOS:A1995RU75700028
J	HOWARD, PW; MAURER, RA				HOWARD, PW; MAURER, RA			A COMPOSITE ETS/PIT-1 BINDING-SITE IN THE PROLACTIN GENE CAN MEDIATE TRANSCRIPTIONAL RESPONSES TO MULTIPLE SIGNAL-TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; CELL-SPECIFIC EXPRESSION; RAT GROWTH-HORMONE; SYNERGISTIC INTERACTIONS; PROXIMAL REGION; PHORBOL ESTER; FACTOR PIT-1; PITUITARY; PROMOTER	Binding sites for the tissue-specific transcription factor, Pit-1, are required for basal and hormonally induced prolactin gene transcription, Although Pit-1 is phosphorylated in response to several signaling pathways, the mechanism by which Pit-1 contributes to hormonal induction of gene transcription has not been defined, Recent reports suggest that phosphorylation of Pit-1 may not be required for hormonal regulation of the prolactin promoter, Analysis of the contribution of individual Pit-1 binding sites has been complicated due to the fact that some of the elements appear to be redundant, To better understand the role of Pit-1 sites in mediating hormonal regulation of the prolactin gene, we have performed enhancer tests using the three most proximal Pit-1 binding sites of the rat prolactin gene which are designated the 1P, 2P, and 3P sites. The results demonstrate that multimers of the 3P Pit-1 binding site are much more responsive to several hormonal and intracellular signaling pathways than multimers of the 1P or 2P sites. The 3P DNA element was found to contain a consensus binding site for the Ets family of proteins. Mutation of the Ets binding site greatly decreased the ability of epidermal growth factor, phorbol esters, Ras, or the Raf kinase to induce reporter gene activity, Mutation of the Ets site had little effect on basal enhancer activity, In contrast, mutation of the consensus Pit-1 binding site in the 3P element essentially abolished all basal enhancer activity, Overexpression of Ets-1 in GH(3) pituitary cells enhanced both basal and Ras induced activity from the 3P enhancer, These data describe a composite element in the prolactin gene containing binding sites for two different factors and the studies suggest a mechanism by which Ets proteins and Pit-1 functionally cooperate to permit transcriptional regulation by different signaling pathways.	OREGON HLTH SCI UNIV,DEPT DEV & CELL BIOL,PORTLAND,OR 97201; UNIV IOWA,MOLEC BIOL PHD PROGRAM,IOWA CITY,IA 52242	Oregon Health & Science University; University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUTIERREZHARTMA.A, 1994, MOL ENDOCRINOL, V8, P1447; GUTIERREZHARTMANN, 1987, P NATL ACAD SCI USA, V84, P5211; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HOWARD PW, 1994, J BIOL CHEM, V269, P28662; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KIM KE, 1988, MOL ENDOCRINOL, V3, P1374; KIM MK, 1993, J BIOL CHEM, V268, P23366; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STANLEY F, 1988, J BIOL CHEM, V263, P13444; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; VOSS JWL, 1992, GENE DEV, V5, P1309; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	73	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20930	20936		10.1074/jbc.270.36.20930	http://dx.doi.org/10.1074/jbc.270.36.20930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673116	hybrid			2022-12-27	WOS:A1995RU05400013
J	IMAGAWA, M; ISHIKAWA, Y; SHIMANO, H; OSADA, S; NISHIHARA, T				IMAGAWA, M; ISHIKAWA, Y; SHIMANO, H; OSADA, S; NISHIHARA, T			CTG TRIPLET REPEAT IN MOUSE GROWTH-INHIBITORY FACTOR METALLOTHIONEIN-III GENE PROMOTER REPRESSES THE TRANSCRIPTIONAL ACTIVITY OF THE HETEROLOGOUS PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; MYOTONIC-DYSTROPHY; MOLECULAR-CLONING; MAMMALIAN-CELLS; MESSENGER-RNA; FACTOR CDNA; EXPRESSION; PROTEIN; BRAIN; DNA	Growth inhibitory factor/metallothionein III (GIF/MT-III) is expressed specifically in brain, and neither mRNA nor protein is detected in other organs, This tissue-specific expression might be regulated by negative elements as well as positive elements, such as tissue-specific enhancers, To investigate the repression mechanisms of this gene in organs other than the brain, transfection experiments were performed by using various deletion mutants, Interestingly, a 25 x CTG repeat in the promoter region seemed to contribute to the repression activity, Moreover, the repression activity of this 25 x CTG repeat was also observed in various promoters and in a direction and position independent manner, indicating that this element could act as a silencer. However, no binding protein was detected by gel-shift and footprint analyses. These results strongly suggest that the CTG repeat functions as a negative element, and that this effect is caused by unknown mechanisms, rather than by interactions between specific cis-elements and specific trans-acting factors as reported previously, It is also possible that the CTG repeat functions as a general silencer in many genes.			IMAGAWA, M (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,DEPT ENVIRONM BIOCHEM,1-6 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; 				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Erlich H.A., 1989, PCR TECHNOLOGY; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HAMER DH, 1986, ANN REV BIOCH, V56, P913; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLTZMAN DM, 1991, TRENDS BIOCHEM SCI, V16, P140, DOI 10.1016/0968-0004(91)90056-2; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KOBAYASHI H, 1993, MOL BRAIN RES, V19, P188, DOI 10.1016/0169-328X(93)90025-K; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MARTIN JB, 1993, SCIENCE, V262, P674, DOI 10.1126/science.8235586; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J, 1989, MOL CLONING LABORATO; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2	26	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20898	20900		10.1074/jbc.270.36.20898	http://dx.doi.org/10.1074/jbc.270.36.20898			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673112	hybrid			2022-12-27	WOS:A1995RU05400008
J	TOURKINE, N; SCHINDLER, C; LAROSE, M; HOUDEBINE, LM				TOURKINE, N; SCHINDLER, C; LAROSE, M; HOUDEBINE, LM			ACTIVATION OF STAT FACTORS BY PROLACTIN, INTERFERON-GAMMA, GROWTH-HORMONES, AND A TYROSINE PHOSPHATASE INHIBITOR IN RABBIT PRIMARY MAMMARY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SIGNAL-TRANSDUCTION PATHWAY; CASEIN GENE PROMOTER; BETA-CASEIN; EXTRACELLULAR-MATRIX; NUCLEAR FACTOR; KINASE-C; TRANSCRIPTION FACTOR; LACTOGENIC HORMONES; RECEPTOR	In numerous studies on mammary epithelial cell lines multiple factors, added to the medium or contained in the serum, were required for casein gene expression. It has been shown in these systems that the mammary gland factor (MGF) is implicated in the activation of the beta-casein gene promoter. In the present study, we determined the relationship between known agents that affect casein gene expression and MGF activity using the properties of rabbit primary mammary epithelial cells to respond to PRL alone, when cultured in chemically defined medium. We demonstrate that MGF is rapidly activated by PRL alone or by human growth hormone, a natural ligand of many PRL receptors (PRL-Rs), in the cytoplasm and accumulated in the nucleus, The MGF activation by PRL occurred in the absence of endogenous extracellular matrix, a condition where casein synthesis is known to be markedly reduced. Different inhibitors of protein-tyrosine kinases, which have been shown to reduce casein mRNA synthesis, but not of protein kinase C, decrease the MGF activity. A tyrosine phosphatase inhibitor, sodium pervanadate, induced two GAS-binding complexes related to MGF and STAT1. Our data show that MGF is a latent cytoplasmic factor rapidly activated in mammary epithelial cells, by a mechanism involving a tyrosine kinase and a tyrosine phosphatase.	INRA, UNITE DIFFERENCIAT CELLULAIRE, F-78352 JOUY EN JOSAS, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Columbia University								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAYATSARMADI M, 1993, MOL CELL ENDOCRINOL, V92, P127, DOI 10.1016/0303-7207(93)90083-V; BAYATSARMADI M, IN PRESS INT J BIOCH; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLUM JL, 1988, J CELL PHYSIOL, V135, P13, DOI 10.1002/jcp.1041350103; CAHOREAU C, 1992, BIOCHIMIE, V74, P1053, DOI 10.1016/0300-9084(92)90003-W; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAULFIELD JJ, 1986, J ENDOCRINOL, V109, P29, DOI 10.1677/joe.0.1090029; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DJIANE J, 1982, ENDOCRINOLOGY, V110, P791, DOI 10.1210/endo-110-3-791; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOUDEBINE LM, 1990, REPROD NUTR DEV, V30, P431, DOI 10.1051/rnd:19900317; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MITEV V, 1995, IN PRESS REPROD NUTR, V35; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; NICOLL CS, 1980, FED PROC, V39, P2563; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PUISSANT C, 1991, CELL BIOL INT REP, V15, P121, DOI 10.1016/0309-1651(91)90103-P; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; TERNYNCK T, 1987, TECHNIQUES IMMUNOENZ, P14; THEPOT D, 1991, GENE, V97, P301, DOI 10.1016/0378-1119(91)90067-L; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOURKINE N, 1989, ONCOGENE, V4, P973; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	78	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20952	20961		10.1074/jbc.270.36.20952	http://dx.doi.org/10.1074/jbc.270.36.20952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673119	hybrid			2022-12-27	WOS:A1995RU05400016
J	ANGLARD, P; MELOT, T; GUERIN, E; THOMAS, G; BASSET, P				ANGLARD, P; MELOT, T; GUERIN, E; THOMAS, G; BASSET, P			STRUCTURE AND PROMOTER CHARACTERIZATION OF THE HUMAN STROMELYSIN-3 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IV COLLAGENASE GENE; ONCOGENE-INDUCED TRANSIN; RETINOIC ACID RECEPTORS; AP1 BINDING-SITE; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; HUMAN FIBROBLASTS; CELL CARCINOMA	In the present study, we have isolated the human stromelysin-3 (ST3) gene which encodes a matrix metalloproteinase (MMP) expressed in fibroblastic cells of tissues associated with intense remodeling. The gene was found to span 11.5 kilobases (kb) including 8 exons and 7 introns. The genomic organization of ST3 gene exons is well conserved compared to other members of the MMP family, except for the 3 last exons corresponding to the hemopexin-like domain and to a long 3'-untranslated region. The transcription initiation site was located 31 nucleotides downstream of a TATA box. Analysis of 1.4 kb of 5'-flanking DNA sequence in the ST3 gene promoter revealed the presence of putative regulatory elements, but no consensus sequence for AP1-binding site in contrast to other MMP promoters. However, a specific cis-acting retinoic acid responsive element of the DR1 type was identified in the proximal region (-385) of the ST3 gene promoter. Transient transfection experiments demonstrated that a minimal promoter activity could be modulated by various sequences within the 3.4 kb of 5'-flanking region, and that the ST3 promoter was transactivated by retinoic acid receptors in the presence of retinoic acid. These findings indicate that the human ST3 gene promoter is characterized by structural and functional features which differ from those previously described in other MMP promoters, and further supports the possibility that ST3 gene expression is controlled by specific factors during tissue remodeling.	INST CURIE,INSERM,U434,GENET TUMEURS LAB,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ANGLARD, P (corresponding author), ULP,CNRS,INSERM,INST GENET BIOL & MOLEC CELLULAIRE,BP163,F-67404 ILLKIRCH GRAFFENS,FRANCE.		Guerin, Eric/R-3426-2016; Anglard, Patrick/M-6618-2019	Anglard, Patrick/0000-0001-5701-441X; GUERIN, ERIC/0000-0003-1388-2834				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGLARD P, 1992, CANCER RES, V52, P348; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; DAVIS LG, 1986, BASIC METHODS MOL BI, P276; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GAIRE M, 1994, J BIOL CHEM, V269, P2032; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KERR LD, 1988, J BIOL CHEM, V263, P16999; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLUNGLAND H, 1993, MOL CELL ENDOCRINOL, V95, P147, DOI 10.1016/0303-7207(93)90040-Q; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V12, P947; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1994, J BIOL CHEM, V269, P25849; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; ROUYER N, 1994, INVAS METAST, V14, P269; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; WINDSOR LJ, 1993, J BIOL CHEM, V268, P17341; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	54	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20337	20344		10.1074/jbc.270.35.20337	http://dx.doi.org/10.1074/jbc.270.35.20337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657606	hybrid			2022-12-27	WOS:A1995RR58400019
J	BOTTI, MG; TAYLOR, MG; BOTTING, NP				BOTTI, MG; TAYLOR, MG; BOTTING, NP			STUDIES ON THE MECHANISM OF MYROSINASE - INVESTIGATION OF THE EFFECT OF GLYCOSYL ACCEPTORS ON ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDASE; CATALYZED SYNTHESIS	Myrosinase (EC 3.2.3.1) is the beta-thioglucosidase enzyme responsible for the hydrolysis of glucosinolates, a group of naturally occurring plant metabolites. The enzyme catalyzes the hydrolysis of these S-glucosides to give D-glucose and an aglycone fragment, which then rearranges to give sulfate and an isothiocyanate. As part of ongoing mechanistic studies on myrosinase, the ability of the enzyme to catalyze transglycosylation reactions has been examined. Enzyme activity and stability were both decreased in the presence of various organic solvents, including simple alcohols, but not sufficiently to prevent reaction taking place. However, in contrast to most other beta-glycosidases, myrosinase did not catalyze transglycosylation reactions either with the alcohols or other suitable glycosyl accepters. Although a wide range of potential accepters were investigated, none proved to be effective. Even when appropriately charged side chains were included in the acceptor molecule to mimic the sulfonic acid in the glucosinolate structure, transglycosylation did not take place. The putative enzyme-glycosyl intermediate therefore appears to be unavailable for reaction, possibly because D-glucose is the first product released from the enzyme. The transition state analogue, glucono-delta-lactone, a potent competitive inhibitor of beta-glucosidase, was found to be a poor noncompetitive inhibitor of myrosinase. Myrosinase is specifically activated by ascorbic acid, and it is proposed that the inhibitor is binding at this alternative site.	UNIV ST ANDREWS,SCH CHEM,ST ANDREWS KY16 9ST,FIFE,SCOTLAND	University of St Andrews								BJORKLING F, 1988, TETRAHEDRON, V44, P2957; BJORKMAN R, 1973, BIOCHIM BIOPHYS ACTA, V327, P121, DOI 10.1016/0005-2744(73)90109-5; DALE MP, 1986, BIOCHEMISTRY-US, V25, P2522, DOI 10.1021/bi00357a036; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; DURHAM PL, 1990, Z NATURFORSCH C, V45, P173; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GOPALAN V, 1992, J BIOL CHEM, V267, P9629; HANLEY AB, 1990, J SCI FOOD AGR, V51, P417, DOI 10.1002/jsfa.2740510314; Larsen PO, 1981, BIOCH PLANT PRODUCTS, V7, P501; OHTSURU M, 1969, AGR BIOL CHEM TOKYO, V33, P1320; OHTSURU M, 1979, BIOCHIM BIOPHYS ACTA, V567, P384, DOI 10.1016/0005-2744(79)90124-4; PALMIERI S, 1982, ANAL BIOCHEM, V123, P320, DOI 10.1016/0003-2697(82)90452-3; Schachter H, 1975, Methods Enzymol, V41, P3; SINNOTT ML, 1973, BIOCHEM J, V133, P81, DOI 10.1042/bj1330081; Tookey H. L., 1980, Toxic constituents of plant foodstuffs., P103; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; TSURUO I, 1968, AGR BIOL CHEM TOKYO, V32, P1425; WITHERS SG, 1994, CURR OPIN STRUC BIOL, V4, P885	19	36	38	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20530	20535		10.1074/jbc.270.35.20530	http://dx.doi.org/10.1074/jbc.270.35.20530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657629	hybrid			2022-12-27	WOS:A1995RR58400047
J	KNOLL, LJ; SCHALL, OF; SUZUKI, I; GOKEL, GW; GORDON, JI				KNOLL, LJ; SCHALL, OF; SUZUKI, I; GOKEL, GW; GORDON, JI			COMPARISON OF THE REACTIVITY OF TETRADECENOIC ACIDS, A TRIACSIN, AND UNSATURATED OXIMES WITH 4 PURIFIED SACCHAROMYCES-CEREVISIAE FATTY-ACID ACTIVATION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; ESCHERICHIA-COLI; N-MYRISTOYLTRANSFERASE; MYRISTOYL-COA; REGULATED EXPRESSION; OLE1 GENE; SPECIFICITY; DESATURASE; INHIBITION	Saccharomyces cerevisiae contains at least five acyl-CoA synthetases (fatty acid activation proteins, or Faaps). Four FAA genes have been recovered to date. Recent genetic studies indicate that Faa1p and Faa4p are involved in the activation of imported fatty acids, while Faa2p activates endogenous pools of fatty acids. We have now purified Faa4p from S. cerevisiae and compared its fatty acid substrate specificity in vitro with the specificities of purified Faa1p, Faa2p, and Faa3p. Among C8-C18 saturated fatty acids, Faa4p and Faa1p both prefer C14:0. Surveys of C14 fatty acids with single cis-double bonds at C2-C12 indicated that Faa4p and Faa1p prefer Z9-tetradecenoic acid, although Faa4p's preference is much greater and also evident in C16 and C18 fatty acids. Faa4p's selectivity for fatty acids with a C9-C10 cis-double bond is a feature it shares with Faa3p and is notable since in yeast Ole1p, a microsomal cis-Delta(9) desaturase, accounts for de nova production of monoenoic acyl-CoAs from saturated acyl-CoA substrates. Faa4p has no detectable acyl-CoA synthetase activity when incubated with tetradecenoic acids having a trans-double bond at C2-3, C4-5, C5-6, C6-7, C7-8, or C9-10. Faa3p can only use E9-tetradecenoic acid as a substrate, while E4-, E6- and E9-tetradecenoic acids can be used by Faa1p and Faa2p. E2-tetradecenoic acid is an Faap inhibitor, with Faa2p exhibiting the greatest sensitivity (IC50 = 2.6 +/- 0.2 mu m). Triacsin C (1-hydroxy-3-(E,E,E,2',4',7'-undecatrienylidine)-1,2 has trans-double bonds at positions that correspond to those in E2-, E5-, and E7-tetradecenoic acids. This compound is a potent inhibitor of Faa2p (K-i = 15 +/- 1 nm; competitive with fatty acid), less potent against Faa4p K-i = 2 mu m) and not active against Faa1p or Faa3p (IC50 > 500 mu m). Analysis of an n-tetradecanal plus a series of oximes (tridecanal oxime, 1-azadeca-1,3,5-trienol, and 1-azaundeca-1,3,5-trienol) indicated that the combination of an azenol moiety (R-CH=N-OH) plus adjacent unsaturation are critical for triacsin C's selective inhibition of Faa2p. Triacsin C and oxime derivatives appear to be very useful for defining differences in molecular recognition among S. cerevisiae acyl-CoA synthetases. The > 25,000-fold range in the inhibitory effects of triacsin C on these four Faaps suggests that it may be possible to develop other selective inhibitors of eukaryotic acyl-CoA synthetases.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NIAID NIH HHS [AI27179, AI38200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, R01AI038200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BARTANA J, 1972, BIOCHEM J, V129, P1101, DOI 10.1042/bj1291101; BARTANA J, 1964, BIOCHEM J, V93, P533, DOI 10.1042/bj0930533; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BARTANA J, 1971, BIOCHEM J, V122, P853; BERG P, 1956, J BIOL CHEM, V222, P991; BERG P, 1958, SCIENCE, V129, P895; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; Eadie GS, 1942, J BIOL CHEM, V146, P85; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HSU L, 1991, J BIOL CHEM, V266, P13783; HUNTER K, 1972, BIOCHIM BIOPHYS ACTA, V260, P639, DOI 10.1016/0005-2760(72)90013-6; ICHIHARA K, 1991, J LIPID RES, V32, P1709; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; NUNN WD, 1986, J BIOL CHEM, V261, P167; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; ROCK CO, 1985, J BIOL CHEM, V260, P2720; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TANAKA H, 1982, J ANTIBIOT, V35, P157, DOI 10.7164/antibiotics.35.157; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WILMAN DEV, 1992, J CHEM RES-S, P55	38	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20090	20097		10.1074/jbc.270.34.20090	http://dx.doi.org/10.1074/jbc.270.34.20090			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650027	hybrid			2022-12-27	WOS:A1995RQ99100063
J	SIMPSON, JC; DASCHER, C; ROBERTS, LM; LORD, JM; BALCH, WE				SIMPSON, JC; DASCHER, C; ROBERTS, LM; LORD, JM; BALCH, WE			RICIN CYTOTOXICITY IS SENSITIVE TO RECYCLING BETWEEN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; CELLS; TOXIN; INHIBITION; PROTEINS; SEQUENCE; RECEPTOR; PATHWAY; NETWORK	Cytotoxic proteins that kill mammalian cells by catalytically inhibiting protein synthesis must enter the cytosol in order to reach their substrates. With the exception of diphtheria toxin, which enters the cytosol from acidified endosomes, the intracellular site of translocation of other toxins including ricin, Escherichia coli Shiga-like toxin-1, and Pseudomonas exotoxin A is likely to involve early compartments of the secretory pathway. We have used a molecular approach to identify the site and mechanism of toxin delivery to the cytosol by transiently expressing mutant GTPases that inhibit the assembly of biochemical complexes mediating anterograde and retrograde transport in the exocytic and endocytic pathways, The results provide evidence to suggest that receptors actively recycling between the endoplasmic reticulum and terminal Golgi compartments are essential for toxin translocation to the cytosol from the endoplasmic reticulum, The rapid kinetics of intoxication demonstrate a substantial level of bidirectional membrane flow and sorting through the early secretory pathway.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	SIMPSON, JC (corresponding author), UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.			Simpson, Jeremy/0000-0002-7956-7805	NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGENT RH, 1994, J BIOL CHEM, V269, P26705; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; EIKLID K, 1983, INFECT IMMUN, V42, P771, DOI 10.1128/IAI.42.2.771-777.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; Schmid SL, 1993, CURR OPIN CELL BIOL, V5, P621, DOI 10.1016/0955-0674(93)90131-9; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WALES R, 1993, J BIOL CHEM, V268, P23986; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	40	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20078	20083		10.1074/jbc.270.34.20078	http://dx.doi.org/10.1074/jbc.270.34.20078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650025	hybrid			2022-12-27	WOS:A1995RQ99100061
J	IYPE, LE; INMAN, RB; COX, MM				IYPE, LE; INMAN, RB; COX, MM			BLOCKED RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE-REACTIONS ARE REVERSED BY THE RUVA AND RUVB PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; 3-STRANDED DNA; CONJUGATIONAL RECOMBINATION; NUCLEOSIDE TRIPHOSPHATE; PARTIAL DENATURATION; ATP HYDROLYSIS; M13 VECTORS; REPAIR	RecA protein is unable to complete a DNA strand exchange reaction between a circular single-stranded DNA and a linear duplex DNA substrate with heterologous sequences of 375 base pairs at the distal end. Instead, it generates a branched intermediate in which strand exchange has proceeded up to the homology/heterology junction, Addition of the RuvA and RuvB proteins to these stalled intermediates leads to the rapid conversion of intermediates back to the original substrates, The reversal reaction is initiated at the branch, and the hybrid DNA is unwound in the direction opposite to that of the RecA reaction that created it, Under optimal conditions the rate of the reaction exhibits only a modest dependence on the length of hybrid DNA that must be unwound. Products of the reversal reaction are detected within minutes after addition of RuvAB, and appear with an apparent first order progress curve exhibiting a t(1/2) in the range of 6-12 min under optimal conditions. Few molecules that have undergone only partial reversal are detected, This suggests that the assembly or activation of RuvAB on the branched substrate is rate-limiting, while any migration of RuvAB on the DNA to effect unwinding of the hybrid DNA (and reformation of substrate DNA) is very fast. The results are discussed in the context of the role of RuvA and RuvB proteins in recombinational DNA repair. We suggest that one function of the RuvAB proteins is to act as an antirecombinase, to eliminate intragenomic crossovers between homologous segments of the bacterial chromosome that might otherwise lead to deleterious inversions or deletions.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1994, P NATL ACAD SCI USA, V91, P9901, DOI 10.1073/pnas.91.21.9901; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; IYPE LE, 1994, J BIOL CHEM, V269, P24967; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LUISIDELUCA C, 1989, GENETICS, V122, P269; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1994, EXPERIENTIA, V50, P216; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Ochman H, 1987, ESCHERICHIA COLI SAL, P1649; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SEGALL A, 1988, SCIENCE, V241, P1314, DOI 10.1126/science.3045970; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1992, MOL MICROBIOL, V6, P2755, DOI 10.1111/j.1365-2958.1992.tb01454.x; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WEST SC, 1993, COLD SPRING HARB SYM, V58, P525, DOI 10.1101/SQB.1993.058.01.059; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x	54	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19473	19480		10.1074/jbc.270.33.19473	http://dx.doi.org/10.1074/jbc.270.33.19473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642631	hybrid			2022-12-27	WOS:A1995RP70300045
J	LOO, TW; HO, C; CLARKE, DM				LOO, TW; HO, C; CLARKE, DM			EXPRESSION OF A FUNCTIONALLY ACTIVE HUMAN RENAL SODIUM-CALCIUM EXCHANGER LACKING A SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; NA+-CA2+ EXCHANGER; MEMBRANE; PROTEIN; CA; LOCALIZATION; RETICULUM; INVITRO	The Na+-Ca2+ exchanger is an unusual membrane transport protein as it contains an NH2-terminal signal sequence which is co-translationally removed in the endoplasmic reticulum during synthesis, To determine if the signal sequence was essential for biosynthesis, mutations were introduced in the NH2 terminus of the cDNA coding for the human renal Na+-Ca2+ exchanger in order to alter processing of the protein, To prevent cleavage of the signal sequence during biosynthesis, the last residue of the consensus signal sequence, Ala(-1), was changed to Phe. Deletion mutants were also constructed to encode for exchangers which lacked the signal sequence, the signal sequence and the first extracellular loop, or all of the NH2 terminus including the first transmembrane segment of the mature protein. These mutants were expressed in HEK 293 cells and assayed for Na+-Ca2+ exchange activity. Mutants lacking either a signal sequence or containing a noncleavable signal sequence were still targeted to the plasma membrane, where they exhibited Na+-Ca2+ exchange activity. By contrast, the mutants which had more than the signal sequence deleted did not demonstrate any exchange activity. These mutants were, however, still integrated into the membrane and were resistant to alkali extraction, These results show that the signal sequence is not essential for biogenesis of the Na+-Ca2+ exchanger and suggests that the molecule contains one or more internal signal sequences for insertion into the membrane during biosynthesis.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BOURDEAU JE, 1993, J AM SOC NEPHROL, V4, P105; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; FULLMER CS, 1987, P NATL ACAD SCI USA, V84, P4772, DOI 10.1073/pnas.84.14.4772; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HYRSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOLLING R, 1994, FEBS LETT, V351, P155, DOI 10.1016/0014-5793(94)00825-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOO TW, 1994, AM J PHYSIOL, V267, pF70, DOI 10.1152/ajprenal.1994.267.1.F70; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1994, J BIOL CHEM, V269, P28683; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; Philipson K D, 1993, Int Rev Cytol, V137C, P199; REILLY RF, 1993, AM J PHYSIOL, V265, pF327, DOI 10.1152/ajprenal.1993.265.2.F327; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; TAM LY, 1994, J BIOL CHEM, V269, P32542; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19345	19350		10.1074/jbc.270.33.19345	http://dx.doi.org/10.1074/jbc.270.33.19345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642612	hybrid			2022-12-27	WOS:A1995RP70300026
J	REIN, T; FORSTER, R; KRAUSE, A; WINNACKER, EL; ZORBAS, H				REIN, T; FORSTER, R; KRAUSE, A; WINNACKER, EL; ZORBAS, H			ORGANIZATION OF THE ALPHA-GLOBIN PROMOTER AND POSSIBLE ROLE OF NUCLEAR FACTOR-I IN AN ALPHA-GLOBIN-INDUCIBLE AND IN A NONINDUCIBLE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; RNA POLYMERASE-II; GENE-TRANSCRIPTION; CHROMATIN STRUCTURE; BINDING PROTEIN; NF-I; ERYTHROID-DIFFERENTIATION; EUKARYOTIC TRANSCRIPTION; METHYLATED CPGS; EXPRESSION	Nuclear factor I (NFI) was suggested to be involved in the expression of the human alpha-globin gene. Two established cell lines, which express alpha-globin differentially, were therefore compared for differences in binding of NFI at the alpha-globin promoter in vivo. HeLa cells, in which alpha-globin is repressed, show a high density promoter occupation with several proteins associated with structurally distorted DNA. Cell line K562, which is inducible for alpha-globin, surprisingly was found to be heterogeneous consisting mainly of cells (similar to 95%) unable to express alpha-globin. However, the promoter of the nonexpressing K562 cells was clearly different from that of HeLa cells, being occupied only at basal transcriptional elements. Therefore, the alpha-globin gene in these K562 cells may not be truly repressed, but in an intermediate state between repression and active transcription. The NFI site of the alpha-globin promoter appeared occupied in HeLa but free of proteins in K562 cells. All cells of both cell lines produce NFI, but the composition and DNA binding affinity of NFI species differ significantly between the two cell fines. Therefore, distinct forms of NFI may repress alpha-globin transcription in HeLa cells. However, NFI is apparently not involved in establishing the latent transcriptional state of the majority of K562 cells.	UNIV MUNICH,INST BIOCHEM,D-81375 MUNICH,GERMANY	University of Munich			Förster, Reinhold/D-6770-2011	Forster, Reinhold/0000-0001-6190-7923; Rein, Theo/0000-0003-2850-4289				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVELLI O, 1982, J BIOL CHEM, V257, P6783; CLARK L, 1990, J VIROL, V64, P1335, DOI 10.1128/JVI.64.3.1335-1344.1990; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FORSTER R, 1993, BIOCHEM BIOPH RES CO, V196, P1496, DOI 10.1006/bbrc.1993.2421; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIL G, 1988, J BIOL CHEM, V263, P19009; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAHAM GH, 1988, EMBO J, V7, P2191; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIM CG, 1990, MOL CELL BIOL, V12, P5985; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KRAUSE A, 1993, HETEROLOGOUS NFI EXP; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; MCQUILLAN JJ, 1991, NUCLEIC ACIDS RES, V19, P6627, DOI 10.1093/nar/19.23.6627; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OVERBEEK PA, 1981, BIOCHIM BIOPHYS ACTA, V656, P195, DOI 10.1016/0005-2787(81)90087-3; PLUMB M, 1991, J VIROL, V65, P1991, DOI 10.1128/JVI.65.4.1991-1999.1991; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZORBAS H, 1992, J BIOL CHEM, V267, P8478; ZORBAS H, 1989, NUCLEIC ACIDS RES, V19, P7735	87	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19643	19650		10.1074/jbc.270.33.19643	http://dx.doi.org/10.1074/jbc.270.33.19643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642653				2022-12-27	WOS:A1995RP70300069
J	BJORBAEK, C; ZHAO, Y; MOLLER, DE				BJORBAEK, C; ZHAO, Y; MOLLER, DE			DIVERGENT FUNCTIONAL ROLES FOR P90(RSK) KINASE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; PHORBOL ESTER; XENOPUS EGGS; INSULIN; PHOSPHORYLATION; CELLS	A unique and highly conserved structural feature of approximate to 90-kDa ribosomal S6 kinase (p90(rsk) or RSK) is the presence of two non-identical kinase domains. To explore the mechanism of RSK activation, a cloned human RSK cDNA (RSK3) was used to generate and characterize several site directed RSK mutants: K91A (N-Lys, NH2-terminal ATP-binding mutant), K444A (C-Lys, COOH-terminal ATP-binding mutant), N/C-Lys (double ATP-binding mutant), T570A (C-Thr, mutant of the putative MAPK phosphorylation site in subdomain MI of the C-domain), S218A (N-Ser, mutant of the corresponding NH2-terminal residue). Epitope-tagged RSKs were expressed in transfected COS cells followed by immunoprecipitation with or without prior in vivo epidermal growth factor stimulation. Kinase activity (S6 peptide) of N/C-Lys and N-Lys was ablated (and partially impaired with N-Ser). In contrast, both C-Lys and C-Thr retained high levels of kinase activity and were capable of responding to stimulation, C-Lys also retained partial kinase activity toward other substrates (c-Fos, S40 ribosomes, protein phosphatase 1 G-subunit, histones, and Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide)) whereas N-Lys did not. The isolated NH2- and COOH-terminal domains were also expressed; the C-domain was inactive, whereas the N-domain retained partial activity. Relative to wild-type, both N-Lys and C-Lys (as well as N-Ser and C-Thr) underwent partial in vitro autophosphorylation that was further stimulated by EGF protein tyrosine phosphatase. We conclude that 1) the NB-terminal RSK kinase domain mediates substrate Phosphorylation; 2) both domains contribute to autophosphorylation; 3) the putative MAPK phosphorylation site is not required for growth factor-stimulated autophosphorylation or kinase activation.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Bjorbaek, Christian/S-4727-2019		PHS HHS [R01 45874-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ERIKSON RL, 1988, 1ST P INT C GEN REG, P13; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1986, ENZYMES ENZYME CONTR, P191; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, FRONTIERS MOL BIOL; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; ZHAO Y, 1995, IN PRESS MOL CELL BI; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	55	95	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18848	18852		10.1074/jbc.270.32.18848	http://dx.doi.org/10.1074/jbc.270.32.18848			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642538	hybrid			2022-12-27	WOS:A1995RN95400025
J	HARENDZA, S; POLLOCK, AS; MERTENS, PR; LOVETT, DH				HARENDZA, S; POLLOCK, AS; MERTENS, PR; LOVETT, DH			TISSUE-SPECIFIC ENHANCER-PROMOTER INTERACTIONS REGULATE HIGH-LEVEL CONSTITUTIVE EXPRESSION OF MATRIX METALLOPROTEINASE-2 BY GLOMERULAR MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; RNA POLYMERASE-II; IV COLLAGENASE; TRANSGENIC MICE; Z-DNA; GENE; SECRETE; INHIBITORS; EFFICIENT; SEQUENCES	The 72-kDa gelatinase A (MMP-2) is a central mediator of the response of the intrinsic glomerular mesangial cell to inflammatory stimuli and is regulated in a unique, cell-specific manner, We isolated a 6-kilobase pair genomic fragment of the rat MMP-2 gene and sequenced and characterized 1686-base pair of the 5'-flanking region, Using a series of 5' deletion constructs of the proximal 5'-flanking region, a strong MMP-2 enhancer element was identified, Gel shift and mutational analyses suggest that the enhancer region represents the binding site for a complex transcription factor demonstrating separable DNA-binding and transcriptional activating domains. The presence and activity of the enhancer element was evaluated in several cell types with varying capabilities to synthesize MMP-2 including mesangial cells, glomerular epithelial cells, and the monocytic U937 cell. Although binding activity was present in all cell types studied, enhancer activity was demonstrated only in mesangial and glomerular epithelial cells, Additional transcriptional control resided in a tissue-specific promoter, which supported transcription only in mesangial cells. These results indicate that the final control of mesangial cell specific synthesis of MMP-2 derives from an interaction between the strong enhancer element and the tissue-specific MMP-2 promoter.	DEPT VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776, R01DK031398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776, DK 31398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURDON TG, 1994, FEBS LETT, V350, P177, DOI 10.1016/0014-5793(94)00757-8; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRISCH SM, 1990, MOL CELL BIOL, V10, P6514; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GARBISA S, 1986, J BIOL CHEM, V261, P2369; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; HANSEN PK, 1993, J MOL BIOL, V233, P191, DOI 10.1006/jmbi.1993.1499; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LOVETT DH, 1992, AM J PATHOL, V141, P85; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NITCH D, 1993, MOL CELL BIOL, V13, P4494; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO H, 1992, ONCOGENE, V7, P77; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TRYGGVASON K, 1990, CELL DIFFER DEV, V32, P307, DOI 10.1016/0922-3371(90)90044-W; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	41	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18786	18796		10.1074/jbc.270.32.18786	http://dx.doi.org/10.1074/jbc.270.32.18786			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642529				2022-12-27	WOS:A1995RN95400016
J	OBARA, K; NIKCEVIC, G; PESTIC, L; NOWAK, G; LORIMER, DD; GUERRIERO, V; ELSON, EL; PAUL, RJ; DELANEROLLE, P				OBARA, K; NIKCEVIC, G; PESTIC, L; NOWAK, G; LORIMER, DD; GUERRIERO, V; ELSON, EL; PAUL, RJ; DELANEROLLE, P			FIBROBLAST CONTRACTILITY WITHOUT AN INCREASE IN BASAL MYOSIN LIGHT-CHAIN PHOSPHORYLATION IN WILD-TYPE CELLS AND CELLS EXPRESSING THE CATALYTIC DOMAIN OF MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE MYOSIN; ISOMETRIC CONTRACTION; PURIFICATION	We investigated the role of myosin light chain (MLC(20)) phosphorylation (MLC-P) in non-muscle contractility by comparing MLC-P and the contractile properties of wild type 3T3 fibroblasts and 3T3 fibroblasts expressing the catalytic domain of myosin light chain kinase (tMK), MLC-P is 0.96 mol of PO4/mol of MLC(20) in cells expressing tMK compared to 0.20 mol of PO4/mol of MLC(20) in control cells, Expressing tMK also results in a 2-fold increase in cortical stiffness compared to control cells. Contractile properties were quantified by growing wild type and transfected fibroblasts in collagen and attaching the ensuing fibers to an apparatus for performing mechanical measurements, Serum stimulation resulted in a dose-dependent increase in force with maximal force generated in the presence of 30% (v/v) serum. Surprisingly, MLC-P did not increase in wild type cells following stimulation with 30% serum, and tMK expression did not affect the contractile properties of fibers made from these cells. Moreover, the dose responses to serum, maximal force, force-Velocity relationships, and dynamic stiffness were similar in the wild type cells and fibroblasts expressing tMK. These data demonstrate that non-muscle cells can generate force without an increase in MLC-P, and that an increase in MLC-P does not affect the contractile properties of fibroblast fibers.	UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45221; UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612; UNIV ARIZONA,DEPT ANIM SCI,TUCSON,AZ 85721; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University System of Ohio; University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; Washington University (WUSTL)					NHLBI NIH HHS [HL 23240, HL 43651] Funding Source: Medline; NIGMS NIH HHS [GM 38838] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043651, R01HL023240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038838] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; DELANEROLLE P, 1988, J BIOL CHEM, V263, P9071; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KOPP SJ, 1979, J BIOL CHEM, V254, P2007; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OBARA K, 1994, BIOPHYS J, V66, pA412; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P1919, DOI 10.1021/bi00537a034; WILSON AK, 1992, CANCER METAST REV, V11, P79, DOI 10.1007/BF00047605; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255	19	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18734	18737		10.1074/jbc.270.32.18734	http://dx.doi.org/10.1074/jbc.270.32.18734			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642521	hybrid			2022-12-27	WOS:A1995RN95400007
J	SEUBERT, P; MAWALDEWAN, M; BARBOUR, R; JAKES, R; GOEDERT, M; JOHNSON, GVW; LITERSKY, JM; SCHENK, D; LIEBERBURG, I; TROJANOWSKI, JQ; LEE, VMY				SEUBERT, P; MAWALDEWAN, M; BARBOUR, R; JAKES, R; GOEDERT, M; JOHNSON, GVW; LITERSKY, JM; SCHENK, D; LIEBERBURG, I; TROJANOWSKI, JQ; LEE, VMY			DETECTION OF PHOSPHORYLATED SER(262) IN FETAL TAU, ADULT TAU, AND PAIRED HELICAL FILAMENT TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; ALZHEIMER-LIKE STATE; MICROTUBULE-BINDING; NEUROFIBRILLARY PATHOLOGY; ABNORMAL PHOSPHORYLATION; DISEASE; BRAIN; ISOFORMS; SITES	Paired helical filaments (PHFs) are the major structural elements of Alzheimer's disease neurofibrillary lesions, and these filaments are formed from hyperphosphorylated brain tau known as PHF-tau, Recent studies showed that many previously identified phosphorylated residues in PHF-tau also are phosphate acceptor sites in fetal and rapidly processed adult brain tau, However, Ser(262) has been suggested to be uniquely phosphorylated in PHF-tau and a key regulator of the binding of tau to microtubules. For these reasons, we generated a monoclonal antibody (12E8) specific for phosphorylated Se-262 and showed that 12E8 binds to PHF-tau, rat and human fetal brain tau, as well as to rapidly processed adult rat and biopsy-derived human brain tau, Further, phosphorylation at Ser(262) was developmentally regulated, and endogenous brain phosphatases rapidly dephosphorylated Ser(262) in biopsy-derived brain tau isolates. Finally, the phosphorylation of Ser(262) did not eliminate the binding of tau to microtubules. Thus, we speculate that the binding of tau to microtubules is regulated by phosphorylation at multiple sites and that the generation of PHF-tau in Alzheimer's disease results from the reduced efficiency of phosphatases leading to the incremental accumulation of hyperphosphorylated tau.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV ANAT PATHOL,PHILADELPHIA,PA 19104; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV ALABAMA,DEPT PSYCHIAT,BIRMINGHAM,AL 35294	University of Pennsylvania; MRC Laboratory Molecular Biology; University of Alabama System; University of Alabama Birmingham			Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404				BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; ISHIGURO K, 1993, FEBS LETT, V336, P417; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MORISHIMAKAWASHIMA, 1995, J BIOL CHEM, V270, P823; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	46	318	329	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18917	18922		10.1074/jbc.270.32.18917	http://dx.doi.org/10.1074/jbc.270.32.18917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642549	hybrid			2022-12-27	WOS:A1995RN95400036
J	ZHOU, W; RODIC, V; KITANOVIC, S; FLANAGAN, CA; CHI, L; WEINSTEIN, H; MAAYANI, S; MILLAR, RP; SEALFON, SC				ZHOU, W; RODIC, V; KITANOVIC, S; FLANAGAN, CA; CHI, L; WEINSTEIN, H; MAAYANI, S; MILLAR, RP; SEALFON, SC			A LOCUS OF THE GONADOTROPIN-RELEASING-HORMONE RECEPTOR THAT DIFFERENTIATES AGONIST AND ANTAGONIST BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; GNRH RECEPTOR; MOLECULAR-CLONING; RAT PITUITARY; FUNCTIONAL-CHARACTERIZATION; EXPRESSION	The decapeptide gonadotropin-releasing hormone controls reproductive function via interaction with a heptahelical G protein-coupled receptor, Because a molecular model of the receptor predicts that Lys(121) in the third transmembrane helix contributes to the binding pocket, the function of this side chain was studied by site-directed mutagenesis, Substitution of Arg at this position preserved high affinity agonist binding, whereas Gln at this position reduced binding below the limits of detection, Leu and Asp at this locus abolished both binding and detectable signal transduction, The EC(50) of concentration-response curves for coupling to phosphatidyl inositol hydrolysis obtained with the Gln(121) receptor was more than 3 orders of magnitude higher than that obtained for the wild-type receptor, In order to determine whether the increased EC(50) obtained with this mutant reflects an altered receptor affinity, the effect of decreases in wild-type receptor density on concentration-response curves was determined by irreversible antagonism, Progressively decreasing the concentration of the wild-type receptor increased the EC(50) values obtained to a maximal level of 2.4 +/- 0.2 nM. Comparison of this value with the EC(50) of 282 +/- 52 nM observed with the Gln(121) receptor mutant indicates that the agonist affinity for this mutant is reduced more than 100-fold. In contrast, antagonist had comparable high affinities for the wild-type, Arg(121), and Gln(121) mutants, The results indicate that a charge-strengthened hydro gen bond donor is required at this locus for high affinity agonist binding but not for high affinity antagonist binding.	MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT ANESTHESIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT NEUROL,NEW YORK,NY 10029; UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,CAPE TOWN 7925,SOUTH AFRICA; UNIV CAPE TOWN,SCH MED,DEPT MED,MRC REGULATORY PEPTIDES RES UNIT,CAPE TOWN 7925,SOUTH AFRICA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Cape Town; University of Cape Town			WEINSTEIN, HAREL/O-8245-2019; Flanagan, Colleen/ABG-2109-2020	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986	NIDA NIH HHS [KO5 DA00060] Funding Source: Medline; NIDDK NIH HHS [R01 DK46943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000060] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADHAM N, 1993, MOL PHARMACOL, V43, P427; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; EIDNE KA, 1992, MOL CELL ENDOCRINOL, V90, pR5, DOI 10.1016/0303-7207(92)90116-N; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; FONG TM, 1993, NATURE, V362, P350; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FURCHGOTT RF, 1966, ADV DRUG RES, P21; HAYNES R, 1967, BIOCHEMISTRY-US, V6, P541, DOI 10.1021/bi00854a023; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; JANOVICK JA, 1993, ENDOCRINOLOGY, V133, P942, DOI 10.1210/en.133.2.942; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KAKAR SS, 1993, DOMEST ANIM ENDOCRIN, V10, P335, DOI 10.1016/0739-7240(93)90037-C; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Kenakin TP, 1993, PHARM ANAL DRUG RECE, P39; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LAWS SC, 1990, ENDOCRINOLOGY, V127, P373, DOI 10.1210/endo-127-1-373; MEI L, 1989, J PHARMACOL EXP THER, V251, P90; MILLAR RP, 1989, J BIOL CHEM, V264, P21007; MUNSON PJ, 1980, ANAL BIOCHEM, V58, P220; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REINHART J, 1992, J BIOL CHEM, V267, P21281; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; VANDERSPUY ZM, 1987, EARLY CLIN STUDIES L, P293; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; ZHOU W, 1994, MOL PHARMACOL, V45, P165	34	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18853	18857		10.1074/jbc.270.32.18853	http://dx.doi.org/10.1074/jbc.270.32.18853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642539	hybrid			2022-12-27	WOS:A1995RN95400026
J	GUPTABANSAL, R; FREDERICKSON, RCA; BRUNDEN, KR				GUPTABANSAL, R; FREDERICKSON, RCA; BRUNDEN, KR			PROTEOGLYCAN-MEDIATED INHIBITION OF A-BETA PROTEOLYSIS - A POTENTIAL CAUSE OF SENILE PLAQUE ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HEPARAN-SULFATE PROTEOGLYCAN; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; DERMATAN SULFATE; PEPTIDES; DEPOSITS; MUTATION; INVITRO; CDNA	Senile plaques of Alzheimer's disease brain contain, in addition to beta amyloid peptide (A beta), multiple proteoglycans. glycans, Systemic amyloidotic deposits also routinely contain proteoglycan, suggesting that these glycoconjugates are generally involved in amyloid plaque formation and/or persistence. We demonstrate that heparan sulfate proteoglycan (HSPG) and chondroitin sulfate proteoglycan (CSPG) inhibit the proteolytic degradation of fibrillar, but not non-fibrillar, A beta at physiological pH. In accordance with the proteolysis studies, high affinity binding of proteoglycans to fibrillar A beta(1-40) and A beta(1-42) is observed from pH 4 to 9, whereas appreciable binding of HSPG or CSPG to non-fibrillar peptide is only seen at pH < 6, This differing pH dependence of binding suggests that a lysine residue is involved in proteoglycan association with fibrillar A beta, whereas a protonated histidine appears to be needed for binding of the glycoconjugates to non-fibrillar peptide, Scatchard analysis of fibrillar A beta association with proteoglycans indicates a single affinity interaction, and the binding of both HSPG and CSPG to fibrillar A beta is completely inhibited by free glycosaminoglycan chains. This implies that these sulfated carbohydrate moieties are primarily responsible for proteoglycan . A beta interaction, The ability of proteoglycans to bind fibrillar A beta and inhibit its proteolytic degradation suggests a possible mechanism of senile plaque accumulation and persistence in Alzheimer's disease.			GUPTABANSAL, R (corresponding author), GLIATECH INC,DISCOVERY RES GRP,23420 COMMERCE PK RD,CLEVELAND,OH 44122, USA.		Brunden, Kurt/D-1994-2009					BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CANNING DR, 1993, EXP NEUROL, V124, P289, DOI 10.1006/exnr.1993.1199; CARRINO DA, 1991, BIOCHEM INT, V24, P485; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FREDERICKSON RCA, 1994, ALZ DIS ASSOC DIS, V8, P159, DOI 10.1097/00002093-199408030-00002; FREDERICKSON RCA, 1991, NEUROBIOL AGING, V13, P239; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLLIN PA, 1992, NEUROREPORT, V3, P201, DOI 10.1097/00001756-199202000-00020; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; Hertz L., 1989, DISSECTION TISSUE CU, P105; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIVILEVSKY R, 1994, MOL NEUROBIOL, V8, P65; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; PERLMUTTER L S, 1992, Neurobiology of Aging, V13, pS89; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1992, NEUROREPORT, V3, P769, DOI 10.1097/00001756-199209000-00012; REBECK GW, 1993, NEURON, V11, P575; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SNOW A D, 1991, Society for Neuroscience Abstracts, V17, P1106; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1985, LAB INVEST, V53, P37; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STENSTAD T, 1994, BIOCHEM J, V303, P663, DOI 10.1042/bj3030663; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367	47	156	159	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18666	18671		10.1074/jbc.270.31.18666	http://dx.doi.org/10.1074/jbc.270.31.18666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629198	hybrid			2022-12-27	WOS:A1995RM64200080
J	CHEN, ZG; LI, Y; SCHOCK, HB; HALL, D; CHEN, E; KUO, LC				CHEN, ZG; LI, Y; SCHOCK, HB; HALL, D; CHEN, E; KUO, LC			3-DIMENSIONAL STRUCTURE OF A MUTANT HIV-1 PROTEASE DISPLAYING CROSS-RESISTANCE TO ALL PROTEASE INHIBITORS IN CLINICAL-TRIALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS	Analysis of mutational effects in the human immunodeficiency virus type-1 (HIV-1) provirus has revealed that as few as four amino acid side-chain substitutions in the HIV-1 protease (M46I/L63P/V82T/I84V) suffice to yield viral variants cross-resistant to a panel of protease inhibitors either in or being considered for clinical trials (Condra, J. H., Schleif, W. A., Blahy, O. M., Gadryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995) Nature 374, 569-571). As an initial effort toward elucidation of the molecular mechanism of drug resistance in AIDS therapies, the three-dimensional structure of the HIV-1 protease mutant containing the four substitutions has been determined to 2.4-Angstrom resolution with an R factor of 17.1%. The structure of its complex with MK639, a protease inhibitor of the hy droxyaminopentane amide class of peptidomimetics currently in Phase III clinical trials, has been resolved at 2.0 Angstrom with an R factor of 17.0%. These structures are compared with those of the wild-type enzyme and its complex with MK639 (Chen, Z., Li, Y., Chen, E., Hall, D. L., Darke, P. L., Culberson, C., Shafer, J., and Rue, L. C. (1994) J. Biol. Chem. 269, 26344-26348). There is no gross structural alteration of the protease due to the site-specific mutations. The C alpha tracings of the two native structures are identical with a root mean-square deviation of 0.5 Angstrom and the four substituted side chains are clearly revealed in the electron density map. In the MK639-bound form, the V82T substitution introduces an unfavorable hydrophilic moiety for binding in the active site and the I84V substitution creates a cavity (unoccupied by water) that should lead to a decrease in van der Wads contacts with the inhibitor. These changes are consistent with the observed 70-fold increase in the K-i value (similar to 2.5 kcal/mol) for MK639 as a result of the mutations in the HIV-1 protease. The role of the M46I and L63P substitutions in drug resistance is not obvious from the crystallographic data, but they induce conformational perturbations (0.9-1.1 Angstrom) in the flap domain of the native enzyme and may affect the stability and/or activity of the enzyme unrelated directly to binding.			CHEN, ZG (corresponding author), MERCK RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.							ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN E, 1994, METHOD ENZYMOL, V241, P29; CHEN ZG, 1994, J BIOL CHEM, V269, P26344; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HUSSON RN, 1993, J PEDIATR-US, V123, P9, DOI 10.1016/S0022-3476(05)81530-6; IDO E, 1991, J BIOL CHEM, V266, P24359; RICHMAN DD, 1995, NATURE, V374, P494, DOI 10.1038/374494a0; RICHMAN DD, 1994, TXB AIDS MED, P795; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	15	70	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21433	21436		10.1074/jbc.270.37.21433	http://dx.doi.org/10.1074/jbc.270.37.21433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665551	hybrid			2022-12-27	WOS:A1995RU75700002
J	NAKAE, J; MORIOKA, H; OHTSUKA, E; FUJIEDA, K				NAKAE, J; MORIOKA, H; OHTSUKA, E; FUJIEDA, K			REPLACEMENTS OF LEUCINE-87 IN HUMAN INSULIN-RECEPTOR ALTER AFFINITY FOR INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; ALPHA-SUBUNIT; GROWTH-FACTOR; LIGAND SPECIFICITY; IMPAIRS TRANSPORT; TYROSINE KINASE; PLASMA-MEMBRANE; MUTATION; BINDING; SUBSTITUTION	In a previous analysis, we identified a point mutation that substituted Pro (<C(C)under bar G>) for Leu (<C(T)under bar G>) at amino acid 87 in the alpha-subunit of the insulin receptor (IR) in a Japanese patient with leprechaunism. In the present study, we transfected either the wild type (Leu-87) or the mutant (Pro-87) IR cDNA into NIH3T3 cells. Pulse-chase in nonreducing conditions revealed that the dimerization of Pro-87 IR was slightly impaired. However, cell surface biotinylation showed that Pro-87 IR was transported to the cell surface. The Pro-87 IR reduced the insulin binding affinity to about 15% of Leu-87 IR, and the dissociation of insulin in Pro-87 IR was more rapid than in Leu-87 IR. The autophosphorylation of Pro-87 IR was less sensitive to insulin than that of Leu-87 IR, suggesting the reduced insulin binding affinity. Site-directed mutagenesis at amino acid 87 was performed to substitute Ile or Ala for Leu. Both mutant IRs were transported to the cell surface and labeled by cell surface biotinylation. The Ile-87 IR enhanced the insulin binding affinity about 4-fold. The insulin binding affinity of Ala-87 IR was reduced by 85% relative to that of Leu-87 IR. In addition, the dissociation of insulin in Ile-87 IR was slower than in Leu-87 IR, but in Ala-87 IR it was more rapid. These results provide the first direct evidence for a critical role of Leu-87 in binding insulin.	HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University			Nakae, Jun/Q-6141-2019					ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DONOHUE WL, 1954, J PEDIATR-US, V45, P505, DOI 10.1016/S0022-3476(54)80113-2; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; GRONSKOV K, 1993, BIOCHEM BIOPH RES CO, V192, P905, DOI 10.1006/bbrc.1993.1501; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KASUGA M, 1982, J BIOL CHEM, V257, P392; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LEEMMLI UK, 1970, NATURE, V227, P680; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; OLSEN T, 1988, J BIOL CHEM, V263, P7342; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SL, 1982, J CLIN ENDOCR METAB, V54, P914; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WHITE MF, 1994, J BIOL CHEM, V269, P1	33	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22017	22022		10.1074/jbc.270.37.22017	http://dx.doi.org/10.1074/jbc.270.37.22017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665623	hybrid			2022-12-27	WOS:A1995RU75700088
J	ROWLEY, DR; DANG, TD; LARSEN, M; GERDES, MJ; MCBRIDE, L; LU, B				ROWLEY, DR; DANG, TD; LARSEN, M; GERDES, MJ; MCBRIDE, L; LU, B			PURIFICATION OF A NOVEL PROTEIN (PS20) FROM UROGENITAL SINUS MESENCHYMAL CELLS WITH GROWTH-INHIBITORY PROPERTIES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL-EPITHELIAL INTERACTIONS; RODENT URINARY-BLADDER; FUNCTIONAL CYTODIFFERENTIATION; PROSTATIC DEVELOPMENT; TISSUE RECOMBINANTS; INDUCTION; DIFFERENTIATION; TRACT; DUCT	Our previous studies have characterized mesenchyme-derived proteins to identify biologically active proteins and novel markers for stromal cell paracrine action relative to stromal-epithelial interactions. Previous reports have characterized properties of a growth inhibitory activity (to bladder and prostatic epithelial cells), secreted by U4F fetal rat urogenital sinus mesenchymal cells, not cross-reactive with antibodies to known cytokines, and provisionally termed UGIF. The present study reports the characterization, purification, and biological properties of a 20-21-kDa protein responsible for UGIF activity. The 20-21-kDa protein (termed ps20) was purified to near homogeneity, the amino-terminal sequence was determined, and biological properties were characterized in vitro. Amino-terminal sequence analysis indicated no direct matches or regions of homology with known proteins. Purified ps20 induced a linear and saturable inhibition of [H-3]thymidine incorporation in PC-3 prostatic carcinoma cells (half-maximal activity at 2.6 nM), inhibited cell proliferation (increased population doubling time from 19.8 to 25.8 h), and induced a 210% stimulation in the synthesis of secreted proteins. These data suggest that ps20 may be a candidate paracrine effector protein and may play a role in stromal-epithelial cell interactions in the prostate gland.	BAYLOR COLL MED,CELL & MOLEC BIOL PROGRAM,HOUSTON,TX 77030	Baylor College of Medicine	ROWLEY, DR (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA58093] Funding Source: Medline; NIDDK NIH HHS [DK45909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; CHUNG LWK, 1988, BIOL REPROD, V39, P50, DOI 10.1095/biolreprod39.1.50; COOKE PS, 1986, P NATL ACAD SCI USA, V83, P2109, DOI 10.1073/pnas.83.7.2109; CUNHA GR, 1976, INT REV CYTOL, V47, P137, DOI 10.1016/S0074-7696(08)60088-1; CUNHA GR, 1983, J CELL BIOL, V96, P1662, DOI 10.1083/jcb.96.6.1662; CUNHA GR, 1972, ANAT REC, V172, P179, DOI 10.1002/ar.1091720206; CUNHA GR, 1992, J ANDROL, V13, P465; CUNHA GR, 1980, BIOL REPROD, V22, P19, DOI 10.1095/biolreprod22.1.19; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DREWS U, 1977, CELL, V10, P401, DOI 10.1016/0092-8674(77)90027-7; FUJII H, 1982, J UROLOGY, V128, P858, DOI 10.1016/S0022-5347(17)53221-8; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAYASHI N, 1991, CANCER RES, V51, P4924; HIGGINS SJ, 1989, DEVELOPMENT, V106, P219; HIGGINS SJ, 1989, DEVELOPMENT, V106, P235; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; LACROIX B, 1985, BIOL CELL, V54, P235, DOI 10.1111/j.1768-322X.1985.tb00399.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH CM, 1983, CANCER RES, V43, P1355; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3066, DOI 10.1210/en.130.5.3066; ROWLEY DR, 1995, CANCER RES, V55, P781; ROWLEY DR, 1992, IN VITRO CELL DEV-AN, V28A, P29; ROWLEY DR, 1987, CANCER RES, V47, P2955; ROWLEY DR, 1992, ENDOCRINOLOGY, V130, P471; SMITH BT, 1983, P NATL ACAD SCI-BIOL, V80, P1951, DOI 10.1073/pnas.80.7.1951	28	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22058	22065		10.1074/jbc.270.37.22058	http://dx.doi.org/10.1074/jbc.270.37.22058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665628	hybrid			2022-12-27	WOS:A1995RU75700094
J	PEARCE, DA; SHERMAN, F				PEARCE, DA; SHERMAN, F			DEGRADATION OF CYTOCHROME-OXIDASE SUBUNITS IN MUTANTS OF YEAST LACKING CYTOCHROME-C AND SUPPRESSION OF THE DEGRADATION BY MUTATION OF YME1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; HEME LYASE; NUCLEAR MUTATIONS; GENE; PROTEIN; MITOCHONDRIA; IMPORT; IDENTIFICATION; DENITRIFICANS; DEFICIENT	We have confirmed by spectral analysis that cytochrome oxidase is not present in strains of the yeast Saccharomyces cerevisiae having a primary deficiency in cytochrome c, and we have demonstrated by immunological procedures that such strains lack the mitochondrially encoded subunits I, II, and III of cytochrome oxidase. Furthermore, pulse-chase experiments demonstrated that subunit II is rapidly degraded in vivo. This degradation can be at least partially suppressed by disruption of the nuclear gene YME1, which encodes a putative ATP-Zn2+-dependent protease. We suggest that the cytochrome oxidase subunits are not properly assembled in the absence of cytochrome c, and that Yme1 and possibly other proteases degrade the unassembled mitochondrial-encoded subunits of cytochrome oxidase.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BOTTORFF DA, 1994, CURR GENET, V26, P329, DOI 10.1007/BF00310497; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; DOWNIE JA, 1977, J MOL BIOL, V113, P364; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; NAKAI T, 1994, J BIOCHEM-TOKYO, V116, P752, DOI 10.1093/oxfordjournals.jbchem.a124592; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; REID GA, 1983, METHOD ENZYMOL, V97, P324; REILLY C, 1965, BIOCHIM BIOPHYS ACTA, V95, P640, DOI 10.1016/0005-2787(65)90518-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SHERMAN F, 1966, P NATL ACAD SCI USA, V55, P1498, DOI 10.1073/pnas.55.6.1498; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; THORSNESS PE, 1993, GENETICS, V134, P21; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WEBER ER, 1995, GENETICS, V140, P435; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YAMAMOTO T, 1992, GENETICS, V131, P811	43	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20879	20882		10.1074/jbc.270.36.20879	http://dx.doi.org/10.1074/jbc.270.36.20879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673107	hybrid			2022-12-27	WOS:A1995RU05400003
J	KOSAKI, A; PILLAY, TS; XU, L; WEBSTER, NJG				KOSAKI, A; PILLAY, TS; XU, L; WEBSTER, NJG			THE B-ISOFORM OF THE INSULIN-RECEPTOR SIGNALS MORE EFFICIENTLY THAN THE A-ISOFORM IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; KINASE FAMILY; PROTEIN; SUBUNIT; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INTERNALIZATION; MECHANISM; VARIANTS; DOMAINS	We have demonstrated previously that dexamethasone treatment of HepG2 cells caused an enhancement of insulin's metabolic effects (Kosaki, A, and Webster, N. J. (1993) J. Biol. Chem. 268, 21990-21996). This correlated with increased expression of the mRNA encoding the B isoform of the insulin receptor (IR). In the present study, we have demonstrated that dexamethasone treatment caused in addition an enhancement in insulin-stimulated immediate-early gene expression (c-fos and egr-1). Dexamethasone treatment caused an increase in in vivo IR autophosphorylation and insulin receptor substrate-1 (IRS-1) phosphorylation both early events in the insulin signaling pathway. Furthermore, the IRS-1 phosphorylation was distinctly left shifted, although the level of IRS-1 protein was unchanged. Total cellular tyrosine phosphatase activity was unaltered when assayed with P-32-labeled IR and IRS-1. Studies in vitro on wheat-germ agglutinin-purified receptors showed that the B isoform of the IR had increased kinase activity both toward itself and the exogenous substrates poly-glu(4):tyr(1) and recombinant IRS-1 protein. In addition, two dimensional tryptic phosphopeptide maps indicated that the B isoform has an additional phosphopeptide that is not seen for the A isoform. In conclusion, it appears that the B isoform of the IR signals more efficiently than the A isoform in HepG2 cells.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; DEPT VET AFFAIRS MED CTR,MED RES SERV,SAN DIEGO,CA 92121	University of California System; University of California San Diego			Webster, Nick/AAI-8410-2021	pillay, tahir/0000-0002-9982-9710	NIDDK NIH HHS [DK44643] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044643] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRILLON DJ, 1989, DIABETES, V38, P397, DOI 10.2337/diabetes.38.3.397; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EDGE ASB, 1994, BIOCHEM BIOPH RES CO, V200, P852, DOI 10.1006/bbrc.1994.1529; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; KAHN CR, 1985, ANNU REV MED, V36, P429; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PILLAY TS, 1991, FEBS LETT, V288, P206, DOI 10.1016/0014-5793(91)81035-7; PODSKALNY JM, 1985, EUR J BIOCHEM, V150, P401, DOI 10.1111/j.1432-1033.1985.tb09034.x; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P767; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILLIAMS JF, 1990, ENDOCRINOLOGY, V127, P1706, DOI 10.1210/endo-127-4-1706; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	35	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20816	20823		10.1074/jbc.270.35.20816	http://dx.doi.org/10.1074/jbc.270.35.20816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657666	hybrid			2022-12-27	WOS:A1995RR58400087
J	SPHYRIS, N; LORD, JM; WALES, R; ROBERTS, LM				SPHYRIS, N; LORD, JM; WALES, R; ROBERTS, LM			MUTATIONAL ANALYSIS OF THE RICINUS LECTIN B-CHAINS - GALACTOSE-BINDING ABILITY OF THE 2-GAMMA SUBDOMAIN OF RICINUS-COMMUNIS AGGLUTININ B-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM; SEQUENCE; OLIGOSACCHARIDES; SPECIFICITY; SACCHARIDES; PRODUCT; RESIDUE; BEANS; SITE	Ricin B-chain (RTB) is a galactose-specific lectin that folds into two globular domains, each of which binds a single galactoside. The two binding sites are structurally similar and both contain a conserved tripeptide kink and an aromatic residue that comprises a sugar-binding platform. Whereas the critical RTB residues implicated in lectin activity are conserved in domain 1 of Ricinus communis agglutinin (RCA) B chain, the sugar platform aromatic residue Tyr-248 present in domain 2 of RTB is replaced by His in RCA B-chain. In this study, key residues in the vicinity of the binding sites of the Ricinus lectin B chains were altered by site directed mutagenesis. The recombinant B-chains were produced in Xenopus oocytes in soluble, stable, and core-glycosylated forms. Both sites of RCA B chain must be simultaneously modified in order to abolish lectin activity, indicating the presence of two independent, functional binding sites/molecule. Activity associated with the domain 2 site of RCA B chain is abrogated by the conversion of Trp-258 to Ser. Moreover, the domain 2 site appears responsible for a weak binding interaction of recombinant RCA B-chain with GalNAc, not observed with native tetrameric RCA. Finally, the introduction of His at position 248 of RTB severely disrupts but does not abolish GalNAc binding.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick			SPHYRIS, NATHALIE/GQY-6349-2022	Sphyris, Nathalie/0000-0003-1860-1958				ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; [Anonymous], 1981, BIOCHEM J; ARAKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P191, DOI 10.1016/0167-4838(87)90008-2; CAWLEY DB, 1979, BIOCHIM BIOPHYS ACTA, V581, P51, DOI 10.1016/0005-2795(79)90220-4; CAWLEY DB, 1978, ARCH BIOCHEM BIOPHYS, V190, P744, DOI 10.1016/0003-9861(78)90335-1; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; GREEN ED, 1987, J BIOL CHEM, V262, P12030; HATAKEYAMA T, 1990, AGR BIOL CHEM TOKYO, V54, P1085, DOI 10.1080/00021369.1990.10870063; HATAKEYAMA T, 1986, J BIOCHEM, V99, P1049, DOI 10.1093/oxfordjournals.jbchem.a135568; HATAKEYAMA T, 1989, J BIOCHEM-TOKYO, V105, P444, DOI 10.1093/oxfordjournals.jbchem.a122684; HOUSTON LL, 1982, J BIOL CHEM, V257, P4147; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LORD JM, 1985, FEBS LETT, V189, P72, DOI 10.1016/0014-5793(85)80844-9; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NICOLSON GL, 1972, BIOCHIM BIOPHYS ACTA, V266, P543, DOI 10.1016/0005-2736(72)90109-5; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OLSNES A, 1982, MOL ACTIONS TOXINS V, P52; PODDER SK, 1974, EUR J BIOCHEM, V44, P151, DOI 10.1111/j.1432-1033.1974.tb03468.x; RICHARDSON PT, 1988, BIO-TECHNOL, V6, P565, DOI 10.1038/nbt0588-565; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SOLIS D, 1993, EUR J BIOCHEM, V214, P677, DOI 10.1111/j.1432-1033.1993.tb17968.x; SUROLIA A, 1978, INDIAN J BIOCHEM BIO, V15, P248; VILLAFRANCA JE, 1981, J BIOL CHEM, V256, P554; WALES R, 1991, J BIOL CHEM, V266, P19172; WRIGHT CS, 1980, J MOL BIOL, V141, P267, DOI 10.1016/0022-2836(80)90181-3; YAMASAKI N, 1985, J BIOCHEM-TOKYO, V98, P1555, DOI 10.1093/oxfordjournals.jbchem.a135424; ZENTZ C, 1978, BIOCHIM BIOPHYS ACTA, V536, P18, DOI 10.1016/0005-2795(78)90047-8	32	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20292	20297		10.1074/jbc.270.35.20292	http://dx.doi.org/10.1074/jbc.270.35.20292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657599	hybrid			2022-12-27	WOS:A1995RR58400012
J	GARCIACUELLAR, MP; ESTEBAN, LM; FUJIMURA, T; RODRIGUEZCOUSINO, N; ESTEBAN, R				GARCIACUELLAR, MP; ESTEBAN, LM; FUJIMURA, T; RODRIGUEZCOUSINO, N; ESTEBAN, R			YEAST VIRAL 20S RNA IS ASSOCIATED WITH ITS COGNATE RNA-DEPENDENT RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; GENES; REPLICATION; SPORULATION; EXPRESSION; REPLICON; FORM	Most Saccharomyces cerevisiae strains carry in their cytoplasm 20 S RNA, a Linear single-stranded RNA molecule of 2.5 kilobases in size. 20 S RNA copy number is greatly induced in stress conditions such as starvation, with up to 100,000 copies per cell. 20 S RNA has coding capacity for a protein of 91 kDa (p91) with sequences diagnostic of RNA-dependent RNA polymerases of (+) strand and double-stranded RNA viruses. We detected p91 in 20 S RNA-carrying strains with specific antisera. The amount of p91 in growing cells is higher than that of stationary cells and similar to the one in 20 S RNA-induced cells. Although 20 S RNA is not encapsidated into viral particles, p91 non-covalently forms a ribonucleoprotein complex with 20 S RNA. This suggests a role of p91 in the RNA to RNA synthesis processes required for 20 S RNA replication. Although the strain analyzed also harbors 23 S RNA, a closely related single-stranded RNA, 23 S RNA is not associated with p91 but with its putative RNA polymerase, p104. Similarly, 20 S RNA is not associated with p104 but with p91. These results suggest that 20 S RNA and 23 S RNA replicate independently using their respective cognate RNA polymerases.	UNIV SALAMANCA,CONSEJO SUPER INVEST CIENTIFICAS,DEPT GENET & MICROBIOL,INST MICROBIOL BIOQUIM,E-37071 SALAMANCA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca			Fujimura, Tsutomu/K-5807-2014; Rodríguez-Cousiño, Nieves/K-6465-2014; Esteban, Rosa/K-4356-2014	Fujimura, Tsutomu/0000-0002-9457-6769; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Esteban, Rosa/0000-0001-6804-7209				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1992, J BIOL CHEM, V287, P10874; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; FRIED HM, 1978, P NATL ACAD SCI USA, V75, P4224, DOI 10.1073/pnas.75.9.4224; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARVIK B, 1978, J BACTERIOL, V134, P261, DOI 10.1128/JB.134.1.261-269.1978; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Matthews REF., 2002, PLANT VIROLOGY; MEYER F, 1981, J MOL BIOL, V153, P631, DOI 10.1016/0022-2836(81)90411-3; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLASHOCK JJ, 1994, P NATL ACAD SCI USA, V91, P8680, DOI 10.1073/pnas.91.18.8680; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1978, GENETICS, V88, P419; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	32	16	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20084	20089		10.1074/jbc.270.34.20084	http://dx.doi.org/10.1074/jbc.270.34.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650026	hybrid			2022-12-27	WOS:A1995RQ99100062
J	JOSEPH, M; NAGARAJ, R				JOSEPH, M; NAGARAJ, R			CONFORMATIONS OF PEPTIDES CORRESPONDING TO FATTY ACYLATION SITES IN PROTEINS - A CIRCULAR-DICHROISM STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION SIGNAL; COMPLETE SEQUENCE; WATER SOLUTION; BETA-TURNS; FRAGMENTS; INITIATION; VIRUS; ACID; MYRISTYLATION; TYROSINE	Fatty acid acylation is a posttranslational modification found in membrane proteins that have hydrophobic sequences serving as transmembrane segments as well as those that do not have them. The fatty acids myristate and palmitate are linked through an amide bond to N-terminal glycine and SH of cysteine via a thioester bond, respectively. In order to elucidate whether or how fatty acid acylation would modulate peptide structure, especially in hydrophobic environment, we have carried out circular dichroism studies on synthetic peptides both hydrophobic and hydrophilic in nature, corresponding to fatty acylation sites and their fatty acyl derivatives. The hydrophilic peptides were similar to 12 residues in length as studies on proteins modified by site directed mutagenesis indicated that a peptide segment of similar to 12 residues is sufficient to direct acylation as well as membrane association, especially when the fatty acid is myristic acid. The peptide corresponding to a transmembrane segment composed of 31 residues as well as its palmitoyl derivative was found to adopt alpha-helical structure. Acylation appeared to favor increased partitioning into micelles even in the case of a hydrophobic peptide. The hydrophilic peptides and their myristoyl or palmitoyl derivatives showed very little ordered structure in micelles. Our results suggest that the myristoyl and the palmitoyl moieties do not have the ability to ''force'' a hydrophilic peptide segment into a hydrophobic micellar environment. Thus, the mere presence of a fatty acid moiety may not be sufficient for membrane binding and recycling as is assumed especially in proteins in which no hydrophobic segment is present.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								Atherton E., 1990, SOLID PHASE PEPTIDE; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BRAHMACHARI SK, 1981, J AM CHEM SOC, V103, P1703, DOI 10.1021/ja00397a020; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GILLEN MF, 1975, CAN J CHEM, V53, P2351, DOI 10.1139/v75-329; GISIN BF, 1973, HELV CHIM ACTA, V56, P1476, DOI 10.1002/hlca.19730560503; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOSEPH M, 1993, BIOORG MED CHEM LETT, V3, P1025, DOI 10.1016/S0960-894X(00)80280-2; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KEMMINK J, 1993, J MOL BIOL, V234, P861, DOI 10.1006/jmbi.1993.1631; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; RENIL M, 1994, TETRAHEDRON, V50, P6681, DOI 10.1016/S0040-4020(01)89696-4; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; Stewart JM, 1984, SOLID PHASE PEPTIDE; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19439	19445		10.1074/jbc.270.33.19439	http://dx.doi.org/10.1074/jbc.270.33.19439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642626	hybrid			2022-12-27	WOS:A1995RP70300040
J	HUGHES, CA; BENNETT, V				HUGHES, CA; BENNETT, V			ADDUCIN - A PHYSICAL MODEL WITH IMPLICATIONS FOR FUNCTION IN ASSEMBLY OF SPECTRIN-ACTIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ERYTHROCYTE ADDUCIN; MEMBRANE SKELETON; ALPHA-ADDUCIN; BETA-ADDUCIN; CALMODULIN; BINDING; PURIFICATION; CLONING; DOMAIN	Adducin binds to spectrin-actin complexes, promotes association of spectrin with actin, and is subject to regulation by calmodulin as well as protein kinases A and C. Adducin is a heteromer comprised of homologous alpha- and beta-subunits with an NH2-terminal protease-resistant head domain, connected by a neck region to a COOH-terminal hydrophilic, protease-sensitive region, This study provides evidence that adducin in solution is a mixture of heterodimers and tetramers. CD spectroscopy of COOH-terminal domains of alpha- and beta-adducin bacterial recombinants provides direct evidence for an unstructured random coil configuration, Cross-linking, proteolysis, and blot binding experiments suggest a model for the adducin tetramer in which four head domains contact one another to form a globular core with extended interacting alpha- and beta-adducin tails. The site for binding to spectrin-actin complexes on adducin was identified as the COOH-terminal tail of both the alpha- and beta-adducin subunits. The capacity of native adducin to recruit spectrin to actin filaments is similar to that of adducin tail domains. Thus, adducin tail domains alone are sufficient to interact with F-actin and a single spectrin and to recruit additional spectrin molecules to the ternary complex.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University	HUGHES, CA (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GARDNER K, 1988, P293; GILLIGAN DM, 1991, J CELL BIOL, V115, P42; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LING E, 1986, J BIOL CHEM, V261, P13875; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; NEHLS V, 1991, BLOOD, V78, P1692; NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINARD JH, 1994, MOL BIOL CELL, V5, P421; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanford C, 1961, PHYS CHEM MACROMOLEC, P364; TAYLOR KA, 1993, J MOL BIOL, V230, P196, DOI 10.1006/jmbi.1993.1136; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WASEEM A, 1988, FASEB J, V2, pA349; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	41	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18990	18996		10.1074/jbc.270.32.18990	http://dx.doi.org/10.1074/jbc.270.32.18990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642559	hybrid			2022-12-27	WOS:A1995RN95400047
J	LOW, SC; HARNEY, JW; BERRY, MJ				LOW, SC; HARNEY, JW; BERRY, MJ			CLOTTING AND FUNCTIONAL-CHARACTERIZATION OF HUMAN SELENOPHOSPHATE SYNTHETASE, AN ESSENTIAL COMPONENT OF SELENOPROTEIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; 3' UNTRANSLATED REGION; OPEN READING FRAME; SELD GENE-PRODUCT; ESCHERICHIA-COLI; TRANSFER-RNA; SELENOCYSTEINE SYNTHASE; CLOSTRIDIUM-KLUYVERI; NUCLEOTIDE-SEQUENCE; TRANSLATION FACTOR	Selenocysteine is co translationally incorporated into prokaryotic and eukaryotic selenoproteins at in-frame UGA codons. However, the only component of the eukaryotic selenocysteine incorporation machinery identified to date is the selenocysteine-specific tRNA(Sec). In prokaryotes, selenocysteine is synthesized from seryl-tRNA(Sec) and the active selenium donor, selenophosphate. Selenophosphate is synthesized from selenide and ATP by the selD gene product, selenophosphate synthetase, and is required for selenocysteine synthesis and incorporation into bacterial selenoproteins. We have now cloned human selD and shown that transfection of the human selD cDNA into mammalian cells results in increased selenium labeling of a mammalian selenoprotein, type 1 iodothyronine deiodinase. Despite significant differences between the mechanisms of selenoprotein synthesis in prokaryotes and eukaryotes, human selD weakly complements a bacterial selD mutation, partially restoring selenium incorporation into bacterial selenoproteins. Human selenophosphate synthetase has only 32% homology with the bacterial protein, although a highly homologous region that has similarity to a consensus ATP/GTP binding domain has been identified. Point mutations within this region result in decreased incorporation of selenium into type 1 iodothyronine deiodinase in all but one case. Further analysis revealed that reduced selenium labeling was due to altered ATP binding properties of the mutant selenophosphate synthetases.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LOW, SC (corresponding author), BRIGHAM & WOMENS HOSP,DIV THYROID,75 FRANCIS ST,BOSTON,MA 02115, USA.				NIDDK NIH HHS [DK47320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320, R56DK047320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bock A, 1988, Biofactors, V1, P245; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; COWIE DB, 1957, BIOCHIM BIOPHYS ACTA, V26, P252, DOI 10.1016/0006-3002(57)90003-3; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GLASS RS, 1993, BIOCHEMISTRY-US, V32, P12555, DOI 10.1021/bi00210a001; GOLEMIS EA, 1994, CURRENT PROTOCOLS S, V27; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTMANIS MGN, 1982, P NATL ACAD SCI-BIOL, V79, P4912, DOI 10.1073/pnas.79.16.4912; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; HUBER RE, 1967, BIOCHIM BIOPHYS ACTA, V141, P581; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM IY, 1992, J BIOL CHEM, V267, P19650; KIM IY, 1993, J BIOL CHEM, V268, P27020; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9696; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LIU F, 1992, J BIOL CHEM, V267, P2388; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEED B, 1983, NUCLEIC ACIDS RES, V11, P2427, DOI 10.1093/nar/11.8.2427; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SLIWKOWSKI MX, 1985, J BIOL CHEM, V260, P3140; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TORMAY P, 1994, J BACTERIOL, V176, P1268, DOI 10.1128/jb.176.5.1268-1274.1994; VERES Z, 1994, J BIOL CHEM, V269, P10597; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	48	158	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21659	21664		10.1074/jbc.270.37.21659	http://dx.doi.org/10.1074/jbc.270.37.21659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665581	hybrid			2022-12-27	WOS:A1995RU75700038
J	FIRTH, JD; EBERT, BL; RATCLIFFE, PJ				FIRTH, JD; EBERT, BL; RATCLIFFE, PJ			HYPOXIC REGULATION OF LACTATE-DEHYDROGENASE-A - INTERACTION BETWEEN HYPOXIA-INDUCIBLE FACTOR-1 AND CAMP RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; GLUCAGON-DEPENDENT ACTIVATION; RAT HEPATOCYTE CULTURES; HEME PROTEIN; TRANSCRIPTIONAL ENHANCER; FUNCTIONAL-ANALYSIS; OXYGEN SENSOR; CYCLIC-AMP; FACTOR-I	The oxygen-regulated control system responsible for the induction of erythropoietin (Epo) by hypoxia is present in most (if not all) cells and operates on other genes, including those involved in energy metabolism. To understand the organization of cis-acting sequences that are responsible for oxygen-regulated gene expression, we have studied the 5' flanking region of the mouse gene encoding the hypoxically inducible enzyme lactate dehydrogenase A (LDH). Deletional and mutational analysis of the function of mouse LDH-reporter fusion gene constructs in transient transfection assays defined three domains, between -41 and -84 base pairs up stream of the transcription initiation site, which were crucial for oxygen-regulated expression, The most important of these, although not capable of driving hypoxic induction in isolation, had the consensus of a hypoxia-inducible factor 1 (HIF-1) site, and cross-competed for the binding of HIF-1 with functionally active Epo and phosphoglycerate kinase-1 sequences. The second domain was positioned close to the HIF-1 site, in an analogous position to one of the critical regions in the Epo 3' hypoxic enhancer, The third domain had the motif of a cAMP response element (CRE), Activation of cAMP by forskolin had no effect on the level of LDH mRNA in normoxia, but produced a magnified response to hypoxia that was dependent upon the integrity of the CRE, indicating an interaction between inducible factors binding the HIF-1 and CRE sites.			FIRTH, JD (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,ERYTHROPOIETIN GRP,RM 420,OXFORD OX3 9DU,ENGLAND.			Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BECK I, 1993, BLOOD, V82, P704; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GORLACH A, 1994, FEBS LETT, V348, P216, DOI 10.1016/0014-5793(94)00607-5; JUNGMANN RA, 1982, J BIOL CHEM, V258, P5312; KIETZMANN T, 1992, FEBS LETT, V311, P251, DOI 10.1016/0014-5793(92)81113-Z; KIETZMANN T, 1993, BIOCHEM BIOPH RES CO, V195, P792, DOI 10.1006/bbrc.1993.2115; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MARTI HH, 1994, PFLUG ARCH EUR J PHY, V429, P216, DOI 10.1007/BF00374315; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MILES MF, 1981, J BIOL CHEM, V256, P2545; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; RODGERS GM, 1972, P SOC EXP BIOL MED, V140, P977; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHORT S, 1991, J BIOL CHEM, V266, P22164; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WOLFLE D, 1985, EUR J BIOCHEM, V151, P299, DOI 10.1111/j.1432-1033.1985.tb09100.x	34	392	401	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21021	21027		10.1074/jbc.270.36.21021	http://dx.doi.org/10.1074/jbc.270.36.21021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673128	hybrid			2022-12-27	WOS:A1995RU05400025
J	FRIEDBERG, I; BELZER, I; OGEDPLESZ, O; KUEBLER, D				FRIEDBERG, I; BELZER, I; OGEDPLESZ, O; KUEBLER, D			ACTIVATION OF CELL-GROWTH INHIBITOR BY ECTOPROTEIN KINASE-MEDIATED PHOSPHORYLATION IN TRANSFORMED MOUSE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCTION PATHWAYS LEAD; ATP-STIMULATED MITOGENESIS; TUMOR-BEARING HOSTS; EXTRACELLULAR ATP; PROTEIN-KINASE; ADENINE-NUCLEOTIDES; EXOGENOUS ATP; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; SYNAPTIC TRANSMISSION	Our previous studies have shown that exogenous ATP induces cell growth inhibition in transformed mouse fibroblasts, 3T6 cells, whereas the growth of their nontransformed counterparts, Swiss 3T3 cells, is only slightly affected. In this study a similar selective, ATP-induced growth inhibition was found in Balb/c SV40-3T3 cells and in primary cultures of adenovirus-transformed murine fibroblasts. The inhibitory activity was found in the conditioned media of ATP-treated cultures. Several lines of evidence have shown that ectoprotein kinase (ecto-PK) plays a major role in the ATP-induced growth inhibition. (a) There is a good correlation between the activity of ecto-PK and the ability of ATP to induce cell growth inhibition. (b) The removal of the ecto-PK from the cell surface prevents the ATP-induced growth inhibition. (c) Addition of the removed enzyme to the cell culture reconstitutes the ability of ATP to induced growth inhibition. (d) Serum-containing, or serum-free, conditioned media from untreated cultures gain an inhibitory activity after their phosphorylation, and dephosphorylation of conditioned media from ATP-treated cultures results in the loss of the inhibitory activity. (e) Growth medium by itself does not inhibit cell proliferation after its phosphorylation. The findings described in d and e indicate, as well, that the ATP-induced growth inhibitor is produced by the cells. The putative inhibitor was found to be a protein, with an apparent molecular mass of 13 kDa. The selectivity of the inhibition for transformed cells is due to the higher level of ecto-PK in these cells, as well as to their higher susceptibility to the inhibitor, as compared with their nontransformed counterparts.	GERMAN CANC RES CTR, DKFZ, DIV PATHOCHEM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	FRIEDBERG, I (corresponding author), TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; AHARONI D, 1991, J BASIC CLIN PHYSL P, V3, pA3; BELZER I, 1984, ISRAEL J MED SCI, V20, P483; BELZER I, 1989, J CELL PHYSIOL, V140, P524, DOI 10.1002/jcp.1041400318; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1978, EUR J PHARMACOL, V49, P145, DOI 10.1016/0014-2999(78)90070-5; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CHAHWALA SB, 1984, J BIOL CHEM, V259, P3717; CHAUDRY IH, 1984, SURG FORUM, V35, P13; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; DE BK, 1991, BIOCHEM BIOPH RES CO, V178, P830, DOI 10.1016/0006-291X(91)90966-B; DELAVEGA MCL, 1994, BIOCHEM J, V298, P99; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FEHST M, 1985, BIOCHEM BIOPH RES CO, V133, P8, DOI 10.1016/0006-291X(85)91834-0; FRIEDBERG I, 1985, J MEMBRANE BIOL, V83, P251, DOI 10.1007/BF01868699; FRIEDBERG I, 1990, ANN NY ACAD SCI, V603, P513; GONZALEZ FA, 1989, BIOCHEM BIOPH RES CO, V164, P706, DOI 10.1016/0006-291X(89)91517-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAREL L, 1985, J CELL PHYSIOL, V123, P139, DOI 10.1002/jcp.1041230120; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HIRASAWA H, 1985, CIRC SHOCK, V16, P337; HSU YM, 1986, J CELL BIOL, V102, P362, DOI 10.1083/jcb.102.2.362; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; HUANG NN, 1992, BIOCHEM BIOPH RES CO, V182, P836, DOI 10.1016/0006-291X(92)91808-4; JORDAN P, 1994, BIOCHEMISTRY-US, V33, P14696, DOI 10.1021/bi00253a007; JORDAN P, 1992, BIOCHEM INT, V26, P97; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1992, EUR J BIOCHEM, V206, P179, DOI 10.1111/j.1432-1033.1992.tb16915.x; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1990, ANN NY ACAD SCI, V603, P516; KUBLER D, 1982, J BIOL CHEM, V257, P322; MASTRO AM, 1976, J BIOL CHEM, V251, P7899; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/bj2880897; PIZZO P, 1992, J IMMUNOL, V149, P3372; PRAT A, 1992, J GEN PHYSIOL, V444, pA33; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; RAPAPORT E, 1983, CANCER RES, V43, P4402; RAPAPORT E, 1983, J CELL PHYSIOL, V114, P279, DOI 10.1002/jcp.1041140305; RAPAPORT E, 1993, DRUG DEVELOP RES, V28, P428, DOI 10.1002/ddr.430280344; RAPAPORT E, 1988, EUR J CANCER CLIN ON, V24, P1491, DOI 10.1016/0277-5379(88)90340-9; RAPAPORT E, 1990, ANN NY ACAD SCI, V603, P142; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SPUNGIN B, 1993, J CELL PHYSIOL, V157, P502, DOI 10.1002/jcp.1041570309; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1991, CURR OPIN IMMUNOL, V3, P71, DOI 10.1016/0952-7915(91)90080-K; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UNSWORTH CD, 1990, P NATL ACAD SCI USA, V87, P553, DOI 10.1073/pnas.87.2.553; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; WANG P, 1992, CIRC SHOCK, V36, P277; WEISMAN GA, 1984, FED PROC, V43, P520; WEISMAN GA, 1989, METHOD ENZYMOL, V171, P857; WEISMAN GA, 1988, J BIOL CHEM, V263, P12367; WEISMAN GA, 1984, J CELL PHYSIOL, V119, P211, DOI 10.1002/jcp.1041190211; WINKLER H, 1987, ANN NY ACAD SCI, V493, P3, DOI 10.1111/j.1749-6632.1987.tb27176.x; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	71	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20560	20567		10.1074/jbc.270.35.20560	http://dx.doi.org/10.1074/jbc.270.35.20560			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657633	hybrid			2022-12-27	WOS:A1995RR58400052
J	ITOH, T; SUZUKI, A; WATANABE, Y; MINO, T; NAKA, M; TANAKA, T				ITOH, T; SUZUKI, A; WATANABE, Y; MINO, T; NAKA, M; TANAKA, T			A CALPONIN PEPTIDE ENHANCES CA2+ SENSITIVITY OF SMOOTH-MUSCLE CONTRACTION WITHOUT AFFECTING MYOSIN LIGHT-CHAIN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MESENTERIC-ARTERY; PROTEIN-KINASE-C; CHICKEN GIZZARD; TENSION; ACTOMYOSIN; ACTIN; COMPONENTS; CALMODULIN	In permeabilized smooth muscle, exogenously applied calponin binds to myofibrils and reduces Ca2+-activated tension (Itoh, T., Suzuki, S., Suzuki, A., Nakamura, F., Naka, M., and Tanaka, T. (1994) Pflugers Arch. Eur. J. Physiol. 427, 301-308). A calponin peptide (calponin Phe(173)-Arg(185)), which inhibits the binding of calponin to actin, blocks the action of calponin and enhances the contraction induced by submaximal Ca2+ in permeabilized vascular smooth muscle. Unlike calmodulin, this peptide enhances the Ca2+-induced contraction without a corresponding increase in the level of myosin light chain phosphorylation. These results suggest that calponin decreases the sensitivity of smooth muscle to Ca2+ at a given level of myosin light chain phosphorylation.	KYUSHU UNIV,FAC MED,DEPT PHARMACOL,FUKUOKA 812,JAPAN; MIE UNIV,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,TSU,MIE 514,JAPAN	Kyushu University; Mie University								ADELSTEIN RS, 1980, REV BIOCH, V44, P921; CASSIDY P, 1982, BIOCHIM BIOPHYS ACTA, V705, P63, DOI 10.1016/0167-4838(82)90336-3; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITOH T, 1992, J PHYSIOL-LONDON, V457, P297, DOI 10.1113/jphysiol.1992.sp019379; ITOH T, 1986, J PHYSIOL-LONDON, V376, P231, DOI 10.1113/jphysiol.1986.sp016151; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; ITOH T, 1994, PFLUG ARCH EUR J PHY, V427, P301, DOI 10.1007/BF00374538; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MORELAND S, 1992, AM J PHYSIOL, V263, pC540, DOI 10.1152/ajpcell.1992.263.2.C540; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; NODA S, 1992, BIOCHEM BIOPH RES CO, V185, P481, DOI 10.1016/S0006-291X(05)81010-1; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SUZUKI A, 1993, BRIT J PHARMACOL, V109, P703, DOI 10.1111/j.1476-5381.1993.tb13631.x; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	27	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20400	20403		10.1074/jbc.270.35.20400	http://dx.doi.org/10.1074/jbc.270.35.20400			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657614	hybrid			2022-12-27	WOS:A1995RR58400027
J	RAO, S; ORR, GA; CHAUDHARY, AG; KINGSTON, DGI; HORWITZ, SB				RAO, S; ORR, GA; CHAUDHARY, AG; KINGSTON, DGI; HORWITZ, SB			CHARACTERIZATION OF THE TAXOL BINDING-SITE ON THE MICROTUBULE - 2-(M-AZIDOBENZOYL)TAXOL PHOTOLABELS A PEPTIDE (AMINO-ACIDS 217-231) OF BETA-TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ASSEMBLY INVITRO; PROTEINS; IDENTIFICATION; COLCHICINE; MECHANISM; CLEAVAGE; ABSENCE; AGENT	Photoaffinity labeling methods are being used to define the molecular contacts between taxol and its target protein, tubulin. Our laboratory has demonstrated previously that [H-3]3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin (Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. (1994) J. Biol. Chem. 269, 3132-3134). The interaction of a second photoaffinity analogue of taxol, [H-3]2-(m-azidobenzoyl)taxol, with tubulin has been investigated. This analogue specifically photolabels beta-tubulin and the photolabeling is competed by both taxol and unlabeled 2-(m-azidobenzoyl)taxol indicating a common binding domain. To identify the site(s) of photoincorporation, [H-3]2-(m-azidobenzoyl)taxol-photolabeled beta-tubulin was subjected to sequential cyanogen bromide and tryptic digestions. Radiolabeled peptides were purified by reverse phase high performance liquid chromatography, and amino acid sequencing studies identified a peptide containing amino acid residues 217-231 of beta-tubulin as the major photolabeled domain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; VIRGINIA POLYTECH INST & STATE UNIV,DEPT CHEM,BLACKSBURG,VA 24061	Yeshiva University; Albert Einstein College of Medicine; Virginia Polytechnic Institute & State University			Kingston, David G. I./B-4272-2009	Kingston, David G. I./0000-0001-8944-246X	NCI NIH HHS [CA13330, CA56677, CA39821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056677, R35CA039821, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL HM, 1969, J ORG CHEM, V34, P3923, DOI 10.1021/jo01264a038; CHUDHARY AG, 1994, J AM CHEM SOC, V116, P4097; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; GROVER S, 1995, BIOCHEMISTRY-US, V34, P3927, DOI 10.1021/bi00012a009; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HALL JL, 1983, MOL CELL BIOL, V3, P854, DOI 10.1128/MCB.3.5.854; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HORWITZ SB, 1982, COLD SPRING HARB SYM, V46, P219; JAYARAM B, 1994, J BIOL CHEM, V269, P3233; KINGSTON DGI, 1994, TRENDS BIOTECHNOL, V12, P222, DOI 10.1016/0167-7799(94)90120-1; KUMAR N, 1981, J BIOL CHEM, V256, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILSON L, 1973, J CELL BIOL, V58, P709, DOI 10.1083/jcb.58.3.709; Wilson Leslie, 1994, V13, P59	32	218	233	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20235	20238		10.1074/jbc.270.35.20235	http://dx.doi.org/10.1074/jbc.270.35.20235			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657589	hybrid			2022-12-27	WOS:A1995RR58400001
J	COTTRELL, TJ; HARRIS, LJ; TANAKA, T; YADA, RY				COTTRELL, TJ; HARRIS, LJ; TANAKA, T; YADA, RY			THE SOLE LYSINE RESIDUE IN PORCINE PEPSIN WORKS AS A KEY RESIDUE FOR CATALYSIS AND CONFORMATIONAL FLEXIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ASPARTIC PROTEINASES; ACTIVE-SITE; CHYMOSIN; RESOLUTION; INCLUSION; EFFICIENT; REVEALS	Pepsin contains a single lysine residue which protrudes from the enzyme's surface, behind the active site cleft, on the C-terminal domain. Mutations of pepsin by site-directed mutagenesis of the Lys-319 residue were generated to study the structure-function relationships. Kinetic parameters, pH activity profiles, along with conformational analysis using circular dichroism (CD), and molecular modelling were examined for the wild-type (non-mutant) and mutant enzymes. The pepsin mutations, Lys-319 --> Met and Lys-319 --> Glu, resulted in a progressive increase in the K-m and similar decrease in k(cat), respectively, as well as being denatured at a lower pH than the wild-type pepsin. CD analysis indicated that mutations at Lys-319 resulted in changes in secondary structure fractions which were reflected in changes in enzymatic activity as compared to the wild-type pepsin, i.e. kinetic data and pH denaturation study. Molecular modelling of mutant enzymes indicated differences in flexibility in the flap loop region of the active site, the region around the entrance of the active site cleft, subsite regions for peptide binding, and in the subdomains of the C-terminal domain when compared to the wildtype enzyme. The results suggest that Lys-319, which is distal to the active site, is important to the flexibility/stability of the enzyme, as well as to its catalytic machinery.	UNIV GUELPH, DEPT FOOD SCI, GUELPH, ON N1G 2W1, CANADA	University of Guelph			Tanaka, Takuji/AAN-8462-2020; Harris, Linda J/B-5030-2011; Yada, Rickey Y/A-8289-2013	Harris, Linda J/0000-0002-1911-752X; Yada, Rickey/0000-0002-8648-2156				ABADZAPATERO C, 1990, PROTEINS, V8, P62, DOI 10.1002/prot.340080109; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN LQ, 1992, ACTA CRYSTALLOGR B, V48, P476, DOI 10.1107/S0108768192001939; CONRAD M, 1979, B MATH BIOL, V41, P387, DOI 10.1016/S0092-8240(79)90019-3; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P26; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; FUSEK M, 1990, J BIOL CHEM, V265, P1496; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIN XL, 1992, J BIOL CHEM, V267, P17257; LIN XL, 1993, PROTEIN SCI, V2, P1383, DOI 10.1002/pro.5560020903; Northrop JH, 1930, J GEN PHYSIOL, V13, P739, DOI 10.1085/jgp.13.6.739; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PITTS JE, 1992, SCAND J CLIN LAB INV, V52, P39, DOI 10.3109/00365519209104653; RYLE AP, 1966, BIOCHEM J, V98, P485, DOI 10.1042/bj0980485; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI J, 1990, PROTEIN ENG, V4, P69, DOI 10.1093/protein/4.1.69; SUZUKI J, 1989, PROTEIN ENG, V2, P563, DOI 10.1093/protein/2.7.563; TICHY PJ, 1993, PROTEIN EXPRES PURIF, V4, P59, DOI 10.1006/prep.1993.1009; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WILLIAMS RJP, 1993, TRENDS BIOCHEM SCI, V18, P115, DOI 10.1016/0968-0004(93)90015-F; YADA RY, 1986, J FOOD BIOCHEM, V10, P155, DOI 10.1111/j.1745-4514.1986.tb00098.x; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	26	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19974	19978		10.1074/jbc.270.34.19974	http://dx.doi.org/10.1074/jbc.270.34.19974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650014	hybrid			2022-12-27	WOS:A1995RQ99100047
J	HERSHENSON, MB; CHAO, TSO; ABE, MK; GOMES, I; KELLEHER, MD; SOLWAY, J; ROSNER, MR				HERSHENSON, MB; CHAO, TSO; ABE, MK; GOMES, I; KELLEHER, MD; SOLWAY, J; ROSNER, MR			HISTAMINE ANTAGONIZES SEROTONIN AND GROWTH FACTOR-INDUCED MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN BOVINE TRACHEAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PATHWAYS; ASTHMA; RAF; BRONCHOCONSTRICTION; PHOSPHORYLATION; STIMULATION; INHIBITION; CAMP	We examined the effects of the bronchoconstrictor agonists serotonin (5-hydroxytryptamine; 5-HT) and histamine on mitogen-activated protein (MAP) kinase activation in cultured bovine tracheal myocytes, Kinase renaturation assays demonstrated activation of the 42-and 44-kDa MAP kinases within 2 min of 5-HT exposure, MAP kinase activation was mimicked by alpha-methyl-5-HT and reduced by pretreatment with either phorbol 12,13-dibutyrate or forskolin, suggesting activation of the 5-HT, receptor, protein kinase C, and Raf-1, respectively, Raf-1 activation was confirmed by measurement of Raf-1 activity, and the requirement of Raf-1 for 5-HT-induced MAP binase activation was demonstrated by transient transfection of cells with a dominant-negative allele of Raf-1, Histamine pretreatment significantly inhibited 5-HT and insulin-derived growth factor-1-induced MAP kinase activation, Attenuation of MAP kinase activation was reversed by cimetidine, mimicked by forskolin, and accompanied by cAMP accumulation and inhibition of Raf-1, suggesting activation of the H-2 receptor and cAMP-dependent protein kinase A. However, histamine treatment inhibited Raf-1 but not MAP kinase activation following treatment with either platelet-derived growth factor or epidermal growth factor, implying a Raf-1-independent MAP kinase activation pathway, In summary, our data suggest a model whereby 5-HT activates MAP kinase via a protein kinase C/Raf-1 pathway, and histamine attenuates MAP kinase activation by serotonin via activation of cAMP-dependent protein kinase A and inhibition of Raf-1.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; University of Chicago			Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054685] Funding Source: NIH RePORTER; NCI NIH HHS [CA35541] Funding Source: Medline; NHLBI NIH HHS [HL02731, HL54685] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BUCKNER CK, 1991, J PHARMACOL EXP THER, V257, P26; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FLORIO C, 1992, AM J RESP CELL MOL, V7, P582, DOI 10.1165/ajrcmb/7.6.582; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HARTMANN T, 1992, AM J PHYSIOL, V262, pL528, DOI 10.1152/ajplung.1992.262.5.L528; HERSHENSON MB, 1994, AM J RESP CELL MOL, V11, P296, DOI 10.1165/ajrcmb.11.3.8086167; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; KAO LC, 1984, PEDIATRICS, V73, P509; KELLEHER MD, 1995, IN PRESS AM J PHYSL; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOTLIKOFF MI, 1987, AM J PHYSIOL, V253, pC561, DOI 10.1152/ajpcell.1987.253.4.C561; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGRAF LR, 1992, AM REV RESPIR DIS, V143, P391; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; PANETTIERI R, 1994, AM J RESP CRIT CARE, V149, pA303; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	37	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19908	19913		10.1074/jbc.270.34.19908	http://dx.doi.org/10.1074/jbc.270.34.19908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650005	hybrid			2022-12-27	WOS:A1995RQ99100037
J	MCDONALD, NQ; CHAO, MV				MCDONALD, NQ; CHAO, MV			STRUCTURAL DETERMINANTS OF NEUROTROPHIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTORS; AFFINITY NGF RECEPTOR; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; NEURONAL SURVIVAL; FACTOR FAMILY; TRK; PROTEIN; BINDING		CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021	Cornell University	MCDONALD, NQ (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND.			Chao, Moses/0000-0002-6969-3744				ANGELETT.RH, 1971, P NATL ACAD SCI USA, V68, P2417, DOI 10.1073/pnas.68.10.2417; ARAKAWA T, 1994, J BIOL CHEM, V269, P27833; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERG MM, 1991, P NATL ACAD SCI USA, V88, P857; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRADSHAW RA, 1993, TRENDS BIOCHEM SCI, V18, P48, DOI 10.1016/0968-0004(93)90052-O; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAO MV, 1995, TRENDS NEUROSCI, V19, P321; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; CURTIS R, 1995, NEURON, V14, P1201, DOI 10.1016/0896-6273(95)90267-8; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAVIES AM, 1994, CURR BIOL, V4, P273, DOI 10.1016/S0960-9822(00)00064-6; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DECHANT G, 1993, DEVELOPMENT, V119, P545; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FANDL JP, 1994, J BIOL CHEM, V269, P755; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; GROB PM, 1985, J BIOL CHEM, V260, P8044; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; ILAG LL, 1994, J BIOL CHEM, V269, P19941; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KELLY JA, 1994, PROTEIN SCI, V3, P982; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD N, IN PRESS WENNER GREN; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHI R, 1994, SCIENCE, V265, P1052, DOI 10.1126/science.8066443; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Server A C, 1977, Adv Protein Chem, V31, P339, DOI 10.1016/S0065-3233(08)60221-1; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; TREANOR JJS, 1995, IN PRESS J BIOL CHEM, V269; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	90	72	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19669	19672		10.1074/jbc.270.34.19669	http://dx.doi.org/10.1074/jbc.270.34.19669			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649974	hybrid			2022-12-27	WOS:A1995RQ99100001
J	UENO, H; HIRANO, N; KOZUTSUMI, H; SASAKI, K; TANAKA, T; YAZAKI, Y; HIRAI, H				UENO, H; HIRANO, N; KOZUTSUMI, H; SASAKI, K; TANAKA, T; YAZAKI, Y; HIRAI, H			AN EPIDERMAL GROWTH-FACTOR RECEPTOR-LEUKOCYTE TYROSINE KINASE CHIMERIC RECEPTOR GENERATES LIGAND-DEPENDENT GROWTH SIGNALS THROUGH THE RAS SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; INSULIN-RECEPTOR; EXTRACELLULAR DOMAIN; SH3 DOMAINS; HUMAN LTK; PROTEIN; GRB2; CELLS; ASSOCIATION; PHOSPHORYLATION	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase that belongs to the insulin receptor family. LTR is mainly expressed in pre B cells and brain, Previously we cloned the full-length cDNA of human LTR, but no ligands have so far been identified, and hence, very little is known about the physiological role of LTK. To analyze the function of the LTK kinase, we constructed chimeric receptors composed of the extracellular domain of epidermal growth factor receptor and the transmembrane and the cytoplasmic domains of LTK and established cell lines that stably express these chimeric molecules. When cultured in medium containing EGF, growth of these cell lines was stimulated, and these fusion proteins became autophosphorylated and associated with She in uiuo in a ligand-dependent manner, By treatment with EGF, She was associated with the Grb2/Ash-Sos complex, Our analyses demonstrate that LTK associates with Grb2/Ash through an internal adaptor, Shc, depending on a ligand stimulation, The LTK binding site for She was tyrosine 862 at the carboxyl-terminal domain and to a lesser extent tyrosine 485 at the juxtamembrane domain, Both of them are located in NP/AXY motif which is consistent with binding sites for She. These findings demonstrate that LTR can activate the Ras pathway in a ligand dependent manner and that at least one of the functions of this kinase is involved in the cell growth.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008					BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; HAASE VH, 1991, ONCOGENE, V6, P2319; HERBST R, 1991, J BIOL CHEM, V266, P19908; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20135	20142		10.1074/jbc.270.34.20135	http://dx.doi.org/10.1074/jbc.270.34.20135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650032	hybrid			2022-12-27	WOS:A1995RQ99100068
J	KOTANIDES, H; MOCZYGEMBA, M; WHITE, MF; REICH, NC				KOTANIDES, H; MOCZYGEMBA, M; WHITE, MF; REICH, NC			CHARACTERIZATION OF THE INTERLEUKIN-4 NUCLEAR ACTIVATED FACTOR/STAT AND ITS ACTIVATION INDEPENDENT OF THE INSULIN-RECEPTOR SUBSTRATE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; GAMMA-CHAIN; MAP KINASE; IL-4; EXPRESSION; DISTINCT; IDENTIFICATION; LYMPHOKINE; ELEMENTS	The activation of a latent DNA binding factor by interleukin-4 (IL-4), the IL-4 nuclear activated factor (IL-4 NAF), occurs within minutes of IL-4 binding to its receptor. Molecular characterization of IL-4 NAF by ultraviolet light cross-linking experiments revealed a single protein of 120-130 kDa in contact with the DNA target site. Glycerol gradient sedimentation analysis indicated a molecular mass of IL-4 NAF consistent with a monomer that is capable of binding DNA. The IL-4 NAF target site is a palindromic sequence that is also recognized by the interferon-induced transcription factor, p91/STAT1 alpha. However, IL-4 NAF and p91/STAT1 alpha display distinguishable DNA binding specificities that may generate one level of specificity in the expression of target genes. Previous studies suggested the involvement of the insulin receptor substrate-1 (IRS-1) in the IL-4 signal transduction pathway. Although IRS-1 is involved in the stimulation of mitogenesis, our results demonstrate that activation of IL-4 NAF is independent of IRS-signaling proteins. The results of this study indicate that IL-4 stimulates bifurcating signal pathways that can direct mitogenesis via the IRS-signaling proteins and specific gene expression via the IL-4 NAF.	SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONROE JG, 1988, CLIN IMMUNOL IMMUNOP, V49, P292, DOI 10.1016/0090-1229(88)90119-5; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKUDA K, 1992, BLOOD, V79, P2880; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUTER U, 1989, J IMMUNOL, V143, P3087; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	39	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19481	19486		10.1074/jbc.270.33.19481	http://dx.doi.org/10.1074/jbc.270.33.19481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642632	hybrid			2022-12-27	WOS:A1995RP70300046
J	DERGUINI, F; NAKANISHI, K; HAMMERLING, U; CHUA, R; EPPINGER, T; LEVI, E; BUCK, J				DERGUINI, F; NAKANISHI, K; HAMMERLING, U; CHUA, R; EPPINGER, T; LEVI, E; BUCK, J			13,14-DIHYDROXY-RETINOL, A NEW BIOACTIVE RETINOL METABOLITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALL-TRANS-RETINOL; NUCLEAR RECEPTOR; BINDING PROTEIN; ACID; GROWTH; CELLS; DIFFERENTIATION; IDENTIFICATION; ANHYDRORETINOL; FIBROBLASTS	Deprivation of vitamin A (retinol) leads to reduced potential of B cell proliferation and nearly complete block of T cell activation in vitro. Retinol, which is thought to function as a pro-hormone, is enzymatically converted into intracellular messenger molecules. Thus, 14-hydroxy-retro-retinol (14-HRR) is an intracellular messenger molecule linked to activation and growth regulation of lymphocytes; whereas, anhydroretinol, another natural retro-retinoid, is an antagonist of 14-HRR effects. In this article, we describe the isolation, structure determination, synthesis, and biological properties of a new intracellular retinol derivative, 13,14-dihydroxy-retinol (DHR), which also supports the viability of retinol-deprived lymphocytes. DHR is found in numerous cell lines representing a large cross-section of tissues and animals hom insects to mammals. In T lymphocytes the production of DHR and 14-HRR is up-regulated by phorbol ester. DHR is converted to 14-HRR by mild acid treatment, but not by cells; therefore DHR is not a biosynthetic intermediate in the conversion of retinol to 14-HRR. DHR is a distinct end point of retinol metabolism. Although it is linked to cell proliferation, its biological role remains to be determined.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM IMMUNOL,NEW YORK,NY 10021	Columbia University; Cornell University; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA038351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036564] Funding Source: NIH RePORTER; NCI NIH HHS [CA-38351] Funding Source: Medline; NIGMS NIH HHS [GM-36564] Funding Source: Medline; PHS HHS [JM-47599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baer E, 1939, J BIOL CHEM, V128, P463; BHAT PV, 1979, J LIPID RES, V20, P357; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BREITMAN TR, 1984, METHODS SERUM FREE C, P215; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DAVIS CY, 1983, J NUTR, V113, P1914, DOI 10.1093/jn/113.10.1914; DENNERT G, 1984, RETINOIDS, V2, P373; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DERGUINI F, 1994, ANGEW CHEM INT EDIT, V33, P1837, DOI 10.1002/anie.199418371; Edisbury JR, 1932, BIOCHEM J, V26, P1164, DOI 10.1042/bj0261164; Embree ND, 1939, J BIOL CHEM, V128, P187; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONELLA NC, 1982, J AM CHEM SOC, V104, P3775; Harada N., 1983, CIRCULAR DICHROIC SP; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NOACK K, 1979, HELV CHIM ACTA, V62, P1902, DOI 10.1002/hlca.19790620620; Olive J L, 1969, Bull Soc Chim Fr, V9, P3247; PALMER HJ, 1989, IN VITRO CELL DEV B, V25, P1009; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; VARMA TNR, 1965, J PHARM PHARMACOL, V17, P474, DOI 10.1111/j.2042-7158.1965.tb07707.x; WIESLER WT, 1986, J AM CHEM SOC, V108, P6811, DOI 10.1021/ja00281a063; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239	34	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18875	18880		10.1074/jbc.270.32.18875	http://dx.doi.org/10.1074/jbc.270.32.18875			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642543				2022-12-27	WOS:A1995RN95400030
J	HORTSCH, M; WANG, YME; MARIKAR, Y; BIEBER, AJ				HORTSCH, M; WANG, YME; MARIKAR, Y; BIEBER, AJ			THE CYTOPLASMIC DOMAIN OF THE DROSOPHILA CELL-ADHESION MOLECULE NEUROGLIAN IS NOT ESSENTIAL FOR ITS HOMOPHILIC ADHESIVE PROPERTIES IN S2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; FASCICLIN-I; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; NG-CAM; BINDING; EXPRESSION; RNA; COMPONENT; L1	Drosophila neuroglian is a transmembrane glycoprotein that has strong structural and sequence homology to the vertebrate L1 gene family of cell adhesion molecules (Bieber, A J., Snow, P. M., Hortsch, M., Patel, N. H., Jacobs, J. R., Traquina, Z. R., Schilling, J., and Goodman, C. S. (1989) Cell 59, 447-460). Two different neuroglian protein forms that are generated by a differential splicing process are expressed in a tissue-specific fashion by embryonic and larval cells (Hortsch, M., Bieber, A. J., Patel, N. H., and Goodman, C. S. (1990) Neuron 4, 697-709). The two neuroglian polypeptides differ only in their cytoplasmic domains. Both of these neuroglian species, when transfected into and expressed in Drosophila S2 cells, induce the calcium-independent, homophilic aggregation of transformed cells. A third artificial neuroglian protein form was constructed by substituting the neuroglian transmembrane segment and cytoplasmic domains with the glycosyl phosphatidylinositol attachment signal of the Drosophila fasciclin I protein. This cDNA construct generates a glycosyl phosphatidylinositol-anchored form of neuroglian, which retains the ability to induce homophilic cell aggregation when expressed in S2 cells, and was able to interact with both of the two naturally occurring neuroglian polypeptides. These results demonstrate that neuroglian mediates a calcium-independent, homophilic cell adhesion activity and that neither cytoplasmic neuroglian domains nor a direct interaction with cytoskeletal elements is essential for this property.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	HORTSCH, M (corresponding author), UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA.			Hortsch, Michael/0000-0002-3750-737X	NICHD NIH HHS [HD29388] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388, R29HD029388] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIEBER AJ, 1994, DROSOPHILA MELANOGAS, V44, P683; BRUMMENDORF T, 1993, NEURON, V10, P711; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1992, J NEUROSCI RES, V31, P1, DOI 10.1002/jnr.490310102; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; HORTSCH M, 1994, DROSOPHILA MELANOGAS, V44, P289; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1992, J BIOL CHEM, V267, P10752; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RATHJEN FG, 1984, EMBO J, V3, P1; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SANTONI MJ, 1987, NUCLEIC ACIDS RES, V15, P8621, DOI 10.1093/nar/15.21.8621; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; WONG MH, 1994, J CELL BIOL, V126, P1089, DOI 10.1083/jcb.126.4.1089; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	48	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18809	18817		10.1074/jbc.270.32.18809	http://dx.doi.org/10.1074/jbc.270.32.18809			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642532	hybrid			2022-12-27	WOS:A1995RN95400019
J	KAGEYAMA, T; ICHINOSE, M; YONEZAWA, S				KAGEYAMA, T; ICHINOSE, M; YONEZAWA, S			PROCESSING OF THE PRECURSORS TO NEUROTENSIN AND OTHER BIOACTIVE PEPTIDES BY CATHEPSIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; ASPARTIC PROTEINASES; CONVERTING ENZYME; NUCLEOTIDE-SEQUENCE; SECRETORY VESICLES; PROCATHEPSIN-E; B-CHAIN; PURIFICATION; SPECIFICITY; CLEAVAGE	Cathepsin E (EC 3.4.23.34), an intracellular aspartic proteinase, was purified from monkey intestine by simple procedures that included affinity chromatography and fast protein liquid chromatography, Cathepsin E was very active at weakly acidic pH in the processing of chemically synthesized precursors such as the precursor to neurotensin/neuromedin, proopiomelanocortin, the precursor to xenopsin, and angiotensinogen. The processing sites were adjacent to a dibasic motif in the former two precursors and at hydrophobic recognition sites in the latter two, The common structural features that specified the processing sites were found in the carboxyl-terminal sequences of the active peptide moieties of these precursors; namely, the sequence Pro-Xaa-X'aa-hydrophobic amino acid was found at positions P4 through P1. Pro at the P4 position is thought to be important for directing the processing sites of the various precursor molecules to the active site of cathepsin E, Although the positions of Xaa and X'aa were occupied by various amino acids, including hydrophobic and aromatic amino acids, some of these had a negative effect, as typically observed when Glu/Arg and Pro were present at the P3 and P2 positions, respectively, Cathepsin D was much less active or was almost inactive in the processing of the precursors to neurotensin and related peptides as a result of the inability of the Pro-directed conformation of the precursor molecules to gain access to the active site of cathepsin D. Thus, the consensus sequence of precursors, Pro-Xaa-X'aa-hydrophobic amino acid, might not only generate the best conformation for cleavage by cathepsin E but might be responsible for the difference in specificities between cathepsins E and D.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 1, BUNKYO KU, TOKYO 113, JAPAN; AICHI HUMAN SERV CTR, INST DEV RES, KASUGAI, AICHI 48003, JAPAN	University of Tokyo	KAGEYAMA, T (corresponding author), KYOTO UNIV, PRIMATE RES INST, DEPT MOLEC & CELLULAR BIOL, INUYAMA, AICHI 484, JAPAN.		Ichinose, Masao/HAB-1645-2022					ATHAUDA SBP, 1991, FEBS LETT, V292, P53, DOI 10.1016/0014-5793(91)80832-N; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; CARRAWAY RE, 1987, J BIOL CHEM, V262, P5968; CARRAWAY RE, 1985, J BIOL CHEM, V260, P921; CARRAWAY RE, 1990, PEPTIDES, V11, P747, DOI 10.1016/0196-9781(90)90190-G; CARRAWAY RE, 1987, ENDOCRINOLOGY, V120, P2101, DOI 10.1210/endo-120-5-2101; CARRAWAY RE, 1992, ANN NY ACAD SCI, V668, P1, DOI 10.1111/j.1749-6632.1992.tb27335.x; CARRAWAY RE, 1992, PEPTIDES, V13, P319, DOI 10.1016/0196-9781(92)90115-J; CARRAWAY RE, 1977, ANN NY ACAD SCI, P209; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FINLEY EM, 1994, J BIOL CHEM, V269, P31259; FRIEDMAN TC, 1994, ENDOCRINOLOGY, V135, P854, DOI 10.1210/en.135.3.854; FRUTON JS, 1970, ADV ENZYMOL REL S BI, V33, P401; GALEN FX, 1978, BIOCHIM BIOPHYS ACTA, V523, P485, DOI 10.1016/0005-2744(78)90051-7; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; INAGAMI T, 1977, J BIOL CHEM, V252, P2978; KAGEYAMA T, 1986, J BIOL CHEM, V261, P4395; KAGEYAMA T, 1995, METHOD ENZYMOL, V248, P120; KAGEYAMA T, 1992, J BIOL CHEM, V267, P16450; KAGEYAMA T, 1993, EUR J BIOCHEM, V216, P717, DOI 10.1111/j.1432-1033.1993.tb18191.x; KAY J, 1992, SCAND J CLIN LAB INV, V52, P23, DOI 10.3109/00365519209104651; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapresle C, 1971, TISSUE PROTEINASES, P135; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; LOH YP, 1985, J BIOL CHEM, V260, P7194; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MATSUZAKI O, 1988, BIOMED RES-TOKYO, V9, P515; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; OKAMURA T, 1981, P NATL ACAD SCI-BIOL, V78, P6940, DOI 10.1073/pnas.78.11.6940; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; POWERS JC, 1977, ACID PROTEASES STRUC, P141, DOI DOI 10.1007/978-1-4757-0719-9_9; RAO C, 1991, ADV EXP MED BIOL, V306, P143; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SAKU T, 1991, J BIOCHEM-TOKYO, V110, P956, DOI 10.1093/oxfordjournals.jbchem.a123696; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SLATER EE, 1981, METHOD ENZYMOL, V80, P427; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TANJI M, 1991, BIOMED RES-TOKYO, V12, P339, DOI 10.2220/biomedres.12.339; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; YONEZAWA S, 1988, ARCH BIOCHEM BIOPHYS, V267, P176, DOI 10.1016/0003-9861(88)90021-5; YONEZAWA S, 1987, ARCH BIOCHEM BIOPHYS, V256, P499, DOI 10.1016/0003-9861(87)90607-2	55	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19135	19140		10.1074/jbc.270.32.19135	http://dx.doi.org/10.1074/jbc.270.32.19135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642580	hybrid			2022-12-27	WOS:A1995RN95400068
J	PFALLER, R; NEWPORT, JW				PFALLER, R; NEWPORT, JW			ASSEMBLY DISASSEMBLY OF THE NUCLEAR-ENVELOPE MEMBRANE - CHARACTERIZATION OF THE MEMBRANE-CHROMATIN INTERACTION USING PARTIALLY PURIFIED REGULATORY ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHROMOSOME CONDENSATION; FORMATION INVITRO; PROTEIN-KINASE; XENOPUS EGGS; COMPONENTS; INDUCTION; EXTRACTS; VESICLES; BINDING	Assembly and disassembly of the nucleus at mitosis in eukaryotes involves the reversible interaction of chromatin with the nuclear membrane. previously we have shown that this interaction is regulated by the antagonistic activities of a kinase and a phosphatase. The kinase promotes membrane release while the phosphatase stimulates binding. In this report we describe four steps in the purification of the kinase needed for release of membranes from chromatin. We also show that the release kinase and the mitotic initiation kinase, cdcs, are distinct and are separated from each other during the second purification step. Reconstitution experiments using these two kinases demonstrate that the release kinase and cdc2 kinase work in concert to cause membrane release from chromatin. In phosphorylation experiments, protein targets that are substrates for the regulatory release kinase are identified on the membranes. These phosphorylated proteins are candidates for regulated proteins mediating membrane-chromatin interaction. Finally, we find that membrane release activity can also be extracted from membranes by high salt treatment, indicating a possible dual localization of this activity.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; LABBE JC, 1989, EMBO J, V8, P3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	18	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19066	19072		10.1074/jbc.270.32.19066	http://dx.doi.org/10.1074/jbc.270.32.19066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642570				2022-12-27	WOS:A1995RN95400058
J	WU, JJ; EYRE, DR				WU, JJ; EYRE, DR			STRUCTURAL-ANALYSIS OF CROSS-LINKING DOMAINS IN CARTILAGE TYPE-XI COLLAGEN - INSIGHTS ON POLYMERIC ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; AMINO-TERMINAL PROPEPTIDE; IX COLLAGEN; II COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; NH2-TERMINAL DOMAIN; MOLECULAR-CLONING; CHAIN; IDENTIFICATION; EXPRESSION	The collagen framework of hyaline cartilage is based on copolymers of types II, IX, and XI collagens, Previous studies have established specific covalent interactions between types II and IX collagens, The present study examined cross-linking sites in type XI collagen to define better the full heteropolymeric assembly, Pepsin-solubilized type XI collagen was purified from fetal bovine cartilage, The cross-linking amino acids in the preparation were primarily divalent, borohydride-reducible structures; pyridinoline residues were essentially absent. Individual alpha 1(XI), alpha 2(XI), and alpha 3(XI) chains were resolved by high performance liquid chromatography, Telopeptides still attached by cross-links to helical sites were released by periodate oxidation and identified by microsequencing, Analysis of cross-linked peptides isolated from trypsin digests of each alpha-chain identified the attachment helical sites for the telopeptides. A high degree of interchain specificity was evident in the cross-linking between type XI collagen molecules, The dominant cross-links were between N-telopeptides and the COOH terminus of the triple-helix, consistent with a head-to tail interaction of molecules staggered by 4D (D = 67 nm) periods. In addition, alpha 1(II) C-telopeptide was linked to the amino terminal site of the alpha 1(XI) triple helix. In summary, the results show that type XI collagen molecules are primarily cross-linked to each other in cartilage, implying that a homopolymer is initially formed. Links to type II collagen are also indicated, consistent with an eventual cofibrillar assembly. Analysis of cartilage extracts showed that all three chains, alpha 1(XI), alpha 2(XI), and alpha 3(XI), had at least in part retained their N-propeptides in cartilage matrix and that the alpha 3(XI) chain was the IIB splicing variant product of the COL2A1 gene. Of particular note was the finding that the N-telopeptide cross-linking site in both alpha 1(XI) and alpha 2(XI) is located amino-terminal to the putative N-propeptidase cleavage site, This structural feature provides a potential mechanism for the proteolytic depolymerization of type XI collagen by proteases that can cleave between the cross-link and the triple helix (e.g. stromelysin).			WU, JJ (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,ORTHOPAED RES LABS,BOX 356500,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R37AR036794] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR036794, R37 AR037318, AR36794] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; DIAB M, 1994, AM J MED GENET, V49, P402, DOI 10.1002/ajmg.1320490411; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE, P132; Eyre D, 1987, STRUCTURE FUNCTION C, P261; EYRE D R, 1990, P188; EYRE DR, 1984, BIOCHEM BIOPH RES CO, V118, P724, DOI 10.1016/0006-291X(84)91454-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; EYRE DR, 1987, J RHEUMATOL, V14, P25; EYRE DR, 1973, BIOCHEM J, V135, P393, DOI 10.1042/bj1350393; EYRE DR, 1980, BIOCHEM BIOPH RES CO, V92, P403, DOI 10.1016/0006-291X(80)90347-2; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; KIMURA T, 1989, J BIOL CHEM, V264, P13910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; OKADA Y, 1992, LAB INVEST, V66, P680; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SMITH GN, 1987, COLLAGEN REL RES, V7, P17; SMITH GN, 1985, J BIOL CHEM, V260, P761; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; WU JJ, 1985, ANN NY ACAD SCI, V460, P520, DOI 10.1111/j.1749-6632.1985.tb51228.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	44	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18865	18870		10.1074/jbc.270.32.18865	http://dx.doi.org/10.1074/jbc.270.32.18865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642541	hybrid			2022-12-27	WOS:A1995RN95400028
J	CHEN, YG; DANOFF, A; SHIELDS, D				CHEN, YG; DANOFF, A; SHIELDS, D			THE PROPEPTIDE OF ANGLERFISH PREPROSOMATOSTATIN-I RESCUES PROSOMATOSTATIN-II FROM INTRACELLULAR DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; SECRETORY PATHWAY; PRO-REGION; PROHORMONE CONVERTASES; ASPARTYL PROTEASE; YEAST; EXPRESSION; SOMATOSTATIN; CELLS; PRECURSOR	Polypeptide hormones and neuropeptides are initially synthesized as precursors possessing one or several domains that constitute the propeptide. Previous work from our laboratory demonstrated that expression of anglerfish prosomatostatin-I (proSRIF-I) in rat anterior pituitary GH(3) cells resulted in efficient and accurate cleavage of the prohormone to generate the mature 14-amino acid peptide, SRIF-I. We also implicated the propeptide in mediating intracellular sorting to the trans Golgi network where proteolytic processing is initiated. In contrast, expression of a second form of the precursor, proSRIF-II in GH(3) cells resulted in its intracellular degradation in an acidic, post-trans Golgi network compartment, most probably lysosomes. To further investigate the positive sorting signal present in proSRIF-I, we constructed a chimera comprising the signal peptide and proregion of SRIF-I fused to proSRIF-II and expressed the cDNA in GH(3) cells. Here we demonstrate that the propeptide of SRIF-I rescued proSRIF-II from intracellular degradation quantitatively and diverted it to secretory vesicles. Furthermore, the chimera was processed to SRIF-28, an amino-terminally extended form of the hormone that is the physiological cleavage product of proSRIF-II processing in vivo. Most significantly, the SRIF-I propeptide functioned only in cis as part of the fusion protein and not in trans when expressed as a separate polypeptide. These data suggest that the SRIF-I propeptide may possess a sorting signal for sequestration into the secretory pathway rather than functioning as an intramolecular chaperone to promote protein folding.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860, DK 18994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DANOFF A, 1991, J BIOL CHEM, V266, P10004; ELGORT A, 1994, J BIOL CHEM, V269, P30668; FABRE E, 1992, J BIOL CHEM, V267, P15049; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; HOBART P, 1980, NATURE, V288, P137, DOI 10.1038/288137a0; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MAINS RE, 1988, J BIOL CHEM, V263, P7887; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCCRACKEN AA, 1989, J BIOL CHEM, V264, P20843; MCDONALD JK, 1987, J HISTOCHEM CYTOCHEM, V35, P155, DOI 10.1177/35.2.2878951; NOE BD, 1983, J BIOL CHEM, V258, P1121; NOE BD, 1987, SOMATOSTATIN BASIC C, P59; SEETHALER G, 1991, J CELL BIOL, V114, P1125, DOI 10.1083/jcb.114.6.1125; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	39	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18598	18605		10.1074/jbc.270.31.18598	http://dx.doi.org/10.1074/jbc.270.31.18598			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629190	hybrid			2022-12-27	WOS:A1995RM64200070
J	WHITEHEAD, I; KIRK, H; TOGNON, C; TRIGOGONZALEZ, G; KAY, R				WHITEHEAD, I; KIRK, H; TOGNON, C; TRIGOGONZALEZ, G; KAY, R			EXPRESSION CLONING OF LFC, A NOVEL ONCOGENE WITH STRUCTURAL SIMILARITIES TO GUANINE-NUCLEOTIDE EXCHANGE FACTORS AND TO THE REGULATORY REGION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; ADRENERGIC-RECEPTOR KINASE; BETA-GAMMA-SUBUNITS; VAV PROTOONCOGENE; CAENORHABDITIS-ELEGANS; DIACYLGLYCEROL KINASE; MOLECULAR-CLONING; UNC-13 GENE; PRODUCT; DBL	In order to identify cDNAs that can induce oncogenic transformation, a retroviral vector was used to transfer a library of cDNAs from the murine 32D hemopoietic cell line into NIH 3T3 fibroblasts. We have identified and recovered a provirus containing a 1.8-kilobase pair cDNA whose expression causes morphological transformation in NIH 3T3 cells. The transforming cDNA contains a complete open reading frame that encodes a protein (designated Lfc) with a region of sequence similarity to the product of the lbc oncogene. This region includes a domain that is characteristic of the CDC24 family of guanine nucleotide exchange factors in tan dem with a pleckstrin homology (PH) domain. The Lfc protein is distinguished from Lbc by a 150-amino acid NH2-terminal extension that contains a cysteine- and histidine-rich domain similar to the diacylglycerol-binding site (zinc butterfly) found in protein kinase C. NH2- and COOH-terminal deletion analysis revealed that both the PH and putative guanine nucleotide exchange factor domains are required, but the zinc butterfly is dispensable, for transformation. Although the removal of the PH domain of the Lfc protein completely eliminated its ability to transform MH 3T3 cells, replacement of this domain with an isoprenylation site restored all of its transforming activity. This suggests that a PH domain-dependent recruitment of the Lfc protein to the cellular membrane is a necessary step for cellular transformation. The lfc gene is expressed in a broad range of tissues as well as in a variety of hemopoietic and non-hemopoietic cell lines. Lfc appears to be a new member of a growing family of proteins that are likely to act as activators of Ras-like proteins in a developmental or cell-lineage specific manner.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,DEPT MED GENET,VANCOUVER,BC V5Z 4E6,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V5Z 4E6,CANADA	British Columbia Cancer Agency; University of British Columbia								ADAMS JM, 1992, ONCOGENE, V7, P611; AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BELL RM, 1991, J BIOL CHEM, V266, P4661; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN AML, 1994, ONCOGENE, V9, P1057; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HUBBARD SR, 1991, SCIENCE, V254, P1776; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PASTERIS NG, 1994, CELL, V79, P669; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOGELI G, 1985, ANAL BIOCHEM, V151, P442, DOI 10.1016/0003-2697(85)90202-7; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	72	141	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18388	18395		10.1074/jbc.270.31.18388	http://dx.doi.org/10.1074/jbc.270.31.18388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629163	hybrid			2022-12-27	WOS:A1995RM64200039
J	LAZAROFF, M; PATANKAR, S; YOON, SO; CHIKARAISHI, DM				LAZAROFF, M; PATANKAR, S; YOON, SO; CHIKARAISHI, DM			THE CYCLIC-AMP RESPONSE ELEMENT DIRECTS TYROSINE-HYDROXYLASE EXPRESSION IN CATECHOLAMINERGIC CENTRAL AND PERIPHERAL NERVOUS-SYSTEM CELL-LINES FROM TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; DEPENDENT PROTEIN-KINASE; LEUCINE ZIPPER STRUCTURE; INTESTINAL-PEPTIDE GENE; CAMP-REGULATED ENHANCER; PANCREATIC-ISLET CELLS; RAT SOMATOSTATIN GENE; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; ATF CDNA CLONES	Enhancer elements regulating the neuronal gene, tyrosine hydroxylase (TH), were identified in TH-expressing peripheral nervous system PATH and central nervous system CATH cell lines. Mutational analysis in which rat TH 5'-flanking sequences directed chloramphenicol acetyltransferase (CAT) reporter gene expression demonstrated that mutating the cyclic AMP response element (CRE) at -45 base pair reduced expression by 80-90%. A CRE linked to an enhancerless TH promoter fully supported expression. Cotransfection of a dominant-negative CREB protein reduced expression 50-60%, suggesting that the CRE is bound by CREB or a CREB dimerization partner. Although mutating the AP1/dyad (AD) element at -205 base pair only modestly reduced CAT levels, AD minimal enhancer constructs gave 45-80% of wild type expression when positioned at -91 or -95. However, in its native context at -205, the AD could not support expression. In contrast, a CRE, moved from its normal position at -45 to -206, gave full activity. These results indicate that the CBE is critical for TH transcription in central nervous system CATH and peripheral nervous system PATH cells, whereas the AD is less important and its enhancer activity is context- and/or position dependent. These results represent the first attempts to map regulatory elements directing TH expression in central nervous system cell lines.	TUFTS UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02111	Tufts University; Tufts University			Yoon, Sung Ok/C-5992-2012		NINDS NIH HHS [NS29679, NS22675] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022675, R01NS029679] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; BLACK IB, 1985, BRAIN RES, V339, P151, DOI 10.1016/0006-8993(85)90635-3; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COKER GT, 1988, BIOCHEM BIOPH RES CO, V157, P1341, DOI 10.1016/S0006-291X(88)81022-2; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DAWSON SJ, 1994, NUCLEIC ACIDS RES, V22, P1023, DOI 10.1093/nar/22.6.1023; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FAUCONBIGUET N, 1989, NEUROSCI LETT, V104, P189; FINK JS, 1991, J BIOL CHEM, V266, P3882; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; FUNG BP, 1991, J NEUROSCI, V11, P701; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GANDELMAN KY, 1990, J NEUROCHEM, V55, P2149, DOI 10.1111/j.1471-4159.1990.tb05811.x; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HEFTI F, 1982, J NEUROSCI, V2, P1554; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG ZM, 1991, MOL BRAIN RES, V11, P309, DOI 10.1016/0169-328X(91)90040-5; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LAZAROFF M, 1992, SOC NEUR ABSTR, V18; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU J, 1994, SOC NEUR ABSTR, V20; MACGREGOR PF, 1990, ONCOGENE, V4, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIN N, 1994, SOC NEUR ABSTR, V20; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; POWERS AC, 1989, J BIOL CHEM, V264, P10048; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SURI C, 1993, J NEUROSCI, V13, P1280; TANK AW, 1986, MOL PHARMACOL, V30, P497; TANK AW, 1985, J NEUROCHEM, V45, P1030, DOI 10.1111/j.1471-4159.1985.tb05519.x; TANK AW, 1990, CATECHOLAMINE GENES, P81; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WIDNELL KL, 1994, P NATL ACAD SCI USA, V91, P10947, DOI 10.1073/pnas.91.23.10947; WONG SC, 1994, J NEUROCHEM, V62, P1691; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	86	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21579	21589		10.1074/jbc.270.37.21579	http://dx.doi.org/10.1074/jbc.270.37.21579			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665571	hybrid			2022-12-27	WOS:A1995RU75700026
J	MICHAELY, P; BENNETT, V				MICHAELY, P; BENNETT, V			THE ANK REPEATS OF ERYTHROCYTE ANKYRIN FORM 2 DISTINCT BUT COOPERATIVE BINDING-SITES FOR THE ERYTHROCYTE ANION-EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; HEREDITARY SPHEROCYTOSIS; MEMBRANE-SKELETON; BAND-3; SPECTRIN; PROTEIN; ASSOCIATION; PHOSPHORYLATION; EXPRESSION; DELETION	The 24 ANK repeats of the membrane-binding domain of ankyrin form four folded subdomains of six ANK repeats each. These four repeat subdomains mediate interactions with at least seven different families of membrane proteins. In the erythrocyte, the main membrane target of ankyrin is the Cl-/HCO3- anion exchanger. This report presents the first evidence that ankyrin contains two separate binding sites for anion exchanger dimers. One site utilizes repeat subdomain two (repeats 7-12) while the other requires both repeat subdomains three and four (repeats 13-24). The two sites are positively coupled with a Hill coefficient of 1.4. Since the anion exchanger exists as a dimer in the membrane, the presence of two binding sites on ankyrin allows ankyrin to interact with four anion exchangers simultaneously. These findings provide a direct demonstration of the versatility of ANK repeats in protein recognition, and have important implications for the organization of ankyrin-linked integral membrane proteins in erythrocytes as well as other cells.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University	MICHAELY, P (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BENNETT V, 1982, BIOCHIM BIOPHYS ACTA, V689, P475, DOI 10.1016/0005-2736(82)90305-4; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1979, NATURE, V281, P597, DOI 10.1038/281597a0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DING Y, 1994, J BIOL CHEM, V269, P32201; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1992, J CLIN INVEST, V93, P121; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NIGG E, 1979, NATURE, V277, P493, DOI 10.1038/277493a0; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANNER MJA, 1991, BLOOD, V78, P2785; THEVENIN B, 1990, J BIOL CHEM, V285, P16166; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WEINSTEIN RS, 1980, MEMBRANE TRANSPORT E, P35; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	40	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22050	22057		10.1074/jbc.270.37.22050	http://dx.doi.org/10.1074/jbc.270.37.22050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665627	hybrid			2022-12-27	WOS:A1995RU75700093
J	RYAN, MT; NAYLOR, DJ; HOOGENRAAD, NJ; HOJ, PB				RYAN, MT; NAYLOR, DJ; HOOGENRAAD, NJ; HOJ, PB			AFFINITY PURIFICATION, OVEREXPRESSION, AND CHARACTERIZATION OF CHAPERONIN-10 HOMOLOGS SYNTHESIZED WITH AND WITHOUT N-TERMINAL ACETYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY-PREGNANCY FACTOR; GROES-LIKE CHAPERONIN; ESCHERICHIA-COLI; RAT-LIVER; PROTEIN; IDENTIFICATION; MITOCHONDRIA; INVITRO; CHLOROPLASTS; DENATURATION	Utilizing the ability of bacterial chaperonin 60 (GroEL) to functionally interact with chaperonin 10 (Cpn10) homologues in an ATP-dependent fashion, we have purified substantial amounts of mammalian, chloroplast, and thermophilic Cpn10 homologues from their natural host. In addition, large amounts of recombinant rat Cpn10 were produced in Escherichia coli and found to be identical to its authentic counterpart except for the lack of N-terminal acetylation. By comparing these two forms of Cpn10, it was found that acetylation does not influence the oligomeric structure of Cpn10 and is not essential for chaperone activity or mitochondrial import in vitro. In contrast, N-terminal acetylation proved crucial in the protection of Cpn10 against degradation by N-ethylmaleimide-sensitive proteases derived from organellar preparations of rat liver. The availability of large amounts of both affinity-purified and recombinant Cpn10 will facilitate not only further characterization of the eukaryotic folding machinery but also further scrutiny of the reported function of Cpn10 as early pregnancy factor.	LA TROBE UNIV, SCH BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA; UNIV ADELAIDE, DEPT HORT VITICULTURE & OENOL, GLEN OSMOND, SA 5064, AUSTRALIA	La Trobe University; University of Adelaide			Hoj, Peter B/E-8526-2011; Ryan, Michael/X-2152-2019; Ryan, Michael T/C-6673-2011; Hoogenraad, Nicholas J/C-7505-2011	Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; 				ATHANASASPLATSIS S, 1991, J REPROD FERTIL, V92, P443, DOI 10.1530/jrf.0.0920443; ATHANASASPLATSIS S, 1989, J REPROD FERTIL, V87, P495, DOI 10.1530/jrf.0.0870495; BANEYX F, 1995, J BIOL CHEM, V270, P10695, DOI 10.1074/jbc.270.18.10695; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURT WJE, 1994, FEBS LETT, V339, P139, DOI 10.1016/0014-5793(94)80401-X; CAVANAGH AC, 1994, EUR J BIOCHEM, V222, P551, DOI 10.1111/j.1432-1033.1994.tb18897.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DICKSON R, 1994, J BIOL CHEM, V269, P26858; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GRIFFITH D, 1989, PROTEIN PURIFICATION, P108; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HARTMAN DJ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P219, DOI 10.1016/0167-4838(93)90251-L; HOJ PB, 1982, CARLSBERG RES COMMUN, V47, P119, DOI 10.1007/BF02914031; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LEGNAME G, 1995, FEBS LETT, V361, P211, DOI 10.1016/0014-5793(95)00184-B; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MAEDA K, 1992, BIOCHEM J, V284, P551, DOI 10.1042/bj2840551; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTINUS RD, 1995, FASEB J, V9, P371, DOI 10.1096/fasebj.9.5.7896006; MONZINI N, 1994, BBA-GENE STRUCT EXPR, V1218, P478, DOI 10.1016/0167-4781(94)90211-9; MORTON H, 1987, CURR TOP DEV BIOL, V23, P73; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; NIKAWA T, 1992, EUR J BIOCHEM, V204, P381, DOI 10.1111/j.1432-1033.1992.tb16647.x; NOONAN FP, 1979, NATURE, V278, P649, DOI 10.1038/278649a0; PARADIS H, 1991, INT J PEPT PROT RES, V37, P72; PERALTA D, 1993, EUR J BIOCHEM, V211, P881, DOI 10.1111/j.1432-1033.1993.tb17621.x; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PILKINGTON SJ, 1993, J DNA SEQ MAPPING, V3, P291; QUINN KA, 1994, HEPATOLOGY, V20, P1294, DOI 10.1016/0270-9139(94)90771-4; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SPANGFORT MD, 1993, FEBS LETT, V320, P160, DOI 10.1016/0014-5793(93)80083-7; STAHL PD, 1972, METHOD ENZYMOL, V28, P814; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TORRESRUIZ JA, 1992, ARCH BIOCHEM BIOPHYS, V295, P172, DOI 10.1016/0003-9861(92)90503-O; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; VEBER DF, 1985, TRENDS NEUROSCI, V8, P392, DOI 10.1016/0166-2236(85)90140-7; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22037	22043		10.1074/jbc.270.37.22037	http://dx.doi.org/10.1074/jbc.270.37.22037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665625	hybrid			2022-12-27	WOS:A1995RU75700091
J	STREULI, CH; EDWARDS, GM; DELCOMMENNE, M; WHITELAW, CBA; BURDON, TG; SCHINDLER, C; WATSON, CJ				STREULI, CH; EDWARDS, GM; DELCOMMENNE, M; WHITELAW, CBA; BURDON, TG; SCHINDLER, C; WATSON, CJ			STAT5 AS A TARGET FOR REGULATION BY EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED BASEMENT-MEMBRANE; CASEIN GENE-EXPRESSION; BETA-CASEIN; MAMMARY; DIFFERENTIATION; COMPONENTS; CELLS	Transcription of tissue-specific genes in mammary gland requires signals from both prolactin and basement membrane. Here we address the mechanism by which this specialized extracellular matrix regulates transcription. Using mammary cell cultures derived from transgenic mice harboring the ovine beta-lactoglobulin gene, we show that either a basement membrane extract, or purified laminin-1, induced high levels of beta-lactoglobulin synthesis. It is known that prolactin signals through Stat5 (signal transducer and activator of transcription). This transcription factor interacts with gamma-interferon activation site-related motifs within the beta-lactoglobulin promoter, which we show are required for matrix dependence of beta-lactoglobulin expression. The DNA binding activity of Stat5 was present only in extracts of mammary cells cultured on basement membrane, indicating that the activation state of Stat5 is regulated by the type of substratum the cell encounters. Thus, basement membrane controls transcription of milk protein genes through the Stat5-mediated prolactin signaling pathway, providing a molecular explanation for previous studies implicating extracellular matrix in the control of mammary differentiation.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND; ROSLIN INST EDINBURGH,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	University of Manchester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Columbia University			watson, Christine J/B-1431-2012	Whitelaw, Bruce/0000-0002-2918-1605	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; BURDON TG, 1994, FEBS LETT, V350, P177, DOI 10.1016/0014-5793(94)00757-8; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LI S, 1995, MOL CELL BIOL, V15, P2063; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; STREULI CH, 1995, IN PRESS LAMININS; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WHITELAW CBA, 1992, BIOCHEM J, V286, P31, DOI 10.1042/bj2860031; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	42	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21639	21644		10.1074/jbc.270.37.21639	http://dx.doi.org/10.1074/jbc.270.37.21639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665578	hybrid			2022-12-27	WOS:A1995RU75700035
J	FALNES, PO; OLSNES, S				FALNES, PO; OLSNES, S			CELL-MEDIATED REDUCTION AND INCOMPLETE MEMBRANE TRANSLOCATION OF DIPHTHERIA-TOXIN MUTANTS WITH INTERNAL DISULFIDES IN THE A-FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; A-FRAGMENT; VERO CELLS; PLASMA-MEMBRANE; B-FRAGMENT; ENTRY; PROTEINS; CYTOSOL; INHIBITION; PENETRATION	Active diphtheria toxin consists of two fragments, A and B, joined by a disulfide bond. The B fragment binds to cell surface receptors and aids in the translocation of the enzymatically active A fragment to the cytosol. Normally, the toxin A fragment enters the cytosol from acidic endosomes, but translocation can also be induced at the level of the plasma membrane by exposing cells with surface-bound toxin to low pH. Recently, we showed that disulfide bonds introduced into the A fragment by mutation are inhibitory for translocation. In the present work, we found that although the complete translocation of the A fragment is blocked, three mutant toxins underwent reduction of the interfragment disulfide bond upon low pH exposure, whereas the internal disulfide in the A fragment remained intact. In the case of two of these mutants, the A fragment was released into the extracellular medium upon exposure of cell-bound toxin to low pH. The pH profile for the release of the mutant A fragments was the same as for translocation of wild-type A fragment to the cytosol, and the release was inhibited by conditions that interfere with A fragment translocation. In the case of the third mutant, which remained cell-associated upon reduction of the interfragment disulfide bond, a translocation intermediate was detected. The results show that the reduction of the interfragment disulfide bond can occur in the absence of complete translocation of the A fragment to the cytosol, and they indicate that the reduction takes place at an early stage in the translocation process. Our findings suggest that the translocation of the A fragment across the membrane is initiated at the C terminus.			FALNES, PO (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; CHAU MH, 1991, FEBS LETT, V291, P296, DOI 10.1016/0014-5793(91)81305-R; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FALNES PO, 1994, J BIOL CHEM, V269, P8402; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1971, J BIOL CHEM, V246, P4251; HU VW, 1984, J BIOL CHEM, V259, P2226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MADSHUS IH, 1994, J BIOL CHEM, V269, P17723; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1993, J BIOL CHEM, V268, P1567; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SANDVIG K, 1986, J BIOL CHEM, V261, P1570; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; UCHIDA T, 1972, SCIENCE, V175, P901, DOI 10.1126/science.175.4024.901; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANDERSPEK J, 1994, J BIOL CHEM, V269, P21455; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	39	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20787	20793		10.1074/jbc.270.35.20787	http://dx.doi.org/10.1074/jbc.270.35.20787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657662	hybrid			2022-12-27	WOS:A1995RR58400083
J	FRANTZ, JD; GILBERT, W				FRANTZ, JD; GILBERT, W			A NOVEL YEAST GENE-PRODUCT, G4P1, WITH A SPECIFIC AFFINITY FOR QUADRUPLEX NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERIC DNA; GENOMIC RNA; DIMERIZATION; MUTATIONS	G4 nucleic acids are four-stranded helical structures that are formed in vitro by nucleic acids that contain guanine tracts. These structures anneal readily under physiological conditions and are unusually stable once formed. G4 nucleic acids are thought to participate in telomere function, retroviral genome dimerization, chromosome alignment during homologue pairing, and mitotic recombination, although the in vivo demonstration of these structures in any of these situations has not yet been achieved. Here we purify and characterize an activity from yeast, G4p1, which has a high and specific affinity for G4 nucleic acids. G4p1 prefers substrates containing multiple G4 domains, has an equal affinity for parallel and antiparallel G4 structures, and binds equivalently to RNA and DNA in G4 form. The Keg for G4p1 binding to a G4 DNA oligomer is 5.0 x 10(8) M(-1) under near physiological conditions. G4p1 was purified and shown to derive from a 42-kDa protein (p42). We have cloned and sequenced the gene encoding p42 and show it to encode a novel protein with a region significantly homologous to bacterial methionyl-tRNA synthetase dimerization domains, We have reconstituted the G4p1 binding activity with recombinant p42 and present evidence that G4p1 is a homodimer of p42.			FRANTZ, JD (corresponding author), HARVARD UNIV, BIOL LABS, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM41895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALLAGHER SR, 1992, CURRENT PROTOCOLS MO, V2; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM JM, 1990, GENETICS, V126, P799; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; SNYDER M, 1986, P NATL ACAD SCI USA, V83, P730, DOI 10.1073/pnas.83.3.730; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	25	59	61	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20692	20697		10.1074/jbc.270.35.20692	http://dx.doi.org/10.1074/jbc.270.35.20692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657649	hybrid			2022-12-27	WOS:A1995RR58400069
J	KEIGHTLEY, JA; ZIMMERMANN, BH; MATHER, MW; SPRINGER, P; PASTUSZYN, A; LAWRENCE, DM; FEE, JA				KEIGHTLEY, JA; ZIMMERMANN, BH; MATHER, MW; SPRINGER, P; PASTUSZYN, A; LAWRENCE, DM; FEE, JA			MOLECULAR-GENETIC AND PROTEIN CHEMICAL CHARACTERIZATION OF THE CYTOCHROME BA(3) FROM THERMUS-THERMOPHILUS HB8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OXIDASE SUBUNIT-I; BO UBIQUINOL OXIDASE; AMINO-ACID-SEQUENCE; ARCHAEBACTERIAL TERMINAL OXIDASE; SITE-DIRECTED MUTAGENESIS; C-OXIDASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BRADYRHIZOBIUM-JAPONICUM; RHODOBACTER-SPHAEROIDES	Thermus thermophilus HB8 cells grown under reduced dioxygen tensions contain a substantially increased amount of heme A, much of which appears to be due to the presence of the terminal oxidase, cytochrome ba,. We describe a purification procedure for this enzyme that yields similar to 100 mg of pure protein from 2 kg of wet mass of cells grown in less than or equal to 50 mu M O-2. Examination of the protein by SDS-polyacrylamide gel electrophoresis followed by staining with Coomassie Blue reveals one strongly staining band at similar to 35 kDa and one very weakly staining band at similar to 18 kDa as reported earlier (Zimmermann, B. H., Nitsche, C. I., Fee, J. A., Rusnak, F., and Munck, E. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 5779-5783). By contrast, treatment of the gels with AgNO3 reveals that the larger polypeptide stains quite weakly while the smaller polypeptide stains very strongly. These results suggested the presence of two polypeptides in this protein. Using partial amino acid sequences from both proteins to obtain DNA sequence information, we isolated and sequenced a portion of the Thermus chromosome containing the genes encoding the larger protein, subunit I (cbaA), and the smaller protein, subunit II (cbaB). The two polypeptides were isolated using reversed phase liquid chromatography, and their mole percent amino acid compositions are consistent with the proposed translation of their respective genes. The two genes appear to be part of a larger operon, but we have not extended the sequencing to identify initiation and termination sequences. The deduced amino acid sequence of subunit I includes the six canonical histidine residues involved in binding the low spin heme B and the binuclear center Cu-B/heme A. These and other conserved amino acids are placed along the polypeptide among alternating hydrophobic and hydrophilic segments in a pattern that shows clear homology to other members of the heme- and copper-requiring terminal oxidases. The deduced amino acid sequence of the subunit II contains the Cu-A binding motif, including two cysteines, two histidines, and a methionine, but, in contrast to most other subunits II, it has only one region of hydrophobic sequence near its N terminus. Alignment of these two polypeptides with other cytochrome c and quinol oxidases, combined with secondary structure analysis and previous spectral studies, clearly establish cytochrome ba(3) as a bona fide member of the superfamily of heme- and copper-requiring oxidases. The alignments further indicate that cytochrome ba(3) is phylogenetically distant from other cytochrome c and quinol oxidases, and they substantially decrease the number of conserved amino acid residues.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; LOS ALAMOS NATL LAB, LOS ALAMOS, NM 87545 USA; UNIV NEW MEXICO, PROT CHEM LAB, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, DEPT BIOL, ALBUQUERQUE, NM 87131 USA	University of California System; University of California San Diego; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico; University of New Mexico				Zimmermann, Barbara H./0000-0002-2891-976X; Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTINGMEES MA, 1992, METHOD ENZYMOL, V216, P483; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAUMANN M, 1993, ANAL BIOCHEM, V214, P142, DOI 10.1006/abio.1993.1469; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BISSON R, 1982, FEBS LETT, V144, P359, DOI 10.1016/0014-5793(82)80672-8; BLAIR DF, 1986, BIOPHYS J, V50, P713, DOI 10.1016/S0006-3495(86)83511-1; BLANKENSHIP RE, 1988, PHOTOSYNTHETIC BACTE, P119; BOTT M, 1992, ARCH MICROBIOL, V158, P335, DOI 10.1007/BF00245362; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; BUSE G, 1989, EUR J BIOCHEM, V181, P261, DOI 10.1111/j.1432-1033.1989.tb14720.x; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P10905, DOI 10.1021/bi00091a046; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1986, URFS ORFS PRIMER HOW; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; FALK JE, 1964, PORPHYRINS METALLOPO; FAWCETT TW, 1990, BIOTECHNIQUES, V9, P46; FEE JA, 1984, J BIOL CHEM, V259, P124; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; FEE JA, 1995, BIOCHEM BIOPH RES CO, V212, P77, DOI 10.1006/bbrc.1995.1938; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FERGUSONMILLER S, 1993, J BIOENERG BIOMEMBR, V25; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GABEL C, 1990, NUCLEIC ACIDS RES, V18, P6143, DOI 10.1093/nar/18.20.6143; Gabriel, 1971, METHOD ENZYMOL, V22, P565, DOI 10.1016/0076-6879(71)22041-3; GENNIS RB, 1993, BIOCHEM SOC T, V21, P992, DOI 10.1042/bst0210992; GENNIS RB, 1992, BIOCHIM BIOPHYS ACTA, V1101, P184, DOI 10.1016/0005-2728(92)90220-V; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; HIESEL R, 1987, EMBO J, V6, P29, DOI 10.1002/j.1460-2075.1987.tb04714.x; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HOSLER JP, 1994, BIOCHEMISTRY-US, V33, P1194, DOI 10.1021/bi00171a019; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; JACOBS HT, 1988, J MOL BIOL, V202, P185, DOI 10.1016/0022-2836(88)90452-4; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KEIGHTLEY JA, 1992, FASEB J, V6, pA194; KEIGHTLEY JA, 1993, THESIS U NEW MEXICO; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; KUNAI K, 1986, EUR J BIOCHEM, V160, P433, DOI 10.1111/j.1432-1033.1986.tb09991.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPPALAINEN P, 1994, BBA-BIOENERGETICS, V1187, P222, DOI 10.1016/0005-2728(94)90115-5; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, MOL MICROBIOL, V13, P327, DOI 10.1111/j.1365-2958.1994.tb00426.x; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; LUBBEN M, 1994, SYST APPL MICROBIOL, V16, P556; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MA JX, 1993, BIOCHEMISTRY-US, V32, P7692, DOI 10.1021/bi00081a013; Maniatis T., 1982, MOL CLONING; MATHER MW, 1990, PLASMID, V24, P45, DOI 10.1016/0147-619X(90)90024-7; MATHER MW, 1993, METHOD ENZYMOL, V218, P695; MATHER MW, 1991, J BIOL CHEM, V266, P5025; MATHER MW, 1993, J BIOL CHEM, V268, P5395; MATHER MW, 1990, MOL BASIS BACTERIAL, P94; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NISHIYAMA M, 1986, J BIOL CHEM, V261, P14178; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; ROBINSON NC, 1990, ARCH BIOCHEM BIOPHYS, V281, P239, DOI 10.1016/0003-9861(90)90438-5; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1986, FEBS LETT, V206, P154, DOI 10.1016/0014-5793(86)81359-X; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONE N, 1982, BIOCHIM BIOPHYS ACTA, V682, P216, DOI 10.1016/0005-2728(82)90101-3; SURERUS KK, 1992, P NATL ACAD SCI USA, V89, P3195, DOI 10.1073/pnas.89.8.3195; SURPIN MA, 1994, GENE, V143, P73, DOI 10.1016/0378-1119(94)90607-6; TABOR S, 1990, J BIOL CHEM, V265, P8322; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P11173, DOI 10.1021/bi00092a029; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; VIEBROCK A, 1988, J BACTERIOL, V170, P4658, DOI 10.1128/jb.170.10.4658-4668.1988; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WITTUNG P, 1994, FEBS LETT, V349, P286, DOI 10.1016/0014-5793(94)00694-6; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; YOSHIDA T, 1984, J BIOL CHEM, V259, P112; ZIAIE Z, 1987, CURR GENET, V12, P357, DOI 10.1007/BF00405758; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779; ZIMMERMANN BH, 1988, THESIS U MICHIGAN	102	75	78	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20345	20358		10.1074/jbc.270.35.20345	http://dx.doi.org/10.1074/jbc.270.35.20345			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657607	hybrid			2022-12-27	WOS:A1995RR58400020
J	NOMIZU, M; KIM, WH; YAMAMURA, K; UTANI, A; SONG, SY; OTAKA, A; ROLLER, PP; KLEINMAN, HK; YAMADA, Y				NOMIZU, M; KIM, WH; YAMAMURA, K; UTANI, A; SONG, SY; OTAKA, A; ROLLER, PP; KLEINMAN, HK; YAMADA, Y			IDENTIFICATION OF CELL-BINDING SITES IN THE LAMININ ALPHA-1 CHAIN CARBOXYL-TERMINAL GLOBULAR DOMAIN BY SYSTEMATIC SCREENING OF SYNTHETIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; AMINO-ACID-SEQUENCE; A-CHAIN; HEPARIN-BINDING; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; NEURITE OUTGROWTH; IKVAV SEQUENCE; ADHESION; FIBRONECTIN	The laminin al chain carboxyl-terminal globular domain has been identified as a site of multiple biological activities. Using a systematic screening for cell binding sites with 113 overlapping synthetic peptide beads that covered this domain, we found 19 potential active sequences. Corresponding synthetic peptides were evaluated for direct cell attachment, spreading, and inhibition of cell spreading to a laminin-1 substrate using several cell lines. Five peptides (AG-10, AG-22, AG-32, AG-56, and AG-73) showed cell attachment activities with cell-type specificities. Cell spreading on AG-10 was inhibited by beta 1 and alpha 6 integrin antibodies and on AG-32 was inhibited by beta 1, alpha 2, and alpha 6 integrin antibodies. In contrast, cell adhesion and spreading on peptide AG-73 were not inhibited by these antibodies. The minimum active sequences of AG-10, AG-32, and AG-73 were determined to be SIYITRF, IAFQRN, and LQVQLSIR, respectively. These sequences are highly conserved among the different species and different laminin alpha chains, suggesting that they play a critical role for biological function and for interaction with cell surface receptors.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	NOMIZU, M (corresponding author), NIDR,DEV BIOL LAB,BLDG 30,BETHESDA,MD 20892, USA.		Kim, Wooho/G-3703-2011					AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011; AOTA S, 1991, J BIOL CHEM, V266, P15938; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; Bodanszky M., 1983, PEPTIDES, V5, P111; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUJII N, 1989, PEPTIDE CHEM 1988, P147; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JUNG G, 1992, ANGEW CHEM INT EDIT, V21, P367; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; NOMIZU M, 1994, J BIOL CHEM, V269, P30386; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAVIA MR, 1993, BIOORG MED CHEM LETT, V3, P387, DOI 10.1016/S0960-894X(01)80220-1; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSHBACHER MD, 1984, NATURE, V301, P30; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SKUBITZ APN, 1990, CANCER RES, V50, P7612; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; YAJIMA H, 1988, TETRAHEDRON, V44, P805, DOI 10.1016/S0040-4020(01)86118-4; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	58	231	237	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20583	20590		10.1074/jbc.270.35.20583	http://dx.doi.org/10.1074/jbc.270.35.20583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657636	hybrid			2022-12-27	WOS:A1995RR58400055
J	WHITE, ZW; FISHER, KE; EISENSTEIN, E				WHITE, ZW; FISHER, KE; EISENSTEIN, E			A MONOMERIC VARIANT OF GROEL BINDS NUCLEOTIDES BUT IS INACTIVE AS A MOLECULAR CHAPERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; FLUORESCENT-PROBE; LOW-TEMPERATURE; CENTRAL CAVITY; PURIFICATION; HYDROLYSIS; RHODANESE	The heat shock protein GroEL from Escherichia coli is a tetradecameric oligomer that facilitates the refolding of nonnative polypeptides in an ATP-hydrolysis dependent reaction. A mutant in GroEL was prepared in which lysine 3 was substituted with glutamate, which destabilizes the oligomeric structure of GroEL (Horovitz, A., Bochkareva, E.S., and Girshovich, A.S. (1993) J. Biol. Chem. 268, 9957-9959). The highly expressed and purified GroEL(K3E) was judged to be monomeric by sedimentation equilibrium, yielding a molecular weight of 54,500, despite a weak tendency of the mutant to reversibly form higher order aggregates above 4 mg ml(-1). The monomeric variant appears to be folded based on the far UV circular dichroism spectrum, which shows significant alpha-helical content, but with slight differences in conformation relative to wild-type GroEL. The increase in exposed hydrophobic surface of the monomer was probed with the dye 4,4'-bis-1-anilino-3-naphthalenesulfonate (bis-ANS). The fluorescence of bis-ANS increases approximately 150-fold in the presence of the mutant, and about 4 mol of bis-ANS bind per mol of monomer, with a binding constant of 1.6 mu m. Adenosine nucleotide binding to monomeric GroEL(K3E) resulted in considerable quenching of bis-ANS fluorescence, correlating with significant structural changes as seen in the far UV circular dichroism, and permitted the measurement of binding isotherms for ATP and ADP. Hyperbolic ATP binding isotherms yield a dissociation constant of 82 mu M, about 4-fold weaker than the K-0.5 for ATP seen in steady-state kinetics assays of the wild-type GroEL ATPase. A similar difference was seen for ADP binding. These results suggest that the mutation disrupts the native tetradecameric quaternary structure through conformational changes that may also weaken nucleotide binding. The monomeric mutant exhibited no chaperone activity as evidenced by a failure to inhibit or facilitate the refolding of chemically denatured enolase, an inability to refold denatured rhodanese above spontaneous levels, and a lack of binding to alpha-casein, a competitor in many chaperonin promoted refolding reactions. Thus, the formation of assembly incompetent monomers by the lysine 3 to glutamate mutation results in a dramatic decrease in the affinity for nonnative polypeptide chains and suggests that the oligomeric nature of GroEL is crucial for its molecular chaperone function.	UNIV MARYLAND,INST BIOTECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049316] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08937] Funding Source: Medline; NIGMS NIH HHS [GM49316] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURNETT BP, 1994, J BACTERIOL, V176, P6980, DOI 10.1128/JB.176.22.6980-6985.1994; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; EISENSTEIN E, 1991, J BIOL CHEM, V266, P5801; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29416; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KUBO T, 1993, J BIOL CHEM, V268, P19346; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; NOBLE RW, 1969, J MOL BIOL, V39, P479, DOI 10.1016/0022-2836(69)90139-9; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; TAGUCHI H, 1994, J BIOL CHEM, V269, P8529; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZHUANG P, 1994, BIOCHEMISTRY-US, V33, P4237, DOI 10.1021/bi00180a018	42	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20404	20409		10.1074/jbc.270.35.20404	http://dx.doi.org/10.1074/jbc.270.35.20404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657615	hybrid			2022-12-27	WOS:A1995RR58400028
J	PREVIS, SF; FERNANDEZ, CA; YANG, DW; SOLOVIEV, MV; DAVID, F; BRUNENGRABER, H				PREVIS, SF; FERNANDEZ, CA; YANG, DW; SOLOVIEV, MV; DAVID, F; BRUNENGRABER, H			LIMITATIONS OF THE MASS ISOTOPOMER DISTRIBUTION ANALYSIS OF GLUCOSE TO STUDY GLUCONEOGENESIS - SUBSTRATE CYCLING BETWEEN GLYCEROL AND TRIOSE PHOSPHATES IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLE ISOTOPES; BIOSYNTHESIS; HUMANS; INVIVO	Mass isotopomer distribution analysis allows studying the synthesis of polymeric biomolecules from N-15, C-13-, or H-2-labeled monomeric units in the presence of unlabeled polymer, The mass isotopomer distribution of the polymer allows calculation of (i) the enrichment of the monomer and (ii) the dilution of the newly synthesized polymer by unlabeled polymer, We tested the conditions of validity of mass isotopomer distribution analysis of glucose labeled from [U-C-13(3)]lactate, [U-C-13(3)]glycerol, and [2-C-13]glycerol to calculate the fraction of glucose production derived from gluconeogenesis. Experiments were conducted in perfused rat livers, Live rats, and live monkeys, In all cases, [C-13]glycerol yielded labeling patterns of glucose that are incompatible with glucose being formed from a single pool of triose phosphates of constant enrichment, We show evidence that variations in the enrichment of triose phosphates result from (i) the large fractional decrease in physiological glycerol concentration in a single pass through the liver and (ii) the release of unlabeled glycerol by the liver, presumably via lipase activity, This zonation of glycerol metabolism in Liver results in the calculation of artifactually low contributions of gluconeogenesis to glucose production when the latter is labeled from [C-13]glycerol, In contrast, [U-C-13(3)]lactate appears to be a suitable tracer for mass isotopomer distribution analysis of gluconeogenesis in vivo, but not in the perfused liver, In other perfusion experiments with [H-2(5)]glycerol, we showed that the rat liver releases glycerol molecules containing one to four H-2 atoms, This indicates the operation of a substrate cycle between extracellular glycerol and liver triose phosphates, where H-2 is lost in the reversible reactions catalyzed by alpha-glycerophosphate dehydrogenase, triose-phosphate isomerase, and glycolytic enzymes, This substrate cycle presumably involves alpha-glycerophosphate hydrolysis.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biemann K., 1962, MASS SPECTROMETRY OR, P223; BIRD RB, 1960, TRANSPORT PHENOMENA, P554; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEBEER LJ, 1982, FEBS LETT, V140, P159, DOI 10.1016/0014-5793(82)80884-3; FERNANDEZ CA, 1994, 1994 P S INT FED AUT, P367; GRUNNET N, 1967, EUR J BIOCHEM, V3, P78, DOI 10.1111/j.1432-1033.1967.tb19500.x; HAUSSINGER D, 1984, TRENDS BIOCHEM SCI, V9, P300, DOI 10.1016/0968-0004(84)90294-9; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HETENYI G, 1982, FED PROC, V41, P104; JUNGERMANN K, 1986, ENZYME, V35, P161, DOI 10.1159/000469338; JUNGERMANN K, 1986, REGULATION HEPATIC M, P211; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KHARROUBI AT, 1992, AM J PHYSIOL, V263, pE667, DOI 10.1152/ajpendo.1992.263.4.E667; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LANDAU BR, 1993, ADV EXP MED BIOL, V334, P209; LASDON LS, 1989, GRG USERS GUIDE; LEADLAY PF, 1976, BIOCHEMISTRY-US, V15, P5617, DOI 10.1021/bi00670a029; LEE WNP, 1994, AM J PHYSIOL, V266, pE699, DOI 10.1152/ajpendo.1994.266.5.E699; LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372; LEE WP, 1993, DIABETES, V42, pA178; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; OLSON AC, 1966, BIOCHIM BIOPHYS ACTA, V125, P185, DOI 10.1016/0005-2760(66)90159-7; PERONI O, 1995, IN PRESS AM J PHYSL; PREVIS SF, 1994, ANAL BIOCHEM, V218, P192, DOI 10.1006/abio.1994.1159; ROBINSON J, 1969, BIOCHEM J, V112, P455, DOI 10.1042/bj1120455; ROSE IA, 1962, J BIOL CHEM, V237, P3325; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SCRUTTON MC, 1969, METHOD ENZYMOL, V13, P235; SESTOFT L, 1975, BIOCHIM BIOPHYS ACTA, V375, P462, DOI 10.1016/0005-2736(75)90360-0; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; STRONG JM, 1985, J BIOL CHEM, V260, P4276; TURNER SM, 1994, FASEB J, V8, pA956; WINKLER B, 1969, AM J PHYSIOL, V216, P191, DOI 10.1152/ajplegacy.1969.216.1.191	42	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19806	19815		10.1074/jbc.270.34.19806	http://dx.doi.org/10.1074/jbc.270.34.19806			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649990	hybrid			2022-12-27	WOS:A1995RQ99100022
J	JEAN, F; BOUDREAULT, A; BASAK, A; SEIDAH, NG; LAZURE, C				JEAN, F; BOUDREAULT, A; BASAK, A; SEIDAH, NG; LAZURE, C			FLUORESCENT PEPTIDYL SUBSTRATES AS AN AID IN STUDYING THE SUBSTRATE-SPECIFICITY OF HUMAN PROHORMONE CONVERTASE PC1 AND HUMAN FURIN AND DESIGNING A POTENT IRREVERSIBLE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN FAMILY; KEX2-LIKE ENDOPROTEASE; ENZYMATIC-PROPERTIES; PROCESSING ENZYMES; CLEAVAGE SITE; PRECURSOR; ENDOPEPTIDASE; PURIFICATION; BIOSYNTHESIS; TRYPSIN	The substrate specificities of two human prohormone convertases, furin and PC1, were examined with a series of 7-amino-4-methylcoumarinamide (MCA) containing peptidyl substrates. Using acetyl-Arg-Ser-lys-Arg-MCA as model, P4 Arg substitution by Lys or Orn resulted for furin in a 538- and a 280-fold lower k(cat)/K-m value, but only in a 14 and 18-fold decrease for PC1, Substitution of P3 Ser by either Pro, Glu, or Lys does not modify significantly the k(cat)/K-m value for PC1, whereas furin activity is seriously impaired by the Glu substitution. Elongating the peptidyl sequence up to the P8 position decreases the k(cat)/K-m value for furin but not for PC1. In both the P3 or P5 Glu substitution, the decrease of k(cat)/K-m was due primarily to lower k(cat) rather than higher K-m, possibly because of the presence of a negatively charged side chain. Finally, an octapeptidyl chloromethane derivative proved to be a potent irreversible inhibitor of either PC1 and furin, The 811-fold difference in the apparent K-app/[I] (1.63 x 10(6) s(-1) M(-1)), and k(cat)/K-m determined with the corresponding peptidyl MCA substrate (2.01 x 10(9) s(-1) M(-1)), supports the proposal that cleavage of the acylenzyme represents the rate-limiting step for PC1 and furin.	UNIV MONTREAL,CLIN RES INST MONTREAL,NEUROPEPTIDE STRUCT & METAB LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,JA DE SEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ALARCON C, 1994, BIOCHEM J, V301, P257, DOI 10.1042/bj3010257; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISTOL JA, 1993, J BIOL CHEM, V268, P7577; CHAUVET J, 1987, FEBS LETT, V217, P180, DOI 10.1016/0014-5793(87)80659-2; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KITZ R, 1962, J BIOL CHEM, V237, P3245; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KREUTTER K, 1994, BIOCHEMISTRY-US, V33, P13792, DOI 10.1021/bi00250a033; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; POWERS JC, 1977, CHEM BIOCH AMINO ACI, V4, P65; REHEMTULLA A, 1992, BLOOD, V79, P2349; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; ZIMMERMAN M, 1977, ANAL BIOCHEM, V70, P258	45	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19225	19231		10.1074/jbc.270.33.19225	http://dx.doi.org/10.1074/jbc.270.33.19225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642593	hybrid			2022-12-27	WOS:A1995RP70300007
J	BUKHTIYAROV, YE; OMER, CA; ALLEN, CM				BUKHTIYAROV, YE; OMER, CA; ALLEN, CM			PHOTOREACTIVE ANALOGS OF PRENYL DIPHOSPHATES AS INHIBITORS AND PROBES OF HUMAN PROTEIN FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; METHYL-ESTER; TRANSFERASE; BINDING; CLONING; BRAIN	Photoreactive analogues of prenyl diphosphates have been useful in studying prenyltransferases. The effectiveness of analogues with different chain lengths as probes of recombinant human protein prenyltransferases is established here. A putative geranylgeranyl diphosphate analogue, 2-diazo-3,3,3-trifluoropropionyloxy-farnesyl diphosphate (DATFP-FPP), was the best inhibitor of both protein farnesyltransferase (PFT) and protein geranylgeranyltransferase-I (PGGT-I), Shorter photoreactive isoprenyl diphosphate analogues with geranyl and dimethylallyl moieties and the DATFP-derivative of farnesyl monophosphate were much poorer inhibitors. DATFP-FPP was a competitive inhibitor of both PFT and PGGT-I with K-i values of 100 and 18 nM, respectively, [P-32]DATFP-FPP specifically photoradiolabeled the beta-subunits of both PFT and PGGT-I. Photoradiolabeling of PGGT-I was inhibited more effectively by geranylgeranyl diphosphate than farnesyl diphosphate, whereas photoradiolabeling of PFT was inhibited better by farnesyl diphosphate than geranylgeranyl diphosphate. These results lead to the conclusions that DATFP-FPP is an effective probe of the prenyl diphosphate binding domains of PFT and PGGT-I. Furthermore, the beta-subunits of protein prenyltransferases must contribute significantly to the recognition and binding of the isoprenoid substrate.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,W POINT,PA 19486	State University System of Florida; University of Florida; Merck & Company				Bukhtiyarov, Yuri/0000-0003-3370-5413				ALLEN CM, 1985, METHOD ENZYMOL, V111, P281; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BABA T, 1985, J BIOL CHEM, V260, P467; BABA T, 1983, BIOCHEMISTRY-US, V23, P1312; BHALERAO UT, 1971, J AM CHEM SOC, V93, P4835; BREMS DN, 1979, BIOCHEMISTRY-US, V18, P860, DOI 10.1021/bi00572a019; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAN KC, 1968, J ORG CHEM, V33, P3382, DOI 10.1021/jo01273a004; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAS NP, 1991, BIOCHEM BIOPH RES CO, V81, P729; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DOGDO O, 1987, BIOCHIM BIOPHYS ACTA, V920, P140; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1993, CURR BIOL, V3, P770, DOI 10.1016/0960-9822(93)90027-L; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOLY A, 1991, J BIOL CHEM, V266, P13495; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MARSHALL J A, 1986, Journal of Organic Chemistry, V51, P4316, DOI 10.1021/jo00372a048; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, J BIOL CHEM, V266, P10672; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; UMBREIT M, 1977, JA M CHEM SOC, V94, P5526; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; [No title captured]	44	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19035	19040		10.1074/jbc.270.32.19035	http://dx.doi.org/10.1074/jbc.270.32.19035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642565	hybrid			2022-12-27	WOS:A1995RN95400053
J	HUTCHISON, KA; STANCATO, LF; OWENSGRILLO, JK; JOHNSON, JL; KRISHNA, P; TOFT, DO; PRATT, WB				HUTCHISON, KA; STANCATO, LF; OWENSGRILLO, JK; JOHNSON, JL; KRISHNA, P; TOFT, DO; PRATT, WB			THE 23-KDA ACIDIC PROTEIN IN RETICULOCYTE LYSATE IS THE WEAKLY-BOUND COMPONENT OF THE HSP FOLDOSOME THAT IS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A FUNCTIONAL HETEROCOMPLEX WITH HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR; RECONSTITUTION; COMPLEX; BINDING	The heat shock proteins hsp90 and hsp70 have been immunopurified from rabbit reticulocyte lysate in a multiprotein complex that acts as a self-sufficient protein folding machine. This immunopurified ''foldosome'' directs the assembly of the glucocorticoid receptor-hsp90 complex and refolds the receptor to the steroid binding state (Hutchison, K. A., Dittmar, K. D., and Pratt, W. B. (1994) J. Biol, Chem. 269, 27894-27899). Extensive washing of the immunoadsorbed foldosome eliminates a weakly bound component required for receptor heterocomplex assembly and folding. This protein factor is contained in a Centricon C-100 filtrate of lysate which reconstitutes the receptor activating activity of the washed foldosome. This hsp90-associated protein folding system is present in both animal and plant cells, and the Centricon C-100 fraction of rabbit reticulocyte ly sate potentiates receptor folding directed by wheat germ lysate. We have used this ability to stimulate wheat germ lysate-directed folding of the glucocorticoid receptor as a rapid assay for the factor. We demonstrate that the activity segregates with the 23-kDa acidic protein component of the hsp90 foldosome when rabbit reticulocyte lysate is fractionated by ammonium sulfate precipitation and ion exchange chromatography, Immunoadsorption of the Centricon C-100 filtrate with a monoclonal antibody against p23 eliminates its ability to stimulate the wheat germ heterocomplex assembly/receptor folding system, and the activity is replaced by purified, bacterially expressed p23. Immunodepletion of p23 also eliminates the ability of the Centricon C-100 filtrate to reconstitute receptor activating activity of the washed foldosome and addition of purified, bacterially expressed p23 restores its activity, confirming that p23 is the weakly bound component of the foldosome complex required for refolding of the receptor to the steroid binding conformation.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; MAYO GRAD SCH,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV WESTERN ONTARIO,DEPT PLANT SCI,LONDON,ON N6A 5B7,CANADA	University of Michigan System; University of Michigan; Mayo Clinic; Western University (University of Western Ontario)				Krishna, Priti/0000-0001-6394-3012	NICHD NIH HHS [HDO9140] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; ERHART JC, 1988, ONCOGENE, V3, P595; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WHITELAW ML, 1991, J BIOL CHEM, V266, P6708	20	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18841	18847		10.1074/jbc.270.32.18841	http://dx.doi.org/10.1074/jbc.270.32.18841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642537				2022-12-27	WOS:A1995RN95400024
J	NEL, AE; GUPTA, S; LEE, L; LEDBETTER, JA; KANNER, SB				NEL, AE; GUPTA, S; LEE, L; LEDBETTER, JA; KANNER, SB			LIGATION OF THE T-CELL ANTIGEN RECEPTOR (TCR) INDUCES ASSOCIATION OF HSOS1, ZAP-70, PHOSPHOLIPASE C-GAMMA-1, AND OTHER PHOSPHOPROTEINS WITH GRB2 AND THE ZETA-CHAIN OF THE TCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; LYMPHOCYTE-T; ACTIVATION; PHOSPHORYLATION; STIMULATION; RAS; P21RAS; SH2	Signaling by the T-cell antigen receptor (TCR) involves both phospholipase C (PLC)-gamma 1 and p21(ras) activation. While failing to induce Shc/Grb2 association, ligation of the TCR/CDS receptor in Jurkat T-cells induced hSos1-Grb2 complexes. In addition to hSos1, Grb2 participates in the formation of a tyrosine phosphoprotein complex that includes 145-, 95-, 70-, 54-, and 36-38 kDa proteins. p145 was identified as PLC-gamma 1 and p70 as the protein tyrosine kinase, ZAP-70. Although of the same molecular weight, p95 was not recognized by an antiserum to p95 Vav. The SH2 domains of Grb2 and PLC-gamma 2 were required for the formation of this protein complex. In anti-CD3-treated cells, Grb2 redistributed from the cytosol to a particulate cell compartment along with p36/p38, ZAP-70, and PLC-gamma 1. Part of the Grb2 complex associated with the particulate compartment could be extracted with Nonidet P-40, while the rest was Nonidet P-40 insoluble. In both the detergent-soluble and -insoluble fractions, Grb2 coimmunoprecipitated with the zeta chain of the TCR. Taken together, these results indicate that anti-CDS induces Grb2-hSos1-PLC-gamma 1-p36/p38-ZAP70 complexes, which localize in the vicinity of TCR-zeta.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb	NEL, AE (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.		Nel, Andre E/J-2808-2012		NIGMS NIH HHS [GM41576] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLIPSTONE NA, 1992, NATURE, V357, P659; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GEPEPRT TD, 1991, J IMMUNOL, V46, P3298; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUPTA S, 1994, J BIOL CHEM, V269, P17349; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KUBO RT, 1989, J IMMUNOL, V142, P2736; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NEL AE, 1990, J IMMUNOL, V144, P2683; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; SANCHO J, 1993, J IMMUNOL, V150, P3230; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, SCIENCE, V239, P1018; YANG LJ, 1994, J BIOL CHEM, V269, P7156	48	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18428	18436		10.1074/jbc.270.31.18428	http://dx.doi.org/10.1074/jbc.270.31.18428			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629168	hybrid			2022-12-27	WOS:A1995RM64200045
J	BARRONCASELLA, EA; TORRES, MA; SCHERER, SW; HENG, HHQ; TSUI, LC; CASELLA, JF				BARRONCASELLA, EA; TORRES, MA; SCHERER, SW; HENG, HHQ; TSUI, LC; CASELLA, JF			SEQUENCE-ANALYSIS AND CHROMOSOMAL LOCALIZATION OF HUMAN CAP-Z - CONSERVED RESIDUES WITHIN THE ACTIN-BINDING DOMAIN MAY LINK CAP-Z TO GELSOLIN/SEVERIN AND PROFILIN PROTEIN FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING PROTEIN; ALPHA-SUBUNIT; INSITU HYBRIDIZATION; SKELETAL-MUSCLE; BETA-SUBUNIT; VILLIN; GENES; YEAST; IDENTIFICATION; PURIFICATION	From a human retinal cDNA library, we have isolated cDNAs that are homologs for the alpha 2 and beta subunits of chicken Cap Z. The derived human alpha subunit shares 95% amino acid identity with the chicken alpha 2 subunit; the beta subunit is 99% identical to the chicken subunit residues 1-243. The remaining portion of the human beta subunit (244-272) diverges significantly with only 8 out of 29 C-terminal amino acids conserved between the two species, This lack of conservation is of particular interest because the chicken C terminus contains an actin-binding domain, Cosedimentation assays with F-actin show that human Cap Z binds actin with an affinity equal that of chicken Cap Z, These results point to the eight shared amino acids as critical for actin binding, three of which are regularly spaced leucines, These apolar residues and one outside the region of divergence align well with those residues of the actin-binding alpha-helix proposed for gelsolin segment 1. The apolar residues as well as three polar amino acids are also conserved in other capping, capping and severing, and monomer-binding proteins, Amino acid substitutions in the chicken beta subunit of the two most highly conserved leucines result in significant decreases in F-actin binding activity, The human alpha 2 gene (CAPZA2) has been mapped to chromosome 7 position q31.2-q31.3 and the beta gene (CAPZB) to chromosome 1 region p36.1.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	BARRONCASELLA, EA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV HEMATOL,ROSS RES BLDG,RM 1125,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040697] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR40697] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; AMPE C, 1985, J BIOL CHEM, V260, P834; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CALDWELL JE, 1989, J BIOL CHEM, V264, P12648; CASELLA JF, 1989, P NATL ACAD SCI USA, V86, P5800, DOI 10.1073/pnas.86.15.5800; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CASELLA JF, 1994, J BIOL CHEM, V269, P6992; COOPER JA, 1991, CELL MOTIL CYTOSKEL, V18, P204, DOI 10.1002/cm.970180306; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KERE J, 1989, CYTOGENET CELL GENET, V50, P226, DOI 10.1159/000132765; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SCHERER SW, 1993, HUM MOL GENET, V2, P751, DOI 10.1093/hmg/2.6.751; SCHERER SW, 1994, AM J HUM GENET, V55, P12; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; TSUI LC, 1988, J MED GENET, V25, P294, DOI 10.1136/jmg.25.5.294; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WADDLE JA, 1993, MOL BIOL CELL, V4, P907, DOI 10.1091/mbc.4.9.907; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1992, J BIOL CHEM, V267, P14616	37	50	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21472	21479		10.1074/jbc.270.37.21472	http://dx.doi.org/10.1074/jbc.270.37.21472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665558	hybrid			2022-12-27	WOS:A1995RU75700012
J	GORCZYCA, WA; POLANS, AS; SURGUCHEVA, IG; SUBBARAYA, I; BAEHR, W; PALCZEWSKI, K				GORCZYCA, WA; POLANS, AS; SURGUCHEVA, IG; SUBBARAYA, I; BAEHR, W; PALCZEWSKI, K			GUANYLYL CYCLASE-ACTIVATING PROTEIN - A CALCIUM-SENSITIVE REGULATOR OF PHOTOTRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP-GATED CHANNEL; ROD OUTER SEGMENTS; BINDING PROTEINS; RETINAL RODS; IDENTIFICATION; PHOTORECEPTORS; RECOVERIN; CELLS; MOUSE	Guanylyl cyclase activating protein (GCAP1) has been proposed to act as a calcium-dependent regulator of retinal photoreceptor guanylyl cyclase (GC) activity. Using immunocytochemical and biochemical methods, we show here that GCAP1 is present in rod and cone photoreceptor outer segments where phototransduction occurs. Recombinant and native GCAP1 activate recombinant human retGC (outer segment-specific GC) and endogenous GC(s) in rod outer segment (ROS) membranes at low calcium. In addition, we isolate and clone a retinal homolog, termed GCAP2, that shows similar to 50% identity with GCAP1. Like GCAP1, GCAP2 activates photoreceptor GC in a calcium-dependent manner. Both GCAP1 and GCAP2 presumably act on GCs by a similar mechanism; however, GCAP1 specifically localizes to photoreceptor outer segments, while in these experiments GCAP2 was isolated from extracts of retina but not ROS. These results demonstrate that GCAP1 is an activator of ROS GC, while the finding of a second activator, GCAP2, suggests that a similar mechanism of GC regulation may be present in outer segments, other subcellular compartments of the photoreceptor, or other cell types.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,PORTLAND,OR 97209; BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030	University of Washington; University of Washington Seattle; Baylor College of Medicine	GORCZYCA, WA (corresponding author), UNIV WASHINGTON,DEPT OPHTHALMOL,BOX 356485,SEATTLE,WA 98195, USA.				NATIONAL EYE INSTITUTE [R01EY008061, R29EY007089, P30EY001730, R01EY007089, R29EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [EY01730, EY08061, EY07089] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMBELL AM, 1984, MONOCLONAL ANTIBODY, V13; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GORODOVIKOVA EN, 1994, FEBS LETT, V349, P187, DOI 10.1016/0014-5793(94)00661-X; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; POLANS AS, 1988, INVEST OPHTH VIS SCI, V29, P1523; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; QIN N, 1994, J BIOL CHEM, V269, P3265; QIN N, 1993, FEBS LETT, V321, P6, DOI 10.1016/0014-5793(93)80609-X; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUBBARAYA I, 1994, J BIOL CHEM, V269, P31080; UMBARGER KO, 1992, J BIOL CHEM, V267, P19494; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	45	190	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22029	22036		10.1074/jbc.270.37.22029	http://dx.doi.org/10.1074/jbc.270.37.22029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665624	hybrid			2022-12-27	WOS:A1995RU75700090
J	GRAVES, PR; ROACH, PJ				GRAVES, PR; ROACH, PJ			ROLE OF COOH-TERMINAL PHOSPHORYLATION IN THE REGULATION OF CASEIN KINASE I-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE GLYCOGEN-SYNTHASE; DEPENDENT PROTEIN-KINASE; SUBSTRATE DETERMINANTS; RNA-POLYMERASE; PURIFICATION; MULTIPLE; THYMUS; DNA; IDENTIFICATION; EXPRESSION	Casein kinase I delta is a member of the casein kinase I (CKI) family, a group of second messenger independent protein kinases. We present evidence that the COOH-terminal domain of CKI delta has regulatory properties. CKI delta expressed in Escherichia coli was activated by heparin, as found previously, and by treatment with the catalytic subunit of type-1 protein phosphatase (CS1). Concomitant with activation by CS1, there was a reduction in the apparent molecular weight of CKI delta from 55,000 to 49,000 as judged by polyacrylamide gel electro-phoresis in the presence of sodium dodecyl sulfate. Truncation of CKI delta by removal of the COOH-terminal 110 amino acids eliminated the ability of CS1 to activate or to increase electrophoretic mobility. Casein kinase I alpha, a 37-kDa isoform that lacks an extended COOH-terminal domain, was not activated by CS1 or the presence of heparin. However, a chimeric enzyme consisting of CKI alpha fused to the COOH-terminal domain of CKI delta was activated by both heparin and CS1. Analysis of the effects of CS1 on a series of CKI delta COOH-terminal truncation mutants identified an inhibitory region between His(317) and Pro(342), which contained six potential phosphorylation sites. From analysis of the specific activities of these truncation mutants, removal of the same region resulted in enzyme with a specific activity nearly 10-fold greater than wild-type. Thus, CKI delta activity can be regulated by phosphorylation of its COOH terminus, which may serve to create an autoinhibitory domain. This mechanism of regulation could have important consequences in vivo.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221, R56DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1982, J BIOL CHEM, V257, P8348; AHMAD Z, 1984, J BIOL CHEM, V259, P3420; AHN NG, 1991, J BIOL CHEM, V266, P4220; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CHAUHAN VPS, 1993, BIOCHIM BIOPHYS ACTA, V1177, P318, DOI 10.1016/0167-4889(93)90128-C; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELPECH M, 1986, EUR J BIOCHEM, V160, P333, DOI 10.1111/j.1432-1033.1986.tb09976.x; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KEARNEY PH, 1994, BIOCHEM BIOPH RES CO, V203, P231, DOI 10.1006/bbrc.1994.2172; KLIMCZAK LJ, 1993, BIOCHEM J, V293, P283, DOI 10.1042/bj2930283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE K, 1989, J NEUROSCI, V9, P1883; MARIN O, 1994, EUR J BIOCHEM, V223, P647, DOI 10.1111/j.1432-1033.1994.tb19037.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MILNE DM, 1992, ONCOGENE, V7, P1361; OSPINA B, 1990, BIOCHIM BIOPHYS ACTA, V1052, P483, DOI 10.1016/0167-4889(90)90159-B; PINNA LA, 1989, PEPTIDES PROTEIN PHO, P145; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAPIA C, 1994, FEBS LETT, V349, P307, DOI 10.1016/0014-5793(94)00679-2; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALCZAK CE, 1993, BIOCHEM J, V296, P729, DOI 10.1042/bj2960729; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	49	139	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21689	21694		10.1074/jbc.270.37.21689	http://dx.doi.org/10.1074/jbc.270.37.21689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665585	hybrid			2022-12-27	WOS:A1995RU75700043
J	CARDENAS, ME; LIM, E; HEITMAN, J				CARDENAS, ME; LIM, E; HEITMAN, J			MUTATIONS THAT PERTURB CYCLOPHILIN A LIGAND-BINDING POCKET CONFER CYCLOSPORINE-A RESISTANCE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CIS-TRANS-ISOMERIZATION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HOMOLOG NINAA; A-BINDING; SIGNAL-TRANSDUCTION; ACTIVE-SITE; CALCINEURIN; PROTEIN	In complex with the peptidyl-prolyl isomerase cyclophilin A, the immunosuppressive antifungal drug cyclosporin A (CsA) inhibits a Ca2+/calmodulin-dependent protein phosphatase, calcineurin, which regulates signal transduction. We isolated and characterized cyclophilin A mutations that confer CsA resistance in a Saccharomyces cerevisiae strain whose growth is CsA-sensitive. Three mutations (G70S, H90Y, and G102A) alter single amino acids conserved between yeast and human cyclophilin A, which structural analyses implicate in CsA binding to human cyclophilin A. By Western analysis, all three mutant proteins are expressed in yeast, In vitro, two purified mutant cyclophilins (G70S, G102A) retain prolyl isomerase activity and have moderately reduced affinity for CsA and calcineurin but, when bound to CsA, do bind and inhibit calcineurin phosphatase activity. In contrast, the purified H90Y mutant cyclophilin is dramatically decreased in prolyl isomerase activity, CsA affinity, and calcineurin binding and inhibition. These studies identify conserved cyclophilin A residues that participate in CsA binding and catalysis.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021		NHLBI NIH HHS [P01 HL50985-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; FEJZO J, 1994, BIOCHEMISTRY-US, V33, P5711, DOI 10.1021/bi00185a007; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOOR F, 1992, NATURE, V360, P682; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; MIKOL V, 1994, PROTEIN ENG, V7, P597, DOI 10.1093/protein/7.5.597; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ONDEK B, 1992, J BIOL CHEM, V267, P16460; PARENT SA, 1993, J GEN MICROBIOL, V139, P2973, DOI 10.1099/00221287-139-12-2973; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; YE RR, 1992, EUR J BIOCHEM, V204, P713, DOI 10.1111/j.1432-1033.1992.tb16686.x; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20997	21002		10.1074/jbc.270.36.20997	http://dx.doi.org/10.1074/jbc.270.36.20997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673124	hybrid			2022-12-27	WOS:A1995RU05400021
J	WEBER, J; BOWMAN, C; WILKEMOUNTS, S; SENIOR, AE				WEBER, J; BOWMAN, C; WILKEMOUNTS, S; SENIOR, AE			ALPHA-ASPARTATE-261 IS A KEY RESIDUE IN NONCATALYTIC SITES OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; DIRECTED MUTAGENESIS; MITOCHONDRIAL F1-ATPASE; CATALYTIC PROPERTIES; ATP BINDING; SYNTHASE; SUBUNIT; F(1)-ATPASE; SPECIFICITY	X-ray structure analysis of the noncatalytic sites of F-1-ATPase revealed that residue alpha-Asp(261) lies close to the Mg of bound Mg-5'-adenylyl-beta,gamma imidodiphosphate. Here, the mutation alpha D261N was generated in Escherichia coli and combined with the alpha R365W mutation, allowing nucleotide binding at F-1 noncatalytic sites to be specifically monitored by tryptophan fluorescence spectroscopy. Purified alpha D261N/alpha R365W F-1-ATPase showed catalytic activity similar to wild-type. An important feature was that, without any resort to nucleotide depletion procedures, the noncatalytic sites in purified native enzyme were already empty. Binding studies with MgATP, MgADP, and the corresponding free nucleotides led to the following conclusions. Residue alpha-Asp(261) interacts with the Mg of Mg-nucleotide in noncatalytic sites and provides a large component of the binding energy (similar to 3 kcal/mol). It is the primary determinant of the preference of noncatalytic sites for Mg-nucleotide. The natural ligands at these sites in wild-type enzyme are the Mg-nucleotides and free nucleotides bind poorly. Under conditions where noncatalytic sites were empty, alpha D261N/alpha R365W F-1 showed significant hydrolysis of MgATP. This establishes unequivocally that occupancy of noncatalytic sites by nucleotide is not required for catalysis.			WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, BOX 607, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; COX GB, 1978, BIOCHEM J, V170, P593, DOI 10.1042/bj1700593; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V1141, P171; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1994, J BIOL CHEM, V269, P11261; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	26	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21045	21049		10.1074/jbc.270.36.21045	http://dx.doi.org/10.1074/jbc.270.36.21045			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673131	hybrid			2022-12-27	WOS:A1995RU05400029
J	CAMIRE, RM; KALAFATIS, M; CUSHMAN, M; TRACY, RP; MANN, KG; TRACY, PB				CAMIRE, RM; KALAFATIS, M; CUSHMAN, M; TRACY, RP; MANN, KG; TRACY, PB			THE MECHANISM OF INACTIVATION OF HUMAN PLATELET FACTOR VA FROM NORMAL AND ACTIVATED PROTEIN C-RESISTANT INDIVIDUALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; BOVINE FACTOR-V; POOR ANTICOAGULANT RESPONSE; FACTOR-XA; CATALYZED ACTIVATION; ENZYME COMPLEXES; THROMBIN; BINDING; PROTHROMBINASE; THROMBOPHILIA	The inactivation of human platelet factor Va by activated protein C (APC) was analyzed by functional assessment of cofactor activity and Western blotting analysis to visualize the factor Va fragments accompanying proteolysis. Platelets were treated with thrombin to facilitate both their activation as well as the release and further activation of platelet factor Va, followed by APC addition. The rates of inactivation were donor-dependent such that 15-60% of the initial cofactor activity was lost within 5 min of APC addition with as much as 10-20% of the activity still remaining after 2 h of incubation. Western blot analysis using a monoclonal antibody that recognizes an epitope between amino acid residues 307 and 506 of the factor V molecule suggested that the factor Va activity resistant to APC inactivation was due to residual heavy chain. Furthermore, in contrast to studies with normal plasma-derived factor Va, two possible cleavage mechanisms could explain the platelet factor Va fragments observed. APC can cleave platelet factor Va initially at Arg(506), with subsequent cleavages occurring at Ar-306 and Arg(679). Alternatively, APC can cleave at Arg(306) initially, with further cleavage at Arg(679) then at Arg(506) or at Arg(506) followed by cleavage at Arg(679). Similar results were obtained if platelets were removed from the inactivation mixtures and phospholipid vesicles were used to supply the membrane surface required for inactivation, suggesting that the order of platelet factor Va peptide bond cleavage or the amount of cofactor activity remaining was not altered by either of these surfaces. Thus, APC is unable to effect the complete inactivation of platelet factor Va, even though it would appear that the same cleavages which render the plasma cofactor inactive are occurring in the platelet cofactor. Analogous protocols were used to study an individual heterozygous for the Arg(506), Gln(506) mutation (Factor V Leiden, Factor V-R506Q). With respect to the mutant platelet factor Va in the presence of APC, >70% of the initial cofactor activity remained after 1 min, with 30% activity still remaining after 2 h. As seen in studies of the APC catalyzed inactivation of plasma factor Va(R506Q), proteolysis of the mutant platelet factor Va confirms that even though cleavage at Arg(306) will occur in the absence of cleavage at Arg(506), the rate of inactivation is slower. Collectively these data suggest that when compared to normal plasma factor Va, differences in normal platelet factor Va which define: 1) whether the heavy chain is susceptible to cleavage at Arg(306) Or Arg(506) and 2) the extent to which it is cleaved initially at Arg(306), in contrast to cleavage of Arg(506), will define both the extent and rate of inactivation.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	University of Vermont; University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703, T32HL007594, R37HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07594, R37 HL34575, HL-P01-46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P394; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GRIFFIN JH, 1993, BLOOD, V82, P1989; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; Jesty J, 1976, Methods Enzymol, V45, P95; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1980, J BIOL CHEM, V255, P1170; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MONKOVIC DD, 1990, J BIOL CHEM, V265, P17132; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1986, J CLIN INVEST, V77, P405, DOI 10.1172/JCI112318; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OSTERUD B, 1977, BLOOD, V49, P819; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; RAND MD, 1994, BLOOD, V83, P2180; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1984, J CLIN INVEST, V74, P1221, DOI 10.1172/JCI111531; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1982, BLOOD, V60, P59; VISKUP RW, 1987, BLOOD, V69, P1188; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WENCELDRAKE JD, 1986, BLOOD, V68, P244	47	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20794	20800		10.1074/jbc.270.35.20794	http://dx.doi.org/10.1074/jbc.270.35.20794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657663	hybrid			2022-12-27	WOS:A1995RR58400084
J	HAUGHTON, MA; CAPALDI, RA				HAUGHTON, MA; CAPALDI, RA			ASYMMETRY OF ESCHERICHIA-COLI F1-ATPASE AS A FUNCTION OF THE INTERACTION OF ALPHA-BETA SUBUNIT PAIRS WITH THE GAMMA-SUBUNIT AND EPSILON-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE ACTIVITY; GLUTAMIC-ACID RESIDUE; ATP-SYNTHASE; F1 ATPASE; STRUCTURAL ASYMMETRY; MITOCHONDRIAL F1-ATPASE; CATALYTIC SITES; H+-ATPASE; BINDING; DICYCLOHEXYLCARBODIIMIDE	The asymmetry of Escherichia coli F-1-ATPase (ECF(1)) has been explored in chemical modification experiments involving two mutant enzyme preparations. One mutant contains a cysteine (Cys) at position 149 of the beta subunit, along with conversion of a Val to Ala at residue 198 to suppress the deleterious effect of the Cys for Gly at 149 mutation (mutant beta G149C:V198A). The second mutant has these mutations and also Cys residues at positions 381 of beta and 108 of the epsilon subunit (mutant beta G149C:V198A:E381C/epsilon S108C). On CuCl2 treatment of this second mutant, there is cross-linking of one copy of the beta subunit to gamma via the Cys at 381, a second to the epsilon subunit (between beta Cys(381) and epsilon Cys(108)), while the third beta subunit in the ECF, complex is mostly free (some crosslinking to delta); thereby distinguishing the three beta subunits as beta(gamma), beta(epsilon), and beta(free), respectively. Both mutants have ATPase activities similar to wild-type enzyme. Under all nucleotide conditions, including with essentially nucleotide-free enzyme, the three different beta subunits were found to react differently with N-ethylmaleimide (NEM) which reacts with Cys(149) dicyclohexyl carbodiimide (DCCD) which reacts with Glu(192), and 7-chloro-4-nitrobenzofurazan (NbfCl) which reacts with Tyr(297). Thus, beta(gamma) reacted with BOOB but not NEM or NbfCl; beta(free) was reactive with all three reagents; beta(epsilon), reacted with NEM, but was poorly reactive to DCCD or NbfCl. There was a strong nucleotide dependence of the reaction of Cys(149) in beta(epsilon) (but not in beta(free)) with NEM, indicative of the important role that the epsilon subunit plays in functioning of the enzyme.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon			Haughton, Margaret/F-8033-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; ANDREWS WW, 1984, J BIOL CHEM, V259, P8219; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; Davis L.G., 1986, BASIC METHODS MOL BI, P89; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; ESCH FS, 1981, J BIOL CHEM, V256, P9084; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LOTSCHER HR, 1984, BIOCHEM BIOPH RES CO, V121, P331; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; Sambrook J, 1989, MOL CLONING LABORATO; SATRE M, 1979, BIOCHEMISTRY-US, V18, P3134, DOI 10.1021/bi00581a034; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STANLOTTER H, 1986, EUR J BIOCHEM, V154, P321, DOI 10.1111/j.1432-1033.1986.tb09400.x; STANLOTTER H, 1986, ARCH BIOCHEM BIOPHYS, V248, P116, DOI 10.1016/0003-9861(86)90407-8; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WEBER J, 1994, J BIOL CHEM, V269, P20462; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; WISE JG, 1981, J BIOL CHEM, V256, P383; YOSHIDA M, 1981, J BIOL CHEM, V256, P148	43	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20568	20574		10.1074/jbc.270.35.20568	http://dx.doi.org/10.1074/jbc.270.35.20568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657634	hybrid			2022-12-27	WOS:A1995RR58400053
J	ZHAO, XF; VYAS, K; NGUYEN, BD; RAJARATHNAM, K; LAMAR, GN; LI, TS; PHILLIPS, GN; EICH, RF; OLSON, JS; LING, JS; BOCIAN, DF				ZHAO, XF; VYAS, K; NGUYEN, BD; RAJARATHNAM, K; LAMAR, GN; LI, TS; PHILLIPS, GN; EICH, RF; OLSON, JS; LING, JS; BOCIAN, DF			A DOUBLE MUTANT OF SPERM WHALE MYOGLOBIN MIMICS THE STRUCTURE AND FUNCTION OF ELEPHANT MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DISTAL HEME POCKET; LIGAND-BINDING; RESONANCE ASSIGNMENT; 2-DIMENSIONAL NMR; CARBON-MONOXIDE; SYNTHETIC GENE; BOUND LIGAND; H-1-NMR; SPECTROSCOPY	The functional, spectral, and structural properties of elephant myoglobin and the L29F/H64Q mutant of sperm whale myoglobin have been compared in detail by conventional kinetic techniques, infrared and resonance Raman spectroscopy, H-1 NMR, and x-ray crystal lography. There is a striking correspondence between the properties of the naturally occurring elephant protein and those of the sperm whale double mutant, both of which are quite distinct from those of native sperm whale myoglobin and the single H64Q mutant. These results and the recent crystal structure determination by Bisig et al. (Bisig, D. A., Di Iorio, E. E., Diederichs, K., Winterhalter, K. H., and Piontek, K. (1995) J. Biol. Chem. 270, 20754-20762) confirm that a Phe residue is present at position 29 (B10) in elephant myoglobin, and not a Leu residue as is reported in the published amino acid sequence. The single Gln(64)(E7) substitution lowers oxygen affinity similar to 5 fold and increases the rate of autooxidation 3-fold. These unfavorable effects are reversed by the Phe(29)(B10) replacement in both elephant myoglobin and the sperm whale double mutant. The latter, genetically engineered protein was originally constructed to be a blood substitute prototype with moderately low O-2 affinity, large rate constants, and increased resistance to autooxidation. Thus, the same distal pocket combination that we designed rationally on the basis of proposed mechanisms for ligand binding and autooxidation is also found in nature.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; RICE UNIV,WM KECK CTR COMP BIOL,HOUSTON,TX 77005; UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521	Rice University; Rice University; University of California System; University of California Davis; University of California System; University of California Riverside				Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036243] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16087] Funding Source: Medline; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM36243] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALASUBRAMANIAN S, 1993, P NATL ACAD SCI USA, V90, P4718, DOI 10.1073/pnas.90.10.4718; BAX A, 1982, 2 DIMENSIONAL NMR LI; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHIU ML, 1992, STRUCTURE DYNAMICS M; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DENE H, 1980, PROC R SOC SER B-BIO, V207, P111, DOI 10.1098/rspb.1980.0016; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GUPTA RK, 1976, J MAGN RESON, V24, P461, DOI 10.1016/0022-2364(76)90124-4; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P546; LAI HH, 1995, IN PRESS PROTEINS ST; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LING JH, 1994, BBA-BIOENERGETICS, V1188, P417, DOI 10.1016/0005-2728(94)90063-9; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; OLSON JS, 1994, ARTIF CELL BLOOD SUB, V22, P429, DOI 10.3109/10731199409117872; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; QIN J, 1993, BIOPHYS J, V65, P2178, DOI 10.1016/S0006-3495(93)81270-0; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1993, J MOL BIOL, V231, P2009; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1993, BIOCHEMISTRY-US, V32, P5670, DOI 10.1021/bi00072a024; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMEROHERRERA AE, 1981, J MOL EVOL, V17, P140, DOI 10.1007/BF01733907; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; VAINSHTEIN BK, 1978, SOV PHYS-CRYSTALLOGR, V23, P4966; VYAS K, 1993, J BIOL CHEM, V268, P14826; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; YU LP, 1990, BIOCHEMISTRY-US, V29, P2578, DOI 10.1021/bi00462a021; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	58	76	77	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20763	20774		10.1074/jbc.270.35.20763	http://dx.doi.org/10.1074/jbc.270.35.20763			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657659	hybrid			2022-12-27	WOS:A1995RR58400080
J	KWONG, CH; ADAMS, AG; LETO, TL				KWONG, CH; ADAMS, AG; LETO, TL			CHARACTERIZATION OF THE EFFECTOR-SPECIFYING DOMAIN OF RAC INVOLVED IN NADPH OXIDASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SIGNAL TRANSDUCTION; EXCHANGE PROTEINS; IN-VITRO; SUPEROXIDE; COMPONENTS; MEMBRANE; CLONING	Production of microbicidal oxidants by phagocytic leukocytes requires activation of a latent NADPH oxidase by the coordinated assembly of a membrane-associated flavocytochrome b(558), with three cytosolic components, p47(phox), p67(phox), and the low molecular weight GTP-binding protein Rac. Rac1 and Rac2 have 92% sequence identity and are both active in supporting the oxidase, while CDC42Hs, the closest relative to Pac with 70% sequence identity, only weakly supports oxidase activation in vitro, We have used CDC42Hs as a foil to identify residues in Pac that are critical for oxidase activation. Most of the divergent sequences of CDC42Hs could be incorporated into Rac-CDC42Hs chimeric proteins without affecting cell-free NADPH oxidase activity, However, incorporation of the amino-terminal segment of CDC42Hs (residues 1-40), which differs from Rad by only four residues (positions 3, 27, 30, and 33), resulted in a marked loss of oxidase activation capacity. Point mutagenesis studies showed that this was due to changes at residues 27 and 30, but nob residues 3 and 33. Conversely, incorporation of the amino terminus of Rac1 (residues 1-40) into CDC42Hs increased its activity to that of Rac1, indicating that this terminus contains the effector-specifying domain of Rac. Taken together, these studies show that the difference in the activity between CDC42Hs and Rac1 is due entirely to differences in amino acids at position 27 and 30.			KWONG, CH (corresponding author), NIAID,HOST DEF LAB,BETHESDA,MD 20892, USA.							ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ANDO S, 1992, J BIOL CHEM, V267, P25709; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SELF AJ, 1993, ONCOGENE, V8, P655; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	42	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19868	19872		10.1074/jbc.270.34.19868	http://dx.doi.org/10.1074/jbc.270.34.19868			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649999	hybrid			2022-12-27	WOS:A1995RQ99100031
J	ARRUDA, LK; VAILES, LD; MANN, BJ; SHANNON, J; FOX, JW; VEDVICK, TS; HAYDEN, ML; CHAPMAN, MD				ARRUDA, LK; VAILES, LD; MANN, BJ; SHANNON, J; FOX, JW; VEDVICK, TS; HAYDEN, ML; CHAPMAN, MD			MOLECULAR-CLONING OF A MAJOR COCKROACH (BLATTELLA-GERMANICA) ALLERGEN, BLA-G-2 - SEQUENCE HOMOLOGY TO THE ASPARTIC PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUST MITE ALLERGEN; T-CELL EPITOPES; DER-P-II; HOUSE-DUST; MONOCLONAL-ANTIBODIES; RIBONUCLEIC-ACID; POLLEN ALLERGEN; RISK-FACTORS; CATHEPSIN-D; IDENTIFICATION	Inhalation of allergens produced by the German cockroach (Blattella germanica) elicits IgE antibody formation and the development of asthma in genetically predisposed individuals. We compared the allergenic importance of two cockroach (CR) allergens, Bla g 1 and Bla g 2, and determined the complete amino acid sequence of the major 36-kDa allergen, Bla g 2. A survey of 106 sera from CR allergic patients showed the prevalence of IgE antibodies to Bla gl and Bla g 2 to be 30.2% and 57.6%, respectively. Immediate skin tests on 7 selected patients gave positive reactions using 10(-3) mu g/ml either allergen, whereas controls showed no response to 10 mu g/ml. Natural Bla g 2 was purified and the sequence of the NH2 terminus and tryptic peptides, comprising 36% of the molecule, was determined. The cDNA for Bla g 2 was cloned from a B. germanica expression library and encoded a 24 amino acid signal peptide and a 328-amino acid mature protein, which showed sequence homology to aspartic proteases. Bla g 2 showed the highest degree of identity to mosquito (Aedes aegypti) lysosomal aspartic protease (30.8%), with similar identity to pepsin, cathepsins D and E, renin, and chymosin, Bla g 2 mRNA and protein were detected in B, germanica, but not in Periplaneta americana, the other principal domiciliary CR species in the U. S. High concentrations of Bla g 2 were found in CR digestive organs (esophagus, gut, and proventriculus). The results show that Ela g 2 is a major species-specific allergen of B. germanica and suggest that the allergen functions as a digestive enzyme in the cockroach.	UNIV VIRGINIA, HLTH SCI CTR, CTR ASTHMA & ALLERG DIS, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; SIBIA INC, LA JOLLA, CA 92037 USA	University of Virginia	ARRUDA, LK (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, CTR ASTHMA & ALLERG DIS, DEPT INTERNAL MED, BOX 225, CHARLOTTESVILLE, VA 22908 USA.		Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607, R01AI032557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1995, IN PRESS INT ARCH AL; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BELL WJ, 1981, LABORATORY COCKROACH; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1993, CLIN EXP ALLERGY, V23, P459, DOI 10.1111/j.1365-2222.1993.tb03230.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; EBNER C, 1993, J IMMUNOL, V150, P1047; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FOLTMANN B, 1979, J BIOL CHEM, V254, P8447; GEISOW MJ, 1980, ENZYMOLOGY POSTTRANS, P259; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HELM RM, 1995, J ALLERGY CLIN IMMUN, V95, P158; HULETT AC, 1979, ANN ALLERGY, V42, P160; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1989, ANN ALLERGY, V63, P207; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; MCKITTRICK FA, 1964, MEMOIR CORNELL U AGR, V389; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; RUSSELL PJ, 1984, MOL GEN GENET, V196, P275, DOI 10.1007/BF00328060; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x; WU CH, 1995, IN PRESS J ALLERGY C; YSSEL H, 1992, J IMMUNOL, V148, P738; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	52	148	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19563	19568		10.1074/jbc.270.33.19563	http://dx.doi.org/10.1074/jbc.270.33.19563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642642	hybrid			2022-12-27	WOS:A1995RP70300058
J	BARLEV, NA; CANDAU, R; WANG, LA; DARPINO, P; SILVERMAN, N; BERGER, SL				BARLEV, NA; CANDAU, R; WANG, LA; DARPINO, P; SILVERMAN, N; BERGER, SL			CHARACTERIZATION OF PHYSICAL INTERACTIONS OF THE PUTATIVE TRANSCRIPTIONAL ADAPTER, ADA2, WITH ACIDIC ACTIVATION DOMAINS AND TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; GLUTATHIONE-S-TRANSFERASE; EARLY GENE-EXPRESSION; FACTOR-TFIIB; FUNCTIONAL DISSECTION; BASAL TRANSCRIPTION; YEAST; VP16; COMPLEX; COACTIVATORS	RNA polymerase II transcription requires functional interactions between activator proteins bound to upstream DNA sites and general factors bound to the core promoter. Accessory transcription factors, such as adaptors and coactivators, have important, but still unclear, roles in the activation process. We tested physical interactions of the putative adaptor ADA2 with activation domains derived from acidic activator proteins and with certain general transcription factors. ADA2 associated with the herpesvirus VP16 and yeast GCN4 activation domains but not with the activation domain of yeast HAP4, which previously was shown to be independent of ADA2 function in vivo and in vitro. Furthermore, the amino terminus of ADA2 directly interacted with the VP16 activation domain, suggesting that ADA2 provides determinants for interaction between activation domains and the adaptor complex. Both TATA-binding protein (TBP) and TFIIB have previously been shown to interact directly with the VP16 activation domain in vitro (Stringer, K. F., Ingles, C. J., and Greenblatt, J. (1990) Nature 345, 783-786; Lin, Y. S., Ha, I., Maldonado, E., Reinberg, D., and Green, M. R. (1991) Nature 353, 569-571). Interestingly, when binding was tested between VP16 and these general factors in yeast nuclear extracts, both factors interacted with VP16, but only the TBP/VP16 association was dependent on ADA2. In addition, ADA2 physically associated with TBP, but not with TFIIB. These results suggest that the role of ADA2 in transcriptional activation is to promote physical interaction between activation domains and TBP.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	The Wistar Institute; Massachusetts Institute of Technology (MIT)			Barlev, Nikolai A/K-5268-2017	Barlev, Nikolai A/0000-0001-7111-2446; Silverman, Neal/0000-0002-4259-456X; Berger, Shelley/0000-0001-5398-4400	NCI NIH HHS [CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; POON D, 1993, J BIOL CHEM, V268, P15325; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSE MD, 1988, METHODS YEAST GENETI; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG L, 1995, GENE, V158, P163, DOI 10.1016/0378-1119(95)00126-Q; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	73	164	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19337	19344		10.1074/jbc.270.33.19337	http://dx.doi.org/10.1074/jbc.270.33.19337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642611	hybrid			2022-12-27	WOS:A1995RP70300025
J	GOPAL, D; BURKE, M				GOPAL, D; BURKE, M			FORMATION OF STABLE INHIBITORY COMPLEXES OF MYOSIN SUBFRAGMENT-1 USING FLUOROSCANDIUM ANIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERYLLIUM FLUORIDE; ADENOSINE-TRIPHOSPHATASE; ALUMINUM FLUORIDE; VANADATE ION; F-19 NMR; F-ACTIN; PHOSPHATE; BINDING; ATPASE; NUCLEOTIDE	Evidence is presented that MgADP can be noncovalently trapped in myosin subfragment 1 in the presence of ScFx resulting in the concomitant loss of ATPase function. The rate of inactivation in the presence of MgCl2 at 25 degrees C is 8.7 M(-1) s(-1) which is too slow for a simple collisional mechanism and suggests that a subsequent slow isomerization step is responsible for formation of a stable ternary complex, S1 . MgADP . ScFx in a manner analogous to that proposed for the Vi stabilized complex by Goodno (Goodno, C. C. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 2620-2624). It is also found that ADP can be trapped in subfragment 1 in the absence of MgCl2 indicating the formation of an S1 . ADP . ScFx complex. The stability of these complexes at 4 degrees C was studied by following the loss of trapped [C-14]ADP with a chase with ADP. The rate of nucleotide loss at 4 degrees C was biphasic for both complexes suggesting that the inhibitory complexes exist in two distinct states as previously proposed for the ternary complex stabilized by Vi (Mihashi, K., Ooi, A., and Hiratsuka, T. (1990) J. Biochem. (Tokyo) 107, 464-469). Formation of these complexes resulted in a marked enhancement of the intrinsic tryptophyl fluorescence suggesting that conformationally they may resemble the steady-state intermediate formed with MgATP. The failure to observe photolysis in the presence of excess Vi at sites associated with the ATP consensus sequence suggests that in these complexes ScFx occupies the site responsible for these cleavage reactions and that it is not displaced by the added Vi.	CASE WESTERN RESERVE UNIV,COLL ARTS & SCI,DEPT BIOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015319] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15319] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BECK TW, 1992, BIOPHYS J, V61, pA2506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; GOLDSTEIN G, 1964, ANAL CHEM, V36, P243, DOI 10.1021/ac60207a074; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; LUO Y, 1994, BIOPHYS J, V66, pA79; MARUTA S, 1993, J BIOL CHEM, V268, P7093; MIHASHI K, 1990, J BIOCHEM-TOKYO, V107, P464, DOI 10.1093/oxfordjournals.jbchem.a123068; MOCZ G, 1989, EUR J BIOCHEM, V179, P373, DOI 10.1111/j.1432-1033.1989.tb14563.x; Nowacki W, 1939, Z KRISTALLOGR, V101, P273; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PHAN B, 1992, BIOCHEMISTRY-US, V31, P4787, DOI 10.1021/bi00135a007; RAJASEKHARAN KN, 1987, J BIOL CHEM, V262, P11207; RINGEL I, 1990, BIOCHEMISTRY-US, V29, P9091, DOI 10.1021/bi00490a029; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; SMITH SJ, 1990, EUR J BIOCHEM, V193, P69, DOI 10.1111/j.1432-1033.1990.tb19305.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Van Eldik R., 1986, INORGANIC HIGH PRESS; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; [No title captured]	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19282	19286		10.1074/jbc.270.33.19282	http://dx.doi.org/10.1074/jbc.270.33.19282			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642602	hybrid			2022-12-27	WOS:A1995RP70300016
J	MASSILLON, D; BOLLEN, M; DEWULF, H; OVERLOOP, K; VANSTAPEL, F; VANHECKE, P; STALMANS, W				MASSILLON, D; BOLLEN, M; DEWULF, H; OVERLOOP, K; VANSTAPEL, F; VANHECKE, P; STALMANS, W			DEMONSTRATION OF A GLYCOGEN/GLUCOSE 1-PHOSPHATE CYCLE IN HEPATOCYTES FROM FASTED RATS - SELECTIVE INACTIVATION OF PHOSPHORYLASE BY 2-DEOXY-2-FLUORO-ALPHA-D-GLUCOPYRANOSYL FLUORIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE PHOSPHATASE-ACTIVITY; GLUCOSE; LIVER; ACTIVATION; MECHANISM; GLUCOSE-6-PHOSPHATE; SPECIFICITY; METABOLITES; SYNTHETASE; SUBSTRATE	In search for a nonmetabolized, superior glucose analogue to study the mechanism of glucose-induced glycogen synthesis, we have tested 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride, which inhibits muscle phosphorylase b 10 fold better than does glucose (Street, I. P., Armstrong, C. R., and Withers, S. G. (1986) Biochemistry 25, 6021-6027), In a gel-filtered liver extract, 0.6 mM analogue and 10 mM glucose equally accelerated the inactivation of phosphorylase and shortened the latency before the activation of glycogen synthase, The analogue was not measurably defluorinated or phosphorylated by intact hepatocytes, as monitored by F-19 NMR. When added to isolated hepatocytes, 10 mM analogue inactivated phosphorylase more extensively than did 50 mM glucose, but unlike glucose, it did not result in the activation of glycogen synthase, Therefore, the binding of glucose to phosphorylase a can account for the inactivation of phosphorylase, but the metabolism of glucose (probably to Glc-6-P) appears to be required to achieve activation of glycogen synthase. The livers of overnight-fasted, anesthetized mice contained appreciable amounts of both phosphorylase a and glycogen synthase a, without net glycogen accumulation, Likewise, hepatocytes isolated from fasted rats and incubated with 10 mM glucose contained 41% of phosphorylase and 32% of glycogen synthase in the a form, and these values remained stable for 1 h, while glycogen accumulated at only 22% of the rate expected from the glycogen synthase activity, The addition of 10 mM analogue decreased phosphorylase a to 10% without significant change in glycogen synthase a (38%), but with a 4-fold increased rate of glycogen accumulation. These findings imply that synthase a is fully active in the liver of the fasted animal and that the absence of net glycogen synthesis is due to continuous glycogenolysis by phosphorylase a.	CATHOLIC UNIV LEUVEN,FAK GENEESKUNDE,AFDELING BIOCHEM,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,FAK GENEESKUNDE,BIOMED NMR EENHEID,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven				Vanstapel, Florent/0000-0001-6273-856X				ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; BESSELL EM, 1972, BIOCHEM J, V128, P199, DOI 10.1042/bj1280199; BOLLEN M, 1988, BIOCHEM J, V255, P327; BOLLEN M, 1983, BIOCHEM J, V210, P783, DOI 10.1042/bj2100783; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; CRISP DM, 1972, BIOCHEM J, V126, P1009, DOI 10.1042/bj1261009; DEWULF H, 1968, EUR J BIOCHEM, V6, P552; DOPERE F, 1980, EUR J BIOCHEM, V104, P137, DOI 10.1111/j.1432-1033.1980.tb04409.x; FEDDERS G, 1994, EUR J BIOCHEM, V219, P1063, DOI 10.1111/j.1432-1033.1994.tb18589.x; GRUNNET N, 1994, ARCH BIOCHEM BIOPHYS, V309, P18, DOI 10.1006/abbi.1994.1077; HALL LD, 1971, CAN J CHEMISTRY, V49, P118, DOI 10.1139/v71-017; HARRIS RA, 1989, J BIOL CHEM, V264, P14674; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; JUHL H, 1982, BIOCHEM BIOPH RES CO, V106, P210, DOI 10.1016/0006-291X(82)92079-4; KORYTNYK W, 1980, TETRAHEDRON LETT, V21, P1493, DOI 10.1016/S0040-4039(00)92755-2; LAVOIE L, 1991, ENDOCRINOLOGY, V129, P2674, DOI 10.1210/endo-129-5-2674; LIU W, 1991, BIOCHEMISTRY-US, V30, P1419, DOI 10.1021/bi00219a036; MASSILLON D, 1994, BIOCHEM J, V299, P123, DOI 10.1042/bj2990123; MICHAL G, 1984, METHOD ENZYMAT AN, V6, P191; MVUMBI L, 1983, BIOCHEM J, V212, P407, DOI 10.1042/bj2120407; MVUMBI L, 1987, BIOCHEM J, V246, P367, DOI 10.1042/bj2460367; NAKADA T, 1985, BIOCHEM ARCH, V1, P163; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; STALMANS W, 1974, EUR J BIOCHEM, V49, P415, DOI 10.1111/j.1432-1033.1974.tb03847.x; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; TAN AWH, 1982, J BIOL CHEM, V257, P5004; VANDEBROECK A, 1985, EUR J BIOCHEM, V153, P621, DOI 10.1111/j.1432-1033.1985.tb09345.x; VANDEWERVE G, 1984, AM J PHYSIOL, V247, pE241; VANSCHAFTINGEN E, 1993, EUR J BIOCHEM, V218, P745; VILLARPALASI C, 1994, BBA-PROTEIN STRUCT M, V1207, P88, DOI 10.1016/0167-4838(94)90055-8; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; WAJNGOT A, 1991, METABOLISM, V40, P877, DOI 10.1016/0026-0495(91)90019-S; WANG P, 1972, EUR J BIOCHEM, V27, P297, DOI 10.1111/j.1432-1033.1972.tb01839.x; WATSON KA, 1994, BIOCHEMISTRY-US, V33, P5745, DOI 10.1021/bi00185a011; WERA S, 1991, J BIOL CHEM, V266, P339; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; YOUN JH, 1986, J BIOL CHEM, V261, P5960	40	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19351	19356		10.1074/jbc.270.33.19351	http://dx.doi.org/10.1074/jbc.270.33.19351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642613	hybrid			2022-12-27	WOS:A1995RP70300027
J	POWER, CA; MEYER, A; NEMETH, K; BACON, KB; HOOGEWERF, AJ; PROUDFOOT, AEI; WELLS, TNC				POWER, CA; MEYER, A; NEMETH, K; BACON, KB; HOOGEWERF, AJ; PROUDFOOT, AEI; WELLS, TNC			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF A NOVEL CC-CHEMOKINE RECEPTOR CDNA FROM A HUMAN BASOPHILIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; COUPLED RECEPTORS; PEPTIDE RECEPTOR; T-CELLS; RANTES; FAMILY; ACTIVATION; CYTOKINES; MONOCYTE; SEQUENCE	We report the cloning and characterization of a novel basophil CC chemokine receptor, K5-5, from the human immature basophilic cell line KU-812. The predicted protein sequence of K5-5 shows only 49% identity to the macrophage inflammatory protein-1 alpha/RANTES receptor (CC CKR-1) and 47% identity to monocyte chemotactic protein-1 receptor (b form), suggesting that this cDNA encodes a novel member of the CC chemokine receptor family. Analysis of K5-5 mRNA expression indicates that it is restricted to leukocyte-rich tissues, In addition, we have shown significant levels of K5-5 mRNA in human basophils, which were up-regulated by treatment with interleukin-5. The CC chemokines, macrophage inflammatory protein-1 alpha, RANTES, and monocyte chemotactic protein-1 were able to stimulate a Ca2+-activated chloride channel in Xenopus laevis oocytes injected with R5-5 cRNA, whereas no signal was detected in response to monocyte chemotactic protein-2, macrophage inflammatory protein-1 beta, or the CXC chemokine, interleukin-8. Taken together, these results indicate for the first time the presence of a CC chemokine receptor on basophils, which functions as a ''shared'' CC chemokine receptor and may therefore be implicated in the pathogenesis of basophil-mediated allergic diseases.			POWER, CA (corresponding author), GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.			Wells, Timothy/0000-0001-9796-847X				ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; AVALOS BR, 1994, BLOOD, V84, P1790, DOI 10.1182/blood.V84.6.1790.bloodjournal8461790; BACON KB, 1994, IMMUNOLOGY, V82, P473; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRANT JA, 1986, FASEB J, V45, P2653; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEGER M, 1992, J IMMUNOL, V149, P2662; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MORITA M, 1993, JAP J CLIN EXP MED, V51, P712; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458, DOI 10.1002/jlb.45.5.458; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHULTZ P, 1992, BIOCHEM J, V284, P207, DOI 10.1042/bj2840207; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TURCATTI G, 1993, J RECEPTOR RES, V13, P639, DOI 10.3109/10799899309073684; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; VANRIPER G, 1994, J IMMUNOL, V152, P4055; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yoshimura T, 1992, Cytokines, V4, P131	51	248	291	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19495	19500		10.1074/jbc.270.33.19495	http://dx.doi.org/10.1074/jbc.270.33.19495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642634				2022-12-27	WOS:A1995RP70300048
J	FAGO, A; CARRATORE, V; DIPRISCO, G; FEUERLEIN, RJ; SOTTRUPJENSEN, L; WEBER, RE				FAGO, A; CARRATORE, V; DIPRISCO, G; FEUERLEIN, RJ; SOTTRUPJENSEN, L; WEBER, RE			THE CATHODIC HEMOGLOBIN OF ANGUILLA-ANGUILLA - AMINO-ACID-SEQUENCE AND OXYGEN EQUILIBRIA OF A REVERSE BOHR EFFECT HEMOGLOBIN WITH HIGH OXYGEN-AFFINITY AND HIGH PHOSPHATE SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROUT SALMO-IRIDEUS; LIGAND-BINDING; ALPHA-CHAIN; NUCLEOSIDE TRIPHOSPHATES; FUNCTIONAL-PROPERTIES; ALLOSTERIC MECHANISM; MULTIPLE HEMOGLOBINS; RANA-CATESBEIANA; FISH HEMOGLOBINS; CYPRINUS-CARPIO	As in other fish, the cathodic hemoglobin of the eel Anguilla anguilla is considered to play an important role in oxygen transport under hypoxic and acidotic conditions. In the absence of phosphates this hemoglobin shows a reverse Bohr effect and high oxygen affinity, which is strongly modulated over a wide pH range by GTP (whose concentration in the red blood cells varies with ambient oxygen availability), GTP obliterates the reverse Bohr effect in the cathodic hemoglobin. The molecular basis for the reverse Bohr effect in fish hemoglobins has remained obscure due to the lack of structural data. We have determined the complete amino acid sequence of the alpha and beta chains of the cathodic hemoglobin of A. anguilla and relate it to the oxygen equilibrium characteristics. Several substitutions in crucial positions are observed compared with other hemoglobins, such as the replacement of the C-terminal His of the beta chain by Phe (that suppresses the alkaline Bohr effect) and of residues at the switch region between alpha and beta subunits (that may alter the allosteric equilibrium, thus causing the high intrinsic oxygen affinity and low cooperativity). The residues binding organic phosphate in the beta cleft of fish hemoglobins are conserved, which explains the strong effect of GTP on oxygen affinity and suggests that these residues contribute to the reverse Bohr effect in the absence of alkaline Bohr groups. Moreover, His(beta 14S) that is considered to be responsible for the reverse Bohr effect in human and tadpole Hbs is replaced by Lys.	AARHUS UNIV,INST BIOL SCI,DEPT ZOOPHYSIOL,DK-8000 AARHUS C,DENMARK; CNR,INST PROT BIOCHEM & ENZYMOL,I-80125 NAPLES,ITALY; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK	Aarhus University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Aarhus University			Fago, Angela/J-5946-2013	Fago, Angela/0000-0001-7315-2628				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ATHA DH, 1979, J BIOL CHEM, V254, P3393; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; BINOTTI I, 1971, ARCH BIOCHEM BIOPHYS, V142, P274, DOI 10.1016/0003-9861(71)90284-0; BONAVENTURA C, 1977, NATURE, V265, P474, DOI 10.1038/265474a0; BONAVENTURA C, 1978, BIOCH CLIN ASPECTS H, P641; BOSSA F, 1978, BIOCHIM BIOPHYS ACTA, V536, P298, DOI 10.1016/0005-2795(78)90077-6; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRUNORI M, 1979, COMP BIOCHEM PHYS A, V62, P173, DOI 10.1016/0300-9629(79)90751-5; CARUSO C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P273, DOI 10.1016/0167-4838(91)90569-L; CONDO SG, 1981, EUR J BIOCHEM, V120, P323, DOI 10.1111/j.1432-1033.1981.tb05707.x; DAVINO R, 1989, EUR J BIOCHEM, V179, P707, DOI 10.1111/j.1432-1033.1989.tb14604.x; DAVINO R, 1992, POLAR BIOL, V12, P135, DOI 10.1007/BF00239974; di Prisco G., 1991, BIOL ANTARCTIC FISH; FAGO A, 1992, EUR J BIOCHEM, V210, P963, DOI 10.1111/j.1432-1033.1992.tb17501.x; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; FANELLI AR, 1958, BIOCHIM BIOPHYS ACTA, V30, P608, DOI 10.1016/0006-3002(58)90108-2; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; FEUERLEIN RJ, 1993, J EXP BIOL, V189, P273; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; GARLICK RL, 1979, COMP BIOCHEM PHYS A, V62, P219, DOI 10.1016/0300-9629(79)90759-X; GILLEN RG, 1972, J BIOL CHEM, V247, P6039; GILLEN RG, 1973, J BIOL CHEM, V248, P1961; GRONENBORN AM, 1984, J MOL BIOL, V178, P731, DOI 10.1016/0022-2836(84)90249-3; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GRUJICINJAC B, 1980, H-S Z PHYSIOL CHEM, V361, P1629, DOI 10.1515/bchm2.1980.361.2.1629; HYDE DA, 1987, J COMP PHYSIOL B, V157, P635, DOI 10.1007/BF00700984; KILMARTIN JV, 1970, NATURE, V228, P766, DOI 10.1038/228766a0; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; LICATA VJ, 1993, PROTEINS, V17, P279, DOI 10.1002/prot.340170306; MARTIN JP, 1979, COMP BIOCHEM PHYS A, V62, P155, DOI 10.1016/0300-9629(79)90748-5; MARUYAMA T, 1980, J BIOL CHEM, V255, P3285; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MORPURGO G, 1970, NATURE, V225, P76, DOI 10.1038/225076a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; PETRUZZELLI R, 1989, BIOCHIM BIOPHYS ACTA, V995, P255, DOI 10.1016/0167-4838(89)90043-5; POWERS DA, 1972, J BIOL CHEM, V247, P6686; RIGGS AF, 1988, ANNU REV PHYSIOL, V50, P181, DOI 10.1146/annurev.ph.50.030188.001145; RODEWALD K, 1984, H-S Z PHYSIOL CHEM, V365, P95, DOI 10.1515/bchm2.1984.365.1.95; RODEWALD K, 1987, BIOL CHEM H-S, V368, P795, DOI 10.1515/bchm3.1987.368.2.795; SHIH DTB, 1993, J MOL BIOL, V230, P1291; SHIH TB, 1984, J BIOL CHEM, V259, P967; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; WATT KWK, 1980, J BIOL CHEM, V255, P3294; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1979, COMP BIOCHEM PHYS A, V62, P179, DOI 10.1016/0300-9629(79)90752-7; WEBER RE, 1990, COMP PHYSIOL, V6, P58; WEBER RE, 1976, J EXP BIOL, V65, P333; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WOOD SC, 1972, NATURE-NEW BIOL, V237, P278, DOI 10.1038/newbio237278a0; WOOD SC, 1973, AM J PHYSIOL, V225, P849, DOI 10.1152/ajplegacy.1973.225.4.849	62	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18897	18902		10.1074/jbc.270.32.18897	http://dx.doi.org/10.1074/jbc.270.32.18897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642546	hybrid			2022-12-27	WOS:A1995RN95400033
J	FUKAZAWA, T; REEDQUIST, KA; TRUB, T; SOLTOFF, S; PANCHAMOORTHY, G; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H				FUKAZAWA, T; REEDQUIST, KA; TRUB, T; SOLTOFF, S; PANCHAMOORTHY, G; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H			THE SH3 DOMAIN-BINDING T-CELL TYROSYL PHOSPHOPROTEIN P120 - DEMONSTRATION OF ITS IDENTITY WITH THE C-CBL PROTOONCOGENE PRODUCT AND IN-VIVO COMPLEXES WITH FYN, GRB2, AND PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; PROTO-ONCOGENE; TRANSFORMATION; KINASES; CLONING; GENE; RAS; LYMPHOCYTES	Previously, we have identified p120 as a Fyn/Lck SH3 and SH2 domain-binding protein that is tyrosine phosphorylated rapidly after T cell receptor triggering. Here, we used direct protein purification, amino acid sequence analysis, reactivity with antibodies, and two-dimensional gel analyses to identify p120 as the human c-cbl protooncogene product. We demonstrate in, vivo complexes of p120(cbl) with Fyn tyrosine kinase, the adaptor protein Grb2, and the p85 subunit of phosphatidylinositol (PI) 3-kinase, The association of p120(cbl) with Fyn and the p85 subunit of PI 3-kinase (together with PI 3-kinase activity) was markedly increased by T cell activation, consistent with in vitro binding of p120(cbl) to their SH2 as well as SH3 domains, In contrast, a large fraction of p120(cbl) was associated with Grb2 prior to activation, and this association did not change upon T cell activation. In vitro, p120(cbl) interacted with Grb2 exclusively through its SH3 domains, These results demonstrate a novel Grb2-p120(cbl) signaling complex in T cells, distinct from the previously analyzed Grb2-Sos complex. The association of p120(cbl) with ubiquitous signaling proteins strongly suggests a general signal transducing function for this enigmatic protooncogene with established leukemogenic potential but unknown physiological function.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, JOSLIN DIABET CTR,RES DIV, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Druker, Brian/0000-0001-8331-8206	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIAID NIH HHS [R29-AI28508] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Harlow E, 1988, ANTIBODIES LABORATOR, P521; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JONES PP, 1984, METHOD ENZYMOL, V108, P452; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARONEY AC, 1992, ONCOGENE, V7, P1207; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	61	194	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19141	19150		10.1074/jbc.270.32.19141	http://dx.doi.org/10.1074/jbc.270.32.19141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642581	hybrid			2022-12-27	WOS:A1995RN95400069
J	KIEHLBAUCH, CC; LAM, YF; RINGER, DP				KIEHLBAUCH, CC; LAM, YF; RINGER, DP			HOMODIMERIC AND HETERODIMERIC ARYL SULFOTRANSFERASES CATALYZE THE SULFURIC-ACID ESTERIFICATION OF N-HYDROXY-2-ACETYLAMINOFLUORENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLUTATHIONE TRANSFERASES; N-HYDROXYARYLAMINE; GROWTH-HORMONE; IV; HEPATOCARCINOGENESIS; EXPRESSION; CDNA; DNA; IDENTIFICATION	Three aryl sulfotransferases (ASTs) isolated from rat liver catalyze the sulfuric acid esterification of the carcinogen N-hydroxy-2-acetylaminofluorene (N-OH-2AAF), These three ASTs were separated by high resolution anion exchange chromatography and were designated Q1, Q2, and Q3. Q1 and Q2 had high N-OH-2AAF sulfonation activity, whereas Q3 showed low activity, Reversed phase high performance liquid chromatography/mass spectrometry analysis showed Q1 Q3 to be comprised of 33,945- and 35,675-Da protein subunits, Q1 contained only the 35,675-Da protein subunit, Q2 contained equal quantities of 33,945- and 35,675-Da subunits, and Q3 contained only the 33,945-Da subunit. The subunit compositions of Q1-Q3 were confirmed by immunochemical analysis, Size exclusion high performance Liquid chromatography confirmed that the active quaternary structure of the three isoenzymes was dimeric, Analysis of liver cytosols for the relative contributions of Q1-Q3 to total cytosolic N-OH-2AAF sulfotransferase activity indicated that Q1, Q2, and Q3 accounted for 44, 46, and 10% of the activity, respectively, These results demonstrate the existence of both homodimeric and heterodimeric aryl sulfotransferases and show that two ASTs, a homodimer of 35,675-Da subunits and a heterodimer of a 33,945- and a 35,675-Da subunit, are primarily responsible for hepatic N-OH-2AAF sulfotransferase activity.	OKLAHOMA MED RES FDN, NOBLE CTR BIOMED RES, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation								BLANCK A, 1991, CARCINOGENESIS, V12, P1259, DOI 10.1093/carcin/12.7.1259; CHEN X, 1992, PROTEIN EXPRES PURIF, V3, P421, DOI 10.1016/S1046-5928(05)80045-2; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; DEBAUN JR, 1970, CANCER RES, V30, P577; DUFFEL MW, 1991, MOL PHARMACOL, V40, P36; FARBER E, 1984, CANCER RES, V44, P5463; GONG DW, 1991, J BIOCHEM-TOKYO, V110, P226, DOI 10.1093/oxfordjournals.jbchem.a123561; HAYES JD, 1994, J BIOL CHEM, V269, P20707; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRSHEY SJ, 1992, MOL PHARMACOL, V42, P257; JACOBY W, 1981, METHOD ENZYMOL, V77, P197; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; KATO R, 1994, DRUG METAB REV, V26, P413, DOI 10.3109/03602539409029806; KHAN AS, 1993, GENE, V137, P321, DOI 10.1016/0378-1119(93)90028-2; LAI CC, 1985, CARCINOGENESIS, V6, P1037, DOI 10.1093/carcin/6.7.1037; MANGOLD BLK, 1990, CARCINOGENESIS, V11, P1563, DOI 10.1093/carcin/11.9.1563; MEERMAN JHN, 1981, CARCINOGENESIS, V2, P413, DOI 10.1093/carcin/2.5.413; Miller E C, 1985, Carcinog Compr Surv, V10, P93; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; Mulder G.J., 1990, CONJUGATION REACTION, P107; NAGATA K, 1993, J BIOL CHEM, V268, P24720; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RINGER DP, 1994, MOL CARCINOGEN, V9, P2, DOI 10.1002/mc.2940090103; RINGER DP, 1988, CANCER LETT, V40, P247, DOI 10.1016/0304-3835(88)90083-3; RINGER DP, 1990, CANCER RES, V50, P5301; RINGER DP, 1994, CHEM-BIOL INTERACT, V92, P1; ROBERTSON IGC, 1986, CARCINOGENESIS, V7, P295; SATO K, 1989, ADV CANCER RES, V52, P205; SCOPES RK, 1987, PROTEIN PURIFICATION, P278; SEKURA RD, 1981, ARCH BIOCHEM BIOPHYS, V211, P352, DOI 10.1016/0003-9861(81)90464-1; WEBB EC, 1992, ENZYME NOMENCLATURE, P299; WESTRA JG, 1976, CHEM-BIOL INTERACT, V15, P149, DOI 10.1016/0009-2797(76)90160-5; YAMAZOE Y, 1987, MOL PHARMACOL, V32, P536; YEROKUN T, 1992, CANCER RES, V52, P4779	37	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18941	18947		10.1074/jbc.270.32.18941	http://dx.doi.org/10.1074/jbc.270.32.18941			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642552	hybrid			2022-12-27	WOS:A1995RN95400040
J	LEE, JH; LEE, JS; JAYARAM, M				LEE, JH; LEE, JS; JAYARAM, M			JUNCTION MOBILITY AND RESOLUTION OF HOLLIDAY STRUCTURES BY FLP SITE-SPECIFIC RECOMBINASE - TESTING PARTNER COMPATIBILITY DURING RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA; STRAND TRANSFER; HALF-SITE; PROTEIN; HOMOLOGY; RECOGNITION; PLASMID; MUTANTS; BINDING	Absolute homology between partner substrates within the strand exchange region (spacer) is an essential requirement for recombination mediated by the yeast site-specific recombinase Flp. Recent experiments suggest that 3-base pair homology adjacent to the points of exchange at each end of the spacer is utilized in a base complementarity-dependent strand joining reaction. Homology of the central 2 base pairs of the spacer is also critical, but how homology is tested at these two positions is unknown, We have addressed the role of homology-dependent branch migration in Flp recombination by assaying strand cleavage and resolution in a set of synthetic Holliday junctions in which the branch point is freely or partially mobile through the spacer, or is immobilized at each position within the spacer or immediately nanking it A strong bias in the direction of Holliday resolution is observed only when the branch point is located just outside the spacer (at the junction of the Flp, binding element and the spacer). A significantly smaller bias is noticed when the branch point is frozen immediately adjacent to this position within the spacer. Resolution in these cases is most often mediated by exchange of the scissile phosphodiesters at the branch point or proximal to it, and rarely by exchange of the scissile phosphodiesters distal to it. In light of these and previous results, we discuss possible checkpoints for testing partner compatibility during Flp recombination.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ARCISZEWSKA LK, 1995, IN PRESS EMBO J; BAUER CE, 1985, J MOL BIOL, V181, P187, DOI 10.1016/0022-2836(85)90084-1; BAUER CE, 1984, COLD SPRING HARB SYM, V49, P699, DOI 10.1101/SQB.1984.049.01.079; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; CHEN JW, 1992, GENE, V119, P37; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P627; COWART M, 1991, J MOL BIOL, V220, P621, DOI 10.1016/0022-2836(91)90105-F; COX MM, 1988, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KHO SH, 1994, EMBO J, V13, P2714, DOI 10.1002/j.1460-2075.1994.tb06562.x; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; Maniatis T., 1982, MOL CLONING; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; QIAN XH, 1990, J BIOL CHEM, V265, P21779; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; YANG SH, 1994, J BIOL CHEM, V269, P12789	33	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19086	19092		10.1074/jbc.270.32.19086	http://dx.doi.org/10.1074/jbc.270.32.19086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642573	hybrid			2022-12-27	WOS:A1995RN95400061
J	HE, JS; LIANG, QW; FULCO, AJ				HE, JS; LIANG, QW; FULCO, AJ			THE MOLECULAR-CLONING AND CHARACTERIZATION OF BM1P1 AND BM1P2 PROTEINS, PUTATIVE POSITIVE TRANSCRIPTION FACTORS INVOLVED IN BARBITURATE-MEDIATED INDUCTION OF THE GENES ENCODING CYTOCHROME P450(BM-1) OF BACILLUS-MEGATERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; BINDING; NIFA; OPERATOR; PROMOTER; EXPRESSION; REPRESSOR; SITE	Analysis of a 1,3-kilobase segment of 5'-flanking DNA from the barbiturate-inducible P450(BM-1) gene (CYP106) of Bacillus megaterium revealed two open reading frames. One, BMIP1, encodes 98 amino acids and is located 267 base pairs upstream from the sequence encoding cytochrome P450(BM-1) but in the opposite orientation, The second, B2M1P2 (88 amino acids), is 892 base pairs upstream from the P450(BM-1) coding sequence and in the same coding strand. The expression of BM1P1 and BM1P2 was strongly stimulated in cells grown in the presence of pentobarbital, and the BM1P1 gene product exerted positive control on expression of P450(BM-1), When a 177-base pair fragment encompassing the overlapping promoter regions of the P450(BM-1) and BM1P1 genes was used as a probe in DNA binding assays, the BM1P1 and BM1P2 gene products and Bm3R1 (the repressor protein regulating the barbiturate-mediated expression of P450(BM-3)) could bind individually, but the addition of BM1P1 or BM1P2 to a binding mixture containing Bm3R1 completely prevented the appearance of a Bm3R1 binding band, When a 208 base pair fragment containing a Barbie box sequence and located upstream of the 177-base pair fragment was used as a probe, only a Bm3R1 binding band was detected, Although neither BM1P1 and BM1P2 appeared to bind to this 208-base pair fragment, their presence strongly inhibited the binding of Bm3R1 to the same probe, The evidence suggests that BM1P1 and BM1P2 may, in part, act as positive regulatory proteins involved in the expression of the P450(BM-1) gene by interfering with the binding of the repressor protein, Bm3R1, to the regulatory regions of P450(BM-1).	UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23913] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRON PG, 1992, J BACTERIOL, V174, P4120, DOI 10.1128/jb.174.12.4120-4129.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CANNON W, 1991, J MOL BIOL, V220, P915, DOI 10.1016/0022-2836(91)90363-B; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, ADV ENZYMOL RELAT AR, V47, P45; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FULCO AJ, 1983, MOL CELL BIOCHEM, V53-4, P155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HE JS, 1991, J BIOL CHEM, V266, P7864; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; KINGSTON RE, 1987, CURRENT PROTOCOLS MO, V1; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; MCLAUGHLIN JR, 1981, J BIOL CHEM, V256, P1283; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; NARHI LO, 1982, J BIOL CHEM, V257, P2147; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; RUETTINGER RT, 1984, BIOCHIM BIOPHYS ACTA, V801, P372, DOI 10.1016/0304-4165(84)90141-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SURZA EM, 1991, J GEN MICROBIOL, V137, P1511; TRIPATHI AK, 1991, MOL GEN GENET, V227, P86, DOI 10.1007/BF00260711; WEN LP, 1989, J BIOL CHEM, V264, P10996; 1990, APPLICATION PROTOCOL	32	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18615	18625		10.1074/jbc.270.31.18615	http://dx.doi.org/10.1074/jbc.270.31.18615			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629192	hybrid			2022-12-27	WOS:A1995RM64200072
J	YANG, Y; MINUCCI, S; OZATO, K; HEYMAN, RA; ASHWELL, JD				YANG, Y; MINUCCI, S; OZATO, K; HEYMAN, RA; ASHWELL, JD			EFFICIENT INHIBITION OF ACTIVATION-INDUCED FAS LIGAND UP-REGULATION AND T-CELL APOPTOSIS BY RETINOIDS REQUIRES OCCUPANCY OF BOTH RETINOID-X RECEPTORS AND RETINOIC ACID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; THYROID-HORMONE; SURFACE ANTIGEN; CYCLOSPORINE-A; GLUCOCORTICOID RECEPTOR; DIRECT REPEAT; BINDING-SITE; CYCLE BLOCK; DNA-BINDING; ALL-TRANS	Two retinoic acid (RA) receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), have been identified. All-trans-RA and its 9-cis-isomer are ligands for RARs, but only 9-cis-RA binds RXRs with high affinity, Activation-induced T cell hybridoma death is mediated via the engagement of Fas by activation-up-regulated Fas ligand, and RA prevents this type of apoptosis by inhibiting the induction of Fas ligand expression. To investigate the mechanism of RA action, T hybridoma cells were transfected with cDNA encoding RXR beta or dominant-negative RXR beta. Cells that overexpressed RXR beta were more sensitive to 9-cis-RA rescue from activation-induced death than cells transfected with vector alone, In contrast, cells expressing the dominant-negative RXR beta could not be rescued from death with 9-cis-RA. In wild type cells, an RAR-selective synthetic retinoid had little effect on activation-induced apoptosis, while an RXR-selective agonist prevented apoptosis but only at concentrations about similar to 10-fold greater than that required for 9-cis-RA. Simultaneous addition of the RAR- and RXR-selective retinoids completely prevented activation-induced apoptosis at concentrations where either alone had relatively little protective effect, The same hierarchy of efficacy was found for activation-induced Fas ligand expression, These data demonstrate that binding of both RARs and RXRs is required for efficient inhibition of activation-induced Fas ligand up-regulation and T cell apoptosis by retinoic acid.	NCI, BIOL RESPONSE MODIFIERS PROGRAM, IMMUNE CELL BIOL LAB, BETHESDA, MD 20892 USA; NICHHD, MOLEC GROWTH REGULAT LAB, BETHESDA, MD 20892 USA; LIGAND PHARMACEUT INC, SAN DIEGO, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ligand Pharmaceuticals			Minucci, Saverio/J-9669-2012					ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOSSU P, 1993, J IMMUNOL, V151, P7233; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHENG JH, 1995, J IMMUNOL, V154, P1239; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; HEERY DM, 1994, NUCLEIC ACIDS RES, V22, P726, DOI 10.1093/nar/22.5.726; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IWATA M, 1992, J IMMUNOL, V149, P3302; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MERCEP M, 1988, J IMMUNOL, V140, P324; MERCEP M, 1989, J IMMUNOL, V142, P4085; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OEHM A, 1992, J BIOL CHEM, V267, P10709; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STARUCH MJ, 1991, INT J IMMUNOPHARMACO, V13, P677, DOI 10.1016/0192-0561(91)90180-F; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; UCKER DS, 1989, J IMMUNOL, V143, P3461; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU S, 1993, J IMMUNOL, V150, P2211; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZACHARCHUK CM, 1991, ANN NY ACAD SCI, V636, P52, DOI 10.1111/j.1749-6632.1991.tb33438.x; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	72	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18672	18677		10.1074/jbc.270.31.18672	http://dx.doi.org/10.1074/jbc.270.31.18672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629199	hybrid			2022-12-27	WOS:A1995RM64200081
J	CARTER, BD; ZIRRGIEBEL, U; BARDE, YA				CARTER, BD; ZIRRGIEBEL, U; BARDE, YA			DIFFERENTIAL REGULATION OF P21(RAS) ACTIVATION IN NEURONS BY NERVE GROWTH-FACTOR AND BRAIN-DERIVED NEUROTROPHIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC SENSORY NEURONS; SYMPATHETIC NEURONS; PC12 CELLS; BDNF; SURVIVAL; EXPRESSION; RECEPTORS; NT-3; NGF; SYSTEM	Neurotrophins activate the Trk tyrosine kinase receptors, which subsequently initiate signaling pathways that have yet to be fully resolved, resulting in neuronal survival and differentiation. The ability of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) to activate GTP binding to p2l(ras) was investigated using cultured embryonic chick neurons. In both sympathetic and sensory neurons, the addition of NGF markedly increased the formation of Ras-GTP. The magnitude of the effect was found to depend upon the developmental stage, peaking at embryonic day 11 in sympathetic neurons and at embryonic day 9 in sensory neurons, times when large numbers of neurons depend on NGF for survival. Surprisingly, following the addition of BDNF, no formation of Ras-GTP could be observed in neurons cultured with BDNF. When sensory neurons were cultured with NGF alone, both NGF and BDNF stimulated GTP binding to Ras. In rat cerebellar granule cells, while the acute exposure of these cells to BDNF resulted in the formation Ras-GTP, no response was observed following previous exposure of the cells to BDNF, as was observed with sensory neurons. However, this desensitization was not observed in a transformed cell line expressing TrkB. In neurons, the mechanism underlying the loss of the BDNF response appeared to involve a dramatic loss of binding to cell-surface receptors, as determined by cross-linking with radiolabeled BDNF. Receptor degradation could not account for the desensitization since cell lysates from neurons pretreated with BDNF revealed that the levels of TrkB were comparable to those in untreated cells. These results indicate that in neurons, the pathways activated by NGF and BDNF are differentially regulated and that prolonged exposure to BDNF results in the inability of TrkB to bind its ligand.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society	CARTER, BD (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 MARTINSRIED,GERMANY.		Barde, Yves/F-6019-2011	Barde, Yves/0000-0002-7627-461X				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIFFO S, 1995, DEVELOPMENT, V121, P2461; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; DECHANT G, 1993, DEVELOPMENT, V119, P545; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; GAESE F, 1994, DEVELOPMENT, V120, P1613; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HERZOG KH, 1994, DEVELOPMENT, V120, P1643; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KNUSEL B, 1994, J NEUROSCI, V14, P1542, DOI 10.1523/JNEUROSCI.14-03-01542.1994; LEAH J, 1988, INT J DEV NEUROSCI, V6, P403; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; MUROYA K, 1992, ONCOGENE, V7, P277; NG NFL, 1993, J BIOL CHEM, V268, P25329; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; SUTTER A, 1979, J BIOL CHEM, V254, P5972; WIDMER HR, 1993, BRAIN RES, V614, P325, DOI 10.1016/0006-8993(93)91051-S; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	32	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21751	21757		10.1074/jbc.270.37.21751	http://dx.doi.org/10.1074/jbc.270.37.21751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665594	hybrid			2022-12-27	WOS:A1995RU75700053
J	IVESTER, CT; TUXWORTH, WJ; COOPER, G; MCDERMOTT, PJ				IVESTER, CT; TUXWORTH, WJ; COOPER, G; MCDERMOTT, PJ			CONTRACTION ACCELERATES MYOSIN HEAVY-CHAIN SYNTHESIS RATES IN ADULT CARDIOCYTES BY AN INCREASE IN THE RATE OF TRANSLATIONAL INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC PERFUSION-PRESSURE; PROTEIN-SYNTHESIS; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; FELINE CARDIOCYTES; SKELETAL-MUSCLE; LOAD REGULATION; MESSENGER-RNAS; HEART-CELLS; OVERLOAD	The purpose of this study was to determine the mechanism by which contraction acutely accelerates the synthesis rate of the contractile protein myosin heavy chain (MHC). Laminin-adherent adult feline cardiocytes were maintained in a serum-free medium and induced to contract at 1 Hz via electrical field stimulation. Electrical stimulation of contraction accelerated rates of MHC synthesis 28%, p < 0.05 by 4 h as determined by incorporation of [H-3]phenylalanine into MHC. MHC mRNA expression as measured by RNase protection was unchanged after 4 h of electrical stimulation. MHC mRNA levels in messenger ribonucleoprotein complexes and translating polysomes were examined by sucrose gradient fractionation. The relative percentage of polysome-bound MHC mRNA was equal at 47% in both electrically stimulated and control cardiocytes. However, electrical stimulation of contraction resulted in a reproducible shift of MHC mRNA from smaller polysomes into larger polysomes, indicating an increased rate of initiation. This shift resulted in significant increases in MHC mRNA levels in the fractions containing the larger polysomes of electrically stimulated cardiocytes as compared with nonstimulated controls. These data indicate that the rate of MHC synthesis is accelerated in contracting cardiocytes via an increase in translational efficiency.	RALPH H JOHNSON DEPT VET AFFAIRS MED CTR, CARDIOL SECT, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT MED, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT PHYSIOL, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT CELL BIOL & ANAT, CHARLESTON, SC 29401 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48788-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BOOTH FW, 1991, BIOCHEM SOC T, V19, P374, DOI 10.1042/bst0190374; CLARK WA, 1993, CIRC RES, V73, P1163, DOI 10.1161/01.RES.73.6.1163; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; DILLMANN WH, 1989, ENDOCR RES, V15, P565, DOI 10.3109/07435808909036352; DOETSCHMAN TC, 1980, DIFFERENTIATION, V16, P149, DOI 10.1111/j.1432-0436.1980.tb01071.x; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EVERETT AW, 1979, J MOL CELL CARDIOL, V11, P1253, DOI 10.1016/0022-2828(79)90005-1; EVERETT AW, 1977, BIOCHEM J, V166, P315, DOI 10.1042/bj1660315; FAGAN RJ, 1993, MOL CELL ENDOCRINOL, V90, P171, DOI 10.1016/0303-7207(93)90149-E; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; JOHNSON TB, 1994, CIRC RES, V74, P448, DOI 10.1161/01.RES.74.3.448; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; MOALIC JM, 1984, J MOL CELL CARDIOL, V16, P875, DOI 10.1016/S0022-2828(84)80024-3; MORGAN HE, 1985, BASIC RES CARDIOL, V80, P115; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; NAGAI R, 1988, AM J PHYSIOL, V255, pH325, DOI 10.1152/ajpheart.1988.255.2.H325; OJAMAA K, 1994, P NATL ACAD SCI USA, V91, P3468, DOI 10.1073/pnas.91.8.3468; PETERSON MB, 1972, CIRC RES, V31, P317, DOI 10.1161/01.RES.31.3.317; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; UMEDA PK, 1987, AM J CARDIOL, V59, pA49, DOI 10.1016/0002-9149(87)90176-7; WIESNER RJ, 1991, AM J PHYSIOL, V260, pL179, DOI 10.1152/ajplung.1991.260.4.L179; WISENBAUGH T, 1984, AM J PHYSIOL, V247, pH146, DOI 10.1152/ajpheart.1984.247.1.H146; YOUNG RB, 1981, EUR J CELL BIOL, V26, P184	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21950	21957		10.1074/jbc.270.37.21950	http://dx.doi.org/10.1074/jbc.270.37.21950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665617	hybrid			2022-12-27	WOS:A1995RU75700080
J	RICHARD, P; PITARD, B; RIGAUD, JL				RICHARD, P; PITARD, B; RIGAUD, JL			ATP SYNTHESIS BY THE F0F1-ATPASE FROM THE THERMOPHILIC BACILLUS PS3 CO-RECONSTITUTED WITH BACTERIORHODOPSIN INTO LIPOSOMES - EVIDENCE FOR STIMULATION OF ATP SYNTHESIS BY ATP BOUND TO A NONCATALYTIC BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING; BETA-SUBUNIT; CHLOROPLAST-F1 ATPASE; H+-ATPASE; F1-ATPASE; 2-AZIDO-ATP; BACTERIUM; ADP; INACTIVATION	F-type ATPase from the thermophilic Bacillus PS3, TF0F1, which was essentially free of bound nucleotides after isolation and purification, was co-reconstituted into liposomes with the light-driven proton pump bacteriorhodopsin, The time course of the light-induced ATP synthesis was biphasic; an initial slow phase accelerated to a final steady-state rate two to three times faster, Adding ATP before initiating the reaction suppressed the slow phase, suggesting that the state of occupancy of specific sites by ATP regulated the synthetic activity of TF0F1. Incubating the purified TF0F1 with ADP and ATP revealed one ADP and two ATP binding sites that were stable to gel filtration, We analyzed the time courses of light-induced ATP synthesis for the enzyme with different nucleotide content, after co-reconstitution into liposomes with bacteriorhodopsin. The two ATP sites were identified to have regulatory function. A complex containing TF0F1 . ADP, 1:1, was co-reconstituted with various quantities of ATP to obtain a range of molar ratios of TF0F1 . ADP:ATP of between 1:0 and 1:1.7, It was found that the initial rate of ATP synthesis increased with the level of ATP bound to the enzyme. After binding one ATP, a stimulation of ATP synthesis by a factor of 2 was observed. The second ATP site also exhibited regulatory properties, It stimulated ATP synthesis but to a much smaller extent; the stimulation did not exceed 20%, finding of the photoreactive analogues 2-azido-[alpha-P-32]ADP and 2-azido-[alpha-P-32]ATP to the TF0F1 and their effects on the rate of ATP synthesis are described further, Importantly, after covalent labeling of the enzyme, tryptic digestion, and high performance liquid chromatography purification, the label was found associated with the beta Y364-containing tryptic peptide in all cases, beta Y364 is in the region of conserved residues GXEHYXXA, which is in the beta subunit and known to be part of the noncatalytic site.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOENERGET SECT,F-91191 GIF SUR YVETTE,FRANCE; INST CURIE,PHYS CHIM SECT,F-75231 PARIS 5,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Richard, Peter/A-4229-2009; Pitard, Bruno F/K-9270-2015	Richard, Peter/0000-0003-0922-6092; 				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALOISE P, 1991, J BIOL CHEM, V266, P10368; BARZVI D, 1985, BIOCHIM BIOPHYS ACTA, V807, P293, DOI 10.1016/0005-2728(85)90261-0; BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; COX GB, 1992, MOL MECHANISMS BIOEN, P283; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; CZARNECKI JJ, 1993, EUR J BIOCHEM, V136, P19; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FROUD RJ, 1986, BIOCHEMISTRY-US, V25, P7544, DOI 10.1021/bi00371a043; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GRABER P, 1990, BIOELECTROCHEMISTRY, V3, P247; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V463, P245; HARTOG AF, 1992, BIOCHIM BIOPHYS ACTA, V1100, P267, DOI 10.1016/0167-4838(92)90481-R; HISABORI T, 1994, J BIOCHEM-TOKYO, V115, P497, DOI 10.1093/oxfordjournals.jbchem.a124365; JAULT JM, 1994, J BIOL CHEM, V269, P319; JAULT JM, 1994, ARCH BIOCHEM BIOPHYS, V310, P282, DOI 10.1006/abbi.1994.1168; JUNESCH U, 1985, BIOCHIM BIOPHYS ACTA, V809, P429, DOI 10.1016/0005-2728(85)90194-X; KAGAWA Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P45, DOI 10.1016/0304-4173(78)90008-3; KAGAWA Y, 1979, J BIOENERG BIOMEMBR, V11, P39, DOI 10.1007/BF00743196; Kagawa Y, 1979, Methods Enzymol, V55, P781; Kagawa Y, 1979, Methods Enzymol, V55, P777; MELESE T, 1988, J BIOL CHEM, V263, P5833; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MIWA K, 1989, J BIOCHEM-TOKYO, V106, P679, DOI 10.1093/oxfordjournals.jbchem.a122916; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; Penefsky H S, 1988, Prog Clin Biol Res, V273, P261; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; POSSMAYER FE, 1995, THESIS U STUTTGART; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RICHARD P, 1992, EUR J BIOCHEM, V210, P287, DOI 10.1111/j.1432-1033.1992.tb17419.x; RIGAUD JL, 1995, IN PRESS BIOCH BIOPH; SCHAFER HJ, 1989, FEBS LETT, V253, P264, DOI 10.1016/0014-5793(89)80972-X; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; TOZAWA K, 1993, J BIOL CHEM, V268, P19044; VIGNAIS PV, 1984, MOL CELL BIOCHEM, V60, P33; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOSHIDA M, 1975, BIOCHEM BIOPH RES CO, V67, P1295, DOI 10.1016/0006-291X(75)90167-9; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714	51	58	60	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21571	21578		10.1074/jbc.270.37.21571	http://dx.doi.org/10.1074/jbc.270.37.21571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665570	hybrid			2022-12-27	WOS:A1995RU75700025
J	BISIG, DA; DIIORIO, EE; DIEDERICHS, K; WINTERHALTER, KH; PIONTEK, K				BISIG, DA; DIIORIO, EE; DIEDERICHS, K; WINTERHALTER, KH; PIONTEK, K			CRYSTAL-STRUCTURE OF ASIAN ELEPHANT (ELEPHAS-MAXIMUS) CYANO-METMYOGLOBIN AT 1.78-ANGSTROM RESOLUTION - PHE(29)(B10) ACCOUNTS FOR ITS UNUSUAL LIGAND-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS; DISTAL HISTIDINE; CARBON-MONOXIDE; MYOGLOBIN; REFINEMENT; AUTOOXIDATION; OXYMYOGLOBIN; HEMOGLOBIN; PROGRAM; MUTANTS	The crystal structure of Asian elephant cyano-metmyoglobin which has a glutamine instead of the usual distal site histidine has been determined to high resolution. In addition to this replacement, the substitution of a conserved leucine residue in position 29(B10) at the distal side by a phenylalanine was unambiguously identified based on the available electron density. The suspicion, that there were errors in the original sequence which has caused some confusion, is thus confirmed. Comparison with other myoglobin structures in various ligated forms reveals an essentially unchanged tertiary structure in elephant myoglobin despite the two amino acid substitutions in the heme pocket. Our current structural model shows that the N epsilon 2 atom of Gln(64)(E7) has moved with respect to the corresponding nitrogen position of His(64)(E7) in the CO complex of sperm whale myoglobin. The newly assigned residue Phe(29)(B10) penetrates into the distal side of the heme pocket approaching the ligand within van der Waals distance and causing a much more crowded heme pocket compared to other myoglobins. Kinetic properties of Asian elephant myoglobin, wild type, and recombinant sperm whale myoglobins are discussed in relation to the structural consequences of the two amino acid substitutions H64Q and L29F.	ETH ZURICH,BIOCHEM LAB 1,CH-8092 ZURICH,SWITZERLAND; UNIV FREIBURG,INST BIOPHYS,D-79104 FREIBURG,GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Freiburg								BISIG DA, 1993, THESIS SWISS FEDERAL; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR VERSION 2 1 S; Brunger AT, 1992, X PLOR VERSION 3 0 S; CARVER TE, 1992, J BIOL CHEM, V267, P1443; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUPANE A, 1993, BIOPHYS J, V65, P2461, DOI 10.1016/S0006-3495(93)81311-0; DENE H, 1980, PROC R SOC SER B-BIO, V207, P111, DOI 10.1098/rspb.1980.0016; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAUENFELDER H, 1985, SCIENCE, V229, P3337; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GLUMOFF T, 1991, THESIS SWISS FEDERAL; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KENDREW JC, 1958, NATURE, V181, P662, DOI 10.1038/181662a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, 1986, J MOL BIOL, V192, P1333; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A, 1982, PREPARATION ANAL PRO; Millikan GA, 1939, PHYSIOL REV, V19, P503, DOI 10.1152/physrev.1939.19.4.503; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; ROMEROHERRERA AE, 1981, J MOL EVOL, V17, P140, DOI 10.1007/BF01733907; ROYER WE, 1989, J BIOL CHEM, V264, P21052; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; STRAUB JE, 1991, CHEM PHYS, V158, P221, DOI 10.1016/0301-0104(91)87068-7; VYAS K, 1993, J BIOL CHEM, V268, P14826; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; Wittenberg J.B., 1981, Methods in Enzymology, V76, P29; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YU LP, 1990, BIOCHEMISTRY-US, V29, P2578, DOI 10.1021/bi00462a021; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763; SERC COLLABORATIVE P	44	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20754	20762		10.1074/jbc.270.35.20754	http://dx.doi.org/10.1074/jbc.270.35.20754			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657658	Green Published, hybrid			2022-12-27	WOS:A1995RR58400079
J	BRINK, S; FISCHER, K; KLOSGEN, RB; FLUGGE, UI				BRINK, S; FISCHER, K; KLOSGEN, RB; FLUGGE, UI			SORTING OF NUCLEAR-ENCODED CHLOROPLAST MEMBRANE-PROTEINS TO THE ENVELOPE AND THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; SPINACH-CHLOROPLASTS; PHOSPHATE TRANSLOCATOR; INTERMEMBRANE SPACE; PRECURSOR PROTEIN; PEA-CHLOROPLASTS; FOREIGN PROTEIN; INNER MEMBRANE; ATP SYNTHASE; IMPORT	The spinach triose phosphate/phosphate translocator and the 37-kDa protein are both integral components of the chloroplast inner envelope membrane. They are synthesized in the cytosol with N-terminal extensions, the transit peptides, that are different in structural terms from those of imported stromal or thylakoid proteins. In order to determine if these N-terminal extensions are essential for the correct localization to the envelope membrane, they were linked to the mature parts of thylakoid membrane proteins, the light-harvesting chlorophyll a/b binding protein and the CF0II-subunit of the thylakoid ATP synthase, respectively. In addition, the transit peptide of the CF0II-subunit that contains signals for the transport across both the envelope and the thylakoid membrane was fused to the mature parts of both envelope membrane proteins. The chimeric proteins were imported into isolated spinach chloroplasts, and the intraorganellar routing of the proteins was analyzed. The results obtained show that the N-terminal extensions of both envelope membrane proteins possess a stroma-targeting function only and that the information for the integration into the envelope membrane is contained in the mature parts of the proteins. At least part of the integration signal is provided by hydrophobic domains in the mature sequences since the removal of such a hydrophobic segment from the 37-kDa protein leads to missorting of the protein to the stroma and the thylakoid membrane.	UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	University of Cologne; University of Munich				Brink, Susanne C./0000-0002-3272-9707				ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BONNER WM, 1974, EUR J BIOCHEM, V46, P84; BRINKS S, 1994, J BIOL CHEM, V269, P16478; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRESESWERRINGLOER, 1991, EUR J BIOCHEM, V0195, P00361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HENNIG J, 1986, MOL GEN GENET, V203, P117, DOI 10.1007/BF00330392; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KYTE J, 1982, J MOL BIOL, V257, P105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1992, J BIOL CHEM, V267, P18999; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MURAKAMI S, 1978, ARCH BIOCHEM BIOPHYS, V185, P30, DOI 10.1016/0003-9861(78)90140-6; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P1500; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745	45	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20808	20815		10.1074/jbc.270.35.20808	http://dx.doi.org/10.1074/jbc.270.35.20808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657665	hybrid			2022-12-27	WOS:A1995RR58400086
J	PARK, JC; YASEEN, NR; HOGAN, PG; RAO, A; SHARMA, S				PARK, JC; YASEEN, NR; HOGAN, PG; RAO, A; SHARMA, S			PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR NFATP INHIBITS ITS DNA-BINDING ACTIVITY IN CYCLOSPORINE-A-TREATED HUMAN B-CELLS AND T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR; INTERLEUKIN-2 PROMOTER; ANTIGEN RECEPTOR; LYMPHOCYTE; IDENTIFICATION; ACTIVATION; CALCINEURIN; GENE; ENHANCER; COMPLEX	Cyclosporin A (CsA) exerts its immunosuppressive effect by inhibiting the activity of nuclear factor of activated T cells (NFAT), thus preventing transcriptional induction of several cytokine genes. This effect is thought to be largely mediated through inactivation of the phosphatase calcineurin, which in turn inhibits translocation of an NFAT component to the nucleus. Here we report that CsA treatment of Raji B and Jurkat T cell lines yields a phosphorylated form of NFATp that is inhibited in DNA-binding and in its ability to form an NFAT complex with Fos and Jun. Immunoblot analyses and metabolic labeling with [P-32]orthophosphate show that CsA alters NFATp migration on SDS-polyacrylamide gel electrophoresis by increasing its phosphorylation level without affecting subcellular distribution. Dephosphorylation by in vitro treatment with calcineurin or alkaline phosphatase restores NFATp DNA binding activity and its ability to reconstitute an NFAT complex with Fos and Jun proteins. These data point to a new mechanism for CsA-sensitive regulation of NFATp in which dephosphorylation is critical for DNA binding.	BROWN UNIV,ROGERS WILLIAMS MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Brown University; Roger Williams Medical Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School				Yaseen, Nabeel/0000-0001-6902-5116	NATIONAL CANCER INSTITUTE [R37CA042471, R01CA055910, R01CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471, CA55910] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CAHN RD, 1962, SCIENCE, V136, P962, DOI 10.1126/science.136.3520.962; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HO AM, 1994, J BIOL CHEM, V269, P28181; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TSUBOI A, 1994, MOL BIOL CELL, V5, P119, DOI 10.1091/mbc.5.1.119; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WANG DZ, 1995, IN PRESS ANN NY ACAD; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	42	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20653	20659		10.1074/jbc.270.35.20653	http://dx.doi.org/10.1074/jbc.270.35.20653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657645	hybrid			2022-12-27	WOS:A1995RR58400064
J	KHANNA, M; QIN, KN; WANG, RW; CHENG, KC				KHANNA, M; QIN, KN; WANG, RW; CHENG, KC			SUBSTRATE-SPECIFICITY, GENE STRUCTURE, AND TISSUE-SPECIFIC DISTRIBUTION OF MULTIPLE HUMAN 3-ALPHA-HYDROXYSTEROID DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDRODIOL DEHYDROGENASE; LIVER CYTOSOL; RAT; REDUCTASE; RECEPTOR; IDENTIFICATION; PURIFICATION; ORGANIZATION; CHLORDECONE; CRYSTALLIN	We have expressed in Escherichia coli functionally active proteins encoded by two human cDNAs that were isolated previously by using rat 3 alpha(-)hydroxysteroid dehydrogenase cDNA as the probe, The expressed proteins catalyzed the interconversion between 5 alpha-dihydrotestosterone and 5 alpha-androstane-3 alpha, 17 beta-diol. Therefore, we name these two enzymes type I and type II 3 alpha-hydroxysteroid dehydrogenases. The type I enzyme has a high affinity for dihydrotestosterone, whereas the type II enzyme has a low affinity for the substrate, The tissue-specific distribution of these two enzymes was determined by reverse transcription polymerase chain reaction using gene-specific oligonucleotide primers, The mRNA transcript of the type I enzyme was found only in the Liver, whereas that of the type II enzyme appeared in the brain, kidney, liver, lung, placenta, and testis, The structure and sequence of the genes encoding these two 3 alpha-hydroxysteroid dehydrogenases were determined by analysis of genomic clones that were isolated from a lambda EMBL3 SP6/T7 library, The genes coding for the type I and type II enzymes were found to span approximately 20 and 16 kilobase pairs, respectively, and to consist of 9 exons of the same sizes and boundaries, The exons range in size from 77 to 223 base pairs (bp), whereas the introns range in size from 375 bp to approximately 6 kilobase pairs. The type I gene contains a TATA box that is located 27 bp upstream of multiple transcription start sites, In contrast, the type II gene contains two tandem AP2 sequences juxtaposed to a single transcription start site.	CORNELL UNIV,COLL MED,DEPT PEDIAT,NEW YORK,NY 10021; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT DRUG METAB,RAHWAY,NJ 07065	Cornell University; Merck & Company					NIDDK NIH HHS [DK-44177] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044177] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; CHENG KC, 1983, J BIOL CHEM, V258, P1738; CHENG KC, 1991, ARCH BIOCHEM BIOPHYS, V291, P258, DOI 10.1016/0003-9861(91)90132-3; GLATT HR, 1979, NATURE, V277, P319, DOI 10.1038/277319a0; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; IYER RB, 1992, J STEROID BIOCHEM, V43, P343, DOI 10.1016/0960-0760(92)90169-J; KADOR PF, 1982, ENZYMOLOGY CARBONYL, P243; KHANNA M, 1995, GENOMICS, V25, P488; LOU H, 1994, J BIOL CHEM, V269, P8416; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MOLOWA DT, 1986, J TOXICOL ENV HEALTH, V17, P375, DOI 10.1080/15287398609530832; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; QIN KN, 1994, BIOCHEMISTRY-US, V33, P3223, DOI 10.1021/bi00177a012; QIN KN, 1993, J STEROID BIOCHEM, V46, P673, DOI 10.1016/0960-0760(93)90308-J; QIN KN, 1994, GENE, V149, P357; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Selye H, 1942, ENDOCRINOLOGY, V30, P437, DOI 10.1210/endo-30-3-437; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STOLZ A, 1987, J CLIN INVEST, V79, P427, DOI 10.1172/JCI112829; TAKIKAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1043, P153, DOI 10.1016/0005-2760(90)90289-A; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; VOGEL K, 1980, J BIOL CHEM, V255, P9621; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1987, ENZYMOLOGY MOL BIOL, P297; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034; WORNER W, 1984, FEBS LETT, V170, P263, DOI 10.1016/0014-5793(84)81325-3; ZANG DE, 1994, J BIOL CHEM, V269, P11425	33	165	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20162	20168		10.1074/jbc.270.34.20162	http://dx.doi.org/10.1074/jbc.270.34.20162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650035	hybrid			2022-12-27	WOS:A1995RQ99100072
J	LASKY, SR; IWATA, K; ROSMARIN, AG; CAPRIO, DG; MAIZEL, AL				LASKY, SR; IWATA, K; ROSMARIN, AG; CAPRIO, DG; MAIZEL, AL			DIFFERENTIAL REGULATION OF JUND BY DIHYDROXYCHOLECALCIFEROL IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VITAMIN-D RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; RETINOIC ACID; DNA-BINDING; C-JUN; FOS; AP-1; PROLIFERATION; RICKETS	1,25-Dihydroxyvitamin D-3 inhibits the proliferation of the chronic myelogenous leukemia cell Line RWLeu-4 but not the resistant variant, JMRD(3). Although these cells exhibit no detectable differences in the vitamin D receptor, alterations in the interaction of nuclear extracts with the osteocalcin-1,25-dihydroxyvitamin D-3-response element are noted, It is shown herein that the 1,25-dihydroxyvitamin D, receptor binds to the osteocalcin-1,25-dihydroxyvitamin D-3-response element along with activator protein-1 (AP-I) complexes and that the DNA binding activities of members of the Jun and Fos proto oncogene families, which make up the AP-1 transcription factor, are differentially regulated by 1,25-dihydroxyvitamin D-3. It is shown that JunD DNA binding activity is enhanced by 1,25-dihydroxyvitamin DQ during cell cycle arrest in the sensitive cells but is decreased in the resistant cells. These results suggest that the level of JunD DNA binding activity may be a critical factor in the regulation of proliferation.	BROWN UNIV, MIRIAM HOSP, SCH MED, DIV HEMATOL, PROVIDENCE, RI 02908 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital	LASKY, SR (corresponding author), ROGER WILLIAMS CANC MED CTR, MED CTR, EXPTL PATHOL SECT, 825 CHALKSTONE AVE, PROVIDENCE, RI 02908 USA.				NCI NIH HHS [CA50558, CA13943, CA45148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050558, P30CA013943, R37CA045148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEDI A, 1994, BLOOD, V83, P2038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY MO, 1992, ANN NY ACAD SCI, V660, P124, DOI 10.1111/j.1749-6632.1992.tb21065.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FELDMAN D, 1990, MOL CELL ENDOCRINOL, V72, pC57, DOI 10.1016/0303-7207(90)90137-W; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KOEFFLER HP, 1985, VITAMIN D MYELOID DI, V29, P409; KOLLA SS, 1994, CANCER RES, V54, P1418; LASKY SR, 1990, CANCER RES, V50, P3087; LASKY SR, 1994, BLOOD, V84, P4283, DOI 10.1182/blood.V84.12.4283.bloodjournal84124283; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MALLOY PJ, 1989, J CLIN ENDOCR METAB, V68, P263, DOI 10.1210/jcem-68-2-263; MCDONNELL DP, 1988, J STEROID BIOCHEM, V30, P41, DOI 10.1016/0022-4731(88)90074-X; PAPAVASSILIOU AG, 1993, ANTICANCER RES, V13, P2213; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; THOMAS M, 1994, LEUKEMIA RES, V18, P401, DOI 10.1016/0145-2126(94)90075-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19676	19679		10.1074/jbc.270.34.19676	http://dx.doi.org/10.1074/jbc.270.34.19676			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649976	hybrid			2022-12-27	WOS:A1995RQ99100003
J	LYKO, F; MARTOGLIO, B; JUNGNICKEL, B; RAPOPORT, TA; DOBBERSTEIN, B				LYKO, F; MARTOGLIO, B; JUNGNICKEL, B; RAPOPORT, TA; DOBBERSTEIN, B			SIGNAL SEQUENCE PROCESSING IN ROUGH MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SEC11 PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; RECOGNITION PARTICLE; ANTIGEN PRESENTATION; PEPTIDE PEPTIDASE; SECRETORY PROTEIN; MESSENGER-RNA; TRANSLOCATION; MEMBRANE	Secretory proteins are synthesized with a signal sequence that is usually cleaved from the nascent protein during the translocation of the polypeptide chain into the lumen of the endoplasmic reticulum. To determine the fate of a cleaved signal sequence, we used a synchronized in vitro translocation system. Fire found that the cleaved signal peptide of preprolactin is further processed close to its COOH terminus. The resulting fragment accumulated in the microsomal fraction and with time was released into the cytosol. Signal sequence cleavage and processing could be reproduced with reconstituted vesicles containing Sec61, signal recognition particle receptor, and signal peptidase complex.	UNIV HEIDELBERG, ZMBH, D-69052 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-10115 BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine								BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHEN LL, 1989, ARCH MICROBIOL, V153, P90, DOI 10.1007/BF00277547; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HABENER JF, 1979, J BIOL CHEM, V254, P596; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGH S, 1993, J BIOL CHEM, V268, P26745; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSSAIN M, 1982, EUR J BIOCHEM, V129, P233, DOI 10.1111/j.1432-1033.1982.tb07044.x; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOLLAY C, 1982, P NATL ACAD SCI-BIOL, V79, P2260, DOI 10.1073/pnas.79.7.2260; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SUNG M, 1992, J BIOL CHEM, V267, P13154; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	38	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19873	19878		10.1074/jbc.270.34.19873	http://dx.doi.org/10.1074/jbc.270.34.19873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650000	Green Published, hybrid			2022-12-27	WOS:A1995RQ99100032
J	MACDONALD, MJ				MACDONALD, MJ			FEASIBILITY OF A MITOCHONDRIAL PYRUVATE MALATE SHUTTLE PANCREATIC-ISLETS - FURTHER IMPLICATION OF CYTOSOLIC NADPH IN INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIC ENZYME-ACTIVITY; BETA-CELL; GLYCERALDEHYDE PHOSPHATE; GLUTAMATE-DEHYDROGENASE; METHYL SUCCINATE; COA CARBOXYLASE; PENTOSE CYCLE; MALONYL-COA; REDOX STATE; RAT ISLETS	Previous studies indicated that in pancreatic islets the amount of glucose-derived pyruvate that enters mitochondrial metabolism via carboxylation is approximately equal to that entering via decarboxylation and that both carboxylation and decarboxylation are correlated with capacitation of glucose metabolism and insulin release. The relatively high rate of carboxylation is consistent with the current study's finding that pyruvate carboxylase is as abundant in pancreatic islets as it is in liver and kidney, Since islets do not contain phosphoenolpyruvate carboxykinase and, therefore, cannot carry out glyconeogenesis from pyruvate, the carboxylase might be present in the islet to participate in novel anaplerotic reactions, This idea was first explored by incubating mitochondria from various tissues with pyruvate, Mitochondria from tissues, such as pancreatic islets, liver, and kidney, in which pyruvate carboxylase is abundant, exported a large amount of malate and little or no citrate, isocitrate, and aspartate to the medium, The amount of malate within the mitochondria was <1% that in the medium, When pancreatic islet mitochondria were incubated with [1-C-14]pyruvate, radioactive carbon appeared in the medium primarily in malate, Very little radioactivity appeared in amino acids, and little or no radioactivity appeared in citrate and isocitrate. Carbon 1 of pyruvate can be incorporated into malate and other citric acid cycle intermediates only via carboxylation, as this carbon would be lost via decarboxylation when pyruvate enters the citric acid cycle as acetyl-CoA via the pyruvate dehydrogenase reaction, The amount of malate formed equaled the (CO2)-C-14, formed and the radioactivity from C-1 of pyruvate recovered in malate slightly exceeded the formation of (CO2)-C-14 in agreement with our previous studies that reported a high rate of carboxylation of pyruvate in intact islets, When intact pancreatic islets were incubated with methyl [U-C-14]succinate as a mitochondrial source of four-carbon dicarboxylic acids, radioactivity appeared in pyruvate and lactate, Taken together with previous studies, the current results suggest that during glucose-induced insulin secretion there is a shuttle operating across the mitochondrial membrane in which glucose-derived pyruvate is taken up by mitochondria and carboxylated to oxaloacetate by pyruvate carboxylase, The oxaloacetate is converted to malate which exits the mitochondrion, where, in the cytosol, it is decarboxylated to pyruvate in the reaction catalyzed by malic enzyme, This pyruvate re-enters mitochondrial pools, Such a cycle produces NADPH in the cytosol, Since it is a cycle, this shuttle can produce far more NADPH than the pentose phosphate pathway, which is known to be a very minor route of glucose metabolism in the islet, If it is accepted that this shuttle is active in the insulin cell, this implicates NADPH regeneration in insulin secretion.			MACDONALD, MJ (corresponding author), UNIV WISCONSIN,SCH MED,CTR CHILDRENS DIABET,RM 3459,1300 UNIV AVE,MADISON,WI 53706, USA.				NIDDK NIH HHS [DK42176, DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042176, R01DK028348, R55DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1985, CELL BIOCHEM FUNCT, V3, P157, DOI 10.1002/cbf.290030302; AMMON HPT, 1980, DIABETES, V29, P830, DOI 10.2337/diabetes.29.10.830; ANJANEYULU K, 1982, BIOCHIMIE, V64, P29, DOI 10.1016/S0300-9084(82)80606-8; ASHCROFT SJ, 1970, BIOCHEM J, V119, P5, DOI 10.1042/bj1190005; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; BOBYLEVA V, 1993, J BIOENERG BIOMEMBR, V25, P313, DOI 10.1007/BF00762592; BROLIN SE, 1981, ACTA ENDOCRINOL-COP, V96, P93, DOI 10.1530/acta.0.0960093; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; COLEMAN DL, 1991, J BIOL CHEM, V266, P21997; COLEMAN DL, 1992, METABOLISM, V41, P1134, DOI 10.1016/0026-0495(92)90299-P; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIS EJ, 1980, EUR J BIOCHEM, V110, P255, DOI 10.1111/j.1432-1033.1980.tb04863.x; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; GIROIX MH, 1985, FEBS LETT, V185, P1, DOI 10.1016/0014-5793(85)80728-6; GRILL V, 1991, ENDOCRINOLOGY, V128, P2195, DOI 10.1210/endo-128-4-2195; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Hansson H.A., 1986, THIOREDOXIN GLUTARED, P177; Hedeskov C J, 1980, Horm Metab Res Suppl, VSuppl 10, P8; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KELLEHER JK, 1985, ANAL BIOCHEM, V151, P55, DOI 10.1016/0003-2697(85)90052-1; KOHNERT KD, 1981, MOL CELL ENDOCRINOL, V22, P305, DOI 10.1016/0303-7207(81)90039-3; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P650; LENZEN S, 1985, J BIOL CHEM, V260, P2629; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE608, DOI 10.1152/ajpendo.1992.262.5.E608; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MACDONALD MJ, 1991, ENDOCRINOLOGY, V129, P1370, DOI 10.1210/endo-129-3-1370; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACDONALD MJ, 1978, BIOCHEM J, V175, P495; MALAISSE WJ, 1978, EUR J BIOCHEM, V87, P121, DOI 10.1111/j.1432-1033.1978.tb12357.x; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE434, DOI 10.1152/ajpendo.1993.264.3.E434; MALAISSE WJ, 1980, MOL CELL ENDOCRINOL, V20, P171, DOI 10.1016/0303-7207(80)90080-5; MALAISSE WJ, 1985, BIOCHIM BIOPHYS ACTA, V844, P256, DOI 10.1016/0167-4889(85)90098-9; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE440; MALAISSELAGAE F, 1982, J BIOL CHEM, V257, P3754; MATSCHIN.FM, 1968, DIABETES, V17, P475, DOI 10.2337/diab.17.8.475; McGarry JD., 1992, TXB BIOCH CLIN CORRE, P387; MOLLERING H, 1985, METHOD ENZYMAT AN, V7, P2; PANTEN U, 1975, DIABETOLOGIA, V11, P569, DOI 10.1007/BF01222108; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PEUHKURINEN KJ, 1984, J MOL CELL CARDIOL, V16, P487, DOI 10.1016/S0022-2828(84)80637-9; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REINKE LA, 1984, BIOCHEM PHARMACOL, V33, P1315, DOI 10.1016/0006-2952(84)90186-2; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; SHRAGO E, 1986, CLIN ASPECTS HUMAN C, P28; SNYDER PJ, 1979, AM J PHYSIOL, V219, P876; TALJEDAL IB, 1981, DIABETOLOGIA, V21, P1; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WALTER P, 1966, J BIOL CHEM, V241, P2523; Williamson J. R., 1976, GLUCONEOGENESIS ITS, P165; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843; ZUHLKE H, 1977, ACTA BIOL MED GER, V36, P1695	69	234	235	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20051	20058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650022				2022-12-27	WOS:A1995RQ99100057
J	CHIRMULE, N; GOONEWARDENA, H; PAHWA, S; PASIEKA, R; KALYANARAMAN, VS; PAHWA, S				CHIRMULE, N; GOONEWARDENA, H; PAHWA, S; PASIEKA, R; KALYANARAMAN, VS; PAHWA, S			HIV-1 ENVELOPE GLYCOPROTEINS INDUCE ACTIVATION OF ACTIVATED PROTEIN-1 IN CD4+ T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-JUN; DNA-BINDING; AIDS PATHOGENESIS; IMMUNE-SYSTEM; AP-1; KINASE; EXPRESSION; MOLECULE; COMPLEX	Activation of CD4 positive T cells is a primary requirement for human immunodeficiency virus (HIV) entry, efficient HIV replication, and progression to AIDS, Utilizing CD4 positive T cell lines and purified T cells from normal individuals, we have demonstrated that native envelope glycoproteins of HIV, gp160, can induce activation of transcription factor, activated protein-1 (AP-1), The stimulatory effects of gp160 are mediated through the CD4 molecule, since treatment of gp160 with soluble CD4-IgG abrogates its activity, and CD4 negative T cell lines fail to be stimulated with gp160. Immunoprecipitation of the gp160-induced nuclear extracts with polyclonal antibodies to Fos and Jun proteins indicates that AP-1 complex is comprised of members of these family of proteins, The gp160-induced AP-1 complex is dependent upon protein tyrosine phosphorylation and is protein synthesis-independent. This stimulation can also be abolished by inhibitors of protein kinase C, but it is unaffected by calcium channel blocker or cyclosporine A, This gp160 treatment adversely affects the functional capabilities of T cells; pretreatment of CD4+ T cells with gp160 for 4 h at 37 degrees C inhibited anti-CD3-induced interleukin-2 secretion, Effects similar to gp160 were seen with anti-CD4 mAb. The aberrant activation of AP-1 by gp160 in CD4 positive T cells could result in up-regulation of cytokines containing AP-1 sites, e.g. interleukin-3 and granulocyte macrophage colony-stimulating factor, and concurrently lead to T cell unresponsiveness by inhibiting interleukin-2 secretion.	ADV BIOSCI LABS INC,KENSINGTON,MD 20872		CHIRMULE, N (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT PEDIAT,MANHASSET,NY 11030, USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028281] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 0047] Funding Source: Medline; NIAID NIH HHS [AI 35414, AI 28281] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BIDDISON WE, 1983, J IMMUNOL, V131, P152; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CARREL S, 1991, RES IMMUNOL, V142, P97, DOI 10.1016/0923-2494(91)90017-D; CHIRMULE N, 1990, BLOOD, V75, P152; CHIRMULE N, 1993, J IMMUNOL, V150, P2478; CHIRMULE N, 1994, BIOCHEM BIOPH RES CO, V203, P498, DOI 10.1006/bbrc.1994.2210; COFFER P, 1994, ONCOGENE, V9, P911; CRUIKSHANK WW, 1990, BIOMED PHARMACOTHER, V44, P5, DOI 10.1016/0753-3322(90)90062-E; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; GOLDMAN F, 1994, J IMMUNOL, V153, P2905; GOWDA SD, 1989, J IMMUNOL, V142, P773; GUBLINS H, 1994, MOL CELL BIOL, V14, P4749; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HSU JC, 1993, CANCER RES, V53, P3789; JAIN J, 1992, J IMMUNOL, V148, P1240; Janeway C A Jr, 1991, Semin Immunol, V3, P153; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KRIAKIS JM, 1994, NATURE, V369, P156; LAVIN MF, 1994, ONCOGENE, V9, P2305; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MESSIER H, 1992, J IMMUNOL, V149, P1980; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; ORLOFF GM, 1991, AIDS RES HUM RETROV, V7, P587, DOI 10.1089/aid.1991.7.587; OYAIZU N, 1992, J CLIN INVEST, V89, P1807, DOI 10.1172/JCI115785; OYAIZU N, 1994, BLOOD, V84, P2622; OYAIZU N, 1989, P NATL ACAD SCI USA, V87, P2379; PARK JH, 1993, J BIOL CHEM, V268, P6299; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THAN S, 1994, BLOOD, V84, P184; VANLINT C, 1991, J VIROL, V65, P7066, DOI 10.1128/JVI.65.12.7066-7072.1991; Veillette A, 1991, Semin Immunol, V3, P143; WEISS A, 1984, J IMMUNOL, V133, P123; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	58	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19364	19369		10.1074/jbc.270.33.19364	http://dx.doi.org/10.1074/jbc.270.33.19364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642615	hybrid			2022-12-27	WOS:A1995RP70300029
J	MATSUMOTO, R; SALI, A; GHILDYAL, N; KARPLUS, M; STEVENS, RL				MATSUMOTO, R; SALI, A; GHILDYAL, N; KARPLUS, M; STEVENS, RL			PACKAGING OF PROTEASES AND PROTEOGLYCANS IN THE GRANULES OF MAST-CELLS AND OTHER HEMATOPOIETIC-CELLS - A CLUSTER OF HISTIDINES ON MOUSE MAST-CELL PROTEASE-7 REGULATES ITS BINDING TO HEPARIN SERGLYCIN PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-E-PROTEOGLYCAN; MOLECULAR-CLONING; SERINE PROTEASES; CARBOXYPEPTIDASE-A; NEUTRAL PROTEASES; RAT; GENE; DIFFERENTIATION; IDENTIFICATION; TRANSCRIPTION	Mouse mast cell protease 7 (mMCP-7) is a tryptase stored in the secretory granules of mast cells. At the granule pH of 5.5, mMCP-7 is fully active and is bound to heparin-containing serglycin proteoglycans. To understand the interaction of mMCP-7 with heparin inside and outside the mast cell, this tryptase was first studied by comparative protein modeling. The ''pro'' form of mMCP-7 was then expressed in insect cells and studied by site-directed mutagenesis. Although mMCP-7 lacks known linear sequences of amino acids that interact with heparin, the three-dimensional model of mMCP-7 revealed an area on the surface of the folded protein away from the substrate-binding site that exhibits a strong positive electrostatic potential at the acidic pH of the granule. In agreement with this calculation, recombinant pro-mMCP-7 bound to a heparin-affinity column at pH 5.5 and readily dissociated from the column at pH > 6.5. Site directed mutagenesis confirmed the prediction that the conversion of His residues 8, 68, and 70 in the positively charged region into Glu prevents the binding of pro-mMCP-7 to heparin. Because the binding requires positively charged His residues, native mMCP-7 is able to dissociate from the protease/proteoglycan macromolecular complex when the complex is exocytosed from bone marrow-derived mast cells into a neutral pH environment. Many hematopoietic effector cells store positively charged proteins in granules that contain serglycin proteoglycans. The heparin/mMCP-7 interaction, which depends on the tertiary structure of the tryptase, may be representative of a general control mechanism by which hematopoietic cells maximize storage of properly folded, enzymatically active proteins in their granules.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University					NIAID NIH HHS [AI-23483] Funding Source: Medline; NIAMS NIH HHS [AR-36308, AR-07530] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530, P60AR036308] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROOKS BR, 1988, J COMPUT CHEM, V4, P187; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHU W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P83, DOI 10.1016/0167-4838(92)90340-J; DAVIS ME, 1990, COMP PHYS COMMUN, V62, P187; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; Ehrlich P, 1878, THESIS U LEIPZIG GER; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; GUO NH, 1992, J BIOL CHEM, V267, P19349; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Jorpes E, 1935, Biochem J, V29, P1817; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEJLER G, 1994, J BIOL CHEM, V269, P14451; RAVIN E, 1982, J BIOL CHEM, V257, P7229; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SALI A, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P64; SALI A, 1993, J BIOL CHEM, V268, P9023; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P363; SCHECHTER NM, 1994, J IMMUNOL, V152, P4062; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; URATA H, 1993, J BIOL CHEM, V268, P24318; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405	58	104	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19524	19531		10.1074/jbc.270.33.19524	http://dx.doi.org/10.1074/jbc.270.33.19524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642636	hybrid			2022-12-27	WOS:A1995RP70300052
J	OKA, S; BRUSES, JL; NELSON, RW; RUTISHAUSER, U				OKA, S; BRUSES, JL; NELSON, RW; RUTISHAUSER, U			PROPERTIES AND DEVELOPMENTAL REGULATION OF POLYSIALYLTRANSFERASE ACTIVITY IN THE CHICKEN-EMBRYO BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALOSYL UNITS; VASE EXON; RAT-BRAIN; BIOSYNTHESIS; ACID; GLUCURONOSYLTRANSFERASE; GLYCOPROTEINS; EXPRESSION; ANTIBODY; NCAM	The properties and developmental regulation of vertebrate polysialyltransferase (PST), an enzyme activity responsible for extension of alpha 2,8-linked sialic acid homopolymers (PSA) associated with the fifth Ig domain of the neural cell adhesion molecule (NCAM), have been studied. The assay for PST used exogenous NCAM as a substrate, with a PSA-specific endoneuraminidase as a control for specificity. Optimal conditions for PST activity at 37 degrees C were found to be pH 6.0 in the presence of divalent cations (Mn2+, 20 mM). The enzyme K-m was found to increase with increasing polymer length, ranging from 0.7 to 0.07 mu M. The developmental regulation both of PST activity and of the addition of PSA to NCAM were studied in chick whole brain, tectum, and cerebellum and found to be precisely coordinated. In each tissue PSA and PST were highest during early stages of morphogenesis, followed by a decrease as development reached completion. The insertion of the VASE exon in the fourth Ig domain of NCAM was also found to parallel closely the developmental down regulation of PSA, and on this basis could be considered a potential determinant in the specific polysialylation of NCAM. However, in direct tests of this hypothesis in transfected cells the presence of VASE did not markedly alter the level of NCAM polysialylation or alter the affinity of PST for the NCAM substrate.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University					NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD18369, HD07104] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018369, R37HD018369, T32HD007104] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCARAZ G, 1991, EUR J CELL BIOL, V55, P165; BELLAIRS R, 1995, DEV DYNAM, V202, P333, DOI 10.1002/aja.1002020403; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1985, J BIOL CHEM, V260, P1265; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; OKA S, 1992, J BIOL CHEM, V267, P22711; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; RUTISHAUSER U, 1992, DEVELOPMENT, P99; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; YANG PF, 1994, J BIOL CHEM, V269, P23039; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	26	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19357	19363		10.1074/jbc.270.33.19357	http://dx.doi.org/10.1074/jbc.270.33.19357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642614				2022-12-27	WOS:A1995RP70300028
J	VENEMA, K; PALMGREN, MG				VENEMA, K; PALMGREN, MG			METABOLIC MODULATION OF TRANSPORT COUPLING RATIO IN YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATION STOICHIOMETRY; SARCOPLASMIC-RETICULUM; REGULATORY DOMAIN; H+/ATP STOICHIOMETRY; VOLTAGE-DEPENDENCE; NEUROSPORA-CRASSA; LIPID VESICLES; CALCIUM-PUMP; BINDING; PLANT	The plasma membrane proton pump (H+-ATPase) of yeast energizes solute uptake by secondary transporters and regulates cytoplasmic pH. The addition of glucose to yeast cells stimulates proton efflux mediated by the H+- ATPase. A >50-fold increase in proton extrusion from yeast cells is observed in vivo, whereas the ATPase activity of purified plasma membranes is increased maxi mally 8-fold after glucose treatment (Serrano, R. (1983) FEES Lett. 156, 11-14). The low capacity of yeast cells for proton extrusion in the absence of glucose can be ex plained by the finding that, in H+-ATPase isolated from glucose-starved cells, ATP hydrolysis is essentially uncoupled from proton pumping, The number of protons transported per ATP hydrolyzed is significantly increased after glucose activation, We suggest that intrinsic uncoupling is an important mechanism for regulation of pump activity.	ROYAL VET & AGR UNIV,DEPT PLANT BIOL,DK-1871 FREDERIKSBERG C,DENMARK	University of Copenhagen			Venema, Kees/G-9558-2015; Palmgren, Michael/A-9808-2013	Venema, Kees/0000-0001-5177-6464; Palmgren, Michael/0000-0002-9982-6114				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERBERIAN G, 1993, BIOCHIM BIOPHYS ACTA, V1153, P283, DOI 10.1016/0005-2736(93)90417-X; BLAIR DF, 1986, BIOPHYS J, V50, P713, DOI 10.1016/S0006-3495(86)83511-1; BLAKE MS, 1984, ANAL BIOCHEM, V128, P302; BLATT MR, 1990, J MEMBRANE BIOL, V114, P205, DOI 10.1007/BF01869215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUER D, 1989, PLANT PHYSIOL, V89, P464, DOI 10.1104/pp.89.2.464; BRISKIN DP, 1991, PLANT PHYSIOL, V95, P242, DOI 10.1104/pp.95.1.242; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CAPLAN SR, 1988, ION PUMPS STRUCTURE, P377; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1988, J BIOL CHEM, V263, P14134; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; Dixon M., 1979, ENZYMES, Vthird; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; FROHLICH O, 1988, J MEMBRANE BIOL, V101, P189, DOI 10.1007/BF01872834; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; INESI G, 1989, J BIOL CHEM, V264, P5929; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KRENN BE, 1993, BIOCHEM J, V294, P705, DOI 10.1042/bj2940705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauger P., 1991, ELECTROGENIC ION PUM; MELTZER S, 1984, J BIOL CHEM, V259, P4244; MONK BC, 1991, J BIOL CHEM, V266, P18097; Morrison J F, 1979, Methods Enzymol, V63, P257; MULLER AWJ, 1993, PHYSIOL CHEM PHYS ME, V25, P95; NAVARRO J, 1984, BIOPHYS J, V46, P709, DOI 10.1016/S0006-3495(84)84069-2; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PIETROBON D, 1986, BIOCHEMISTRY-US, V25, P767, DOI 10.1021/bi00352a005; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SANDERS D, 1990, ANNU REV PLANT PHYS, V41, P77, DOI 10.1146/annurev.pp.41.060190.000453; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SOLER F, 1990, EUR J BIOCHEM, V192, P347, DOI 10.1111/j.1432-1033.1990.tb19233.x; STUCKI JW, 1980, EUR J BIOCHEM, V109, P269, DOI 10.1111/j.1432-1033.1980.tb04792.x; TU SI, 1987, ARCH BIOCHEM BIOPHYS, V256, P625, DOI 10.1016/0003-9861(87)90620-5; VANWALRAVEN HS, 1990, BIOCHIM BIOPHYS ACTA, V1015, P425, DOI 10.1016/0005-2728(90)90075-F; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WARNCKE J, 1980, BIOCHIM BIOPHYS ACTA, V591, P224, DOI 10.1016/0005-2728(80)90154-1; WESTERHOFF HV, 1984, TRENDS BIOCHEM SCI, V7, P112; YOSHINORI M, 1988, ION PUMPS STRUCTURE, P387; ZIEGLER W, 1993, GEN PHYSIOL BIOPHYS, V12, P429	60	65	65	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19659	19667		10.1074/jbc.270.33.19659	http://dx.doi.org/10.1074/jbc.270.33.19659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642655	hybrid			2022-12-27	WOS:A1995RP70300071
J	ZHU, XL; CHANG, KH; HE, DC; MANCINI, MA; BRINKLEY, WR; LEE, WH				ZHU, XL; CHANG, KH; HE, DC; MANCINI, MA; BRINKLEY, WR; LEE, WH			THE C-TERMINUS OF MITOSIN IS ESSENTIAL FOR ITS NUCLEAR-LOCALIZATION, CENTROMERE/KINETOCHORE TARGETING, AND DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CENTROMERE; CENP-B; PROTEIN; KINETOCHORE; IDENTIFICATION; SUBUNIT; DOMAINS	Mitosin is a novel 350-kDa nuclear phosphoprotein that dramatically relocates from the evenly nuclear distribution in S phase to the centromere/kinetochore and mitotic apparatus in M phase. The dynamic relocalization of mitosin is accompanied by the phosphorylation of itself, suggesting that mitosin plays a role in mitotic progression. The molecular basis of nuclear localization and targeting of mitosin to the centromere/kinetochore were characterized using a set of epitope-tagged deletion mutants. The data indicate that the extreme C terminus (amino acids 2,487-3,113) of mitosin has both an independent centromere/kinetochore targeting domain and an unusually spaced bipartite nuclear localization signal. Moreover, the same centromere/kinetochore targeting domain was shown to be essential for the ability of mitosin to bind to itself or other putative mitosin-associated proteins through use of the yeast two hybrid system. These results suggest that the C terminus of the mitosin is essential for its role in influencing cell cycle progression.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine								BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; Brinkley B R, 1992, Trends Cell Biol, V2, P15, DOI 10.1016/0962-8924(92)90139-E; CASIANO CA, 1993, J CELL SCI, V106, P1045; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN CJ, 1988, ANNU REV GENET, V22, P51, DOI 10.1146/annurev.ge.22.120188.000411; Forrest D, 1992, CURR OPIN GENET DEV, V2, P19, DOI 10.1016/S0959-437X(05)80316-8; HE D, 1995, IN PRESS INT REV CYT; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; RATTNER JB, 1992, CHROMOSOMA, V101, P259, DOI 10.1007/BF00346003; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAITOH H, 1992, CELL, V170, P115; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	21	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19545	19550		10.1074/jbc.270.33.19545	http://dx.doi.org/10.1074/jbc.270.33.19545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642639	hybrid			2022-12-27	WOS:A1995RP70300055
J	CHOU, TY; HART, GW; DANG, CV				CHOU, TY; HART, GW; DANG, CV			C-MYC IS GLYCOSYLATED AT THREONINE-58, A KNOWN PHOSPHORYLATION SITE AND A MUTATIONAL HOT-SPOT IN LYMPHOMAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURKITT-LYMPHOMA; TERMINAL DOMAIN; POINT MUTATIONS; PROTEIN; CELLS; GENE; TRANSFORMATION; IDENTIFICATION; LOCALIZATION; ONCOPROTEINS	c-Myc is a helix-loop-helix leucine zipper phosphoprotein that heterodimerizes with Max and regulates gene transcription in cell proliferation, cell differentiation, and programmed cell death, Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C. V., and Hart, G. W. (1995) Proc, Natl, Acad, Sci, U.S.A. 92, 4417-4421), In this paper, we identified the O-GlcNAc attachment site(s) on c-Myc, c-Myc purified from sf9 insect cells was trypsinized, and its GlcNAc moieties were enzymically labeled with [H-3]galactose, The [H-3]galactose-labeled glycopeptides were isolated by reverse phase high performance liquid chromatography and then subjected to gas-phase sequencing, manual Edman degradation, and laser desorption/ionization mass spectrometry. These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc. Mutation of threonine 58, frequently found in retroviral v-Myc proteins and in human Burkitt and AIDS-related lymphomas, is associated with enhanced transforming activity and tumorigenicity. The reciprocal glycosylation and phosphorylation at this biologically significant amino acid residue may play an important role in the regulation of the functions of c-Myc.	UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; JOHNS HOPKINS UNIV,SCH MED,BIOCHEM CELLULAR & MOLEC BIOL TRAINING PROGRAM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205	University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins University			Dang, Chi/Y-3375-2019	Hart, Gerald/0000-0001-7812-4351; Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA57341, CA42486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042486, R01CA057341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1990, SCIENCE, V251, P1149; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CLARK HM, 1994, CANCER RES, V54, P3383; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAULKNER P, 1992, J VIROL, P3324; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRYKBERG L, 1987, ONCOGENE, V1, P415; GREIS KD, 1994, J VIROL, V68, P8339, DOI 10.1128/JVI.68.12.8339-8349.1994; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, 44TH C MOSB GLYC CEL, P91; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOLT GD, 1986, J BIOL CHEM, V261, P8049; IBERG N, 1986, J BIOL CHEM, V261, P3542; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1989, MOL CELL BIOL, V10, P5914; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KU NO, 1994, EXP CELL RES, V211, P24, DOI 10.1006/excr.1994.1054; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MEEK JL, 1981, J CHROMATOGR, V211, P15, DOI 10.1016/S0021-9673(00)81169-3; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MOORE JP, 1987, ONCOGENE RES, V2, P65; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SETH A, 1991, J BIOL CHEM, V226, P23521; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Summers MD, 1987, MANUAL METHODS BACUL; SYMONDS G, 1989, ONCOGENE, V4, P285; YANO T, 1993, ONCOGENE, V8, P2741	41	336	366	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18961	18965		10.1074/jbc.270.32.18961	http://dx.doi.org/10.1074/jbc.270.32.18961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642555	hybrid			2022-12-27	WOS:A1995RN95400043
J	FUTER, O; DECENZO, MT; ALDAPE, RA; LIVINGSTON, DJ				FUTER, O; DECENZO, MT; ALDAPE, RA; LIVINGSTON, DJ			FK506 BINDING-PROTEIN MUTATIONAL ANALYSIS - DEFINING THE SURFACE RESIDUE CONTRIBUTIONS TO STABILITY OF THE CALCINEURIN CO-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; SITE-SPECIFIC MUTAGENESIS; ENDOPLASMIC-RETICULUM; FK506-BINDING PROTEIN; PHENOTYPIC SELECTION; IMMUNOPHILIN LIGAND; CYCLOSPORINE-A; RAPAMYCIN; EFFICIENT; FKBP-13	The 12 and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus). The FKBP12 . FK506 complex is immunosuppressive, acting as an inhibitor of the protein phosphatase calcineurin, We have examined the role of the key surface residues of FKBP12 and FKBP13 in calcineurin interactions by generating substitutions at these residues by site-directed mutagenesis. All mutants are active catalysts of the prolyl isomerase reaction, and bind FK506 or rapamycin with high affinity, Mutations at FKBP12 residues Asp-37, Arg-42, His-87, and Ile-90 decrease calcineurin affinity of the mutant FKBP12 FK506 complex by as much as 2600-fold in the case of I90K, Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin, These results confirm the role of two loop regions of FKBP12 (residues 40-44 and 84-91) as part of the effector face that interacts with calcineurin.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; ARMISTEAD DM, 1993, ANNU REP MED CHEM, V28, P207; ARMISTEAD DM, 1995, IN PRESS ACTA CRYSTA; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; DILELLA AG, 1991, BIOCHEMISTRY-US, V30, P8512, DOI 10.1021/bi00099a002; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HENDRICKSON BA, 1993, GENE, V134, P271, DOI 10.1016/0378-1119(93)90106-D; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; ITOH S, 1995, IN PRESS BIOORG MED, V5; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KLEE CB, 1988, MOL ASPECTS CELL REG, V5, P225; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEPRE CA, 1994, BIOCHEMISTRY-US, V33, P13571, DOI 10.1021/bi00250a009; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NIGAM SK, 1993, BIOCHEM J, V294, P511, DOI 10.1042/bj2940511; PARK ST, 1992, J BIOL CHEM, V267, P3316; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PEATTIE DA, 1994, GENE, V150, P251, DOI 10.1016/0378-1119(94)90434-0; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1992, SCIENCE, V251, P283; SCHULTZ LW, 1994, J AM CHEM SOC, V116, P3129, DOI 10.1021/ja00086a055; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WILSON KP, 1995, IN PRESS ACTA CRYSTA; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	39	51	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18935	18940		10.1074/jbc.270.32.18935	http://dx.doi.org/10.1074/jbc.270.32.18935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642551				2022-12-27	WOS:A1995RN95400039
J	GIANNINI, E; BROUCHON, L; BOULAY, F				GIANNINI, E; BROUCHON, L; BOULAY, F			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION SITES IN HUMAN C5A ANAPHYLATOXIN RECEPTOR IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FORMYL PEPTIDE RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; DIFFERENTIATED HL-60 CELLS; PLATELET-ACTIVATING-FACTOR; 3RD INTRACELLULAR LOOP; FUNCTIONAL EXPRESSION; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTORS; CHEMOTACTIC RECEPTOR	Interaction of human C5a anaphylatoxin with cell surface receptors mediates cell activation and receptor desensitization, Treatment of differentiated HL60 cells or transiently transfected COS-7 cells with C5a or phorbol 12-myristate 13-acetate (PMA) results in rapid hyperphosphorylation of the C5aR. In an attempt to gain more insight into the function of phosphorylation in the desensitization of C5aR, we have initiated experiments to identify phosphoacceptor sites at the amino acid level after stimulation of cells with either C5a or PMA. In this report we show that C5aR is phosphorylated exclusively on serine residues in both differentiated HL60 and transfected COS-7 cells irrespective of the stimulus used. Peptide mapping after cyanogen bromide cleavage of phosphorylated C5aR indicates that despite the presence of a protein kinase C consensus motif the third cytoplasmic loop is not phosphorylated when cells are challenged with either C5a or PMA. Thus, whether the cells are stimulated with C5a or PMA, the phosphorylation sites appear to be restricted to serine residues in the carboxyl tail. Phosphoamino acid analysis of a series of mutants in which an individual serine residue was replaced by a threonine residue indicates that the C5aR undergoes C5a-dependent phosphorylation to the maximal stoichiometry of 6 mol of PO4/mol of receptor at Ser(314), Ser(317), Ser(327), Ser(332), Ser(334), and Ser(338). Simultaneous substitution of serine residues by alanine at positions 332, 334, and 338 affected neither the binding of C5a nor the cell surface expression of the mutant, but resulted in a dramatic reduction (more than 80%) of both C5a- and PMA-mediated phosphorylation as compared to the wild type receptor. This result suggests that phosphorylation on the segment extending from Ser(332) to Ser(338) is required for the subsequent phosphorylation of the carboxyl-terminal tail of C5aR.	CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,CEA,BIOCHIM LAB,CNRS,URA 1130,F-38054 GRENOBLE 9,FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS)								ALI H, 1993, J BIOL CHEM, V268, P24247; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GIANNINI E, 1995, J IMMUNOL, V154, P4055; HAGA T, 1994, J NEUROCHEM, V63, P400; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; KLOS A, 1994, FEBS LETT, V344, P79, DOI 10.1016/0014-5793(94)00350-5; LAEMMLI UK, 1973, NATURE, V220, P680; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MERY L, 1994, J BIOL CHEM, V269, P3457; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PAINTER RG, 1987, J CELL BIOL, V105, P2959, DOI 10.1083/jcb.105.6.2959; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TARDIF M, 1993, J IMMUNOL, V150, P3534; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WILDE MW, 1989, J BIOL CHEM, V264, P190; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILTFANG J, 1991, ELECTROPHORESIS, V12, P352, DOI 10.1002/elps.1150120507; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	49	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19166	19172		10.1074/jbc.270.32.19166	http://dx.doi.org/10.1074/jbc.270.32.19166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642584	hybrid			2022-12-27	WOS:A1995RN95400072
J	SCHWARTZ, EL; BAPTISTE, N; WADLER, S; MAKOWER, D				SCHWARTZ, EL; BAPTISTE, N; WADLER, S; MAKOWER, D			THYMIDINE PHOSPHORYLASE MEDIATES THE SENSITIVITY OF HUMAN COLON-CARCINOMA CELLS TO 5-FLUOROURACIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED COLORECTAL-CARCINOMA; RECOMBINANT INTERFERON ALFA-2A; GROWTH-FACTOR; PHASE-II; FLUOROURACIL; EXPRESSION; METABOLISM; CANCER; RESISTANCE	Interferon-alpha (IFN alpha) potentiates the antitumor activity of 5-fluorouracil (FUra) in colon cancer in vitro, in vivo, and clinically. A likely mechanism for this action is the induction by IFN alpha of thymidine phosphorylase (TP), the first enzyme in one pathway for the metabolic activation of FUra to fluorodeoxyribonucleotides. To test this hypothesis, an expression vector containing the TP cDNA was transfected into HT-29 human colon carcinoma cells. Five stable transfectants were selected and analyzed. All showed increased sensitivity to FUra cytotoxicity, ranging from a 2-fold to a 19-fold decrease in the IC50 for FUra, compared to wild-type cells. Levels of TP mRNA, protein, and enzyme activity were elevated in the transfectants, and there was a significant correlation between the relative increase in sensitivity to FUra and both the increase in both TP mRNA levels and TP activity. Transfected cells exhibited increased formation of FdUMP, but not the ribonucleotides FUDP and FUTP, from FUra when compared to wild-type cells, The changes in TP activity, FdUMP formation, and FUra sensitivity in the transfected cells were comparable with those seen after treatment of wild-type cells with IFN alpha. These studies provide direct evidence for the role of TP in mediating the sensitivity of colon carcinoma cells to FUra, and further support the importance of the induction of TP in the biomodulating action of IFN alpha on FUra chemosensitivity.	ALBERT EINSTEIN COLL MED,DEPT ONCOL,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine	SCHWARTZ, EL (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R01CA054422, P30CA013330, R55CA054422] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330, CA54422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNIE GD, 1963, BIOCHEMISTRY-US, V2, P566, DOI 10.1021/bi00903a031; CHU E, 1990, MOL PHARMACOL, V38, P410; EDA H, 1993, CANCER CHEMOTH PHARM, V32, P333, DOI 10.1007/BF00735915; ELIAS L, 1989, BIOCHEM BIOPH RES CO, V163, P867, DOI 10.1016/0006-291X(89)92302-4; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDKIN M, 1953, J BIOL CHEM, V207, P245; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; ILTZSCH MH, 1985, BIOCHEMISTRY-US, V24, P6799, DOI 10.1021/bi00345a011; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KRENITSKY TA, 1968, J BIOL CHEM, V243, P2871; LUCCIONI C, 1994, INT J CANCER, V58, P517, DOI 10.1002/ijc.2910580411; MAEHARA Y, 1989, J SURG ONCOL, V42, P184, DOI 10.1002/jso.2930420311; MARSH JC, 1964, J CLIN INVEST, V43, P267, DOI 10.1172/JCI104911; MARTINUSSEN J, 1994, J BACTERIOL, V176, P6457, DOI 10.1128/JB.176.21.6457-6463.1994; MOGHADDAM A, 1992, BIOCHEMISTRY-US, V31, P12141, DOI 10.1021/bi00163a024; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; PAULY JL, 1978, P SOC EXP BIOL MED, V157, P262; PAULY JL, 1977, J NATL CANCER I, V58, P1587, DOI 10.1093/jnci/58.6.1587; PAZDUR R, 1990, J CLIN ONCOL, V8, P2027, DOI 10.1200/JCO.1990.8.12.2027; PETERS GJ, 1991, CANCER, V68, P1903, DOI 10.1002/1097-0142(19911101)68:9<1903::AID-CNCR2820680910>3.0.CO;2-9; REYNOLDS K, 1994, J NATL CANCER I, V86, P1234, DOI 10.1093/jnci/86.16.1234; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; SCHWARTZ EL, 1994, CANCER RES, V54, P1472; SCHWARTZ EL, 1992, BIOCHEM BIOPH RES CO, V182, P1232, DOI 10.1016/0006-291X(92)91863-L; SCHWARTZ EL, 1995, IN PRESS CANCER RES, V55; SHAW T, 1988, MUTAT RES, V200, P117, DOI 10.1016/0027-5107(88)90075-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SPEARS CP, 1988, CANCER RES, V48, P5894; Takebayashi Y., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P90; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WADLER S, 1989, J CLIN ONCOL, V7, P1769, DOI 10.1200/JCO.1989.7.12.1769; WADLER S, 1991, J CLIN ONCOL, V9, P1806, DOI 10.1200/JCO.1991.9.10.1806; YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2618; 1995, J CLIN ONCOL, V13, P921	39	110	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19073	19077		10.1074/jbc.270.32.19073	http://dx.doi.org/10.1074/jbc.270.32.19073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642571	hybrid			2022-12-27	WOS:A1995RN95400059
J	WILSON, SA; WILLIAMS, RJ; PEARL, LH; DREW, RE				WILSON, SA; WILLIAMS, RJ; PEARL, LH; DREW, RE			IDENTIFICATION OF 2 NEW GENES IN THE PSEUDOMONAS-AERUGINOSA AMIDASE OPERON, ENCODING AN ATPASE (AMIB) AND A PUTATIVE INTEGRAL MEMBRANE-PROTEIN (AMIS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ALIPHATIC AMIDASE; BINDING PROTEIN; EXPRESSION; CLONING; PURIFICATION; COMPONENTS; PRODUCT; SUBUNIT	The nucleotide sequence of the amidase operon of Pseudomonas aeruginosa has been completed and two new genes identified amiB and amiS. The complete gene order for the operon is thus amiEBCRS. The amiB gene encodes a 42-kDa protein containing an ATP binding motif that shares extensive homology with the Clp family of proteins and also to an open reading frame adjacent to the amidase gene from Rhodococcus erythropolis. Deletion of the amiB gene has no apparent effect on inducible amidase expression and it is thus unlikely to encode a regulatory protein, A maltose binding protein-AmiB fusion has been purified and shown to have an intrinsic ATPase activity (K-m = 174 +/- 15 mM; V-max = 2.4 +/- 0.1 mM/min/mg), which is effectively inhibited by ammonium vanadate and ADP, The amiS gene encodes an 18-kDa protein with a high content of hydrophobic residues. Hydropathy analysis suggests the presence of six transmembrane helices in this protein, The AmiS sequence is homologous to an open reading frame identified adjacent to the amidase gene from Mycobacterium smegmatis and to the ureI gene from the urease operon of Helicobacter pylori. AmiS and its homologs appear to be a novel family of integral membrane proteins, Together AmiB and AmiS resemble two components of an ABC transporter system.	UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London				Pearl, Laurence/0000-0002-6910-1809; wilson, stuart/0000-0003-3073-258X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; BRAMMAR WJ, 1964, J GEN MICROBIOL, V37, P307, DOI 10.1099/00221287-37-3-307; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; COUSENS DJ, 1987, J GEN MICROBIOL, V133, P2041; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAY MJ, 1975, THESIS U LONDON; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREW R, 1989, J GEN MICROBIOL, V135, P817; DREW RE, 1980, MOL GEN GENET, V177, P311, DOI 10.1007/BF00267444; FERRERO RL, 1991, ITAL J GASTROENTE S2, V23, P3; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KAGAWA Y, 1979, J BIOENERG BIOMEMBR, V11, P39, DOI 10.1007/BF00743196; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWE N, 1989, FEBS LETT, V246, P39, DOI 10.1016/0014-5793(89)80249-2; MAHENTHIRALINGAM E, 1993, J GEN MICROBIOL, V139, P575, DOI 10.1099/00221287-139-3-575; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; Sambrook J, 1989, MOL CLONING LABORATO; SOUBRIER F, 1992, GENE, V116, P99, DOI 10.1016/0378-1119(92)90635-3; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; TAI JTN, 1994, MOL MICROBIOL, V12, P31, DOI 10.1111/j.1365-2958.1994.tb00992.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WILSON SA, 1993, EMBO J, V12, P3637, DOI 10.1002/j.1460-2075.1993.tb06037.x; WILSON SA, 1991, J MOL BIOL, V222, P869, DOI 10.1016/0022-2836(91)90579-U	41	25	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18818	18824		10.1074/jbc.270.32.18818	http://dx.doi.org/10.1074/jbc.270.32.18818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642533	hybrid			2022-12-27	WOS:A1995RN95400020
J	BU, CH; POURMOTABBED, T				BU, CH; POURMOTABBED, T			MECHANISM OF ACTIVATION OF HUMAN NEUTROPHIL GELATINASE-B - DISCRIMINATING BETWEEN THE ROLE OF CA2+ IN ACTIVATION AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; IV COLLAGENASE; CYSTEINE SWITCH; MATRIX METALLOPROTEINASES; SEQUENCE IDENTIFICATION; INHIBITION; PURIFICATION; PRECURSOR; INVASION; CELLS	Gelatinase B is a Zn2+- and Ca2+ dependent endopeptidase that is secreted from cells as an inactive proenzyme. The enzyme can be activated in vitro by organomercurial compounds and by trypsin. The role of Ca2+ in autoproteolytic processing initiated by 4-aminophenylmercuric acetate and trypsin and in catalytic activity of the activated enzyme was investigated by zymography and by kinetic analysis. Treatment of unglycosylated 57.5-kDa pro-gelatinase B with 4-aminophenylmercuric acetate (1 mM) in the absence of Ca2+ generated a 49-kDa inactive intermediate (E'), whereas a 41.5-kDa active species (E '') was generated in the presence of Ca2+ (5 mM). Upon addition of Ca2+ to the reaction mixture of Ca2+ depleted E' or E '' at 37 degrees C, E' showed a lag period in generation of the product as a function of time, but E '' presented an immediate activity. The appearance of enzymatic activity of E' correlated with the generation of the E '' species. NH2-terminal sequence analyses showed that E' and E '' had the same NH2 termini. i.e. Met-75, suggesting that Ca2+-dependent removal of COOH terminus of E' is required for activation of the enzyme, Treatment of pro-gelatinase B with trypsin in the absence of Ca2+, led to degradation of the enzyme, In the presence of Ca2+, trypsin processed the pro enzyme to a 40-kDa active species. In contrast to E '', this active species did not require Ca2+ for activity. The Ca2+ dependence of E '' activity was also abolished by treatment of the enzyme with trypsin. NH2-terminal sequence analysis indicated that amino acid residues 75-87 had been re moved from the NH2 terminus of E '' by trypsin, suggesting that these residues are responsible for the Ca2+-dependent activity of the enzyme. Removal of Ca2+ and catalytic Zn2+ inhibited the activities of both E '' and trypsin treated E ''. In the absence of Ca2+, either Zn2+, Co2+, Mn2+, or Cd2+ was able to restore the activity of trypsin-treated E ''. None of the divalent cations tested however, was able to stimulate the activity of E '' in the absence of Ca2+. These experiments further suggest that binding of Ca2+ to E '' or removal of the NH2-terminal residues of the enzyme by trypsin induces a conformational change in the protein and makes the active site of the enzyme accessible to various metal ions rendering the enzyme active.	UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041843, R29AR041843] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41843] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; DECLERCK YA, 1991, CANCER RES, V51, P2151; DECLERCK YA, 1992, CANCER RES, V52, P701; FREIMARK BD, 1994, J BIOL CHEM, V269, P26982; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MORDOMI T, 1992, BIOCHEM J, V285, P603; NAGAI Y, 1972, BIOCHIM BIOPHYS ACTA, V263, P564, DOI 10.1016/0005-2795(72)90037-2; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PARK AJ, 1991, J BIOL CHEM, V266, P1584; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; POURMOTABBED T, 1995, IN PRESS J PROTEIN C; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schultz R M, 1991, Cancer Treat Res, V54, P119; SELTZER JL, 1976, ARCH BIOCHEM BIOPHYS, V173, P355, DOI 10.1016/0003-9861(76)90270-8; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSO.WG, 1991, AM J MED SCI, V302, P163; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P1353; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINEFORDNER JD, 1975, APPL SPECTROSC, V25, P369; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18563	18569		10.1074/jbc.270.31.18563	http://dx.doi.org/10.1074/jbc.270.31.18563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629187	hybrid			2022-12-27	WOS:A1995RM64200065
J	ROSENBERG, HF; DYER, KD				ROSENBERG, HF; DYER, KD			EOSINOPHIL CATIONIC PROTEIN AND EOSINOPHIL-DERIVED NEUROTOXIN - EVOLUTION OF NOVEL FUNCTION IN A PRIMATE RIBONUCLEASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL RIBONUCLEASE; MOLECULAR-CLONING; INHIBITOR; ANGIOGENIN; IDENTITY; MELITTIN; CDNA	Human eosinophil derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are members of a unique subfamily of rapidly evolving primate ribonuclease genes that emerged via a gene duplication event occurring after the divergence of Old World from New World monkeys (Rosenberg, H. F., Dyer, K. D., Tiffany, H. L., and Gonzalez, M. (1995) Nature Genet, 10, 219-223). In this work, we studied the activity of the protein encoded by the EDN/ECP homolog of the New World monkey, Saguinus oedipus (marmoset), a representative of the ''ancestral'' single sequences, Although the nucleotide sequence of the single marmoset gene (mEDN) was equally homologous (82%) to both human genes, the en coded amino acid sequence, calculated isoelectric point, and immunoreactivity all suggested a closer relation ship with EDN. Furthermore, mEDN (at 0.3-1.0 mu M concentrations) had no measurable anti-staphylococcal activity, suggesting functional as well as structural similarity to EDN. However, with yeast tRNA as substrate, mEDN had significantly less ribonuclease activity than EDN; Michaelis constants were nearly identical (K-m (mEDN) = 0.67 mu M; K-m (EDN) = 0.70 mu M), while turnover numbers differed by a factor of 100 (k(cat) (mEDN) = 0.91 s(-1); k(cat) (EDN) = 0.64 x 10(-2) s(-1)), Thus, evolutionary constraints appear to have promoted two novel functions: increased cationicity/toxicity (ECP) and enhanced ribonuclease activity (EDN), The latter result is particularly intriguing, as it suggests a crucial role for ribonuclease activity in the (as yet to be determined) physiologic function of EDN.			ROSENBERG, HF (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N104,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BARKER RL, 1989, J IMMUNOL, V143, P952; BLACKBURN P, 1982, ENZYMES, P317; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; DURACK DT, 1979, P NATL ACAD SCI USA, V76, P1443, DOI 10.1073/pnas.76.3.1443; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HIGUCHI R, 1990, PCR PROTOCOLS, pCH22; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LI HH, 1991, FUNDAMENTALS MOL EVO, pCH5; MAKINO S, 1993, EOSINOPHILS BIOL CLI; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; Nei M., 1987, MOL EVOLUTIONARY GEN; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; NEWTON DL, 1994, J NEUROSCI, V14, P538; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1994, J LEUKOCYTE BIOL, V56, P502, DOI 10.1002/jlb.56.4.502; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; Spry CJ, 1988, EOSINOPHILS COMPREHE; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	33	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21539	21544		10.1074/jbc.270.37.21539	http://dx.doi.org/10.1074/jbc.270.37.21539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665566	hybrid			2022-12-27	WOS:A1995RU75700021
J	WRIGHT, KL; MOORE, TL; VILEN, BJ; BROWN, AM; TING, JPY				WRIGHT, KL; MOORE, TL; VILEN, BJ; BROWN, AM; TING, JPY			MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-ASSOCIATED INVARIANT CHAIN GENE-EXPRESSION IS UP-REGULATED BY COOPERATIVE INTERACTIONS OF SP1 AND NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; TRANSCRIPTION FACTOR BINDING; GAMMA-INDUCED EXPRESSION; SERUM RESPONSE ELEMENT; RNA POLYMERASE-II; INTERFERON-GAMMA; SYNERGISTIC ACTIVATION; IFN-GAMMA; BOX-BINDING; CCAAT-BOX	Expression of the major histocompatibility complex (MHC) class II-associated invariant chain (Ii) is required for efficient and complete presentation of antigens by MHC class II molecules and a normal immune response. The Ii gene is generally co-regulated with the MHC class II molecules at the level of transcription and a shared SXY promoter element has been described. This report defines the proximal promoter region of Ii which may regulate Ii transcription distinct from MHC class II, In vivo genomic footprinting identified an occupied, imperfect CCAAT box and an adjacent GC box in the proximal region, These sites are bound in Ii-ositive cell lines and upon interferon-gamma induction of Ii transcription. In contrast, both sites are unoccupied in Ii-egative cell lines and in inducible cell lines prior to interferon-gamma treatment, Together these two sites synergize to stimulate transcription, Independently, the transcription factor NF-Y binds poorly to the imperfect CCAAT box with a rapid off rate, while Sp1 binds to the GC box. Stabilization of NF-Y binding occurs upon Sp1 binding to DNA, In addition, the half-life of Sp1 binding also increased in the presence of NF-Y binding. These findings suggest a mechanism for the complete functional synergy of the GC and CCAAT elements observed in Ii transcription. Furthermore, this report defines a CCAAT box of imperfect sequence which binds NF-Y and activates transcription only when stabilized by an adjacent factor, Sp1.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MICROBIOL IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA48185] Funding Source: Medline; NIAID NIH HHS [AI29564, T32-AI07232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI029564, R01AI029564, R37AI029564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BARR CL, 1991, J BIOL CHEM, V266, P3475; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; BROWN AM, 1991, J IMMUNOL, V146, P3183; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN RB, 1986, MOL CELL BIOL, V6, P821, DOI 10.1128/MCB.6.3.821; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CRESSWELL P, 1990, NATURE, V343, P593, DOI 10.1038/343593a0; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOYLE C, 1990, P NATL ACAD SCI USA, V87, P4590, DOI 10.1073/pnas.87.12.4590; EADES AM, 1990, J IMMUNOL, V144, P4399; FABER M, 1990, J BIOL CHEM, V265, P22243; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GROYERSCHWEIZER G, 1992, J STEROID BIOCH MOL, V41, P747; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOOD L, 1983, ANNU REV IMMUNOL, P529; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONES PP, 1978, IMMUNOCHEMISTRY, V16, P51; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KING DP, 1985, J IMMUNOL, V135, P632; KOCH N, 1984, J IMMUNOL, V132, P1361; KOCH N, 1984, J IMMUNOL, V132, P12; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMB CA, 1992, J IMMUNOL, V148, P3478; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PETERLIN BM, 1990, IMMUNOL RES, V9, P164, DOI 10.1007/BF02918176; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RAHMSDORF HJ, 1983, EMBO J, V6, P811; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952-7915(94)90034-5; SASAKI A, 1990, J NEUROIMMUNOL, V29, P213, DOI 10.1016/0165-5728(90)90164-I; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKIGUCHI M, 1985, EUR J IMMUNOL, V15, P809, DOI 10.1002/eji.1830150813; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZHU L, 1990, MOL CELL BIOL, V10, P3906, DOI 10.1128/MCB.10.8.3906	90	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20978	20986		10.1074/jbc.270.36.20978	http://dx.doi.org/10.1074/jbc.270.36.20978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673122	hybrid, Green Published			2022-12-27	WOS:A1995RU05400019
J	MCKINNON, LA; NATHANSON, NM				MCKINNON, LA; NATHANSON, NM			TISSUE-SPECIFIC REGULATION OF MUSCARINIC ACETYLCHOLINE-RECEPTOR EXPRESSION DURING EMBRYONIC-DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING CHICK HEART; PHOSPHOINOSITIDE HYDROLYSIS; BINDING PROTEIN; CELLS; DIFFERENTIATION; SUBTYPES; STIMULATION; PIRENZEPINE; AGONISTS; CLONING	We used solution hybridization, immunoprecipitation, and immunoblot analyses to examine the developmental expression of chicken m2 (cm2), cm3, and cm4 muscarinic acetylcholine receptor (mAChR) mRNA and protein in embryonic and post-hatched chick heart and retina in order to correlate developmental expression patterns with known physiological events. cm2 is the predominant mAChR subtype expressed in chick heart. cm3 and cm4 protein and mRNA expression is very low in chick heart, and cm3 expression is highest early in development. The decrease in cm3 expression correlates well with the developmental decrease in mAChR-mediated activation of phospholipase C. cm4 is the predominant mAChR subtype expressed in chick. retina. The expression of both cm4 protein and mRNA is highest early in development and decreases as development progresses. cm2 and cm3 mAChR are expressed at approximately equivalent levels and have similar patterns of expression. The cm2 and cm3 protein levels increase throughout development, while cm2 and cm3 mRNA levels peak at embryonic day 15 and then decrease after hatching. Our data indicate that the three mAChR subtypes are differentially regulated in chick heart and retina and that the patterns of expression of mAChR may be important in the development and physiology of these tissues.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL030630] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30630] Funding Source: Medline; NIGMS NIH HHS [GM07750] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADBUT AP, 1994, J BIOL CHEM, V269, P25823; BARNETT JV, 1990, BIOCHEM J, V271, P443, DOI 10.1042/bj2710443; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BROWN JH, 1985, MOL PHARMACOL, V27, P525; CORABOEUF E, 1970, AM J CARDIOL, V25, P285, DOI 10.1016/S0002-9149(70)80005-4; GALPER JB, 1977, J BIOL CHEM, V252, P8692; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HALVORSEN SW, 1984, BIOCHEMISTRY-US, V23, P5813, DOI 10.1021/bi00319a021; HOSEY MM, 1985, J PHARMACOL EXP THER, V232, P795; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; HUNTER DD, 1986, J NEUROSCI, V6, P3739; JAMES WM, 1988, J NEUROSCI, V8, P4225; KIRBY ML, 1985, CIRC RES, V56, P392, DOI 10.1161/01.RES.56.3.392; KIRBY ML, 1983, J MOL CELL CARDIOL, V15, P685, DOI 10.1016/0022-2828(83)90258-4; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LARGE TH, 1985, P NATL ACAD SCI USA, V82, P8785, DOI 10.1073/pnas.82.24.8785; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; MCKNIGHT GS, 1988, METHOD ENZYMOL, V159, P299; MUBAGWA K, 1992, J PHARMACOL EXP THER, V260, P1323; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; ORELLANA SA, 1985, BIOCHEM PHARMACOL, V34, P1321, DOI 10.1016/0006-2952(85)90512-X; PAPPANO AJ, 1974, J PHARMACOL EXP THER, V191, P109; PAPPANO AJ, 1991, J CARDIOVASC ELECTR, V2, P262; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PORTAS LL, 1990, EUR J PHARMACOL, V175, P215; RENAUD JF, 1980, DEV BIOL, V78, P184, DOI 10.1016/0012-1606(80)90328-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKORUPA AF, 1993, J NEUROCHEM, V60, P2087, DOI 10.1111/j.1471-4159.1993.tb03493.x; SUGIYAMA H, 1977, P NATL ACAD SCI USA, V74, P5524, DOI 10.1073/pnas.74.12.5524; SULLIVAN JK, 1985, CARDIAC MORPHOGENESI, P253; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828	36	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20636	20642		10.1074/jbc.270.35.20636	http://dx.doi.org/10.1074/jbc.270.35.20636			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657643	hybrid			2022-12-27	WOS:A1995RR58400062
J	YANG, WY; MALEK, SN; DESIDERIO, S				YANG, WY; MALEK, SN; DESIDERIO, S			AN SH3-BINDING SITE CONSERVED IN BRUTONS TYROSINE KINASE AND RELATED TYROSINE KINASES MEDIATES SPECIFIC PROTEIN INTERACTIONS IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SH3 DOMAIN; DEVELOPMENTAL REGULATION; CRYSTAL-STRUCTURE; GENE; EXPRESSION; ACTIVATION; RECEPTOR; CELLS; BINDS	Mutations in Bruton's tyrosine kinase (Btk) have been associated with immunodeficiencies in man and in the mouse. Btk and two related proteins, Itk and Tee, are members of a distinct family of tyrosine kinases. These kinases are believed to function in various receptor-mediated signaling pathways, but their specific functions are as yet undefined. Btk and its homologues share extensive sequence similarity, including a conserved region, the Tec homology (TH) domain, that has been proposed to mediate specific intermolecular or intramolecular interactions. The TH region of Btk contains a functional SH3-binding site at residues 189-192. SH3 binding is selective: Btk is retained by the SH3 domain of Fyn but not by that of Blk, another Src-type kinase. TH-SH3 binding in vitro is abolished by specific, single amino acid substitutions within the Btk TH domain or the Fyn SH3 domain. We provide two lines of evidence that the SH3-binding site in the Btk TH domain mediates protein interactions in intact cells. First, treatment of cells with pervanadate induces an increase in the phosphotyrosine content of kinase-inactive Btk; this response is substantially reduced by a mutation that inactivates the SH3-binding site in the Btk TH domain. Second, in cell lysates Btk is found in association with an as yet unidentified 72-kDa phosphotyrosine containing protein; this interaction requires a functional SH3-binding site in the TH domain. The TH domain may therefore interact in vivo with other proteins that regulate the phosphorylation state of Btk.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOKE M P, 1989, New Biologist, V1, P66; DESIDERIO S, 1994, CHEM IMMUNOL, V59, P191; DESIDERIO S, 1993, NATURE, V361, P202, DOI 10.1038/361202a0; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LIN W, 1994, NATURE, V372, P375; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEARL ER, 1978, J IMMUNOL, V120, P1169; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	47	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20832	20840		10.1074/jbc.270.35.20832	http://dx.doi.org/10.1074/jbc.270.35.20832			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657668	hybrid			2022-12-27	WOS:A1995RR58400089
J	YAO, H; LABUDDA, K; RIM, C; CAPODIECI, P; LODA, M; STORK, PJS				YAO, H; LABUDDA, K; RIM, C; CAPODIECI, P; LODA, M; STORK, PJS			CYCLIC ADENOSINE-MONOPHOSPHATE CAN CONVERT EPIDERMAL GROWTH-FACTOR INTO A DIFFERENTIATING FACTOR IN NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURITE OUTGROWTH; DEPENDENT PROTEIN-KINASE; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; MAP KINASES; NERVE; AMP; EXPRESSION; CAMP; RAS	The rat pheochromocytoma (PC12) cell line is a model for studying the mechanism of growth factor action. Both epidermal growth factor and nerve growth factor stimulate mitogen-activated protein (MAP) kinase in these cells. Recent data suggest that the transient activation of MAP kinase may trigger proliferation, whereas sustained activation triggers differentiation in these cells. We have tested this model by asking whether agents that stimulate MAP kinase without inducing differentiation can act additively to trigger differentiation. Neither forskolin nor epidermal growth factor can stimulate differentiation, yet both activate MAP kinase in these cells. Together, their actions on MAP kinase are synergistic. Cells treated with both agents differentiate, measured morphologically and by the induction of neural-specific genes. We propose that cellular responses to growth factor action are dependent not only on the activation of growth factor receptors by specific growth factors but on synchronous signals that may elevate MAP kinase levels within the same cells.	OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02138	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	YAO, H (corresponding author), OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045921] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45921-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BALBI D, 1994, MOL BRAIN RES, V23, P310, DOI 10.1016/0169-328X(94)90240-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; FILLMORE HL, 1992, J NEUROSCI RES, V31, P662, DOI 10.1002/jnr.490310410; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGUIRE JC, 1978, CELL, V15, P357, DOI 10.1016/0092-8674(78)90004-1; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PITTMAN RN, 1988, DEV NEUROSCI, V11, P41; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; RICHTERLANDSBER.C, 1986, J CELL BIOL, V102, P821; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STEIN R, 1988, NEURON, V7, P463; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAMIR A, 1994, J IMMUNOL, V152, P3391; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	48	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20748	20753		10.1074/jbc.270.35.20748	http://dx.doi.org/10.1074/jbc.270.35.20748			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657657	hybrid			2022-12-27	WOS:A1995RR58400078
J	DAVIE, JR; WYNN, RM; MENG, MS; HUANG, YS; AAHUND, G; CHUANG, DT; LAU, KS				DAVIE, JR; WYNN, RM; MENG, MS; HUANG, YS; AAHUND, G; CHUANG, DT; LAU, KS			EXPRESSION AND CHARACTERIZATION OF BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE FROM THE RAT - IS IT A HISTIDINE-PROTEIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOVINE KIDNEY; COMPLEX; PURIFICATION; LIVER; PHOSPHORYLATION; ACTIVATION; ASPARTATE; DOMAINS; BINDING	The recombinant rat branched-chain Lu-ketoacid dehydrogenase kinase has been amplified from rat kidney cDNA, based on the previously reported rat cDNA sequence (Popov, K.M., Zhao, Y., Shimomura, Y., Kuntz, M.J., and Harris, R.A. (1992) J. Biol. Chem. 267, 13127-13130), This kinase was expressed in Escherichia coli as a fusion protein with bacterial maltose-binding protein (MBP), Expression was improved by overexpression of chaperonins GroEL and GroES, The MBP-kinase, when reconstituted with lipoylated recombinant E2 (dihydro lipoyl transacylase), catalyzed phosphorylation of recombinant El (branched-chain alpha-ketoacid decarboxylase) with a K-cat of 28.5 nmol of phosphate/min/nmol of MEP-kinase at 25 degrees C, Recombinant MBP kinase alone demonstrated a slow rate of autophosphorylation with a k(cat) of 3.25 pmol of phosphate/min/nmol of kinase at 25 degrees C, Serine 22 of the kinase was identified as the possible site of autophosphorylation by Edman microsequencing analysis, Autophosphorylated kinase cannot transfer phosphate to E1, indicating that autophosphorylation of kinase is not an intermediate in ATP-dependent phosphorylation of E1, Therefore, despite the reported sequence similarity to prokaryotic histidine protein kinases, the mitochondrial rat branched chain cu-ketoacid dehydrogenase kinase apparently does not phosphorylate E1 via a histidine-mediated phosphotransfer reaction, Significant corrections to the published cDNA sequence of rat branched-chain cu-ketoacid dehydrogenase kinase are included.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Huang, Yi-Shuian/P-2824-2018	Huang, Yi-Shuian/0000-0001-9000-7748; Davie, James/0000-0002-0420-6888; Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37373] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFTRING RP, 1988, AM J PHYSIOL, V254, pE292, DOI 10.1152/ajpendo.1988.254.3.E292; ALI ST, 1990, BIOCHEM J, V271, P139, DOI 10.1042/bj2710139; BLOCK KP, 1985, BIOCHEM J, V232, P593, DOI 10.1042/bj2320593; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; CHUANG JL, 1994, AM J HUM GENET, V55, P297; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; CHUANG JL, 1993, J BIOL CHEM, V268, P8309; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOTTFERT M, 1990, P NATL ACAD SCI USA, V87, P2680, DOI 10.1073/pnas.87.7.2680; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRIS RA, 1986, BIOCHEM J, V234, P285, DOI 10.1042/bj2340285; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LAU KS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P360, DOI 10.1016/0167-4838(90)90249-F; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; MILLER RH, 1988, J BIOL CHEM, V263, P3454; ONO K, 1993, J BIOL CHEM, V268, P26135; PAUL HS, 1982, J BIOL CHEM, V257, P4875; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RORRER K, 1992, J GEN VIROL, V73, P775, DOI 10.1099/0022-1317-73-4-775; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	35	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19861	19867		10.1074/jbc.270.34.19861	http://dx.doi.org/10.1074/jbc.270.34.19861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649998	hybrid			2022-12-27	WOS:A1995RQ99100030
J	GRYCZYNSKI, Z; LUBKOWSKI, J; BUCCI, E				GRYCZYNSKI, Z; LUBKOWSKI, J; BUCCI, E			HEME-PROTEIN INTERACTIONS IN HORSE HEART MYOGLOBIN AT NEUTRAL PH AND EXPOSED TO ACID INVESTIGATED BY TIME-RESOLVED FLUORESCENCE IN THE PICOSECOND TO NANOSECOND TIME RANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; LINEAR DICHROISM; ENERGY-TRANSFER; ORIENTATIONAL DISORDER; CIRCULAR-DICHROISM; DECAY KINETICS; TRYPTOPHANS; CHROMOPHORE; RESOLUTION	We measured the steady state and time-resolved emission intensity decay of horse heart myoglobin at various pH values from neutral to pH 4.42. The steady state intensity was reversibly increased with the decreasing pH, almost doubling at pH 4.5, Frequency domain data for emission decay were analyzed separately for each pH and simultaneously by global analyses, The results indicated the presence of four lifetime components, conserved throughout the pH titrations at 40, 116, 1363, and 4822 ps, respectively, The titration affected only their fractional intensitie. Assignments of the lifetimes were based on the Forster theory of radiationless dipole dipole interaction and the atomic coordinates of the system, We assigned the two shorter lifetimes to Trp-14 and Trp-7, respectively, in the presence of normal hemes, The 1363-ps lifetime was assigned to Trp-7 with inverted hemes (i.e. rotated 180 degrees around the alpha-gamma-meso axis of the porphyrin ring). The 4822-ns lifetime was assigned to reversibly heme-dissociated myoglobin, Lorentzian lifetime distributions were narrow for the lifetimes at 40, 116, and 4822 ps, indicating a homogeneous protein structure, Instead the lifetime at 1363 ns had a broad, ps-independent distribution consistent with small angle wobblings of inverted hemes inside the heme pocket, These analyses revealed the presence of three species originating from heme-protein interactions: the native form of crystalline myoglobin, the conformation with disordered hemes, and the reversibly dissociated heme-free myoglobin. There was increased heme inversion and heme dissociability at lower pH, consistent with the titration of the proximal and distal histidines inside the heme pocket.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM,BALTIMORE,MD 21201; UNIV GDANSK,DEPT CHEM,PL-80952 GDANSK,POLAND	University System of Maryland; University of Maryland Baltimore; Fahrenheit Universities; University of Gdansk					NCRR NIH HHS [RR-08119] Funding Source: Medline; NHLBI NIH HHS [R01-HL-1364, P01-HL-48517] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINSSON B, 1989, J PHYS CHEM-US, V93, P6646, DOI 10.1021/j100355a016; ALBINSSON B, 1992, J PHYS CHEM-US, V96, P6204, DOI 10.1021/j100194a023; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AOJULA HS, 1986, BIOCHEM J, V237, P613, DOI 10.1042/bj2370613; BEECHEM JM, 1991, TOPICS FLUORESCENCE, V1, P241; BENESCH RE, 1994, METHOD ENZYMOL, V231, P496; BISMUTO E, 1989, BIOCHEMISTRY-US, V28, P1508, DOI 10.1021/bi00430a013; BISMUTO E, 1994, J MOL BIOL, V241, P103, DOI 10.1006/jmbi.1994.1477; BOTELHO LH, 1978, BIOCHEMISTRY-US, V17, P5197, DOI 10.1021/bi00617a020; BOTELHO LH, 1978, BIOCHEMISTRY-US, V17, P5188, DOI 10.1021/bi00617a019; BUNN HF, 1967, J BIOL CHEM, V243, P465; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GRATTON E, 1986, PROGR CHALLENGE NATU; GRYCZYNSKI Z, 1993, BIOPHYS CHEM, V48, P31, DOI 10.1016/0301-4622(93)80039-L; GRYCZYNSKI Z, 1993, PHOTOCHEM PHOTOBIOL, V58, P492, DOI 10.1111/j.1751-1097.1993.tb04920.x; GRYCZYNSKI Z, 1993, BIOPHYS J, V65, P1951, DOI 10.1016/S0006-3495(93)81266-9; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; HARGROVE MS, 1994, BIOCHEMISTRY-US, V30, P11767; HOCHSTRASSER RM, 1984, P NATL ACAD SCI-BIOL, V81, P4399, DOI 10.1073/pnas.81.14.4399; IRACE G, 1986, ARCH BIOCHEM BIOPHYS, V244, P459, DOI 10.1016/0003-9861(86)90614-4; JANES SM, 1987, BIOPHYS J, V51, P653, DOI 10.1016/S0006-3495(87)83390-8; JUE T, 1983, J AM CHEM SOC, V105, P6395; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LAKOWICZ JR, 1987, BIOPHYS CHEM, V28, P35, DOI 10.1016/0301-4622(87)80073-X; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LAMAR GN, 1983, J MOL BIOL, V168, P887, DOI 10.1016/S0022-2836(83)80080-1; LIGHT WR, 1987, J BIOL CHEM, V262, P46; LIVINGSTON DJ, 1984, J AM CHEM SOC, V106, P3025, DOI 10.1021/ja00322a043; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P241, DOI 10.1111/j.1432-1033.1991.tb16007.x; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; WILLIS KJ, 1990, BIOCHEMISTRY-US, V29, P5270, DOI 10.1021/bi00474a008	36	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19232	19237		10.1074/jbc.270.33.19232	http://dx.doi.org/10.1074/jbc.270.33.19232			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642594	hybrid			2022-12-27	WOS:A1995RP70300008
J	NAKSHATRI, H; NAKSHATRI, P; CURRIE, RA				NAKSHATRI, H; NAKSHATRI, P; CURRIE, RA			INTERACTION OF OCT-1 WITH TFIIB - IMPLICATIONS FOR A NOVEL RESPONSE ELICITED THROUGH THE PROXIMAL OCTAMER SITE OF THE LIPOPROTEIN-LIPASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; TATA-BINDING PROTEIN; HEAVY-CHAIN PROMOTER; TYPE-1 TRANSACTIVATOR VMW65; POU-SPECIFIC DOMAIN; NF-KAPPA-B; DNA-BINDING; ACTIVATION DOMAIN; GENE-TRANSCRIPTION	The ubiquitous human POU domain protein, Oct-1, and the related B-cell protein, Oct-2, regulate transcription from a variety of eukaryotic genes by binding to a common cis-acting octamer element, 5'-ATTTGCAT-3'. The binding of Oct-1 and Oct-2 to the functionally important lipoprotein lipase (LPL) promoter octamer site was stimulated by the general transcription factor, TFIIB. Comparative analysis of the LPL, histone H2B (H2B), and herpes simplex virus ICPO gene promoter octamer sites revealed that nucleotide sequences within and flanking the octamer sequence determined the degree of TFII-mediated stimulation of Oct-1 DNA binding. TFIIB was found to decrease the rate of dissociation of Oct-1 from the LPL octamer site, whereas it increased the rate of association, as well as decreased the rate of dissociation, of Oct-1 from the H2B octamer site. A monoclonal antibody against TFIIB immunoprecipitated a ternary complex containing TFIIB, Oct-1, and the LPL and H2B octamer binding sites. TFIIB did not alter the DNase I footprints generated by Oct-1 on the LPL and H2B promoters. However, Oct-1 prevented TATA-binding protein and TFIIB from footprinting the perfect TATA box sequence located 5' of the LPL NF-Y binding site. In transfection experiments, transcription from reporters containing the LPL octamer, and either the SV40 or the yeast transcription factor GAL4-dependent enhancers, initiated at a precise position within the octamer sequence. Transcription from reporters containing the H2B octamer and the SV40 enhancer initiated at several positions within and flanking the octamer site, whereas transcription initiated at a precise position within the octamer from reporters with both the H2B octamer and the GAL4-dependent enhancer. These results suggest that octamers and their flanking sequences play an important role in positioning the site of transcription initiation, and that this could be a function of the interaction of Oct-1 with TFIIB.	PICOWER INST MED RES, GENE REGULAT LAB, MANHASSET, NY 11030 USA	Northwell Health			Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326; Nakshatri, Harikrishna/0000-0001-8876-0052	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047272, R01DK047272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Ausubel FM, 1988, MOL REPROD DEV; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; Flint S. J, 1981, DNA TUMOR VIRUSES; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; ING NH, 1992, J BIOL CHEM, V267, P17617; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEID M, 1994, J BIOL CHEM, V269, P14175; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PREVIATO L, 1991, J BIOL CHEM, V266, P18958; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, COLD SPRING HARB SYM, V56, P285; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	103	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19613	19623		10.1074/jbc.270.33.19613	http://dx.doi.org/10.1074/jbc.270.33.19613			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642649	hybrid, Green Submitted			2022-12-27	WOS:A1995RP70300065
J	RYAN, MG; RATNAM, K; HILLE, R				RYAN, MG; RATNAM, K; HILLE, R			THE MOLYBDENUM CENTERS OF XANTHINE-OXIDASE AND XANTHINE DEHYDROGENASE - DETERMINATION OF THE SPECTRAL CHANGE ASSOCIATED WITH REDUCTION FROM THE MO(VI) TO THE MO(IV) STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HALF-REACTION; MECHANISM; INACTIVATION	The UV-visible absorbance change associated with reduction of the molybdenum centers of xanthine oxidase and xanthine dehydrogenase has been determined using a double-difference technique, At pH 8.5, the Mo(VI) minus Mo(IV) difference spectrum seen with xanthine oxidase exhibits a positive feature at 420 nm, having an extinction change of similar to 3,000 M(-1) cm(-1) as well as evidence for a negative feature below 340 nm, In xanthine oxidase this change is found to exhibit a marked pH dependence, implicating protonation/deprotonation events associated with changes in the molybdenum oxidation state, Application of the double-difference protocol to the respective circular dichroism spectra of xanthine oxidase and xanthine dehydrogenase reveals appreciable CD changes at 420 and 580 nm associated with the reduction of the molybdenum center. The present results demonstrate a direct spectroscopic handle on the molybdenum centers of both xanthine oxidase and xanthine dehydrogenase.			RYAN, MG (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.							BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; CRAMER SP, 1985, CHEM BIOL MOLYBDENUM, P411; DAVIS MD, 1982, J BIOL CHEM, V257, P4730; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1995, IN PRESS FASEB J; HUNT J, 1994, J BIOL CHEM, V269, P18904; KIM JH, 1993, J BIOL CHEM, V268, P44; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MORRISON M, 1963, J BIOL CHEM, V238, P2847; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V29, P4363; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; STEIFEL EI, 1977, PROG INORG CHEM, V21, P1	25	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19209	19212		10.1074/jbc.270.33.19209	http://dx.doi.org/10.1074/jbc.270.33.19209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642590				2022-12-27	WOS:A1995RP70300004
J	SUN, Y; HEGAMYER, G; KIM, HT; SITHANANDAM, K; LI, H; WATTS, R; COLBURN, NH				SUN, Y; HEGAMYER, G; KIM, HT; SITHANANDAM, K; LI, H; WATTS, R; COLBURN, NH			MOLECULAR-CLONING OF MOUSE-TISSUE INHIBITOR OF METALLOPROTEINASES-3 AND ITS PROMOTER - SPECIFIC LACK OF EXPRESSION IN NEOPLASTIC JB6 CELLS MAY REFLECT ALTERED GENE METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; POINT MUTATION; MESSENGER-RNA; PHORBOL ESTER; BINDING-SITE; LIVER CELLS; HA-RAS; TRANSFORMATION; P53	Mouse tissue inhibitor of metalloproteinases-3 (mTIMP-3), a gene specifically not expressed in neoplastic JB6 cells, has been isolated recently through the use of the mRNA differential display technique (Sun, Y., Hegamyer, G., and Colburn, N. H. (1994) Cancer Res. 54, 1139-1144). We report here the full-length mTIMP-3 cDNA sequence, the promoter sequence and partial characterization, expression and induction of TIMP-3, and the possible molecular basis for the lack of mTIMP-3 expression in neoplastic JB6 cells. There are three transcripts arising from alternative polyadenylation of mouse TIMP-3 gene, having sizes of 4.6, 2.8, and 2.3 kilobase pairs, respectively. All three TIMP-3 transcripts are expressed in preneoplastic but not neoplastic JB6 cells. Computer analysis of cloned TIMP-3 promoter revealed six AP-1 binding sites, two NF-kappa B sites, a c-Myc site, and two copies of a p53 binding motif separated by eight base pairs with two mismatches at the second motif, along with many other cis elements, TIMP-3 gene expression was inducible by AP-1 and NF-kappa B activators, 12-O-tetradecanoylphorbol-13-acetate, and tumor necrosis factor-alpha only in preneoplastic cells with an induction peak at 2 h post-treatment, suggesting classification of mTIMP-3 as a member of the immediate early gene family. Southern blot, mutational analysis, and transient transcriptional activation experiments revealed that the lack of expression of mTIMP-3 in neoplastic JB6 cells was due neither to gross deletion nor to promoter mutation of the gene, nor was there a lack of transcription factors required for transcriptional activation. Instead, the lack of TIMP-3 expression in neoplastic JB6 cells may reflect an abnormal methylation of the gene. Both hyper- and hypomethylation of the mTIMP-3 gene are associated with complete down-regulation of gene expression in neoplastic JB6 cell lines. Treatment of neoplastic cells with the methylase inhibitor 5-azacytidine caused reexpression of the mTIMP-3 gene in a tumor cell line that showed hypermethylation but not in another that showed hypomethylation of the gene, suggesting a complex role for methylation in the silencing of gene expression.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,CELL BIOL SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,DYN CORP,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS & DEV P,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SUN, Y (corresponding author), PARKE DAVIS PHARMACEUT RES,DEPT CANC RES,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTS SS, 1994, DEV DYNAM, V200, P177; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; BIRKEDALHANSEN H, 1992, CRIT REV ORAL BIOL M, V4, P197; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DARNELL J, 1990, MOL CELL BIOL, P639; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DIBENEDETTI F, 1990, MOL CELL BIOL CYTOKI, P275; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GALLOWAY DA, 1983, NATURE, V301, P21; Gindhart T D, 1985, Carcinog Compr Surv, V8, P341; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JONES PA, 1991, CANCER RES, V51, P3617; Jones PA, 1984, DNA METHYLATION BIOC, P165; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; KHOKHA R, 1989, INVAS METAST, V9, P391; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P444; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; SUN Y, 1993, CARCINOGENESIS, V14, P1505, DOI 10.1093/carcin/14.8.1505; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1995, ONCOGENE, V10, P785; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SUN Y, 1993, BIOTECHNIQUES, V15, P372; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1995, CANCER EPIDEM BIOMAR, V4, P261; SUN Y, 1992, BIOTECHNIQUES, V12, P639; SUN Y, 1995, INT J ONCOL, V6, P465; URIA JA, 1994, CANCER RES, V54, P2091; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WICK M, 1994, J BIOL CHEM, V269, P17953; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	59	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19312	19319		10.1074/jbc.270.33.19312	http://dx.doi.org/10.1074/jbc.270.33.19312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642607	hybrid			2022-12-27	WOS:A1995RP70300021
J	XU, X; ZHAO, H; DIAZ, J; MUALLEM, S				XU, X; ZHAO, H; DIAZ, J; MUALLEM, S			REGULATION OF [NA+](I) IN RESTING AND STIMULATED SUBMANDIBULAR SALIVARY DUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MANDIBULAR GLANDS; RAT SUBMAXILLARY GLAND; NA+-H+ EXCHANGE; ELECTROLYTE TRANSPORT; K/H EXCHANGE; ACINAR-CELLS; MAIN DUCT; COTRANSPORT; EPITHELIUM; MECHANISM	In the preceding manuscript (Zhao, H., Xu, X., Diaz, J., and Muallem, S. (1995) J. Biol. Chem. 270, 19599-19605), we described a K-out(+)-dependent H+/HCO3- and Na+ influx pathway in the luminal membrane of salivary duct cells. In the present studies, we further characterized this pathway to show that the K-out(+)-dependent Na+ influx was not mediated by the luminal amiloride-sensitive Na+ channel, the Na+/H+ exchangers, or any electroneutral or conductive Cl--dependent transport pathway. Thus, K+ efflux probably maintained electroneutrality during Na+ influx induced by removal of K-out(+). Accordingly, Na+ influx was largely inhibited by 2.5 mM external Ba2+. The K+ site of the K-out(+)-dependent Na+ influx showed the selectivity sequence Cs+ > K+ > NH4+ >> > Li+ which is different from that of several known K+ channels. More importantly, Na+ influx is 50% inhibited at about 20 mM K-out(+), and significant Na+ influx occurred even at 80 mM K-out(+). This is a critical property for the pathway to play a role in Na+ reabsorption and K+ secretion by the duct. The large Na+ influx in resting duct cells is matched by high activity of the ductal Na+ pump which is about 8-fold faster than that of acinar cells. Stimulation of submandibular ducts with various agonists increased [Na+](i) in an agonist-specific manner. The parasympathetic agonist epinephrine was more effective than isoproterenol and the sympathetic agonist carbachol. The use of various inhibitors of Na+ and K+ transporters suggests that different pathways mediate Na+ influx in stimulated acinar and duct cells of the gland. In duct cells, Na+ influx was inhibited only by extracellular Cs+ and Ba2+. The overall findings support a significant role for the K-out(+)-dependent pathway(s) in Na+ reabsorption and K+ and HCO3- secretion and explain several features of transepithelial electrolyte transport by salivary ducts.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 36591, DK 38938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1987, J GEN PHYSIOL, V90, P209, DOI 10.1085/jgp.90.2.209; AUGUSTUS J, 1977, NATURE, V268, P657, DOI 10.1038/268657a0; BIJMAN J, 1983, PFLUG ARCH EUR J PHY, V398, P96, DOI 10.1007/BF00581055; BONANNO JA, 1991, AM J PHYSIOL, V260, pC618, DOI 10.1152/ajpcell.1991.260.3.C618; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; COMPTON JS, 1980, J PHYSIOL-LONDON, V309, P429, DOI 10.1113/jphysiol.1980.sp013518; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN J, 1988, J BIOL CHEM, V263, P5012; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HOFER AM, 1992, J MEMBRANE BIOL, V126, P245; KNAUF H, 1982, AM J PHYSIOL, V242, pF132, DOI 10.1152/ajprenal.1982.242.2.F132; KNAUF H, 1976, EUR J CLIN INVEST, V6, P43, DOI 10.1111/j.1365-2362.1976.tb00492.x; KNAUF H, 1975, PFLUG ARCH EUR J PHY, V361, P55, DOI 10.1007/BF00587339; KNAUF H, 1972, PFLUG ARCH EUR J PHY, V333, P82, DOI 10.1007/BF00586044; MANGOS JA, 1966, PFLUG ARCH GES PHYS, V291, P99, DOI 10.1007/BF00362655; MARTIN CJ, 1971, PFLUG ARCH EUR J PHY, V327, P303, DOI 10.1007/BF00588450; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; SCHNEYER LH, 1969, AM J PHYSIOL, V217, P1324, DOI 10.1152/ajplegacy.1969.217.5.1324; SCHNEYER LH, 1968, AM J PHYSIOL, V215, P664, DOI 10.1152/ajplegacy.1968.215.3.664; WALL SM, 1988, AM J PHYSIOL, V255, pF331, DOI 10.1152/ajprenal.1988.255.2.F331; YOUNG JA, 1967, PFLUG ARCH GES PHYS, V295, P157, DOI 10.1007/BF00362747; YOUNG JA, 1966, PFLUG ARCH GES PHYS, V291, P85, DOI 10.1007/BF00362654; YOUNG JA, 1970, PFLUG ARCH EUR J PHY, V319, P185, DOI 10.1007/BF00586449; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599; [No title captured]	31	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19606	19612		10.1074/jbc.270.33.19606	http://dx.doi.org/10.1074/jbc.270.33.19606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642648	hybrid			2022-12-27	WOS:A1995RP70300064
J	YOKOMIZO, A; KOHNO, K; WADA, M; ONO, M; MORROW, CS; COWAN, KH; KUWANO, M				YOKOMIZO, A; KOHNO, K; WADA, M; ONO, M; MORROW, CS; COWAN, KH; KUWANO, M			MARKEDLY DECREASED EXPRESSION OF GLUTATHIONE-S-TRANSFERASE-PI GENE IN HUMAN CANCER CELL-LINES RESISTANT TO BUTHIONINE SULFOXIMINE, AN INHIBITOR OF CELLULAR GLUTATHIONE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CANCER; DNA TOPOISOMERASE-II; ELECTROPHILE-RESPONSIVE ELEMENT; YA-SUBUNIT GENE; CHEMICAL CARCINOGENS; NUCLEOTIDE-SEQUENCE; DRUG ACCUMULATION; ALKYLATING-AGENTS; ESCHERICHIA-COLI; MESSENGER-RNA	Buthionine sulfoximine (BSO) is a synthetic amino acid that irreversibly inhibits an enzyme, gamma-glutamyl-cysteine synthetase (gamma-GCS), which is a critical step in glutathione biosynthesis. We isolated three BSO-resist ant sublines, KB/BSO1, KB/BSO2, and KB/BSO3, from human epidermoid cancer KB cells. These cell lines showed 10-to 13-fold higher resistance to BSO, respectively, and had collateral sensitivity to cisplatin, ethacrynic acid, and alkylating agents such as melphalan and nitrosourea. Cellular levels of glutathione S-transferase pi (GST-pi) and its mRNA in BSO-resistant cell lines were less than 10% of the parental cells, Nuclear run-on assay showed that the transcriptional activity of GST-pi was decreased in BSO-resistant cells, and transient transfection of GST-pi promoter-chloramphenicol acetyltransferase constructs revealed that the sequences between -130 and -80 base pairs of the 5'-flanking region were at least partially responsible for the decreased expression of the GST-pi gene. By contrast, gamma-GCS mRNA levels were 3-to 5-fold higher in resistant cell lines than in KB cells, and the gamma-GCS gene was found to be amplified in the BSO-resistant cell lines. GST-pi mRNA levels appeared to be inversely correlated with gamma-GCS mRNA levels in BSO-resistant cells. We further established the transfectants, KB/BSO3-pi 1 and KB/BSO3-pi 2, that overexpressed GST-pi; from KB/BSO3, after introducing a GST-pi expression plasmid. These two transfectants had similar levels in gamma-GCS mRNA, drug sensitivity to alkylating agents, and glutathione content as those of KB cells. These findings suggest that the cellular levels of GST-pi and gamma-GCS might be co-regulated in these novel BSO-resistant cells.	KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81282, JAPAN; WAKE FOREST UNIV, MED CTR, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; NCI, MED BRANCH, BETHESDA, MD 20892 USA	Kyushu University; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABE H, 1994, ANTICANCER RES, V14, P1807; AHOKAS JT, 1985, BIOCHEM PHARMACOL, V34, P2157, DOI 10.1016/0006-2952(85)90411-3; ALIOSMAN F, 1989, CANCER RES, V49, P5258; ARRICK BA, 1984, CANCER RES, V44, P4224; BATIST G, 1986, J BIOL CHEM, V261, P5544; BEHRENS BC, 1987, CANCER RES, V47, P414; BERGELSON S, 1994, CANCER RES, V54, P36; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHU G, 1994, J BIOL CHEM, V269, P787; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOODSPEED DC, 1989, GENE, V76, P1, DOI 10.1016/0378-1119(89)90002-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JA, 1984, CANCER RES, V44, P5427; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JELINEK J, 1988, CARCINOGENESIS, V9, P81, DOI 10.1093/carcin/9.1.81; KANO T, 1987, CANCER RES, V47, P5626; KATAOKA H, 1986, EMBO J, V5, P3195, DOI 10.1002/j.1460-2075.1986.tb04629.x; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1994, J BIOL CHEM, V269, P20503; KOTOH S, 1994, CANCER RES, V54, P3248; LOUIE KG, 1985, CANCER RES, V45, P2110; MATSUO K, 1990, CANCER RES, V50, P5819; MATSUO K, 1993, CANCER RES, V53, P1085; MEISTER A, 1979, CANCER TREAT REP, V63, P1115; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A., 1988, MECHANISMS DRUG RESI, P99; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; MORIMURA S, 1992, CELL GROWTH DIFFER, V3, P685; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; NAKAGAWA M, 1993, J UROLOGY, V150, P1970, DOI 10.1016/S0022-5347(17)35948-7; ODWYER PJ, 1992, J NATL CANCER I, V84, P264, DOI 10.1093/jnci/84.4.264; OKUYAMA T, 1994, CANCER, V74, P1230, DOI 10.1002/1097-0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; OZOLS RF, 1987, BIOCHEM PHARMACOL, V36, P147, DOI 10.1016/0006-2952(87)90392-3; OZOLS RF, 1988, MECHANISMS DRUG RESI, P289; RELLESOMFAI S, 1984, BIOCHEM PHARMACOL, V33, P485; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SABURI Y, 1989, CANCER RES, V49, P7020; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1989, ADV CANCER RES, V52, P205; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; TAKANO H, 1991, CANCER RES, V51, P3951; TEW KD, 1994, CANCER RES, V54, P4313; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	60	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19451	19457		10.1074/jbc.270.33.19451	http://dx.doi.org/10.1074/jbc.270.33.19451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642628	hybrid			2022-12-27	WOS:A1995RP70300042
J	FUKUYAMA, K; KUNISHIMA, N; AMADA, F; KUBOTA, T; MATSUBARA, H				FUKUYAMA, K; KUNISHIMA, N; AMADA, F; KUBOTA, T; MATSUBARA, H			CRYSTAL-STRUCTURES OF CYANIDE-BOUND AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES-RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES - PERTURBATIONS OF ACTIVE-SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COPRINUS-CINEREUS PEROXIDASE; X-RAY-DIFFRACTION; LIGNIN PEROXIDASE; CRYSTALLOGRAPHIC REFINEMENT; PHANEROCHAETE-CHRYSOSPORIUM; HORSERADISH-PEROXIDASE; WEISSENBERG CAMERA; RESTING STATE; RESOLUTION	The structures of the cyanide and triiodide complexes of Arthromyces ramosus peroxidase (ARP) at different pH values were investigated by x-ray crystallography in order to examine the behavior of the invariant residues of arginine (Arg-52) and distal histidine (His-56) during the enzyme reaction as well as to provide the structural basis of the active site of peroxidase. The models of the cyanide complexes at pH 7.5, 5.0, and 4.0, respectively, were refined to the R-factors of 17.8, 17.8, and 18.5% using 7.0-1.6-Angstrom resolution data, and those of the triiodide complexes at pH 6.5 and 5.0 refined to 16.9 and 16.8% using 7.0-1.9-Angstrom resolution data. The structures of the cyanide complexes at pH 7.5, 5.0, and 4.0 are identical within experimental error. Cyanide ion bound to the heme in the bent conformation rather than in the tilt conformation. Upon cyanide ion binding, the N-epsilon atom of His-56 moved toward the ion by rotation of the imidazole ring around the C-beta-C-gamma bond, but there was little conformational change in the remaining residues. The distance between the N-epsilon atom of His-56 and the nitrogen atom of the cyanide suggests the presence of a hydrogen bond between them in the pH range investigated. In the triiodide complexes, one of the two triiodides bound to ARP was located at the distal side of the heme. When triiodide bound to ARP, unlike the rearrangement of the distal arginine of cytochrome c peroxidase that occurs on formation of the fluoride complex or compound I, the side chain of Arg-52 moved little. The conformation of the side chain of His-56, however, changed markedly, Conformational flexibility of His-56 appears to be a requisite for proton translocation from one oxygen atom to the other of HOO- by acid-base catalysis to produce compound I. The iron atom in each cyanide complex (low-spin ferric) is located in the heme plane, whereas in each triiodide complex (high-spin ferric) the iron atom is displaced from the plane about 0.2 Angstrom toward the proximal side.			FUKUYAMA, K (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		Kunishima, Naoki/N-7464-2015; Kubota, Tomomi/J-1492-2018	Kubota, Tomomi/0000-0002-0723-135X; Kunishima, Naoki/0000-0001-9826-9902				AKIMOTO K, 1990, ANAL BIOCHEM, V189, P182, DOI 10.1016/0003-2697(90)90104-H; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BANCI L, 1991, P NATL ACAD SCI USA, V88, P6956, DOI 10.1073/pnas.88.16.6956; BAUNSGAARD L, 1993, EUR J BIOCHEM, V213, P605, DOI 10.1111/j.1432-1033.1993.tb17800.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR 3 0; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KUNISHIMA N, 1993, PROTEINS, V15, P216, DOI 10.1002/prot.340150213; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LUKAT GS, 1989, BIOCHEMISTRY-US, V28, P3338, DOI 10.1021/bi00434a032; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MORITA Y, 1988, J BIOCHEM-TOKYO, V103, P693, DOI 10.1093/oxfordjournals.jbchem.a122331; NEYA S, 1993, J BIOL CHEM, V268, P8935; PEDERSEN AH, 1994, 13TH INT S LIF SCI K, P24; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SATTERLEE JD, 1991, BIOCHEMISTRY-US, V30, P4398, DOI 10.1021/bi00232a005; SAWAIHATANAKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1221, DOI 10.1271/bbb.59.1221; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; VEITCH NC, 1994, EUR J BIOCHEM, V222, P909, DOI 10.1111/j.1432-1033.1994.tb18939.x; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]	38	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21884	21892		10.1074/jbc.270.37.21884	http://dx.doi.org/10.1074/jbc.270.37.21884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665612	hybrid			2022-12-27	WOS:A1995RU75700072
J	LEE, SH; KIM, DK; DRISSI, R				LEE, SH; KIM, DK; DRISSI, R			HUMAN XERODERMA-PIGMENTOSUM GROUP-A PROTEIN INTERACTS WITH HUMAN REPLICATION PROTEIN-A AND INHIBITS DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; SV40 T-ANTIGEN; A COMPLEMENTING PROTEIN; BINDING-PROTEIN; POLYMERASE-ALPHA; EXCISION REPAIR; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; INVITRO	Human replication protein A (RPA; also known as human single-stranded DNA binding protein, or HSSB) is a multisubunit complex involved in both DNA replication and repair. While the role of RPA in replication has been well studied, its function in repair is less clear, although it is known to be involved in the early stages of the repair process. We found that RPA interacts with xeroderma pigmentosum group A complementing protein (XPAC), a protein that specifically recognizes UV-damaged DNA. We examined the effect of this XPAC-RPA interaction on in vitro simian virus 40 (SV40) DNA replication catalyzed by the monopolymerase system. XPAC inhibited SV40 DNA replication in vitro, and this inhibition was reversed by the addition of RPA but not by the addition of DNA polymerase alpha-primase complex, SV40 large tumor antigen, or topoisomerase I. This inhibition did not result from an interaction between XPAC and single-stranded DNA (ssDNA), or from competition between RPA and XPAC for DNA binding, because XPAC does not show any ssDNA binding activity and, in fact, stimulates RPA's ssDNA binding activity. Furthermore, XPAC inhibited DNA polymerase alpha activity in the presence of RPA but not in RPA's absence. These results suggest that the inhibitory effect of XPAC on DNA replication probably occurs through its interaction with RPA.	UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	LEE, SH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38101 USA.				NCI NIH HHS [5P30 CA 21765-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069	43	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21800	21805		10.1074/jbc.270.37.21800	http://dx.doi.org/10.1074/jbc.270.37.21800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665601	hybrid			2022-12-27	WOS:A1995RU75700060
J	SMITH, KE; FISHER, MT				SMITH, KE; FISHER, MT			INTERACTIONS BETWEEN THE GROE CHAPERONINS AND RHODANESE - MULTIPLE INTERMEDIATES AND RELEASE AND REBINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CAVITY; PROTEINS; POLYPEPTIDE; BINDS; DNAJ	Efficient renaturation of urea-denatured rhodanese using the chaperonin GroE system requires GroEL, GroES, and ATP. At high concentrations this renaturation also requires the substrate thiosulfate to have been present during GroEL-rhodanese complex formation. When thiosulfate is present the GroEL rhodanese complex can be concentrated to greater than 1 mg/ml. rhodanese with little effect on the efficiency of renaturation. However, if complex is formed in the absence of thiosulfate, renaturation of rhodanese in the presence of thiosulfate shows a critical concentration of approximately 0.4 mg/ml, above which renaturation yields drop dramatically, This critical concentration appears to be related to an aggregation event in the refolding of rhodanese. The nucleotide free or ADP-bound form of GroEL also binds to rhodanese that has been either already renatured or never denatured, The bound rhodanese has no activity but can be released from GroEL with ATP recovering 90% of control activity, The data presented herein support a release and rebinding mechanism for the GroE-assisted refolding of rhodanese. It also suggests GroEL binds several protein folding intermediates along the entire refolding pathway.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1993, SCIENCE, V260, P1902; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; DILL KA, 1993, P NATL ACAD SCI USA, V90, P1942, DOI 10.1073/pnas.90.5.1942; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FISHER MT, 1994, J BIOL CHEM, V269, P16329; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZOA JA, 1992, J BIOL CHEM, V266, P16973; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; SCMIDT M, 1994, J BIOL CHEM, V269, P10304; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Westley J, 1981, Methods Enzymol, V77, P285; WIESSMAN JS, 1994, CELL, V78, P693	34	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21517	21523		10.1074/jbc.270.37.21517	http://dx.doi.org/10.1074/jbc.270.37.21517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665563	hybrid			2022-12-27	WOS:A1995RU75700018
J	LAZAR, DF; WIESE, RJ; BRADY, MJ; MASTICK, CC; WATERS, SB; YAMAUCHI, K; PESSIN, JE; CUATRECASAS, P; SALTIEL, AR				LAZAR, DF; WIESE, RJ; BRADY, MJ; MASTICK, CC; WATERS, SB; YAMAUCHI, K; PESSIN, JE; CUATRECASAS, P; SALTIEL, AR			MITOGEN-ACTIVATED PROTEIN-KINASE KINASE INHIBITION DOES NOT BLOCK THE STIMULATION OF GLUCOSE-UTILIZATION BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MAP KINASE; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; OKADAIC ACID; PHOSPHATASE INHIBITOR; GLYCOGEN-SYNTHASE; PHOSPHORYLATION; RAS	Insulin stimulates the activity of mitogen-activated protein kinase (MAPK) via its upstream activator, MAPK kinase (MEK), a dual specificity kinase that phosphorylates MAPK on threonine and tyrosine. The potential role of MAPK activation in insulin action was investigated with the specific MEK inhibitor PD98059. Insulin stimulation of MAPK activity in 3T3-L1 adipocytes (2.7-fold) and L6 myotubes (1.4-fold) was completely abolished by pretreatment of cells with the MER inhibitor, as was the phosphorylation of MAPK and pp90(Rsk), and the transcriptional activation of c-fos. Insulin receptor autophosphorylation on tyrosine residues and activation of phosphatidylinositol 3'-kinase were unaffected. Pretreatment of cells with PD98059 had no effect on basal and insulin stimulated glucose uptake, lipogenesis, and glycogen synthesis. Glycogen synthase activity in extracts from 3T3-L1 adipocytes and L6 myotubes was increased 3-fold and 1.7-fold, respectively, by insulin. Pretreatment with 10 mu M PD98059 was without effect. Similarly, the 2-fold activation of protein phosphatase 1 by insulin was insensitive to PD98059. These results indicate that stimulation of the MAPK pathway by insulin is not required for many of the metabolic activities of the hormone in cultured fat and muscle cells.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Pfizer; University of Iowa			Saltiel, Alan/L-3632-2019; Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				BALLOU LM, 1990, NATURE, V349, P348; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAWRENCE JC, 1977, J BIOL CHEM, V252, P444; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, NEURON, V9, P767; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PANG L, 1994, J BIOL CHEM, V269, P10604; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REESJONES R, 1985, J BIOL CHEM, V240, P4461; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROLBAND GC, 1993, ENDOCRINOLOGY, V133, P1437, DOI 10.1210/en.133.3.1437; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUNG CK, 1991, J CELL BIOCHEM, V48, P1; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANTI JF, 1991, J BIOL CHEM, V266, P2099; THOMAS G, 1992, BIOCHEM SOC T, V20, P679; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WEISE RJ, 1995, J BIOL CHEM, V270, P3442; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	62	331	336	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20801	20807		10.1074/jbc.270.35.20801	http://dx.doi.org/10.1074/jbc.270.35.20801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657664	hybrid			2022-12-27	WOS:A1995RR58400085
J	TATE, BF; GRIPPO, JF				TATE, BF; GRIPPO, JF			MUTAGENESIS OF THE LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR-ALPHA IDENTIFIES CRITICAL RESIDUES FOR 9-CIS-RETINOIC ACID-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTORS; ACTIVATION; SUPERFAMILY; PROTEINS; GENES	We have recently identified a small region (amino acids 405-419) within the ligand binding domain of a truncated human retinoic acid receptor alpha (Delta 419) that is required for binding of g-cis-retinoic acid (RA), but not all-trans-retinoic acid (t-RA). To probe the structural determinants of this high affinity 9-cis-RA binding site, a series of Delta 419 mutants were prepared whereby an individual alanine residue was substituted for each amino acid within this region. These modified receptors were expressed in mammalian COS-1 cells and assayed for their ability to bind 9-cis-RA as well as t-RA. Only two of the mutants, M406A (mutation of methionine 406 to alanine), and I410A (mutation of isoleucine 410 to alanine) exhibit no detectable binding of 9-cis-RA when analyzed using saturation binding kinetics. Substitution of methionine 406 with the amino acids leucine, isoleucine, and valine yields mutant receptors that exhibit decreased binding for 9-cis-RA as the length or hydrophobicity of the R group decreases. Further substitution of methionine 406 with the small polar amino acid, threonine, results in a loss of detectable 9-cis-RA binding. Since amino acids 405-419 on a human RAR alpha (hRAR alpha) are predicted to form a short amphipathic alpha-helix, modeling of this structure into a helical wheel indicates that these two amino acids, methionine 406 and isoleucine 410, are actually positioned proximal to each other. Data presented here suggest that high affinity 9-cis-RA binding to a hRAR alpha depends on an interaction with the two amino acids methionine 406 and isoleucine 410.	HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110	Roche Holding								ADEYEMO O, 1993, HUM MOL GENET, V2, P1809, DOI 10.1093/hmg/2.11.1809; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MORRISSKAY G, 1992, RETINOIDS NORMAL DEV; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1994, TRENDS ENDOCRIN MET, V5, P189, DOI 10.1016/1043-2760(94)90076-0; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20258	20263		10.1074/jbc.270.35.20258	http://dx.doi.org/10.1074/jbc.270.35.20258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657595	hybrid			2022-12-27	WOS:A1995RR58400007
J	KUNKEL, T; SPETH, V; BUCHE, C; SCHAFER, E				KUNKEL, T; SPETH, V; BUCHE, C; SCHAFER, E			IN-VIVO CHARACTERIZATION OF PHYTOCHROME-PHYCOCYANOBILIN ADDUCTS IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE GENE; AVENA-SATIVA L; ELECTRON-MICROSCOPY; BETA-GLUCURONIDASE; FUSION MARKER; ARABIDOPSIS; EXPRESSION; PROTEIN; INVIVO; APOPHYTOCHROME	The in vivo reconstitution of phycocyanobilin with apophytochrome leads to photoreversible adducts in living yeast cells. Investigations with the rice phytochrome A phycocyanobilin adduct (PHYA*) and the tobacco phytochrome B phycocyanobilin adduct (PHYB*) show that the protein stability in yeast is independent of the form of the photoreceptor. After in vivo assembly and irradiation with red light, 25.6% of the far-red light-absorbing form of PHYB* exhibited dark reversion with a half-life time of approximately 20 min. Control experiments with PHYA* revealed no dark reversion, The data indicate that the molecular basis for this reaction is the formation of heterodimers between the red and the far-red light absorbing form of phytochrome. Electron microscopic in situ localizations and in, vitro sequestering experiments showed that phytochrome A was able to sequester in yeast, On the electron microscopic level, the sequestered areas of phytochrome from etiolated plants and yeast are indistinguishable, The sequestering reaction in yeast is independent of the formation of the far-red light absorbing form of phytochrome, Therefore, we discuss a new model for this reaction in plant. Since it is unlikely that yeast cells contain elements that distinguish between phytochrome A and B, we conclude that sequestering and dark reversion reflect intrinsic properties of phytochrome.	UNIV FREIBURG,INST BIOL 2,D-79104 FREIBURG,GERMANY	University of Freiburg								ABE A, 1988, AGR BIOL CHEM TOKYO, V52, P2035; BORTHWICK HA, 1964, AM NAT, V902, P347; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROCKMANN J, 1987, PLANT CELL ENVIRON, V10, P105, DOI 10.1111/1365-3040.ep11602037; BUTLER WL, 1963, PLANT PHYSIOL, V38, P514, DOI 10.1104/pp.38.5.514; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DEHESH K, 1993, PLANT CELL, V5, P1081, DOI 10.1105/tpc.5.9.1081; DONALD RGK, 1990, EMBO J, V9, P1727, DOI 10.1002/j.1460-2075.1990.tb08296.x; FROHNMEYER H, 1992, PLANT J, V2, P899, DOI 10.1111/j.1365-313X.1992.00899.x; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HILLMAN WS, 1964, AM J BOT, V51, P1102, DOI 10.2307/2439958; HOFMANN E, 1991, PLANTA, V183, P265, DOI 10.1007/BF00197798; JACOBS E, 1986, ANAL BIOCHEM, V155, P583; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; KAISER T, 1995, PLANT MOL BIOL, V28, P219, DOI 10.1007/BF00020242; KAISER T, 1995, PLANT MOL BIOL, V28, P231, DOI 10.1007/BF00020243; KAY SA, 1989, NUCLEIC ACIDS RES, V17, P2865, DOI 10.1093/nar/17.7.2865; KEIZER I, 1992, FEMS MICROBIOL LETT, V93, P7, DOI 10.1016/0378-1097(92)90481-3; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KERN R, 1993, PLANT PHYSIOL, V102, P1363, DOI 10.1104/pp.102.4.1363; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; LI LM, 1994, P NATL ACAD SCI USA, V91, P12535, DOI 10.1073/pnas.91.26.12535; LI LM, 1992, J BIOL CHEM, V267, P19204; MARME D, 1971, PLANTA, V100, P331, DOI 10.1007/BF00385197; MCCURDY DW, 1986, J CELL BIOL, V103, P2541, DOI 10.1083/jcb.103.6.2541; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PARDEKOOPER M, 1994, PHOTOCHEM PHOTOBIOL, V59, P161; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PIKE CS, 1972, PLANT PHYSIOL, V49, P514, DOI 10.1104/pp.49.4.514; QUAIL PH, 1978, PLANT PHYSIOL, V62, P773, DOI 10.1104/pp.62.5.773; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; SCHAFER E, 1974, PLANTA, V116, P257, DOI 10.1007/BF00390231; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; SMITH H, 1976, LIGHT PLANT DEV; SOMMERS DE, 1991, PLANT CELL, V3, P1263; SPETH V, 1987, PLANTA, V171, P332, DOI 10.1007/BF00398678; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TOMIZAWA K, 1995, PLANT CELL PHYSIOL, V36, P511, DOI 10.1093/oxfordjournals.pcp.a078787; VIERSTRA RD, 1994, PLANT PHYSIOL, V103, P679; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x	51	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20193	20200		10.1074/jbc.270.34.20193	http://dx.doi.org/10.1074/jbc.270.34.20193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650038	hybrid			2022-12-27	WOS:A1995RQ99100076
J	SIPOS, G; PUOTI, A; CONZELMANN, A				SIPOS, G; PUOTI, A; CONZELMANN, A			BIOSYNTHESIS OF THE SIDE-CHAIN OF YEAST GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS IS OPERATED BY NOVEL MANNOSYLTRANSFERASES LOCATED IN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN GLYCOSYLATION; SECRETORY PATHWAY; MEMBRANE ANCHOR; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; GLYCOPROTEIN; MUTANTS; GENE; MEMBER; OLIGOSACCHARIDES	Glycosylphosphatidylinositol (GPI) anchors of the yeast Saccharomyces cerevisiae have been reported to contain three different types of side chains attached to the alpha 1,2-linked mannose of the conserved protein-ethanolamine-PO4-Man alpha 1,2Man alpha 1,6Man alpha 1,4Glc glycan core. The possible side chains are Man alpha 1,2- or Man alpha 1,2Man alpha 1,2- or Man alpha 1,3Man alpha 1,2- (Fankhauser, C., Homan, S. W., Thomas Gates, J. E., McConville, M. J., Desponds, C., Conzelmann, A, and Ferguson, M. A. (1993) J. Biol. Chem. 268, 26365-26374). To determine in what subcellular compartment these side chains are made, we metabolically labeled GPI anchored membrane proteins with myo-[2-H-3]inositol in secretion mutants blocked at various stages of the secretory pathway and analyzed the anchor structure of the labeled glycoproteins. When the exit of vesicles from the endoplasmic reticulum or entry into the cis-Golgi were blocked in sec12 or sec18 cells, all anchors contained a side chain consisting of a single alpha 1,2-linked mannose. GPI proteins trapped in the cis-Golgi of sec7 contained Man alpha 1,3Man alpha 1,2- but no Man alpha 1,2Man alpha 1,2- side chains. Mutants blocked at later stages of the secretory pathway made increased amounts of side chains containing two mannoses. Man alpha 1,2Man alpha 1,2- and Man alpha 1,2Man alpha 1,2- side chains were preferentially associated with ceramide- and diacylglycerol containing GPI anchors, respec tively. Mnn1, mnn2, mnn3, mnn5, and mnt1(= kre2), i.e. mutants which lack or down-regulate 1,2- and 1,3-mannosyltransferases used in the elongation of N . and O-glycans in the Golgi, add the fifth mannose to GPI anchors normally. The same conclusion was reached through the analysis of deletion mutants in KTR1, KTR2, KTR3, KTR4, and YUR1 which all are open reading frames with high homology to MNT1. Mutants deficient in the Golgi elongation of N-glycans such as anp1, van1, mnn9 are deficient in the maturation of the N-glycans of GPI-anchored glycoproteins, but process the GPI anchor side chain normally. Data are consistent with the idea that the fourth mannose is added to proteins as part of the anchor precursor glycolipid in the endoplasmic reticulum, whereas the fifth mannose is added by not yet identified alpha 1,3- and alpha 1,2-mannosyltransferases located in the Golgi apparatus.	UNIV FRIBOURG,INST BIOCHEM,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg			Puoti, Alessandro/E-5700-2012; Sipos, György/AAC-8267-2019; Sipos, Gyorgy/D-9287-2011; Puoti, Alessandro/ABE-9963-2021	Sipos, György/0000-0002-6666-1384; Puoti, Alessandro/0000-0002-1396-7662				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AMTHAUER R, 1992, CLIN CHEM, V38, P2510; ANTALIS C, 1973, J BIOL CHEM, V248, P4655; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BUSSEREAU F, 1993, YEAST, V9, P797, DOI 10.1002/yea.320090714; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COHEN RE, 1980, J BIOL CHEM, V255, P7700; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DEVLIN C, 1990, MOL MICROBIOL, V4, P1993, DOI 10.1111/j.1365-2958.1990.tb02049.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HAYNES PA, 1993, EUR J BIOCHEM, V216, P729, DOI 10.1111/j.1432-1033.1993.tb18192.x; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MULLER G, 1993, J CELL BIOL, V122, P325, DOI 10.1083/jcb.122.2.325; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; SMITH SW, 1974, J BIOL CHEM, V249, P3395; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	43	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19709	19715		10.1074/jbc.270.34.19709	http://dx.doi.org/10.1074/jbc.270.34.19709			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649981	hybrid			2022-12-27	WOS:A1995RQ99100009
J	ZHAO, H; XU, X; DIAZ, J; MUALLEM, S				ZHAO, H; XU, X; DIAZ, J; MUALLEM, S			NA+, K+, AND H+/HCO3- TRANSPORT IN SUBMANDIBULAR SALIVARY DUCTS - MEMBRANE LOCALIZATION OF TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MANDIBULAR GLANDS; RAT SUBMAXILLARY GLAND; GRANULAR DUCTS; ACINAR-CELLS; K/H EXCHANGE; H+ EXCHANGE; MAIN DUCT; RABBIT; STIMULATION; EPITHELIUM	The mechanisms mediating transepithelial ion transport in salivary ducts were characterized and localized by studying the regulation of [Na+](i), [K+]i, and pH(i) in isolated intralobular ducts and perfused main ducts of the submandibular salivary gland. A new procedure was developed for the rapid preparation of intralobular ducts. Measurements of pH(i) revealed the presence of Na+/H+ and Cl-/HCO3- exchange activities in intralobular duct cells. We could not obtain evidence for a coupled K+/H+ exchange activity which was postulated to exist in the luminal membrane of duct cells. Rather, a K-out(+)-dependent pathway which mediates the transport of H+/HCO3- and Na+ was found. This pathway was absent from acinar cells of the same gland and was active in unstimulated duct cells incubated in 5 mM K-out(+). Accordingly, inhibition of the Na+ pump with ouabain resulted in rapid and large Na+ influx in duct but not acinar cells. Perfusion experiments with the experimentally accessible main duct and measurements of pH,were used to provide the first direct localization of ion transporters in salivary ducts. The luminal and basolateral membranes of the duet express separate Na+/H+ and Cl-/HCO3- exchangers. Na+/H+ exchange activity in both membranes was similar, whereas the luminal Cl-/ HCO3- exchange activity was higher than that in the basolateral membrane. The perfused main duct was also used to localize the newly discovered K-out(+)-dependent H+/HCO3- and Na+ transport pathway to the luminal membrane, which suggests that this pathway may play an important role in Na+ reabsorption and K+ and HCO3- secretion by the salivary ductal system.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK36591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1987, J GEN PHYSIOL, V90, P209, DOI 10.1085/jgp.90.2.209; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BONANNO JA, 1991, AM J PHYSIOL, V260, pC618, DOI 10.1152/ajpcell.1991.260.3.C618; CASE RM, 1986, EXOCRINE PANCREAS BI, P213; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; DEHAYE JP, 1991, AM J PHYSIOL, V261, pC490, DOI 10.1152/ajpcell.1991.261.3.C490; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; DENNISS AR, 1978, AM J PHYSIOL, V235, pF548, DOI 10.1152/ajprenal.1978.235.6.F548; DENNISS AR, 1978, PFLUG ARCH EUR J PHY, V376, P73, DOI 10.1007/BF00585250; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DINUDOM A, 1993, CELL CALCIUM, V14, P631, DOI 10.1016/0143-4160(93)90088-N; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; GRAY MA, 1993, AM J PHYSIOL, V264, pC591, DOI 10.1152/ajpcell.1993.264.3.C591; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HOFER AM, 1992, J MEMBRANE BIOL, V126, P245; KNAUF H, 1982, AM J PHYSIOL, V242, pF132, DOI 10.1152/ajprenal.1982.242.2.F132; KNAUF H, 1976, EUR J CLIN INVEST, V6, P43, DOI 10.1111/j.1365-2362.1976.tb00492.x; KNAUF H, 1975, PFLUG ARCH EUR J PHY, V361, P55, DOI 10.1007/BF00587339; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTIN CJ, 1973, PFLUG ARCH EUR J PHY, V341, P131, DOI 10.1007/BF00587320; MARTIN CJ, 1971, PFLUG ARCH EUR J PHY, V327, P303, DOI 10.1007/BF00588450; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PORONNIK P, 1993, FEBS LETT, V315, P307, DOI 10.1016/0014-5793(93)81184-2; SCHNEYER LH, 1968, AM J PHYSIOL, V215, P664, DOI 10.1152/ajplegacy.1968.215.3.664; SCHNEYER LH, 1973, AM J PHYSIOL, V224, P136, DOI 10.1152/ajplegacy.1973.224.1.136; SCHNEYER LH, 1977, AM J PHYSIOL, V233, pF22, DOI 10.1152/ajprenal.1977.233.1.F22; SCHNEYER LH, 1976, AM J PHYSIOL, V230, P341, DOI 10.1152/ajplegacy.1976.230.2.341; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; THAYSEN JH, 1960, ALKALI METAL IONS BI, P424; TRAYSEN JH, 1954, AM J PHYSIOL, V178, P155; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; XU X, 1995, J BIOL CHEM, V270, P19606, DOI 10.1074/jbc.270.33.19606; YHOUNG JA, 1987, PHYSL GASTROINTESTIN, P773; YOUNG JA, 1970, PFLUG ARCH EUR J PHY, V319, P185, DOI 10.1007/BF00586449; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57	38	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19599	19605		10.1074/jbc.270.33.19599	http://dx.doi.org/10.1074/jbc.270.33.19599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642647	hybrid			2022-12-27	WOS:A1995RP70300063
J	GU, Y; SARNECKI, C; ALDAPE, RA; LIVINGSTON, DJ; SU, MSS				GU, Y; SARNECKI, C; ALDAPE, RA; LIVINGSTON, DJ; SU, MSS			CLEAVAGE OF POLY(ADP-RIBOSE) POLYMERASE BY INTERLEUKIN-1-BETA CONVERTING-ENZYME AND ITS HOMOLOGS TX AND NEDD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEATH GENE CED-3; INHIBITION; APOPTOSIS; ENCODES	The proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) is an early biochemical event, which occurs during apoptosis. A recent study suggested that PARP cleavage can be mediated by a novel cytosolic protease (prICE) that resembles interleukin-1 beta converting enzyme (ICE), but cannot be mediated by ICE itself (Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347). We have used a COS cell co-transfection assay to investigate if ICE or any known ICE-like protease is active in PARP cleavage within the cell. Here we report that coexpression of human PARP with human ICE, or the ICE homologs TX and Nedd-2, resulted in a cleavage of PARP identical to that observed in apoptotic cells. Experiments with purified recombinant human ICE indicated that PARE polypeptide can be specifically cleaved in vitro by ICE in a time- and enzyme concentration de pendent manner. PARP cleavage, however, requires a 50-100-fold higher ICE concentration than does processing of the interleukin-1 beta precursor at an equivalent substrate concentration. The abilities of ICE, TX, and Nedd-2, when expressed at high intracellular concentrations, to cleave PARP are consistent with their induction of apoptosis in transfected cells.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								AYALA JM, 1994, J IMMUNOL, V153, P2592; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V9, P1914; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V9, P1923; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	169	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18715	18718		10.1074/jbc.270.32.18715	http://dx.doi.org/10.1074/jbc.270.32.18715			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642516	hybrid			2022-12-27	WOS:A1995RN95400002
J	DO, KY; DO, SI; CUMMINGS, RD				DO, KY; DO, SI; CUMMINGS, RD			ALPHA-LACTALBUMIN INDUCES BOVINE-MILK BETA-1,4-GALACTOSYLTRANSFERASE TO UTILIZE UDP-GALNAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; GLOBULE-MEMBRANE GLYCOPROTEINS; N-ACETYLGALACTOSAMINE; LACTOSE SYNTHETASE; STRUCTURAL ELUCIDATION; SIALYLATED OLIGOSACCHARIDES; GALACTOSYL TRANSFERASE; CARBOHYDRATE CHAINS; SUGAR CHAINS	We now report that alpha-lactalbumin (alpha-LA) has a novel effect on bovine milk UDP-Gal:GlcNAc-beta 1,4 galactosyltransferase (beta 1,41-GT) and induces the enzyme to efficiently utilize UDP-GalNAc as a donor. In the presence of alpha-LA the enzyme transfers GalNAc to free GlcNAc to produce GalNAc beta 1-4GlcNAc at a rate 55% of that compared to the rate when UDP-Gal is the donor in the absence of alpha-LA. The stimulation by alpha-LA is dependent on the concentrations of alpha-LA, acceptor, and sugar nucleotide. Interestingly, beta 1,4-GT is unable to transfer GalNAc to Glc with or without alpha-LA. alpha-LA also stimulates the transfer of GalNAc from UDP GalNAc to various chitin oligomers, although the degree of stimulation decreases as the acceptor size increases. Thus, bovine milk beta 1,4-GT has an inherent ability to utilize two different sugar nucleotides and the sugar nucleotide preference is regulatable by alpha-LA.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREE PJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P489; BELL JE, 1976, J BIOL CHEM, V251, P3003; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BERLINER LJ, 1982, BIOCHEMISTRY-US, V21, P6340, DOI 10.1021/bi00268a003; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; BREW K, 1975, J BIOL CHEM, V250, P1434; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BROWNE WJ, 1969, J MOL BIOL, V42, P65, DOI 10.1016/0022-2836(69)90487-2; CARDINI CE, 1957, J BIOL CHEM, V225, P317; CHIU MH, 1994, J BIOL CHEM, V269, P16195; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Ebner KE, 1973, ENZYMES            B, P363; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GROBLER JA, 1994, J BIOL CHEM, V269, P5106; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HINTON DA, 1994, TRENDS GLYCOSCI GLYC, V6, P375; KANG S, 1993, J PARASITOL, V79, P815, DOI 10.2307/3283717; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KLEE WA, 1970, BIOCHEM BIOPH RES CO, V39, P833, DOI 10.1016/0006-291X(70)90398-0; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; NYAME K, 1989, J BIOL CHEM, V264, P3235; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PIERCE M, 1980, ANAL BIOCHEM, V102, P441, DOI 10.1016/0003-2697(80)90180-3; PIERCE M, 1979, BIOCHIM BIOPHYS ACTA, V571, P166, DOI 10.1016/0005-2744(79)90238-9; POWELL JT, 1976, J BIOL CHEM, V251, P3653; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; SATO T, 1993, J BIOCHEM-TOKYO, V114, P890, DOI 10.1093/oxfordjournals.jbchem.a124273; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; Tilley CA, 1991, GLYCOCONJUGATE J, V8, P249; TOMIYA N, 1993, J BIOL CHEM, V268, P113; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; UJITA M, 1993, FEBS LETT, V332, P119, DOI 10.1016/0014-5793(93)80496-H; WARME PK, 1974, BIOCHEMISTRY-US, V13, P768, DOI 10.1021/bi00701a020; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698	55	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18447	18451		10.1074/jbc.270.31.18447	http://dx.doi.org/10.1074/jbc.270.31.18447			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629170	hybrid			2022-12-27	WOS:A1995RM64200047
J	JACOB, R; BULLEID, NJ; NAIM, HY				JACOB, R; BULLEID, NJ; NAIM, HY			FOLDING OF HUMAN INTESTINAL LACTASE-PHLORHIZIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; MICROVILLAR PROTEINS; PHLORHIZIN HYDROLASE; EPITHELIAL-CELLS; DISULFIDE BONDS; BIOSYNTHESIS; MEMBRANE; GLYCOSYLATION; MATURATION	The folding of human intestinal prolactase-phlorizin hydrolase (pro-LPH) has been analyzed in a cell-free transcription/translation system. In the presence of the thiol oxidant GSSG, disulfide bond formation in pro-LPH can be promoted concomitant with the binding of the molecule to a conformation-specific monoclonal anti-LPH antibody. Under these conditions, pro-LPH does not bind to the molecular chaperone BiP. In the absence of GSSG, on the other hand, pro-LPH does not bind to the monoclonal anti-LPH antibody, but can be immunoprecipitated with a polyclonal antibody that is directed against a denatured form of the enzyme. In this case, interaction of pro-LPH with immunoglobulin heavy chain binding protein can be discerned. The results demonstrate the existence of intramolecular disulfide bonds that are essential for the promotion of pro-LPH to a native conformation. Furthermore, BiP is involved in the folding events of pro-LPH.	UNIV DUSSELDORF,INST MICROBIOL,PROT SECRET GRP,D-40225 DUSSELDORF,GERMANY; UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,DIV BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	Heinrich Heine University Dusseldorf; University of Manchester				Bulleid, Neil/0000-0002-9839-5279				BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DANIELSEN EM, 1990, BIOCHEMISTRY-US, V29, P305, DOI 10.1021/bi00453a042; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MONTGOMERY RK, 1991, FASEB J, V13, P2824; MOSTOV K, 1992, J CELL BIOL, V114, P577; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	35	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18678	18684		10.1074/jbc.270.31.18678	http://dx.doi.org/10.1074/jbc.270.31.18678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629200	hybrid			2022-12-27	WOS:A1995RM64200082
J	KAISE, M; MURAOKA, A; YAMADA, J; YAMADA, T				KAISE, M; MURAOKA, A; YAMADA, J; YAMADA, T			EPIDERMAL GROWTH-FACTOR INDUCES H+,K+-ATPASE ALPHA-SUBUNIT GENE-EXPRESSION THROUGH AN ELEMENT HOMOLOGOUS TO THE 3' HALF-SITE OF THE C-FOS SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED PARIETAL-CELLS; RAPID INDUCTION; RAT FIBROBLASTS; ACID-SECRETION; STIMULATION; PROTEIN; TRANSCRIPTION; INHIBITION; BINDING; ONCOGENE	Epidermal growth factor (EGF) acutely inhibits acid secretion; however, prolonged administration of EGF has been reported to increase acid production. We undertook these studies to examine whether the physiological effects of EGF on acid secretion are mediated by regulation of gastric H+,K+-ATPase, the principle enzyme responsible for acid secretion. EGF in concentrations equivalent to those in plasma increased H+,K+-ATPase alpha-subunit mRNA levels. Using H+,K+-ATPase-luciferase constructs transfected into primary cultured parietal cells, a significant step up in EGF inducibility was observed between bases -162 and -156 (5'-GA-CATGG-3') relative to the cap site, This EGF response element (ERE) conferred EGF inducibility when linked to homologous and heterologous promoters, The ERE is homologous to the 3' half site of the c-fos serum response element to which rNFIL-6, rE12, and SRE-ZBP bind. Electrophoretic mobility shift assays using an ERE probe and parietal cell nuclear extracts revealed a specific DNA-protein complex, the formation of which was changed by neither E12 and NFIL-6 consensus oligonucleotides nor antibodies for NFIL-6, SRE-ZBP, and E12, Our studies indicate that EGF induces gastric H+,K+-ATPase alpha-subunit gene expression via an interaction between a specific ERE and a novel transcriptional factor and that this may be a physiologic mechanism by which EGF regulates acid secretion.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIDDK NIH HHS [R01-DK34306, P30-DK34933, R30-DK33500] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK034306, R01DK033500, R37DK033500] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; CARPENTER G, 1978, ANN REV BIOCH, V48, P193; CHATTERJEE AK, 1986, HORM METAB RES, V18, P873, DOI 10.1055/s-2007-1012461; CHEW CS, 1994, AM J PHYSIOL-GASTR L, V267, pG818, DOI 10.1152/ajpgi.1994.267.5.G818; DEMBINSKI A, 1986, J PHYSIOL-LONDON, V387, P347; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HATT JF, 1988, BIOCHEM J, V255, P789, DOI 10.1042/bj2550789; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; KONTUREK SJ, 1989, SCAND J GASTROENTERO, V48, P193; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LOGSDON CD, 1983, GASTROENTEROLOGY, V85, P339; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; METZ R, 1991, ONCOGENE, V6, P2165; MURAOKA A, 1994, GASTROENTEROLOGY, V106, pA145; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OPLETAMADSEN K, 1991, AM J PHYSIOL, V260, pG807, DOI 10.1152/ajpgi.1991.260.6.G807; PODOLSKY DK, 1994, PHYSL GASTROINTESTIN, V1, P129; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SACHS G, 1987, PHYSL GASTROINTESTIN, V1, P865; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SHAW GP, 1987, BIOCHEM J, V244, P699, DOI 10.1042/bj2440699; SOLL AH, 1980, AM J PHYSIOL, V238, pG366, DOI 10.1152/ajpgi.1980.238.4.G366; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG L, 1993, J PHARMACOL EXP THER, V265, P308	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18637	18642		10.1074/jbc.270.31.18637	http://dx.doi.org/10.1074/jbc.270.31.18637			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629193	hybrid			2022-12-27	WOS:A1995RM64200075
J	SCHROEDER, WA; JOHNSON, EA				SCHROEDER, WA; JOHNSON, EA			SINGLET OXYGEN AND PEROXYL RADICALS REGULATE CAROTENOID BIOSYNTHESIS IN PHAFFIA-RHODOZYMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CAROTENE; ASTAXANTHIN; ANTIOXIDANT; YEAST; GROWTH; LIGHT	Carotenoids have recently received considerable interest because of their potential in delaying or preventing degenerative diseases such as arteriosclerosis, cancer, and aging. In this study we show that the active oxygen species singlet oxygen (O-1(2)) and peroxyl radicals differently affect carotenoid composition and biosynthesis in the yeast Phaffia rhodozyma. Photochemical generation of (1)0(2) with rose bengal or alpha-terthienyl induced carotenoid accumulation. In contrast, peroxyl radicals derived from t-butylhydroperoxide (tBOOH) or H2O2 decreased the content of astaxanthin and increased beta-carotene by similar to 4-fold, suggesting end product feedback regulation by astaxanthin or inhibition of bio synthetic enzymes, C-14 labeling of carotenoids during oxidative stress supported the possibility of end product regulation. Carotenoids were bleached by 8 mM tBOOH within 6 h when carotenogenesis was inhibited by thymol. When treated with peroxides, a previously unreported pigment in P. rhodozyma was formed, The carotenoid had a mass of 580 Da and a molecular formula of C40H52O3. Chemical derivatizations combined with mass and absorbance spectroscopy tentatively identified the carotenoid as dehydroflexixanthin (3,1'-dihydroxy2,3,3 ',4'-tetradehydro 1',2'-dihydro beta,psi-carotene-4-one). This study provides the first report of induction of astaxanthin biosynthesis by (1)0(2), probable feedback control by astaxanthin, and the oxidative degradation of astaxanthin to novel pigments in P. rhodozyma.	UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AN GH, 1989, APPL ENVIRON MICROB, V55, P116, DOI 10.1128/AEM.55.1.116-124.1989; AN GH, 1990, ANTON LEEUW INT J G, V57, P191, DOI 10.1007/BF00400151; AN GH, 1991, THESIS U WISCONSIN M; ANDREWES AG, 1976, PHYTOCHEMISTRY, V15, P1003, DOI 10.1016/S0031-9422(00)84390-3; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; DAVIES BH, 1976, CHEM BIOCH PLANT PIG, V2, P142; DI MASCIO P, 1992, METHOD ENZYMOL, V213, P429; FONTES M, 1993, EMBO J, V12, P1265, DOI 10.1002/j.1460-2075.1993.tb05771.x; Foppen F H, 1971, Chromatogr Rev, V14, P133, DOI 10.1016/0009-5907(71)80012-1; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GOLUBEV WI, 1995, YEAST, V11, P101, DOI 10.1002/yea.320110202; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Hodgson D, 1993, MYXOBACTERIA, VII, P157; JOHNSON EA, 1979, J GEN MICROBIOL, V115, P173, DOI 10.1099/00221287-115-1-173; JOHNSON EA, 1991, CRIT REV BIOTECHNOL, V11, P297, DOI 10.3109/07388559109040622; JOHNSON EA, 1980, AQUACULTURE, V20, P123, DOI 10.1016/0044-8486(80)90041-1; JOHNSON EA, 1992, PROFILES BIOTECHNOLO, P289; KELLY S, 1990, THESIS U WISCONSIN M; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12362, DOI 10.1073/pnas.91.26.12362; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12365, DOI 10.1073/pnas.91.26.12365; KRINSKY NI, 1977, TRENDS BIOCHEM SCI, V2, P35, DOI 10.1016/0968-0004(77)90253-5; KYO M, 1990, PLANT CELL REP, V9, P393, DOI 10.1007/BF00232407; LAMBERTS JJM, 1985, TETRAHEDRON, V41, P2183, DOI 10.1016/S0040-4020(01)96591-3; MEYER PS, 1994, SYST APPL MICROBIOL, V17, P24, DOI 10.1016/S0723-2020(11)80027-5; MILLER MW, 1976, INT J SYST BACTERIOL, V26, P286, DOI 10.1099/00207713-26-2-286; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P291, DOI 10.1016/0003-9861(92)90675-M; PALOZZA P, 1992, METHOD ENZYMOL, V213, P403; PICHORNER H, 1993, ARCH BIOCHEM BIOPHYS, V300, P258, DOI 10.1006/abbi.1993.1036; SCHROEDER WA, 1993, J GEN MICROBIOL, V139, P907, DOI 10.1099/00221287-139-5-907; SCHROEDER WA, 1995, IN PRESS J IND MICRO; SIMIC MG, 1988, MUTAT RES, V202, P377, DOI 10.1016/0027-5107(88)90199-6; SIMIC MG, 1992, METHOD ENZYMOL, V213, P444; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TADA M, 1982, PLANT CELL PHYSIOL, V23, P615; TERAO J, 1989, LIPIDS, V24, P659, DOI 10.1007/BF02535085	37	147	159	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18374	18379		10.1074/jbc.270.31.18374	http://dx.doi.org/10.1074/jbc.270.31.18374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629161	hybrid			2022-12-27	WOS:A1995RM64200037
J	KINGMA, PS; CORBETT, AH; BURCHAM, PC; MARNETT, LJ; OSHEROFF, N				KINGMA, PS; CORBETT, AH; BURCHAM, PC; MARNETT, LJ; OSHEROFF, N			ABASIC SITES STIMULATE DOUBLE-STRANDED DNA CLEAVAGE MEDIATED BY TOPOISOMERASE-II - DNA LESIONS AS ENDOGENOUS TOPOISOMERASE-II POISONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DRUG-INTERACTION DOMAINS; ACUTE MYELOID-LEUKEMIA; DROSOPHILA-MELANOGASTER; ANTINEOPLASTIC DRUGS; ENZYME; RELIGATION; AGENTS; ACID; EPIPODOPHYLLOTOXINS; INHIBITION	Several clinically relevant anticancer drugs induce genomic mutations and cell death by increasing topoisomerase II-mediated DNA breakage. To determine whether endogenous DNA damage also affects this cleavage event, the effects of abasic sites (the most commonly formed spontaneous DNA lesion) on topoisomer ase II activity were investigated. The presence of 3 abasic sites/plasmid stimulated enzyme-mediated DNA breakage >6-fold, primarily by enhancing the forward rate of cleavage, This corresponds to a potency that is >2000-fold higher than that of the anticancer drug, etoposide. These findings suggest that abasic sites represent endogenous topoisomerase II poisons and imply that anticancer drugs mimic the cleavage-enhancing actions of naturally occurring DNA lesions.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL CANCER INSTITUTE [R35CA047479, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479, CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1990, CANCER RES, V50, P6919; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FRIEDBERG EC, 1995, DNA REPAIR; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; Lloyd RS, 1993, NUCLEASES, P263; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; NETO JBC, 1992, J BIOL CHEM, V267, P19718; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROSS JA, 1994, J NATL CANCER I, V86, P1678, DOI 10.1093/jnci/86.22.1678; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; SMITH MA, 1993, J NATL CANCER I, V85, P554, DOI 10.1093/jnci/85.7.554; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23	42	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21441	21444		10.1074/jbc.270.37.21441	http://dx.doi.org/10.1074/jbc.270.37.21441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665552	hybrid			2022-12-27	WOS:A1995RU75700004
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			RAPID PURIFICATION OF HUMAN P-GLYCOPROTEIN MUTANTS EXPRESSED TRANSIENTLY IN HEK-293 CELLS BY NICKEL-CHELATE CHROMATOGRAPHY AND CHARACTERIZATION OF THEIR DRUG-STIMULATED ATPASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PREDICTED TRANSMEMBRANE DOMAIN; FUNCTIONAL CONSEQUENCES; PROTEIN; MUTATIONS; BINDING	P-glycoprotein containing 10 tandem histidine residues at the COOH end of the molecule was transiently expressed in HEK 293 cells and purified by nickel chelate chromatography. The purified protein had an apparent mass of 170 kDa, and its verapamil-stimulated ATPase activity in the presence of phospholipid was 1.2 mu mol/min/mg of P-glycoprotein. We then characterized P-glycoprotein mutants that exhibited altered drug-resistant phenotypes and analyzed the contribution of the two nucleotide binding folds to drug-stimulated ATPase activity, Mutation of residues in either nucleotide binding fold abolished drug-stimulated ATPase activity. The pattern of drug-stimulated ATPase activities of mutants, which conferred increased relative resistance to colchicine (G141V, G185V, G830V) or decreased relative resistance to all drugs (F978A), correlated with their drug-resistant phenotypes, By contrast, the ATPase activity of mutant F335A was significantly higher than that of wild-type enzyme when assayed in the presence of verapamil (3.4 fold), colchicine (9.1-fold), or vinblastine (3.7-fold), even though it conferred little resistance to vinblastine in transfected cells. These results suggest that both nucleotide-binding domains must be intact to couple drug binding to ATPase activity and that the drug-stimulated ATPase activity profile of a mutant does not always correlate with its drug-resistant phenotype.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; RAO US, 1995, J BIOL CHEM, V270, P6686; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	20	190	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21449	21452		10.1074/jbc.270.37.21449	http://dx.doi.org/10.1074/jbc.270.37.21449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665554	hybrid			2022-12-27	WOS:A1995RU75700006
J	CHAMBERLIN, SG; SARGOOD, KJ; RICHTER, A; MELLOR, JM; ANDERSON, DW; RICHARDS, NGJ; TURNER, DL; SHARMA, RP; ALEXANDER, P; DAVIES, DE				CHAMBERLIN, SG; SARGOOD, KJ; RICHTER, A; MELLOR, JM; ANDERSON, DW; RICHARDS, NGJ; TURNER, DL; SHARMA, RP; ALEXANDER, P; DAVIES, DE			CONSTRAINED PEPTIDE ANALOGS OF TRANSFORMING GROWTH-FACTOR-ALPHA RESIDUES CYSTEINE-21-32 ARE MITOGENICALLY ACTIVE - USE OF PROLINE MIMETICS TO ENHANCE BIOLOGICAL POTENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; SYNTHETIC FRAGMENTS; ROTATING-FRAME; SITE; SPECTROSCOPY; EGF	Two proline mimetics, the enantiomers of 2-aza-bicyclo[2,2,1]heptane-3-carboxylic acid, have been incorporated in place of Pro(30) into synthetic peptides based on the B-loop beta-sheet sequence of human transforming growth factor-alpha (TGF-alpha) (residues Cys(21)-Cys(32)). The peptides were further modified by inclusion of an N-terminal phenylalanine and constrained by formation of an intramolecular disulfide bond. While no mitogenic response was observed in the parental NR6 cell line, the peptides stimulated DNA synthesis in NR6/HER cells (NR6 fibroblasts transfected with the human epidermal growth factor receptor). Induction of DNA synthesis was dose dependent, with EC(50) values in the range 130-330 mu M; in the presence of low doses of TGF-alpha, the mitogenic effect of the peptides was additive, up to the plateau response achieved by maximal doses of TGF-alpha alone. These effects are consistent with the peptides acting via the same mechanism as TGF-alpha. Analysis of the structure of the peptides by NMR indicated that the presence of the mimetics significantly increased the propensity of the peptidyl-proline bond to adopt the cis conformation. These data confirm the role of the beta-sheet in receptor activation, and emphasize the importance of presentation of peptides in an appropriate conformation for recognition.	SOUTHAMPTON GEN HOSP,CANC RES CAMPAIGN MEC ONCOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT BIOCHEM,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND; CHEM & BIOL DEF ESTAB,SALISBURY SP4 0JQ,WILTS,ENGLAND	University of Southampton; University of Southampton; University of Southampton			Davies, Donna E/H-2993-2012; Turner, David/B-8267-2009; Turner, David L/B-9061-2011	Turner, David L/0000-0002-3754-6459				ATHERTON E, 1991, PEPTIDES 1990, P243; BAILIE JR, 1994, INT J PEPT PROT RES, V43, P225; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DARLAK K, 1988, J CELL BIOCHEM, V36, P341, DOI 10.1002/jcb.240360404; DAVIES DE, 1994, BRIT J CANCER, V70, P263, DOI 10.1038/bjc.1994.290; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DONZEL B, 1972, HELV CHIM ACTA, V55, P947, DOI 10.1002/hlca.19720550321; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; EPSTEIN DA, 1989, J CELL PHYSL, V141, P420; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; Han K H, 1988, J Mol Recognit, V1, P116, DOI 10.1002/jmr.300010304; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KOPPLE KD, 1988, J AM CHEM SOC, V110, P4168, DOI 10.1021/ja00221a012; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LEE DC, 1991, PEPTIDE GROWTH FACTO, V2, P61; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MELLOR JM, 1994, IN PRESS TETRAHEDRON; NELSON J, 1991, CARCINOGENESIS, V12, P1823, DOI 10.1093/carcin/12.10.1823; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; SCHULZ GE, 1985, PRINCIPLES PROTEIN S; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TAM JP, 1991, INT J PEPT PROT RES, V38, P204; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G	39	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21062	21067		10.1074/jbc.270.36.21062	http://dx.doi.org/10.1074/jbc.270.36.21062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673134	hybrid			2022-12-27	WOS:A1995RU05400032
J	MOSER, MJ; LEE, SY; KLEVIT, RE; DAVIS, TN				MOSER, MJ; LEE, SY; KLEVIT, RE; DAVIS, TN			CA2+ BINDING TO CALMODULIN AND ITS ROLE IN SCHIZOSACCHAROMYCES-POMBE AS REVEALED BY MUTAGENESIS AND NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPINDLE POLE BODY; YEAST CALMODULIN; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL CHANGE; CALCIUM-BINDING; VERTEBRATE CALMODULIN; ASPERGILLUS-NIDULANS; POINT MUTATIONS; TROPONIN-C	As a first step toward identifying the important structural elements of calmodulin from Schizosaccharomyces pombe, we examined the ability of heterologous calmodulins and Ca2+-binding site mutant S. pombe calmodulins to replace the essential cam1(+) gene, A cDNA encoding vertebrate calmodulin allows growth of S. pombe. However, calmodulin from Saccharomyces cerevisiae does not support growth even though the protein is produced at high levels. With one exception, all mutant S. pombe calmodulins with one or more intact Ca2+ binding sites allow growth at 21 degrees C. A mutant containing only an intact Ca2+-binding site 3 fails to support growth, as does S. pombe calmodulin with all four Ca2+ binding sites mutated. Several of the mutant proteins confer a temperature-sensitive phenotype. Analysis of the degree of temperature sensitivity allows the Ca2+ binding sites to be ranked by their ability to support fission yeast proliferation. Site 2 is more important than site 1, which is more important than site 4, which is more important than site 3. A visual colony color screen based on the fission yeast ade1(+) gene was developed to perform these genetic analyses. To compare the Ca2+ binding properties of individual sites to their functional importance for viability, Ca2+ binding to calmodulin from S. pombe was studied by H-1 NMR spectroscopy. NMR analysis indicates a Ca2+-binding profile that differs from those previously determined for vertebrate and S. cerevisiae calmodulins. Ca2+-binding site 3 has the highest relative affinity for Ca2+, while the affinities of sites 1, 2, and 4 are indistinguishable. A combination of an in vivo functional assay and an in vitro physical assay reveals that the relative affinity of a site for Ca2+ does not predict its functional importance.	UNIV WASHINGTON,DEPT BIOCHEM SJ70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Davis, Trisha/F-8584-2010	Davis, Trisha/0000-0003-4797-3152	NIDDK NIH HHS [DK-35187] Funding Source: Medline; NIGMS NIH HHS [GM-40506, T32 GM-08437] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035187, R23DK035187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008437, R01GM040506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BROCKERHOFF SE, 1992, PROTEIN SCI, V1, P504; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COHEN P, 1988, CALMODULIN, P123; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DALGARNO DC, 1983, EUR J BIOCHEM, V137, P523, DOI 10.1111/j.1432-1033.1983.tb07857.x; DALGARNO DC, 1984, BIOCHIM BIOPHYS ACTA, V791, P164, DOI 10.1016/0167-4838(84)90006-2; DAVIS TN, 1992, J CELL BIOL, V118, P607, DOI 10.1083/jcb.118.3.607; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ELLIOTT S, 1986, J BIOL CHEM, V261, P2936; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GUTZ H, 1972, HDB GENETICS, V1, P395; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2573, DOI 10.1021/bi00279a039; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; IKURA M, 1985, BIOCHEMISTRY-US, V24, P4264, DOI 10.1021/bi00337a002; KLEVIT RE, 1984, EUR J BIOCHEM, V139, P109, DOI 10.1111/j.1432-1033.1984.tb07983.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; MATSUURA I, 1991, J BIOCHEM-TOKYO, V109, P190, DOI 10.1093/oxfordjournals.jbchem.a123344; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MCKENZIE R, 1987, CURR GENET, V12, P591, DOI 10.1007/BF00368061; Miller J.H., 1972, EXPT MOL GENETICS; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PONTICELLI AS, 1989, GENETICS, V123, P45; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAROVASNIK MA, 1993, BIOCHEMISTRY-US, V32, P3261, DOI 10.1021/bi00064a008; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; Stull J, 1988, CALMODULIN, P91; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; SUN GH, 1992, PROTOPLASMA, V166, P1625; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; YOSHIDA T, 1994, J CELL SCI, V107, P1725	55	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20643	20652		10.1074/jbc.270.35.20643	http://dx.doi.org/10.1074/jbc.270.35.20643			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657644	hybrid			2022-12-27	WOS:A1995RR58400063
J	SCHIEVEN, GL; WAHL, AF; MYRDAL, S; GROSMAIRE, L; LEDBETTER, JA				SCHIEVEN, GL; WAHL, AF; MYRDAL, S; GROSMAIRE, L; LEDBETTER, JA			LINEAGE-SPECIFIC INDUCTION OF B-CELL APOPTOSIS AND ALTERED SIGNAL-TRANSDUCTION BY THE PHOSPHOTYROSINE PHOSPHATASE INHIBITOR BIS(MALTOLATO)OXOVANADIUM(IV)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; T-CELLS; PHENYLARSINE OXIDE; LYMPHOCYTES-B; KINASE; ACTIVATION; DEATH; VANADATE; EXPRESSION	Protein tyrosine phosphorylation is known to play key roles in lymphocyte signal transduction, and phosphotyrosine phosphatases (PTP) can act as both positive and negative regulators of these lymphocyte signals. We sought to examine the role of PTP further in these processes by characterizing the effects of bis(maltolato)oxovanadium(IV) (BMLOV), previously known to be a nontoxic insulin mimetic agent in vivo. BMLOV was found to be a potent phosphotyrosine phosphatase inhibitor. BMLOV induced cellular tyrosine phosphorylation in B cells in a pattern similar to that observed following antigen receptor stimulation, whereas little tyrosine phosphorylation was induced in T cells. In B cells, BMLOV treatment resulted in tyrosine phosphorylation of Syk and phospholipase C gamma(2), while sIgM-induced signals were inhibited. By contrast, T cell receptor signals were moderately increased by BMLOV, and the cells displayed greater induction of IL-2 receptor without toxicity. The compound selectively induced apoptosis in B cell lymphoma and myeloid leukemia cell lines, but not in T cell leukemia or colon carcinoma cells. Interleukin-4 plus anti-CD40 antibody treatment of normal human peripheral B cells rescued the cells from BMLOV-induced death. These results suggest that phosphotyrosine phosphatase inhibitors can activate B cell signal pathways in a lineage-specific manner, resulting in desensitization of receptor-mediated signaling and induction of apoptosis.			SCHIEVEN, GL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BURG DL, 1993, J BIOL CHEM, V268, P2304; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CORTIZO AM, 1994, BIOL TRACE ELEM RES, V41, P331, DOI 10.1007/BF02917433; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DAMLE NK, 1993, EUR J IMMUNOL, V23, P1513, DOI 10.1002/eji.1830230718; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; FROST SC, 1985, J BIOL CHEM, V260, P2646; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANSEN JA, 1984, LEUKOCYTE TYPING, V1, P195; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAYNES BF, 1986, LEUKOCYTE TYPING 2, V2, P3; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MCNEILL JH, 1992, J MED CHEM, V35, P1489, DOI 10.1021/jm00086a020; NING ZQ, 1993, EUR J IMMUNOL, V23, P3369, DOI 10.1002/eji.1830231247; NOSSAL GJV, 1992, ADV IMMUNOL, V52, P283, DOI 10.1016/S0065-2776(08)60878-0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; STEWART CP, 1972, J CHEM SOC DALTON, P1661, DOI 10.1039/dt9720001661; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKATA M, 1995, J CELL BIOCH A S, V21, P85; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VUIST WMJ, 1994, BLOOD, V83, P899; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAO XR, 1993, IMMUNOL REV, V132, P163, DOI 10.1111/j.1600-065X.1993.tb00842.x; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946	58	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20824	20831		10.1074/jbc.270.35.20824	http://dx.doi.org/10.1074/jbc.270.35.20824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657667	hybrid			2022-12-27	WOS:A1995RR58400088
J	MAXZUD, MK; DANIOTTI, JL; MACCIONI, HJF				MAXZUD, MK; DANIOTTI, JL; MACCIONI, HJF			FUNCTIONAL COUPLING OF GLYCOSYL TRANSFER STEPS FOR SYNTHESIS OF GANGLIOSIDES IN GOLGI MEMBRANES FROM NEURAL RETINA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BREFELDIN-A; BIOSYNTHESIS; APPARATUS; GLYCOSYLTRANSFERASES; SIALYLTRANSFERASES; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; TRANSLOCATION; TRANSPORT	The synthesis of the oligosaccharide of gangliosides is carried out in the Golgi complex by successive sugar transfers to proper glycolipid accepters, To examine how the product of one glycosylation step couples with the next transfer step, the endogenous gangliosides of Golgi membranes from 14-day-old chick. embryo retina were labeled from CMP-[H-3]NeuAc or UDP-[H-3]GalNAc or UDP-[H-3]Gal in conditions which do not allow vesicular intercompartmental transport, After saturation of the endogenous acceptor capacity, labeling was mostly in the immediate accepters of the corresponding labeled sugars, However, some labeled intermediates progressed to more glycosylated gangliosides if the membranes were incubated in a second step in the presence of the necessary unlabeled sugar nucleotides. This was particularly evident in the case of membranes incubated with UDP-[H-3]Gal, in which most of the [H-3]Gal-labeled lactosylceramide synthesized in the first step was converted to GM3 and GD3, or to GM2 or to GD1a in a second incubation step in the presence of unlabeled CMP-NeuAc alone, or together with UDP-GalNAc, or together with UDP-Gal plus UDP-GalNAc, respectively, Conversion was time dependent and dilution-independent, Since prior reports using brefeldin A indicate that transfer steps catalyzed by GalNAc-T, Gal-T2, and Sial-T4 localize in the trans-Golgi network (TGN), our results lead to the following major conclusions: (a) transfer steps catalyzed by GalNAc-T, Gal-T2, and Sial-T4 colocalize and are functionally coupled in the TGN; (b) proximal Golgi Gal-T1, Sial-T1, and Sial-T2, and their corresponding glycolipid accepters, extend their presence to the TGN, and (c), GalNAc-T and Sial-T2 compete for a common pool of acceptor GM3 in the synthesis of GM2 and GD3.	NATL UNIV CORDOBA,FAC CIENCIAS QUIM,DEPT QUIM BIOL,CONICET,CIQUIBIC,RA-5016 CORDOBA,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba								ARCE A, 1971, BIOCHEM J, V121, P483, DOI 10.1042/bj1210483; CAPUTTO R, 1974, MOL CELL BIOCHEM, V4, P97, DOI 10.1007/BF01770290; DANIOTTI JL, 1991, J NEUROCHEM, V57, P2054, DOI 10.1111/j.1471-4159.1991.tb06421.x; DANIOTTI JL, 1994, J NEUROCHEM, V62, P1131; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; FRITZ VMR, 1995, IN PRESS J NEUROCHEM; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; JECKEL J, 1992, J CELL BIOL, V29, P75; KLAUSNER RD, 1992, J CELL BIOL, V16, P1071; LANDA CA, 1981, J NEUROCHEM, V37, P813, DOI 10.1111/j.1471-4159.1981.tb04466.x; MACCIONI HJ, 1974, BIOCHEM J, V138, P291, DOI 10.1042/bj1380291; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NORES GA, 1994, J CHROMATOGR A, V686, P155, DOI 10.1016/S0021-9673(94)89015-3; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PANZETTA P, 1987, J NEUROCHEM, V49, P1763, DOI 10.1111/j.1471-4159.1987.tb02434.x; PANZETTA P, 1980, J NEUROCHEM, V35, P100, DOI 10.1111/j.1471-4159.1980.tb12494.x; REINER JM, 1959, BEHAVIOR ENZYME SYST, P89; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; YOUNG WW, 1992, J BIOL CHEM, V267, P12011; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	36	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20207	20214		10.1074/jbc.270.34.20207	http://dx.doi.org/10.1074/jbc.270.34.20207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650040	hybrid			2022-12-27	WOS:A1995RQ99100078
J	NOTARNICOLA, SM; PARK, K; GRIFFITH, JD; RICHARDSON, CC				NOTARNICOLA, SM; PARK, K; GRIFFITH, JD; RICHARDSON, CC			A DOMAIN OF THE GENE-4 HELICASE-PRIMASE OF BACTERIOPHAGE-T7 REQUIRED FOR THE FORMATION OF AN ACTIVE HEXAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; ACID REPLICATION INVITRO; NUCLEOTIDE-BINDING SITE; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; DNA-POLYMERASE; DUPLEX DNA; PROTEIN; SEQUENCE; PURIFICATION	The bacteriophage T7 gene 4 protein, like a number of helicases, is believed to function as a hexamer, The amino acid sequence of the T7 gene 4 protein from residue 475 to 491 is conserved in the homologous proteins of the related phages T3 and SP6. In addition, part of this region is conserved in DNA helicases such as Escherichia coli DnaB protein and phage T4 gp41. Mutations within this region of the T7 gene 4 protein can reduce the ability of the protein to form hexamers, The His(475)-->Ala and Asp(485)-->Gly mutant proteins show decreases in nucleotide hydrolysis, single-stranded DNA binding, double-stranded DNA unwinding, and primer synthesis in proportion to their ability to form hexamers, The mutation Arg(487)-->Ala has little effect on oligomerization, but nucleotide hydrolysis by this mutant protein is inhibited by single stranded DNA, and it has a higher affinity for dTTP, suggesting that this protein is defective in the protein-protein interactions required for efficient nucleotide hydrolysis and translocation on single-stranded DNA, Gene 4 protein can form hexamers in the absence of a nucleotide, but dTTP increases hexamer formation, as does dTDP, to a lesser extent, demonstrating that the protein self-association affinity is influenced by the nucleotide bound, Together, the data demonstrate that this region of the gene 4 protein is important for the protein-protein contacts necessary for both hexamer formation and the interactions between the subunits of the hexamer required for coordinated nucleotide hydrolysis, translocation on single stranded DNA, and unwinding of double-stranded DNA. The fact that the gene 4 proteins form dimers, but not monomers, even while hexamer formation is severely diminished by some of the mutations, suggests that the proteins associate in a manner with two separate and distinct protein-protein interfaces.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline; NIGMS NIH HHS [GM-31819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; HAMES BD, 1990, GEL ELECTROPHORESIS, P15; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; HUBER HE, 1988, CANCER CELL, V6, P11; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1985, J BIOL CHEM, V259, P2281; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; PATEL SS, 1993, J BIOL CHEM, V268, P10668; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDIER FW, 1969, VIROLOGY, V39, P575, DOI 10.1016/0042-6822(69)90105-6; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WONG I, 1992, J BIOL CHEM, V267, P7596	44	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20215	20224		10.1074/jbc.270.34.20215	http://dx.doi.org/10.1074/jbc.270.34.20215			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650041	hybrid, Green Published, Green Submitted			2022-12-27	WOS:A1995RQ99100079
J	BALLARIN, C; SORGATO, MC				BALLARIN, C; SORGATO, MC			AN ELECTROPHYSIOLOGICAL STUDY OF YEAST MITOCHONDRIA - EVIDENCE FOR 2 INNER MEMBRANE ANION CHANNELS SENSITIVE TO ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT MITOCHONDRIA; K+-CHANNEL	The inner membrane of mitochondria from various strains of Saccharomyces cerevisiae has been analyzed with the patch clamp technique for comparison with the better known homologous membrane in mammals (Sorgato, M. C., and Moran, O. (1993) CRC Grit. Rev. Biochem. Mol. Biol. 18, 127-171). Differently than in mammals, the yeast inner membrane was found to harbor essentially two channels with similar anionic selectivity but otherwise different functional behavior. One had a conductance of around 45 picosiemens (in symmetrical 150 mM KCl) and an activity only marginally sensitive to voltage. The other channel was prominent for the higher outwardly rectifying current and for the dependence upon voltage of the open probability that induced rapid closure at physiological (negative) membrane potentials. Particularly interesting was the effect of ATP (Mg2+ free) added on the matrix side of the membrane, In the case of the lower conducting channel, the nucleotide caused an immediate block of activity (IC50, 0.240 mM), whereas it locked the larger conductance in the open state at both positive and negative potentials, In proteoliposomes containing both mitochondrial membranes, the small conductance was clearly evident, whereas a larger channel, cationic and without the voltage dependence typical of that in the native inner membrane, was found.	UNIV PADUA,DIPARTIMENTO CHIM BIOL,I-35121 PADUA,ITALY	University of Padua				BALLARIN, Cristina/0000-0001-7934-7477				BALLARIN C, 1995, BIOENERGETICS PRACTI, P133; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DAUM G, 1982, J BIOL CHEM, V257, P3028; GUERIN B, 1994, J BIOL CHEM, V269, P25406; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MORAN O, 1992, EUR BIOPHYS J BIOPHY, V20, P311, DOI 10.1007/BF00196590; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	18	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19262	19268		10.1074/jbc.270.33.19262	http://dx.doi.org/10.1074/jbc.270.33.19262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642599	hybrid			2022-12-27	WOS:A1995RP70300013
J	LANEUVILLE, O; BREUER, DK; XU, NX; HUANG, ZH; GAGE, DA; WATSON, JT; LAGARDE, M; DEWITT, DL; SMITH, WL				LANEUVILLE, O; BREUER, DK; XU, NX; HUANG, ZH; GAGE, DA; WATSON, JT; LAGARDE, M; DEWITT, DL; SMITH, WL			FATTY-ACID SUBSTRATE SPECIFICITIES OF HUMAN PROSTAGLANDIN ENDOPEROXIDE-H SYNTHASE-1 AND SYNTHASE-2 - FORMATION OF 12-HYDROXY-(9Z,13E/Z,15Z)-OCTADECATRIENOIC ACIDS FROM ALPHA-LINOLENIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; G/H SYNTHASE; MESSENGER-RNA; COMPLEMENTARY-DNA; BINDING-SITES; HEME-BINDING; CYCLOOXYGENASE; EXPRESSION; CELLS; GENE	Human prostaglandin-endoperoxide H synthase-l and -2 (hPGHS-1 and hPGHS-2) were expressed by transient transfection of COS-1 cells. Microsomes prepared from the transfected cells were used to measure the rates of oxygenation of several 18- and 20-carbon polyunsaturated fatty acid substrates including eicosapentaenoic, arachidonic, dihomo-gamma-linolenic, alpha-linolenic (Delta(9,12,15)), gamma-linolenic, and linoleic acids. Comparisons of k(cat)/K-m values indicate that the order of efficiency of oxygenation is arachidonate > dihomo-gamma-linolenate > linoleate > alpha-linolenate for both isozymes; while the order of efficiency was the same for hPGHS-1 and hPGHS-2, alpha-linoleate was a particularly poor substrate for hPGHS-1. gamma-Linolenate and eicosapentaenoate were poor substrates for both isozymes, but in each case, these two fatty acids were better substrates for hPGHS-2 than hPGHS-1. These studies of substrate specificities are consistent with previous studies of the interactions of PGHS isozymes with nonsteroidal anti-inflammatory drugs that have indicated that the cyclooxygenase active site of PGHS-2 is somewhat larger and more accommodating than that of PGHS-1. The major products formed from linoleate and alpha-linolenate were characterized. 13-Hydroxy-(9Z,11E)-octadecadienoic acid was found to be the main product formed from alpha-linoleate by both isozymes. The major products of oxygenation of alpha-linolenate were determined by mass spectrometry to be 12-hydroxy-(9Z,13E/Z,15Z)-octadecatrieno acids. This result suggests that alpha-linolenate is positioned in the cyclooxygenase active site with a kink in the carbon chain such that hydrogen abstraction occurs from the omega 5-position in contrast to abstraction of the omega 8-hydrogen from other substrates.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; INSA,CHIM BIOL LAB,F-69621 VILLEURBANNE,FRANCE; INSA,INSERM,U352,F-69621 VILLEURBANNE,FRANCE	Michigan State University; Institut National des Sciences Appliquees de Lyon - INSA Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022042, R37DK022042, R01DK042509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline; NIGMS NIH HHS [GM40713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARNETT J, 1994, BIOCHIM BIOPHYS ACTA, V209, P130; CARTY TJ, 1980, PROSTAGLANDINS, V19, P671, DOI 10.1016/0090-6980(80)90166-5; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DRAFFAN GH, 1968, ORG MASS SPECTROM, V1, P669, DOI 10.1002/oms.1210010508; EGLINTON G, 1968, ORG MASS SPECTROM, V1, P593, DOI 10.1002/oms.1210010413; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HAMBERG M, 1990, ADV PROSTAGLANDIN TH, V21, P117; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KATE M, 1972, TECHNIQUES LIPIDOLOG, P381; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; LANDS WEM, 1968, BIOCHIM BIOPHYS ACTA, V164, P426, DOI 10.1016/0005-2760(68)90168-9; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORITA I, 1993, J BIOL CHEM, V258, P10197; MURPHY RC, 1993, HDB LIPIDS, V7, P173; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NUGTEREN DH, 1970, BIOCHIM BIOPHYS ACTA, V210, P171, DOI 10.1016/0005-2760(70)90072-X; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WILLIS AL, 1987, CRC HDB EICOSANOIDS, P3; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; [No title captured]	69	207	209	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19330	19336		10.1074/jbc.270.33.19330	http://dx.doi.org/10.1074/jbc.270.33.19330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642610	hybrid			2022-12-27	WOS:A1995RP70300024
J	OHNISHI, J; KIHARA, T; HAMABATA, T; TAKAHASHI, K; TAKAHASHI, T				OHNISHI, J; KIHARA, T; HAMABATA, T; TAKAHASHI, K; TAKAHASHI, T			CLEAVAGE SPECIFICITY OF PORCINE FOLLIPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA KALLIKREIN; TISSUE PLASMINOGEN-ACTIVATOR; FOLLICULAR PLASMINOGEN; FUNCTIONAL-PROPERTIES; RAT OVARY; OVULATION; PROTEINS; CLONING; PURIFICATION; EXPRESSION	Follipsin purified from the follicular fluid of porcine ovaries was studied for its specificity against various synthetic and peptide substrates. The enzyme cleaved only by an endopeptidase activity at the amide and peptide bonds of Arg-X, indicating strict specificity of the S-1 pocket for arginine. The specificity for pocket S-2 appears to favor either hydrophobic or basic side chains. A 10-residue peptide containing a portion of the activation site of human tissue plasminogen activator was synthesized and tested with the enzyme, The peptide was cleaved by follipsin at the Arg-Ile bond, as expected from the specificity deduced above. Furthermore, the enzyme successfully converted single-chain precursor tissue plasminogen activator (sctPA) to its active, two-chain form by cleaving the corresponding peptide bond, Comparison of the rates of single-chain precursor tissue plasminogen activator activation and tissue plasminogen activator peptide hydrolysis revealed that the former is a more efficient substrate than the latter.	HOKKAIDO UNIV, GRAD SCH SCI, DIV BIOL SCI, SAPPORO, HOKKAIDO 060, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Hokkaido University; University of Tokyo								ANDREASEN PA, 1984, EMBO J, V3, P51, DOI 10.1002/j.1460-2075.1984.tb01760.x; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BEERS WH, 1975, CELL, V6, P379, DOI 10.1016/0092-8674(75)90187-7; CANIPARI R, 1985, J BIOL CHEM, V260, P5121; COLMAN RW, 1985, BLOOD, V65, P311; ESPEY LL, 1965, AM J PHYSIOL, V208, P208, DOI 10.1152/ajplegacy.1965.208.1.208; ESPEY LL, 1967, AM J PHYSIOL, V212, P1397, DOI 10.1152/ajplegacy.1967.212.6.1397; HAMABATA T, 1994, J BIOL CHEM, V269, P17899; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43, DOI 10.1016/s0074-7696(08)61524-7; ICHINOSE A, 1984, FEBS LETT, V175, P412, DOI 10.1016/0014-5793(84)80779-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU YX, 1991, EUR J BIOCHEM, V195, P549, DOI 10.1111/j.1432-1033.1991.tb15736.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILWIDSKY A, 1989, FERTIL STERIL, V52, P274; NY T, 1988, DNA-J MOLEC CELL BIO, V7, P671, DOI 10.1089/dna.1988.7.671; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; REICH R, 1985, ENDOCRINOLOGY, V116, P516, DOI 10.1210/endo-116-2-516; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; Rondell P., 1970, Biol. Reprod., V2, P64, DOI 10.1095/biolreprod2.Supplement_2.64; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; Schochet SS, 1916, ANAT REC, V10, P447, DOI 10.1002/ar.1090100605; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAHASHI T, 1992, ZOOL SCI, V9, P343; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAFRIRI A, 1989, ENDOCRINOLOGY, V124, P415, DOI 10.1210/endo-124-1-415; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x	28	9	9	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19391	19394		10.1074/jbc.270.33.19391	http://dx.doi.org/10.1074/jbc.270.33.19391			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642619	hybrid			2022-12-27	WOS:A1995RP70300033
J	BURGESS, TL; ROSS, SL; QIAN, YX; BRANKOW, D; HU, S				BURGESS, TL; ROSS, SL; QIAN, YX; BRANKOW, D; HU, S			BIOSYNTHETIC PROCESSING OF NEU DIFFERENTIATION FACTOR - GLYCOSYLATION, TRAFFICKING, AND REGULATED CLEAVAGE FROM THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INDUCING ACTIVITY; GLIAL GROWTH-FACTOR; TGF-ALPHA; ACETYLCHOLINE-RECEPTOR; KIT-LIGAND; TRANSMEMBRANE; EXPRESSION; PROTEIN; GENE; AMPLIFICATION	neu differentiation factor (NDF), also known as heregulin, is structurally related to the epidermal growth factor family of growth factors; it stimulates tyrosine phosphorylation of the neu/HER-2 oncogene and causes differentiation of certain human breast cancer cell lines, Alternative splicing of a single gene gives rise to multiple isoforms of NDF/heregulin, as well as the neuronal homologues, designated ARIA (acetylcholine receptor inducing activity) and GGF (glial growth factor); at least 15 structural variants are known. All but two of the NDF/heregulin cDNAs are predicted to encode transmembrane, glycosylated precursors of soluble NDF. In this report we characterized the biosynthetic processing of different NDF isoforms in stably transfected Chinese hamster ovary cells expressing individual NDF isoforms, and in the native cell line Rat 1-EJ, which expresses at least six different NDF isoforms. We found that the precursors for NDF undergo typical glycosyIation and trafficking. A portion of the molecules are proteolyticafly cleaved intracellularly leading to the constitutive secretion of soluble, mature NDF into the culture media, However, a significant portion of the newly synthesized NDF precursor molecules escape intracellufar cleavage and are transported to the cell surface of both transfected and native cells, where they reside as fulllength, transmembrane proteins. Finally we show that these full-length, transmembrane NDF molecules can undergo phorbol ester regulated cleavage from the membrane, releasing the soluble growth factor into the medium.			BURGESS, TL (corresponding author), AMGEN INC,DEPT MAMMALIAN CELL MOLEC BIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BERGER MS, 1988, CANCER RES, V48, P1238; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CORFAS G, 1993, J NEUROSCI, V13, P2118; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; HAFEN E, 1994, PROG NEUROBIOL, V42, P287, DOI 10.1016/0301-0082(94)90067-1; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LU HS, 1995, IN PRESS J BIOL CHEM; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Ullrich Axel, 1989, SCIENCE, V244, P707, DOI DOI 10.1126/SCIENCE.2470152; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Woods D F, 1993, J Cell Sci Suppl, V17, P171; YAMAMOTO D, 1994, BIOESSAYS, V16, P237, DOI 10.1002/bies.950160406; YEOMAN LC, 1993, ONCOL RES, V5, P489	49	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19188	19196		10.1074/jbc.270.32.19188	http://dx.doi.org/10.1074/jbc.270.32.19188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642587				2022-12-27	WOS:A1995RN95400075
J	TAKAHASHI, K; YONEZAWA, K; NISHIMOTO, I				TAKAHASHI, K; YONEZAWA, K; NISHIMOTO, I			INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR-ACTIVATED BY A TRANSMEMBRANE MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANTIBODY ALPHA-IR-3; PROTEIN-KINASES; POINT MUTATION; SIGNAL; DOMAIN; SUBSTITUTION; SPECIFICITY; ONCOPROTEIN; EXPRESSION	We constructed mutant receptors by mutating transmembrane Val(922) of the human insulin-like growth factor I receptor (IGF-IR). Assays of receptor kinase and autophosphorylation revealed constitutively augmented tyrosine kinase activity of V922E IGF-IR in both transient and stable expression. The constitutively active tyrosine kinase of this mutant was verified by promoted tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in the absence of IGF-I. In CHO cells stably expressing V922E IGF-IR, both IRS-1 phosphorylation and the IRS-1-associated phosphoinositide 3-kinase activity were stimulated in the absence of IGF-I to the level attained by 1 nM IGF-I stimulation of wild type IGF-IR, whereas the Ras-mitogen-activated protein kinase pathway was not activated under the same condition. In these CHO cells, V922E IGF-IR significantly stimulated glucose uptake but did not promote mitogenesis in the absence of IGF-I. We thus conclude that the V922E mutation of IGF-IR switches on the intrinsic tyrosine kinase and differentially activates the downstream pathways. This mutant is extremely useful in clarifying the turning on mechanism of IGF-IR as well as the differential roles of individual downstream pathways of receptor tyrosine kinases.	MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								[Anonymous], 1991, INSULIN LIKE GROWTH; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEZU T, 1994, J BIOL CHEM, V269, P31955; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KOZMA LM, 1990, MOL CELL BIOL, V10, P1301; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LONGO N, 1992, J BIOL CHEM, V267, P12416; MIURA M, 1994, CANCER RES, V54, P2472; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIAO S, 1994, J BIOL CHEM, V269, P21244; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YONEZAWA K, 1992, J BIOL CHEM, V267, P23435; ZHANG B, 1992, J BIOL CHEM, V267, P18320	41	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19041	19045		10.1074/jbc.270.32.19041	http://dx.doi.org/10.1074/jbc.270.32.19041			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642566	hybrid			2022-12-27	WOS:A1995RN95400054
J	WANGE, RL; GUITIAN, R; ISAKOV, N; WATTS, JD; AEBERSOLD, R; SAMELSON, LE				WANGE, RL; GUITIAN, R; ISAKOV, N; WATTS, JD; AEBERSOLD, R; SAMELSON, LE			ACTIVATING AND INHIBITORY MUTATIONS IN ADJACENT TYROSINES IN THE KINASE DOMAIN OF ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL ANTIGEN RECEPTOR; ZETA-CHAIN; PROTEIN; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PP60C-SRC; SITES; REPLACEMENT; PERVANADATE; EXPRESSION	ZAP-70 is a 70-kDa protein tyrosine kinase, expressed exclusively in T cells and NK cells, and plays a critical role in mediating T cell activation in response to T cell receptor engagement, The strong correlation between tyrosine phosphorylation of ZAP-70 and its acquisition of increased kinase activity suggests that it is positively regulated by tyrosine phosphorylation, Previously, we identified tyrosines 492 and 493 of ZAP-70 as being sites of in vivo phosphorylation in response to T cell receptor engagement, To determine the role of phosphorylation in regulating ZAP-70 activity, we mutated each of these tyrosines individually to phenylalanine, When expressed in COS cells, Y493F-mutated ZAP-70 demonstrated normal basal kinase activity, but, unlike wild type ZAP-70, could not be activated by tyrosine phosphorylation induced by incubation with pervanadate or by co-expression of constitutively activated Lck, This suggests that Tyr-493 phosphorylation is required for the tyrosine phosphorylation-induced activation of ZAP-70, The Y492F mutation resulted in 4-fold higher basal kinase activity, which could be stimulated further by tyrosine phosphorylation, These results reveal that critical tyrosine residues in the kinase domain of ZAP-70 are important in regulation of its catalytic activity.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Washington; University of Washington Seattle			Wange, Ronald/AAI-2505-2021	Isakov, Noah/0000-0002-1412-0957; Wange, Ronald/0000-0001-9593-3572				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHU HKG, 1994, MOL CELL BIOL, V14, P6868, DOI 10.1128/MCB.14.10.6868; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; ZHANG B, 1991, J BIOL CHEM, V266, P990	42	175	177	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18730	18733		10.1074/jbc.270.32.18730	http://dx.doi.org/10.1074/jbc.270.32.18730			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642520	hybrid			2022-12-27	WOS:A1995RN95400006
J	YAGI, H; KATO, T; NAGATA, T; HABU, T; NOZAKI, M; MATSUSHIRO, A; NISHIMUNE, Y; MORITA, T				YAGI, H; KATO, T; NAGATA, T; HABU, T; NOZAKI, M; MATSUSHIRO, A; NISHIMUNE, Y; MORITA, T			REGULATION OF THE MOUSE HISTONE H2A.X GENE PROMOTER BY THE TRANSCRIPTION FACTOR E2F AND CCAAT BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; MESSENGER-RNA; SITE; REPRESSION; INTERACTS; COMPLEXES; SEQUENCE; ELEMENTS; PRODUCT	We have molecularly cloned the genomic gene encoding the mouse histone variant H2A.X and characterized the promoter, The promoter region of the H2A.X gene was characterized by chloramphenicol acetyltransferase analysis using Balb/c 3T3 cells, Maximal promoter activity was found in the construct containing up to -282 base pairs H2A.X upstream region, Within this region, we found two sequences regulating the promoter activation: one was an E2F site and another was a CCAAT box, These sequences were also required for the DNA/protein binding activities, Thus, these activities corresponded to the promoter activities, implying that the promoter activity of H2A.X gene was controlled by both the transcription factor E2F and H1TF2 through the E2F and CCAAT element, The CCAAT box binding activity was constitutive when cell cycle was progressed by release from G1 arrest, but transiently transfected chloramphenicol acetyltransferase activity slightly increased when cells entered S phase, Similarly, the level of the smallest form of E2F (free E2F) became higher when cells reentered the cell cycle, indicating that the free E2F was one capable of inducing the promoter activation, Thus, the free E2F and CCAAT DNA binding activity correlated with regulation of the promoter activity.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC EMBRYOL,SUITA,OSAKA 565,JAPAN; KINKI UNIV,FAC BIOL SCI,DEPT BIOTECHNOL,WAKAYAMA 64964,JAPAN	Osaka University; Kindai University (Kinki University)			Habu, Toshiyuki/ABC-6644-2021	Habu, Toshiyuki/0000-0003-4131-3938; Kato, Tomohisa/0000-0002-3047-9847				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUANG SY, 1986, P NATL ACAD SCI USA, V83, P3738, DOI 10.1073/pnas.83.11.3738; IVANOVA VS, 1994, J BIOL CHEM, V269, P24189; KEYOMARSI K, 1991, CANCER RES, V5, P3602; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NAGATA T, 1991, NUCLEIC ACIDS RES, V19, P2441, DOI 10.1093/nar/19.9.2441; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN GS, 1994, J CELL BIOCHEM, V45, P393; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zweidler A, 1984, HISTONE GENES STRUCT, P339	40	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18759	18765		10.1074/jbc.270.32.18759	http://dx.doi.org/10.1074/jbc.270.32.18759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642525	hybrid			2022-12-27	WOS:A1995RN95400012
J	DECOSTER, E; VANHAESEBROECK, B; VANDENABEELE, P; GROOTEN, J; FIERS, W				DECOSTER, E; VANHAESEBROECK, B; VANDENABEELE, P; GROOTEN, J; FIERS, W			GENERATION AND BIOLOGICAL CHARACTERIZATION OF MEMBRANE-BOUND, UNCLEAVABLE MURINE TUMOR-NECROSIS-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTORS; FACTOR-ALPHA; CELL-LINES; FACTOR TNF; MONOCLONAL-ANTIBODIES; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; GM-CSF; EXPRESSION	Tumor necrosis factor (TNF) is produced as a membrane-bound, 26-kDa preform from which the mature, 17-kDa TNF subunit is released by proteolytic cleavage. In order to compare the biological activity of membrane-bound versus soluble TNF, mutational analysis of potential cleavage sites in murine TNF was carried out. The biological activity was assessed after transfection in L929 cells. Deletion of the first nine codons of the mature part of the murine TNF gene still led to the production of secretable TNF, indicating alternative cleavage sites separate from the -1/+1junction. However, an additional deletion of 3 amino acids, generating TNF Delta 1-12, resulted in a membrane-bound form of TNF. Site-directed mutagenesis revealed Lys(11) as the critical residue for alternative cleavage. Mutation of this residue to Glu in a TNF Delta 1-9 mutant gave rise to uncleavable, membrane-bound TNF with biological activities similar to wild-type TNF. Induction of apoptosis, proliferation, or cytokine production by triggering of either 55-kDa or 75-kDa TNF receptors in appropriate cell lines occurred efficiently both with soluble and with membrane-bound TNF. The latter was, however, less active in the cytotoxic assays on U937 cells in which the 75-kDa TNF receptor is not signaling, but contributes to maximal TNF activity by ligand passing. This indicates that membrane-bound TNF cannot be passed from the 75-kDa to the 55-kDa TNF receptor.	STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM	Ghent University			Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822				BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARLINO JA, 1987, J BIOL CHEM, V263, P958; CREASEY AA, 1987, CANCER RES, V47, P145; DECKER T, 1987, J IMMUNOL, V138, P957; DELAMARTER JF, 1985, EMBO J, V4, P2575, DOI 10.1002/j.1460-2075.1985.tb03973.x; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Fiers W, 1993, NATURAL IMMUNE SYSTE, P65; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; KIM KU, 1993, IMMUNOLOGY, V80, P134; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; OSAWA T, 1989, DEV BIOL, V135, P459; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; RANGES GE, 1989, J IMMUNOL, V142, P1203; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SCUDERI P, 1989, EUR J IMMUNOL, V19, P939, DOI 10.1002/eji.1830190523; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SHERRY B, 1990, BIOCHEM BIOPH RES CO, V173, P1072, DOI 10.1016/S0006-291X(05)80895-2; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TAVERNIER J, 1990, J MOL BIOL, V211, P493, DOI 10.1016/0022-2836(90)90367-U; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1994, ANNU REV IMMUNOL, V12, P491; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANDENABEELE P, 1990, LYMPHOKINE RES, V9, P381; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	54	99	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18473	18478		10.1074/jbc.270.31.18473	http://dx.doi.org/10.1074/jbc.270.31.18473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629174	hybrid			2022-12-27	WOS:A1995RM64200051
J	PRASAD, MVVSV; DERMOTT, JM; HEASLEY, LE; JOHNSON, GL; DHANASEKARAN, N				PRASAD, MVVSV; DERMOTT, JM; HEASLEY, LE; JOHNSON, GL; DHANASEKARAN, N			ACTIVATION OF JUN KINASE STRESS-ACTIVATED PROTEIN-KINASE BY GTPASE-DEFICIENT MUTANTS OF G-ALPHA(12) AND G-ALPHA(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; DNA-BINDING; GENE; PHOSPHORYLATION; TRANSCRIPTION; COOPERATION; EXPRESSION; FAMILY; DOMAIN; CELLS	Signal transduction pathways regulated by G(12) and G(13) heterotrimeric G proteins are largely unknown, Expression of activated, GTPase-deficient mutants of alpha(12) and alpha(12) alter physiological responses such as Na+/H+ exchanger activity, but the effector pathways controlling these responses have not been defined, We have found that the expression of GTPase-deficient mutants of alpha(12) (alpha(12)Q229L) or alpha(13) (alpha(13)Q226L) leads to robust activation of the Jun kinase/stress-activated protein kinase (JNK/SAPK) pathway. Inducible alpha(12)Q226L and alpha(13)Q226L expression vectors stably transfected in NIH 3T3 cells demonstrated JNK/SAPK activation but not extracellular response/mitogen-activated protein kinase activation, Transient transfection of alpha(12)Q229L and alpha(13)Q226L also activated the JNK/SAPK pathway in COS-1 cells, Expression of the GTPase-deficient mutant of alpha(q) (alpha(q)Q209L) but not alpha(i) (alpha(i)Q205L) or alpha(s) (alpha(s)Q227L) was also able to activate the JNK/SAPK pathway, Functional Ras signaling was required for alpha(12)Q229L and alpha(13)Q226L activation of the JNK/SAPK pathway; expression of competitive inhibitory N(17)Ras inhibited JNK/SAPK activation in response to both alpha(12)Q229L and alpha(13)Q226L. The results describe for the first time a Ras-dependent signal transduction pathway involving JNK/SAPK regulated by alpha(12) and alpha(13).	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV COLORADO,SCH MED,DEPT RENAL MED,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NCI NIH HHS [CA 58187, 5-P30-CA 12227] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRD TA, 1994, J BIOL CHEM, V269, P31836; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRINSTEIN S, 1994, BIOCHEM SOC T, V22, P512, DOI 10.1042/bst0220512; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KRYIAKIS JM, 1994, NATURE, V369, P156; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V10, P6683; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798	34	172	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18655	18659		10.1074/jbc.270.31.18655	http://dx.doi.org/10.1074/jbc.270.31.18655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629196	hybrid			2022-12-27	WOS:A1995RM64200078
J	DOMANSKI, P; WITTE, M; KELLUM, M; RUBINSTEIN, M; HACKETT, R; PITHA, P; COLAMONICI, OR				DOMANSKI, P; WITTE, M; KELLUM, M; RUBINSTEIN, M; HACKETT, R; PITHA, P; COLAMONICI, OR			CLONING AND EXPRESSION OF A LONG FORM OF THE BETA-SUBUNIT OF THE INTERFERON ALPHA-BETA RECEPTOR THAT IS REQUIRED FOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELLS	The interferon alpha beta receptor (IFN alpha R) or type I IFN-R is formed by a 110-kDa alpha subunit or IFNAR and by a beta subunit, which has short and long forms (molecular masses of 55 and 95-100 kDa, respectively). In this report, we demonstrate that the IFN alpha/beta R cDNA recently cloned corresponds to the 55-kDa or short form of the beta subunit, while the 95-100-kDa species reported here corresponds to a longer form of the IFN alpha/beta R cDNA that is probably produced by alternative splicing of the same gene. Stable transfection of the alpha subunit with either form of the beta subunit results in the expression of low and high affinity receptors, while expression of either form of the beta subunit alone only produces low affinity receptors. More important, only expression of the alpha and long form of the human beta subunits in mouse L-929 cells reconstitutes the activation of the Jak kinases and the Stat factors, as well as the antiviral response to human type I IFNs.	UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; US FDA,BETHESDA,MD 20892	University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Weizmann Institute of Science; US Food & Drug Administration (FDA)					NCI NIH HHS [CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1994, J BIOL CHEM, V269, P27275; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1989, GENE DEV, V3, P1203; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PLATANIAS LC, 1993, J IMMUNOL, V150, P3226; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	23	234	244	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21606	21611		10.1074/jbc.270.37.21606	http://dx.doi.org/10.1074/jbc.270.37.21606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665574	hybrid			2022-12-27	WOS:A1995RU75700030
J	EKBERG, K; CHANDRAMOULI, V; KUMARAN, K; SCHUMANN, WC; WAHREN, J; LANDAU, BR				EKBERG, K; CHANDRAMOULI, V; KUMARAN, K; SCHUMANN, WC; WAHREN, J; LANDAU, BR			GLUCONEOGENESIS AND GLUCURONIDATION IN LIVER IN-VIVO AND THE HETEROGENEITY OF HEPATOCYTE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							60-HOUR FASTED HUMANS; METABOLISM; FRUCTOSE	In order to examine metabolic zonation in human liver, [2-C-14]glycerol, which labels carbons 2 and 5 of glucose-6-P, and [1-C-14]lactate, which labels carbons 3 and 4 of glucose-6-P, in the process of gluconeogenesis, were infused intravenously into healthy subjects who ingested acetaminophen and had fasted 36 h. Distributions of C-14 were determined in glucose in blood and in the glucuronic acid moiety of acetaminophen glucuronide excreted in urine. Ratios of C-14 in carbons 2 and 5 to C-14 in carbons 3 and 4 were significantly higher in blood glucose than in glucuronide. Since glucose and glucuronic acid are formed from glucose-6-P in liver without randomization of carbon, the differences in the ratios indicate that the pool of glucose-6-P in liver is not homogeneous. The glucuronide sampled glucose-6-P with more label from lactate than glycerol compared to the glucose-6-P sampled by the glucose. The apparent explanation is the greater decrease in glycerol compared with lactate concentration as blood streams from the periportal to the perivenous zones of the liver lobule. Glucuronidation is then expressed in humans relatively more in the perivenous than periportal zones and gluconeogenesis from glycerol more in the periportal than perivenous zones.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; KAROLINSKA HOSP,DEPT CLIN PHYSIOL,S-17671 STOCKHOLM,SWEDEN	Case Western Reserve University; Case Western Reserve University; Karolinska Institutet; Karolinska University Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014507, R01DK014507] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 14507] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORKMAN O, 1980, DIABETES, V29, P610, DOI 10.2337/diab.29.8.610; BJORKMAN O, 1982, DIABETES, V31, P516, DOI 10.2337/diabetes.31.6.516; CERSOSIMO E, 1994, J CLIN INVEST, V93, P2584, DOI 10.1172/JCI117270; Dutton G. J., 1980, GLUCURONIDATION DRUG, P149; HOSTETLER KY, 1969, J BIOL CHEM, V244, P2075; JUNGERMANN K, 1989, PHYSIOL REV, V69, P703; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; MAGNUSSON I, 1988, P NATL ACAD SCI USA, V85, P4682, DOI 10.1073/pnas.85.13.4682; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; SNEDECOR GW, 1980, STATISTICAL METHODS, P54; WAHREN J, 1977, J CLIN INVEST, V59, P299, DOI 10.1172/JCI108641; WALS PA, 1988, J BIOL CHEM, V263, P4876	14	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21715	21717		10.1074/jbc.270.37.21715	http://dx.doi.org/10.1074/jbc.270.37.21715			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665589	hybrid			2022-12-27	WOS:A1995RU75700047
J	JACKSON, SM; ERICSSON, J; OSBORNE, TF; EDWARDS, PA				JACKSON, SM; ERICSSON, J; OSBORNE, TF; EDWARDS, PA			NF-Y HAS A NOVEL ROLE IN STEROL-DEPENDENT TRANSCRIPTION OF 2 CHOLESTEROGENIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIPOPROTEIN RECEPTOR PROMOTER; MHC CLASS-II; REGULATORY ELEMENT; NUCLEAR-PROTEIN; BINDING; REDUCTASE; SEQUENCE; CLONING	The transcription of farnesyl diphosphate (FPP) synthase is regulated up to 30-fold by the sterol status of the cell. Point mutations in a 6-base pair ATTGGC sequence in the promoter disrupt both sterol-dependent transcription in vivo as well as binding of the transcription factor NF-Y in vitro. Co-transfection of cells with NF YA29, a dominant negative form of NF-Y, and various promoter-reporter genes specifically inhibits the sterol-dependent regulation of FPP synthase and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase. In contrast, NP-YA29 does not affect the regulation of reporter genes under the control of promoters derived from either the HMG-CoA reductase or the low density lipoprotein receptor gene. Transient expression of the 68 kDa transcriptionally active fragment of sterol regulatory element-binding protein in cells stimulates an HMG-CoA synthase-reporter gene over 90-fold. This induction is blocked in cells eo expressing NF-YA29. We hypothesize that NF-Y plays a novel role in sterol-de pendent regulation of two key genes in the cholesterol biosynthetic pathway and that this role requires a specific interaction with the sterol regulatory element-binding protein or related transcription factors.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Irvine			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NHLBI NIH HHS [HL48044, HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TRONCHE F, 1991, J MOL BIOL, V221, P31; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; WANG XD, 1993, J BIOL CHEM, V268, P14497; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	26	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21445	21448		10.1074/jbc.270.37.21445	http://dx.doi.org/10.1074/jbc.270.37.21445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665553	hybrid			2022-12-27	WOS:A1995RU75700005
J	AKOMPONG, T; INMAN, RS; WESSLINGRESNICK, M				AKOMPONG, T; INMAN, RS; WESSLINGRESNICK, M			PHORBOL ESTERS STIMULATE NON-TRANSFERRIN IRON UPTAKE BY K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; BOUND IRON; DIFFERENTIATION; TRANSPORT; RECEPTORS; RETICULOCYTES; INDUCTION; BINDING; SYSTEM; LINE	Characterization of non-transferrin (non-Tf) iron transport by K562 cells has revealed unique properties relative to iron uptake mechanisms present in other cell types (Inman, R. S., and Wessling-Resnick, M, (1993) J, Biol, Chem, 268, 8521-8528). Since treatment of K562 cells with phorbol esters promotes stable megakaryocytic differentiation, we examined the uptake of non-Tf iron in response to protein kinase C activation, Treatment of K562 cells with phorbol esters increased the cellular uptake of Fe-56 4-6-fold compared with untreated cells. The phorbol ester-induced stimulation of Fe-55 uptake was time and dose-dependent, with significantly enhanced transport observed only after prolonged administration of 50 nM phorbol 12,13-dibutyrate (> 8 h). These effects can be attributed to an increased V-max of transport (14.0 +/- 5 versus 0.6 +/- 0.2 pmol/min/10(6) cells) as well as a 6-fold increase in the apparent K-m (1.2 +/- 0.4 versus 0.2 +/- 0.06 mu M) It is thought that the reduction of Fe3+ to Fe2+ is required as a first step in the uptake mechanism, and the associated ferrireductase activity of K562 cells is also enhanced with phorbol ester treatment by 5-10-fold (337 +/- 53 versus 43 +/- 3 pmol/min/10(6) cells), Bryostatin-1, a protein kinase C activator that fails to induce differentiation of K562 cells, did not promote this effect, indicating that the enhanced transport activity is dependent on the differentiation response, The idea that synthesis of a new class of transporters is responsible for this effect is supported by the observation that actinomycin D blocks up-regulation of non-Tf iron transport. The increased transport and ferrireductase activity induced upon differentiation also correlate with the appearance of saturable iron-binding sites on the surface of K562 cells with K-d similar to 0.4 mu M. These results indicate that non-Tf iron transport activity and the expression of cell surface iron-binding proteins can be controlled by environmental factors that promote megakaryocytic differentiation of K562 cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK095737] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK95737] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BARISANI D, 1995, IN PRESS AM J PHYSL; BASSET P, 1986, CANCER RES, V46, P1644; CONRAD ME, 1994, J BIOL CHEM, V269, P7169; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; HO PTC, 1989, CANCER RES, V49, P1989; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HU HYY, 1977, SCIENCE, V197, P559, DOI 10.1126/science.267327; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; QIAN ZM, 1991, BIOCHIM BIOPHYS ACTA, V1073, P456, DOI 10.1016/0304-4165(91)90215-3; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEI I, 1982, BIOCHEM BIOPH RES CO, V107, P1419, DOI 10.1016/S0006-291X(82)80157-5; TESTA U, 1984, CANCER RES, V44, P4981; TESTA U, 1982, EXP CELL RES, V140, P251, DOI 10.1016/0014-4827(82)90112-4; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; YEH CJG, 1982, EXP CELL RES, V138, P429, DOI 10.1016/0014-4827(82)90192-6	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20937	20941		10.1074/jbc.270.36.20937	http://dx.doi.org/10.1074/jbc.270.36.20937			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673117	hybrid			2022-12-27	WOS:A1995RU05400014
J	HERZIG, MCS; LEEBLUNDBERG, LMF				HERZIG, MCS; LEEBLUNDBERG, LMF			THE AGONIST BINDING-SITE ON THE BOVINE BRADYKININ B2 RECEPTOR IS ADJACENT TO A SULFHYDRYL AND IS DIFFERENTIATED FROM THE ANTAGONIST BINDING-SITE BY CHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID-CELLS; SWISS 3T3 CELLS; LIGAND-BINDING; NEURO-BLASTOMA; PHARMACOLOGICAL CHARACTERIZATION; N-ETHYLMALEIMIDE; KININ RECEPTORS; HORMONE BINDING; PHOSPHOLIPASE-C; PROTEINS	Chemical cross-linking was used to analyze the binding sites for the agonist bradykinin (BK) and the antagonists NPC17731 and HOE140 on the bovine B2 bradykinin receptor. [H-3]BK and [H-3]NPC17731 bound with high affinity to the same B2 receptor in bovine myometrial membranes as determined by the total number of specific binding sites and pharmacological specificity of the binding of these two radioligands. Cross-linking experiments were done using a series of bifunctional reagents reactive either primarily to amines (homobifunctional) or reactive to amines in one end and to sulfhydryls in the opposite end (heterobifunctional). All the heterobifunctional reagents plus the homobifunctional arylhalide 1,5-difluoro-2,4-dinitrobenzene were effective in cross-linking the [H-3]BK N terminus specifically to a sulfhydryl in the receptor, and this crosslinking occurred at 5-100 mu M reagent, In contrast, the homobifunctional N-hydroxysuccinimide ester reagents, at less than or equal to 1 mM, were only able to cross-link [H-3]BK to membrane proteins nonspecifically. The sulfhydryl reagents N-ethylnaleimide, iodoacetamide, and phenylarsine oxide blocked cross linking, whereas these re agents did not inhibit reversible specific [H-3]BK binding. Immunoblotting with anti-BK antiserum revealed that low concentrations of BK (5-50 mu M) were cross-linked to a receptor-specific species of 65 kDa. All cross-linking of [H-3]NPC17731 was nonspecific with both homobifunctional and heterobifunctional reagents. The 65 kDa receptor specific species was observed on anti-HOE140 immunoblots, but only when proteins were cross linked with very high concentrations of HOE140 (greater than or equal to 500 nM). Our results provide direct biochemical evidence that the binding site for the agonist BK in the bovine B2 receptor is adjacent to a cysteine and is differentiated from the binding site(s) for the antagonists NPC17731 and HOE140.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [GM41659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDALLA S, 1993, J BIOL CHEM, V268, P17277; ASANO T, 1986, MOL PHARMACOL, V29, P244; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1993, MOL BIOL PHARM BRADY, P81; BURCH RM, 1993, MOL BIOL PHARM BRADY, P7; DELACADENA RA, 1993, BLOOD, V81, P3313; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FARMER SG, 1991, IMMUNOPHARMACOLOGY, V22, P1, DOI 10.1016/0162-3109(91)90051-Y; FONG TM, 1992, J BIOL CHEM, V267, P25664; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FREDRICK MJ, 1984, BIOCHEM PHARMACOL, V33, P2887, DOI 10.1016/0006-2952(84)90212-0; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIGASHIDA H, 1986, P NATL ACAD SCI USA, V83, P942, DOI 10.1073/pnas.83.4.942; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; HONG SL, 1978, J BIOL CHEM, V251, P5814; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; JI TH, 1983, METHOD ENZYMOL, V91, P580; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1991, BRADYKININ ANTAGONIS, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE RTW, 1989, NEUROPEPTIDES, V14, P51, DOI 10.1016/0143-4179(89)90034-6; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; MATHIS SA, 1991, BIOCHEM J, V276, P141, DOI 10.1042/bj2760141; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; REISER G, 1982, BRAIN RES, V239, P191, DOI 10.1016/0006-8993(82)90841-1; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERANKA LR, 1991, BRADYKININ ANTAGONIS, P191; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; Weipert J, 1989, Prog Clin Biol Res, V308, P983; WILSON DD, 1989, CIRC SHOCK, V27, P93; Wold F, 1972, Methods Enzymol, V25, P623, DOI 10.1016/S0076-6879(72)25061-3; YANO K, 1984, J BIOL CHEM, V259, P201; YAQOOB M, 1994, J NEUROCHEM, V62, P17	63	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20591	20598		10.1074/jbc.270.35.20591	http://dx.doi.org/10.1074/jbc.270.35.20591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657637	hybrid			2022-12-27	WOS:A1995RR58400056
J	KAPLON, T; JACQUET, M				KAPLON, T; JACQUET, M			THE CELLULAR CONTENT OF CDC25P, THE RAS EXCHANGE FACTOR IN SACCHAROMYCES-CEREVISIAE, IS REGULATED BY DESTABILIZATION THROUGH A CYCLIN DESTRUCTION BOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL PART; GENE-PRODUCT; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PROTEIN-KINASE; LACZ FUSIONS; YEAST-CELLS; HEAT-SHOCK; CAMP; CONSTRUCTION	The Cdc25p and Sdc25p proteins were the first members of the family of guanine nucleotide exchange factors to be identified. These proteins promote the formation of active Ras . GTP complex from inactive Ras . GDP complex by exchange of GDP for GTP. Therefore Cdc25p which is the main positive regulator of Ras, regulates through Ras the activity of adenylate cyclase in Saccharomyces cerevisiae. The amino terminal part of Cdc25p has a sequence similar to the cyclin destruction box (CDB) of mitotic cyclins. This sequence has been reported to be required for ubiquitin-dependent proteolysis. In this study we show that Cdc25p is an unstable polypeptide with a half-life of 15-20 min. Its instability depends upon the presence of the CDB which can also confer instability to other proteins. Degradation of Cdc25p and CDB containing beta-galactosidase was found to be independent of various cell cycle arrest points. The fast degradation of Cdc25p opens the possibility that Ras and the cAMP cascade in yeast are directly modulated by the cellular content of the guanine nucleotide exchange factor rather than variation in activity or localization control.	UNIV PARIS 11, INST GENET & MICROBIOL,INFORMAT GENET & DEV GRP, CNRS,URA 1354, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; BOYMARCOTTE E, 1993, CURR GENET, V23, P397, DOI 10.1007/BF00312625; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DAIGNANFORNIER B, 1988, GENE, V62, P45, DOI 10.1016/0378-1119(88)90578-1; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GROSS E, 1992, MOL CELL BIOL, V12, P2653, DOI 10.1128/MCB.12.6.2653; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2647; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MARINUS MG, 1975, MUTAT RES, V28, P15, DOI 10.1016/0165-1218(75)90278-5; MARTEGANI E, 1986, EMBO J, V5, P2363, DOI 10.1002/j.1460-2075.1986.tb04505.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NUGENT JHA, 1991, J CELL SCI, V99, P669; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RICHAUD C, 1987, J BACTERIOL, V169, P1454, DOI 10.1128/jb.169.4.1454-1459.1987; Rose MD., 1990, METHODS YEAST GENETI; RUBY SW, 1983, METHOD ENZYMOL, V101, P253; Sambrook J, 1989, MOL CLONING LABORATO; SCALFANI RA, 1984, P NATL ACAD SCI USA, V81, P5821; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; VANAELST L, 1990, EUR J BIOCHEM, V193, P675; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989	48	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20742	20747		10.1074/jbc.270.35.20742	http://dx.doi.org/10.1074/jbc.270.35.20742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657656	hybrid			2022-12-27	WOS:A1995RR58400077
J	MATSUNAGA, T; MU, D; PARK, CH; REARDON, JT; SANCAR, A				MATSUNAGA, T; MU, D; PARK, CH; REARDON, JT; SANCAR, A			HUMAN DNA-REPAIR EXCISION NUCLEASE - ANALYSIS OF THE ROLES OF THE SUBUNITS INVOLVED IN DUAL INCISIONS BY USING ANTI-XPG AND ANTI-ERCC1 ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; STRANDED-DNA; (A)BC EXCINUCLEASE; ACTIVE-SITE; 5' INCISION; ENDONUCLEASE; COMPLEMENTATION; DEFECTS; BINDING; MUTANTS	Human DNA repair excision nuclease removes DNA damage by incising on both sides of the lesion in a precise manner. The activity requires participation of 16-17 polypeptides. Of these, the XPF . ERCC1 complex and XPG were predicted to carry the nuclease active sites based on studies with the recombinant proteins and the yeast homologs of these proteins. Furthermore, recent work with model (undamaged) substrates have led to predictions of the roles of these proteins in incising 5' or 3' to the lesion. We have used damaged DNA substrates and antibodies to XPG and ERCC1 to test these predictions. Our results reveal that anti-XPG antibodies change the site of 3' incision and at high concentration inhibit the 3' incision without significantly affecting the 5' incision, indicating that XPG makes the 3' incision and further that under this condition 5' incision can occur without 3' incision. In contrast, anti-ERCC1 antibodies inhibit both the 3' and 5' incisions. Using a defined system for excision repair we also demonstrate that the 3' incision can occur without the 5' incision, leading us to conclude that under certain conditions the two incisions can occur independently.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; FRIEDBERG EC, 1995, DNA REPAIR; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TATEISHI S, 1993, BIOCHEMISTRY-US, V32, P1541, DOI 10.1021/bi00057a019; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1988, MUTAT RES, V193, P123, DOI 10.1016/0167-8817(88)90042-9	29	174	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20862	20869		10.1074/jbc.270.35.20862	http://dx.doi.org/10.1074/jbc.270.35.20862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657672	hybrid			2022-12-27	WOS:A1995RR58400093
J	ZHANG, CS; LU, Q; VERMA, DPS				ZHANG, CS; LU, Q; VERMA, DPS			REMOVAL OF FEEDBACK INHIBITION OF DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHETASE, A BIFUNCTIONAL ENZYME CATALYZING THE FIRST 2 STEPS OF PROLINE BIOSYNTHESIS IN PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DELTA-1-PYRROLINE-5-CARBOXYLATE REDUCTASE; OSMOTIC-STRESS; WATER STRESS; GENE; KINASE; TOLERANCE	Delta(1)-Pyrroline-5 carboxylate synthetase (P5CS) catalyzes the first two steps in proline biosynthesis in plants. The Vigna aconitifolia P5CS cDNA was expressed in Escherichia coli, and the enzyme was purified to homogeneity. The Vigna P5CS exhibited two activities, gamma-glutamyl kinase (gamma-GK) and glutamic acid-5-semialdehyde (GSA) dehydrogenase. The gamma-GK activity of the P5CS was detected by the hydroxamate assay and by a [C-14]glutamate assay. The native molecular mass of the P5CS was 450 kDa with six identical subunits. The Vigna P5CS showed a K-m of 3.6 mM for glutamate, while the K-m for ATP was 2.7 mM. The gamma-GK activity of the P5CS was competitively inhibited by proline, while its GSA dehydrogenase activity was insensitive to proline. In addition, a protein inhibitor of the P5CS was observed in the plant cell. Western blot showed that the level of the P5CS was enhanced in Vigna root under salt stress. A single substitution of an alanine for a phenylalanine at amino acid residue 129 of the P5CS resulted in a significant reduction of proline feedback inhibition. The 50% inhibition values of gamma-GK activity of the wild type and the mutant P5CS were observed at 5 mM and 960 mM proline, respectively. The other properties of the mutant P5CS remained unchanged. These results may allow genetic manipulation of proline biosynthesis and overproduction of proline in plants for conferring water stress tolerance.	OHIO STATE UNIV,CTR PLANT BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT PLANT BIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University								ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; BAICH A, 1969, BIOCHIM BIOPHYS ACTA, V192, P462, DOI 10.1016/0304-4165(69)90395-X; BOGGESS S F, 1976, Australian Journal of Plant Physiology, V3, P513; BOGGESS SF, 1976, PLANT PHYSIOL, V58, P398, DOI 10.1104/pp.58.3.398; CSONKA LN, 1988, GENE, V64, P199, DOI 10.1016/0378-1119(88)90335-6; CSONKA LN, 1981, MOL GEN GENET, V182, P82, DOI 10.1007/BF00422771; DANDEKAR AM, 1988, J BACTERIOL, V170, P5943, DOI 10.1128/jb.170.12.5943-5945.1988; DELAUNEY AJ, 1993, PLANT J, V4, P215, DOI 10.1046/j.1365-313X.1993.04020215.x; DELAUNEY AJ, 1993, J BIOL CHEM, V268, P18673; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; GAMPER H, 1974, BIOCHIM BIOPHYS ACTA, V354, P75, DOI 10.1016/0304-4165(74)90055-5; HANSON AD, 1982, ANNU REV PLANT PHYS, V33, P163, DOI 10.1146/annurev.pp.33.060182.001115; HARLOW E, 1988, ANTIBODIES LABORATOR, P61; HAYZER DJ, 1980, J GEN MICROBIOL, V118, P287; HAYZER DJ, 1981, BIOCHEM J, V197, P269, DOI 10.1042/bj1970269; HIGCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LI W, 1992, J BACTERIOL, V174, P4148, DOI 10.1128/jb.174.12.4148-4156.1992; MEZL VA, 1976, ANAL BIOCHEM, V74, P441; RAYAPATI PJ, 1991, PLANT PHYSIOL, V95, P787, DOI 10.1104/pp.95.3.787; RUDULIER DL, 1984, SCIENCE, V224, P1064; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; STEWART CR, 1977, PLANT PHYSIOL, V59, P930, DOI 10.1104/pp.59.5.930; SZOKE A, 1992, PLANT PHYSIOL, V99, P1642, DOI 10.1104/pp.99.4.1642; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x	27	200	227	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20491	20496		10.1074/jbc.270.35.20491	http://dx.doi.org/10.1074/jbc.270.35.20491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657626	hybrid			2022-12-27	WOS:A1995RR58400041
J	TSIANG, M; GIBBS, CS; GRIFFIN, LC; DUNN, KE; LEUNG, LLK				TSIANG, M; GIBBS, CS; GRIFFIN, LC; DUNN, KE; LEUNG, LLK			SELECTION OF A SUPPRESSOR MUTATION THAT RESTORES AFFINITY OF AN OLIGONUCLEOTIDE INHIBITOR FOR THROMBIN USING IN-VITRO GENETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANION-BINDING EXOSITE; STRANDED-DNA APTAMER; RNA; THROMBOMODULIN; RECOGNITION; SPECIFICITY; QUADRUPLEX; FIBRINOGEN; MOLECULES	The thrombin aptamer is a single-stranded DNA of 15 nucleotides that was identified by the selection of thrombin-binding molecules from a large combinatorial library of oligonucleotides. This prototype aptamer of thrombin has a unique double G-tetrad structure capable of inhibiting thrombin at nanomolar concentrations through binding to a specific region within thrombin exosite I. Substitution of arginine 70 in thrombin exosite I with glutamic acid effectively eliminated binding of the prototype thrombin aptamer, In contrast, aptamers selected against R70E thrombin were able to bind and inhibit both wild-type and R70E thrombins, and displayed potassium-independent inhibition. Aptamers selected against R70E thrombin bound to sites identical or overlapping with that of the prototype thrombin aptamer. These aptamers retained the potential to form double G-tetrad structures; however, these structures would be destabilized by a T --> A substitution, disrupting the T-4-T-13 base pairing found in the prototype. This destabilization appeared to be partially compensated by newly recruited structural elements, Thus, selection against R70E thrombin did not lead to aptamers that bound to alternative sites, but instead to ssDNA structures with a suppressor mutation that accommodated the mutation in thrombin within a double G-tetrad context. These results provide insight into the aptamer-thrombin interaction and suggest that the binding site for the prototype is the dominant aptamorigenic site on thrombin.			TSIANG, M (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1992, PROTEIN SCI, V1, P426; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DAVIS S, 1994, J BIOMOL INTERACT AN, V1, P29; EDGINGTON SM, 1993, BIO-TECHNOL, V11, P285, DOI 10.1038/nbt0393-285; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z; GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271; GRIFFIN LC, 1995, IN PRESS MOL REPERTO; GRIFFIN LC, 1995, IN PRESS METHODS MOL; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KENAN DJ, 1994, TRENDS BIOCHEM SCI, V19, P57, DOI 10.1016/0968-0004(94)90033-7; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LI WX, 1994, BLOOD, V83, P677, DOI 10.1182/blood.V83.3.677.677; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MUCKE K, 1987, VIROLOGY, V158, P112; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; RYDEL TJ, 1990, SCIENCE, V249, P7095; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1	35	51	53	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19370	19376		10.1074/jbc.270.33.19370	http://dx.doi.org/10.1074/jbc.270.33.19370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642616	hybrid			2022-12-27	WOS:A1995RP70300030
J	CHAFIN, DR; GUO, HL; PRICE, DH				CHAFIN, DR; GUO, HL; PRICE, DH			ACTION OF ALPHA-AMANITIN DURING PYROPHOSPHOROLYSIS AND ELONGATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; TERNARY COMPLEXES; CALF THYMUS; FACTOR-SII; DNA; INITIATION; INHIBITION; MECHANISM; PROTEIN; INVITRO	Using defined elongation complexes formed on dC-tailed templates with Drosophila RNA polymerase II, we have examined elongation, pyrophosphorolysis, and DmS-II-mediated transcript cleavage and the inhibitory effect of alpha-amanitin on these processes. Analysis of pyrophosphorolysis on soluble or immobilized DNA templates confirmed that NTPs are liberated instead of dinucleotides that are released during DmS-II-meditated transcript cleavage, 10 mu g/ml alpha-amanitin completely inhibited DmS-II-mediated transcript cleavage but allowed extended pyrophosphorolysis and nucleotide addition to occur. alpha-Amanitin dramatically decreased the V-max for nucleotide addition but only slightly affected the K-m for nucleotides. Although the processes are mechanistically distinct, both pyrophosphorolysis and DmS-II-mediated transcript cleavage frequently resulted in similar patterns of shortened transcript. Since polymerase molecules encounter similar kinetic barriers during both processes, it is possible that there is a common step in the reverse movement of the polymerase.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; DUPONT MERCK PHARMACEUT CO,EXPTL STN E4005435,WILMINGTON,DE 19880	University of Iowa; DuPont			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BHARGAVA P, 1989, FEBS LETT, V248, P195, DOI 10.1016/0014-5793(89)80460-0; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; FENG GH, 1994, J BIOL CHEM, V269, P22282; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	34	49	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19114	19119		10.1074/jbc.270.32.19114	http://dx.doi.org/10.1074/jbc.270.32.19114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642577	hybrid			2022-12-27	WOS:A1995RN95400065
J	KNOL, JC; VANDERSLIK, AR; VANKESTEREN, ER; PLANTA, RJ; VANHEERIKHUIZEN, H; VREUGDENHIL, E				KNOL, JC; VANDERSLIK, AR; VANKESTEREN, ER; PLANTA, RJ; VANHEERIKHUIZEN, H; VREUGDENHIL, E			A NOVEL G-PROTEIN ALPHA-SUBUNIT CONTAINING ATYPICAL GUANINE-NUCLEOTIDE-BINDING DOMAINS IS DIFFERENTIALLY EXPRESSED IN A MOLLUSCAN NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING; ACTIVATION; SEQUENCES; CDNA; DIVERSITY; CLONING; GENE; SITE	We describe the characterization of a novel G protein alpha subunit, G alpha(a). cDNA encoding this subunit was cloned from the central nervous system of the mollusc Lymnaea stagnalis, The deduced protein contains all characteristic guanine nucleotide-binding domains of G alpha subunits but shares only a limited degree of overall sequence identity with known subtypes (similar to 30%). Moreover, two of the nucleotide binding domains exhibit salient deviations from corresponding sequences in other G protein alpha subunits, The A domain, determining kinetic features of the GTPase cycle, contains a markedly unique amino acid sequence (ILIIGGPGAGK). In addition, the C domain is also clearly distinct (DVAGQRSL). The presence of a leucine in this motif, instead of glutamic acid has important implications for hypotheses concerning the GTPase mechanism, In contrast to other G alpha subtypes, G alpha(a) has no appropriate N-terminal residues that could be acylated, It does contain the strictly conserved arginine residue that serves as a cholera toxin substrate in G alpha(s) and G alpha(t) but lacks a site for ADP-ribosylation by pertussis toxin, In situ hybridization experiments indicate that G alpha(a)-encoding mRNA is expressed in a limited subpopulation of neurons within the Lymnaea brain, These data suggest that G alpha(a) defines a separate class of G proteins with cell type-specific functions.	VRIJE UNIV AMSTERDAM,GRAD SCH NEUROSCI AMSTERDAM,NEUROSCI RES INST,1081 HV AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,FAC CHEM,DEPT BIOCHEM & MOLEC BIOL,1081 HV AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,FAC BIOL,DEPT EXPTL ZOOL,1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam				van der Slik, Arno/0000-0002-8920-0118				Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLOEM LJ, 1990, NUCLEIC ACIDS RES, V18, P2830, DOI 10.1093/nar/18.9.2830; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BULLOCH AGM, 1992, TRENDS NEUROSCI, V15, P422, DOI 10.1016/0166-2236(92)90004-R; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; ILTZSCH MH, 1992, J BIOL CHEM, V267, P14504; ITOH H, 1988, J BIOL CHEM, V263, P6656; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KNOL JC, 1994, BBA-MOL CELL RES, V1222, P129, DOI 10.1016/0167-4889(94)90035-3; KNOL JC, 1992, FEBS LETT, V314, P215, DOI 10.1016/0014-5793(92)81474-Z; KNOL JC, 1995, EUR J BIOCHEM, V230, P198; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; QUAN F, 1993, P NATL ACAD SCI USA, V9, P4236; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SWNINDDALE NV, 1976, PHILOS T R SOC LOND, V274, P169; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WENDELAARBONGA SE, 1972, GEN COMP ENDOCR    S, V3, P308; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691	52	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18804	18808		10.1074/jbc.270.32.18804	http://dx.doi.org/10.1074/jbc.270.32.18804			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642531	hybrid, Green Submitted			2022-12-27	WOS:A1995RN95400018
J	CHUANG, TT; LEVINE, H; DEBLASI, A				CHUANG, TT; LEVINE, H; DEBLASI, A			PHOSPHORYLATION AND ACTIVATION OF BETA-ADRENERGIC-RECEPTOR KINASE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; MULTIGENE FAMILY; BOVINE BRAIN; CALPHOSTIN-C; DESENSITIZATION; IDENTIFICATION; EXPRESSION; INHIBITION; SUBSTRATE; GAMMA	The aim of this study was to test the possible modification of beta-adrenergic receptor kinase (beta ARK) activity by second messengers and/or their downstream components. Using human mononuclear leukocytes (MNL), we found that calcium ionophores could elevate beta ARK activity by about 80% in a protein kinase C (PKC)-dependent manner. This was confirmed by the ability of the PKC activator phorbol 12-myristate 13-acetate (PMA) to produce a similar effect, suggesting a PKC dependent modulation of beta ARK activity. In vitro experiments with purified proteins showed that PKC could directly phosphorylate beta ARK1 with an apparent K-m for beta ARK1 of 6 nM. The ability of beta ARK1 to phosphorylate rhodopsin was 61% greater when it was phosphorylated by PKC. The level of phosphorylation of beta ARK1 immunoprecipitated from MNL and Sf9 cells overexpressing this kinase was enhanced by about 2-3-fold after PMA treatment. Functional significance of PKC-dependent increase in beta ARK activity was demonstrated by beta-adrenergic receptor (beta AR) homologous desensitization experiments in MNL. beta AR desensitization, as induced by exposure to 10 mu M isoproterenol (5 min at 37 degrees C), was increased from 42 +/- 10% in control to 68 +/- 8% in PMA-pretreated MNL. PARK inhibitor heparin (160 mu g/ml) prevented the augmenting effect of PMA on beta AR desensitization. These results show that beta ARK activity can be increased through phosphorylation by PKC, thus indicating that beta ARK can be preconditioned to modulate the subsequent cellular responsiveness to receptor activation, providing the cell with a mechanism by which specific homologous desensitization can be regulated heterologously.	CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,I-66030 SANTA MARIA IMBAR,ITALY; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT NEURODEGENERAT DIS,ANN ARBOR,MI 48105	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Pfizer					Fondazione Telethon Funding Source: Custom; Telethon [E.0062] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BELL JD, 1987, AM J PHYSIOL, V252, pE783, DOI 10.1152/ajpendo.1987.252.6.E783; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DEBLASI A, 1985, J CLIN ENDOCR METAB, V61, P1081, DOI 10.1210/jcem-61-6-1081; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARRUTI G, 1993, BIOCHEM BIOPH RES CO, V190, P475, DOI 10.1006/bbrc.1993.1072; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOUHARA K, 1993, J BIOL CHEM, V269, P10217; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	35	148	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18660	18665		10.1074/jbc.270.31.18660	http://dx.doi.org/10.1074/jbc.270.31.18660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629197	hybrid			2022-12-27	WOS:A1995RM64200079
J	GUAN, GM; JIANG, GJ; KOCH, RL; SHECHTER, I				GUAN, GM; JIANG, GJ; KOCH, RL; SHECHTER, I			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF THE PROMOTER OF THE HUMAN SQUALENE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT; COENZYME-A REDUCTASE; BINDING PROTEINS; DNA-REPLICATION; TRANSCRIPTION; EXPRESSION; SEQUENCE; REGION; IDENTIFICATION	We have cloned and characterized the 5'-flanking region of the gene encoding human squalene synthase. We report here the promoter activity of successively 5'-truncated sections of a 1 kilobase of this region by fusing it to the coding region of a luciferase reporter gene. DNA segments of 200 base pairs (bp) 5' to the transcription start site, as determined by primer extension analysis, show a strong promoter effect on the expression of the luciferase chimeric gene and a high response to the presence of sterols when transiently transfected into the human hepatoma cell line HepG2 or to the hamster-derived CHO-K1 cells. An approximately 50-fold induction of luciferase activity, in the absence of sterols, was observed in transiently transfected HepG2 cells for fusion constructs containing sections of 200, 459, and 934 bp of the putative human squalene synthase promoter. Loss of promoter activity and response to sterols was localized to a 69-bp section located 131 nucleotides 5' to the transcription start site. Sequence analysis of this region showed that it contained a sterol regulatory element 1 (SRE-1) previously identified in other sterol regulated genes (Smith, J. R., Osborne, T. F., Brown, M. S., Goldstein, J. L., and Gil, G. (1988). J. Biol. Chem. 263, 18480-18487) and two potential NF-1 binding sites. Additional CCAAT box, SRE-1 element, and two Sp1 sites were identified 3' to this section. Sequences within this 69-bp DNA, including the SRE-1 cis-acting element, show strong binding to the purified nuclear transcription factor ADD1 (Tonzonoz, P., Kim, J. B., Graves, R. A., and Spiegelman B. M. (1993) Mol. Cell Biol. 13, 4753-4759) by mobility shift assay and footprinting analyses.	ELEANOR ROOSEVELT INST,BOETTCHER LAB MOLEC GENET,DENVER,CO 80206						NHLBI NIH HHS [HL50628, HL48540] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048540, R01HL050628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHAM BE, 1976, J LIPID RES, V17, P176; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIL G, 1986, J BIOL CHEM, V261, P3717; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAWABE Y, 1994, BIOCHEM BIOPH RES CO, V202, P1460, DOI 10.1006/bbrc.1994.2095; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TONZONOZ P, 1993, MOL CELL BIOL, V13, P4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V76, P187	32	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21958	21965		10.1074/jbc.270.37.21958	http://dx.doi.org/10.1074/jbc.270.37.21958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665618	hybrid			2022-12-27	WOS:A1995RU75700081
J	LUBYPHELPS, K; HORI, M; PHELPS, JM; WON, D				LUBYPHELPS, K; HORI, M; PHELPS, JM; WON, D			CA2+-REGULATED DYNAMIC COMPARTMENTALIZATION OF CALMODULIN IN LIVING SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; PHOTOBLEACHING RECOVERY; BINDING DOMAIN; F-ACTIN; CALCIUM; DIFFUSION; SEQUENCE; PEPTIDE; CA-2+	A key assumption of most models for calmodulin regulation of smooth and non-muscle contractility is that calmodulin is freely diffusible at resting intracellular concentrations of free Ca2+. However, fluorescence recovery after photobleaching (FRAP) measurements of three different fluorescent analogs of calmodulin in cultured bovine tracheal smooth muscle cells suggest that free calmodulin may be limiting in unstimulated cells, Thirty-seven % of microinjected calmodulin is immobile by FRAP and the fastest recovering component has an effective diffusion coefficient 7-fold slower than a dextran of equivalent size. Combining the FRAP data with extraction data reported in a previous paper (Tansey, M., Luby-Phelps, K., Kamm, K. E., and Stull, J. T. (1994) J. Biol. Chem. 269, 9912-9920), we estimate that at most 5% of total endogenous calmodulin in resting smooth muscle cells is unbound (freely diffusible). Examination of the Ca2+ dependence of calmodulin mobility in permeabilized cells reveals that binding persists even at intracellular Ca2+ concentrations as low as 17 nM. When Ca2+ is elevated to between 450 nM and 3 mu M, some of the bound calmodulin is released, as indicated by an increase in the effective diffusion coefficient and the per cent mobile fraction, At higher Ca2+, calmodulin becomes increasingly immobilized. In about 50% of the cell population, clamping Ca2+ at micromolar levels results in translocation of cytoplasmic calmodulin to the nucleus, The compartmentalization and complex dynamics of calmodulin in living smooth muscle cells have profound implications for understanding how calmodulin regulates contractility in response to extracellular signals.			LUBYPHELPS, K (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA.			Luby-Phelps, Katherine/0000-0002-8378-1409				BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HOU L, 1990, BIOPHYS J, V58, P31, DOI 10.1016/S0006-3495(90)82351-1; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LUBYPHELPS K, 1985, J CELL BIOL, V101, P1245, DOI 10.1083/jcb.101.4.1245; LUBYPHELPS K, 1994, COMMENTS MOL CELL BI, V8, P199; MAYR GW, 1983, BIOCHEMISTRY-US, V22, P4316, DOI 10.1021/bi00287a024; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MINTON AP, 1990, INT J BIOCHEM, V22, P1063, DOI 10.1016/0020-711X(90)90102-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAKANISHI S, 1991, ANAL BIOCHEM, V195, P313, DOI 10.1016/0003-2697(91)90336-R; OLWIN BB, 1984, J BIOL CHEM, V259, P949; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ONO T, 1992, BRIT J PHARMACOL, V106, P539, DOI 10.1111/j.1476-5381.1992.tb14371.x; PERSECHINI A, 1993, BIOCHIM BIOPHYS ACTA, V1163, P309, DOI 10.1016/0167-4838(93)90167-P; PROVANCE DW, 1993, J CELL SCI, V106, P565; SHMIDT HHHW, 1992, CELL CALCIUM, V13, P427, DOI 10.1016/0143-4160(92)90055-W; SIMON JR, 1988, BIOPHYS J, V54, P801, DOI 10.1016/S0006-3495(88)83018-2; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011; YGUERABIDE J, 1982, BIOPHYS J, V40, P69, DOI 10.1016/S0006-3495(82)84459-7; ZIMPRICH F, 1995, CELL CALCIUM, V17, P233, DOI 10.1016/0143-4160(95)90038-1	31	93	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21532	21538		10.1074/jbc.270.37.21532	http://dx.doi.org/10.1074/jbc.270.37.21532			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665565	hybrid			2022-12-27	WOS:A1995RU75700020
J	WAYMAN, GA; IMPEY, S; STORM, DR				WAYMAN, GA; IMPEY, S; STORM, DR			CA2+ INHIBITION OF TYPE-III ADENYLYL-CYCLASE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ADP-RIBOSYLATION; WHOLE CELLS; RAT-BRAIN; CALMODULIN; CALCIUM; CLONING; EXPRESSION; STIMULATION; IDENTIFICATION	Type III adenylyl cyclase is stimulated by beta-adrenergic agonists and glucagon in vitro and in vivo, but not by Ca2+ and calmodulin. However, the enzyme is stimulated by Ca2+ and calmodulin in vitro when it is concomitantly activated by the guanyl nucleotide stimulatory protein G(s) (Choi, E. J., Xia, Z., and Storm, D. R. (1992a) Biochemistry 31, 6492-6498). Here, we examined regulation of type III adenylyl cyclase by G(s)-coupled receptors and intracellular Ca2+ in vivo. Surprisingly, intracellular Ca2+ inhibited hormone-stimulated type III adenylyl cyclase activity, Submicromolar concentrations of intracellular free Ca2+, which stimulated type I adenylyl cyclase, inhibited glucagon- or isoproterenol-stimulated type III adenylyl cyclase. Inhibition of type III adenylyl cyclase by intracellular Ca2+ was not mediated by G(i), cAMP-dependent protein kinase, or protein kinase C. However, an inhibitor of CaM kinases antagonized Ca2+ inhibition of the enzyme, and coexpression of constitutively activated CaM kinase II completely inhibited isoproterenol-stimulated type III adenylyl cyclase activity. We propose that Ca2+ inhibition of type III adenylyl cyclase may serve as a regulatory mechanism to attenuate hormone-stimulated cAMP levels in some tissues.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACSKAI BJ, 1983, SCIENCE, V260, P222; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SALOMON Y, 1979, ANAL BIOCHEM, V58, P541; SEAMON K, 1981, J BIOL CHEM, V256, P9799; STEER ML, 1975, J BIOL CHEM, V250, P2080; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	41	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21480	21486		10.1074/jbc.270.37.21480	http://dx.doi.org/10.1074/jbc.270.37.21480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665559	hybrid			2022-12-27	WOS:A1995RU75700013
J	ZENNARO, MC; KEIGHTLEY, MC; KOTELEVTSEV, Y; CONWAY, GS; SOUBRIER, F; FULLER, PJ				ZENNARO, MC; KEIGHTLEY, MC; KOTELEVTSEV, Y; CONWAY, GS; SOUBRIER, F; FULLER, PJ			HUMAN MINERALOCORTICOID RECEPTOR GENOMIC STRUCTURE AND IDENTIFICATION OF EXPRESSED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; COMPLEMENTARY-DNA; RIBONUCLEIC-ACID; RAT HIPPOCAMPUS; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTION; SUPERFAMILY; PROMOTERS	Most of the known effects of aldosterone are mediated by the mineralocorticoid receptor, an intracellular receptor belonging to the steroid/thyroid hormone/retinoic acid receptor superfamily. We determined the genomic structure of the human MR (hMR) and identified 10 exons in the gene, including two exons (1 alpha and 1 beta) that encode different 5'-untranslated sequence. Expression of the two different hMR variants is under the control of two different promoters that contain no obvious TATA element, but multiple GC boxes. Our results indicate that hMR expression is regulated by alternative promoters perhaps in a tissue- or developmental-specific manner.	COLL FRANCE,INSERM,U36,F-75005 PARIS,FRANCE; PRINCE HENRYS INST MED RES,CLAYTON,VIC 3168,AUSTRALIA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Prince Henry's Institute of Medical Research			Zennaro, Maria-Christina/G-2841-2013; Kotelevtsev, Yuri V/R-1772-2016	Zennaro, Maria-Christina/0000-0001-5449-9191; Keightley, Maria-Cristina/0000-0001-8141-4069; Fuller, Peter/0000-0002-0948-2072; Kotelevtsev, Yuri/0000-0002-7255-7794				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CASTREN M, 1993, J NEUROENDOCRINOL, V5, P461, DOI 10.1111/j.1365-2826.1993.tb00508.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAIRE M, 1980, J BIOL CHEM, V256, P142; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAN YS, 1989, CYTOGENET CELL GENET, V52, P83, DOI 10.1159/000132846; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; JACKSON SP, 1990, CELL, P155; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KOMESAROFF PA, 1994, J CLIN ENDOCR METAB, V79, P27, DOI 10.1210/jc.79.1.27; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWAK SP, 1993, ENDOCRINOLOGY, V133, P2344, DOI 10.1210/en.133.5.2344; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; MARVER D, 1985, BIOCHEM ACTION HORM, P385; MEYER AS, 1994, ENDOCRINOLOGY, V134, P1163, DOI 10.1210/en.134.3.1163; MISRAHI M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P289, DOI 10.1016/0167-4781(93)90156-8; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORRISON N, 1990, HUM GENET, V85, P130; OCHMAN H, 1990, PCR PROTOCOLS GUIDE; PATEL PD, 1989, MOL ENDOCRINOL, V3, P1877, DOI 10.1210/mend-3-11-1877; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEPHENSON G, 1987, AM J PHYSIOL, V252, pE525, DOI 10.1152/ajpendo.1987.252.4.E525; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZENNARO MC, 1994, J CLIN ENDOCR METAB, V79, P32, DOI 10.1210/jc.79.1.32; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	47	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21016	21020		10.1074/jbc.270.36.21016	http://dx.doi.org/10.1074/jbc.270.36.21016			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673127	hybrid			2022-12-27	WOS:A1995RU05400024
J	STOLE, E; BRYANT, FR				STOLE, E; BRYANT, FR			SPECTROSCOPIC DEMONSTRATION OF A LINKAGE BETWEEN THE KINETICS OF NTP HYDROLYSIS AND THE CONFORMATIONAL STATE OF THE RECA-SINGLE-STRANDED DNA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED ATP HYDROLYSIS; ESCHERICHIA-COLI; PROTEIN; EXCHANGE; RECOMBINATION; INHIBITION; ADP	We recently constructed a mutant recA protein in which His-163 was replaced by a tryptophan residue; the [H163W]recA protein is functionally identical to the wild-type protein, and the Trp-163 side chain serves as a reporter group for the conformational transitions of the [H163W]recA-single-stranded DNA (ssDNA) complex. We have now examined the fluorescence properties of the [H163W]recA-ssDNA complex in the presence of a series of alternate nucleoside triphosphate cofactors. Under standard conditions (pH 7.5), ATP (S-0.5 = 70 mu M) and purine riboside triphosphate (PTP) (S-0.5 = 110 mu M) effect a 44% decrease in Trp-163 fluorescence and are active as cofactors for the DNA strand exchange reaction. In contrast, ITP (S-0.5 = 400 mu M) elicits only a 20% decrease in Trp-163 fluorescence (a level identical to that observed with the nucleoside diphosphates ADP, PDP, and IDP) and is inactive as a strand exchange cofactor. If the S-0.5 (PTP) is increased to 130 mu M (by increasing the pH of the reaction solution), the PTP-mediated quenching of Trp-163 fluorescence decreases to 20%, and PTP becomes inactive as a strand exchange cofactor. These results provide direct evidence for a linkage between the S-0.5 value of a nucleoside triphosphate and the conformational state of the recA-ssDNA complex, with an S-0.5 of 100-120 mu M or lower required for stabilization of the strand exchange-active conformation.	JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [R01 GM 36516, F32 GM16284] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016284, R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P19; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; MEAH YS, 1993, J BIOL CHEM, V268, P23991; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; MISHRA NC, 1991, J CHEM SOC CHEM COMM, V18, P1276; MUENCH KA, 1991, J BIOL CHEM, V266, P844; PINSINCE JM, 1993, J MOL BIOL, V233, P59, DOI 10.1006/jmbi.1993.1484; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; STOLE E, 1994, J BIOL CHEM, V269, P7919; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	16	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20322	20328		10.1074/jbc.270.35.20322	http://dx.doi.org/10.1074/jbc.270.35.20322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657604	hybrid			2022-12-27	WOS:A1995RR58400017
J	BUHL, AM; OSAWA, S; JOHNSON, GL				BUHL, AM; OSAWA, S; JOHNSON, GL			MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION REQUIRES 2 SIGNAL INPUTS FROM THE HUMAN ANAPHYLATOXIN C5A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; DEPENDENT ACTIVATION; IN-VITRO; RAF; PATHWAY; CELLS; PHOSPHORYLATION; CAMP; TRANSDUCTION; FIBROBLASTS	The anaphylatoxin C5a receptor activates the Ras/Raf/mitogen-activated protein (MAP) kinase pathway in human neutrophils. The signal pathways involved in Ras/Raf/MAP kinase activation in response to C5a and other chemoattractant receptors is poorly understood. Stimulation of the C5a receptor expressed in HEK293 cells results in modest MAP kinase activation which is inhibited by pertussis toxin-catalyzed ADP-ribosylation of G(i). Coexpression of the C5a receptor and the G(16) alpha subunit (alpha(16)) results in the G(16)-mediated activation of phospholipase C beta and a robust MAP kinase activation. Pertussis toxin treatment of C5a receptor/alpha(16)-cotransfected cells inhibits C5a stimulation of MAP kinase activity approximately 60% relative to the control response. Similarly, the protein kinase C inhibitor, GF109203X inhibits activation of MAP kinase activation in C5a receptor/alpha(16)-cotransfected cells by 60%; the protein kinase C inhibitor does not affect the modest C5a receptor response in the absence of alpha(16) expression. These results demonstrate that two independent signals are required for the maximal activation of MAP kinase by G protein-coupled receptors.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; AARHUS UNIV,DEPT CHEM,DIV BIOSTRUCT CHEM,DK-8000 AARHUS C,DENMARK; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; Aarhus University; University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAURE M, 1994, J BIOL CHEM, V269, P7851; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MITCHELL FM, 1995, IN PRESS J BIOL CHEM, V270; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	38	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19828	19832		10.1074/jbc.270.34.19828	http://dx.doi.org/10.1074/jbc.270.34.19828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649993	hybrid			2022-12-27	WOS:A1995RQ99100025
J	HO, SN; THOMAS, DJ; TIMMERMAN, LA; LI, X; FRANCKE, U; CRABTREE, GR				HO, SN; THOMAS, DJ; TIMMERMAN, LA; LI, X; FRANCKE, U; CRABTREE, GR			NFATC3, A LYMPHOID-SPECIFIC NFATC FAMILY MEMBER THAT IS CALCIUM-REGULATED AND EXHIBITS DISTINCT DNA FINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; PLACENTAL ALKALINE-PHOSPHATASE; CYCLOSPORINE-A; ANTIGEN RECEPTOR; INTERLEUKIN-4 GENE; NUCLEAR FACTOR; TRANSCRIPTION; EXPRESSION; PROMOTER; IDENTIFICATION	Signals transduced by the T cell antigen receptor (TCR) regulate developmental transitions in the thymus and also mediate the immunologic activation of mature, peripheral T cells, In both cases TCR stimulation leads to the assembly of the NFAT transcription complex as a result of the calcium-dependent nuclear translocation of cytosolic subunits, NFATc, and the Ras/protein kinase C-dependent induction of a nuclear subunit, NFATn, To further understand the diverse roles of antigen receptor signaling throughout T cell development, we have identified a new NFATc family member, NFATc3, that is expressed at highest levels in the thymus, NFATc3 is the product of a gene on murine chromosome 8 that is not Linked to the other NFATc genes. NFATc3, like other NFATc family members, contains a conserved rel similarity domain, and also defines a region conserved among NFATc family members, the SP repeat region, characterized by the repeated motif SPxxSPxxSPrx-sxx(D/E)(D/E)swl. NFATc3 activates NFAT site-dependent transcription when overexpressed, yet exhibits a pattern of DNA site specificity distinct hom other NFATc proteins, Additionally, thymic NFATc3 undergoes modifications in response to agents that mimic T cell receptor signaling, including a decrease in apparent molecular mass upon elevation of intracellular calcium that is inhibited by the immunosuppressant FK506, Given the preferential expression of NFATc3 in the thymus, NFATc family members may regulate distinct subsets of genes during T cell development.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NCI NIH HHS [CA39612] Funding Source: Medline; NHGRI NIH HHS [HG00298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; CULLEN BR, 1992, METHOD ENZYMOL, V216, P362; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; LI X, 1995, CYTOGENET CELL GENET, V68, P185, DOI 10.1159/000133910; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LYON MF, 1994, MOUSE GENOME, V91, P21; MATSUDA I, 1994, BIOCHEM BIOPH RES CO, V199, P439, DOI 10.1006/bbrc.1994.1248; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSITSIKOV EN, 1994, MOL IMMUNOL, V31, P895, DOI 10.1016/0161-5890(94)90009-4; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139	43	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19898	19907		10.1074/jbc.270.34.19898	http://dx.doi.org/10.1074/jbc.270.34.19898			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650004	hybrid			2022-12-27	WOS:A1995RQ99100036
J	HORIUCHI, M; KOIKE, G; YAMADA, T; MUKOYAMA, M; NAKAJIMA, M; DZAU, VJ				HORIUCHI, M; KOIKE, G; YAMADA, T; MUKOYAMA, M; NAKAJIMA, M; DZAU, VJ			THE GROWTH-DEPENDENT EXPRESSION OF ANGIOTENSIN-II TYPE-2 RECEPTOR IS REGULATED BY TRANSCRIPTION FACTORS INTERFERON REGULATORY FACTOR-1 AND FACTOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN GENE-EXPRESSION; IFN-INDUCIBLE GENES; AT2 BINDING-SITES; CELL-GROWTH; R3T3 CELLS; IRF-1; RAT; BETA; SUBTYPES; INHIBITION	Angiotensin II type 2 (AT(2)) receptor is abundantly and widely expressed in fetal tissues but present only in restricted tissues in the adult such as brain and atretic ovary, This receptor is speculated to be involved in tissue growth and/or differentiation. To elucidate the molecular mechanism of growth-regulated AT(2) receptor expression, we cloned the mouse AT(2) receptor genomic DNA and studied its promoter function in mouse fibroblast-derived R3T3 cells, which express AT(2) receptor in the confluent, quiescent state but very low levels of the receptor in actively growing state, Promoter/luciferase reporter deletion analysis of AT(2) receptor in R3T3 cells showed that the putative negative regulatory region is located between the positions -453 and -225, which plays an important role in the transcriptional control of AT(2) receptor gene expression along with the cell growth, We identified the interferon regulatory factor (IRF) binding motif in this region using DNase footprinting analysis and demonstrated that IRF binding oligonucleotide treatment increased the AT(2) receptor expression in growing R3T3 cells but not in confluent cells, Furthermore, by antisense treatment, we demonstrated that IRF-2 attenuated the AT(2) receptor expression in both growing and confluent R3T3 cells, whereas IRF-1 enhanced AT(2) receptor expression in the confluent cells only, Consistent with this result, gel mobility shift assay demonstrated that growing R3T3 cells exhibited only IRF-2 binding, whereas confluent cells exhibited both IRF-1 and IRF-2 binding, Furthermore, we observed using reverse transcription-polymerase chain reaction that the IRF-1 mRNA expression was more abundant in confluent cells than growing cells, whereas IRF-2 expression did not change with R3T3 cell growth, We conclude that, in confluent cells, the enhanced expression of IRF-1 antagonizes the IRF-2 effect and increases the AT(2) receptor expression. We speculate that these transcriptional factors influence cell growth in part by regulating AT(2) receptor expression.	STANFORD UNIV,SCH MED,FALK CARDIOVASC RES CTR,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R01HL046631, R01HL035252, R37HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V50, P847; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DAUD AI, 1988, ENDOCRINOLOGY, V122, P2727, DOI 10.1210/endo-122-6-2727; DIGNAM JD, 1993, NUCLEIC ACIDS RES, V11, P1475; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; ICHIKI T, 1994, BBA-BIOMEMBRANES, V1189, P247, DOI 10.1016/0005-2736(94)90072-8; JANIAK P, 1992, HYPERTENSION, V20, P737, DOI 10.1161/01.HYP.20.6.737; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MIYAMOTO M, 1988, CELL, V54, P9003; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NAKAMURA M, 1994, HYPERTENSION, V24, P378; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; YAMADA G, 1990, P NATL ACAD SCI USA, V88, P532; Yamada T., 1995, Journal of Investigative Medicine, V43, p290A	41	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20225	20230		10.1074/jbc.270.34.20225	http://dx.doi.org/10.1074/jbc.270.34.20225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650042	hybrid			2022-12-27	WOS:A1995RQ99100080
J	COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A				COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A			ALCOHOLS INHIBIT A CLONED POTASSIUM CHANNEL AT A DISCRETE SATURABLE SITE - INSIGHTS INTO THE MOLECULAR-BASIS OF GENERAL-ANESTHESIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXON; K+ CHANNEL; XENOPUS-OOCYTES; SUBUNIT STOICHIOMETRY; ION CHANNELS; TEA BLOCKADE; RECEPTOR; SHAKER; DROSOPHILA; BINDING	The molecular basis of general anesthetic action on membrane proteins that control ion transport is not yet understood, In a previous report (Covarrubias, M., and Rubin, E. (1993) Proc. Natl. Acad. Sci. 90, 6957-6960), we found that low concentrations of ethanol (17-170 mM) selectively inhibited a noninactivating cloned K+ channel encoded by Drosophila Shaw2. Here, we have conducted equilibrium dose-inhibition experiments, single channel recording, and mutagenesis in vitro to study the mechanism underlying the inhibition of Shaw2 K+ channels by a homologous series of n-alkanols (ethanol to 1-hexanol), The results showed that: (i) these alcohols inhibited Shaw2 whole-cell currents, the equilibrium dose-inhibition relations were hyperbolic, and competition experiments revealed the presence of a discrete site of action, possibly a hydrophobic pocket; (ii) this pocket may be part of the protein because n-alkanol sensitivity can be transferred to novel hybrid K+ channels composed of Shaw2 subunits and homologous ethanol-insensitive subunits; (iii) moreover, a hydrophobic point mutation within a cytoplasmic loop of an ethanol-insensitive K+ channel (human Kv3.4) was sufficient to allow significant inhibition by n-alkanols, with a dose-inhibition relation that closely resembled that of wildtype Shaw2 channels; and (iv) 1-butanol selectively inhibited long duration single channel openings in a manner consistent with a direct effect on channel gating. These results strongly suggest that a discrete site within the ion channel protein is the primary locus of alcohol and general anesthetic action.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	COVARRUBIAS, M (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,1020 LOCUST ST,JAH 25,PHILADELPHIA,PA 19107, USA.			Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [AA07463, AA07186-07] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; ANANTHARAM V, 1992, MOL PHARMACOL, V42, P499; Ausubel FM., 2006, ENZYMATIC MANIPULATI; AVEYARD R, 1969, T FARADAY SOC, V65, P2645, DOI 10.1039/tf9696502645; BRAHM J, 1983, J GEN PHYSIOL, V81, P283, DOI 10.1085/jgp.81.2.283; BRAU ME, 1995, J GEN PHYSIOL, V105, P485, DOI 10.1085/jgp.105.4.485; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; DIETRICH RA, 1989, PHARMACOL REV, V41, P489; DILGER JP, 1994, ANESTHESIOLOGY, V81, P431, DOI 10.1097/00000542-199408000-00022; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; Franks N P, 1991, Alcohol Alcohol Suppl, V1, P197; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FROEMMEL C, 1984, Journal of Theoretical Biology, V111, P247; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P363, DOI 10.1113/jphysiol.1988.sp017209; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P375, DOI 10.1113/jphysiol.1988.sp017210; HAYDON DA, 1983, J PHYSIOL-LONDON, V341, P411, DOI 10.1113/jphysiol.1983.sp014813; HAYDON DA, 1986, J PHYSIOL-LONDON, V373, P311, DOI 10.1113/jphysiol.1986.sp016049; HEIGENBOTHAM L, 1992, NEURON, V8, P483; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; Ledwell J. L., 1995, Biophysical Journal, V68, pA32; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCCORMACK K, 1993, BIOPHYS J, V63, P1740; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MILLER KW, 1986, ANN NY ACAD SCI, V492, P71; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; PRESS WH, 1989, NUMERICAL RECIPES PA, P473; RUDY B, 1991, J NEUROSCI RES, V29, P401, DOI 10.1002/jnr.490290316; SINE SM, 1987, BIOPHYS J, V52, P1047; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOLC CK, 1988, J NEUROSCI, V8, P2556; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Tanford C., 1973, HYDROPHOBIC EFFECT; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; TSUNODA S, 1995, J NEUROSCI, V15, P1741, DOI 10.1523/JNEUROSCI.15-03-01741.1995; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEIGHT FF, 1992, ADV BIOCHEM PSYCHOPH, V47, P335; WEIGHT FF, 1992, INT REV NEUROBIOL, V33, P289, DOI 10.1016/S0074-7742(08)60694-7; WOOD SC, 1995, MOL PHARMACOL, V47, P121; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1988, J NEUROSCI, V8, P4765; ZORN L, NEUROSCI LETT, V161, P81	59	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19408	19416		10.1074/jbc.270.33.19408	http://dx.doi.org/10.1074/jbc.270.33.19408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642622	hybrid			2022-12-27	WOS:A1995RP70300036
J	GORAYA, TY; KESSLER, SP; STANTON, P; HANSON, RW; SEN, GC				GORAYA, TY; KESSLER, SP; STANTON, P; HANSON, RW; SEN, GC			THE CYCLIC-AMP RESPONSE ELEMENTS OF THE GENES FOR ANGIOTENSIN-CONVERTING ENZYME AND PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) CAN MEDIATE TRANSCRIPTIONAL ACTIVATION BY CREM-TAU AND CREM-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; REGULATORY ELEMENT; HEPATOMA-CELLS; PROMOTER; EXPRESSION; INITIATION; INDUCTION; SPERMATOGENESIS; LOCALIZATION; REPRESSES	The potential of the CREM family of proteins to activate transcription of the genes encoding the testis-specific isozyme of angiotensin converting enzyme (ACE(T)) and the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (GTP) (PEPCK) (EC 4.1.1.32) were investigated. Both CREM tau and CREM alpha bind efficiently to the putative cyclic AMP response element (CRE) present in the ACE(T) gene (CRET) and to the CRE in the PEPCK gene, In HepG2 cells, the CRE was required for the strong stimulation by CREM tau of the expression of a chimeric PEPCK (-210 to +73)-chloramphenicol acetyl transferase (CAT) gene, The CRE could be mutated to the CRET sequence without losing the stimulatory effects of CREM tau. However, a similar chimeric gene driven by the regulatory region of the ACE(T) gene, which contains the CRET site, could only be stimulated by CREM tau when its imperfect TATA element was mutated to an authentic TATA. Surprisingly, CREM alpha, an alleged inhibitor of CRE-mediated transcription, stimulated the expression of both PEPCK-CAT and ACE(T)-CAT genes in HepG2 cells, a process which required the presence of the CRE and the CRET sites, respectively, In contrast, when the same CRE elements were used to drive the transcription of a chimeric gene containing the thymidine kinase promoter linked to the CAT structural gene, CREM alpha inhibited its expression in HepG2 and JEG3 cells, The expression of the same chimeric gene, however, was stimulated by CREM alpha in F9 embryonal carcinoma cells. These results demonstrated that the nature of the transcriptional effects of CREM isoforms on CRE-mediated transcription depends on the specific gene, the specific cell type and the promoter context of the CRE site.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline; NIDDK NIH HHS [DK-07678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GORAYA TY, 1994, NUCLEIC ACIDS RES, V22, P1194, DOI 10.1093/nar/22.7.1194; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3	35	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19078	19085		10.1074/jbc.270.32.19078	http://dx.doi.org/10.1074/jbc.270.32.19078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642572	hybrid			2022-12-27	WOS:A1995RN95400060
J	KANG, KR; WOLFF, EC; PARK, MH; FOLK, JE; CHUNG, SN				KANG, KR; WOLFF, EC; PARK, MH; FOLK, JE; CHUNG, SN			IDENTIFICATION OF YHR068W IN SACCHAROMYCES-CEREVISIAE CHROMOSOME-VIII AS A GENE FOR DEOXYHYPUSINE SYNTHASE - EXPRESSION AND CHARACTERIZATION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE; PROTEIN; SPERMIDINE; YEAST; PURIFICATION; CLEAVAGE	Deoxyhypusine synthase catalyzes the formation of deoxyhypusine, the first step in hypusine biosynthesis. Amino acid sequences of five tryptic peptides from rat deoxyhypusine synthase were found to match partially the deduced amino acid sequence of the open reading frame of gene YHR068w of Saccharomyces cerevisiae chromosome VIII (AC:U00061). In order to determine whether the product of this gene corresponds to yeast deoxyhypusine synthase, a 1.17-kilobase pair cDNA with an identical nucleotide sequence to that of the YR068w coding region was obtained from S. cerevisiae cDNA by polymerase chain reaction and was expressed in Escherichia coli B strain BL21(DE3). The recombinant protein was found mostly in the E. coli cytosol fraction and comprised similar to 20% of the total soluble protein. The purified form of the expressed protein effectively catalyzed the formation of deoxyhypusine in yeast eIF-5A precursors as well as in human precursor and in those from Chinese hamster ovary cells. The molecular mass of the enzyme was estimated to be 172,000 a 4,300 Da by equilibrium centrifugation. The mass of its polypeptide subunit was determined to be similar to 43,000 Da, in close agreement with that calculated for the coding region of the YHR068w gene. These findings show that this gene is a coding sequence for yeast deoxyhypusine synthase and that the product of this gene exists in a tetrameric form.	NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOHNSTON M, 1995, SCIENCE, V265, P2077; LOWRY CV, 1983, P NATL ACAD SCI-BIOL, V80, P151, DOI 10.1073/pnas.80.1.151; MAGDOLEN V, 1994, MOL GEN GENET, V224, P646; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHUMANN H, 1989, SYST APPL MICROBIOL, V11, P103, DOI 10.1016/S0723-2020(89)80047-5; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; TAOY, 1995, J BIOL CHEM, V270, P383; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660	22	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18408	18412		10.1074/jbc.270.31.18408	http://dx.doi.org/10.1074/jbc.270.31.18408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629166	hybrid			2022-12-27	WOS:A1995RM64200042
J	WIMALAWANSA, SJ				WIMALAWANSA, SJ			PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF NEUROPEPTIDE Y-2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN PANCREATIC-POLYPEPTIDE; PEPTIDE-YY-RECEPTORS; RAT-BRAIN; CEREBRAL-CORTEX; BINDING-SITES; RABBIT KIDNEY; Y2 RECEPTORS; NPY BINDING; GUINEA-PIG; CELL-LINES	Neuropeptide Y (NPY) receptors consist of three subtypes, designated NPY1, NPY2, and NPY3. The Y-1 receptor tor has been cloned. The present study reports the purification of the NPY-Y-2 receptor from porcine brain and its biochemical characterization. NPY receptors were solubilized and purified by sequential hydrophobic interaction, ion exchange, and NPY-affinity chromatography. By use of SDS-polyacrylamide gel electrophoresis, high performance liquid chromatography gel permeation chromatography, and chemical cross-linking studies, the affinity-purified brain NPY-Y-2 receptor was identified as a monomeric glycoprotein with a molecular mass of 60 kDa. Following deglycosylation, the molecular mass of the Y-2 receptor was decreased to 45 kDa. Although the I-125-NPY binding to the purified NPY receptor was considerably decreased by N-ethylmaleimide, guanine nucleotides had no effect. Therefore, the purified NPY-Y-2 receptor is probably not associated with G-proteins, but may have intramolecular-free sulfhydryl groups. The specific activity of the isolated NPY-Y-2 receptor is 15.8 nmol/mg of protein. The isolated receptor retained its capacity to bind to I-125-NPY, specific to NPY and peptide YY, and showed no cross-reactivity with any other peptides. Highly purified (10(9)-fold purification) NPY receptor from the brain was identified as the Y-2 subtype as demonstrated by its affinity to C-terminal fragments of NPY, including NPY (13-36).			WIMALAWANSA, SJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV GEN INTERNAL MED,HYPERTENS & VASC RES LAB,GALVESTON,TX 77555, USA.			Wimalawansa, Prof. Sunil/0000-0003-1096-8595				ADAMO ML, 1990, ENDOCRINOLOGY, V126, P434, DOI 10.1210/endo-126-1-434; AICHER SA, 1990, NEUROSCI LETT, V130, P32; ALBERS HE, 1984, NEUROSCI LETT, V50, P163, DOI 10.1016/0304-3940(84)90480-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG RSL, 1985, LIFE SCI, V37, P2111, DOI 10.1016/0024-3205(85)90583-1; CHANPALAY V, 1985, J COMP NEUROL, V238, P382, DOI 10.1002/cne.902380403; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; DALSGAARD CJ, 1986, CELL TISSUE RES, V243, P477; DRUMHELLER A, 1988, Society for Neuroscience Abstracts, V14, P287; DUMONT Y, 1990, EUR J PHARMACOL, V191, P501, DOI 10.1016/0014-2999(90)94189-5; EDVINSSON L, 1987, TRENDS PHARMACOL SCI, V8, P231, DOI 10.1016/0165-6147(87)90069-1; GIMPL G, 1990, J BIOL CHEM, V265, P18142; GLOVER ID, 1985, EUR J BIOCHEM, V142, P379; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; HEDO JA, 1984, RECEPTOR PURIFICATIO, V2, P45; HJELMELAND LM, 1984, RECEPTOR BIOCH METHO, V1, P35; INUI A, 1992, ENDOCRINOLOGY, V130, P3314, DOI 10.1210/en.130.6.3314; INUI A, 1992, ENDOCRINOLOGY, V131, P2090, DOI 10.1210/en.131.5.2090; INUI A, 1989, ENDOCRINOLOGY, V124, P402, DOI 10.1210/endo-124-1-402; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LI W, 1992, J BIOL CHEM, V267, P7570; LINDSTROM JM, 1978, NEUROTRANSMITTER REC, P91; LUNDBERG JM, 1983, NEUROSCI LETT, V42, P167, DOI 10.1016/0304-3940(83)90401-9; LUNDBERG JM, 1984, ACTA PHYSIOL SCAND, V121, P325, DOI 10.1111/j.1748-1716.1984.tb07463.x; MARTEL JC, 1986, PEPTIDES, V7, P55, DOI 10.1016/0196-9781(86)90061-6; MCDONALD JK, 1988, CRIT REV NEUROBIOL, V4, P97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATA K, 1990, BIOCHEM BIOPH RES CO, V171, P330, DOI 10.1016/0006-291X(90)91397-B; NGUYEN TD, 1990, J BIOL CHEM, V265, P6416; ODONOHUE TL, 1985, PEPTIDES, V6, P755, DOI 10.1016/0196-9781(85)90180-9; OKITA M, 1991, ENDOCRINOLOGY, V129, P2512, DOI 10.1210/endo-129-5-2512; PARROTT RF, 1986, PHYSIOL BEHAV, V36, P523, DOI 10.1016/0031-9384(86)90325-2; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; SARIA A, 1985, European Journal of Pharmacology, V107, P105; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1991, J BIOL CHEM, V266, P23959; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; SORENSEN MB, 1989, J NEUROCHEM, V52, P1545; STANLEY BG, 1985, BRAIN RES BULL, V14, P521, DOI 10.1016/0361-9230(85)90100-5; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; UNDEN A, 1984, FEBS LETT, V177, P125, DOI 10.1016/0014-5793(84)80995-3; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; WAHLESTEDT C, 1985, J PHARMACOL EXP THER, V234, P735; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	53	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18523	18530						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629181				2022-12-27	WOS:A1995RM64200059
J	GROVER, J; CHEN, XN; KORENBERG, JR; ROUGHLEY, PJ				GROVER, J; CHEN, XN; KORENBERG, JR; ROUGHLEY, PJ			THE HUMAN LUMICAN GENE - ORGANIZATION, CHROMOSOMAL, LOCATION, AND EXPRESSION IN ARTICULAR-CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; INTRON-EXON JUNCTIONS; HUMAN DECORIN GENE; CORE PROTEINS; BIGLYCAN; FIBROMODULIN; SEQUENCE; LOCALIZATION; SITES; CDNA	A human lumican cDNA sequence was derived by polymerase chain reaction techniques from RNA obtained from intestine, placenta, and articular cartilage. A contiguous sequence of 1729 bases was obtained corresponding to an observed message size of 1.8 kilobases (kb). The cDNA sequence consists of an 80-base pair (bp) 5'-untranslated region, a 1014-bp coding sequence, and a 618-bp 3'-untranslated region terminating in a 17-bp poly(A) tail. The deduced lumican protein sequence has 338 amino acids, including a putative 18-residue signal peptide. The human lumican gene was shown to be spread over about 7.5 kb of genomic DNA and to be located on chromosome 12q22. The gene consists of 3 exons separated by introns of 2.2 and 3.5 kb. The shorter 5'-intron resides 21 bases prior to the translation initiation codon, and the 3'-intron resides 152 bases prior to the translation termination codon. The lumican message is expressed at high levels in adult articular chondrocytes but at low levels in the young juvenile. This age-related trend in message level is not, however, common to all tissues in which the lumican gene is expressed. Lumican is present in the extracellular matrix of human articular cartilage at all ages, although its abundance is far greater in the adult. In the adult cartilage lumican exists predominantly in a glycoprotein form lacking keratan sulfate, whereas the juvenile form of the molecule is a proteoglycan.	SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL,PQ H3G 1A6,CANADA; UNIV CALIF LOS ANGELES,CEDARS SINAI RES INST,AHMANSON DEPT PED,DIV MED GENET,LOS ANGELES,CA 90048	McGill University; McGill University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NHLBI NIH HHS [HL50025] Funding Source: Medline; NICHD NIH HHS [HD17449, HD22657] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657, P01HD017449] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050025] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P20613; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, pN415; KORENBERG JR, 1995, CYTOGENET CELL GENET, V69, P196, DOI 10.1159/000133962; KORENBERG JR, 1993, GENOMICS, V16, P546, DOI 10.1006/geno.1993.1228; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; ROUGHLEY PJ, 1994, MICROSC RES TECHNIQ, V28, P385, DOI 10.1002/jemt.1070280505; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTER V, 1982, BIOCHIM BIOPHYS ACTA, V716, P277, DOI 10.1016/0304-4165(82)90017-4; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; TRAUPE H, 1992, GENOMICS, V13, P481, DOI 10.1016/0888-7543(92)90279-2; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; [No title captured]	46	156	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21942	21949		10.1074/jbc.270.37.21942	http://dx.doi.org/10.1074/jbc.270.37.21942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665616	hybrid			2022-12-27	WOS:A1995RU75700079
J	JIRACEK, J; YIOTAKIS, A; VINCENT, B; LECOQ, A; NICOLAOU, A; CHECLER, F; DIVE, V				JIRACEK, J; YIOTAKIS, A; VINCENT, B; LECOQ, A; NICOLAOU, A; CHECLER, F; DIVE, V			DEVELOPMENT OF HIGHLY POTENT AND SELECTIVE PHOSPHINIC PEPTIDE INHIBITORS OF ZINC ENDOPEPTIDASE-24-15 USING COMBINATORIAL CHEMISTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NEUROTENSIN-DEGRADING METALLOENDOPEPTIDASE; HORMONE-RELEASING HORMONE; THIMET OLIGOPEPTIDASE; PZ-PEPTIDASE; RAT TESTES; LUTEINIZING-HORMONE; NATURAL PEPTIDES; DRUG DISCOVERY; SLOW-BINDING	Several hundred phosphinic peptides having the general formula Z-((L,D))Phe psi(PO2CH2)((L,D))Xaa'-Yaa'-Zaa', where Xaa' = Gly or Ala and Yaa' and Zaa' represent 20 different amino acids, have been synthesized by the combinatorial chemistry approach. Peptide mixtures or individual peptides were evaluated for their ability to inhibit the rat brain zinc endopeptidases 24-15 and 24-16. Numerous phosphinic peptides of this series act as potent (K-i in the nanomolar range) mixed inhibitors of these two peptidases. However, our systematic and comparative strategy led us to delineate the residues located in P-2' and P-3' positions of the inhibitors that are preferred by these two peptidases. Thus, endopeptidase 24-15 exhibits a marked preference for inhibitors containing a basic residue (Arg or Lys) in the P-2' position, while 24-16 prefers a proline in this position. The P-3' position has less influence on the inhibitory potency and selectivity, both peptidases preferring a hydrophobic residue at this position. On the basis of these observations, we have prepared highly potent and selective inhibitors of endopeptidase 24-15. The Z-((L,D))Phe psi(PO2-CH2)((L,D))Ala-Arg-Met compound (mixture of the four diastereoisomers) displays a K-i value of 70 pM for endopeptidase 24-15. The most selective inhibitor of endopeptidase 24-15 in this series, Z-((L,D))Phe psi(PO2CH2)((L,D))Ala-Arg-Phe, exhibits a K-i value of 0.160 nM and is more than 3 orders of magnitude less potent toward endopeptidase 24-16 (K-i = 530 nM). Furthermore, at 1 mu M this selective inhibitor is unable to affect the activity of several other zinc peptidases, namely endopeptidase 24-11, angiotensin-converting enzyme, aminopeptidase M, leucine aminopeptidase, and carboxypeptidases A and B. Therefore, Z-((L,D))Phe psi(PO2CH2)((L,D))Ala-Arg-Phe can be considered as the most potent and specific inhibitor of endopeptidase 24-15 developed to date, This new inhibitor should be useful in assessing the contribution of this proteolytic activity in the physiological inactivation of neuropeptides known to be hydrolyzed, at least in vitro, by endopeptidase 24-15, Our study also demonstrates that the combinatorial chemistry approach leading to the development of phosphinic peptide libraries is a powerful strategy for discovering highly potent and selective inhibitors of zinc metalloproteases and should find a broader application in studies of this important class of enzymes.	CTR ETUD SACLAY,DSV,DEPT INGN & ETUD PROT,CEA,F-91191 GIF SUR YVETTE,FRANCE; UNIV ATHENS,DEPT ORGAN CHEM,ORGAN CHEM LAB,GR-15771 ATHENS,GREECE; UNIV NICE,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; National & Kapodistrian University of Athens; UDICE-French Research Universities; Universite Cote d'Azur			Jiracek, Jiri/A-7124-2008; Checler, Frederic/C-1241-2009; Nicolaou, Anna/D-4025-2018; Jiracek, Jiri/Y-6703-2019	Jiracek, Jiri/0000-0003-3848-2773; Checler, Frederic/0000-0003-2098-1750; Nicolaou, Anna/0000-0002-1314-413X; Jiracek, Jiri/0000-0003-3848-2773; Vincent, Bruno/0000-0003-3876-2118				BARELLI H, 1994, BRIT J PHARMACOL, V112, P127, DOI 10.1111/j.1476-5381.1994.tb13041.x; BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BARELLI H, 1991, NEUROCHEM LIFE SCI A, V10, P115; BARLOS K, 1991, INT J PEPT PROT RES, V37, P513; BARRETT AJ, 1989, BIOCHEM J, V261, P1047, DOI 10.1042/bj2611047; BARTLETT PA, 1987, BIOCHEMISTRY-US, V26, P8553, DOI 10.1021/bi00400a009; CAMARGO ACM, 1972, J NEUROCHEM, V19, P37, DOI 10.1111/j.1471-4159.1972.tb01251.x; CAMPBELL DA, 1994, J AM CHEM SOC, V116, P6039, DOI 10.1021/ja00092a093; CARDOZO C, 1993, PEPTIDES, V14, P1259, DOI 10.1016/0196-9781(93)90185-J; CHAPPELL MC, 1992, PEPTIDES, V13, P943, DOI 10.1016/0196-9781(92)90053-6; CHECLER F, 1986, J BIOL CHEM, V261, P1274; CHECLER F, 1988, BIOCHIMIE, V70, P75, DOI 10.1016/0300-9084(88)90161-7; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DIVE V, 1990, EUR J BIOCHEM, V191, P685, DOI 10.1111/j.1432-1033.1990.tb19175.x; DIVE V, 1993, INNOVATIONS PROTEASE, P299; DOULUT S, 1993, J MED CHEM, V36, P1369, DOI 10.1021/jm00062a009; GENDEN EM, 1991, HYPERTENSION, V18, P360, DOI 10.1161/01.HYP.18.3.360; GRECO WR, 1979, J BIOL CHEM, V254, P2104; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KATZ A, 1994, EUR J BIOCHEM, V221, P159; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KEST B, 1992, PSYCHOPHARMACOLOGY, V106, P408, DOI 10.1007/BF02245427; KNIGHT CG, 1991, FEBS LETT, V294, P183, DOI 10.1016/0014-5793(91)80664-O; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LASDUN A, 1990, J PHARMACOL EXP THER, V253, P1265; MCKIE N, 1993, BIOCHEM J, V295, P57, DOI 10.1042/bj2950057; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; TISLJAR U, 1990, BIOCHEM J, V267, P531, DOI 10.1042/bj2670531; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TISLJAR U, 1990, ANAL BIOCHEM, V186, P112, DOI 10.1016/0003-2697(90)90582-T; VINCENT B, 1994, EUR J BIOCHEM, V221, P297, DOI 10.1111/j.1432-1033.1994.tb18741.x; VINCENT B, 1995, IN PRESS BR J PHARM, V113; WILLIAMS CH, 1993, BIOCHEM J, V294, P681, DOI 10.1042/bj2940681; YIOTAKIS A, 1994, BIOCHEM J, V303, P323, DOI 10.1042/bj3030323; YIOTAKIS A, 1994, J MED CHEM, V37, P2713, DOI 10.1021/jm00043a011; YIOTAKIS A, 1995, IN PRESS ASTACINS ST	45	95	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21701	21706		10.1074/jbc.270.37.21701	http://dx.doi.org/10.1074/jbc.270.37.21701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665587	hybrid			2022-12-27	WOS:A1995RU75700045
J	LUE, NF; WANG, JC				LUE, NF; WANG, JC			ATP-DEPENDENT PROCESSIVITY OF A TELOMERASE ACTIVITY FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							YEAST; IDENTIFICATION; RNA; ELONGATION; EXTRACTS	Extracts of Saccharomyces cerevisiae were shown to support the elongation of oligodeoxynucleotides with telomere-like sequences. The primer sequence specificity of this elongation activity, its incorporation of dG and dT but not dA or dC from the corresponding triphosphates, and its sensitivity to RNase A and RNase H are all consistent with it being a telomerase. In contrast to the reported properties of other telomerases, the presence of ATP enhances the efficiency of initiation of the yeast enzyme and improves its processivity. Hydrolysis of ATP appears to be unnecessary for the observed effects, as the beta,gamma-imido or the gamma-thio derivative of ATP is nearly as effective.			LUE, NF (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955	20	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21453	21456		10.1074/jbc.270.37.21453	http://dx.doi.org/10.1074/jbc.270.37.21453			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665555	hybrid			2022-12-27	WOS:A1995RU75700007
J	SABATINI, DM; PIERCHALA, BA; BARROW, RK; SCHELL, MJ; SNYDER, SH				SABATINI, DM; PIERCHALA, BA; BARROW, RK; SCHELL, MJ; SNYDER, SH			THE RAPAMYCIN AND FKBP12 TARGET (RAFT) DISPLAYS PHOSPHATIDYLINOSITOL 4-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; PHOSPHOINOSITIDE KINASES; MACROLIDES FK-506; CELL-LINE; ACTIVATION; YEAST; 3-KINASE; LYMPHOCYTES; COMPLEXES; RECEPTOR	The immunosuppressant rapamycin prevents cell cycle progression in several mammalian cell lines and the yeast Saccharomyces cerevisiae. In mammalian cells, rapamycin binds to the small FK506-binding protein, FKBP12, allowing the drug-receptor complex to interact with the 289-kDa RAFT1/FRAP proteins. These proteins, along with their yeast homologs, TOR1/DRR1 and TOR2/DRR2, contain a C-terminal domain with amino acid homology to several phosphatidylinositol (PI) 4- and 3-kinases. However, no direct demonstration of kinase activity for this family of proteins has been reported. We now show that RAFT1, immunoprecipitated from rat brain and MG63 and HEK293 cells, contains PI 4-kinase activity and that rapamycin-FKBP12 has no effect on this activity. Thus, it is likely that, in vivo, rapamycin does not directly inhibit the PI 4-kinase activity and affects the RAFT1/FRAP protein through another mechanism.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University				Schell, Michael/0000-0003-1553-3582	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R44DA027190, P50DA000266, R43DA027190] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-271-90-7408, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLACKSTONE CD, 1992, ANN NEUROL, V31, P680, DOI 10.1002/ana.410310620; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COCHET C, 1991, J BIOL CHEM, V266, P637; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; HEITMAN J, 1994, SCIENCE, V253, P905; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WENG QP, 1995, MOL CELL BIOL, V15, P2833; WONG K, 1994, J BIOL CHEM, V269, P28878; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	47	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20875	20878		10.1074/jbc.270.36.20875	http://dx.doi.org/10.1074/jbc.270.36.20875			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673106	hybrid			2022-12-27	WOS:A1995RU05400002
J	BARON, CB; OZAKI, S; WATANABE, Y; HIRATA, M; LABELLE, EF; COBURN, RF				BARON, CB; OZAKI, S; WATANABE, Y; HIRATA, M; LABELLE, EF; COBURN, RF			INOSITOL 1,4,5-TRISPHOSPHATE BINDING TO PORCINE TRACHEAL SMOOTH-MUSCLE ALDOLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYTIC-ENZYMES; TRISPHOSPHATE RECEPTOR; COUPLING MECHANISMS; POLYACRYLAMIDE GELS; INTRACELLULAR PH; CALCIUM RELEASE; PROTEINS; CELLS; IDENTIFICATION; PURIFICATION	A cytoskeletal fraction of porcine tracheal smooth muscle (PTSM) was found to contain > 90% of total cellular aldolase (fructose 1,6-bisphosphate aldolase, EC 4.1.2.13) activity. PTSM aldolase was purified by DEAE and inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) affinity chromatography and found to react with an antibody directed against human aldolase C, but not anti aldolase A and B. The molecular mass of native aldolase was about 138 kDa (on Sephacryl S-300); SDS-denatured enzyme was 35 kDa (comigrated with rabbit skeletal muscle aldolase). Total cellular aldolase tetramer (aldolase(4)) content was 34.5 pmol/100 nmol lipid P-i. Ins(1,4,5)P-3) binding activity coeluted with aldolase during Sephacryl 300, DEAE, and Ins(1,4,5)P-3 affinity chromatography. Ins(1,4,5)P-3 bound to purified aldolase (at 0 degrees C) in a dose-dependent manner over the range [Ins(1,4,5)P-3] 20 nM to 20 mu M, with maximal binding of 1 mol of Ins(1,4,5)P-3/mol aldolase, and a K-d of 12-14 mu M. Fru(1,6)P-2 and Fru(2,6)P-2 displaced bound Ins(1,4,5)P-3) with a 50% inhibition at 30 and 170 mu M, respectively. Ins(1,3,4)P-3 (20 mu M) and glyceraldehyde 3-phosphate (2 mM) were also potent inhibitors of Ins(1,4,5)P-3 binding, but not inositol 4-phosphate or inositol 1,4-bisphosphate (20 mu M each). Aldolase-bound Ins(1,4,5)P-3 may play a role in phospholipase C-independent increases in free [Ins(1,4,5)P-3]	BOCKUS RES INST,PHILADELPHIA,PA 19146; EHIME UNIV,FAC ENGN,DEPT APPL CHEM,MATSUYAMA,EHIME 790,JAPAN; KYUSHU UNIV,FAC DENT,DEPT BIOCHEM,FUKUOKA 812,JAPAN	Ehime University; Kyushu University	BARON, CB (corresponding author), UNIV PENN,SCH MED,DEPT PHYSIOL,6085,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050532] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50532-01] Funding Source: Medline; PHS HHS [R37 H137498-08] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM M, 1985, COMP BIOCHEM PHYS B, V80, P847, DOI 10.1016/0305-0491(85)90473-0; ADAMSON ED, 1976, J EMBRYOL EXP MORPH, V35, P355; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ASKALAN R, 1994, J NEUROCHEM, V63, P1477; BABA K, 1989, J PHYSIOL-LONDON, V412, P23, DOI 10.1113/jphysiol.1989.sp017602; BARON CB, 1989, AM J PHYSIOL, V256, pC375, DOI 10.1152/ajpcell.1989.256.2.C375; BARON CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P382, DOI 10.1016/0003-9861(92)90006-I; BATLLE DC, 1993, AM J PHYSIOL, V264, pC932, DOI 10.1152/ajpcell.1993.264.4.C932; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; COBURN RF, 1990, AM J PHYSIOL, V258, pL119, DOI 10.1152/ajplung.1990.258.4.L119; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GU H, 1991, AM J PHYSIOL, V261, pC17, DOI 10.1152/ajpcell.1991.261.1.C17; HARDIN CD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P256, DOI 10.1016/0167-4889(92)90184-D; HASHIMOTO T, 1985, BRIT J PHARMACOL, V86, P191, DOI 10.1111/j.1476-5381.1985.tb09449.x; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; HIRATA M, 1993, METH NEUROSCI, V18, P298; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; JONES LR, 1979, J BIOL CHEM, V254, P530; JOSEPH SK, 1989, MOL PHARMACOL, V35, P355; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; KRAMPETZ IK, 1991, AM J PHYSIOL, V260, pL516, DOI 10.1152/ajplung.1991.260.6.L516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNAT T, 1993, INT J BIOCHEM, V25, P993, DOI 10.1016/0020-711X(93)90112-R; MATHUR RL, 1992, EXP EYE RES, V54, P253, DOI 10.1016/S0014-4835(05)80215-5; MATSUMOTO H, 1995, AM J PHYSIOL-CELL PH, V268, pC458, DOI 10.1152/ajpcell.1995.268.2.C458; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; PATTON C, 1993, MAX CHELATOR V 6 50; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; POPESCU LM, 1983, CELL CALCIUM, V34, P219; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PYNE S, 1993, BRIT J PHARMACOL, V110, P477, DOI 10.1111/j.1476-5381.1993.tb13835.x; RUTTER WJ, 1968, ANN NY ACAD SCI, V151, P102, DOI 10.1111/j.1749-6632.1968.tb11881.x; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAGGART MJ, 1993, J PHYSIOL-LONDON, V472, P23, DOI 10.1113/jphysiol.1993.sp019933; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANSCHIJNDEL JWPM, 1993, FEBS LETT, V336, P239, DOI 10.1016/0014-5793(93)80811-8; VELICK SF, 1949, J PHYS COLLOID CHEM, V53, P135, DOI 10.1021/j150466a011; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	50	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20459	20465		10.1074/jbc.270.35.20459	http://dx.doi.org/10.1074/jbc.270.35.20459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657622	hybrid			2022-12-27	WOS:A1995RR58400036
J	DECARVALHO, MGS; GARRITANO, J; LESLIE, CC				DECARVALHO, MGS; GARRITANO, J; LESLIE, CC			REGULATION OF LYSOPHOSPHOLIPASE ACTIVITY OF THE 85-KDA PHOSPHOLIPASE A(2) AND ACTIVATION IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A(2); CELL-LINE; ACID; LYSOPHOSPHATIDYLCHOLINE; PURIFICATION; BINDING; PHOSPHORYLATION; METABOLITES; PROTEINS	The regulation of the lysophospholipase activity of the 85-kDa cytosolic phospholipase A(2) (PLA(2)) was studied in vitro and in stimulated macrophages. Bovine serum albumin was found to inhibit lysophospholipase activity of the recombinant 85-kDa PLA(2) when assayed at a relatively low substrate concentration. Inhibition could be reversed if the substrate concentration was increased or if Ca2+ was present in the assay. Incubation of recombinant enzyme with macrophage membranes and lipid extracts from macrophage membranes resulted in the release of arachidonic acid, as well as, stearic acid, which is enriched at the sn-1 position of macrophage phospholipids. This suggests that with a bilayer substrate the PLA(2) can sequentially deacylate the sn-2 then sn-1 acyl groups. This was verified by demonstrating that the phospholipids, phosphatidylcholine and phosphatidylinositol, were hydrolyzed to glycerophosphocholine and glycerophosphoinositol by incubation with recombinant 85-kDa PLA(2). The 85-kDa enzyme was identified as the main lysophospholipase activity in mouse peritoneal macrophage cytosols. Addition of Ca2+ to the assay enhanced activity, but this effect decreased as the substrate concentration was increased. Incubation of macrophages with zymosan increased the lysophospholipase activity of the 85-kDa PLA(2) in cytosols. Phosphorylation of recombinant PLA(2) with mitogen-activated protein kinase resulted in an increase in lysophospholipase, as well as, PLA(2) activity. In macrophages stimulated with zymosan release of stearic acid (18:0) and palmitic acid (16:0) was observed in addition to arachidonic acid (20:4). These results are consistent with a role of the 85-kDa PLA(2) in regulating lysophospholipid levels in macrophages during zymosan stimulation.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PATHOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAM BE, 1976, J LIPID RES, V17, P176; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAWSON RMC, 1960, BIOCHEM J, V75, P45, DOI 10.1042/bj0750045; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1993, J LIPID MEDIATOR, V6, P223; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HALL PA, 1991, P SOC EXP BIOL MED, V197, P435; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P1135, DOI 10.1093/oxfordjournals.jbchem.a131169; KLIBANSKY C, 1963, BIOCHIM BIOPHYS ACTA, V70, P176, DOI 10.1016/0006-3002(63)90738-8; KLOPFENSTEIN WE, 1969, BIOCHIM BIOPHYS ACTA, V181, P323, DOI 10.1016/0005-2795(69)90256-6; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE C C, 1990, P216; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LESLIE CC, 1995, IN PRESS ADV MOL CEL; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; METZ SA, 1988, BIOCHIM BIOPHYS ACTA, V968, P239, DOI 10.1016/0167-4889(88)90013-4; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OAKES J, 1973, EUR J BIOCHEM, V36, P553, DOI 10.1111/j.1432-1033.1973.tb02943.x; PORTMAN OW, 1973, BIOCHIM BIOPHYS ACTA, V326, P34, DOI 10.1016/0005-2760(73)90025-8; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SHE HS, 1994, BIOCHEM J, V298, P23, DOI 10.1042/bj2980023; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STOLL LL, 1993, AM J PHYSIOL, V264, pC885, DOI 10.1152/ajpcell.1993.264.4.C885; STRIFE RJ, 1984, J CHROMATOGR, V305, P3, DOI 10.1016/S0378-4347(00)83309-5; SUGIURA T, 1983, LIPIDS, V18, P125, DOI 10.1007/BF02536106; SWITZER S, 1965, J LIPID RES, V6, P506; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	46	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20439	20446		10.1074/jbc.270.35.20439	http://dx.doi.org/10.1074/jbc.270.35.20439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657619	hybrid			2022-12-27	WOS:A1995RR58400033
J	HILDEN, I; HOVEJENSEN, B; HARLOW, KW				HILDEN, I; HOVEJENSEN, B; HARLOW, KW			INACTIVATION OF ESCHERICHIA-COLI PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE BY THE 2',3'-DIALDEHYDE DERIVATIVE OF ATP - IDENTIFICATION OF ACTIVE-SITE LYSINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITE; SALMONELLA-TYPHIMURIUM; PRS GENE; BACILLUS-SUBTILIS; MECHANISM; CLONING; ACID; PURIFICATION; DIPHOSPHATE; HISTIDINE	The enzyme 5-phosphoribosyl-alpha-1-pyrophosphate (PRPP) synthetase from Escherichia coli was irreversibly inactivated on exposure to the affinity analog 2',3'-dialdehyde ATP (oATP). The reaction displayed complex saturation kinetics with respect to oATP with an apparent K-D of approximately 0.8 mM. Reaction with radioactive oATP demonstrated that complete inactivation of the enzyme corresponded to reaction at two or more sites with limiting stoichiometries of approximately 0.7 and 1.3 mol of oATP incorporated/mol of PRPP synthetase subunit. oATP served as a substrate in the presence of ribose 5-phosphate, and the enzyme could be protected against inactivation by ADP or ATP. Isolation of radioactive peptides from the enzyme modified with radioactive oATP, followed by automated Edman sequencing allowed identification of Lys(181), Lys(193), and Lys(230) as probable sites of reaction with the analog. Cysteine 229 may also be labeled by oATP. Of these four residues, Lys(193) is completely conserved within the family of PRPP synthetases, and Lys(181) is found at a position in the sequence where the cognate amino acid (Asp(181)) in human isozyme I PRPP synthetase has been previously implicated in the regulation of enzymatic activity. These results imply a functional role for at least two of the identified amino acid residues.	UNIV COPENHAGEN,INST MOLEC BIOL,CTR ENZYME RES,DK-1353 COPENHAGEN K,DENMARK	University of Copenhagen								ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; BOWER SG, 1988, J BACTERIOL, V170, P3243, DOI 10.1128/jb.170.7.3243-3248.1988; BOWER SG, 1989, J BIOL CHEM, V264, P10287; COLMAN RF, 1990, ENZYMES, P283; Drapeau G R, 1977, Methods Enzymol, V47, P189; EASTERBROOKSMIT.SB, 1976, EUR J BIOCHEM, V62, P125; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; HARLOW KW, 1990, ARCH BIOCHEM BIOPHYS, V276, P466, DOI 10.1016/0003-9861(90)90746-L; HARLOW KW, 1990, J BIOL CHEM, V265, P5487; HENDRICKSON N, 1993, MOL BIOCHEM PARASIT, V59, P15, DOI 10.1016/0166-6851(93)90003-G; HOHENEGGER M, 1992, EUR J BIOCHEM, V205, P173, DOI 10.1111/j.1432-1033.1992.tb16765.x; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; HOVEJENSEN B, 1985, MOL GEN GENET, V201, P269, DOI 10.1007/BF00425670; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; KHORANA HG, 1958, J BIOL CHEM, V230, P941; LOWE PN, 1982, BIOCHEMISTRY-US, V21, P4073, DOI 10.1021/bi00260a025; MILLER GA, 1975, ARCH BIOCHEM BIOPHYS, V171, P732, DOI 10.1016/0003-9861(75)90086-7; MIZIORKO HM, 1990, J BIOL CHEM, V265, P3642; NILSSON D, 1987, GENE, V53, P247, DOI 10.1016/0378-1119(87)90013-8; NILSSON D, 1990, PHOSPHORIBOSYLPYROPH; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; Penefsky H S, 1979, Methods Enzymol, V56, P527; POST DA, 1992, THESIS U ILLINOIS UR; ROBERTS MF, 1978, ARCH BIOCHEM BIOPHYS, V185, P391, DOI 10.1016/0003-9861(78)90181-9; ROESSLER BJ, 1993, J BIOL CHEM, V268, P26476; ROESSLER BJ, 1990, NUCLEIC ACIDS RES, V18, P193, DOI 10.1093/nar/18.1.193; SCHUBERT KR, 1975, J BIOL CHEM, V250, P7492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Switzer R L, 1978, Methods Enzymol, V51, P3; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; SWITZER RL, 1969, J BIOL CHEM, V244, P2854; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; SWITZER RL, 1974, ENZYMES, P607; TAIRA M, 1987, J BIOL CHEM, V262, P14867; TATIBANA M, 1991, ADV EXP MED BIOL, V309, P219; WILLEMOES M, 1993, THESIS U COPENHAGEN; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20730	20736		10.1074/jbc.270.35.20730	http://dx.doi.org/10.1074/jbc.270.35.20730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657655	hybrid			2022-12-27	WOS:A1995RR58400075
J	THOMAS, M; SKALA, H; KAHN, A; TUY, FPD				THOMAS, M; SKALA, H; KAHN, A; TUY, FPD			FUNCTIONAL DISSECTION OF THE BRAIN-SPECIFIC RAT ALDOLASE-C GENE PROMOTER IN TRANSGENIC MICE - ESSENTIAL ROLE OF 2 GC-RICH BOXES AND AN HNF3 BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; FORK-HEAD; SYNERGISTIC INTERACTIONS; NUCLEAR FACTOR; MESSENGER-RNA; EXPRESSION; ENHANCER; TISSUE; CELLS; PROTEINS	The aldolase C gene product is a glycolytic isoenzyme specifically detected in brain. We have previously defined a short 115-base pair promoter fragment able to confer on a reporter chloramphenicol acetyltransferase (CAT) gene a specific expression in brain of transgenic mice. In this promoter fragment, two GC-rich regions (A/A' and B boxes) were detected by in vitro DNase1 footprinting experiments with brain, fibroblast, or liver nuclear extracts. Both A/A' and B boxes, sharing structural homology, are able to interact with Sp1, Krox20/Krox24 factors and with other proteins (Thomas, M., Makeh, I., Briand, P., Kahn, A, and Skala, H. (1993) Eur. J. Biochem. 218, 143-151). In this paper, we describe a new ubiquitous factor termed Ub able to bind the A/A' box. We also delimit a third element (box C) binding a hepatocyte-enriched protein displaced by a hepatocyte nuclear factor 3-specific oligonucleotide. The functional involvement of each binding site in brain-specific transcription of the aldolase C gene has been tested in transgenic mice carrying different mutant promoters cloned in front of the CAT gene. A promoter containing only box C was totally inactive, suggesting an essential role of the region containing A/A' and B boxes. However, mutations or deletions of either the A/A' or the B box have no significant effect on the CAT gene expression. We therefore hypothesize that the A/A' and B sites may be functionally redundant. Indeed, constructs harboring only one of these two boxes (A/A' or B) linked to the C box displayed a brain-specific CAT activity similar to that obtained with the wild type promoter. Furthermore, a transgene with disruption of the C box, keeping intact the A/A' and B boxes, was totally inactive, suggesting a crucial role of the hepatocyte nuclear factor 3 binding site in activation of the aldolase C gene.			THOMAS, M (corresponding author), UNIV PARIS 05,INST COCHIN GENET MOLEC,INSERM,U129,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIDONI D, 1985, SCIENCE, V203, P511; GIGUERE V, 1985, EMBO J, V4, P2017, DOI 10.1002/j.1460-2075.1985.tb03886.x; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; JOHNSON JL, 1994, NUCLEIC ACIDS RES, V22, P5085, DOI 10.1093/nar/22.23.5085; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MAKEH I, 1994, J BIOL CHEM, V269, P4194; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORRIS R, 1985, DEV NEUROSCI-BASEL, V7, P133, DOI 10.1159/000112283; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; OBERDICK J, 1989, NEURON, V3, P385; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PIETTE J, 1985, EMBO J, V4, P2675, DOI 10.1002/j.1460-2075.1985.tb03987.x; POPOVICI T, 1990, FEBS LETT, V268, P189, DOI 10.1016/0014-5793(90)81005-9; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1990, CELL, V57, P645; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x	52	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20316	20321		10.1074/jbc.270.35.20316	http://dx.doi.org/10.1074/jbc.270.35.20316			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657603	hybrid			2022-12-27	WOS:A1995RR58400016
J	HASAN, AAK; CINES, DB; HERWALD, H; SCHMAIER, AH; MULLERESTERL, W				HASAN, AAK; CINES, DB; HERWALD, H; SCHMAIER, AH; MULLERESTERL, W			MAPPING THE CELL-BINDING SITE ON HIGH-MOLECULAR-WEIGHT KININOGEN DOMAIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; MONOCLONAL-ANTIBODIES; PLASMA PREKALLIKREIN; ANIONIC SURFACE; PLATELETS; EXPRESSION; BRADYKININ; IDENTIFICATION	Investigations mapped the region(s) on the light chain of high molecular weight kininogen (HK) that participates in cell binding. Sequential and overlapping peptides of domain 5 (D5(H)) were synthesized to determine its cell binding site(s). Three peptides from non-overlapping regions on D5(H) were found to inhibit biotin-HK binding to endothelial cells. Peptides GKE19 and HNL21 weakly inhibited biotin-HK binding with IC50 of 792 and 215 mu M, respectively. Peptide HKH20 inhibited biotin-HK binding with an IC50 of 0.2 mu M. Two peptides, GGH18 and HVL24, which overlapped HKH20, also inhibited biotin HK binding to endothelial cells with IC50 values of 108 and 0.8 mu M, respectively. Biotinylated HKH20 directly bound to endothelial cells. HK and HKH20 bound at or near the same site on endothelial cells because HK inhibited biotin-HKH20 binding (IC50 0.2 mu M). A polyclonal anti-HKH20 antibody also blocked biotin-HK binding. Peptides HKH20 and HVL24 and anti-HKH20 antibody also inhibited the procoagulant activity of plasma HK. These data indicated that the cell and artificial surface binding sites on D5(H) overlap. The orientation of HK on endothelial cells may be critical for the assembly and activation of contact system enzymes and the expression of kininogen's anti-thrombin activity.	UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, ANN ARBOR, MI 48109 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, W-6500 MAINZ, GERMANY	University of Michigan System; University of Michigan; University of Pennsylvania; Johannes Gutenberg University of Mainz			Schmaier, Alvin/AAM-1063-2020; Herwald, Heiko/AAN-3708-2021	Schmaier, Alvin/0000-0002-3884-6234; Herwald, Heiko/0000-0002-8111-2842	NHLBI NIH HHS [HL35553, HL40387, HL50790] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035553, R01HL050790, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CINES DB, 1984, J CLIN INVEST, V73, P611, DOI 10.1172/JCI111251; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; GUREWICH V, 1993, FEBS LETT, V318, P317, DOI 10.1016/0014-5793(93)80537-5; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERWALD H, 1995, J BIOL CHEM, V270, P14634; HOLLAND JA, 1990, J CELL PHYSIOL, V143, P21, DOI 10.1002/jcp.1041430104; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JIANG YP, 1992, THROMB HAEMOSTASIS, V68, P143; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LOZA JP, 1994, THROMB HAEMOSTASIS, V71, P347; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; NAKASHIMA M, 1993, J CLIN INVEST, V92, P2867, DOI 10.1172/JCI116907; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PURI RN, 1991, BLOOD, V77, P500; REDDIGARI SR, 1993, BLOOD, V81, P1306; SCHMAIER AH, 1989, METHOD ENZYMOL, V169, P276; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1990, BLOOD, V75, P1273; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SMITH D, 1985, BLOOD, V66, P835; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; VOGEL R, 1990, J BIOL CHEM, V265, P12494; ZINI JM, 1993, BLOOD, V81, P2936	40	108	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19256	19261		10.1074/jbc.270.33.19256	http://dx.doi.org/10.1074/jbc.270.33.19256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642598	hybrid			2022-12-27	WOS:A1995RP70300012
J	JIN, RZ; SHARIF, KA; KRAKOW, JS				JIN, RZ; SHARIF, KA; KRAKOW, JS			EVIDENCE FOR CONTACT BETWEEN THE CYCLIC-AMP RECEPTOR PROTEIN AND THE SIGMA(70) SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; TRANSCRIPTION ACTIVATION; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; FUNCTIONAL MAP; DNA-BINDING; CAMP-CRP; PROMOTER; COMPLEX; CAP	The loop at the 52-position of the cAMP receptor pro tein (CRP) has been suggested as a potential site for contacting RNA polymerase on Class II promoters where the CRP binding site is located at position -41.5 (Bell, A., Gaston, K., Williams, R., Chapman, K., Kolb, A., Buc, H., Minchin, S., Williams, J., and Busby, S. (1990) Nucleic Acids Res. 18, 7243-7250), Using protein-protein photo-crosslinking, evidence is presented showing that the 52-loop of CRP is in physical proximity to the cr subunit of RNA polymerase holoenzyme. This interaction required the presence of a functional preinitiation complex. The CRP suppressor mutation, K52N, increased the efficiency of cross-linking, indicating an improved physical interaction between the CRP 52-loop and the cr subunit, Evidence for direct interaction between the CRP 156-162 loop and cu subunit of RNA polymerase on both gal and CRP promoters are also provided. The data indicate that CRP bound to the gal promoter contacts both the alpha and sigma(70) subunits of RNA polymerase.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)					NIGMS NIH HHS [GM22619] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022619] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GIBSON W, 1981, ANAL BIOCHEM, V118, P1, DOI 10.1016/0003-2697(81)90147-0; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XM, 1985, J BIOL CHEM, V260, P4378; Miller J.H., 1972, EXPT MOL GENETICS; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROCKWELL P, 1988, BIOCHEMISTRY-US, V27, P3512, DOI 10.1021/bi00409a058; SHARIF KA, 1994, J BIOL CHEM, V269, P23655; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TAO T, 1985, ARCH BIOCHEM BIOPHYS, V240, P627, DOI 10.1016/0003-9861(85)90070-0; WEST D, 1993, MOL MICROBIOL, V10, P789, DOI 10.1111/j.1365-2958.1993.tb00949.x; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	32	19	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19213	19216		10.1074/jbc.270.33.19213	http://dx.doi.org/10.1074/jbc.270.33.19213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642591				2022-12-27	WOS:A1995RP70300005
J	PICCOLO, S; BONALDO, P; VITALE, P; VOLPIN, D; BRESSAN, GM				PICCOLO, S; BONALDO, P; VITALE, P; VOLPIN, D; BRESSAN, GM			TRANSCRIPTIONAL ACTIVATION OF THE ALPHA-1(VI) COLLAGEN GENE DURING MYOBLAST DIFFERENTIATION IS MEDIATED BY MULTIPLE GA BOXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; VI COLLAGEN; EXPRESSION; PROMOTER; CELLS; CHAIN; FIBROBLASTS; PROTEINS; CLONING; ASSAY	During differentiation of C2C12 myoblasts in vitro, expression of alpha 1(VI) collagen mRNA was transiently stimulated severalfold. Promoter assays on cells transfected with chloramphenicol acetyltransferase (CAT) chimeric constructs have identified a region of the alpha 1(VI) collagen promoter that increases CAT activity about 8-fold during differentiation. The region, which overlaps with transcription initiation sites, was shown to contain three protected segments (A,B, and C) in DNase I footprinting assays. The contact points between nuclear factors and the protected segments were determined by methylation interference assay and included the sequence GGGAGGG (GA box) in all segments. Experiments in which CAT constructs were cotransfected with double-stranded oligonucleotides containing the GA box suggested that this motif was necessary for induction. Transfections with deletion constructs of the natural promoter and with minipromoters made of three copies of A, B, or C showed that the elements have inducing activity and that elements C and, to a lower extent, B are stimulatory for basal transcription, whereas the contribution of A in this process is limited. Electrophoretic mobility shift assays with nuclear extracts from C2C12 cells indicated that the three GA box-containing elements bound several transcription factors, including Spl. Comparison of the properties of the bands shifted under different experimental conditions (presence of 10 mM EDTA, heating of the nuclear extracts, addition of different concentrations of competitor oligonucleotides) established that A, B, and C probes form nine, eight and five main retarded complexes, respectively, and indicated that nuclear factors binding to C and B are subsets of proteins binding to A. UV crosslinking assays identified several peptides (seven with probe A, six with B, and five with C) in the range of 150-32 kDa. Comparison of the gel retardation pattern obtained with nuclear extracts from proliferating and differentiating cells revealed a particular increased intensity of two retarded bands. The data establish that multiple GA boxes mediate induction of the alpha 1(VI) collagen promoter during myoblast differentiation and suggest the attractive hypothesis that the effect may be related to variations of expression of transcription factors binding to these motifs.	UNIV PADUA, INST HISTOL & EMBRYOL, I-35100 PADUA, ITALY	University of Padua				Bonaldo, Paolo/0000-0002-9571-8140; PICCOLO, STEFANO/0000-0002-2037-0004	Telethon [119] Funding Source: Medline	Telethon(Fondazione Telethon)		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BONALDO P, 1993, MATRIX, V13, P223, DOI 10.1016/S0934-8832(11)80006-5; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; DANI C, 1989, J BIOL CHEM, V264, P10119; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; HECKMANN M, 1992, FEBS LETT, V310, P79, DOI 10.1016/0014-5793(92)81151-B; HECKMANN M, 1989, EUR J BIOCHEM, V182, P719, DOI 10.1111/j.1432-1033.1989.tb14884.x; IBRAHIMI A, 1993, BIOCHEM J, V289, P141, DOI 10.1042/bj2890141; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Jackson S. P., 1993, Gene transcription: a practical approach., P189; KOLLER E, 1992, EUR J BIOCHEM, V208, P769, DOI 10.1111/j.1432-1033.1992.tb17246.x; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MARIGO V, 1993, BIOCHIM BIOPHYS ACTA, V1172, P31, DOI 10.1016/0167-4781(93)90265-F; MUONA P, 1993, AM J PATHOL, V142, P1586; QUARTO R, 1993, DEVELOPMENT, V117, P245; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIMANN TE, 1994, J BIOL CHEM, V269, P332; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19583	19590		10.1074/jbc.270.33.19583	http://dx.doi.org/10.1074/jbc.270.33.19583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642645	hybrid			2022-12-27	WOS:A1995RP70300061
J	TOKUMITSU, H; ENSLEN, H; SODERLING, TR				TOKUMITSU, H; ENSLEN, H; SODERLING, TR			CHARACTERIZATION OF A CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE CASCADE - MOLECULAR-CLONING AND EXPRESSION OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN-KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN; BRAIN; GR; AUTOPHOSPHORYLATION; IDENTIFICATION; PURIFICATION; ACTIVATION; SUBUNIT; CELLS	Recent studies have demonstrated that Ca2+/calmodulin dependent protein kinase IV (CaM-kinase IV) can mediate Ca2+-dependent regulation of gene expression through the phosphorylation of transcriptional activating proteins, We have previously identified and purified a 68-kDa rat brain CaM-kinase kinase that phosphorylates and increases total and Ca2+-independent activities of CaM-kinase IV (Tokumitsu, H., Brickey, D. A., Gold, J., Hidaka, H., Sikela, J., and Soderling, T. R. (1994) J. Biol. Chem, 269, 28640-28647), Using a partial amino acid sequence of the purified brain kinase, a CaM-kinase kinase cDNA was cloned from a rat brain cDNA library, Northern blot analysis showed that CaM-kinase kinase mRNA (3.4 kilobases) was expressed in rat brain, thymus, and spleen. Sequence analyses revealed that the cDNA encoded a 505-amino acid protein, which contained consensus protein kinase motifs and was 30-40% homologous with members of the CaM-kinase family, Expression of the cDNA in COS-7 cells yielded an apparent 68-kDa CaM-binding protein, which catalyzed in vitro activation in the presence of Mg2+/ATP and Ca2+/CaM of CaM-kinases I and IV but not of CaM-kinase II. Co-expression of CaM-kinase kinase with CaM-kinase IV gave a 14-fold enhancement of cAMP-response element-binding protein-dependent gene expression compared with CaM-kinase IV alone. These results are consistent with the hypothesis that CaM-kinases I and IV are regulated through a unique signal transduction cascade involving CaM-kinase kinase.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University			Enslen, Hervé/AAH-4492-2021; Enslen, Hervé/M-3400-2017; Tokumitsu, Hiroshi/M-3978-2015	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Tokumitsu, Hiroshi/0000-0002-2193-6794	NIGMS NIH HHS [GM 41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MIYANO O, 1992, J BIOL CHEM, V267, P1198; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WIEMANN S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P254, DOI 10.1016/0167-4781(91)90018-H	32	204	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19320	19324		10.1074/jbc.270.33.19320	http://dx.doi.org/10.1074/jbc.270.33.19320			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642608	hybrid			2022-12-27	WOS:A1995RP70300022
J	WAWRZYNOW, A; ZYLICZ, M				WAWRZYNOW, A; ZYLICZ, M			DIVERGENT EFFECTS OF ATP ON THE BINDING OF THE DNAK AND DNAJ CHAPERONES TO EACH OTHER, OR TO THEIR VARIOUS NATIVE AND DENATURED PROTEIN SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REPLICATION PROTEIN; STRESS PROTEINS; RNA-POLYMERASE; GRPE; HSP70; BIP; DISSOCIATION; PURIFICATION	Using the native proteins lambda P, lambda O, sigma(32), and RepA, as well as permanently unfolded alpha-carboxymethylated lactalbumin, we show that DnaK and DnaJ molecular chaperones possess differential affinity toward these protein substrates. In this paper we present evidence that the DnaK protein binds not only to short hydrophobic peptides, which are in an extended conformation, but also efficiently recognizes large native proteins (RepA, lambda P). The best substrate for either the DnaK or DnaJ chaperone is the native P1 coded replication RepA protein. The native sigma(32) transcription factor binds more efficiently to DnaJ than to DnaK, whereas unfolded alpha-carboxymethylated lactalbumin or native lambda P binds more efficiently to DnaK than to the DnaJ molecular chaperone. The presence of nucleotides does not change the DnaJ affinity to any of the tested protein substrates. In the case of DnaK, the presence of ATP inhibits, while a nonhydrolyzable ATP analogues markedly stimulates the binding of DnaK to all of these various protein substrates. ADP has no effect on these reactions. In contrast to substrate protein binding, DnaK binds to the DnaJ chaperone protein in a radically different manner, namely ATP stimulates whereas a nonhydrolyzable ATP analogue inhibits the DnaK DnaJ complex formation. Moreover, the DnaKc94 mutant protein lacking 94 amino acids from its C terminal domain, which still possesses the ATPase activity and forms a transient complex with protein substrates, does not interact with DnaJ protein. We conclude that the DnaK-ADP form, derived from ATP hydrolysis, possesses low affinity to the protein substrates but can efficiently interact with DnaJ molecular chaperone.			WAWRZYNOW, A (corresponding author), UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,24 KLADKI,PL-80822 GDANSK,POLAND.			Zylicz, Alicja/0000-0003-4174-3073				BANECKI B, 1992, J BIOL CHEM, V267, P25051; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK K, 1993, PROTEIN SCI, V2, P325; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1992, NATURE, V350, P165; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	60	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19300	19306		10.1074/jbc.270.33.19300	http://dx.doi.org/10.1074/jbc.270.33.19300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642605	hybrid			2022-12-27	WOS:A1995RP70300019
J	SAKAI, H; KUMANO, E; IKARI, A; TAKEGUCHI, N				SAKAI, H; KUMANO, E; IKARI, A; TAKEGUCHI, N			A GASTRIC HOUSEKEEPING CL- CHANNEL ACTIVATED VIA PROSTAGLANDIN EP(3) RECEPTOR-MEDIATED CA2+/NITRIC OXIDE/CGMP PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PARIETAL-CELLS; NITRIC-OXIDE; BASOLATERAL MEMBRANE; ADENYLATE-CYCLASE; ARACHIDONIC-ACID; PERTUSSIS TOXIN; CONDUCTANCE; STIMULATION; METABOLISM; CA-2+	Prostaglandin E(2) (PGE(2)) has a cytoprotective role in the gastric parietal cell. PGE(2) opened a housekeeping basolateral Cl- channel of rabbit gastric parietal cells, the single channel conductance of which was about 0.3 picosiemens. In the present patch-clamp and Fura 2 fluorescence studies, we found that PGE(2) increased the intracellular free Ca2+ concentration ([Ca2+](i)) and that PGE(2)-induced opening of the Cl- channel depended on the increase in [Ca2+](i). A novel bifunctional prostaglandin EP(3) agonist/EP(1) antagonist, 5(Z)-7-[(1S, 2S, 3S, 5R)-3-(trans-beta-styren)sulfonamido-6,6-dimethylbicyclo(3.1.1)hept-2-yl]-5-heptenoic acid, also increased both [Ca2+](i) and channel opening. The PGE(2)-induced effect was mediated via production of nitric oxide (NO); that is, N-G-monomethyl-L-arginine, an inhibitor of NO production, markedly inhibited the PGE(2)-induced channel opening, and nitroprusside, a NO donor, induced the channel opening in the absence of PGE(2). Both PGE(2) and A23187, a Ca2+ ionophore, elevated the cGMP content of isolated parietal cells. The A23187-induced channel opening was abolished by methylene blue, a guanylate cyclase inhibitor. In conclusion, we found that the PGE(2)-induced opening of the housekeeping Cl- channel in the parietal cell involves the EP(3) receptor-mediated increase in [Ca2+](i) via a pertussis toxin-sensitive GTP binding protein, resulting in successive production of NO and cGMP.			SAKAI, H (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,DEPT PHARMACEUT PHYSIOL,TOYAMA 93001,JAPAN.							ABOOLIAN A, 1989, AM J PHYSIOL, V3256, pF1135; ATWELL MM, 1988, BIOCHIM BIOPHYS ACTA, V971, P282; BARR DB, 1988, J PHYSIOL-LONDON, V405, P39, DOI 10.1113/jphysiol.1988.sp017320; BEAR CE, 1988, FEBS LETT, V237, P145, DOI 10.1016/0014-5793(88)80189-3; BERGLINDH T, 1980, AM J PHYSIOL, V239, pG90, DOI 10.1152/ajpgi.1980.239.2.G90; BREYER MD, 1993, KIDNEY INT, V43, P1372; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; FRIZZELL RA, 1986, FASEB J, V45, P2727; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; ISHII K, 1991, J CARDIOVASC PHARM, V17, pS246, DOI 10.1097/00005344-199100177-00071; KASHIWAGURA T, 1990, JPN J PHYSIOL, V40, P865, DOI 10.2170/jjphysiol.40.865; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KOIKE M, 1992, BIOCHEM J, V283, P265, DOI 10.1042/bj2830265; LACY ER, 1982, GASTROENTEROLOGY, V83, P619; MARUYAMA T, 1994, 9 INT C PROST REL CO, P88; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NAMBA T, 1993, NATURE, V365, P165; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086; REISER G, 1990, EUR J BIOCHEM, V189, P547, DOI 10.1111/j.1432-1033.1990.tb15521.x; REISER G, 1990, BRIT J PHARMACOL, V101, P722, DOI 10.1111/j.1476-5381.1990.tb14147.x; ROBERT A, 1992, GUT, V33, P444, DOI 10.1136/gut.33.4.444; SAKAI H, 1992, J PHYSIOL-LONDON, V448, P293, DOI 10.1113/jphysiol.1992.sp019042; SAKAI H, 1994, J BIOL CHEM, V269, P23426; SAKAI H, 1993, J PHYSIOL-LONDON, V461, P201, DOI 10.1113/jphysiol.1993.sp019509; SAKAI H, 1989, PFLUG ARCH EUR J PHY, V414, P185, DOI 10.1007/BF00580962; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18781	18785		10.1074/jbc.270.32.18781	http://dx.doi.org/10.1074/jbc.270.32.18781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642528	hybrid			2022-12-27	WOS:A1995RN95400015
J	VANDERWOLK, JPW; KLOSE, M; DEWIT, JG; DENBLAAUWEN, T; FREUDL, R; DRIESSEN, AJM				VANDERWOLK, JPW; KLOSE, M; DEWIT, JG; DENBLAAUWEN, T; FREUDL, R; DRIESSEN, AJM			IDENTIFICATION OF THE MAGNESIUM-BINDING DOMAIN OF THE HIGH-AFFINITY ATP BINDING-SITE OF THE BACILLUS-SUBTILIS AND ESCHERICHIA-COLI SECA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; PLASMA-MEMBRANE; ESSENTIAL COMPONENT; PRECURSOR PROTEINS; CRYSTAL-STRUCTURE; TRIGGER FACTOR; PRO-OMPA; EXPORT; GENE; INVIVO	The homodimeric SecA protein is the peripheral subunit of the translocase, and couples the hydrolysis of ATP to the translocation of precursor proteins across the bacterial cytoplasmic membrane. The high affinity ATP binding activity of SecA resides in the amino-terminal domain of SecA. This domain contains a tandem repeat of the ''so-called'' Walker B-motif, hXhhD (Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951), that in combination with motif A is responsible for the Mg2+-phosphate protein interaction. Two aspartate residues at positions 207 and 215 of the Bacillus subtilis SecA, and Asp-217 in the Escherichia coli SecA, that could be Mg2+ ion ligands, were individually mutated to an asparagine. Mutant SecA proteins were unable to growth complement an E. coli secA amber mutant strain, and the E. coli SecA mutant interfered with the translocation of precursor proteins in vivo. B. subtilis mutant SecA proteins were expressed to a high level and purified to homogeneity. The high affinity ATP and Mg2+-ion binding activity was reduced in the Asp-207 mutant, and completely lost in the Asp-215 mutant. Both SecA proteins were defective in lipid-stimulated ATPase activity. Proteolytic studies suggest that the two subunits of the mutated dimeric SecA proteins are present in different conformational states. These data suggest that Asp-207 and Asp 215 are involved in the binding of the Mg2+-ion when Mg2+-ATP is bound to SecA, while Asp-207 fulfills an additional catalytic role, possibly in accepting a proton during catalysis.	UNIV GRONINGEN, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS; UNIV GRONINGEN, GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST, 9751 NN HAREN, NETHERLANDS; FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST BIOTECHNOL 1, D-52425 JULICH, GERMANY	University of Groningen; University of Groningen; Helmholtz Association; Research Center Julich			Driessen, Arnold J.M./D-1876-2012; Freudl, Roland/N-4179-2017	Freudl, Roland/0000-0003-0743-1279; den Blaauwen, Tanneke/0000-0002-5403-5597; Driessen, Arnold J.M./0000-0001-9258-9104				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM YJ, 1994, CELL, V78, P845; KLOSE M, 1993, J BIOL CHEM, V268, P4504; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2013, PRINCIPLES FLUORESCE; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OVERHOFF B, 1991, MOL GEN GENET, V228, P417, DOI 10.1007/BF00260635; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SADAIE Y, 1991, GENE, V98, P101; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKAMATSU H, 1992, J BACTERIOL, V174, P4308, DOI 10.1128/JB.174.13.4308-4316.1992; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARNER HR, 1978, NATURE, V272, P32, DOI 10.1038/272032a0; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	56	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					18975	18982		10.1074/jbc.270.32.18975	http://dx.doi.org/10.1074/jbc.270.32.18975			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642557	hybrid			2022-12-27	WOS:A1995RN95400045
